,Compound_ID,Uniprot_ID,Compound_Name,Standard_inchi_key,Max_Phase,Target_Pref_Name,Gene_Names,Target_Class,Wild_type_or_mutant,Mutation_information,PubMed_ID,End_Point_Standard_Type,End_Point_Standard_Relation,End_Point_Standard_Value,End_Point_Standard_Units,Endpoint_Mode_of_Action,Assay_Format,Assay_Type,Assay_Sub_Type,Inhibitor_Type,Detection_Technology,Compound_concentration_value,Compound_concentration_value_units,Substrate_type,Substrate_Type_Standard_Relation,Substrate_Type_Standard_Value,Substrate_Type_Standard_Units,Assay_cell_line,Assay_Description,Activity_Comments,Title,Journal,Year,Volume,Issue,Authors,Annotation_Comments,Assay_ID,DTC_Tid,DTC_Activity_ID,DTC_Molregno,Record_ID,DTC_Document_ID,pDTC_Value,SMILES,base_rdkit_smiles
0,CHEMBL10,P28223,SB-203580,CDMGBJANTYXAIV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7484190,DTCC00132413,2089752,46191,,CS(=O)C1=CC=C(C=C1)C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F,C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1
3,CHEMBL1006,P28223,AMIFOSTINE,JKOQGQFVAUAYPM-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7292521,DTCC00224760,898282,46191,,C(CN)CNCCSP(=O)(O)O,NCCCNCCSP(=O)(O)O
5,CHEMBL1009,P28223,LEVODOPA,WTDRDQBEARUVNC-LURJTMIESA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7425271,DTCC00224903,1351112,46191,,C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O,N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O
7,CHEMBL101,P28223,PHENYLBUTAZONE,VYMDGNCVAMGZFE-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7402260,DTCC00142582,217583,46191,,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,CCCCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O
12,CHEMBL101168,P28223,1-AMINOBENZOTRIAZOLE,JCXKHYLLVKZPKE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7302904,DTCC01742000,2057641,46191,,C1=CC=C2C(=C1)N=NN2N,Nn1nnc2ccccc21
14,CHEMBL1016,P28223,CANDESARTAN,HTQMVQVXFRQIKW-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7271683,DTCC00228418,413969,46191,,CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O,CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1
17,CHEMBL1020,P28223,TOLMETIN,UPSPUYADGBWSHF-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7474851,DTCC00229841,477924,46191,,CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)O,Cc1ccc(C(=O)c2ccc(CC(=O)O)n2C)cc1
21,CHEMBL1024,P28223,IFOSFAMIDE,HOMGKSMUEGBAAB-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7308779,DTCC00230672,703982,46191,,C1CN(P(=O)(OC1)NCCCl)CCCl,O=P1(NCCCl)OCCCN1CCCl
23,CHEMBL103,P28223,PROGESTERONE,RJKFOVLPORLFTN-LEKSSAKUSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7374925,DTCC00142899,1092348,46191,,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
27,CHEMBL104,P28223,CLOTRIMAZOLE,VNFPBHJOKIVQEB-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,11142.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7358749,DTCC00143452,1960074,46191,4.953036845876576,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1
30,CHEMBL1042,P28223,CHOLECALCIFEROL,QYSXJUFSXHHAJI-YRZJJWOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7356047,DTCC00235252,1992802,46191,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](CCC3=C)O)C,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C
34,CHEMBL1046,P28223,AMINOCAPROIC ACID,SLXKOJJOQWFEFD-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7300837,DTCC00237384,574618,46191,,C(CCC(=O)O)CCN,NCCCCCC(=O)O
40,CHEMBL105,P28223,MITOMYCIN,NWIBSHFKIJFRCO-WUDYKRTCSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7432733,DTCC00143504,542580,46191,,CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)N,CO[C@@]12[C@H](COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1C[C@@H]1N[C@@H]12
45,CHEMBL1054,P28223,TRICHLORMETHIAZIDE,LMJSLTNSBFUCMU-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7449961,DTCC00242621,2025646,46191,,C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)NC(N2)C(Cl)Cl,NS(=O)(=O)c1cc2c(cc1Cl)NC(C(Cl)Cl)NS2(=O)=O
47,CHEMBL1055,P28223,CHLORTHALIDONE,JIVPVXMEBJLZRO-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7347435,DTCC00242796,1798406,46191,,C1=CC=C2C(=C1)C(=O)NC2(C3=CC(=C(C=C3)Cl)S(=O)(=O)N)O,NS(=O)(=O)c1cc(C2(O)NC(=O)c3ccccc32)ccc1Cl
49,CHEMBL106,P28223,FLUCONAZOLE,RFHAOTPXVQNOHP-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7305393,DTCC00143630,51470,46191,,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F
53,CHEMBL1062,P28223,HYDROXYPROGESTERONE,DBPWSSGDRRHUNT-CEGNMAFCSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7315113,DTCC00245885,1092342,46191,,CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)O,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
55,CHEMBL1064,P28223,SIMVASTATIN,RYMZZMVNJRMUDD-HGQWONQESA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7484288,DTCC00246331,217585,46191,,CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21
69,CHEMBL1065,P28223,METHYSERGIDE,KPJZHOPZRAFDTN-ZRGWGRIASA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,13.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7408918,DTCC00246366,1124452,46191,7.886056647693163,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C,CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4c3c(cn4C)C[C@H]2N(C)C1
72,CHEMBL1068,P28223,OXCARBAZEPINE,CTRLABGOLIVAIY-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7393083,DTCC00246694,1285880,46191,,C1C2=CC=CC=C2N(C3=CC=CC=C3C1=O)C(=O)N,NC(=O)N1c2ccccc2CC(=O)c2ccccc21
74,CHEMBL1069,P28223,VALSARTAN,ACWBQPMHZXGDFX-QFIPXVFZSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7445788,DTCC00246716,1992811,46191,,CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O,CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C
77,CHEMBL107,P28223,COLCHICINE,IAKHMKGGTNLKSZ-INIZCTEOSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7348201,DTCC00144185,153441,46191,,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
79,CHEMBL1070,P28223,NABUMETONE,BLXXJMDCKKHMKV-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7428680,DTCC00246857,1992808,46191,,CC(=O)CCC1=CC2=C(C=C1)C=C(C=C2)OC,COc1ccc2cc(CCC(C)=O)ccc2c1
81,CHEMBL1071,P28223,OXAPROZIN,OFPXSFXSNFPTHF-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7388811,DTCC00246868,1092346,46191,,C1=CC=C(C=C1)C2=C(OC(=N2)CCC(=O)O)C3=CC=CC=C3,O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1
83,CHEMBL1073,P28223,GLIPIZIDE,ZJJXGWJIGJFDTL-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7329503,DTCC00246919,1285876,46191,,CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,Cc1cnc(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc2)cn1
85,CHEMBL1076211,P28223,TOLPERISONE,FSKFPVLPFLJRQB-UHFFFAOYSA-N,2,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7483499,DTCC00627461,315671,46191,,CC1=CC=C(C=C1)C(=O)C(C)CN2CCCCC2,Cc1ccc(C(=O)C(C)CN2CCCCC2)cc1
88,CHEMBL1077,P28223,BROMFENAC,ZBPLOVFIXSTCRZ-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7263129,DTCC00247634,930077,46191,,C1=CC(=C(C(=C1)C(=O)C2=CC=C(C=C2)Br)N)CC(=O)O,Nc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1
101,CHEMBL108,P28223,CARBAMAZEPINE,FFGPTBGBLSHEPO-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7264913,DTCC00144764,249939,46191,,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,NC(=O)N1c2ccccc2C=Cc2ccccc21
104,CHEMBL1080215,P28223,,HMLUJXHOCKZVCO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20149649.0,IC50,=,245.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 60 mins,,"Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,5.0,"Kang SY, Park EJ, Park WK, Kim HJ, Jeong D, Jung ME, Song KS, Lee SH, Seo HJ, Kim MJ, Lee M, Han HK, Son EJ, Pae AN, Kim J, Lee J",,617080.0,DTCT0023186,3228807,DTCC00629252,824714,38109,6.610833915635467,CC1=C(C=C(N1)C2=CC=CC=C2)C(=O)NCCCN3CCN(CC3)C4=CC(=CC=C4)Cl,Cc1[nH]c(-c2ccccc2)cc1C(=O)NCCCN1CCN(c2cccc(Cl)c2)CC1
106,CHEMBL1080522,P28223,,RADDITPPNPJVNF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20149649.0,IC50,=,40.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 60 mins,,"Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,5.0,"Kang SY, Park EJ, Park WK, Kim HJ, Jeong D, Jung ME, Song KS, Lee SH, Seo HJ, Kim MJ, Lee M, Han HK, Son EJ, Pae AN, Kim J, Lee J",,617080.0,DTCT0023186,3228890,DTCC00628579,824710,38109,7.3979400086720375,CC1=C(C=C(N1)C2=CC=CC=C2)C(=O)NCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Cc1[nH]c(-c2ccccc2)cc1C(=O)NCCN1CCN(c2cccc(Cl)c2Cl)CC1
107,CHEMBL1080522,P28223,,RADDITPPNPJVNF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,40.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435451,DTCC00628579,825025,40090,7.3979400086720375,CC1=C(C=C(N1)C2=CC=CC=C2)C(=O)NCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Cc1[nH]c(-c2ccccc2)cc1C(=O)NCCN1CCN(c2cccc(Cl)c2Cl)CC1
108,CHEMBL1080554,P28223,,DUUOOYKRZBNLGD-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20149649.0,IC50,=,61.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 60 mins,,"Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,5.0,"Kang SY, Park EJ, Park WK, Kim HJ, Jeong D, Jung ME, Song KS, Lee SH, Seo HJ, Kim MJ, Lee M, Han HK, Son EJ, Pae AN, Kim J, Lee J",,617080.0,DTCT0023186,3228908,DTCC00628717,1407716,38109,7.214670164989233,CC1=C(C(=CC=C1)N2CCN(CC2)CCCCNC(=O)C3=C(N(C(=C3)C4=CC=CC=C4)C)C)C,Cc1cccc(N2CCN(CCCCNC(=O)c3cc(-c4ccccc4)n(C)c3C)CC2)c1C
109,CHEMBL1080555,P28223,,UQAWWWMXEVRWIO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20149649.0,IC50,=,792.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 60 mins,,"Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,5.0,"Kang SY, Park EJ, Park WK, Kim HJ, Jeong D, Jung ME, Song KS, Lee SH, Seo HJ, Kim MJ, Lee M, Han HK, Son EJ, Pae AN, Kim J, Lee J",,617080.0,DTCT0023186,3228911,DTCC00628718,953972,38109,6.101274818410507,CCCN1C(=C(C=C1C2=CC=CC=C2)C(=O)NCCCCN3CCN(CC3)C4=CC=CC(=C4C)C)C,CCCn1c(-c2ccccc2)cc(C(=O)NCCCCN2CCN(c3cccc(C)c3C)CC2)c1C
111,CHEMBL1080671,P28223,,YGYQFJDPVAAZHI-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20149649.0,IC50,=,354.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 60 mins,,"Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,5.0,"Kang SY, Park EJ, Park WK, Kim HJ, Jeong D, Jung ME, Song KS, Lee SH, Seo HJ, Kim MJ, Lee M, Han HK, Son EJ, Pae AN, Kim J, Lee J",,617080.0,DTCT0023186,3228884,DTCC00628577,695585,38109,6.450996737974212,CC1=C(C=C(N1CC2=CC=CC=C2)C3=CC=CC=C3)C(=O)NCCCN4CCN(CC4)C5=C(C(=CC=C5)Cl)Cl,Cc1c(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc(-c2ccccc2)n1Cc1ccccc1
112,CHEMBL1080672,P28223,,QGNZYFIQHWYSHD-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20149649.0,IC50,=,4383.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 60 mins,,"Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,5.0,"Kang SY, Park EJ, Park WK, Kim HJ, Jeong D, Jung ME, Song KS, Lee SH, Seo HJ, Kim MJ, Lee M, Han HK, Son EJ, Pae AN, Kim J, Lee J",,617080.0,DTCT0023186,3228887,DTCC00628578,340012,38109,5.358228529346041,CC1=C(C=C(N1CC2CCCCC2)C3=CC=CC=C3)C(=O)NCCCN4CCN(CC4)C5=C(C(=CC=C5)Cl)Cl,Cc1c(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc(-c2ccccc2)n1CC1CCCCC1
113,CHEMBL1080683,P28223,,SUYPLBXTJNBFTI-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20149649.0,IC50,=,175.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 60 mins,,"Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,5.0,"Kang SY, Park EJ, Park WK, Kim HJ, Jeong D, Jung ME, Song KS, Lee SH, Seo HJ, Kim MJ, Lee M, Han HK, Son EJ, Pae AN, Kim J, Lee J",,617080.0,DTCT0023186,3228893,DTCC00628580,2017231,38109,6.756961951313706,CC1=C(C=C(N1C)C2=CC=CC=C2)C(=O)NCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Cc1c(C(=O)NCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc(-c2ccccc2)n1C
114,CHEMBL1080711,P28223,,PZNBMHSUVCMXGX-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20149649.0,IC50,=,104.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 60 mins,,"Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,5.0,"Kang SY, Park EJ, Park WK, Kim HJ, Jeong D, Jung ME, Song KS, Lee SH, Seo HJ, Kim MJ, Lee M, Han HK, Son EJ, Pae AN, Kim J, Lee J",,617080.0,DTCT0023186,3228902,DTCC00628648,1504326,38109,6.982966660701219,CCCN1C(=C(C=C1C2=CC=CC=C2)C(=O)NCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl)C,CCCn1c(-c2ccccc2)cc(C(=O)NCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1C
115,CHEMBL1080712,P28223,,ZQHYSZHNEDNQGI-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20149649.0,IC50,=,10.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 60 mins,,"Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,5.0,"Kang SY, Park EJ, Park WK, Kim HJ, Jeong D, Jung ME, Song KS, Lee SH, Seo HJ, Kim MJ, Lee M, Han HK, Son EJ, Pae AN, Kim J, Lee J",,617080.0,DTCT0023186,3228905,DTCC00628649,566400,38109,8.0,CC1=C(C(=CC=C1)N2CCN(CC2)CCCCNC(=O)C3=C(NC(=C3)C4=CC=CC=C4)C)C,Cc1cccc(N2CCN(CCCCNC(=O)c3cc(-c4ccccc4)[nH]c3C)CC2)c1C
116,CHEMBL1080726,P28223,,UOMWETDZWZPAFN-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20149649.0,IC50,=,92.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 60 mins,,"Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,5.0,"Kang SY, Park EJ, Park WK, Kim HJ, Jeong D, Jung ME, Song KS, Lee SH, Seo HJ, Kim MJ, Lee M, Han HK, Son EJ, Pae AN, Kim J, Lee J",,617080.0,DTCT0023186,3228810,DTCC00629253,986377,38109,7.036212172654444,CC1=C(C=C(N1C)C2=CC=CC=C2)C(=O)NCCCN3CCN(CC3)C4=CC(=CC=C4)Cl,Cc1c(C(=O)NCCCN2CCN(c3cccc(Cl)c3)CC2)cc(-c2ccccc2)n1C
117,CHEMBL1080726,P28223,,UOMWETDZWZPAFN-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,92.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435379,DTCC00629253,986678,40090,7.036212172654444,CC1=C(C=C(N1C)C2=CC=CC=C2)C(=O)NCCCN3CCN(CC3)C4=CC(=CC=C4)Cl,Cc1c(C(=O)NCCCN2CCN(c3cccc(Cl)c3)CC2)cc(-c2ccccc2)n1C
118,CHEMBL1080727,P28223,,IGUHNGAQSVMCOM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20149649.0,IC50,=,92.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 60 mins,,"Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,5.0,"Kang SY, Park EJ, Park WK, Kim HJ, Jeong D, Jung ME, Song KS, Lee SH, Seo HJ, Kim MJ, Lee M, Han HK, Son EJ, Pae AN, Kim J, Lee J",,617080.0,DTCT0023186,3228813,DTCC00629254,663297,38109,7.036212172654444,CCN1C(=C(C=C1C2=CC=CC=C2)C(=O)NCCCN3CCN(CC3)C4=CC(=CC=C4)Cl)C,CCn1c(-c2ccccc2)cc(C(=O)NCCCN2CCN(c3cccc(Cl)c3)CC2)c1C
119,CHEMBL1080728,P28223,,JYVCNVVSFMTWGQ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20149649.0,IC50,=,191.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 60 mins,,"Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,5.0,"Kang SY, Park EJ, Park WK, Kim HJ, Jeong D, Jung ME, Song KS, Lee SH, Seo HJ, Kim MJ, Lee M, Han HK, Son EJ, Pae AN, Kim J, Lee J",,617080.0,DTCT0023186,3228816,DTCC00629255,631175,38109,6.718966632752273,CCCN1C(=C(C=C1C2=CC=CC=C2)C(=O)NCCCN3CCN(CC3)C4=CC(=CC=C4)Cl)C,CCCn1c(-c2ccccc2)cc(C(=O)NCCCN2CCN(c3cccc(Cl)c3)CC2)c1C
120,CHEMBL1080728,P28223,,JYVCNVVSFMTWGQ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,191.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435409,DTCC00629255,631469,40090,6.718966632752273,CCCN1C(=C(C=C1C2=CC=CC=C2)C(=O)NCCCN3CCN(CC3)C4=CC(=CC=C4)Cl)C,CCCn1c(-c2ccccc2)cc(C(=O)NCCCN2CCN(c3cccc(Cl)c3)CC2)c1C
122,CHEMBL1080745,P28223,,AZSKJKSQZWHDOK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20149649.0,IC50,=,333.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 60 mins,,"Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,5.0,"Kang SY, Park EJ, Park WK, Kim HJ, Jeong D, Jung ME, Song KS, Lee SH, Seo HJ, Kim MJ, Lee M, Han HK, Son EJ, Pae AN, Kim J, Lee J",,617080.0,DTCT0023186,3228819,DTCC00629315,38851,38109,6.47755576649368,CC1=C(C=C(N1CC(C)C)C2=CC=CC=C2)C(=O)NCCCN3CCN(CC3)C4=CC(=CC=C4)Cl,Cc1c(C(=O)NCCCN2CCN(c3cccc(Cl)c3)CC2)cc(-c2ccccc2)n1CC(C)C
123,CHEMBL1080746,P28223,,LFTMQJKIJXUZLM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20149649.0,IC50,=,441.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 60 mins,,"Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,5.0,"Kang SY, Park EJ, Park WK, Kim HJ, Jeong D, Jung ME, Song KS, Lee SH, Seo HJ, Kim MJ, Lee M, Han HK, Son EJ, Pae AN, Kim J, Lee J",,617080.0,DTCT0023186,3228822,DTCC00629316,1407718,38109,6.355561410532162,CC1=C(C=C(N1N2CCCCC2)C3=CC=CC=C3)C(=O)NCCCN4CCN(CC4)C5=CC(=CC=C5)Cl,Cc1c(C(=O)NCCCN2CCN(c3cccc(Cl)c3)CC2)cc(-c2ccccc2)n1N1CCCCC1
124,CHEMBL1080747,P28223,,SFAXUTJKZSKGCN-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20149649.0,IC50,=,22.9,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 60 mins,,"Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,5.0,"Kang SY, Park EJ, Park WK, Kim HJ, Jeong D, Jung ME, Song KS, Lee SH, Seo HJ, Kim MJ, Lee M, Han HK, Son EJ, Pae AN, Kim J, Lee J",,617080.0,DTCT0023186,3228825,DTCC00629317,857628,38109,7.640164517660112,CC1=C(C=C(N1C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NCCCN4CCN(CC4)C5=CC(=CC=C5)Cl,Cc1c(C(=O)NCCCN2CCN(c3cccc(Cl)c3)CC2)cc(-c2ccccc2)n1-c1ccc(F)cc1
129,CHEMBL1081035,P28223,,LKLHQYZTMSNKTI-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20149649.0,IC50,=,408.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 60 mins,,"Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,5.0,"Kang SY, Park EJ, Park WK, Kim HJ, Jeong D, Jung ME, Song KS, Lee SH, Seo HJ, Kim MJ, Lee M, Han HK, Son EJ, Pae AN, Kim J, Lee J",,617080.0,DTCT0023186,3228896,DTCC00628646,2017232,38109,6.38933983691012,CCCN1C(=C(C=C1C2=CC=CC=C2)C(=O)NCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl)C,CCCn1c(-c2ccccc2)cc(C(=O)NCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1C
130,CHEMBL1081035,P28223,,LKLHQYZTMSNKTI-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,408.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435457,DTCC00628646,2017532,40090,6.38933983691012,CCCN1C(=C(C=C1C2=CC=CC=C2)C(=O)NCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl)C,CCCn1c(-c2ccccc2)cc(C(=O)NCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1C
131,CHEMBL1081036,P28223,,RGKBLDWBOBJRMY-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20149649.0,IC50,=,28.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 60 mins,,"Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,5.0,"Kang SY, Park EJ, Park WK, Kim HJ, Jeong D, Jung ME, Song KS, Lee SH, Seo HJ, Kim MJ, Lee M, Han HK, Son EJ, Pae AN, Kim J, Lee J",,617080.0,DTCT0023186,3228899,DTCC00628647,1375286,38109,7.552841968657781,CC1=C(C=C(N1C)C2=CC=CC=C2)C(=O)NCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Cc1c(C(=O)NCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc(-c2ccccc2)n1C
134,CHEMBL1081302,P28223,,MAOOLDXOCHBHKI-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20149649.0,IC50,=,179.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 60 mins,,"Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,5.0,"Kang SY, Park EJ, Park WK, Kim HJ, Jeong D, Jung ME, Song KS, Lee SH, Seo HJ, Kim MJ, Lee M, Han HK, Son EJ, Pae AN, Kim J, Lee J",,617080.0,DTCT0023186,3228828,DTCC00629381,1342730,38109,6.747146969020107,CC1=C(C=C(N1CC2=CC=CC=C2)C3=CC=CC=C3)C(=O)NCCCN4CCN(CC4)C5=CC(=CC=C5)Cl,Cc1c(C(=O)NCCCN2CCN(c3cccc(Cl)c3)CC2)cc(-c2ccccc2)n1Cc1ccccc1
135,CHEMBL1081303,P28223,,KZWBOSLLKMNBLJ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20149649.0,IC50,=,1067.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 60 mins,,"Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,5.0,"Kang SY, Park EJ, Park WK, Kim HJ, Jeong D, Jung ME, Song KS, Lee SH, Seo HJ, Kim MJ, Lee M, Han HK, Son EJ, Pae AN, Kim J, Lee J",,617080.0,DTCT0023186,3228831,DTCC00629382,469407,38109,5.97183558057553,CC1=C(C=C(N1CC2CCCCC2)C3=CC=CC=C3)C(=O)NCCCN4CCN(CC4)C5=CC(=CC=C5)Cl,Cc1c(C(=O)NCCCN2CCN(c3cccc(Cl)c3)CC2)cc(-c2ccccc2)n1CC1CCCCC1
136,CHEMBL1081468,P28223,,OZHJLELZQHCGSD-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20149649.0,IC50,=,300.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 60 mins,,"Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,5.0,"Kang SY, Park EJ, Park WK, Kim HJ, Jeong D, Jung ME, Song KS, Lee SH, Seo HJ, Kim MJ, Lee M, Han HK, Son EJ, Pae AN, Kim J, Lee J",,617080.0,DTCT0023186,3228834,DTCC00629383,857629,38109,6.522878745280337,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(NC(=C3)C4=CC=CC=C4)C)C,Cc1cccc(N2CCN(CCCNC(=O)c3cc(-c4ccccc4)[nH]c3C)CC2)c1C
137,CHEMBL1081468,P28223,,OZHJLELZQHCGSD-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,300.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435475,DTCC00629383,857933,40090,6.522878745280337,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(NC(=C3)C4=CC=CC=C4)C)C,Cc1cccc(N2CCN(CCCNC(=O)c3cc(-c4ccccc4)[nH]c3C)CC2)c1C
138,CHEMBL1081644,P28223,,NUHJBHFWIFYLHK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20149649.0,IC50,=,57.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 60 mins,,"Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,5.0,"Kang SY, Park EJ, Park WK, Kim HJ, Jeong D, Jung ME, Song KS, Lee SH, Seo HJ, Kim MJ, Lee M, Han HK, Son EJ, Pae AN, Kim J, Lee J",,617080.0,DTCT0023186,3228837,DTCC00629384,727891,38109,7.2441251443275085,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=C3)C4=CC=CC=C4)C)C)C,Cc1cccc(N2CCN(CCCNC(=O)c3cc(-c4ccccc4)n(C)c3C)CC2)c1C
139,CHEMBL1081644,P28223,,NUHJBHFWIFYLHK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,57.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435382,DTCC00629384,728160,40090,7.2441251443275085,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=C3)C4=CC=CC=C4)C)C)C,Cc1cccc(N2CCN(CCCNC(=O)c3cc(-c4ccccc4)n(C)c3C)CC2)c1C
142,CHEMBL1082,P28223,AMOXICILLIN,LSQZJLSUYDQPKJ-NJBDSQKTSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7287568,DTCC00250356,51444,46191,,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O
151,CHEMBL1082723,P28223,NITD609,CKLPLPZSUQEDRT-WPCRTTGESA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20813948.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,Binding affinity to human recombinant serotonin 5-HT2A receptor,,"Spiroindolones, a potent compound class for the treatment of malaria.",Science,2010.0,329.0,5996.0,"Rottmann M, McNamara C, Yeung BK, Lee MC, Zou B, Russell B, Seitz P, Plouffe DM, Dharia NV, Tan J, Cohen SB, Spencer KR, González-Páez GE, Lakshminarayana SB, Goh A, Suwanarusk R, Jegla T, Schmitt EK, Beck HP, Brun R, Nosten F, Renia L, Dartois V, Keller TH, Fidock DA, Winzeler EA, Diagana TT",,658583.0,DTCT0023186,3467860,DTCC00031143,1686650,40818,5.0,C[C@H]1CC2=C([C@]3(N1)C4=C(C=CC(=C4)Cl)NC3=O)NC5=CC(=C(C=C25)F)Cl,C[C@H]1Cc2c([nH]c3cc(Cl)c(F)cc23)[C@@]2(N1)C(=O)Nc1ccc(Cl)cc12
162,CHEMBL1084617,P28223,TEMANOGREL,ZEOQUKRCASTCFR-UHFFFAOYSA-N,1,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20455563.0,IC50,=,5.2,NM,,cell_based,,,,,,,,,,,HEK293,Inverse agonist activity at human 5HT2A receptor expressed in HEK293 cells assessed as inhibition of inositol phosphate accumulation,,Discovery and structure-activity relationship of 3-methoxy-N-(3-(1-methyl-1H-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide (APD791): a highly selective 5-hydroxytryptamine2A receptor inverse agonist for the treatment of arterial thrombosis.,J. Med. Chem.,2010.0,53.0,11.0,"Xiong Y, Teegarden BR, Choi JS, Strah-Pleynet S, Decaire M, Jayakumar H, Dosa PI, Casper MD, Pham L, Feichtinger K, Ullman B, Adams J, Yuskin D, Frazer J, Morgan M, Sadeque A, Chen W, Webb RR, Connolly DT, Semple G, Al-Shamma H",,634153.0,DTCT0023186,3354495,DTCC00645901,1460305,39060,8.2839966563652,CN1C(=CC=N1)C2=C(C=CC(=C2)NC(=O)C3=CC(=CC=C3)OC)OCCN4CCOCC4,COc1cccc(C(=O)Nc2ccc(OCCN3CCOCC3)c(-c3ccnn3C)c2)c1
171,CHEMBL1085155,P28223,,UAVPDLMEWXPRFE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20455563.0,IC50,=,23.0,NM,,cell_based,,,,,,,,,,,HEK293,Inverse agonist activity at human 5HT2A receptor expressed in HEK293 cells assessed as inhibition of inositol phosphate accumulation,,Discovery and structure-activity relationship of 3-methoxy-N-(3-(1-methyl-1H-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide (APD791): a highly selective 5-hydroxytryptamine2A receptor inverse agonist for the treatment of arterial thrombosis.,J. Med. Chem.,2010.0,53.0,11.0,"Xiong Y, Teegarden BR, Choi JS, Strah-Pleynet S, Decaire M, Jayakumar H, Dosa PI, Casper MD, Pham L, Feichtinger K, Ullman B, Adams J, Yuskin D, Frazer J, Morgan M, Sadeque A, Chen W, Webb RR, Connolly DT, Semple G, Al-Shamma H",,634153.0,DTCT0023186,3354494,DTCC00645749,2038132,39060,7.638272163982407,CN1C(=CC=N1)C2=C(C=CC(=C2)NC(=O)C3=CC(=CC=C3)C(F)(F)F)OCCN4CCCC4,Cn1nccc1-c1cc(NC(=O)c2cccc(C(F)(F)F)c2)ccc1OCCN1CCCC1
173,CHEMBL108545,P28223,METHYL SALICYLATE,OSWPMRLSEDHDFF-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7421755,DTCC00280235,1705877,46191,,COC(=O)C1=CC=CC=C1O,COC(=O)c1ccccc1O
186,CHEMBL1086613,P28223,,CVCPNOHIUOTCKW-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20149649.0,IC50,=,75.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 60 mins,,"Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,5.0,"Kang SY, Park EJ, Park WK, Kim HJ, Jeong D, Jung ME, Song KS, Lee SH, Seo HJ, Kim MJ, Lee M, Han HK, Son EJ, Pae AN, Kim J, Lee J",,617080.0,DTCT0023186,3228841,DTCC00629442,1211815,38109,7.1249387366083,CCN1C(=C(C=C1C2=CC=CC=C2)C(=O)NCCCN3CCN(CC3)C4=CC=CC(=C4C)C)C,CCn1c(-c2ccccc2)cc(C(=O)NCCCN2CCN(c3cccc(C)c3C)CC2)c1C
187,CHEMBL1086613,P28223,,CVCPNOHIUOTCKW-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,75.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435478,DTCC00629442,1212117,40090,7.1249387366083,CCN1C(=C(C=C1C2=CC=CC=C2)C(=O)NCCCN3CCN(CC3)C4=CC=CC(=C4C)C)C,CCn1c(-c2ccccc2)cc(C(=O)NCCCN2CCN(c3cccc(C)c3C)CC2)c1C
188,CHEMBL1086626,P28223,,OHODDACZFUFQDV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20149649.0,IC50,=,300.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 60 mins,,"Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,5.0,"Kang SY, Park EJ, Park WK, Kim HJ, Jeong D, Jung ME, Song KS, Lee SH, Seo HJ, Kim MJ, Lee M, Han HK, Son EJ, Pae AN, Kim J, Lee J",,617080.0,DTCT0023186,3228863,DTCC00629569,1984243,38109,6.522878745280337,CC1=C(C=C(N1)C2=CC=CC=C2)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Cc1[nH]c(-c2ccccc2)cc1C(=O)NCCCN1CCN(c2cccc(Cl)c2Cl)CC1
189,CHEMBL1086626,P28223,,OHODDACZFUFQDV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,300.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435460,DTCC00629569,1984517,40090,6.522878745280337,CC1=C(C=C(N1)C2=CC=CC=C2)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Cc1[nH]c(-c2ccccc2)cc1C(=O)NCCCN1CCN(c2cccc(Cl)c2Cl)CC1
190,CHEMBL1086754,P28223,,YIHQDWZWZRGAIH-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20149649.0,IC50,=,46.2,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 60 mins,,"Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,5.0,"Kang SY, Park EJ, Park WK, Kim HJ, Jeong D, Jung ME, Song KS, Lee SH, Seo HJ, Kim MJ, Lee M, Han HK, Son EJ, Pae AN, Kim J, Lee J",,617080.0,DTCT0023186,3228866,DTCC00629570,727893,38109,7.335358024443875,CC1=C(C=C(N1C)C2=CC=CC=C2)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Cc1c(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc(-c2ccccc2)n1C
191,CHEMBL1086754,P28223,,YIHQDWZWZRGAIH-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,46.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435385,DTCC00629570,728161,40090,7.337242168318426,CC1=C(C=C(N1C)C2=CC=CC=C2)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Cc1c(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc(-c2ccccc2)n1C
192,CHEMBL1086755,P28223,,ABKFNWSCLGGDOH-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20149649.0,IC50,=,376.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 60 mins,,"Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,5.0,"Kang SY, Park EJ, Park WK, Kim HJ, Jeong D, Jung ME, Song KS, Lee SH, Seo HJ, Kim MJ, Lee M, Han HK, Son EJ, Pae AN, Kim J, Lee J",,617080.0,DTCT0023186,3228869,DTCC00629571,2081507,38109,6.424812155072339,CCN1C(=C(C=C1C2=CC=CC=C2)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl)C,CCn1c(-c2ccccc2)cc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1C
193,CHEMBL1086756,P28223,,QQGJOZLAJLPARG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20149649.0,IC50,=,324.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 60 mins,,"Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,5.0,"Kang SY, Park EJ, Park WK, Kim HJ, Jeong D, Jung ME, Song KS, Lee SH, Seo HJ, Kim MJ, Lee M, Han HK, Son EJ, Pae AN, Kim J, Lee J",,617080.0,DTCT0023186,3228872,DTCC00629572,598632,38109,6.489454989793388,CCCN1C(=C(C=C1C2=CC=CC=C2)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl)C,CCCn1c(-c2ccccc2)cc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1C
194,CHEMBL1086756,P28223,,QQGJOZLAJLPARG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,324.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435415,DTCC00629572,598938,40090,6.489454989793388,CCCN1C(=C(C=C1C2=CC=CC=C2)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl)C,CCCn1c(-c2ccccc2)cc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1C
195,CHEMBL1087,P28223,MEPIVACAINE,INWLQCZOYSRPNW-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7434368,DTCC00254348,1416035,46191,,CC1=C(C(=CC=C1)C)NC(=O)C2CCCCN2C,Cc1cccc(C)c1NC(=O)C1CCCCN1C
197,CHEMBL1087773,P28223,,XXLRZXFIYXHDKX-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20149649.0,IC50,=,6.9,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 60 mins,,"Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,5.0,"Kang SY, Park EJ, Park WK, Kim HJ, Jeong D, Jung ME, Song KS, Lee SH, Seo HJ, Kim MJ, Lee M, Han HK, Son EJ, Pae AN, Kim J, Lee J",,617080.0,DTCT0023186,3228854,DTCC00629507,1568579,38109,8.161150909262744,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=C3)C4=CC=CC=C4)C5=CC=C(C=C5)F)C)C,Cc1cccc(N2CCN(CCCNC(=O)c3cc(-c4ccccc4)n(-c4ccc(F)cc4)c3C)CC2)c1C
201,CHEMBL1087895,P28223,,CTOTVDSIFQCUNY-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20149649.0,IC50,=,224.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 60 mins,,"Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,5.0,"Kang SY, Park EJ, Park WK, Kim HJ, Jeong D, Jung ME, Song KS, Lee SH, Seo HJ, Kim MJ, Lee M, Han HK, Son EJ, Pae AN, Kim J, Lee J",,617080.0,DTCT0023186,3228857,DTCC00629508,1375295,38109,6.649751981665837,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=C3)C4=CC=CC=C4)CC5=CC=CC=C5)C)C,Cc1cccc(N2CCN(CCCNC(=O)c3cc(-c4ccccc4)n(Cc4ccccc4)c3C)CC2)c1C
202,CHEMBL1087896,P28223,,IXUUTRACMVUZJF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20149649.0,IC50,=,1233.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 60 mins,,"Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,5.0,"Kang SY, Park EJ, Park WK, Kim HJ, Jeong D, Jung ME, Song KS, Lee SH, Seo HJ, Kim MJ, Lee M, Han HK, Son EJ, Pae AN, Kim J, Lee J",,617080.0,DTCT0023186,3228860,DTCC00629509,1018619,38109,5.909036923404268,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=C3)C4=CC=CC=C4)CC5CCCCC5)C)C,Cc1cccc(N2CCN(CCCNC(=O)c3cc(-c4ccccc4)n(CC4CCCCC4)c3C)CC2)c1C
205,CHEMBL1088163,P28223,,FBBKGMWMRVADFV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20149649.0,IC50,=,129.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 60 mins,,"Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,5.0,"Kang SY, Park EJ, Park WK, Kim HJ, Jeong D, Jung ME, Song KS, Lee SH, Seo HJ, Kim MJ, Lee M, Han HK, Son EJ, Pae AN, Kim J, Lee J",,617080.0,DTCT0023186,3228844,DTCC00629443,1568578,38109,6.889410289700751,CCCN1C(=C(C=C1C2=CC=CC=C2)C(=O)NCCCN3CCN(CC3)C4=CC=CC(=C4C)C)C,CCCn1c(-c2ccccc2)cc(C(=O)NCCCN2CCN(c3cccc(C)c3C)CC2)c1C
206,CHEMBL1088163,P28223,,FBBKGMWMRVADFV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,129.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435412,DTCC00629443,1568899,40090,6.889410289700751,CCCN1C(=C(C=C1C2=CC=CC=C2)C(=O)NCCCN3CCN(CC3)C4=CC=CC(=C4C)C)C,CCCn1c(-c2ccccc2)cc(C(=O)NCCCN2CCN(c3cccc(C)c3C)CC2)c1C
207,CHEMBL1088164,P28223,,NPPZKYSUKSUQHL-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20149649.0,IC50,=,897.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 60 mins,,"Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,5.0,"Kang SY, Park EJ, Park WK, Kim HJ, Jeong D, Jung ME, Song KS, Lee SH, Seo HJ, Kim MJ, Lee M, Han HK, Son EJ, Pae AN, Kim J, Lee J",,617080.0,DTCT0023186,3228847,DTCC00629444,1179597,38109,6.047207556955908,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=C3)C4=CC=CC=C4)CC(C)C)C)C,Cc1cccc(N2CCN(CCCNC(=O)c3cc(-c4ccccc4)n(CC(C)C)c3C)CC2)c1C
208,CHEMBL1088165,P28223,,WKVATBBYNLTZNW-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20149649.0,IC50,=,133.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 60 mins,,"Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,5.0,"Kang SY, Park EJ, Park WK, Kim HJ, Jeong D, Jung ME, Song KS, Lee SH, Seo HJ, Kim MJ, Lee M, Han HK, Son EJ, Pae AN, Kim J, Lee J",,617080.0,DTCT0023186,3228851,DTCC00629445,1822325,38109,6.876148359032914,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=C3)C4=CC=CC=C4)N5CCCCC5)C)C,Cc1cccc(N2CCN(CCCNC(=O)c3cc(-c4ccccc4)n(N4CCCCC4)c3C)CC2)c1C
209,CHEMBL1088312,P28223,,UGVUMCKWYHNQJG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20149649.0,IC50,=,406.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 60 mins,,"Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,5.0,"Kang SY, Park EJ, Park WK, Kim HJ, Jeong D, Jung ME, Song KS, Lee SH, Seo HJ, Kim MJ, Lee M, Han HK, Son EJ, Pae AN, Kim J, Lee J",,617080.0,DTCT0023186,3228875,DTCC00629634,1665736,38109,6.391473966422806,CC1=C(C=C(N1CC(C)C)C2=CC=CC=C2)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Cc1c(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc(-c2ccccc2)n1CC(C)C
210,CHEMBL1088313,P28223,,GMJFBSUIRRLORG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20149649.0,IC50,=,67.1,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 60 mins,,"Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,5.0,"Kang SY, Park EJ, Park WK, Kim HJ, Jeong D, Jung ME, Song KS, Lee SH, Seo HJ, Kim MJ, Lee M, Han HK, Son EJ, Pae AN, Kim J, Lee J",,617080.0,DTCT0023186,3228878,DTCC00629635,1407722,38109,7.1732774798310075,CC1=C(C=C(N1N2CCCCC2)C3=CC=CC=C3)C(=O)NCCCN4CCN(CC4)C5=C(C(=CC=C5)Cl)Cl,Cc1c(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc(-c2ccccc2)n1N1CCCCC1
211,CHEMBL1088314,P28223,,HUDVPJBZHXPMCT-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20149649.0,IC50,=,4.1,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 60 mins,,"Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,5.0,"Kang SY, Park EJ, Park WK, Kim HJ, Jeong D, Jung ME, Song KS, Lee SH, Seo HJ, Kim MJ, Lee M, Han HK, Son EJ, Pae AN, Kim J, Lee J",,617080.0,DTCT0023186,3228881,DTCC00629636,241607,38109,8.387216143280265,CC1=C(C=C(N1C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NCCCN4CCN(CC4)C5=C(C(=CC=C5)Cl)Cl,Cc1c(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc(-c2ccccc2)n1-c1ccc(F)cc1
212,CHEMBL1088874,P28223,,UNKSWQVJNKCXOO-JOCHJYFZSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20223662.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,Inhibition of 5HT2A (receptor),,Synthesis and biological evaluation of 3-aminopyrrolidine derivatives as CC chemokine receptor 2 antagonists.,Bioorg. Med. Chem. Lett.,2010.0,20.0,7.0,"Lim JW, Oh Y, Kim JH, Oak MH, Na Y, Lee JO, Lee SW, Cho H, Park WK, Choi G, Kang J",,624447.0,DTCT0023186,3301886,DTCC00636329,1633524,38320,5.0,C1CN(C[C@@H]1NC(=O)CNC(=O)C2=CC(=CC=C2)C(F)(F)F)CCC3CCN(CC3)C(=O)C4=CC=CC=C4Cl,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)N[C@@H]1CCN(CCC2CCN(C(=O)c3ccccc3Cl)CC2)C1
213,CHEMBL1089,P28223,PHENELZINE,RMUCZJUITONUFY-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7376347,DTCC00254379,1188072,46191,,C1=CC=C(C=C1)CCNN,NNCCc1ccccc1
216,CHEMBL1089793,P28223,,QIBDSCJTWMYQTC-OAQYLSRUSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20223662.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,Inhibition of 5HT2A (receptor),,Synthesis and biological evaluation of 3-aminopyrrolidine derivatives as CC chemokine receptor 2 antagonists.,Bioorg. Med. Chem. Lett.,2010.0,20.0,7.0,"Lim JW, Oh Y, Kim JH, Oak MH, Na Y, Lee JO, Lee SW, Cho H, Park WK, Choi G, Kang J",,624447.0,DTCT0023186,3301890,DTCC00636734,1984306,38320,5.0,C1CN(C[C@@H]1NC(=O)CNC(=O)C2=CC(=CC=C2)C(F)(F)F)CCN3CCN(CC3)C(=O)C4=C(C=CC(=C4)F)F,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)N[C@@H]1CCN(CCN2CCN(C(=O)c3cc(F)ccc3F)CC2)C1
217,CHEMBL1089881,P28223,,XSXFFJJDVGJPJE-JOCHJYFZSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20223662.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,Inhibition of 5HT2A (receptor),,Synthesis and biological evaluation of 3-aminopyrrolidine derivatives as CC chemokine receptor 2 antagonists.,Bioorg. Med. Chem. Lett.,2010.0,20.0,7.0,"Lim JW, Oh Y, Kim JH, Oak MH, Na Y, Lee JO, Lee SW, Cho H, Park WK, Choi G, Kang J",,624447.0,DTCT0023186,3301884,DTCC00636207,1918739,38320,5.0,C1CN(C[C@@H]1NC(=O)CNC(=O)C2=CC(=CC=C2)C(F)(F)F)CCC3CCN(CC3)C(=O)C4=CC=CC=C4F,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)N[C@@H]1CCN(CCC2CCN(C(=O)c3ccccc3F)CC2)C1
218,CHEMBL109,P28223,VALPROIC ACID,NIJJYAXOARWZEE-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7444074,DTCC00144879,413980,46191,,CCCC(CCC)C(=O)O,CCCC(CCC)C(=O)O
226,CHEMBL1092238,P28223,,HTXMSBSZASVVFP-OAQYLSRUSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20223662.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,Inhibition of 5HT2A (receptor),,Synthesis and biological evaluation of 3-aminopyrrolidine derivatives as CC chemokine receptor 2 antagonists.,Bioorg. Med. Chem. Lett.,2010.0,20.0,7.0,"Lim JW, Oh Y, Kim JH, Oak MH, Na Y, Lee JO, Lee SW, Cho H, Park WK, Choi G, Kang J",,624447.0,DTCT0023186,3301888,DTCC00636667,534245,38320,5.0,C1CN(C[C@@H]1NC(=O)CNC(=O)C2=CC(=CC=C2)C(F)(F)F)CCN3CCN(CC3)C(=O)C4=CC=CC=C4Cl,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)N[C@@H]1CCN(CCN2CCN(C(=O)c3ccccc3Cl)CC2)C1
227,CHEMBL1092921,P28223,,JOIKNLCNOLUIEO-JOCHJYFZSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20223662.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,Inhibition of 5HT2A (receptor),,Synthesis and biological evaluation of 3-aminopyrrolidine derivatives as CC chemokine receptor 2 antagonists.,Bioorg. Med. Chem. Lett.,2010.0,20.0,7.0,"Lim JW, Oh Y, Kim JH, Oak MH, Na Y, Lee JO, Lee SW, Cho H, Park WK, Choi G, Kang J",,624447.0,DTCT0023186,3301885,DTCC00636274,437759,38320,5.0,C1CN(C[C@@H]1NC(=O)CNC(=O)C2=CC(=CC=C2)C(F)(F)F)CCC3CCN(CC3)C(=O)C4=C(C=CC(=C4)F)F,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)N[C@@H]1CCN(CCC2CCN(C(=O)c3cc(F)ccc3F)CC2)C1
228,CHEMBL1092929,P28223,,MCEPAFGIBULHLP-XMMPIXPASA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20223662.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,Inhibition of 5HT2A (receptor),,Synthesis and biological evaluation of 3-aminopyrrolidine derivatives as CC chemokine receptor 2 antagonists.,Bioorg. Med. Chem. Lett.,2010.0,20.0,7.0,"Lim JW, Oh Y, Kim JH, Oak MH, Na Y, Lee JO, Lee SW, Cho H, Park WK, Choi G, Kang J",,624447.0,DTCT0023186,3301883,DTCC00636058,598690,38320,5.0,C1CN(C[C@@H]1NC(=O)CNC(=O)C2=CC(=CC=C2)C(F)(F)F)CCC3CCN(CC3)C(=O)C4=CC=CC=C4,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)N[C@@H]1CCN(CCC2CCN(C(=O)c3ccccc3)CC2)C1
229,CHEMBL1093469,P28223,,SLAGVDVFVOTFNB-HSZRJFAPSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20223662.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,Inhibition of 5HT2A (receptor),,Synthesis and biological evaluation of 3-aminopyrrolidine derivatives as CC chemokine receptor 2 antagonists.,Bioorg. Med. Chem. Lett.,2010.0,20.0,7.0,"Lim JW, Oh Y, Kim JH, Oak MH, Na Y, Lee JO, Lee SW, Cho H, Park WK, Choi G, Kang J",,624447.0,DTCT0023186,3301887,DTCC00636538,954045,38320,5.0,C1CN(C[C@@H]1NC(=O)CNC(=O)C2=CC(=CC=C2)C(F)(F)F)CCN3CCN(CC3)C(=O)C4=CC=CC=C4,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)N[C@@H]1CCN(CCN2CCN(C(=O)c3ccccc3)CC2)C1
236,CHEMBL1093802,P28223,,RMNQHMQKUFGTQZ-OAQYLSRUSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20223662.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,Inhibition of 5HT2A (receptor),,Synthesis and biological evaluation of 3-aminopyrrolidine derivatives as CC chemokine receptor 2 antagonists.,Bioorg. Med. Chem. Lett.,2010.0,20.0,7.0,"Lim JW, Oh Y, Kim JH, Oak MH, Na Y, Lee JO, Lee SW, Cho H, Park WK, Choi G, Kang J",,624447.0,DTCT0023186,3301889,DTCC00636733,1601190,38320,5.0,C1CN(C[C@@H]1NC(=O)CNC(=O)C2=CC(=CC=C2)C(F)(F)F)CCN3CCN(CC3)C(=O)C4=CC=CC=C4F,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)N[C@@H]1CCN(CCN2CCN(C(=O)c3ccccc3F)CC2)C1
238,CHEMBL1095699,P28223,AZASERINE,MZZGOOYMKKIOOX-VKHMYHEASA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7260998,DTCC00644151,1960073,46191,,C([C@@H](C(=O)O)N)OC(=O)C=[N+]=[N-],[N-]=[N+]=CC(=O)OC[C@H](N)C(=O)O
247,CHEMBL11,P28223,IMIPRAMINE,BCGWQEUPMDMJNV-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23919353.0,IC50,=,220.0,NM,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor (unknown origin) by radioligand binding assay,,Polypharmacology - foe or friend?,J. Med. Chem.,2013.0,56.0,22.0,,,1275659.0,DTCT0023186,12936386,DTCC00132703,57540,56376,6.657577319177793,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCCN1c2ccccc2CCc2ccccc21
248,CHEMBL1103,P28223,FURAZOLIDONE,PLHJDBGFXBMTGZ-WEVVVXLNSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7320661,DTCC00257236,1512809,46191,,C1COC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],O=C1OCCN1/N=C/c1ccc([N+](=O)[O-])o1
251,CHEMBL1105,P28223,6-METHOXY-2-NAPHTHYLACETIC ACID,PHJFLPMVEFKEPL-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7281076,DTCC00257334,1830683,46191,,COC1=CC2=C(C=C1)C=C(C=C2)CC(=O)O,COc1ccc2cc(CC(=O)O)ccc2c1
253,CHEMBL110691,P28223,CHLORMADINONE ACETATE,QMBJSIBWORFWQT-DFXBJWIESA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7355960,DTCC00283843,217574,46191,,CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C=C(C4=CC(=O)CC[C@]34C)Cl)C)OC(=O)C,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
255,CHEMBL1108,P28223,DROPERIDOL,RMEDXOLNCUSCGS-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,2.58,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7334507,DTCC00258432,542573,46191,8.588380294036769,C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F,O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1
257,CHEMBL1109,P28223,SULFAPHENAZOLE,QWCJHSGMANYXCW-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7474013,DTCC00258904,1544901,46191,,C1=CC=C(C=C1)N2C(=CC=N2)NS(=O)(=O)C3=CC=C(C=C3)N,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1
259,CHEMBL1110,P28223,ALOSETRON,JSWZEAMFRNKZNL-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7289869,DTCC00258915,1318437,46191,,CC1=C(N=CN1)CN2CCC3=C(C2=O)C4=CC=CC=C4N3C,Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O
274,CHEMBL1112,P28223,ARIPIPRAZOLE,CEUORZQYGODEFX-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,27173799.0,IC50,=,2790.0,NM,,,,,,,,,,,,,,Antagonistic activity at human 5-HT2A receptor assessed as calcium flux after 10 mins by FLIPR assay,,"Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.",Bioorg. Med. Chem. Lett.,2016.0,26.0,13.0,"Yang F, Jiang X, Li J, Wang Y, Liu Y, Bi M, Wu C, Zhao Q, Chen W, Yin J, Zhang J, Xie Y, Hu T, Xu M, Guo S, Wang Z, He Y, Shen J.",,1576959.0,DTCT0023186,259367,DTCC00106550,1563370,67092,5.554395796726403,C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1
286,CHEMBL1113,P28223,AMOXAPINE,QWGDMFLQWFTERH-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,1.55,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7284633,DTCC00260398,1059327,46191,8.809668301829708,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2
289,CHEMBL1117,P28223,IDARUBICIN,XDXDZDZNSLXDNA-TZNDIEGXSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7327919,DTCC00263156,153444,46191,,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O,CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O
291,CHEMBL111861,P28223,CORTISONE,LPYXTAPPNYMYOP-XDBTXSBWSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7361116,DTCC00283836,671786,46191,,C[C@]12CC[C@H](C=C1CC[C@@H]3[C@@H]2C(=O)C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C)O,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=C[C@H](O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO
293,CHEMBL112,P28223,ACETAMINOPHEN,RZVAJINKPMORJF-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7300506,DTCC00145865,1544892,46191,,CC(=O)NC1=CC=C(C=C1)O,CC(=O)Nc1ccc(O)cc1
295,CHEMBL1123,P28223,DICYCLOMINE,CURUTKGFNZGFSE-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,240.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7351011,DTCC00269590,1798408,46191,6.619788758288394,CCN(CC)CCOC(=O)C1(CCCCC1)C2CCCCC2,CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1
297,CHEMBL11262,P28223,,BMXRASUARGEUDH-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,15848.93,NM,,,,,,,,,,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,,Bioorg. Med. Chem. Lett.,1996.0,6.0,10.0,,,2462.0,DTCT0023186,1272178,DTCC00139296,1275525,1628,4.800000052738446,CCCN(CCC)CC1CC2=C(C=CC=C2OC)OC1,CCCN(CCC)CC1COc2cccc(OC)c2C1
298,CHEMBL113,P28223,CAFFEINE,RYYVLZVUVIJVGH-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7266247,DTCC00145890,51450,46191,,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,Cn1c(=O)c2c(ncn2C)n(C)c1=O
300,CHEMBL1130,P28223,DOXIFLURIDINE,ZWAOHEXOSAUJHY-ZIYNGMLESA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7317409,DTCC00272346,1124449,46191,,C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=C(C(=O)NC2=O)F)O)O,C[C@H]1O[C@@H](n2cc(F)c(=O)[nH]c2=O)[C@H](O)[C@@H]1O
302,CHEMBL113956,P28223,,NFBNIRNKYJTDIE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11585444.0,IC50,=,231.0,NM,,,,,,,,,,,,,,Inhibition of human 5-hydroxytryptamine 2A receptor,,From hit to lead. Analyzing structure-profile relationships.,J. Med. Chem.,2001.0,44.0,21.0,"Poulain R, Horvath D, Bonnet B, Eckhoff C, Chapelain B, Bodinier MC, Déprez B",,2270.0,DTCT0023186,1378129,DTCC00289226,1618321,16444,6.636388020107856,CCOC1=CC=C(C=C1)CCNC(=O)N2CCN(CC2)CCCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,CCOc1ccc(CCNC(=O)N2CCN(CCCC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1
303,CHEMBL114,P28223,SAQUINAVIR,QWAXKHKRTORLEM-UGJKXSETSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7475573,DTCC00146405,703985,46191,,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1
305,CHEMBL1140,P28223,NIACINAMIDE,DFPAKSUCGFBDDF-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7394691,DTCC00277524,800582,46191,,C1=CC(=CN=C1)C(=O)N,NC(=O)c1cccnc1
308,CHEMBL11409,P28223,,OKHZLUNVXJPWKS-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,11220.18,NM,,,,,,,,,,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,,Bioorg. Med. Chem. Lett.,1996.0,6.0,10.0,,,2462.0,DTCT0023186,1256938,DTCC00139261,1631586,1628,4.950000175844591,CCCN1CCN(CC12CC3=C(C=CC=C3OC)OC2)CCCCN4C(=O)CC5(CCCC5)CC4=O,CCCN1CCN(CCCCN2C(=O)CC3(CCCC3)CC2=O)CC12COc1cccc(OC)c1C2
309,CHEMBL11425,P28223,,ZXXWEZYYAYQNEN-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,56.23,NM,,,,,,,,,,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,,Bioorg. Med. Chem. Lett.,1996.0,6.0,10.0,,,2462.0,DTCT0023186,1253359,DTCC00139295,984523,1628,7.250031916490597,C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCNCC3CC4=CC=CC=C4OC3,O=C1CC2(CCCC2)CC(=O)N1CCCCNCC1COc2ccccc2C1
310,CHEMBL1144,P28223,PRAVASTATIN,TUZYXOIXSAXUGO-PZAWKZKUSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7379000,DTCC00280505,413976,46191,,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21
312,CHEMBL1148,P28223,TORSEMIDE,NGBFQHCMQULJNZ-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7459662,DTCC00281790,1830692,46191,,CC1=CC(=CC=C1)NC2=C(C=NC=C2)S(=O)(=O)NC(=O)NC(C)C,Cc1cccc(Nc2ccncc2S(=O)(=O)NC(=O)NC(C)C)c1
314,CHEMBL1149,P28223,LEVOCARNITINE,PHIQHXFUZVPYII-ZCFIWIBFSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7420997,DTCC00283052,51485,46191,,C[N+](C)(C)C[C@@H](CC(=O)[O-])O,C[N+](C)(C)C[C@H](O)CC(=O)[O-]
316,CHEMBL115,P28223,INDINAVIR,CBVCZFGXHXORBI-PXQQMZJSSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7426705,DTCC00146406,51478,46191,,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O
318,CHEMBL115249,P28223,,FOQLLAFYKYEUAL-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11585444.0,IC50,=,980.0,NM,,,,,,,,,,,,,,Inhibition of human 5-hydroxytryptamine 2A receptor,,From hit to lead. Analyzing structure-profile relationships.,J. Med. Chem.,2001.0,44.0,21.0,"Poulain R, Horvath D, Bonnet B, Eckhoff C, Chapelain B, Bodinier MC, Déprez B",,2270.0,DTCT0023186,1365282,DTCC00289261,357097,16444,6.008773924307505,CCOC1=CC=C(C=C1)CCOC(=O)N2CCN(CC2)CCCC3=CC=CC=C3,CCOc1ccc(CCOC(=O)N2CCN(CCCc3ccccc3)CC2)cc1
319,CHEMBL115769,P28223,RWJ-68354,ADQZGIYHFQQPRB-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7466721,DTCC01742367,2057653,46191,,COC1=CC(=NC2=C1C(=C(N2)C3=CC=C(C=C3)F)C4=CC=NC=C4)N,COc1cc(N)nc2[nH]c(-c3ccc(F)cc3)c(-c3ccncc3)c12
321,CHEMBL11592,P28223,,DLLULNTXJPATBC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,1000.0,NM,,,,,,,,,,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,,Bioorg. Med. Chem. Lett.,1996.0,6.0,10.0,,,2462.0,DTCT0023186,1283499,DTCC00139403,952186,1628,6.0,CCCN(CCCCN1C(=O)CC2(CCCC2)CC1=O)C3CC4=C(C=CC=C4OC)OC3,CCCN(CCCCN1C(=O)CC2(CCCC2)CC1=O)C1COc2cccc(OC)c2C1
322,CHEMBL1159650,P28223,CLOBETASOL PROPIONATE,CBGUOGMQLZIXBE-XGQKBEPLSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7354297,DTCC00648029,703979,46191,,CCC(=O)O[C@@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)C)C(=O)CCl,CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
324,CHEMBL116,P28223,AMPRENAVIR,YMARZQAQMVYCKC-OEMFJLHTSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7298380,DTCC00146541,833155,46191,,CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)O)S(=O)(=O)C3=CC=C(C=C3)N,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1
326,CHEMBL1162,P28223,NORETHINDRONE,VIKNJXKGJWUCNN-XGXHKTLJSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7384271,DTCC00288264,510305,46191,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C
330,CHEMBL116463,P28223,,GALCSZPFCCZIBC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11585444.0,IC50,=,683.0,NM,,,,,,,,,,,,,,Inhibition of human 5-hydroxytryptamine 2A receptor,,From hit to lead. Analyzing structure-profile relationships.,J. Med. Chem.,2001.0,44.0,21.0,"Poulain R, Horvath D, Bonnet B, Eckhoff C, Chapelain B, Bodinier MC, Déprez B",,2270.0,DTCT0023186,1367735,DTCC00289654,162133,16444,6.165579296318468,C1CN(CCC1NC(=O)OCCC2=CC=C(C=C2)C#N)CCCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,N#Cc1ccc(CCOC(=O)NC2CCN(CCCC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1
331,CHEMBL1167,P28223,SPECTINOMYCIN,UNFWWIHTNXNPBV-WXKVUWSESA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7484430,DTCC00289197,249944,46191,,C[C@@H]1CC(=O)[C@]2([C@@H](O1)O[C@@H]3[C@H]([C@@H]([C@@H]([C@@H]([C@H]3O2)NC)O)NC)O)O,CN[C@H]1[C@@H](O)[C@@H](NC)[C@H](O)[C@H]2O[C@@H]3O[C@H](C)CC(=O)[C@]3(O)O[C@H]12
333,CHEMBL116735,P28223,,MUAYITOFLINYIL-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11585444.0,IC50,=,1030.0,NM,,,,,,,,,,,,,,Inhibition of human 5-hydroxytryptamine 2A receptor,,From hit to lead. Analyzing structure-profile relationships.,J. Med. Chem.,2001.0,44.0,21.0,"Poulain R, Horvath D, Bonnet B, Eckhoff C, Chapelain B, Bodinier MC, Déprez B",,2270.0,DTCT0023186,1367713,DTCC00289305,162134,16444,5.987162775294828,C1CN(CCN1CCCC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C(=O)CCC4=CC=C(C=C4)F,O=C(CCc1ccc(F)cc1)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
334,CHEMBL1168,P28223,RAMIPRIL,HDACQVRGBOVJII-JBDAPHQKSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7485694,DTCC00289284,1765979,46191,,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@H]3CCC[C@H]3C[C@H]2C(=O)O,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21
336,CHEMBL1169,P28223,AMINOSALICYLIC ACID,WUBBRNOQWQTFEX-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7291308,DTCC00290367,671785,46191,,C1=CC(=C(C=C1N)O)C(=O)O,Nc1ccc(C(=O)O)c(O)c1
341,CHEMBL1172,P28223,DESLORATADINE,JAUOIFJMECXRGI-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,33.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7361424,DTCC00291020,1674143,46191,7.481486060122113,C1CC2=C(C=CC(=C2)Cl)C(=C3CCNCC3)C4=C1C=CC=N4,Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1
367,CHEMBL117405,P28223,S(-)-PINDOLOL,JZQKKSLKJUAGIC-NSHDSACASA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7289116,DTCC01742455,1992798,46191,,CC(C)NC[C@@H](COC1=CC=CC2=C1C=CN2)O,CC(C)NC[C@H](O)COc1cccc2[nH]ccc12
371,CHEMBL117537,P28223,,VGBOISIRCIDEGP-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11585444.0,IC50,=,950.0,NM,,,,,,,,,,,,,,Inhibition of human 5-hydroxytryptamine 2A receptor,,From hit to lead. Analyzing structure-profile relationships.,J. Med. Chem.,2001.0,44.0,21.0,"Poulain R, Horvath D, Bonnet B, Eckhoff C, Chapelain B, Bodinier MC, Déprez B",,2270.0,DTCT0023186,1386916,DTCC00289224,1585624,16444,6.022276394711152,C1CN(CCN1CCCC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C(=O)CCCC4=CC=CC=C4,O=C(CCCc1ccccc1)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
372,CHEMBL1177,P28223,PEMOLINE,NRNCYVBFPDDJNE-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7393410,DTCC00292515,1576126,46191,,C1=CC=C(C=C1)C2C(=O)N=C(O2)N,NC1=NC(=O)C(c2ccccc2)O1
376,CHEMBL118,P28223,CELECOXIB,RZEKVGVHFLEQIL-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7355852,DTCC01738574,51454,46191,,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1
389,CHEMBL1191,P28223,SULFAMETHIZOLE,VACCAVUAMIDAGB-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7460869,DTCC00301538,1577010,46191,,CC1=NN=C(S1)NS(=O)(=O)C2=CC=C(C=C2)N,Cc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1
395,CHEMBL119385,P28223,VX-745,VEPKQEUBKLEPRA-UHFFFAOYSA-N,2,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7447772,DTCC00293200,1092352,46191,,C1=CC(=C(C(=C1)Cl)C2=C3C=CC(=NN3C=NC2=O)SC4=C(C=C(C=C4)F)F)Cl,O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl
398,CHEMBL1194,P28223,PRILOCAINE,MVFGUOIZUNYYSO-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7404936,DTCC00305352,898295,46191,,CCCNC(C)C(=O)NC1=CC=CC=C1C,CCCNC(C)C(=O)Nc1ccccc1C
400,CHEMBL119443,P28223,ERGONOVINE,WVVSZNPYNCNODU-XTQGRXLLSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,2.21,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7328323,DTCC00295305,1798410,46191,8.655607726314889,C[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C,C[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1
402,CHEMBL1196,P28223,PROPARACAINE,KCLANYCVBBTKTO-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7394403,DTCC00305570,1927021,46191,,CCCOC1=C(C=C(C=C1)C(=O)OCCN(CC)CC)N,CCCOc1ccc(C(=O)OCCN(CC)CC)cc1N
405,CHEMBL1198,P28223,PRAMOXINE,DQKXQSGTHWVTAD-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7374706,DTCC00305773,1674146,46191,,CCCCOC1=CC=C(C=C1)OCCCN2CCOCC2,CCCCOc1ccc(OCCCN2CCOCC2)cc1
408,CHEMBL12,P28223,DIAZEPAM,AAOVKJBEBIDNHE-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7365881,DTCC00132806,51463,46191,,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21
411,CHEMBL1200391,P28223,TROMETHAMINE,LENZDBCJOHFCAS-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7451945,DTCC00678381,1092351,46191,,C(C(CO)(CO)N)O,NC(CO)(CO)CO
413,CHEMBL1200396,P28223,BUPIVACAINE HYDROCHLORIDE,SIEYLFHKZGLBNX-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7260310,DTCC00678386,1155677,46191,,CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C.Cl,CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
415,CHEMBL1200406,P28223,DIMENHYDRINATE,NFLLKCVHYJRNRH-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,693.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7368390,DTCC00678394,736259,46191,6.159266765388193,CN1C2=C(C(=O)N(C1=O)C)NC(=N2)Cl.CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,CN(C)CCOC(c1ccccc1)c1ccccc1
421,CHEMBL1200545,P28223,DIFLORASONE DIACETATE,BOBLHFUVNSFZPJ-JOYXJVLSSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7368318,DTCC00678506,1734055,46191,,C[C@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COC(=O)C)OC(=O)C)C)O)F)C)F,CC(=O)OCC(=O)[C@@]1(OC(C)=O)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
423,CHEMBL1200558,P28223,BACITRACIN,CLKOFPXJLQSYAH-ABRJDSQDSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7258210,DTCC00678469,1734054,46191,,CC[C@H](C)[C@H]1C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)NCCCC[C@@H](C(=O)N[C@@H](C(=O)N1)CCCN)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CSC(=N2)[C@H]([C@@H](C)CC)N)CC(=O)N)CC(=O)O)CC3=CN=CN3)CC4=CC=CC=C4,CC[C@H](C)[C@H](N)C1=N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H]2CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)[C@@H](Cc3ccccc3)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCCN)NC2=O)[C@@H](C)CC)CS1
425,CHEMBL1200559,P28223,LACTIC ACID,JVTAAEKCZFNVCJ-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7437807,DTCC00678516,1124450,46191,,CC(C(=O)O)O,CC(O)C(=O)O
427,CHEMBL1200585,P28223,OXYMETHOLONE,ICMWWNHDUZJFDW-DHODBPELSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7380317,DTCC00678533,1577006,46191,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(C/C(=C/O)/C(=O)C4)C,C[C@]12C/C(=C/O)C(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O
429,CHEMBL1200600,P28223,FLUOROMETHOLONE,FAOZLTXFLGPHNG-KNAQIMQKSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7318349,DTCC00678548,1027053,46191,,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@]2([C@@]4(C1=CC(=O)C=C4)C)F)O)C)(C(=O)C)O,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
431,CHEMBL1200604,P28223,TROPICAMIDE,BGDKAVGWHJFAGW-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7453681,DTCC00678551,1416038,46191,,CCN(CC1=CC=NC=C1)C(=O)C(CO)C2=CC=CC=C2,CCN(Cc1ccncc1)C(=O)C(CO)c1ccccc1
433,CHEMBL1200623,P28223,ETHYLESTRENOL,AOXRBFRFYPMWLR-XGXHKTLJSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7319968,DTCC00678568,1544897,46191,,CC[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CCCC[C@H]34)C)O,CC[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3CC[C@@]21C
435,CHEMBL1200624,P28223,ETHYNODIOL DIACETATE,ONKUMRGIYFNPJW-KIEAKMPYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7324220,DTCC00678569,88628,46191,,CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@]4([C@H]([C@@H]3CCC2=C1)CC[C@]4(C#C)OC(=O)C)C,C#C[C@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=C[C@@H](OC(C)=O)CC[C@@H]4[C@H]3CC[C@@]21C
437,CHEMBL1200629,P28223,VECURONIUM BROMIDE,VEPSYABRBFXYIB-PWXDFCLTSA-M,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7450327,DTCC00678574,703989,46191,,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1N4CCCCC4)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C.[Br-],CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CCCCC1
439,CHEMBL1200633,P28223,IVERMECTIN,SPBDXSGPUHCETR-JFUDTMANSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7418392,DTCC00678578,606970,46191,,CC[C@H](C)[C@@H]1[C@H](CC[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)C.C[C@H]1CC[C@]2(C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)O[C@@H]1C(C)C,CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2
441,CHEMBL1200656,P28223,NATAMYCIN,NCXMLFZGDNKEPB-FFPOYIOWSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7385131,DTCC00678594,1351116,46191,,C[C@@H]1C/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@@H]3[C@H](O3)/C=C/C(=O)O1)O)O)O)C(=O)O)O[C@H]4[C@H]([C@H]([C@@H]([C@H](O4)C)O)N)O,C[C@@H]1C/C=C/C=C/C=C/C=C/[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](N)[C@@H]2O)C[C@@H]2O[C@](O)(C[C@@H](O)C[C@H]3O[C@@H]3/C=C/C(=O)O1)C[C@H](O)[C@H]2C(=O)O
443,CHEMBL1200679,P28223,ZINC CHLORIDE,JIAARYAFYJHUJI-UHFFFAOYSA-L,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7450680,DTCC00678612,315674,46191,,[Cl-].[Cl-].[Zn+2],[Zn+2]
447,CHEMBL1200709,P28223,CROTAMITON,DNTGGZPQPQTDQF-XBXARRHUSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7346078,DTCC00678636,1188066,46191,,CCN(C1=CC=CC=C1C)C(=O)/C=C/C,C/C=C/C(=O)N(CC)c1ccccc1C
449,CHEMBL1200748,P28223,CARBIDOPA,QTAOMKOIBXZKND-PPHPATTJSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7479808,DTCC00678662,606973,46191,,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)NN.O,C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O
451,CHEMBL1200845,P28223,HALCINONIDE,MUQNGPZZQDCDFT-JNQJZLCISA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7334001,DTCC00678745,1765972,46191,,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@]2([C@H](C[C@]4([C@H]3C[C@@H]5[C@]4(OC(O5)(C)C)C(=O)CCl)C)O)F,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CCl)O1
453,CHEMBL1200862,P28223,METYROSINE,NHTGHBARYWONDQ-JTQLQIEISA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7434687,DTCC00678758,88631,46191,,C[C@](CC1=CC=C(C=C1)O)(C(=O)O)N,C[C@](N)(Cc1ccc(O)cc1)C(=O)O
455,CHEMBL1200993,P28223,GALLAMINE TRIETHIODIDE,REEUVFCVXKWOFE-UHFFFAOYSA-K,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7307972,DTCC00678870,381013,46191,,CC[N+](CC)(CC)CCOC1=C(C(=CC=C1)OCC[N+](CC)(CC)CC)OCC[N+](CC)(CC)CC.[I-].[I-].[I-],CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC
459,CHEMBL1201010,P28223,FLUDROCORTISONE ACETATE,SYWHXTATXSMDSB-GSLJADNHSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7318256,DTCC00678884,381011,46191,,CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)CC[C@@]43C)F)O)C)O,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
461,CHEMBL1201012,P28223,FLURANDRENOLIDE,POPFMWWJOGLOIF-XWCQMRHXSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7333390,DTCC00678886,381012,46191,,C[C@]12CCC(=O)C=C1[C@H](C[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3C[C@@H]5[C@]4(OC(O5)(C)C)C(=O)CO)C)O)F,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
463,CHEMBL1201024,P28223,METHSCOPOLAMINE BROMIDE,CXYRUNPLKGGUJF-XKTSLVMZSA-M,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7413110,DTCC00678896,1059334,46191,,C[N+]1([C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C.[Br-],C[N+]1(C)[C@H]2CC(OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@H]1O[C@@H]21
466,CHEMBL1201117,P28223,METHOCARBAMOL,GNXFOGHNGIVQEH-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7434453,DTCC00678968,800581,46191,,COC1=CC=CC=C1OCC(COC(=O)N)O,COc1ccccc1OCC(O)COC(N)=O
468,CHEMBL1201139,P28223,MEGESTROL ACETATE,RQZAXGRLVPAYTJ-GQFGMJRRSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7414947,DTCC00678986,639582,46191,,CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
470,CHEMBL1201146,P28223,NORETHINDRONE ACETATE,IMONTRJLAWHYGT-ZCPXKWAGSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7388628,DTCC00678989,703984,46191,,CC(=O)O[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@H]34)C)C#C,C#C[C@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C
472,CHEMBL1201151,P28223,MESTRANOL,IMSSROKUHAOUJS-MJCUULBUSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7413026,DTCC00678994,542579,46191,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)OC,C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(OC)ccc4[C@H]3CC[C@@]21C
474,CHEMBL1201193,P28223,LEVOBUPIVACAINE,LEBVLXFERQHONN-INIZCTEOSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7416714,DTCC00679027,282998,46191,,CCCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C,CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C
476,CHEMBL1201195,P28223,CEFMETAZOLE,SNBUBQHDYVFSQF-HIFRSBDPSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7347259,DTCC00679029,833158,46191,,CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)CSCC#N)OC)SC2)C(=O)O,CO[C@@]1(NC(=O)CSCC#N)C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)CS[C@@H]21
478,CHEMBL1201203,P28223,BENZTROPINE,GIJXKZJWITVLHI-PMOLBWCYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,24.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7278424,DTCC00679037,1609543,46191,7.619788758288394,CN1[C@@H]2CC[C@H]1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4,CN1[C@H]2CC[C@@H]1CC(OC(c1ccccc1)c1ccccc1)C2
480,CHEMBL1201207,P28223,BETAMETHASONE PHOSPHORIC ACID,VQODGRNSFPNSQE-DVTGEIKXSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7280159,DTCC00679040,444634,46191,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COP(=O)(O)O)O)C)O)F)C,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)(O)O
482,CHEMBL1201216,P28223,DAPIPRAZOLE,RFWZESUMWJKKRN-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,606.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7344248,DTCC00679045,1544895,46191,6.217527375833714,CC1=CC=CC=C1N2CCN(CC2)CCC3=NN=C4N3CCCC4,Cc1ccccc1N1CCN(CCc2nnc3n2CCCC3)CC1
484,CHEMBL1201220,P28223,DIATRIZOIC ACID,YVPYQUNUQOZFHG-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7361528,DTCC00679049,444639,46191,,CC(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)NC(=O)C)I,CC(=O)Nc1c(I)c(NC(C)=O)c(I)c(C(=O)O)c1I
486,CHEMBL1201237,P28223,LEVOBUNOLOL,IXHBTMCLRNMKHZ-LBPRGKRZSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7412350,DTCC00679063,736261,46191,,CC(C)(C)NC[C@@H](COC1=CC=CC2=C1CCCC2=O)O,CC(C)(C)NC[C@H](O)COc1cccc2c1CCCC2=O
488,CHEMBL1201346,P28223,BALSALAZID,IPOKCKJONYRRHP-FMQUCBEESA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7264070,DTCC00679132,1512805,46191,,C1=CC(=CC=C1C(=O)NCCC(=O)O)N=NC2=CC(=C(C=C2)O)C(=O)O,O=C(O)CCNC(=O)c1ccc(N=Nc2ccc(O)c(C(=O)O)c2)cc1
490,CHEMBL1201353,P28223,DEXCHLORPHENIRAMINE,SOYKEARSMXGVTM-HNNXBMFYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,3692.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7340047,DTCC00679137,185552,46191,5.432738307646126,CN(C)CC[C@@H](C1=CC=C(C=C1)Cl)C2=CC=CC=N2,CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1
493,CHEMBL1201356,P28223,METHYLERGONOVINE,UNBRKDKAWYKMIV-QWQRMKEZSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,2.55,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7430320,DTCC00679140,1124451,46191,8.593459819566045,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C,CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1
507,CHEMBL1208572,P28223,SALINOMYCIN,KQXDHUJYNAXLNZ-XQSDOZFQSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7466849,DTCC00685596,1641853,46191,,CC[C@H]([C@H]1CC[C@@H]([C@@H](O1)[C@@H](C)[C@@H]([C@H](C)C(=O)[C@H](CC)[C@@H]2[C@H](C[C@H]([C@]3(O2)C=C[C@H]([C@@]4(O3)CC[C@@](O4)(C)[C@H]5CC[C@@]([C@@H](O5)C)(CC)O)O)C)C)O)C)C(=O)O,CC[C@@H](C(=O)[C@@H](C)[C@@H](O)[C@H](C)[C@@H]1O[C@@H]([C@@H](CC)C(=O)O)CC[C@@H]1C)[C@H]1O[C@]2(C=C[C@@H](O)[C@]3(CC[C@@](C)([C@H]4CC[C@](O)(CC)[C@H](C)O4)O3)O2)[C@H](C)C[C@@H]1C
509,CHEMBL12089,P28223,BERBERINE CHLORIDE,VKJGBAJNNALVAV-UHFFFAOYSA-M,1,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7261339,DTCC00140102,1416025,46191,,COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OC.[Cl-],COc1ccc2cc3[n+](cc2c1OC)CCc1cc2c(cc1-3)OCO2
513,CHEMBL121,P28223,ROSIGLITAZONE,YASAKCUCGLMORW-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7483954,DTCC00148715,51506,46191,,CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1
515,CHEMBL1210154,P28223,,CQUWKHKELQQYRI-KGENOOAVSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20591666.0,IC50,>,10000.0,NM,,cell_based,,,,,,,,,,,HEK293,Displacement of [3H]Ketanserin from human recombinant 5HT2A receptor expressed in HEK293 cells,,A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase.,Bioorg. Med. Chem. Lett.,2010.0,20.0,15.0,"Gattinoni S, Simone CD, Dallavalle S, Fezza F, Nannei R, Battista N, Minetti P, Quattrociocchi G, Caprioli A, Borsini F, Cabri W, Penco S, Merlini L, Maccarrone M",,643634.0,DTCT0023186,3413130,DTCC00686944,241890,39814,5.0,C/C(=N\OC(=O)NC1=CC=CC=C1)/C2=CC=CC(=C2)C3=CC=CS3,C/C(=N\OC(=O)Nc1ccccc1)c1cccc(-c2cccs2)c1
516,CHEMBL1212957,P28223,,IFDGOHXTIYJDMW-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,209.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435515,DTCC00689126,1568908,40090,6.679853713888946,CC1=C(C=C(N1C)C2=CN=CC=C2)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Cc1c(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc(-c2cccnc2)n1C
517,CHEMBL12131,P28223,CLOSANTEL,JMPFSEBWVLAJKM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7354475,DTCC00140760,1674142,46191,,CC1=CC(=C(C=C1NC(=O)C2=C(C(=CC(=C2)I)I)O)Cl)C(C#N)C3=CC=C(C=C3)Cl,Cc1cc(C(C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O
519,CHEMBL1213673,P28223,,VICDGQQXZAXNJE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,107.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435536,DTCC00688349,112822,40090,6.97061622231479,CC1=C(C=C(N1)C(C)(C)C)C(=O)NCCCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl.Cl,Cc1[nH]c(C(C)(C)C)cc1C(=O)NCCCN1CCN(c2cccc(Cl)c2Cl)CC1
520,CHEMBL1213674,P28223,,XXOSGQBANRFRIF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,163.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435539,DTCC00688350,1375607,40090,6.787812395596042,CC1=C(C=C(N1C)C(C)(C)C)C(=O)NCCCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl,Cc1c(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc(C(C)(C)C)n1C
521,CHEMBL1213675,P28223,,GOUAXPYSARUMIM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,152.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435554,DTCC00688351,209572,40090,6.818156412055227,CC1=C(C=CC=C1Cl)N2CCN(CC2)CCNC(=O)C3=C(N(C(=C3)C4=CC=CC=C4)C)C,Cc1c(Cl)cccc1N1CCN(CCNC(=O)c2cc(-c3ccccc3)n(C)c2C)CC1
522,CHEMBL1213676,P28223,,IHYPNNNWGXNBMX-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,233.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435555,DTCC00688352,1822624,40090,6.632644078973981,CC1=C(C=CC=C1Cl)N2CCN(CC2)CCNC(=O)C3=C(N(C(=C3)C(C)(C)C)C)C,Cc1c(Cl)cccc1N1CCN(CCNC(=O)c2cc(C(C)(C)C)n(C)c2C)CC1
523,CHEMBL1213856,P28223,,PDPOBDGYEBMUHX-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,213.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435388,DTCC00688506,1822626,40090,6.671620396561262,CC1=C(C=C(N1C)C2=CC=CC=C2)C(=O)NCCCN3CCN(CC3)C4=C(C=C(C=C4)Cl)Cl,Cc1c(C(=O)NCCCN2CCN(c3ccc(Cl)cc3Cl)CC2)cc(-c2ccccc2)n1C
524,CHEMBL1213931,P28223,,MCHASZRLOYWYKB-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,221.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435391,DTCC00688571,1790133,40090,6.655607726314889,CC1=C(C=C(N1C)C2=CC=CC=C2)C(=O)NCCCN3CCN(CC3)C4=CC=CC=C4Br,Cc1c(C(=O)NCCCN2CCN(c3ccccc3Br)CC2)cc(-c2ccccc2)n1C
525,CHEMBL1213932,P28223,,CZXBPXYQHYAPBF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,666.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435394,DTCC00688572,1918967,40090,6.176525770829699,CC1=C(C=C(N1C)C2=CC=CC=C2)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)OC)OC,COc1cccc(N2CCN(CCCNC(=O)c3cc(-c4ccccc4)n(C)c3C)CC2)c1OC
526,CHEMBL1213933,P28223,,JIUFRGXCNZAJEV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,22.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435397,DTCC00688573,1757864,40090,7.657577319177793,CC1=C(C=C(N1C)C2=CC=CC=C2)C(=O)NCCCN3CCN(CC3)C4=CC=C(C=C4)F,Cc1c(C(=O)NCCCN2CCN(c3ccc(F)cc3)CC2)cc(-c2ccccc2)n1C
527,CHEMBL1213934,P28223,,HSGTXFOSGPTDRB-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,352.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435400,DTCC00688574,307621,40090,6.453457336521869,CC1=C(C=C(N1C)C2=CC=CC=C2)C(=O)NCCCN3CCN(CC3)C4=CC=CC5=C4N=CC=C5,Cc1c(C(=O)NCCCN2CCN(c3cccc4cccnc34)CC2)cc(-c2ccccc2)n1C
528,CHEMBL1213985,P28223,,GYTRINPMPBZDFP-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,832.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435403,DTCC00688624,631468,40090,6.079876673709276,CC1=NC2=C(C=CC=C2N3CCN(CC3)CCCNC(=O)C4=C(N(C(=C4)C5=CC=CC=C5)C)C)C=C1,Cc1ccc2cccc(N3CCN(CCCNC(=O)c4cc(-c5ccccc5)n(C)c4C)CC3)c2n1
529,CHEMBL1214045,P28223,,UZOQQWLFKZUEAL-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,54.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435418,DTCC00688684,1504652,40090,7.267606240177032,CCCN1C(=C(C=C1C2=CC=CC=C2)C(=O)NCCCN3CCN(CC3)C4=CC(=C(C=C4)Cl)Cl)C.Cl,CCCn1c(-c2ccccc2)cc(C(=O)NCCCN2CCN(c3ccc(Cl)c(Cl)c3)CC2)c1C
530,CHEMBL1214046,P28223,,WEARRJZMFZNKLA-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,221.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435421,DTCC00688685,274775,40090,6.655607726314889,CCCN1C(=C(C=C1C2=CC=CC=C2)C(=O)NCCCN3CCN(CC3)C4=CC(=CC=C4)Br)C,CCCn1c(-c2ccccc2)cc(C(=O)NCCCN2CCN(c3cccc(Br)c3)CC2)c1C
531,CHEMBL1214047,P28223,,LXGOBFZKOTZTKI-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,953.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435424,DTCC00688686,534468,40090,6.020907099361674,CCCN1C(=C(C=C1C2=CC=CC=C2)C(=O)NCCCN3CCN(CC3)C4=CC=CC=C4OC)C,CCCn1c(-c2ccccc2)cc(C(=O)NCCCN2CCN(c3ccccc3OC)CC2)c1C
532,CHEMBL1214113,P28223,,ZGUZODALWPITEN-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,153.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435427,DTCC00688747,1698078,40090,6.815308569182402,CCCN1C(=C(C=C1C2=CC=CC=C2)C(=O)NCCCN3CCN(CC3)C4=CC(=CC=C4)OC)C,CCCn1c(-c2ccccc2)cc(C(=O)NCCCN2CCN(c3cccc(OC)c3)CC2)c1C
533,CHEMBL1214114,P28223,,YDUDKJGTXYBWJM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,874.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435430,DTCC00688748,1568903,40090,6.058488567365597,CCCN1C(=C(C=C1C2=CC=CC=C2)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)OC)OC)C,CCCn1c(-c2ccccc2)cc(C(=O)NCCCN2CCN(c3cccc(OC)c3OC)CC2)c1C
534,CHEMBL1214115,P28223,,GLNYEIITSMNOCW-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,135.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435433,DTCC00688749,2081810,40090,6.8696662315049934,CCCN1C(=C(C=C1C2=CC=CC=C2)C(=O)NCCCN3CCN(CC3)C4=C(C=CC(=C4)F)F)C,CCCn1c(-c2ccccc2)cc(C(=O)NCCCN2CCN(c3cc(F)ccc3F)CC2)c1C
535,CHEMBL1214116,P28223,,ASOVUEAYNUYTLF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,410.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435436,DTCC00688750,80636,40090,6.3872161432802645,CCCN1C(=C(C=C1C2=CC=CC=C2)C(=O)NCCCN3CCN(CC3)C4=CC=CC(=C4)C(F)(F)F)C.Cl,CCCn1c(-c2ccccc2)cc(C(=O)NCCCN2CCN(c3cccc(C(F)(F)F)c3)CC2)c1C
536,CHEMBL1214175,P28223,,WYBQEAZJHLUAGT-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,210.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435439,DTCC00688802,274778,40090,6.6777807052660805,CCCN1C(=C(C=C1C2=CC=CC=C2)C(=O)NCCCN3CCN(CC3)C4=CC=CC5=C4N=CC=C5)C,CCCn1c(-c2ccccc2)cc(C(=O)NCCCN2CCN(c3cccc4cccnc34)CC2)c1C
537,CHEMBL1214176,P28223,,IEWFOUIWCVNBEV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,17.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435442,DTCC00688803,1212114,40090,7.769551078621726,CCCN1C(=C(C=C1C2=CC=CC=C2)C(=O)N(C)CCCN3CCN(CC3)C4=CC=CC(=C4C)C)C,CCCn1c(-c2ccccc2)cc(C(=O)N(C)CCCN2CCN(c3cccc(C)c3C)CC2)c1C
538,CHEMBL1214177,P28223,,XEIRMWXVTBJAKS-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,39.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435445,DTCC00688804,921985,40090,7.4089353929735005,CC1=C(C=C(N1C)C2=CC=CC=C2)C(=O)N(C)CCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Cc1c(C(=O)N(C)CCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc(-c2ccccc2)n1C
539,CHEMBL1214178,P28223,,PRTPKXGHEAWNMM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,33.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435448,DTCC00688805,1790137,40090,7.481486060122113,CCCN1C(=C(C=C1C2=CC=CC=C2)C(=O)N(C)CCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl)C.Cl,CCCn1c(-c2ccccc2)cc(C(=O)N(C)CCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1C
540,CHEMBL1214185,P28223,ROXITHROMYCIN,RXZBMPWDPOLZGW-XMRMVWPWSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7462329,DTCC00688811,2057652,46191,,CC[C@@H]1[C@@]([C@@H]([C@H](/C(=N/OCOCCOC)/[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)/C(=N\OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
542,CHEMBL1214302,P28223,,JSWAKFCFHYGXHP-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,37.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435463,DTCC00688907,1408009,40090,7.431798275933005,CC1=C(NC(=C1C(=O)NCCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl)C)C4=CC=CC=C4.Cl,Cc1[nH]c(-c2ccccc2)c(C)c1C(=O)NCCN1CCN(c2cccc(Cl)c2Cl)CC1
543,CHEMBL1214303,P28223,,ZRSGNWBZNUVUML-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,33.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435466,DTCC00688908,437994,40090,7.481486060122113,CC1=C(N(C(=C1C(=O)NCCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl)C)C)C4=CC=CC=C4.Cl,Cc1c(C(=O)NCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n(C)c1-c1ccccc1
544,CHEMBL1214304,P28223,,ODUVRQPVBYEEGM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,25.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435469,DTCC00688909,2049663,40090,7.6020599913279625,CCCN1C(=C(C(=C1C2=CC=CC=C2)C)C(=O)NCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl)C.Cl,CCCn1c(C)c(C(=O)NCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)c1-c1ccccc1
545,CHEMBL1214305,P28223,,WNHZBINCGFACEQ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,39.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435472,DTCC00688910,437995,40090,7.4089353929735005,CC1=C(NC(=C1C(=O)NCCCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl)C)C4=CC=CC=C4.Cl,Cc1[nH]c(-c2ccccc2)c(C)c1C(=O)NCCCN1CCN(c2cccc(Cl)c2Cl)CC1
546,CHEMBL1214366,P28223,,XMJXEWWTSPGULA-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,92.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435482,DTCC00125881,307622,40090,7.036212172654444,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(NC(=C3)C4=CC=C(C=C4)Cl)C)C.Cl,Cc1cccc(N2CCN(CCCNC(=O)c3cc(-c4ccc(Cl)cc4)[nH]c3C)CC2)c1C
547,CHEMBL1214367,P28223,,BDSUDJVPVKTNFN-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,213.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435485,DTCC00125882,1698080,40090,6.671620396561262,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=C3)C4=CC=C(C=C4)Cl)C)C)C.Cl,Cc1cccc(N2CCN(CCCNC(=O)c3cc(-c4ccc(Cl)cc4)n(C)c3C)CC2)c1C
548,CHEMBL1214425,P28223,,GOKKWBKIGNJYKO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,151.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435488,DTCC00689012,112829,40090,6.82102305270683,CCN1C(=C(C=C1C2=CC=C(C=C2)Cl)C(=O)NCCCN3CCN(CC3)C4=CC=CC(=C4C)C)C.Cl,CCn1c(-c2ccc(Cl)cc2)cc(C(=O)NCCCN2CCN(c3cccc(C)c3C)CC2)c1C
549,CHEMBL1214426,P28223,,LMNFUDPLNOKROB-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,192.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435491,DTCC00689013,566748,40090,6.716698771296451,CCCN1C(=C(C=C1C2=CC=C(C=C2)Cl)C(=O)NCCCN3CCN(CC3)C4=CC=CC(=C4C)C)C.Cl,CCCn1c(-c2ccc(Cl)cc2)cc(C(=O)NCCCN2CCN(c3cccc(C)c3C)CC2)c1C
550,CHEMBL1214427,P28223,,XKJNEXXERPZSTJ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,105.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435494,DTCC00689014,1018936,40090,6.978810700930062,CC1=C(C=C(N1)C2=CC=C(C=C2)Cl)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl.Cl,Cc1[nH]c(-c2ccc(Cl)cc2)cc1C(=O)NCCCN1CCN(c2cccc(Cl)c2Cl)CC1
551,CHEMBL1214428,P28223,,CJPJTYFLNNQHDT-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,232.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435497,DTCC00689015,857934,40090,6.634512015109101,CC1=C(C=C(N1C)C2=CC=C(C=C2)Cl)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Cc1c(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc(-c2ccc(Cl)cc2)n1C
552,CHEMBL1214488,P28223,,HXWJMEWLVNOYQC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,153.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435500,DTCC00689075,177361,40090,6.815308569182402,CCN1C(=C(C=C1C2=CC=C(C=C2)Cl)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl)C.Cl,CCn1c(-c2ccc(Cl)cc2)cc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1C
553,CHEMBL1214489,P28223,,BVMQHMCUCAPEAK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,333.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435503,DTCC00689076,631480,40090,6.47755576649368,CCCN1C(=C(C=C1C2=CC=C(C=C2)Cl)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl)C.Cl,CCCn1c(-c2ccc(Cl)cc2)cc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1C
554,CHEMBL1214546,P28223,,ITUYJHFAFVQOOR-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,46.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435518,DTCC00689127,1633757,40090,7.337242168318426,CCCN1C(=C(C=C1C2=CN=CC=C2)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl)C,CCCn1c(-c2cccnc2)cc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1C
555,CHEMBL1214547,P28223,,XOMXTKDEJJEEOU-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,39.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435521,DTCC00689128,1375615,40090,7.4089353929735005,CC1=C(C=C(N1C)C2=CC=NC=C2)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Cc1c(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc(-c2ccncc2)n1C
556,CHEMBL1214594,P28223,,NWVMDLGDYVSADK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,34.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435524,DTCC00689170,1790142,40090,7.468521082957745,CCCN1C(=C(C=C1C2=CC=NC=C2)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl)C,CCCn1c(-c2ccncc2)cc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1C
557,CHEMBL1214595,P28223,,QOTNRKMRALTDAA-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,36.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435527,DTCC00689171,469730,40090,7.443697499232713,CC1=C(C(=CC=C1)N2CCN(CC2)CCNC(=O)C3=C(N(C(=C3)C(C)(C)C)C)C)C,Cc1cccc(N2CCN(CCNC(=O)c3cc(C(C)(C)C)n(C)c3C)CC2)c1C
558,CHEMBL1214596,P28223,,JIMTYJXUIMFECK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,386.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435530,DTCC00689172,241921,40090,6.413412695328245,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=C3)C(C)(C)C)C)C)C,Cc1cccc(N2CCN(CCCNC(=O)c3cc(C(C)(C)C)n(C)c3C)CC2)c1C
559,CHEMBL1214597,P28223,,PTHKODBAQNKPNK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,50.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435533,DTCC00689173,1790143,40090,7.301029995663981,CC1=C(C=C(N1C)C(C)(C)C)C(=O)NCCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl.Cl,Cc1c(C(=O)NCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc(C(C)(C)C)n1C
592,CHEMBL1219,P28223,RABEPRAZOLE,YREYEVIYCVEVJK-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7477162,DTCC00316485,574625,46191,,CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCCCOC,COCCCOc1ccnc(C[S+]([O-])c2nc3ccccc3[nH]2)c1C
594,CHEMBL122,P28223,ROFECOXIB,RZJQGNCSTQAWON-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7479690,DTCC00150159,1830689,46191,,CS(=O)(=O)C1=CC=C(C=C1)C2=C(C(=O)OC2)C3=CC=CC=C3,CS(=O)(=O)c1ccc(C2=C(c3ccccc3)C(=O)OC2)cc1
596,CHEMBL1220,P28223,TINIDAZOLE,HJLSLZFTEKNLFI-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7487604,DTCC00316820,1318449,46191,,CCS(=O)(=O)CCN1C(=NC=C1[N+](=O)[O-])C,CCS(=O)(=O)CCn1c([N+](=O)[O-])cnc1C
598,CHEMBL1221,P28223,SULCONAZOLE,AFNXATANNDIXLG-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,3929.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7465152,DTCC00317729,1830690,46191,5.405717971188194,C1=CC(=CC=C1CSC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl,Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1
600,CHEMBL1221449,P28223,,PLVZHOWVQHWPON-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20655748.0,IC50,=,88.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]ketanserin from human 5HT2A expressed in CHOKI cells,,Synthesis and SAR of (piperazin-1-yl-phenyl)-arylsulfonamides: a novel series of atypical antipsychotic agents.,Bioorg. Med. Chem. Lett.,2010.0,20.0,17.0,"Park CM, Kim SY, Park WK, Choi JH, Seong CM",,651487.0,DTCT0023186,3455872,DTCC00690528,145334,40330,7.055517327849832,CN1CCN(CC1)C2=CC(=CC=C2)N(CC3CC3)S(=O)(=O)C4=CC5=CC=CC=C5C=C4,CN1CCN(c2cccc(N(CC3CC3)S(=O)(=O)c3ccc4ccccc4c3)c2)CC1
601,CHEMBL1221452,P28223,,PVAHGORZNPASFQ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20655748.0,IC50,=,50.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]ketanserin from human 5HT2A expressed in CHOKI cells,,Synthesis and SAR of (piperazin-1-yl-phenyl)-arylsulfonamides: a novel series of atypical antipsychotic agents.,Bioorg. Med. Chem. Lett.,2010.0,20.0,17.0,"Park CM, Kim SY, Park WK, Choi JH, Seong CM",,651487.0,DTCT0023186,3455870,DTCC00690531,663623,40330,7.301029995663981,CN1CCN(CC1)C2=CC(=CC=C2)N(CC3=CC=CC=C3)S(=O)(=O)C4=CC5=CC=CC=C5C=C4,CN1CCN(c2cccc(N(Cc3ccccc3)S(=O)(=O)c3ccc4ccccc4c3)c2)CC1
602,CHEMBL1221497,P28223,,VAEXXTRBLCNPTN-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20655748.0,IC50,=,1616.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]ketanserin from human 5HT2A expressed in CHOKI cells,,Synthesis and SAR of (piperazin-1-yl-phenyl)-arylsulfonamides: a novel series of atypical antipsychotic agents.,Bioorg. Med. Chem. Lett.,2010.0,20.0,17.0,"Park CM, Kim SY, Park WK, Choi JH, Seong CM",,651487.0,DTCT0023186,3455891,DTCC00690551,1343043,40330,5.791558643561433,CN1CCN(CC1)C2=CC=CC(=C2)NS(=O)(=O)C3=CC4=CC=CC=C4C=C3,CN1CCN(c2cccc(NS(=O)(=O)c3ccc4ccccc4c3)c2)CC1
603,CHEMBL1221512,P28223,L-744832,PGOKBMWPBDRDGN-IBXSQZDTSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7418470,DTCC00031822,1927016,46191,,CC[C@H](C)[C@@H](CO[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCS(=O)(=O)C)C(=O)OC(C)C)NC[C@H](CS)N,CC[C@H](C)[C@@H](CO[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCS(C)(=O)=O)C(=O)OC(C)C)NC[C@@H](N)CS
605,CHEMBL1222134,P28223,,ZHKSBEBKWSIVCL-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20655748.0,IC50,=,118.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]ketanserin from human 5HT2A expressed in CHOKI cells,,Synthesis and SAR of (piperazin-1-yl-phenyl)-arylsulfonamides: a novel series of atypical antipsychotic agents.,Bioorg. Med. Chem. Lett.,2010.0,20.0,17.0,"Park CM, Kim SY, Park WK, Choi JH, Seong CM",,651487.0,DTCT0023186,3455874,DTCC00690989,890099,40330,6.928117992693875,CC(C)N(C1=CC=CC(=C1)N2CCN(CC2)C)S(=O)(=O)C3=CC4=CC=CC=C4C=C3,CC(C)N(c1cccc(N2CCN(C)CC2)c1)S(=O)(=O)c1ccc2ccccc2c1
606,CHEMBL1222138,P28223,,FUNLPOKPIPLUBX-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20655748.0,IC50,=,172.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]ketanserin from human 5HT2A expressed in CHOKI cells,,Synthesis and SAR of (piperazin-1-yl-phenyl)-arylsulfonamides: a novel series of atypical antipsychotic agents.,Bioorg. Med. Chem. Lett.,2010.0,20.0,17.0,"Park CM, Kim SY, Park WK, Choi JH, Seong CM",,651487.0,DTCT0023186,3455876,DTCC00690993,1408051,40330,6.764471553092451,CC(C)N(C1=CC=CC(=C1)N2CCN(CC2)C)S(=O)(=O)C3=CC=CC=C3,CC(C)N(c1cccc(N2CCN(C)CC2)c1)S(=O)(=O)c1ccccc1
607,CHEMBL1222234,P28223,,VJSKWISJKOVRKJ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20655748.0,IC50,=,122.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]ketanserin from human 5HT2A expressed in CHOKI cells,,Synthesis and SAR of (piperazin-1-yl-phenyl)-arylsulfonamides: a novel series of atypical antipsychotic agents.,Bioorg. Med. Chem. Lett.,2010.0,20.0,17.0,"Park CM, Kim SY, Park WK, Choi JH, Seong CM",,651487.0,DTCT0023186,3455875,DTCC00126018,1277697,40330,6.913640169325252,CC(C)N(C1=CC=CC(=C1)N2CCN(CC2)C)S(=O)(=O)C3=CC=CC4=CC=CC=C43,CC(C)N(c1cccc(N2CCN(C)CC2)c1)S(=O)(=O)c1cccc2ccccc12
608,CHEMBL1222362,P28223,,BMJBTCPPCWVRKS-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20655748.0,IC50,=,1423.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]ketanserin from human 5HT2A expressed in CHOKI cells,,Synthesis and SAR of (piperazin-1-yl-phenyl)-arylsulfonamides: a novel series of atypical antipsychotic agents.,Bioorg. Med. Chem. Lett.,2010.0,20.0,17.0,"Park CM, Kim SY, Park WK, Choi JH, Seong CM",,651487.0,DTCT0023186,3455888,DTCC00691135,1149009,40330,5.846795099915716,CN1CCN(CC1)C2=CC(=CC=C2)N(C)S(=O)(=O)C3=CC4=CC=CC=C4C=C3,CN1CCN(c2cccc(N(C)S(=O)(=O)c3ccc4ccccc4c3)c2)CC1
609,CHEMBL1222363,P28223,,XJHVIMRPUTXKEU-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20655748.0,IC50,=,389.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]ketanserin from human 5HT2A expressed in CHOKI cells,,Synthesis and SAR of (piperazin-1-yl-phenyl)-arylsulfonamides: a novel series of atypical antipsychotic agents.,Bioorg. Med. Chem. Lett.,2010.0,20.0,17.0,"Park CM, Kim SY, Park WK, Choi JH, Seong CM",,651487.0,DTCT0023186,3455881,DTCC00691136,890105,40330,6.410050398674292,CCCN(C1=CC=CC(=C1)N2CCN(CC2)C)S(=O)(=O)C3=CC4=CC=CC=C4C=C3,CCCN(c1cccc(N2CCN(C)CC2)c1)S(=O)(=O)c1ccc2ccccc2c1
610,CHEMBL1222364,P28223,,UJKGBCQEPVZELY-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20655748.0,IC50,=,218.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]ketanserin from human 5HT2A expressed in CHOKI cells,,Synthesis and SAR of (piperazin-1-yl-phenyl)-arylsulfonamides: a novel series of atypical antipsychotic agents.,Bioorg. Med. Chem. Lett.,2010.0,20.0,17.0,"Park CM, Kim SY, Park WK, Choi JH, Seong CM",,651487.0,DTCT0023186,3455877,DTCC00691137,2081845,40330,6.661543506395395,CCN(C1=CC=CC(=C1)N2CCN(CC2)C)S(=O)(=O)C3=CC4=CC=CC=C4C=C3,CCN(c1cccc(N2CCN(C)CC2)c1)S(=O)(=O)c1ccc2ccccc2c1
653,CHEMBL1230333,P28223,,VYTXLSQVYGNWLV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7300173,DTCC00693927,2089742,46191,,C1=CSC(=C1)CCCC(=O)O,O=C(O)CCCc1cccs1
655,CHEMBL1230813,P28223,ALFADEX,HFHDHCJBZVLPGP-RWMJIURBSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7292422,DTCC00693991,1155676,46191,,C([C@@H]1[C@@H]2[C@@H]([C@H]([C@H](O1)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5O)O)O[C@@H]6[C@H](O[C@@H]([C@@H]([C@H]6O)O)O[C@@H]7[C@H](O[C@H](O2)[C@@H]([C@H]7O)O)CO)CO)CO)CO)CO)O)O)O,OC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@@H]6[C@@H](CO)O[C@H](O[C@@H]7[C@@H](CO)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O
657,CHEMBL1231,P28223,OXYBUTYNIN,XIQVNETUBQGFHX-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7404006,DTCC00321776,542581,46191,,CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O,CCN(CC)CC#CCOC(=O)C(O)(c1ccccc1)C1CCCCC1
659,CHEMBL1231107,P28223,CYROMAZINE,LVQDKIWDGQRHTE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7344139,DTCC00694021,1027050,46191,,C1CC1NC2=NC(=NC(=N2)N)N,Nc1nc(N)nc(NC2CC2)n1
667,CHEMBL1231530,P28223,BETAMIPRON,CWXYHOHYCJXYFQ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7260115,DTCC00694066,1830684,46191,,C1=CC=C(C=C1)C(=O)NCCC(=O)O,O=C(O)CCNC(=O)c1ccccc1
669,CHEMBL123292,P28223,CYCLOHEXIMIDE,YPHMISFOHDHNIV-FSZOTQKASA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7356955,DTCC00297204,477915,46191,,C[C@H]1C[C@@H](C(=O)[C@@H](C1)[C@@H](CC2CC(=O)NC(=O)C2)O)C,C[C@H]1C[C@H](C)C(=O)[C@H]([C@H](O)CC2CC(=O)NC(=O)C2)C1
671,CHEMBL1235242,P28223,,XWHHYOYVRVGJJY-QMMMGPOBSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7285279,DTCC00694481,413967,46191,,C1=CC(=CC=C1C[C@@H](C(=O)O)N)F,N[C@@H](Cc1ccc(F)cc1)C(=O)O
675,CHEMBL1236282,P28223,THIAMPHENICOL,OTVAEFIXJLOWRX-NXEZZACHSA-N,1,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7474658,DTCC00694596,1894975,46191,,CS(=O)(=O)C1=CC=C(C=C1)[C@H]([C@@H](CO)NC(=O)C(Cl)Cl)O,CS(=O)(=O)c1ccc([C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl)cc1
677,CHEMBL1237,P28223,LISINOPRIL,RLAWWYSOJDYHDC-BZSNNMDCSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7416846,DTCC00323141,88630,46191,,C1C[C@H](N(C1)C(=O)[C@H](CCCCN)N[C@@H](CCC2=CC=CC=C2)C(=O)O)C(=O)O,NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O
680,CHEMBL1237044,P28223,TRAMADOL,TVYLLZQTGLZFBW-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7457498,DTCC00694678,381017,46191,,CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,COc1cccc(C2(O)CCCCC2CN(C)C)c1
682,CHEMBL1237174,P28223,HYDRAZINE,OAKJQQAXSVQMHS-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7332058,DTCC00126200,639581,46191,,NN,NN
688,CHEMBL1243,P28223,SULFABENZAMIDE,PBCZLFBEBARBBI-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7469504,DTCC00325694,217587,46191,,C1=CC=C(C=C1)C(=O)NS(=O)(=O)C2=CC=C(C=C2)N,Nc1ccc(S(=O)(=O)NC(=O)c2ccccc2)cc1
711,CHEMBL1255834,P28223,BW-723C86,ALFGDCNSEBJYSP-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7277479,DTCC00032296,1124446,46191,,CC(CC1=CNC2=C1C=C(C=C2)OCC3=CC=CS3)N,CC(N)Cc1c[nH]c2ccc(OCc3cccs3)cc12
713,CHEMBL1255837,P28223,DIHYDROERGOCRISTINE MESYLATE,SPXACGZWWVIDGR-SPZWACKZSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,15.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7355373,DTCC00699500,1447881,46191,7.823908740944319,CC(C)[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O
715,CHEMBL1255901,P28223,HUPERZINE A,ZRJBHWIHUMBLCN-HZRLMBICSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7323470,DTCC00699536,930079,46191,,C/C=C/1\[C@@H]2CC3=C([C@@]1(CC(=C2)C)N)C=CC(=O)N3,C/C=C1\[C@H]2C=C(C)C[C@@]1(N)c1ccc(=O)[nH]c1C2
717,CHEMBL1256017,P28223,ARCAINE SULFATE,RWTGFMPOODRXIM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7266520,DTCC00699626,994589,46191,,C(CCN=C(N)N)CN=C(N)N.OS(=O)(=O)O,NC(N)=NCCCCN=C(N)N
788,CHEMBL1261,P28223,CITRIC ACID,KRKNYBCHXYNGOX-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7358521,DTCC00331493,1609544,46191,,C(C(=O)O)C(CC(=O)O)(C(=O)O)O,O=C(O)CC(O)(CC(=O)O)C(=O)O
790,CHEMBL1262,P28223,OXICONAZOLE,QRJJEGAJXVEBNE-HKOYGPOVSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,4163.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7401704,DTCC00332757,1059336,46191,5.380593589113222,C1=CC(=C(C=C1Cl)Cl)CO/N=C(\CN2C=CN=C2)/C3=C(C=C(C=C3)Cl)Cl,Clc1ccc(CO/N=C(\Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1
794,CHEMBL127,P28223,MEROPENEM,DMJNNHOOLUXYBV-PQTSNVLCSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7438604,DTCC00154030,51487,46191,,C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)C(=O)N(C)C)C(=O)O)[C@@H](C)O,C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)N(C)C)C3)[C@H](C)[C@H]12
809,CHEMBL1271698,P28223,,YCNJXWPDTIPJAE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20933409.0,IC50,=,166.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in CHO-K1 cells,,"Arylpiperazine-containing pyrimidine 4-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,22.0,"Kim JY, Kim D, Kang SY, Park WK, Kim HJ, Jung ME, Son EJ, Pae AN, Kim J, Lee J",,675981.0,DTCT0023186,3560802,DTCC00704907,1104985,41557,6.779891911959945,CC1=CC(=NC(=N1)C)C(=O)NCCCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl.Cl,Cc1cc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)nc(C)n1
810,CHEMBL1271756,P28223,,ACMANAOGOCCODN-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20933409.0,IC50,=,113.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in CHO-K1 cells,,"Arylpiperazine-containing pyrimidine 4-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,22.0,"Kim JY, Kim D, Kang SY, Park WK, Kim HJ, Jung ME, Son EJ, Pae AN, Kim J, Lee J",,675981.0,DTCT0023186,3560801,DTCC00704960,1939795,41557,6.94692155651658,CC1=NC(=CC(=N1)C(=O)NCCCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl)C(C)C.Cl,Cc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc(C(C)C)n1
811,CHEMBL1271757,P28223,,TYAARHVMBUJJHW-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20933409.0,IC50,=,35.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in CHO-K1 cells,,"Arylpiperazine-containing pyrimidine 4-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,22.0,"Kim JY, Kim D, Kang SY, Park WK, Kim HJ, Jung ME, Son EJ, Pae AN, Kim J, Lee J",,675981.0,DTCT0023186,3560800,DTCC00704961,1589756,41557,7.455931955649724,CC1=NC(=CC(=N1)C(=O)NCCCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl)C4=CC=CC=C4.Cl,Cc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc(-c2ccccc2)n1
812,CHEMBL1271815,P28223,,IIAHRCHFWAORAO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20933409.0,IC50,=,490.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in CHO-K1 cells,,"Arylpiperazine-containing pyrimidine 4-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,22.0,"Kim JY, Kim D, Kang SY, Park WK, Kim HJ, Jung ME, Son EJ, Pae AN, Kim J, Lee J",,675981.0,DTCT0023186,3560799,DTCC00705015,1168433,41557,6.309803919971486,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=NC(=NC(=C3)C(C)C)C)C.Cl,Cc1nc(C(=O)NCCCN2CCN(c3cccc(C)c3C)CC2)cc(C(C)C)n1
813,CHEMBL1271816,P28223,,VZCUFERKHMSQLK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20933409.0,IC50,=,458.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in CHO-K1 cells,,"Arylpiperazine-containing pyrimidine 4-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,22.0,"Kim JY, Kim D, Kang SY, Park WK, Kim HJ, Jung ME, Son EJ, Pae AN, Kim J, Lee J",,675981.0,DTCT0023186,3560798,DTCC00705016,587370,41557,6.339134521996131,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=CC(=NC(=N3)C)C(C)(C)C)C.Cl,Cc1nc(C(=O)NCCCN2CCN(c3cccc(C)c3C)CC2)cc(C(C)(C)C)n1
814,CHEMBL1271873,P28223,,LQJWRYRUWJQOAL-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20933409.0,IC50,=,274.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in CHO-K1 cells,,"Arylpiperazine-containing pyrimidine 4-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,22.0,"Kim JY, Kim D, Kang SY, Park WK, Kim HJ, Jung ME, Son EJ, Pae AN, Kim J, Lee J",,675981.0,DTCT0023186,3560797,DTCC00705067,1104989,41557,6.562249437179612,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=NC(=NC(=C3)C)C(C)(C)C)C.Cl,Cc1cc(C(=O)NCCCN2CCN(c3cccc(C)c3C)CC2)nc(C(C)(C)C)n1
815,CHEMBL1271874,P28223,,JZFXKOMAODIEPN-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20933409.0,IC50,=,69.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in CHO-K1 cells,,"Arylpiperazine-containing pyrimidine 4-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,22.0,"Kim JY, Kim D, Kang SY, Park WK, Kim HJ, Jung ME, Son EJ, Pae AN, Kim J, Lee J",,675981.0,DTCT0023186,3560796,DTCC00705068,974898,41557,7.161150909262744,CC1=C(C(=CC=C1)N2CCN(CC2)CCNC(=O)C3=NC(=NC(=C3)C)C(C)(C)C)C.Cl,Cc1cc(C(=O)NCCN2CCN(c3cccc(C)c3C)CC2)nc(C(C)(C)C)n1
816,CHEMBL1271929,P28223,,PHBCBKHRAVBVOI-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20933409.0,IC50,=,54.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in CHO-K1 cells,,"Arylpiperazine-containing pyrimidine 4-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,22.0,"Kim JY, Kim D, Kang SY, Park WK, Kim HJ, Jung ME, Son EJ, Pae AN, Kim J, Lee J",,675981.0,DTCT0023186,3560795,DTCC00705121,1875354,41557,7.267606240177032,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=NC(=NC(=C3)C)SC)C.Cl,CSc1nc(C)cc(C(=O)NCCCN2CCN(c3cccc(C)c3C)CC2)n1
817,CHEMBL1271930,P28223,,JXQLUDIGMMJLLB-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20933409.0,IC50,=,47.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in CHO-K1 cells,,"Arylpiperazine-containing pyrimidine 4-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,22.0,"Kim JY, Kim D, Kang SY, Park WK, Kim HJ, Jung ME, Son EJ, Pae AN, Kim J, Lee J",,675981.0,DTCT0023186,3560794,DTCC00705122,69139,41557,7.327902142064283,CC1=C(C(=CC=C1)N2CCN(CC2)CCNC(=O)C3=NC(=NC(=C3)C)SC)C.Cl,CSc1nc(C)cc(C(=O)NCCN2CCN(c3cccc(C)c3C)CC2)n1
818,CHEMBL1271984,P28223,,XRPNXBRSKYDUMU-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20933409.0,IC50,=,55.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in CHO-K1 cells,,"Arylpiperazine-containing pyrimidine 4-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,22.0,"Kim JY, Kim D, Kang SY, Park WK, Kim HJ, Jung ME, Son EJ, Pae AN, Kim J, Lee J",,675981.0,DTCT0023186,3560793,DTCC00705175,1810934,41557,7.259637310505756,CC1=CC(=NC(=N1)SC)C(=O)NCCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl.Cl,CSc1nc(C)cc(C(=O)NCCN2CCN(c3cccc(Cl)c3Cl)CC2)n1
819,CHEMBL1271985,P28223,,KXPDUNKSCJWNNO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20933409.0,IC50,=,256.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in CHO-K1 cells,,"Arylpiperazine-containing pyrimidine 4-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,22.0,"Kim JY, Kim D, Kang SY, Park WK, Kim HJ, Jung ME, Son EJ, Pae AN, Kim J, Lee J",,675981.0,DTCT0023186,3560792,DTCC00705176,1460579,41557,6.59176003468815,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=NC(=NC(=C3)C)C4CC4)C.Cl,Cc1cc(C(=O)NCCCN2CCN(c3cccc(C)c3C)CC2)nc(C2CC2)n1
820,CHEMBL1272040,P28223,,UETCBWKKMOBPNY-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20933409.0,IC50,=,744.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in CHO-K1 cells,,"Arylpiperazine-containing pyrimidine 4-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,22.0,"Kim JY, Kim D, Kang SY, Park WK, Kim HJ, Jung ME, Son EJ, Pae AN, Kim J, Lee J",,675981.0,DTCT0023186,3560791,DTCC00705230,1072221,41557,6.128427064454121,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=NC(=NC(=C3OC)C)C)C.Cl,COc1c(C)nc(C)nc1C(=O)NCCCN1CCN(c2cccc(C)c2C)CC1
821,CHEMBL1272041,P28223,,UNSFBRHQHPUNOY-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20933409.0,IC50,=,842.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in CHO-K1 cells,,"Arylpiperazine-containing pyrimidine 4-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,22.0,"Kim JY, Kim D, Kang SY, Park WK, Kim HJ, Jung ME, Son EJ, Pae AN, Kim J, Lee J",,675981.0,DTCT0023186,3560790,DTCC00705231,619745,41557,6.0746879085003505,CC1=C(C(=CC=C1)N2CCN(CC2)CCNC(=O)C3=NC(=NC(=C3OC)C)C)C.Cl,COc1c(C)nc(C)nc1C(=O)NCCN1CCN(c2cccc(C)c2C)CC1
822,CHEMBL1272092,P28223,,LSXRPPLOEWTOFU-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20933409.0,IC50,=,263.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in CHO-K1 cells,,"Arylpiperazine-containing pyrimidine 4-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20.0,22.0,"Kim JY, Kim D, Kang SY, Park WK, Kim HJ, Jung ME, Son EJ, Pae AN, Kim J, Lee J",,675981.0,DTCT0023186,3560789,DTCC00705281,748949,41557,6.580044251510242,CC1=C(C(=NC(=N1)C)C(=O)NCCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl)OC.Cl,COc1c(C)nc(C)nc1C(=O)NCCN1CCN(c2cccc(Cl)c2Cl)CC1
824,CHEMBL127516,P28223,BUTAMBEN,IUWVALYLNVXWKX-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7271589,DTCC00306410,381006,46191,,CCCCOC(=O)C1=CC=C(C=C1)N,CCCCOC(=O)c1ccc(N)cc1
826,CHEMBL1275709,P28223,,CMJSIPQFDNXSOL-QWHCGFSZSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20949929.0,IC50,=,840.0,NM,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor,,Conformationally restricted homotryptamines. Part 7: 3-cis-(3-aminocyclopentyl)indoles as potent selective serotonin reuptake inhibitors.,J. Med. Chem.,2010.0,53.0,21.0,"King HD, Meng Z, Deskus JA, Sloan CP, Gao Q, Beno BR, Kozlowski ES, Lapaglia MA, Mattson GK, Molski TF, Taber MT, Lodge NJ, Mattson RJ, Macor JE",,685488.0,DTCT0023186,3584615,DTCC00126640,566925,41914,6.075720713938118,CN(C)[C@@H]1CC[C@@H](C1)C2=CNC3=C2C=C(C=C3)C#N,CN(C)[C@@H]1CC[C@H](c2c[nH]c3ccc(C#N)cc23)C1
827,CHEMBL1275791,P28223,,LRSVJJWABVMKRA-PWSUYJOCSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20949929.0,IC50,=,28000.0,NM,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor,,Conformationally restricted homotryptamines. Part 7: 3-cis-(3-aminocyclopentyl)indoles as potent selective serotonin reuptake inhibitors.,J. Med. Chem.,2010.0,53.0,21.0,"King HD, Meng Z, Deskus JA, Sloan CP, Gao Q, Beno BR, Kozlowski ES, Lapaglia MA, Mattson GK, Molski TF, Taber MT, Lodge NJ, Mattson RJ, Macor JE",,685488.0,DTCT0023186,3584616,DTCC00705594,275031,41914,4.552841968657781,CN(C)[C@H]1CC[C@H](C1)C2=CNC3=C2C=C(C=C3)F,CN(C)[C@H]1CC[C@@H](c2c[nH]c3ccc(F)cc23)C1
828,CHEMBL1276308,P28223,MIFEPRISTONE,VKHAHZOOUSRJNA-GCNJZUOMSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7419886,DTCC00706050,120974,46191,,CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C
867,CHEMBL128,P28223,SUMATRIPTAN,KQKPFRSPSRPDEB-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,7752204.0,IC50,=,7943.28,NM,,,,,,,,,,,,,,Binding activity radioligand.,,"Synthesis and serotonergic activity of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine and analogues: potent agonists for 5-HT1D receptors.",J. Med. Chem.,1995.0,38.0,10.0,"Street LJ, Baker R, Davey WB, Guiblin AR, Jelley RA, Reeve AJ, Routledge H, Sternfeld F, Watt AP, Beer MS",,2505.0,DTCT0023186,520900,DTCC00154636,658692,13017,5.100000128334196,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1
871,CHEMBL128,P28223,SUMATRIPTAN,KQKPFRSPSRPDEB-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,9357515.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,"Selective, orally active 5-HT1D receptor agonists as potential antimigraine agents.",J. Med. Chem.,1997.0,40.0,22.0,"MacLeod AM, Street LJ, Reeve AJ, Jelley RA, Sternfeld F, Beer MS, Stanton JA, Watt AP, Rathbone D, Matassa VG",,2467.0,DTCT0023186,712594,DTCC00154636,659675,14385,5.0,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1
873,CHEMBL128,P28223,SUMATRIPTAN,KQKPFRSPSRPDEB-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7482791,DTCC00154636,671796,46191,,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1
875,CHEMBL1282,P28223,IMIQUIMOD,DOUYETYNHWVLEO-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7306621,DTCC00339893,1927015,46191,,CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N,CC(C)Cn1cnc2c(N)nc3ccccc3c21
877,CHEMBL12856,P28223,INAMRINONE,RNLQIBCLLYYYFJ-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7301115,DTCC00141434,1447876,46191,,C1=CN=CC=C1C2=CNC(=O)C(=C2)N,Nc1cc(-c2ccncc2)c[nH]c1=O
883,CHEMBL1289,P28223,HALOPROGIN,CTETYYAZBPJBHE-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,2421.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7306385,DTCC00108442,1512810,46191,5.616005210558267,C1=C(C(=CC(=C1Cl)Cl)Cl)OCC#CI,Clc1cc(Cl)c(OCC#CI)cc1Cl
885,CHEMBL129,P28223,ZIDOVUDINE,HBOMLICNUCNMMY-XLPZGREQSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7446951,DTCC00154782,51517,46191,,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-],Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O
887,CHEMBL12948,P28223,SEMUSTINE,FVLVBPDQNARYJU-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7466958,DTCC00141274,1318442,46191,,CC1CCC(CC1)NC(=O)N(CCCl)N=O,CC1CCC(NC(=O)N(CCCl)N=O)CC1
889,CHEMBL1297,P28223,FENOPROFEN,RDJGLLICXDHJDY-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7309556,DTCC00343797,1830685,46191,,CC(C1=CC(=CC=C1)OC2=CC=CC=C2)C(=O)O,CC(C(=O)O)c1cccc(Oc2ccccc2)c1
891,CHEMBL13,P28223,METOPROLOL,IUBSYMUCCVWXPE-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7421850,DTCC00132868,1798412,46191,,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,COCCc1ccc(OCC(O)CNC(C)C)cc1
893,CHEMBL130,P28223,CHLORAMPHENICOL,WIIZWVCIJKGZOK-RKDXNWHRSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7347356,DTCC00154805,51455,46191,,C1=CC(=CC=C1[C@H]([C@@H](CO)NC(=O)C(Cl)Cl)O)[N+](=O)[O-],O=C(N[C@H](CO)[C@H](O)c1ccc([N+](=O)[O-])cc1)C(Cl)Cl
895,CHEMBL1306,P28223,TERCONAZOLE,BLSQLHNBWJLIBQ-OZXSUGGESA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,8175.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7476586,DTCC00347547,1830691,46191,5.087512238667676,CC(C)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=NC=N4)C5=C(C=C(C=C5)Cl)Cl,CC(C)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4cncn4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
897,CHEMBL1308,P28223,FOMEPIZOLE,RIKMMFOAQPJVMX-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7288076,DTCC00348807,1862712,46191,,CC1=CNN=C1,Cc1cn[nH]c1
900,CHEMBL131,P28223,PREDNISOLONE,OIGNJSKKLXVSLS-VWUMJDOOSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7391976,DTCC00154827,1734061,46191,,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO
903,CHEMBL131482,P28223,,SYTKLFTVOOOLQR-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,8831770.0,IC50,=,8.0,NM,,cell_based,,,,,,,,,,,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,"Structure-activity relationships of a series of novel (piperazinylbutyl)thiazolidinone antipsychotic agents related to 3-[4-[4-(6-fluorobenzo[b]thien-3-yl)-1-piperazinyl]butyl]-2,5,5- trimethyl-4-thiazolidinone maleate.",J. Med. Chem.,1996.0,39.0,20.0,"Hrib NJ, Jurcak JG, Bregna DE, Burgher KL, Hartman HB, Kafka S, Kerman LL, Kongsamut S, Roehr JE, Szewczak MR, Woods-Kettelberger AT, Corbett R",,2272.0,DTCT0023186,1621523,DTCC00312121,357349,13832,8.096910013008056,CC1N(C(=O)C2(S1)CCCC2)CCCCN3CCN(CC3)C4=CSC5=C4C=CC(=C5)F,CC1SC2(CCCC2)C(=O)N1CCCCN1CCN(c2csc3cc(F)ccc23)CC1
907,CHEMBL1319362,P28223,HOMATROPINE HYDROBROMIDE,DWSGTFTVBLXELC-RDYJJYPNSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7319217,DTCC00729363,1027054,46191,,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(C3=CC=CC=C3)O.Br,CN1[C@H]2CC[C@@H]1CC(OC(=O)C(O)c1ccccc1)C2
910,CHEMBL13209,P28223,NITRAZEPAM,KJONHKAYOJNZEC-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7397068,DTCC00141996,477919,46191,,C1C(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3,O=C1CN=C(c2ccccc2)c2cc([N+](=O)[O-])ccc2N1
912,CHEMBL1321,P28223,PROCARBAZINE,CPTBDICYNRMXFX-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7400725,DTCC00352822,671792,46191,,CC(C)NC(=O)C1=CC=C(C=C1)CNNC,CNNCc1ccc(C(=O)NC(C)C)cc1
914,CHEMBL1321154,P28223,ROXARSONE,XMVJITFPVVRMHC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7457957,DTCC00731018,542582,46191,,C1=CC(=C(C=C1[As](=O)(O)O)[N+](=O)[O-])O,O=[N+]([O-])c1cc([As](=O)(O)O)ccc1O
919,CHEMBL1333512,P28223,"N,N'-DIPHENYL-P-PHENYLENEDIAMINE",UTGQNNCQYDRXCH-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7424389,DTCC00742601,1155682,46191,,C1=CC=C(C=C1)NC2=CC=C(C=C2)NC3=CC=CC=C3,c1ccc(Nc2ccc(Nc3ccccc3)cc2)cc1
921,CHEMBL13341,P28223,NIMETAZEPAM,GWUSZQUVEVMBPI-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7384157,DTCC00141962,606971,46191,,CN1C(=O)CN=C(C2=C1C=CC(=C2)[N+](=O)[O-])C3=CC=CC=C3,CN1C(=O)CN=C(c2ccccc2)c2cc([N+](=O)[O-])ccc21
926,CHEMBL13378,P28223,"(R,S)-AMPA",UUDAMDVQRQNNHZ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7286458,DTCC00141891,1220272,46191,,CC1=C(C(=O)NO1)CC(C(=O)O)N,Cc1o[nH]c(=O)c1CC(N)C(=O)O
929,CHEMBL134,P28223,CLONIDINE,GJSURZIOUXUGAL-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7341632,DTCC00155022,51459,46191,,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl,Clc1cccc(Cl)c1NC1=NCCN1
931,CHEMBL134342,P28223,LIPOIC ACID,AGBQKNBQESQNJD-SSDOTTSWSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7487532,DTCC00318217,1220281,46191,,C1CSS[C@@H]1CCCCC(=O)O,O=C(O)CCCC[C@@H]1CCSS1
934,CHEMBL1349,P28223,VALACYCLOVIR,HDOVUKNUBWVHOX-QMMMGPOBSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7453794,DTCC00378678,930089,46191,,CC(C)[C@@H](C(=O)OCCOCN1C=NC2=C1N=C(NC2=O)N)N,CC(C)[C@H](N)C(=O)OCCOCn1cnc2c(=O)[nH]c(N)nc21
936,CHEMBL135,P28223,ESTRADIOL,VOXZDWNPVJITMN-ZBRFXRBCSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7267160,DTCC00155036,51448,46191,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)O,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O
943,CHEMBL1365675,P28223,AMITRAZ,QXAITBQSYVNQDR-ZIOPAAQOSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7295470,DTCC00772476,1027047,46191,,CC1=CC(=C(C=C1)N=CN(C)C=NC2=C(C=C(C=C2)C)C)C,Cc1ccc(N=CN(C)C=Nc2ccc(C)cc2C)c(C)c1
950,CHEMBL137,P28223,METRONIDAZOLE,VAOCPAMSLUNLGC-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7426133,DTCC00155250,51489,46191,,CC1=NC=C(N1CCO)[N+](=O)[O-],Cc1ncc([N+](=O)[O-])n1CCO
952,CHEMBL1370,P28223,BUDESONIDE,VOVIALXJUBGFJZ-KWVAZRHASA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7277367,DTCC00392952,898284,46191,,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@@]5([C@H]4[C@H](C[C@@]3([C@@]2(O1)C(=O)CO)C)O)C,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
954,CHEMBL1370561,P28223,AMINOPHYLLINE,FQPFAHBPWDRTLU-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7284472,DTCC00777070,1383772,46191,,CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N,Cn1c(=O)c2[nH]cnc2n(C)c1=O
956,CHEMBL1371,P28223,CHLORZOXAZONE,TZFWDZFKRBELIQ-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7351707,DTCC00394427,1992801,46191,,C1=CC2=C(C=C1Cl)NC(=O)O2,O=c1[nH]c2cc(Cl)ccc2o1
958,CHEMBL1371125,P28223,BENZO[E]PYRENE,TXVHTIQJNYSSKO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7267084,DTCC00777599,2025635,46191,,C1=CC=C2C(=C1)C3=CC=CC4=C3C5=C(C=CC=C25)C=C4,c1ccc2c(c1)c1cccc3ccc4cccc2c4c31
961,CHEMBL1371937,P28223,PANTHENOL,SNPLKNRPJHDVJA-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7397601,DTCC00778371,1059337,46191,,CC(C)(CO)C(C(=O)NCCCO)O,CC(C)(CO)C(O)C(=O)NCCCO
963,CHEMBL1372,P28223,OXIGLUTATIONE,YPZRWBKMTBYPTK-BJDJZHNGSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7333770,DTCC00395874,898290,46191,,C(CC(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@H](N)C(=O)O)C(=O)NCC(=O)O)C(=O)NCC(=O)O)C(=O)O
965,CHEMBL1373,P28223,MODAFINIL,YFGHCGITMMYXAQ-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7415718,DTCC00396162,1512812,46191,,C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N,NC(=O)C[S+]([O-])C(c1ccccc1)c1ccccc1
967,CHEMBL1381098,P28223,1-NAPHTHYLISOTHIOCYANATE,JBDOSUUXMYMWQH-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7286539,DTCC00786869,866013,46191,,C1=CC=C2C(=C1)C=CC=C2N=C=S,S=C=Nc1cccc2ccccc12
969,CHEMBL1384,P28223,KANAMYCIN,SBUJHOSQTJFQJX-NOAMYHISSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7422672,DTCC00402979,51482,46191,,C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)N)O)N,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O
971,CHEMBL138458,P28223,,IJKYJDDNDXAREJ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11784148.0,IC50,=,460.0,NM,,,,,,,,,,,,,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,Novel spiropiperidines as highly potent and subtype selective sigma-receptor ligands. Part 1.,J. Med. Chem.,2002.0,45.0,2.0,"Maier CA, Wünsch B",,2469.0,DTCT0023186,1330606,DTCC00323189,65365,16958,6.337242168318426,COC1CC2=CC=CC=C2C3(O1)CCN(CC3)CCCC4=CC=CC=C4,COC1Cc2ccccc2C2(CCN(CCCc3ccccc3)CC2)O1
972,CHEMBL1385840,P28223,ERGOCORNINE,UJYGDMFEEDNVBF-OGGGUQDZSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,28.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7324020,DTCC00791188,444641,46191,7.552841968657781,CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=CNC7=CC=CC(=C67)C5=C4)C)O,CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
976,CHEMBL1388,P28223,MONOBENZONE,VYQNWZOUAUKGHI-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7420006,DTCC00405603,833163,46191,,C1=CC=C(C=C1)COC2=CC=C(C=C2)O,Oc1ccc(OCc2ccccc2)cc1
978,CHEMBL138809,P28223,,RZZAEVQHACUOGI-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11784148.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,Novel spiropiperidines as highly potent and subtype selective sigma-receptor ligands. Part 1.,J. Med. Chem.,2002.0,45.0,2.0,"Maier CA, Wünsch B",,2469.0,DTCT0023186,1325460,DTCC00323057,1489511,16958,5.0,COC1C2=CC=CC=C2C3(O1)CCN(CC3)CC4=CC=CC=C4,COC1OC2(CCN(Cc3ccccc3)CC2)c2ccccc21
980,CHEMBL139,P28223,DICLOFENAC,DCOPUUMXTXDBNB-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7344474,DTCC00156996,1220275,46191,,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl
982,CHEMBL1393,P28223,SPIRONOLACTONE,LXMSZDCAJNLERA-ZHYRCANASA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7456274,DTCC00405635,1512816,46191,,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21
984,CHEMBL1395,P28223,METHYLTESTOSTERONE,GCKMFJBGXUYNAG-HLXURNFRSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7297319,DTCC00405823,1798403,46191,,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C)O)C,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
989,CHEMBL139835,P28223,CYPROTERONE ACETATE,UWFYSQMTEOIJJG-FDTZYFLXSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7339844,DTCC00327558,153442,46191,,CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C=C(C4=CC(=O)[C@@H]5C[C@@H]5[C@]34C)Cl)C)OC(=O)C,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C
991,CHEMBL1399,P28223,ANASTROZOLE,YBBLVLTVTVSKRW-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7286231,DTCC00413581,1992800,46191,,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1
994,CHEMBL14,P28223,CARBACHOL,AIXAANGOTKPUOY-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7262005,DTCC00132960,1862714,46191,,C[N+](C)(C)CCOC(=O)N.[Cl-],C[N+](C)(C)CCOC(N)=O
996,CHEMBL1400945,P28223,PREGNENOLONE CARBONITRILE ,VSBHRRMYCDQLJF-ZDNYCOCVSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7400580,DTCC00805254,1220279,46191,,CC(=O)[C@H]1[C@@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C)C#N,CC(=O)[C@H]1[C@H](C#N)C[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C
998,CHEMBL1403281,P28223,ERGOCRYPTINE,YDOTUXAWKBPQJW-NSLWYYNWSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,47.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7295120,DTCC00807428,381005,46191,7.327902142064283,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=CNC7=CC=CC(=C67)C5=C4)C)O,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
1000,CHEMBL1405,P28223,ESTRONE,DNXHEGUUPJUMQT-CBZIJGRNSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7319852,DTCC00418600,606969,46191,,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)O,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CCC2=O
1002,CHEMBL14053,P28223,TRICHLOROACETIC ACID,YNJBWRMUSHSURL-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7451822,DTCC00143400,444644,46191,,C(=O)(C(Cl)(Cl)Cl)O,O=C(O)C(Cl)(Cl)Cl
1004,CHEMBL14060,P28223,PHENOL,ISWSIDIOOBJBQZ-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7389369,DTCC00143418,413974,46191,,C1=CC=C(C=C1)O,Oc1ccccc1
1010,CHEMBL141,P28223,LAMIVUDINE,JTEGQNOMFQHVDC-NKWVEPMBSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7407916,DTCC00160169,51484,46191,,C1[C@H](O[C@H](S1)CO)N2C=CC(=NC2=O)N,Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1
1013,CHEMBL1411979,P28223,METHAPYRILENE,HNJJXZKZRAWDPF-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,628.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7425893,DTCC00815629,153445,46191,6.2020403562628035,CN(C)CCN(CC1=CC=CS1)C2=CC=CC=N2,CN(C)CCN(Cc1cccs1)c1ccccn1
1015,CHEMBL141209,P28223,,POOPPNNSPMKABZ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11784148.0,IC50,=,6600.0,NM,,,,,,,,,,,,,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,Novel spiropiperidines as highly potent and subtype selective sigma-receptor ligands. Part 1.,J. Med. Chem.,2002.0,45.0,2.0,"Maier CA, Wünsch B",,2469.0,DTCT0023186,1333322,DTCC00322694,1360188,16958,5.180456064458132,COC1CC2=CC=CC=C2C3(O1)CCN(CC3)CC4=CC=CC=C4,COC1Cc2ccccc2C2(CCN(Cc3ccccc3)CC2)O1
1016,CHEMBL1413,P28223,CICLOPIROX,SCKYRAXSEDYPSA-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7343289,DTCC00427786,1416026,46191,,CC1=CC(=O)N(C(=C1)C2CCCCC2)O,Cc1cc(C2CCCCC2)n(O)c(=O)c1
1018,CHEMBL141343,P28223,U-78517F,KPZQRBACZSLMPH-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7448335,DTCC01743360,671797,46191,,CC1=C(C2=C(CCC(O2)(C)CN3CCN(CC3)C4=NC(=NC(=C4)N5CCCC5)N6CCCC6)C(=C1O)C)C,Cc1c(C)c2c(c(C)c1O)CCC(C)(CN1CCN(c3cc(N4CCCC4)nc(N4CCCC4)n3)CC1)O2
1023,CHEMBL1419,P28223,SIBUTRAMINE,UNAANXDKBXWMLN-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7475663,DTCC00432414,1765981,46191,,CC(C)CC(C1(CCC1)C2=CC=C(C=C2)Cl)N(C)C,CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1
1025,CHEMBL14192,P28223,BENZYLIMIDAZOLE,KKKDZZRICRFGSD-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7283606,DTCC00143373,381004,46191,,C1=CC=C(C=C1)CN2C=CN=C2,c1ccc(Cn2ccnc2)cc1
1034,CHEMBL1425,P28223,MERCAPTOPURINE,GLVAUDGFNGKCSF-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7300394,DTCC00110799,51440,46191,,C1=NC2=C(N1)C(=S)N=CN2,S=c1nc[nH]c2nc[nH]c12
1038,CHEMBL1428,P28223,NIMODIPINE,UIAGMCDKSXEBJQ-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7388512,DTCC00437760,930083,46191,,CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCOC,COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c1cccc([N+](=O)[O-])c1
1040,CHEMBL1430,P28223,PENICILLAMINE,VVNCNSJFMMFHPL-VKHMYHEASA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7402062,DTCC00441311,898294,46191,,CC(C)([C@H](C(=O)O)N)S,CC(C)(S)[C@@H](N)C(=O)O
1046,CHEMBL1431,P28223,METFORMIN,XZWYZXLIPXDOLR-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7421634,DTCC00441526,1318443,46191,,CN(C)C(=N)N=C(N)N,CN(C)C(=N)N=C(N)N
1048,CHEMBL1433,P28223,DOXYCYCLINE,JBIWCJUYHHGXTC-AKNGSSGZSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7330246,DTCC00443319,381009,46191,,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,C[C@H]1c2cccc(O)c2C(O)=C2C(=O)[C@]3(O)C(O)=C(C(N)=O)C(=O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21
1064,CHEMBL1440,P28223,TETRACYCLINE,OFVLGDICTFRJMM-WESIUVDSSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7457153,DTCC00445351,51511,46191,,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12
1067,CHEMBL1444,P28223,LETROZOLE,HPJKCIUCZWXJDR-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7433701,DTCC00445802,1285878,46191,,C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3,N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1
1073,CHEMBL14460,P28223,SB-243213,ZETBBVYSBABLHL-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18602261.0,IC50,=,32.4,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from human cloned 5HT2A receptor,,Synthesis and structure-activity relationship of 1H-indole-3-carboxylic acid pyridine-3-ylamides: a novel series of 5-HT2C receptor antagonists.,Bioorg. Med. Chem. Lett.,2008.0,18.0,14.0,"Park CM, Kim SY, Park WK, Park NS, Seong CM",,488684.0,DTCT0023186,2776334,DTCC00143939,1178315,30600,7.489454989793388,CC1=CC2=C(C=C1C(F)(F)F)N(CC2)C(=O)NC3=CN=C(C=C3)OC4=C(N=CC=C4)C,Cc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1ccc(Oc3cccnc3C)nc1)CC2
1076,CHEMBL1447,P28223,LINCOMYCIN,OJMMVQQUTAEWLP-KIDUDLJLSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7408181,DTCC00448831,1059331,46191,,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@@H](C)O,CCC[C@@H]1C[C@@H](C(=O)N[C@H]([C@@H](C)O)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)N(C)C1
1078,CHEMBL1451,P28223,TRIAMCINOLONE,GFNANZIMVAIWHM-OBYCQNJPSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7442798,DTCC00451754,1512818,46191,,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@H]([C@@]2(C(=O)CO)O)O)CCC4=CC(=O)C=C[C@@]43C)F)O,C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO
1080,CHEMBL1454,P28223,LEVAMISOLE,HLFSDGLLUJUHTE-SNVBAGLBSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7408051,DTCC00454681,1927017,46191,,C1CSC2=N[C@H](CN21)C3=CC=CC=C3,c1ccc([C@H]2CN3CCSC3=N2)cc1
1083,CHEMBL1454946,P28223,FLUBENDAZOLE,CPEUVMUXAHMANV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7335245,DTCC00855742,51469,46191,,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=C(C=C3)F,COC(=O)Nc1nc2ccc(C(=O)c3ccc(F)cc3)cc2[nH]1
1085,CHEMBL1455,P28223,ALTRETAMINE,UUVWYPNAQBNQJQ-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7284347,DTCC00455954,800569,46191,,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,CN(C)c1nc(N(C)C)nc(N(C)C)n1
1087,CHEMBL1456,P28223,MYCOPHENOLATE MOFETIL,RTGDFNSFWBGLEC-SYZQJQIISA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7437056,DTCC00456082,477918,46191,,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2
1101,CHEMBL1460,P28223,DIDANOSINE,BXZVVICBKDXVGW-NKWVEPMBSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7355307,DTCC00459811,348398,46191,,C1C[C@@H](O[C@@H]1CO)N2C=NC3=C2N=CNC3=O,O=c1[nH]cnc2c1ncn2[C@H]1CC[C@@H](CO)O1
1106,CHEMBL1463,P28223,FLUCYTOSINE,XRECTZIEBJDKEO-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7309698,DTCC00462514,1674145,46191,,C1=NC(=O)NC(=C1F)N,Nc1[nH]c(=O)ncc1F
1108,CHEMBL1464,P28223,WARFARIN,PJVWKTKQMONHTI-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7449629,DTCC00462727,2089753,46191,,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O
1114,CHEMBL1466,P28223,DICUMAROL,DOBMPNYZJYQDGZ-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7348742,DTCC00462777,1480345,46191,,C1=CC=C2C(=C1)C(=C(C(=O)O2)CC3=C(C4=CC=CC=C4OC3=O)O)O,O=c1oc2ccccc2c(O)c1Cc1c(O)c2ccccc2oc1=O
1117,CHEMBL1467,P28223,ALLOPURINOL,OFCNXPDARWKPPY-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7284258,DTCC00463996,51443,46191,,C1=NNC2=C1C(=O)NC=N2,O=c1[nH]cnc2[nH]ncc12
1123,CHEMBL1471412,P28223,,WGYOBGCPSCGBPS-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,22153942.0,IC50,=,537.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]Ketanserin from human recombinant 5HT2A receptor expressed in CHOK1 cells after 60 mins,,5-HT2c receptor selectivity and structure-activity relationship of N-methyl-N-(1-methylpiperidin-4-yl)benzenesulfonamide analogs.,Bioorg. Med. Chem. Lett.,2012.0,22.0,1.0,"Jang JW, Baek JS, Choi GD, Park WK, Cho YS, Baek DJ, Pae AN",,795018.0,DTCT0023186,7579156,DTCC00870781,1577138,46941,6.270025714300444,CN1CCC(CC1)N(C)S(=O)(=O)C2=CC=C(C=C2)Cl,CN1CCC(N(C)S(=O)(=O)c2ccc(Cl)cc2)CC1
1128,CHEMBL1475,P28223,TRIOXSALEN,FMHHVULEAZTJMA-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7448230,DTCC00470391,153447,46191,,CC1=CC(=O)OC2=C1C=C3C=C(OC3=C2C)C,Cc1cc2cc3c(C)cc(=O)oc3c(C)c2o1
1133,CHEMBL1477,P28223,CERIVASTATIN,SEERZIQQUAZTOL-ANMDKAQQSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7364476,DTCC00471235,736257,46191,,CC(C)C1=C(C(=C(C(=N1)C(C)C)COC)C2=CC=C(C=C2)F)/C=C/[C@H](C[C@H](CC(=O)O)O)O,COCc1c(C(C)C)nc(C(C)C)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c1-c1ccc(F)cc1
1135,CHEMBL1479,P28223,DANAZOL,POZRVZJJTULAOH-LHZXLZLDSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,8850.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7370090,DTCC00472761,1512807,46191,5.053056729302175,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC5=C(C[C@]34C)C=NO5,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C
1137,CHEMBL1480,P28223,FELODIPINE,RZTAMFZIAATZDJ-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7328675,DTCC00472762,1894965,46191,,CCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)C,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(Cl)c1Cl
1141,CHEMBL1480987,P28223,CYCLANDELATE,WZHCOOQXZCIUNC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7350342,DTCC00879865,444638,46191,,CC1CC(CC(C1)(C)C)OC(=O)C(C2=CC=CC=C2)O,CC1CC(OC(=O)C(O)c2ccccc2)CC(C)(C)C1
1143,CHEMBL1481,P28223,GLIMEPIRIDE,WIGIZIANZCJQQY-RUCARUNLSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7325181,DTCC00472763,1641848,46191,,CCC1=C(CN(C1=O)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCC(CC3)C)C,CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCC(C)CC3)cc2)C1=O
1147,CHEMBL1483,P28223,ALBENDAZOLE,HXHWSAZORRCQMX-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7297869,DTCC00474063,315661,46191,,CCCSC1=CC2=C(C=C1)N=C(N2)NC(=O)OC,CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1
1157,CHEMBL1487,P28223,ATORVASTATIN,XUKUURHRXDUEBC-KAYWLYCHSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7266714,DTCC00483650,1480343,46191,,CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O
1159,CHEMBL1489,P28223,AZACITIDINE,NMUSYJAQQFHJEW-KVTDHHQDSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7278080,DTCC00484776,1416024,46191,,C1=NC(=NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
1161,CHEMBL1489254,P28223,TRIACETIN,URAYPUMNDPQOKB-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7441189,DTCC00887628,249945,46191,,CC(=O)OCC(COC(=O)C)OC(=O)C,CC(=O)OCC(COC(C)=O)OC(C)=O
1163,CHEMBL1490,P28223,TRIHEXYPHENIDYL,HWHLPVGTWGOCJO-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7442921,DTCC00112203,703988,46191,,C1CCC(CC1)C(CCN2CCCCC2)(C3=CC=CC=C3)O,OC(CCN1CCCCC1)(c1ccccc1)C1CCCCC1
1166,CHEMBL1491,P28223,AMLODIPINE,HTIQEAQVCYTUBX-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7301025,DTCC00112206,217573,46191,,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN,CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl
1168,CHEMBL1493,P28223,FLAVOXATE,SPIUTQOUKAMGCX-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7326637,DTCC00112214,1960075,46191,,CC1=C(OC2=C(C1=O)C=CC=C2C(=O)OCCN3CCCCC3)C4=CC=CC=C4,Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O
1176,CHEMBL1501,P28223,FLUOCINONIDE,WJOHZNCJWYWUJD-IUGZLZTKSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7309793,DTCC00485637,1253323,46191,,CC(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@]4([C@H]3C[C@@H](C5=CC(=O)C=C[C@@]54C)F)F)O)C)OC(O2)(C)C,CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C
1182,CHEMBL1502,P28223,PANTOPRAZOLE,IQPSEEYGBUAQFF-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7401940,DTCC00485677,1027057,46191,,COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC,COc1ccnc(C[S+]([O-])c2nc3ccc(OC(F)F)cc3[nH]2)c1OC
1186,CHEMBL1503,P28223,OMEPRAZOLE,SUBDBMMJDZJVOS-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7401610,DTCC00485679,1609551,46191,,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,COc1ccc2nc([S+]([O-])Cc3ncc(C)c(OC)c3C)[nH]c2c1
1188,CHEMBL1504,P28223,TRIAMCINOLONE ACETONIDE,YNDXUCZADRHECN-JNQJZLCISA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7444380,DTCC00485699,833165,46191,,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)CCC5=CC(=O)C=C[C@@]53C)F)O,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
1190,CHEMBL1509570,P28223,,LNGQSIFKSWPQHF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,22153942.0,IC50,=,831.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]Ketanserin from human recombinant 5HT2A receptor expressed in CHOK1 cells after 60 mins,,5-HT2c receptor selectivity and structure-activity relationship of N-methyl-N-(1-methylpiperidin-4-yl)benzenesulfonamide analogs.,Bioorg. Med. Chem. Lett.,2012.0,22.0,1.0,"Jang JW, Baek JS, Choi GD, Park WK, Cho YS, Baek DJ, Pae AN",,795018.0,DTCT0023186,7579165,DTCC00906332,671913,46941,6.080398976215889,CN1CCC(CC1)N(C)S(=O)(=O)C2=CC=C(C=C2)OC,COc1ccc(S(=O)(=O)N(C)C2CCN(C)CC2)cc1
1191,CHEMBL1512,P28223,FLUNISOLIDE,XSFJVAJPIHIPKU-XWCQMRHXSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7331057,DTCC00486813,703980,46191,,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)C[C@@H](C5=CC(=O)C=C[C@]35C)F)O,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
1193,CHEMBL1513,P28223,IRBESARTAN,YOSHYTLCDANDAN-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7418273,DTCC00486818,1609548,46191,,CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5,CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1
1195,CHEMBL1515,P28223,METHIMAZOLE,PMRYVIKBURPHAH-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7430191,DTCC00486838,153446,46191,,CN1C=CNC1=S,Cn1cc[nH]c1=S
1197,CHEMBL1515611,P28223,BROMISOVALUM,CMCCHHWTTBEZNM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7268824,DTCC00912063,1220274,46191,,CC(C)C(C(=O)NC(=O)N)Br,CC(C)C(Br)C(=O)NC(N)=O
1200,CHEMBL1517,P28223,OXYTETRACYCLINE,IWVCMVBTMGNXQD-PXOLEDIWSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7389016,DTCC00486898,413973,46191,,C[C@@]1([C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O)O,CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3[C@H](O)[C@@H]12
1202,CHEMBL1518,P28223,PROPYLTHIOURACIL,KNAHARQHSZJURB-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7377211,DTCC00486945,348404,46191,,CCCC1=CC(=O)NC(=S)N1,CCCc1cc(=O)[nH]c(=S)[nH]1
1204,CHEMBL1521,P28223,ZALEPLON,HUNXMJYCHXQEGX-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7443511,DTCC00487037,994596,46191,,CCN(C1=CC=CC(=C1)C2=CC=NC3=C(C=NN23)C#N)C(=O)C,CCN(C(C)=O)c1cccc(-c2ccnc3c(C#N)cnn23)c1
1216,CHEMBL15245,P28223,YOHIMBINE,BLGXFZZNTVWLAY-SCYLSFHTSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7453361,DTCC00144859,88638,46191,,COC(=O)[C@H]1[C@H](CC[C@@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@@H]21
1219,CHEMBL1527608,P28223,DOXOFYLLINE,HWXIGFIVGWUZAO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7323652,DTCC00923329,88626,46191,,CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC3OCCO3,Cn1c(=O)c2c(ncn2CC2OCCO2)n(C)c1=O
1226,CHEMBL153062,P28223,4-NONYLPHENOL,IGFHQQFPSIBGKE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7290610,DTCC00341324,1609541,46191,,CCCCCCCCCC1=CC=C(C=C1)O,CCCCCCCCCc1ccc(O)cc1
1233,CHEMBL153479,P28223,AMBROXOL,JBDGDEWWOUBZPM-XYPYZODXSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7289961,DTCC00342236,2057643,46191,,C1CC(CCC1NCC2=C(C(=CC(=C2)Br)Br)N)O,Nc1c(Br)cc(Br)cc1CNC1CCC(O)CC1
1235,CHEMBL1535,P28223,HYDROXYCHLOROQUINE,XXSMGPRMXLTPCZ-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7310813,DTCC00494467,1416033,46191,,CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12
1237,CHEMBL1536,P28223,ERGOCALCIFEROL,MECHNRXZTMCUDQ-RKHKHRCZSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7319778,DTCC00494790,348400,46191,,C[C@H](/C=C/[C@H](C)C(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](CCC3=C)O)C,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)/C=C/[C@H](C)C(C)C
1239,CHEMBL1537,P28223,AZLOCILLIN,JTWOMNBEOCYFNV-NFFDBFGFSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7275266,DTCC00495073,1059328,46191,,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)NC(=O)N4CCNC4=O)C(=O)O)C,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(=O)O
1241,CHEMBL1539,P28223,SULFADOXINE,PJSFRIWCGOHTNF-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7482558,DTCC00495107,1512817,46191,,COC1=C(N=CN=C1OC)NS(=O)(=O)C2=CC=C(C=C2)N,COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC
1246,CHEMBL154,P28223,NAPROXEN,CMWTZPSULFXXJA-VIFPVBQESA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7394575,DTCC00174165,1992809,46191,,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,COc1ccc2cc([C@H](C)C(=O)O)ccc2c1
1248,CHEMBL1540,P28223,PENCICLOVIR,JNTOCHDNEULJHD-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7397723,DTCC00495142,1577007,46191,,C1=NC2=C(N1CCC(CO)CO)N=C(NC2=O)N,Nc1nc2c(ncn2CCC(CO)CO)c(=O)[nH]1
1250,CHEMBL154111,P28223,SALSALATE,WVYADZUPLLSGPU-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7471210,DTCC00343795,1894974,46191,,C1=CC=C(C(=C1)C(=O)OC2=CC=CC=C2C(=O)O)O,O=C(Oc1ccccc1C(=O)O)c1ccccc1O
1252,CHEMBL1542,P28223,AZATHIOPRINE,LMEKQMALGUDUQG-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7266842,DTCC00495633,962447,46191,,CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12
1256,CHEMBL1544,P28223,LIOTHYRONINE,AUYYCJSJGJYCDS-LBPRGKRZSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7297417,DTCC00497321,1480341,46191,,C1=CC(=C(C=C1OC2=C(C=C(C=C2I)C[C@@H](C(=O)O)N)I)I)O,N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O
1259,CHEMBL1550957,P28223,,JLVLNPGKFHWCCQ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23542166.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,Displacement of [3H]-ketanserin from human 5HT2A receptor,,"Structure-activity relationship of 5-chloro-2-methyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole analogues as 5-HT6 receptor agonists.",Eur. J. Med. Chem.,2013.0,63.0,,"Mattsson C, Svensson P, Boettcher H, Sonesson C",,957901.0,DTCT0023186,12414890,DTCC00944758,1127068,54449,5.823908740944319,CC1=C(C2=CC=CC=C2N1)C3=CCNCC3,Cc1[nH]c2ccccc2c1C1=CCNCC1
1260,CHEMBL15511,P28223,ENROFLOXACIN,SPFYMRJSYKOXGV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7332506,DTCC00145113,1577005,46191,,CCN1CCN(CC1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4CC4)F,CCN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC1
1269,CHEMBL1554,P28223,DACTINOMYCIN,RJURFGZVJUQBHK-IIXSONLDSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7365698,DTCC00113195,2089745,46191,,C[C@@H]1[C@@H](C(=O)N[C@@H](C(=O)N2CCC[C@H]2C(=O)N(CC(=O)N([C@H](C(=O)O1)C(C)C)C)C)C(C)C)NC(=O)C3=C4C(=C(C=C3)C)OC5=C(C(=O)C(=C(C5=N4)C(=O)N[C@H]6[C@H](OC(=O)[C@@H](N(C(=O)CN(C(=O)[C@@H]7CCCN7C(=O)[C@H](NC6=O)C(C)C)C)C)C(C)C)C)N)C,Cc1c2oc3c(C)ccc(C(=O)N[C@@H]4C(=O)N[C@H](C(C)C)C(=O)N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)c3nc-2c(C(=O)N[C@@H]2C(=O)N[C@H](C(C)C)C(=O)N3CCC[C@H]3C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]2C)c(N)c1=O
1277,CHEMBL1560,P28223,CAPTOPRIL,FAKRSMQSSFJEIM-RQJHMYQMSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7280586,DTCC00507377,1092341,46191,,C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O,C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O
1280,CHEMBL156455,P28223,"1,1-DICHLOROETHENE",LGXVIGDEPROXKC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7289200,DTCC00349580,866014,46191,,C=C(Cl)Cl,C=C(Cl)Cl
1282,CHEMBL1566,P28223,ACARBOSE,XUFXOAAUWZOOIT-SXARVLRPSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7289631,DTCC00510603,994587,46191,,C[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@H](O[C@@H]([C@@H]([C@H]2O)O)O[C@@H]3[C@H](O[C@H]([C@@H]([C@H]3O)O)O)CO)CO)O)O)N[C@H]4C=C([C@H]([C@@H]([C@H]4O)O)O)CO,C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O
1284,CHEMBL1566249,P28223,AMPIROXICAM,LSNWBKACGXCGAJ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7295518,DTCC00959245,800570,46191,,CCOC(=O)OC(C)OC1=C(N(S(=O)(=O)C2=CC=CC=C21)C)C(=O)NC3=CC=CC=N3,CCOC(=O)OC(C)OC1=C(C(=O)Nc2ccccn2)N(C)S(=O)(=O)c2ccccc21
1286,CHEMBL1566956,P28223,TROXIPIDE,YSIITVVESCNIPR-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7444620,DTCC00959918,283002,46191,,COC1=CC(=CC(=C1OC)OC)C(=O)NC2CCCNC2,COc1cc(C(=O)NC2CCCNC2)cc(OC)c1OC
1288,CHEMBL1567463,P28223,CHOLINE ALFOSCERATE,SUHOQUVVVLNYQR-MRVPVSSYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7364679,DTCC00960399,315662,46191,,C[N+](C)(C)CCOP(=O)([O-])OC[C@@H](CO)O,C[N+](C)(C)CCOP(=O)([O-])OC[C@H](O)CO
1290,CHEMBL1568,P28223,FLUDARABINE,HBUBKKRHXORPQB-FJFJXFQQSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7314008,DTCC00513782,1894966,46191,,C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)F)N,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
1295,CHEMBL157138,P28223,LISURIDE,BKRGVLQUQGGVSM-KBXCAEBGSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,3.04,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7421107,DTCC00350629,1447884,46191,8.517126416391246,CCN(CC)C(=O)N[C@@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C,CCN(CC)C(=O)N[C@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1
1297,CHEMBL1572,P28223,NETILMICIN,CIDUJQMULVCIBT-MQDUPKMGSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7381727,DTCC00514638,1734059,46191,,CCN[C@@H]1C[C@@H]([C@H]([C@@H]([C@H]1O[C@@H]2[C@@H]([C@H]([C@@](CO2)(C)O)NC)O)O)O[C@@H]3[C@@H](CC=C(O3)CN)N)N,CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O
1300,CHEMBL157548,P28223,DANOFLOXACIN,QMLVECGLEOSESV-RYUDHWBXSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7339958,DTCC00348763,1798407,46191,,CN1C[C@@H]2C[C@H]1CN2C3=C(C=C4C(=C3)N(C=C(C4=O)C(=O)O)C5CC5)F,CN1C[C@@H]2C[C@H]1CN2c1cc2c(cc1F)c(=O)c(C(=O)O)cn2C1CC1
1303,CHEMBL15770,P28223,SULINDAC,MLKXDPUZXIRXEP-MFOYZWKCSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7461008,DTCC00145905,930088,46191,,CC\1=C(C2=C(/C1=C\C3=CC=C(C=C3)S(=O)C)C=CC(=C2)F)CC(=O)O,CC1=C(CC(=O)O)c2cc(F)ccc2/C1=C\c1ccc([S+](C)[O-])cc1
1306,CHEMBL158,P28223,AZTREONAM,WZPBZJONDBGPKJ-VEHQQRBSSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7278226,DTCC00182933,510296,46191,,C[C@H]1[C@@H](C(=O)N1S(=O)(=O)O)NC(=O)/C(=N\OC(C)(C)C(=O)O)/C2=CSC(=N2)N,C[C@H]1[C@H](NC(=O)/C(=N\OC(C)(C)C(=O)O)c2csc(N)n2)C(=O)N1S(=O)(=O)O
1313,CHEMBL1586,P28223,BECLOMETHASONE,NBMKJKDGKREAPL-DVTGEIKXSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7272438,DTCC00514882,1188063,46191,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)Cl)C,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
1319,CHEMBL159,P28223,VINBLASTINE,JXLYSJRDGCGARV-CFWMRBGOSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7440999,DTCC00190732,1577012,46191,,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
1322,CHEMBL1592,P28223,QUINAPRIL,JSDRRTOADPPCHY-HSQYWUDLSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7379467,DTCC00515121,1705879,46191,,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)O,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(=O)O
1329,CHEMBL159483,P28223,,DZFRWAZJFQMVAM-GMAHTHKFSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,10052975.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,Synthesis and serotonergic activity of 3-[2-(pyrrolidin-1-yl)ethyl]indoles: potent agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B receptor.,J. Med. Chem.,1999.0,42.0,4.0,"Sternfeld F, Guiblin AR, Jelley RA, Matassa VG, Reeve AJ, Hunt PA, Beer MS, Heald A, Stanton JA, Sohal B, Watt AP, Street LJ",,2269.0,DTCT0023186,1369239,DTCC00354189,1754555,15594,5.522878745280337,C1CN(C[C@@H]1CNCC2=CC=CC=C2)CCC3=CNC4=C3C=C(C=C4)C[C@H]5COC(=O)N5,O=C1N[C@@H](Cc2ccc3[nH]cc(CCN4CC[C@@H](CNCc5ccccc5)C4)c3c2)CO1
1331,CHEMBL1598608,P28223,AZASETRON,WUKZPHOXUVCQOR-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7263926,DTCC00989336,1734053,46191,,CN1C(=O)COC2=C(C=C(C=C21)Cl)C(=O)NC3CN4CCC3CC4,CN1C(=O)COc2c(C(=O)NC3CN4CCC3CC4)cc(Cl)cc21
1335,CHEMBL16,P28223,PHENYTOIN,CXOFVDLJLONNDW-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7376459,DTCC00132980,51500,46191,,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1
1337,CHEMBL160,P28223,CYCLOSPORINE,PMATZTZNYRCHOR-CGLBZJNRSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7365595,DTCC00191777,51461,46191,,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C
1339,CHEMBL160070,P28223,,IKUAJUBZHRXQPW-PTLVVNQVSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,10052975.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,Synthesis and serotonergic activity of 3-[2-(pyrrolidin-1-yl)ethyl]indoles: potent agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B receptor.,J. Med. Chem.,1999.0,42.0,4.0,"Sternfeld F, Guiblin AR, Jelley RA, Matassa VG, Reeve AJ, Hunt PA, Beer MS, Heald A, Stanton JA, Sohal B, Watt AP, Street LJ",,2269.0,DTCT0023186,1373154,DTCC00354187,531200,15594,5.657577319177793,C[C@@H](C1=CC=CC=C1)NC[C@@H]2CCN(C2)CCC3=CNC4=C3C=C(C=C4)C[C@H]5COC(=O)N5,C[C@H](NC[C@@H]1CCN(CCc2c[nH]c3ccc(C[C@H]4COC(=O)N4)cc23)C1)c1ccccc1
1340,CHEMBL1601669,P28223,ALFACALCIDOL,OFHCOWSQAMBJIW-AVJTYSNKSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7281310,DTCC00992187,217572,46191,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C,C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C[C@@H](O)C[C@@H]1O
1344,CHEMBL16068,P28223,BROMOBENZENE,QARVLSVVCXYDNA-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7271482,DTCC00145980,2057646,46191,,C1=CC=C(C=C1)Br,Brc1ccccc1
1346,CHEMBL16073,P28223,PHENACETIN,CPJSUEIXXCENMM-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7372093,DTCC00145899,120977,46191,,CCOC1=CC=C(C=C1)NC(=O)C,CCOc1ccc(NC(C)=O)cc1
1352,CHEMBL1612004,P28223,,VMPITZXILSNTON-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7384363,DTCC01001920,736263,46191,,COC1=CC=CC=C1N,COc1ccccc1N
1355,CHEMBL1614641,P28223,FLUNOXAPROFEN,ARPYQKTVRGFPIS-VIFPVBQESA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7335346,DTCC01003541,510300,46191,,C[C@@H](C1=CC2=C(C=C1)OC(=N2)C3=CC=C(C=C3)F)C(=O)O,C[C@H](C(=O)O)c1ccc2oc(-c3ccc(F)cc3)nc2c1
1357,CHEMBL1617116,P28223,,DCRDNMUOOIZERA-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,22153942.0,IC50,=,519.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]Ketanserin from human recombinant 5HT2A receptor expressed in CHOK1 cells after 60 mins,,5-HT2c receptor selectivity and structure-activity relationship of N-methyl-N-(1-methylpiperidin-4-yl)benzenesulfonamide analogs.,Bioorg. Med. Chem. Lett.,2012.0,22.0,1.0,"Jang JW, Baek JS, Choi GD, Park WK, Cho YS, Baek DJ, Pae AN",,795018.0,DTCT0023186,7579161,DTCC01005164,1927153,46941,6.284832642151542,CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)N(C)C2CCN(CC2)C,CN1CCC(N(C)S(=O)(=O)c2ccc(C(C)(C)C)cc2)CC1
1359,CHEMBL161780,P28223,,MGCUTECDFDAQCK-NRFANRHFSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,10052975.0,IC50,=,5800.0,NM,,,,,,,,,,,,,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,Synthesis and serotonergic activity of 3-[2-(pyrrolidin-1-yl)ethyl]indoles: potent agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B receptor.,J. Med. Chem.,1999.0,42.0,4.0,"Sternfeld F, Guiblin AR, Jelley RA, Matassa VG, Reeve AJ, Hunt PA, Beer MS, Heald A, Stanton JA, Sohal B, Watt AP, Street LJ",,2269.0,DTCT0023186,1401890,DTCC00354237,1533673,15594,5.236572006437063,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN3CC[C@H](C3)CNCC4=CC=CC=C4,CNS(=O)(=O)Cc1ccc2[nH]cc(CCN3CC[C@@H](CNCc4ccccc4)C3)c2c1
1360,CHEMBL1618305,P28223,NALOXONAZINE,AJPSBXJNFJCCBI-YOHUGVJRSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7413769,DTCC01006289,120976,46191,,C=CCN1[C@H]2[C@]3([C@]4(C5=C(C2)C=CC(=C5O[C@H]4/C(=N/N=C\6/[C@@H]7OC8=C(C=CC9=C8[C@]72[C@]([C@@H](C9)N(CC2)CC=C)(CC6)O)O)/CC3)O)CC1)O,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2/C(=N/N=C2\CC[C@@]4(O)[C@H]6Cc7ccc(O)c8c7[C@@]4(CCN6CC=C)[C@H]2O8)CC[C@@]3(O)[C@H]1C5
1363,CHEMBL1619,P28223,CLADRIBINE,PTOAARAWEBMLNO-KVQBGUIXSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7367198,DTCC00525900,217575,46191,,C1[C@@H]([C@H](O[C@H]1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O,Nc1nc(Cl)nc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1
1374,CHEMBL1626,P28223,CLEMASTINE,YNNUSGIPVFPVBX-NHCUHLMSSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,32.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7341443,DTCC00527946,639576,46191,7.494850021680094,C[C@@](C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCC[C@H]3CCCN3C,CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1
1380,CHEMBL1628227,P28223,DOXEPIN,ODQWQRRAPPTVAG-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,38.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7340594,DTCC01015577,898288,46191,7.42021640338319,CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31,CN(C)CCC=C1c2ccccc2COc2ccccc21
1386,CHEMBL1629810,P28223,2-HYDROXYPROPYL-BETA-CYCLODEXTRIN,BIIFEDMBGOQTDO-USCPGHQQSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7302991,DTCC00033243,510295,46191,,CC(COC[C@H]1[C@H]2[C@H]([C@@H](CO1)O[C@H]3[C@@H](O[C@H]([C@H]([C@@H]3O)O)O[C@H]4[C@@H](O[C@H]([C@H]([C@@H]4O)O)O[C@H]5[C@@H](O[C@H]([C@H]([C@@H]5O)O)O[C@H]6[C@@H](O[C@H]([C@H]([C@@H]6O)O)O[C@H]7[C@@H](O[C@H]([C@H]([C@@H]7O)O)O[C@H]8[C@@H](O[C@H]([C@H]([C@@H]8O)O)O[C@H]9[C@@H](O[C@@H](O2)[C@H]([C@@H]9O)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)O)O,CC(O)COC[C@@H]1O[C@H]2O[C@H]3[C@H](COCC(C)O)O[C@@H](O[C@H]4[C@H](COCC(C)O)O[C@@H](O[C@H]5[C@H](COCC(C)O)O[C@@H](O[C@H]6[C@H](COCC(C)O)OC[C@@H](O[C@H]7[C@H](COCC(C)O)O[C@@H](O[C@H]8[C@H](COCC(C)O)O[C@@H](O[C@H]9[C@H](COCC(C)O)O[C@@H](O[C@@H]1[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]9O)[C@@H](O)[C@@H]8O)[C@@H](O)[C@@H]7O)[C@@H]6O)[C@@H](O)[C@@H]5O)[C@@H](O)[C@@H]4O)[C@@H](O)[C@@H]3O
1388,CHEMBL163,P28223,RITONAVIR,NCDNCNXCDXHOMX-XGKFQTDJSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7470946,DTCC00204116,51505,46191,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1
1390,CHEMBL1630578,P28223,TIRILIZAD,RBKASMJPSJDQKY-RBFSKHHSSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,2002.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7457355,DTCC01016434,1798419,46191,5.6985359268567,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4(C3=CC[C@@]2([C@H]1C(=O)CN5CCN(CC5)C6=NC(=NC(=C6)N7CCCC7)N8CCCC8)C)C,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(c2cc(N3CCCC3)nc(N3CCCC3)n2)CC1
1392,CHEMBL1630579,P28223,MYRTECAINE,BZRYYBWNOUALTQ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7411470,DTCC01016435,1416036,46191,,CCN(CC)CCOCCC1=CCC2CC1C2(C)C,CCN(CC)CCOCCC1=CCC2CC1C2(C)C
1413,CHEMBL1642116,P28223,,YLSBAGZHIBFNRL-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21190848.0,IC50,=,366.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]ketanserin from human 5HT2A receptor expressed in cells,,"1-(Arylsulfonyl)-2,3-dihydro-1H-quinolin-4-one derivatives as 5-HT(6) serotonin receptor ligands.",Bioorg. Med. Chem. Lett.,2011.0,21.0,2.0,"Park CM, Choi JI, Choi JH, Kim SY, Park WK, Seong CM",,699510.0,DTCT0023186,5031645,DTCC01018889,1233251,42470,6.436518914605589,CN1CCN(CC1)C2=CC3=C(C=C2)C(=O)CCN3S(=O)(=O)C4=CC5=CC=CC=C5C=C4,CN1CCN(c2ccc3c(c2)N(S(=O)(=O)c2ccc4ccccc4c2)CCC3=O)CC1
1414,CHEMBL1642117,P28223,,TZMHJAWORUSIEG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21190848.0,IC50,=,760.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]ketanserin from human 5HT2A receptor expressed in cells,,"1-(Arylsulfonyl)-2,3-dihydro-1H-quinolin-4-one derivatives as 5-HT(6) serotonin receptor ligands.",Bioorg. Med. Chem. Lett.,2011.0,21.0,2.0,"Park CM, Choi JI, Choi JH, Kim SY, Park WK, Seong CM",,699510.0,DTCT0023186,5031646,DTCC01018890,1778664,42470,6.119186407719209,CN1CCN(CC1)C2=C3C(=O)CCN(C3=CC=C2)S(=O)(=O)C4=CC5=CC=CC=C5C=C4,CN1CCN(c2cccc3c2C(=O)CCN3S(=O)(=O)c2ccc3ccccc3c2)CC1
1415,CHEMBL1642118,P28223,,MLWMWKMYRSHCPJ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21190848.0,IC50,=,1462.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]ketanserin from human 5HT2A receptor expressed in cells,,"1-(Arylsulfonyl)-2,3-dihydro-1H-quinolin-4-one derivatives as 5-HT(6) serotonin receptor ligands.",Bioorg. Med. Chem. Lett.,2011.0,21.0,2.0,"Park CM, Choi JI, Choi JH, Kim SY, Park WK, Seong CM",,699510.0,DTCT0023186,5031647,DTCC01018891,781013,42470,5.835052627378158,CC1CC(=O)C2=C(N1S(=O)(=O)C3=CC4=CC=CC=C4C=C3)C=C(C=C2)N5CCN(CC5)C,CC1CC(=O)c2ccc(N3CCN(C)CC3)cc2N1S(=O)(=O)c1ccc2ccccc2c1
1416,CHEMBL1642123,P28223,,JYJNPJVGVPZHKA-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21190848.0,IC50,=,48.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]ketanserin from human 5HT2A receptor expressed in cells,,"1-(Arylsulfonyl)-2,3-dihydro-1H-quinolin-4-one derivatives as 5-HT(6) serotonin receptor ligands.",Bioorg. Med. Chem. Lett.,2011.0,21.0,2.0,"Park CM, Choi JI, Choi JH, Kim SY, Park WK, Seong CM",,699510.0,DTCT0023186,5031648,DTCC01018896,2038506,42470,7.318758762624412,CC1CC(=O)C2=C(C=CC=C2N1S(=O)(=O)C3=CC4=CC=CC=C4C=C3)N5CCN(CC5)C,CC1CC(=O)c2c(N3CCN(C)CC3)cccc2N1S(=O)(=O)c1ccc2ccccc2c1
1417,CHEMBL1642126,P28223,,PXEURUZEVKVPGJ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21190848.0,IC50,=,455.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]ketanserin from human 5HT2A receptor expressed in cells,,"1-(Arylsulfonyl)-2,3-dihydro-1H-quinolin-4-one derivatives as 5-HT(6) serotonin receptor ligands.",Bioorg. Med. Chem. Lett.,2011.0,21.0,2.0,"Park CM, Choi JI, Choi JH, Kim SY, Park WK, Seong CM",,699510.0,DTCT0023186,5031649,DTCC01018899,1875462,42470,6.341988603342887,CCC1CC(=O)C2=C(C=CC=C2N1S(=O)(=O)C3=CC4=CC=CC=C4C=C3)N5CCN(CC5)C,CCC1CC(=O)c2c(N3CCN(C)CC3)cccc2N1S(=O)(=O)c1ccc2ccccc2c1
1418,CHEMBL1642128,P28223,,NFWRARMIHODAKJ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21190848.0,IC50,=,704.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]ketanserin from human 5HT2A receptor expressed in cells,,"1-(Arylsulfonyl)-2,3-dihydro-1H-quinolin-4-one derivatives as 5-HT(6) serotonin receptor ligands.",Bioorg. Med. Chem. Lett.,2011.0,21.0,2.0,"Park CM, Choi JI, Choi JH, Kim SY, Park WK, Seong CM",,699510.0,DTCT0023186,5031650,DTCC01018901,619858,42470,6.152427340857888,CC1CC(=O)C2=C(C=C(C=C2N1S(=O)(=O)C3=CC4=CC=CC=C4C=C3)C)N5CCN(CC5)C,Cc1cc(N2CCN(C)CC2)c2c(c1)N(S(=O)(=O)c1ccc3ccccc3c1)C(C)CC2=O
1419,CHEMBL164290,P28223,N-NITROSODIETHYLAMINE,WBNQDOYYEUMPFS-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7415822,DTCC00108812,703983,46191,,CCN(CC)N=O,CCN(CC)N=O
1421,CHEMBL1643,P28223,RIBAVIRIN,IWUCXVSUMQZMFG-AFCXAGJDSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7472881,DTCC00540588,217584,46191,,C1=NC(=NN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N,NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1
1473,CHEMBL165,P28223,RESVERATROL,LUKBXSAWLPMMSZ-OWOJBTEDSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7468508,DTCC00217176,930085,46191,,C1=CC(=CC=C1/C=C/C2=CC(=CC(=C2)O)O)O,Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1
1475,CHEMBL1650,P28223,CORTISONE ACETATE,ITRJWOMZKQRYTA-RFZYENFJSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7365475,DTCC00542150,1705875,46191,,CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(CC(=O)[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)O,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@@]21C
1482,CHEMBL1651906,P28223,STREPTOZOTOCIN,ZSJLQEPLLKMAKR-YDEIVXIUSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7482443,DTCC01024120,1318448,46191,,CN(C(=O)N[C@@H]1[C@H]([C@@H]([C@H](OC1O)CO)O)O)N=O,CN(N=O)C(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O
1486,CHEMBL165790,P28223,IPRIFLAVONE,SFBODOKJTYAUCM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7409616,DTCC00358921,542578,46191,,CC(C)OC1=CC2=C(C=C1)C(=O)C(=CO2)C3=CC=CC=C3,CC(C)Oc1ccc2c(=O)c(-c3ccccc3)coc2c1
1489,CHEMBL1660,P28223,RIFAPENTINE,WDZCUPBHRAEYDL-GZAUEHORSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7485821,DTCC00550275,930086,46191,,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C6CCCC6)/C,CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C6CCCC6)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C
1495,CHEMBL1670,P28223,MITOTANE,JWBOIMRXGHLCPP-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7436964,DTCC00555980,2057649,46191,,C1=CC=C(C(=C1)C(C2=CC=C(C=C2)Cl)C(Cl)Cl)Cl,Clc1ccc(C(c2ccccc2Cl)C(Cl)Cl)cc1
1498,CHEMBL1679,P28223,LEUCOVORIN,VVIAGPKUTFNRDU-ABLWVSNPSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7437942,DTCC00560549,1188068,46191,,C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,Nc1nc2c(c(=O)[nH]1)N(C=O)C(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2
1500,CHEMBL167911,P28223,DICHLORVOS,OEBRKCOSUFCWJD-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7340185,DTCC00362299,1544896,46191,,COP(=O)(OC)OC=C(Cl)Cl,COP(=O)(OC)OC=C(Cl)Cl
1506,CHEMBL1687,P28223,TUBOCURARINE CHLORIDE,MHXYWXHKLBMJKL-QBYKQQEBSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7357057,DTCC00570867,1253320,46191,,CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C6[C@@H](CC7=CC(=C(C=C7)O)O3)[N+](CCC6=CC(=C5O)OC)(C)C)OC.[Cl-],COc1cc2c3cc1Oc1cc(ccc1O)C[C@@H]1c4c(cc(OC)c(O)c4Oc4ccc(cc4)C[C@@H]3N(C)CC2)CC[N+]1(C)C
1508,CHEMBL1697694,P28223,AFLATOXIN,OQIQSTLJSLGHID-WNWIJWBNSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7292304,DTCC00127800,1092339,46191,,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,COc1cc2c(c3oc(=O)c4c(c13)CCC4=O)[C@@H]1C=CO[C@@H]1O2
1517,CHEMBL1712923,P28223,IRSOGLADINE MALEATE,PJLVTVAIERNDEQ-BTJKTKAUSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7426830,DTCC01047420,1894969,46191,,C1=CC(=C(C=C1Cl)C2=NC(=NC(=N2)N)N)Cl.C(=C\C(=O)O)\C(=O)O,Nc1nc(N)nc(-c2cc(Cl)ccc2Cl)n1
1520,CHEMBL17157,P28223,TERFENADINE,GUGOEEXESWIERI-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,255.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7480916,DTCC00148306,510307,46191,6.5934598195660445,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
1528,CHEMBL1726,P28223,NISOLDIPINE,VKQFCGNPDRICFG-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7392773,DTCC00583129,1830687,46191,,CC1=C(C(C(=C(N1)C)C(=O)OCC(C)C)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1c1ccccc1[N+](=O)[O-]
1530,CHEMBL1727,P28223,CEPHALEXIN,ZAIPMKNFIOOWCQ-UEKVPHQBSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7360174,DTCC00584128,444636,46191,,CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)SC1)C(=O)O,CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1
1533,CHEMBL1729,P28223,CISAPRIDE,DCSUBABJRXZOMT-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,3.86,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7345649,DTCC00585645,315663,46191,8.413412695328246,COC1CN(CCC1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC
1535,CHEMBL1730,P28223,CEFOTAXIME,GPRBEKHLDVQUJE-QSWIMTSFSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7351532,DTCC00585909,51453,46191,,CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\OC)/C3=CSC(=N3)N)SC1)C(=O)O,CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(C)=O)CS[C@H]12)c1csc(N)n1
1537,CHEMBL1732,P28223,DIHYDROERGOTAMINE,LUZRJRNZXALNLM-JGRZULCMSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,7.96,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7359694,DTCC00586321,381008,46191,8.099086932262331,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21
1539,CHEMBL174,P28223,AMPICILLIN,AVKUERGKIZMTKX-NJBDSQKTSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7292827,DTCC00385816,51446,46191,,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(=O)O
1542,CHEMBL1741,P28223,CLARITHROMYCIN,AGOYDEPGAOXOCK-KCBOHYOISA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7371600,DTCC00596664,1641846,46191,,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
1546,CHEMBL1744448,P28223,BLEOMYCIN A2,LOLFAJUUOFBGSF-KYIYJVAASA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7277275,DTCC00127875,898283,46191,,C[C@@H]([C@H]([C@@H](C)NC(=O)[C@H](C(C1=CN=CN1)O[C@H]2[C@H]([C@H]([C@@H]([C@@H](O2)CO)O)O)O[C@@H]3[C@H]([C@H]([C@@H]([C@H](O3)CO)O)OC(=O)N)O)NC(=O)C4=CC(=NC(=N4)C(CC(=O)N)NCC(C(=O)N)N)N)O)C(=O)N[C@@H](C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C.[Br-],CC(O)[C@H](NC(=O)[C@@H](C)[C@@H](O)[C@@H](C)NC(=O)[C@@H](NC(=O)c1cc(N)nc(C(CC(N)=O)NCC(N)C(N)=O)n1)C(O[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1cnc[nH]1)C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1
1548,CHEMBL1747,P28223,TOBRAMYCIN,NLVFBUXFDBBNBW-PBSUHMDJSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7461729,DTCC00603485,1734066,46191,,C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H](C[C@@H]([C@H](O3)CN)O)N)N,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O
1551,CHEMBL175,P28223,DEXIBUPROFEN,HEFNNWSXXWATRW-JTQLQIEISA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7348602,DTCC00396784,1862715,46191,,C[C@@H](C1=CC=C(C=C1)CC(C)C)C(=O)O,CC(C)Cc1ccc([C@H](C)C(=O)O)cc1
1553,CHEMBL1751,P28223,DIGOXIN,LTMHDMANZUZIPE-PUGKRICDSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7351088,DTCC00607566,51464,46191,,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6C[C@@H](O)[C@]7(C)[C@@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O
1555,CHEMBL1752,P28223,DYPHYLLINE,KSCFJBIXMNOVSH-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7304662,DTCC00607571,2089746,46191,,CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(CO)O,Cn1c(=O)c2c(ncn2CC(O)CO)n(C)c1=O
1557,CHEMBL1753,P28223,CLINDAMYCIN,KDLRVYVGXIQJDK-AWPVFWJPSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7349993,DTCC00607595,898286,46191,,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@H](C)Cl,CCC[C@@H]1C[C@@H](C(=O)N[C@H]([C@H](C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)N(C)C1
1559,CHEMBL1754,P28223,DOXAPRAM,XFDJYSQDBULQSI-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7342760,DTCC00607599,1027051,46191,,CCN1CC(C(C1=O)(C2=CC=CC=C2)C3=CC=CC=C3)CCN4CCOCC4,CCN1CC(CCN2CCOCC2)C(c2ccccc2)(c2ccccc2)C1=O
1566,CHEMBL1760,P28223,TERBUTALINE,XWTYSIMOBUGWOL-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7472251,DTCC00609006,542583,46191,,CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O,CC(C)(C)NCC(O)c1cc(O)cc(O)c1
1569,CHEMBL1762,P28223,TOCAINIDE,BUJAGSGYPOAWEI-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7466119,DTCC00609197,1544903,46191,,CC1=C(C(=CC=C1)C)NC(=O)C(C)N,Cc1cccc(C)c1NC(=O)C(C)N
1575,CHEMBL1766,P28223,DESOXIMETASONE,VWVSBHGCDBMOOT-IIEHVVJPSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7365775,DTCC00610116,348397,46191,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@H]1C(=O)CO)C)O)F)C,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO
1577,CHEMBL177,P28223,AMIKACIN,LKCWBDHBTVXHDL-RMDFUYIESA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7295237,DTCC00409875,1253318,46191,,C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1NC(=O)[C@H](CCN)O)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)O)N,NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O
1581,CHEMBL1771,P28223,CLOPIDOGREL,GKTWGGQPFAXNFI-HNNXBMFYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7345917,DTCC00616891,639577,46191,,COC(=O)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1
1630,CHEMBL177756,P28223,FLUORESCEIN,YKGGGCXBWXHKIZ-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7314102,DTCC00376005,1894967,46191,,C1=CC=C(C(=C1)C2=C3C=CC(=O)C=C3OC4=C2C=CC(=C4)O)C(=O)O,O=C(O)c1ccccc1-c1c2ccc(=O)cc-2oc2cc(O)ccc12
1636,CHEMBL178,P28223,DAUNORUBICIN,STQGQHZAVUOBTE-VGBVRHCVSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7348520,DTCC00413150,477916,46191,,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1
1659,CHEMBL1790041,P28223,RANITIDINE,VMXUWOKSQNHOCA-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7455426,DTCC01089619,2025642,46191,,CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C,CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1
1663,CHEMBL179234,P28223,,REZSROOERNUDJU-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,15634025.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,Inhibition of [3H]ketanserin binding to human 5-HT2 receptor,,2-(4-alkylpiperazin-1-yl)quinolines as a new class of imidazole-free histamine H3 receptor antagonists.,J. Med. Chem.,2005.0,48.0,1.0,"Zaragoza F, Stephensen H, Peschke B, Rimvall K",,305803.0,DTCT0023186,1738460,DTCC00380388,1036839,19220,5.0,C1CC1C(=O)C2=CC3=C(C=C2)N=C(C=C3)N4CCN(CC4)C5CC5,O=C(c1ccc2nc(N3CCN(C4CC4)CC3)ccc2c1)C1CC1
1671,CHEMBL179578,P28223,,HOMYCGKCEABFJF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,15634025.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,Inhibition of [3H]ketanserin binding to human 5-HT2 receptor,,2-(4-alkylpiperazin-1-yl)quinolines as a new class of imidazole-free histamine H3 receptor antagonists.,J. Med. Chem.,2005.0,48.0,1.0,"Zaragoza F, Stephensen H, Peschke B, Rimvall K",,305803.0,DTCT0023186,1738444,DTCC00380592,745883,19220,5.0,C1CC1N2CCN(CC2)C3=NC4=CC=CC=C4C=C3,c1ccc2nc(N3CCN(C4CC4)CC3)ccc2c1
1675,CHEMBL179993,P28223,,MQFKIDUREUWWAN-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,15582404.0,IC50,=,800.0,NM,,,,,,,,,,,,,,Inhibitory concentration against human 5-hydroxytryptamine 2A receptor,,"Modulators of the human CCR5 receptor. Part 1: Discovery and initial SAR of 1-(3,3-diphenylpropyl)-piperidinyl amides and ureas.",Bioorg. Med. Chem. Lett.,2005.0,15.0,1.0,"Burrows JN, Cumming JG, Fillery SM, Hamlin GA, Hudson JA, Jackson RJ, McLaughlin S, Shaw JS",,305882.0,DTCT0023186,1758239,DTCC00385400,2078790,18438,6.096910013008056,CCN(C1CCN(CC1)CCC(C2=CC=CC=C2)C3=CC=CC=C3)C(=O)CC4=CC=C(C=C4)S(=O)(=O)N(C)C,CCN(C(=O)Cc1ccc(S(=O)(=O)N(C)C)cc1)C1CCN(CCC(c2ccccc2)c2ccccc2)CC1
1711,CHEMBL181,P28223,DIAZOXIDE,GDLBFKVLRPITMI-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7370314,DTCC00110806,800574,46191,,CC1=NS(=O)(=O)C2=C(N1)C=CC(=C2)Cl,CC1=NS(=O)(=O)c2cc(Cl)ccc2N1
1728,CHEMBL182,P28223,GANCICLOVIR,IRSCQMHQWWYFCW-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7316568,DTCC00437788,639580,46191,,C1=NC2=C(N1COC(CO)CO)N=C(NC2=O)N,Nc1nc2c(ncn2COC(CO)CO)c(=O)[nH]1
1773,CHEMBL184,P28223,ACYCLOVIR,MKUXAQIIEYXACX-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7289748,DTCC00438001,51442,46191,,C1=NC2=C(N1COCCO)N=C(NC2=O)N,Nc1nc2c(ncn2COCCO)c(=O)[nH]1
1776,CHEMBL184618,P28223,NEOMYCIN,PGBHMTALBVVCIT-VCIWKGPPSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7405514,DTCC00392052,1894971,46191,,C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O)O)N)O)O)N,NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O
1778,CHEMBL184717,P28223,,OKIVGPUCUWMOIH-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,15225734.0,IC50,=,2180.0,NM,,,,,,,,,,,,,,Inhibitory activity against human 5-HT2A receptor,,Structure-activity relationships of a novel series of melanin-concentrating hormone (MCH) receptor antagonists.,Bioorg. Med. Chem. Lett.,2004.0,14.0,15.0,"Arienzo R, Clark DE, Cramp S, Daly S, Dyke HJ, Lockey P, Norman D, Roach AG, Stuttle K, Tomlinson M, Wong M, Wren SP",,304724.0,DTCT0023186,1761346,DTCC00387260,1981680,18167,5.661543506395395,CC1=CC(=NC2=C1C=C(C=C2)NC(=O)COC3=CC=C(C=C3)Cl)N4CCN(CC4)C,Cc1cc(N2CCN(C)CC2)nc2ccc(NC(=O)COc3ccc(Cl)cc3)cc12
1781,CHEMBL185,P28223,FLUOROURACIL,GHASVSINZRGABV-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7322601,DTCC00440753,51471,46191,,C1=C(C(=O)NC(=O)N1)F,O=c1[nH]cc(F)c(=O)[nH]1
1783,CHEMBL1852333,P28223,,NFNYZLRYJMHHBL-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,103.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605728,DTCC01113144,1933107,64683,6.987162775294828,CCCC1=NC(=CN1C2=CC=CC=C2)C(=O)NCCCN3CCN(CC3)C4=CC=CC(=C4C)C,CCCc1nc(C(=O)NCCCN2CCN(c3cccc(C)c3C)CC2)cn1-c1ccccc1
1784,CHEMBL1852333,P28223,,NFNYZLRYJMHHBL-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,133.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605670,DTCC01113144,1933107,64683,6.876148359032914,CCCC1=NC(=CN1C2=CC=CC=C2)C(=O)NCCCN3CCN(CC3)C4=CC=CC(=C4C)C,CCCc1nc(C(=O)NCCCN2CCN(c3cccc(C)c3C)CC2)cn1-c1ccccc1
1785,CHEMBL1852333,P28223,,NFNYZLRYJMHHBL-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,133.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264269,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,178874,DTCC01113144,1933107,64683,6.876148359032914,CCCC1=NC(=CN1C2=CC=CC=C2)C(=O)NCCCN3CCN(CC3)C4=CC=CC(=C4C)C,CCCc1nc(C(=O)NCCCN2CCN(c3cccc(C)c3C)CC2)cn1-c1ccccc1
1786,CHEMBL1852339,P28223,,HCGQCONLMOZSLC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,27.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605649,DTCC01113150,2063734,64683,7.568636235841013,CCC1=NC(=C(N1C2=CC=CC=C2)C)C(=O)NCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,CCc1nc(C(=O)NCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccccc1
1787,CHEMBL1852339,P28223,,HCGQCONLMOZSLC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,27.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264248,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,162104,DTCC01113150,2063734,64683,7.568636235841013,CCC1=NC(=C(N1C2=CC=CC=C2)C)C(=O)NCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,CCc1nc(C(=O)NCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccccc1
1788,CHEMBL1852339,P28223,,HCGQCONLMOZSLC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,62.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605707,DTCC01113150,2063734,64683,7.2076083105017466,CCC1=NC(=C(N1C2=CC=CC=C2)C)C(=O)NCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,CCc1nc(C(=O)NCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccccc1
1789,CHEMBL1852341,P28223,,JXNOGBVEQNMHDF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,12.1,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605701,DTCC01113152,1161852,64683,7.91721462968355,CC1=C(N=C(N1C2=CC=CC=C2)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Cc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccccc1
1790,CHEMBL1852341,P28223,,JXNOGBVEQNMHDF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,18.6,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605643,DTCC01113152,1161852,64683,7.730487055782084,CC1=C(N=C(N1C2=CC=CC=C2)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Cc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccccc1
1791,CHEMBL1852341,P28223,,JXNOGBVEQNMHDF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,18.6,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264242,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,168858,DTCC01113152,1161852,64683,7.730487055782084,CC1=C(N=C(N1C2=CC=CC=C2)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Cc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccccc1
1792,CHEMBL1852345,P28223,,DXQCCZNEUHNYEV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,70.8,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605672,DTCC01113156,1868831,64683,7.149966742310231,CCCC1=NC(=C(N1C2=CC=C(C=C2)OC)C)C(=O)NCCCN3CCN(CC3)C4=CC=CC(=C4C)C,CCCc1nc(C(=O)NCCCN2CCN(c3cccc(C)c3C)CC2)c(C)n1-c1ccc(OC)cc1
1793,CHEMBL1852345,P28223,,DXQCCZNEUHNYEV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,70.8,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264271,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,171691,DTCC01113156,1868831,64683,7.149966742310231,CCCC1=NC(=C(N1C2=CC=C(C=C2)OC)C)C(=O)NCCCN3CCN(CC3)C4=CC=CC(=C4C)C,CCCc1nc(C(=O)NCCCN2CCN(c3cccc(C)c3C)CC2)c(C)n1-c1ccc(OC)cc1
1794,CHEMBL1852345,P28223,,DXQCCZNEUHNYEV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,130.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605730,DTCC01113156,1868831,64683,6.886056647693163,CCCC1=NC(=C(N1C2=CC=C(C=C2)OC)C)C(=O)NCCCN3CCN(CC3)C4=CC=CC(=C4C)C,CCCc1nc(C(=O)NCCCN2CCN(c3cccc(C)c3C)CC2)c(C)n1-c1ccc(OC)cc1
1795,CHEMBL1852346,P28223,,ONVKKRDCLORHEM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,144.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605657,DTCC01113157,936320,64683,6.841637507904751,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4OC)C)C,COc1ccccc1-n1c(C)nc(C(=O)NCCCN2CCN(c3cccc(C)c3C)CC2)c1C
1796,CHEMBL1852346,P28223,,ONVKKRDCLORHEM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,144.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264256,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,170101,DTCC01113157,936320,64683,6.841637507904751,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4OC)C)C,COc1ccccc1-n1c(C)nc(C(=O)NCCCN2CCN(c3cccc(C)c3C)CC2)c1C
1797,CHEMBL1852346,P28223,,ONVKKRDCLORHEM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,146.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605715,DTCC01113157,936320,64683,6.835647144215563,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4OC)C)C,COc1ccccc1-n1c(C)nc(C(=O)NCCCN2CCN(c3cccc(C)c3C)CC2)c1C
1798,CHEMBL1852358,P28223,,NVCPMQGMUOQYGP-SANMLTNESA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,20.1,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605683,DTCC01113169,1836849,64683,7.696803942579511,CC1=C(C=CC=C1Cl)N2CCN(CC2)C[C@H](CNC(=O)C3=C(N(C(=N3)C4=CC=CC=C4)C5=CC=C(C=C5)F)C)O,Cc1c(Cl)cccc1N1CCN(C[C@@H](O)CNC(=O)c2nc(-c3ccccc3)n(-c3ccc(F)cc3)c2C)CC1
1799,CHEMBL1852358,P28223,,NVCPMQGMUOQYGP-SANMLTNESA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,20.1,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264282,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,181607,DTCC01113169,1836849,64683,7.696803942579511,CC1=C(C=CC=C1Cl)N2CCN(CC2)C[C@H](CNC(=O)C3=C(N(C(=N3)C4=CC=CC=C4)C5=CC=C(C=C5)F)C)O,Cc1c(Cl)cccc1N1CCN(C[C@@H](O)CNC(=O)c2nc(-c3ccccc3)n(-c3ccc(F)cc3)c2C)CC1
1800,CHEMBL1852358,P28223,,NVCPMQGMUOQYGP-SANMLTNESA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,534.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605741,DTCC01113169,1836849,64683,6.272458742971444,CC1=C(C=CC=C1Cl)N2CCN(CC2)C[C@H](CNC(=O)C3=C(N(C(=N3)C4=CC=CC=C4)C5=CC=C(C=C5)F)C)O,Cc1c(Cl)cccc1N1CCN(C[C@@H](O)CNC(=O)c2nc(-c3ccccc3)n(-c3ccc(F)cc3)c2C)CC1
1801,CHEMBL1852359,P28223,,QGDLULRBFVJDIF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,80.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605659,DTCC01113170,1648033,64683,7.096910013008056,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4Cl)C)C,Cc1cccc(N2CCN(CCCNC(=O)c3nc(C)n(-c4ccccc4Cl)c3C)CC2)c1C
1802,CHEMBL1852359,P28223,,QGDLULRBFVJDIF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,80.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264258,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,169153,DTCC01113170,1648033,64683,7.096910013008056,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4Cl)C)C,Cc1cccc(N2CCN(CCCNC(=O)c3nc(C)n(-c4ccccc4Cl)c3C)CC2)c1C
1803,CHEMBL1852359,P28223,,QGDLULRBFVJDIF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,200.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605717,DTCC01113170,1648033,64683,6.698970004336019,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4Cl)C)C,Cc1cccc(N2CCN(CCCNC(=O)c3nc(C)n(-c4ccccc4Cl)c3C)CC2)c1C
1804,CHEMBL1852361,P28223,,ZYRAIIWLKDYELQ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,32.4,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605641,DTCC01113172,1648034,64683,7.489454989793388,CCCC1=NC(=CN1C2=CC=C(C=C2)Cl)C(=O)NCCCN3CCN(CC3)C4=CC=CC(=C4C)C,CCCc1nc(C(=O)NCCCN2CCN(c3cccc(C)c3C)CC2)cn1-c1ccc(Cl)cc1
1805,CHEMBL1852361,P28223,,ZYRAIIWLKDYELQ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,32.4,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264240,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,169441,DTCC01113172,1648034,64683,7.489454989793388,CCCC1=NC(=CN1C2=CC=C(C=C2)Cl)C(=O)NCCCN3CCN(CC3)C4=CC=CC(=C4C)C,CCCc1nc(C(=O)NCCCN2CCN(c3cccc(C)c3C)CC2)cn1-c1ccc(Cl)cc1
1806,CHEMBL1852361,P28223,,ZYRAIIWLKDYELQ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,37.9,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605699,DTCC01113172,1648034,64683,7.421360790031928,CCCC1=NC(=CN1C2=CC=C(C=C2)Cl)C(=O)NCCCN3CCN(CC3)C4=CC=CC(=C4C)C,CCCc1nc(C(=O)NCCCN2CCN(c3cccc(C)c3C)CC2)cn1-c1ccc(Cl)cc1
1807,CHEMBL1852362,P28223,,WVYVQPDAOPUYBM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,126.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605678,DTCC01113173,710085,64683,6.8996294548824375,CCCC1=NC(=C(N1C2=CC=C(C=C2)OC)C)C(=O)NCC(CN3CCN(CC3)C4=CC=CC(=C4C)C)O,CCCc1nc(C(=O)NCC(O)CN2CCN(c3cccc(C)c3C)CC2)c(C)n1-c1ccc(OC)cc1
1808,CHEMBL1852362,P28223,,WVYVQPDAOPUYBM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,126.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264277,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,184172,DTCC01113173,710085,64683,6.8996294548824375,CCCC1=NC(=C(N1C2=CC=C(C=C2)OC)C)C(=O)NCC(CN3CCN(CC3)C4=CC=CC(=C4C)C)O,CCCc1nc(C(=O)NCC(O)CN2CCN(c3cccc(C)c3C)CC2)c(C)n1-c1ccc(OC)cc1
1809,CHEMBL1852362,P28223,,WVYVQPDAOPUYBM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,425.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605736,DTCC01113173,710085,64683,6.371611069949688,CCCC1=NC(=C(N1C2=CC=C(C=C2)OC)C)C(=O)NCC(CN3CCN(CC3)C4=CC=CC(=C4C)C)O,CCCc1nc(C(=O)NCC(O)CN2CCN(c3cccc(C)c3C)CC2)c(C)n1-c1ccc(OC)cc1
1810,CHEMBL1852370,P28223,,ANIIFABGCPBBJW-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,16.8,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605695,DTCC01113181,249,64683,7.774690718274137,CC1=C(N=C(N1C2=CC=CC=C2F)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Cc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccccc1F
1811,CHEMBL1852370,P28223,,ANIIFABGCPBBJW-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,16.8,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264294,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,157588,DTCC01113181,249,64683,7.774690718274137,CC1=C(N=C(N1C2=CC=CC=C2F)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Cc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccccc1F
1812,CHEMBL1852370,P28223,,ANIIFABGCPBBJW-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,50.8,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605753,DTCC01113181,249,64683,7.294136287716081,CC1=C(N=C(N1C2=CC=CC=C2F)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Cc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccccc1F
1813,CHEMBL1852372,P28223,,ILGBEANMYUWLKV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,21.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605644,DTCC01113183,191539,64683,7.6777807052660805,CCCC1=NC(=C(N1C2=CC=CC=C2)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,CCCc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccccc1
1814,CHEMBL1852372,P28223,,ILGBEANMYUWLKV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,21.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264243,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,170251,DTCC01113183,191539,64683,7.6777807052660805,CCCC1=NC(=C(N1C2=CC=CC=C2)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,CCCc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccccc1
1815,CHEMBL1852372,P28223,,ILGBEANMYUWLKV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,189.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605702,DTCC01113183,191539,64683,6.723538195826756,CCCC1=NC(=C(N1C2=CC=CC=C2)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,CCCc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccccc1
1816,CHEMBL1852373,P28223,,SDELPNZPQHTXIM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,19.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605675,DTCC01113184,1130589,64683,7.721246399047171,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=CN(C(=N3)C4=CC=CC=C4)C5=CC=C(C=C5)OC)C,COc1ccc(-n2cc(C(=O)NCCCN3CCN(c4cccc(C)c4C)CC3)nc2-c2ccccc2)cc1
1817,CHEMBL1852373,P28223,,SDELPNZPQHTXIM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,19.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264274,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,157610,DTCC01113184,1130589,64683,7.721246399047171,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=CN(C(=N3)C4=CC=CC=C4)C5=CC=C(C=C5)OC)C,COc1ccc(-n2cc(C(=O)NCCCN3CCN(c4cccc(C)c4C)CC3)nc2-c2ccccc2)cc1
1818,CHEMBL1852373,P28223,,SDELPNZPQHTXIM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,101.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605733,DTCC01113184,1130589,64683,6.995678626217358,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=CN(C(=N3)C4=CC=CC=C4)C5=CC=C(C=C5)OC)C,COc1ccc(-n2cc(C(=O)NCCCN3CCN(c4cccc(C)c4C)CC3)nc2-c2ccccc2)cc1
1819,CHEMBL1852374,P28223,,JEKNYMKFHWTAIS-DEOSSOPVSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,646.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605680,DTCC01113185,1389940,64683,6.189767482004916,CC1=C(C(=CC=C1)N2CCN(CC2)C[C@H](CNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4)C)O)C,Cc1cccc(N2CCN(C[C@@H](O)CNC(=O)c3nc(C)n(-c4ccccc4)c3C)CC2)c1C
1820,CHEMBL1852374,P28223,,JEKNYMKFHWTAIS-DEOSSOPVSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,646.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264279,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,185039,DTCC01113185,1389940,64683,6.189767482004916,CC1=C(C(=CC=C1)N2CCN(CC2)C[C@H](CNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4)C)O)C,Cc1cccc(N2CCN(C[C@@H](O)CNC(=O)c3nc(C)n(-c4ccccc4)c3C)CC2)c1C
1821,CHEMBL1852374,P28223,,JEKNYMKFHWTAIS-DEOSSOPVSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,1779.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605738,DTCC01113185,1389940,64683,5.749824051916075,CC1=C(C(=CC=C1)N2CCN(CC2)C[C@H](CNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4)C)O)C,Cc1cccc(N2CCN(C[C@@H](O)CNC(=O)c3nc(C)n(-c4ccccc4)c3C)CC2)c1C
1822,CHEMBL1852387,P28223,,UDZQCEVTHMQRHA-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,58.6,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605696,DTCC01113198,191538,64683,7.23210238398191,CC1=C(C(=CC=C1)N2CCN(CC2)CC(CNC(=O)C3=C(N(C(=N3)C4=CC=CC=C4)C5=CC=CC=C5)C)O)C,Cc1cccc(N2CCN(CC(O)CNC(=O)c3nc(-c4ccccc4)n(-c4ccccc4)c3C)CC2)c1C
1823,CHEMBL1852387,P28223,,UDZQCEVTHMQRHA-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,58.6,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264295,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,173059,DTCC01113198,191538,64683,7.23210238398191,CC1=C(C(=CC=C1)N2CCN(CC2)CC(CNC(=O)C3=C(N(C(=N3)C4=CC=CC=C4)C5=CC=CC=C5)C)O)C,Cc1cccc(N2CCN(CC(O)CNC(=O)c3nc(-c4ccccc4)n(-c4ccccc4)c3C)CC2)c1C
1824,CHEMBL1852387,P28223,,UDZQCEVTHMQRHA-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,525.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605754,DTCC01113198,191538,64683,6.279840696594043,CC1=C(C(=CC=C1)N2CCN(CC2)CC(CNC(=O)C3=C(N(C(=N3)C4=CC=CC=C4)C5=CC=CC=C5)C)O)C,Cc1cccc(N2CCN(CC(O)CNC(=O)c3nc(-c4ccccc4)n(-c4ccccc4)c3C)CC2)c1C
1825,CHEMBL1852418,P28223,,WIADIALKINPUDL-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,45.5,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605653,DTCC01113229,256111,64683,7.341988603342887,CC1=C(C=CC=C1Cl)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)CC(C)C)C,Cc1c(Cl)cccc1N1CCN(CCCNC(=O)c2nc(C)n(CC(C)C)c2C)CC1
1826,CHEMBL1852418,P28223,,WIADIALKINPUDL-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,45.5,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264252,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,162205,DTCC01113229,256111,64683,7.341988603342887,CC1=C(C=CC=C1Cl)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)CC(C)C)C,Cc1c(Cl)cccc1N1CCN(CCCNC(=O)c2nc(C)n(CC(C)C)c2C)CC1
1827,CHEMBL1852418,P28223,,WIADIALKINPUDL-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,2221.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605711,DTCC01113229,256111,64683,5.6534514414515264,CC1=C(C=CC=C1Cl)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)CC(C)C)C,Cc1c(Cl)cccc1N1CCN(CCCNC(=O)c2nc(C)n(CC(C)C)c2C)CC1
1828,CHEMBL1852420,P28223,,UYDMKMOJVOCNCN-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,840.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605655,DTCC01113231,1389939,64683,6.075720713938118,CCCN1C(=C(N=C1C)C(=O)NCC(CN2CCN(CC2)C3=CC=CC(=C3C)C)O)C,CCCn1c(C)nc(C(=O)NCC(O)CN2CCN(c3cccc(C)c3C)CC2)c1C
1829,CHEMBL1852420,P28223,,UYDMKMOJVOCNCN-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,840.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264254,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,173476,DTCC01113231,1389939,64683,6.075720713938118,CCCN1C(=C(N=C1C)C(=O)NCC(CN2CCN(CC2)C3=CC=CC(=C3C)C)O)C,CCCn1c(C)nc(C(=O)NCC(O)CN2CCN(c3cccc(C)c3C)CC2)c1C
1830,CHEMBL1852420,P28223,,UYDMKMOJVOCNCN-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605713,DTCC01113231,1389939,64683,5.0,CCCN1C(=C(N=C1C)C(=O)NCC(CN2CCN(CC2)C3=CC=CC(=C3C)C)O)C,CCCn1c(C)nc(C(=O)NCC(O)CN2CCN(c3cccc(C)c3C)CC2)c1C
1831,CHEMBL1852422,P28223,,XDJQMZTWECSFPC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,10.3,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605686,DTCC01113233,839598,64683,7.987162775294828,CC1=C(N=C(N1C2=CC=CC=C2OC)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,COc1ccccc1-n1c(C)nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1C
1832,CHEMBL1852422,P28223,,XDJQMZTWECSFPC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,10.3,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264285,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,157131,DTCC01113233,839598,64683,7.987162775294828,CC1=C(N=C(N1C2=CC=CC=C2OC)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,COc1ccccc1-n1c(C)nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1C
1833,CHEMBL1852422,P28223,,XDJQMZTWECSFPC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,25.5,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605744,DTCC01113233,839598,64683,7.5934598195660445,CC1=C(N=C(N1C2=CC=CC=C2OC)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,COc1ccccc1-n1c(C)nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1C
1834,CHEMBL1852466,P28223,,CPTMTPODYRWAHG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,12.8,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605685,DTCC01113277,1933108,64683,7.892790030352131,CC1=C(C=CC=C1Cl)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4OC)C,COc1ccccc1-n1c(C)nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3C)CC2)c1C
1835,CHEMBL1852466,P28223,,CPTMTPODYRWAHG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,12.8,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264284,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,172644,DTCC01113277,1933108,64683,7.892790030352131,CC1=C(C=CC=C1Cl)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4OC)C,COc1ccccc1-n1c(C)nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3C)CC2)c1C
1836,CHEMBL1852466,P28223,,CPTMTPODYRWAHG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,37.4,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605743,DTCC01113277,1933108,64683,7.42712839779952,CC1=C(C=CC=C1Cl)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4OC)C,COc1ccccc1-n1c(C)nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3C)CC2)c1C
1837,CHEMBL1852472,P28223,,RAZNWWDFVRZIFC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,39.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605645,DTCC01113283,1454037,64683,7.4089353929735005,CCCC1=NC(=C(N1C2=CC=CC=C2)C)C(=O)NCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,CCCc1nc(C(=O)NCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccccc1
1838,CHEMBL1852472,P28223,,RAZNWWDFVRZIFC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,39.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264244,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,172351,DTCC01113283,1454037,64683,7.4089353929735005,CCCC1=NC(=C(N1C2=CC=CC=C2)C)C(=O)NCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,CCCc1nc(C(=O)NCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccccc1
1839,CHEMBL1852472,P28223,,RAZNWWDFVRZIFC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,109.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605703,DTCC01113283,1454037,64683,6.962573502059376,CCCC1=NC(=C(N1C2=CC=CC=C2)C)C(=O)NCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,CCCc1nc(C(=O)NCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccccc1
1840,CHEMBL1852485,P28223,,KLFKNFRLZJDZER-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,20.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605646,DTCC01113296,1259541,64683,7.698970004336019,CC1=C(N=C(N1C2=CC=C(C=C2)OC)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,COc1ccc(-n2c(C)nc(C(=O)NCCCN3CCN(c4cccc(Cl)c4Cl)CC3)c2C)cc1
1841,CHEMBL1852485,P28223,,KLFKNFRLZJDZER-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,20.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264245,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,166411,DTCC01113296,1259541,64683,7.698970004336019,CC1=C(N=C(N1C2=CC=C(C=C2)OC)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,COc1ccc(-n2c(C)nc(C(=O)NCCCN3CCN(c4cccc(Cl)c4Cl)CC3)c2C)cc1
1842,CHEMBL1852485,P28223,,KLFKNFRLZJDZER-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,88.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605704,DTCC01113296,1259541,64683,7.055517327849832,CC1=C(N=C(N1C2=CC=C(C=C2)OC)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,COc1ccc(-n2c(C)nc(C(=O)NCCCN3CCN(c4cccc(Cl)c4Cl)CC3)c2C)cc1
1843,CHEMBL1852501,P28223,,JEKNYMKFHWTAIS-XMMPIXPASA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,72.5,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605692,DTCC01113312,645878,64683,7.139661993429006,CC1=C(C(=CC=C1)N2CCN(CC2)C[C@@H](CNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4)C)O)C,Cc1cccc(N2CCN(C[C@H](O)CNC(=O)c3nc(C)n(-c4ccccc4)c3C)CC2)c1C
1844,CHEMBL1852501,P28223,,JEKNYMKFHWTAIS-XMMPIXPASA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,72.5,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264291,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,166168,DTCC01113312,645878,64683,7.139661993429006,CC1=C(C(=CC=C1)N2CCN(CC2)C[C@@H](CNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4)C)O)C,Cc1cccc(N2CCN(C[C@H](O)CNC(=O)c3nc(C)n(-c4ccccc4)c3C)CC2)c1C
1845,CHEMBL1852501,P28223,,JEKNYMKFHWTAIS-XMMPIXPASA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,227.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605750,DTCC01113312,645878,64683,6.6439741428068775,CC1=C(C(=CC=C1)N2CCN(CC2)C[C@@H](CNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4)C)O)C,Cc1cccc(N2CCN(C[C@H](O)CNC(=O)c3nc(C)n(-c4ccccc4)c3C)CC2)c1C
1846,CHEMBL1852503,P28223,,WKFAPLKCZNAYLA-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,8.63,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605691,DTCC01113314,774439,64683,8.063989204284791,CC1=C(N=C(N1C2=CC3=C(C=C2)OCCO3)C)C(=O)NCCCN4CCN(CC4)C5=C(C(=CC=C5)Cl)Cl,Cc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccc2c(c1)OCCO2
1847,CHEMBL1852503,P28223,,WKFAPLKCZNAYLA-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,8.63,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264290,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,156817,DTCC01113314,774439,64683,8.063989204284791,CC1=C(N=C(N1C2=CC3=C(C=C2)OCCO3)C)C(=O)NCCCN4CCN(CC4)C5=C(C(=CC=C5)Cl)Cl,Cc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccc2c(c1)OCCO2
1848,CHEMBL1852503,P28223,,WKFAPLKCZNAYLA-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,14.6,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605749,DTCC01113314,774439,64683,7.835647144215563,CC1=C(N=C(N1C2=CC3=C(C=C2)OCCO3)C)C(=O)NCCCN4CCN(CC4)C5=C(C(=CC=C5)Cl)Cl,Cc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccc2c(c1)OCCO2
1849,CHEMBL1852505,P28223,,LHEJTKMJJCJPDM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,23.1,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605679,DTCC01113316,256110,64683,7.636388020107856,CC1=C(C=CC=C1Cl)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4=CC=C(C=C4)OC)C,COc1ccc(-n2c(C)nc(C(=O)NCCCN3CCN(c4cccc(Cl)c4C)CC3)c2C)cc1
1850,CHEMBL1852505,P28223,,LHEJTKMJJCJPDM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,23.1,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264278,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,175798,DTCC01113316,256110,64683,7.636388020107856,CC1=C(C=CC=C1Cl)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4=CC=C(C=C4)OC)C,COc1ccc(-n2c(C)nc(C(=O)NCCCN3CCN(c4cccc(Cl)c4C)CC3)c2C)cc1
1851,CHEMBL1852505,P28223,,LHEJTKMJJCJPDM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,93.6,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605737,DTCC01113316,256110,64683,7.028724151261895,CC1=C(C=CC=C1Cl)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4=CC=C(C=C4)OC)C,COc1ccc(-n2c(C)nc(C(=O)NCCCN3CCN(c4cccc(Cl)c4C)CC3)c2C)cc1
1852,CHEMBL1852507,P28223,,LACMMHDNOBHVQF-JOCHJYFZSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,193.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605751,DTCC01113318,1901207,64683,6.714442690992226,CC1=C(C(=CC=C1)N2CCN(CC2)C[C@@H](CNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4F)C)O)C,Cc1cccc(N2CCN(C[C@H](O)CNC(=O)c3nc(C)n(-c4ccccc4F)c3C)CC2)c1C
1853,CHEMBL1852507,P28223,,LACMMHDNOBHVQF-JOCHJYFZSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,270.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605693,DTCC01113318,1901207,64683,6.568636235841013,CC1=C(C(=CC=C1)N2CCN(CC2)C[C@@H](CNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4F)C)O)C,Cc1cccc(N2CCN(C[C@H](O)CNC(=O)c3nc(C)n(-c4ccccc4F)c3C)CC2)c1C
1854,CHEMBL1852507,P28223,,LACMMHDNOBHVQF-JOCHJYFZSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,270.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264292,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,176400,DTCC01113318,1901207,64683,6.568636235841013,CC1=C(C(=CC=C1)N2CCN(CC2)C[C@@H](CNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4F)C)O)C,Cc1cccc(N2CCN(C[C@H](O)CNC(=O)c3nc(C)n(-c4ccccc4F)c3C)CC2)c1C
1855,CHEMBL1852513,P28223,,LACMMHDNOBHVQF-QFIPXVFZSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,244.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605681,DTCC01113324,1098474,64683,6.61261017366127,CC1=C(C(=CC=C1)N2CCN(CC2)C[C@H](CNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4F)C)O)C,Cc1cccc(N2CCN(C[C@@H](O)CNC(=O)c3nc(C)n(-c4ccccc4F)c3C)CC2)c1C
1856,CHEMBL1852513,P28223,,LACMMHDNOBHVQF-QFIPXVFZSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,244.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264280,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,181682,DTCC01113324,1098474,64683,6.61261017366127,CC1=C(C(=CC=C1)N2CCN(CC2)C[C@H](CNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4F)C)O)C,Cc1cccc(N2CCN(C[C@@H](O)CNC(=O)c3nc(C)n(-c4ccccc4F)c3C)CC2)c1C
1857,CHEMBL1852513,P28223,,LACMMHDNOBHVQF-QFIPXVFZSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,1031.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605739,DTCC01113324,1098474,64683,5.986741334716483,CC1=C(C(=CC=C1)N2CCN(CC2)C[C@H](CNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4F)C)O)C,Cc1cccc(N2CCN(C[C@@H](O)CNC(=O)c3nc(C)n(-c4ccccc4F)c3C)CC2)c1C
1858,CHEMBL1852514,P28223,,VRODRHYZYZUMEV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,595.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605712,DTCC01113325,742405,64683,6.22548303427145,CC1=C(C(=CC=C1)N2CCN(CC2)CC(CNC(=O)C3=C(N(C(=N3)C)CC(C)C)C)O)C,Cc1cccc(N2CCN(CC(O)CNC(=O)c3nc(C)n(CC(C)C)c3C)CC2)c1C
1859,CHEMBL1852514,P28223,,VRODRHYZYZUMEV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,1011.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605654,DTCC01113325,742405,64683,5.995248844408999,CC1=C(C(=CC=C1)N2CCN(CC2)CC(CNC(=O)C3=C(N(C(=N3)C)CC(C)C)C)O)C,Cc1cccc(N2CCN(CC(O)CNC(=O)c3nc(C)n(CC(C)C)c3C)CC2)c1C
1860,CHEMBL1852514,P28223,,VRODRHYZYZUMEV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,1011.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264253,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,158467,DTCC01113325,742405,64683,5.995248844408999,CC1=C(C(=CC=C1)N2CCN(CC2)CC(CNC(=O)C3=C(N(C(=N3)C)CC(C)C)C)O)C,Cc1cccc(N2CCN(CC(O)CNC(=O)c3nc(C)n(CC(C)C)c3C)CC2)c1C
1861,CHEMBL1852516,P28223,,QDRMTYQLXZSORG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,31.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14635517,DTCC01113327,1615914,64683,7.508638306165727,CC1=C(N=C(N1C2=CC=CC=C2)C)C(=O)NCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Cc1nc(C(=O)NCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccccc1
1862,CHEMBL1852516,P28223,,QDRMTYQLXZSORG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,31.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",19821,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,172364,DTCC01113327,1615914,64683,7.508638306165727,CC1=C(N=C(N1C2=CC=CC=C2)C)C(=O)NCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Cc1nc(C(=O)NCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccccc1
1863,CHEMBL1852516,P28223,,QDRMTYQLXZSORG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,66.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14635518,DTCC01113327,1615914,64683,7.180456064458132,CC1=C(N=C(N1C2=CC=CC=C2)C)C(=O)NCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Cc1nc(C(=O)NCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccccc1
1864,CHEMBL1852517,P28223,,FSVRRFIIJNMQRT-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,15.2,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605676,DTCC01113328,191537,64683,7.818156412055227,CCCC1=NC(=C(N1C2=CC=C(C=C2)OC)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)C,CCCc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3C)CC2)c(C)n1-c1ccc(OC)cc1
1865,CHEMBL1852517,P28223,,FSVRRFIIJNMQRT-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,15.2,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264275,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,157606,DTCC01113328,191537,64683,7.818156412055227,CCCC1=NC(=C(N1C2=CC=C(C=C2)OC)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)C,CCCc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3C)CC2)c(C)n1-c1ccc(OC)cc1
1866,CHEMBL1852517,P28223,,FSVRRFIIJNMQRT-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,204.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605734,DTCC01113328,191537,64683,6.690369832574102,CCCC1=NC(=C(N1C2=CC=C(C=C2)OC)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)C,CCCc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3C)CC2)c(C)n1-c1ccc(OC)cc1
1867,CHEMBL1852552,P28223,,FPVNLHBKJTWGSL-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,40.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605694,DTCC01113363,1098473,64683,7.3979400086720375,CC1=C(C=CC=C1Cl)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4F)C,Cc1c(Cl)cccc1N1CCN(CCCNC(=O)c2nc(C)n(-c3ccccc3F)c2C)CC1
1868,CHEMBL1852552,P28223,,FPVNLHBKJTWGSL-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,40.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264293,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,170663,DTCC01113363,1098473,64683,7.3979400086720375,CC1=C(C=CC=C1Cl)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4F)C,Cc1c(Cl)cccc1N1CCN(CCCNC(=O)c2nc(C)n(-c3ccccc3F)c2C)CC1
1869,CHEMBL1852552,P28223,,FPVNLHBKJTWGSL-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,71.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605752,DTCC01113363,1098473,64683,7.1487416512809245,CC1=C(C=CC=C1Cl)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4F)C,Cc1c(Cl)cccc1N1CCN(CCCNC(=O)c2nc(C)n(-c3ccccc3F)c2C)CC1
1870,CHEMBL1852587,P28223,,VLJJUAAYWAAFPF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,217.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605652,DTCC01113398,1259540,64683,6.663540266151471,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)CC(C)C)C)C,Cc1cccc(N2CCN(CCCNC(=O)c3nc(C)n(CC(C)C)c3C)CC2)c1C
1871,CHEMBL1852587,P28223,,VLJJUAAYWAAFPF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,217.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264251,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,160116,DTCC01113398,1259540,64683,6.663540266151471,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)CC(C)C)C)C,Cc1cccc(N2CCN(CCCNC(=O)c3nc(C)n(CC(C)C)c3C)CC2)c1C
1872,CHEMBL1852587,P28223,,VLJJUAAYWAAFPF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,10140.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605710,DTCC01113398,1259540,64683,4.993962045002683,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)CC(C)C)C)C,Cc1cccc(N2CCN(CCCNC(=O)c3nc(C)n(CC(C)C)c3C)CC2)c1C
1873,CHEMBL1852617,P28223,,DGDZAQYQPGLDNH-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,105.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605661,DTCC01113427,839597,64683,6.978810700930062,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C(C)C)C4=CC=CC=C4)C)C,Cc1cccc(N2CCN(CCCNC(=O)c3nc(C(C)C)n(-c4ccccc4)c3C)CC2)c1C
1874,CHEMBL1852617,P28223,,DGDZAQYQPGLDNH-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,105.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264260,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,165704,DTCC01113427,839597,64683,6.978810700930062,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C(C)C)C4=CC=CC=C4)C)C,Cc1cccc(N2CCN(CCCNC(=O)c3nc(C(C)C)n(-c4ccccc4)c3C)CC2)c1C
1875,CHEMBL1852617,P28223,,DGDZAQYQPGLDNH-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,290.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605719,DTCC01113427,839597,64683,6.537602002101044,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C(C)C)C4=CC=CC=C4)C)C,Cc1cccc(N2CCN(CCCNC(=O)c3nc(C(C)C)n(-c4ccccc4)c3C)CC2)c1C
1876,CHEMBL1852659,P28223,,NUEJBTILNWQDFU-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,5.17,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605684,DTCC01113467,1711929,64683,8.286509456906057,CCCC1=NC(=C(N1C2=CC=C(C=C2)OC)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,CCCc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccc(OC)cc1
1877,CHEMBL1852659,P28223,,NUEJBTILNWQDFU-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,5.17,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264283,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,176992,DTCC01113467,1711929,64683,8.286509456906057,CCCC1=NC(=C(N1C2=CC=C(C=C2)OC)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,CCCc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccc(OC)cc1
1878,CHEMBL1852659,P28223,,NUEJBTILNWQDFU-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,146.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605742,DTCC01113467,1711929,64683,6.835647144215563,CCCC1=NC(=C(N1C2=CC=C(C=C2)OC)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,CCCc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccc(OC)cc1
1879,CHEMBL1852665,P28223,,MMAQGTSQMRXGFK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,52.1,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605687,DTCC01113473,1771966,64683,7.283162276700476,CC1=C(N=C(N1C2=CC=CC=C2OC)C)C(=O)NCC(CN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl)O,COc1ccccc1-n1c(C)nc(C(=O)NCC(O)CN2CCN(c3cccc(Cl)c3Cl)CC2)c1C
1880,CHEMBL1852665,P28223,,MMAQGTSQMRXGFK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,52.1,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264286,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,172666,DTCC01113473,1771966,64683,7.283162276700476,CC1=C(N=C(N1C2=CC=CC=C2OC)C)C(=O)NCC(CN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl)O,COc1ccccc1-n1c(C)nc(C(=O)NCC(O)CN2CCN(c3cccc(Cl)c3Cl)CC2)c1C
1881,CHEMBL1852665,P28223,,MMAQGTSQMRXGFK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,76.6,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605745,DTCC01113473,1771966,64683,7.115771230367396,CC1=C(N=C(N1C2=CC=CC=C2OC)C)C(=O)NCC(CN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl)O,COc1ccccc1-n1c(C)nc(C(=O)NCC(O)CN2CCN(c3cccc(Cl)c3Cl)CC2)c1C
1882,CHEMBL1852666,P28223,,BZMIPAGTGZJILI-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,9.86,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605690,DTCC01113474,774438,64683,8.006123085058789,CC1=C(N=C(N1C2=CC3=C(C=C2)OCCO3)C)C(=O)NCC(CN4CCN(CC4)C5=C(C(=CC=C5)Cl)Cl)O,Cc1nc(C(=O)NCC(O)CN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccc2c(c1)OCCO2
1883,CHEMBL1852666,P28223,,BZMIPAGTGZJILI-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,9.86,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264289,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,170842,DTCC01113474,774438,64683,8.006123085058789,CC1=C(N=C(N1C2=CC3=C(C=C2)OCCO3)C)C(=O)NCC(CN4CCN(CC4)C5=C(C(=CC=C5)Cl)Cl)O,Cc1nc(C(=O)NCC(O)CN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccc2c(c1)OCCO2
1884,CHEMBL1852666,P28223,,BZMIPAGTGZJILI-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,94.3,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605748,DTCC01113474,774438,64683,7.0254883072626715,CC1=C(N=C(N1C2=CC3=C(C=C2)OCCO3)C)C(=O)NCC(CN4CCN(CC4)C5=C(C(=CC=C5)Cl)Cl)O,Cc1nc(C(=O)NCC(O)CN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccc2c(c1)OCCO2
1885,CHEMBL1852774,P28223,,CLXHLHGZDIFZAT-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,63.1,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605677,DTCC01113581,1648035,64683,7.199970640755866,CCCC1=NC(=C(N1C2=CC=C(C=C2)OC)C)C(=O)NCC(CN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl)O,CCCc1nc(C(=O)NCC(O)CN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccc(OC)cc1
1886,CHEMBL1852774,P28223,,CLXHLHGZDIFZAT-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,63.1,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264276,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,183030,DTCC01113581,1648035,64683,7.199970640755866,CCCC1=NC(=C(N1C2=CC=C(C=C2)OC)C)C(=O)NCC(CN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl)O,CCCc1nc(C(=O)NCC(O)CN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccc(OC)cc1
1887,CHEMBL1852774,P28223,,CLXHLHGZDIFZAT-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,544.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605735,DTCC01113581,1648035,64683,6.2644011003018205,CCCC1=NC(=C(N1C2=CC=C(C=C2)OC)C)C(=O)NCC(CN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl)O,CCCc1nc(C(=O)NCC(O)CN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccc(OC)cc1
1888,CHEMBL1852777,P28223,,GIFCMCVWGWADSC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,24.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605697,DTCC01113584,1771965,64683,7.619788758288394,CC1=C(N=C(N1C2=CC=CC=C2)C3=CC=CC=C3)C(=O)NCC(CN4CCN(CC4)C5=C(C(=CC=C5)Cl)Cl)O,Cc1c(C(=O)NCC(O)CN2CCN(c3cccc(Cl)c3Cl)CC2)nc(-c2ccccc2)n1-c1ccccc1
1889,CHEMBL1852777,P28223,,GIFCMCVWGWADSC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,24.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264296,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,162862,DTCC01113584,1771965,64683,7.619788758288394,CC1=C(N=C(N1C2=CC=CC=C2)C3=CC=CC=C3)C(=O)NCC(CN4CCN(CC4)C5=C(C(=CC=C5)Cl)Cl)O,Cc1c(C(=O)NCC(O)CN2CCN(c3cccc(Cl)c3Cl)CC2)nc(-c2ccccc2)n1-c1ccccc1
1890,CHEMBL1852777,P28223,,GIFCMCVWGWADSC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,551.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605755,DTCC01113584,1771965,64683,6.258848401148215,CC1=C(N=C(N1C2=CC=CC=C2)C3=CC=CC=C3)C(=O)NCC(CN4CCN(CC4)C5=C(C(=CC=C5)Cl)Cl)O,Cc1c(C(=O)NCC(O)CN2CCN(c3cccc(Cl)c3Cl)CC2)nc(-c2ccccc2)n1-c1ccccc1
1891,CHEMBL1852779,P28223,,GQSLSFIXXDXGCZ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,32.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605662,DTCC01113586,1357311,64683,7.494850021680094,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4=CC(=CC(=C4)OC)OC)C)C,COc1cc(OC)cc(-n2c(C)nc(C(=O)NCCCN3CCN(c4cccc(C)c4C)CC3)c2C)c1
1892,CHEMBL1852779,P28223,,GQSLSFIXXDXGCZ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,32.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264261,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,170151,DTCC01113586,1357311,64683,7.494850021680094,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4=CC(=CC(=C4)OC)OC)C)C,COc1cc(OC)cc(-n2c(C)nc(C(=O)NCCCN3CCN(c4cccc(C)c4C)CC3)c2C)c1
1893,CHEMBL1852779,P28223,,GQSLSFIXXDXGCZ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,159.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605720,DTCC01113586,1357311,64683,6.798602875679548,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4=CC(=CC(=C4)OC)OC)C)C,COc1cc(OC)cc(-n2c(C)nc(C(=O)NCCCN3CCN(c4cccc(C)c4C)CC3)c2C)c1
1894,CHEMBL1852811,P28223,,CDUMRTXECVLKGP-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,48.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605648,DTCC01113618,1680229,64683,7.318758762624412,CCC1=NC(=C(N1C2=CC=CC=C2)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,CCc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccccc1
1895,CHEMBL1852811,P28223,,CDUMRTXECVLKGP-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,48.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264247,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,176712,DTCC01113618,1680229,64683,7.318758762624412,CCC1=NC(=C(N1C2=CC=CC=C2)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,CCc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccccc1
1896,CHEMBL1852811,P28223,,CDUMRTXECVLKGP-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,140.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605706,DTCC01113618,1680229,64683,6.853871964321762,CCC1=NC(=C(N1C2=CC=CC=C2)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,CCc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccccc1
1900,CHEMBL18701,P28223,RO-201724,PDMUULPVBYQBBK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7475316,DTCC00149559,1674149,46191,,CCCCOC1=C(C=CC(=C1)CC2CNC(=O)N2)OC,CCCCOc1cc(CC2CNC(=O)N2)ccc1OC
1902,CHEMBL1873703,P28223,DIELDRIN,DFBKLUNHFCTMDC-PICURKEMSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7359649,DTCC01123582,800575,46191,,C1[C@@H]2[C@H]3[C@@H]([C@H]1[C@H]4[C@@H]2O4)[C@]5(C(=C([C@@]3(C5(Cl)Cl)Cl)Cl)Cl)Cl,ClC1=C(Cl)[C@]2(Cl)[C@@H]3[C@@H]4C[C@H]([C@@H]3[C@@]1(Cl)C2(Cl)Cl)[C@H]1O[C@@H]41
1917,CHEMBL18785,P28223,RU-24969,KRVMLPUDAOWOGN-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23542166.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,Displacement of [3H]-ketanserin from human 5HT2A receptor,,"Structure-activity relationship of 5-chloro-2-methyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole analogues as 5-HT6 receptor agonists.",Eur. J. Med. Chem.,2013.0,63.0,,"Mattsson C, Svensson P, Boettcher H, Sonesson C",,957901.0,DTCT0023186,12414843,DTCC00149969,545212,54449,6.0,COC1=CC2=C(C=C1)NC=C2C3=CCNCC3,COc1ccc2[nH]cc(C3=CCNCC3)c2c1
1927,CHEMBL18797,P28223,SULINDAC SULFIDE,LFWHFZJPXXOYNR-MFOYZWKCSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7465431,DTCC00150119,994595,46191,,CC\1=C(C2=C(/C1=C\C3=CC=C(C=C3)SC)C=CC(=C2)F)CC(=O)O,CSc1ccc(/C=C2/C(C)=C(CC(=O)O)c3cc(F)ccc32)cc1
1935,CHEMBL188921,P28223,BUFLOMEDIL,OWYLAEYXIQKAOL-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7280365,DTCC00395665,1188065,46191,,COC1=CC(=C(C(=C1)OC)C(=O)CCCN2CCCC2)OC,COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1
1937,CHEMBL189,P28223,MILRINONE,PZRHRDRVRGEVNW-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7424156,DTCC00450749,930081,46191,,CC1=C(C=C(C(=O)N1)C#N)C2=CC=NC=C2,Cc1[nH]c(=O)c(C#N)cc1-c1ccncc1
1940,CHEMBL189118,P28223,,RVSLLQIPFFIMSB-KPKJPENVSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16134937.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor,,"6-Acylamino-2-aminoquinolines as potent melanin-concentrating hormone 1 receptor antagonists. Identification, structure-activity relationship, and investigation of binding mode.",J. Med. Chem.,2005.0,48.0,18.0,"Ulven T, Frimurer TM, Receveur JM, Little PB, Rist O, Nørregaard PK, Högberg T",,321345.0,DTCT0023186,1850329,DTCC00398845,713842,19863,5.721246399047171,CC1=CC(=NC2=C1C=C(C=C2)NC(=O)/C=C/C3=CC=C(C=C3)OC(F)(F)F)N(C)CCN(C)C,Cc1cc(N(C)CCN(C)C)nc2ccc(NC(=O)/C=C/c3ccc(OC(F)(F)F)cc3)cc12
1941,CHEMBL189171,P28223,ACEMETACIN,FSQKKOOTNAMONP-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7297750,DTCC00393990,800567,46191,,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)OCC(=O)O,COc1ccc2c(c1)c(CC(=O)OCC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1
1952,CHEMBL190,P28223,THEOPHYLLINE,ZFXYFBGIUFBOJW-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7465927,DTCC00451755,413979,46191,,CN1C2=C(C(=O)N(C1=O)C)NC=N2,Cn1c(=O)c2[nH]cnc2n(C)c1=O
1955,CHEMBL19019,P28223,NALTREXONE,DQCKKXVULJGBQN-XFWGSAIBSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7385963,DTCC00149948,88632,46191,,C1CC1CN2CC[C@]34[C@@H]5C(=O)CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
1957,CHEMBL1902627,P28223,CLORPRENALINE,SSMSBSWKLKKXGG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7350178,DTCC01151693,866018,46191,,CC(C)NCC(C1=CC=CC=C1Cl)O,CC(C)NCC(O)c1ccccc1Cl
1959,CHEMBL1902981,P28223,EPERISONE,SQUNAWUMZGQQJD-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7306962,DTCC01152035,348399,46191,,CCC1=CC=C(C=C1)C(=O)C(C)CN2CCCCC2,CCc1ccc(C(=O)C(C)CN2CCCCC2)cc1
1966,CHEMBL1908355,P28223,TENIDAP,LXIKEPCNDFVJKC-QXMHVHEDSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7454805,DTCC01156858,1285881,46191,,C1=CSC(=C1)C(=O)C2=C(N(C3=C2C=C(C=C3)Cl)C(=O)N)O,NC(=O)n1c(O)c(C(=O)c2cccs2)c2cc(Cl)ccc21
1968,CHEMBL1909048,P28223,,RBCUCXILXJXLTB-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7291652,DTCC00128929,444633,46191,,C1CN(CCC1CC2=CC=CC=C2)C(=O)C3=CC=CC=C3Cl,O=C(c1ccccc1Cl)N1CCC(Cc2ccccc2)CC1
1970,CHEMBL1909049,P28223,,FSIWGHXVLYRBFQ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7297225,DTCC00128930,930074,46191,,COC1=CC=CC=C1C(=O)N2CCC(CC2)CC3=CC=CC=C3,COc1ccccc1C(=O)N1CCC(Cc2ccccc2)CC1
1972,CHEMBL1909050,P28223,,DLDAZIVPAOLETE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7299974,DTCC01157054,413966,46191,,CC1=CC=CC=C1C(=O)N2CCC(CC2)CC3=CC=CC=C3,Cc1ccccc1C(=O)N1CCC(Cc2ccccc2)CC1
1974,CHEMBL1909051,P28223,,LUHHARLTABWBTO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7303101,DTCC01157055,1480342,46191,,C1CN(CCC1CC2=CC=CC=C2)C(=O)C3=CC=CC=C3C(F)(F)F,O=C(c1ccccc1C(F)(F)F)N1CCC(Cc2ccccc2)CC1
1990,CHEMBL1909065,P28223,LYSERGOL,RWVUEZAROXKXRT-VQLSFVLHSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,8.69,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7427617,DTCC01157063,510303,46191,8.060980223551333,C[C@H]1C[C@H]([C@@](O[C@@H]1[C@H]2C[C@@H]([C@@H](O2)[C@@]3(CC[C@@H](O3)[C@@]4(CC[C@@]5(O4)C[C@@H]([C@H]([C@H](O5)[C@@H](C)[C@H]6[C@@H]([C@H]([C@@H]([C@](O6)(CC(=O)O)O)C)OC)OC)C)O)C)C)O[C@@H]7C[C@@H]([C@H]([C@@H](O7)C)OC)OC)(C)O)C,CO[C@H]1C[C@@H](O[C@H]2C[C@H]([C@H]3O[C@](C)(O)[C@H](C)C[C@@H]3C)O[C@H]2[C@]2(C)CC[C@H]([C@]3(C)CC[C@]4(C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H]5O[C@](O)(CC(=O)O)[C@@H](C)[C@H](OC)[C@H]5OC)O4)O3)O2)O[C@@H](C)[C@@H]1OC
1998,CHEMBL1909070,P28223,NAFENOPIN,XJGBDJOMWKAZJS-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7437193,DTCC01157067,866020,46191,,CC(C)(C(=O)O)OC1=CC=C(C=C1)C2CCCC3=CC=CC=C23,CC(C)(Oc1ccc(C2CCCc3ccccc32)cc1)C(=O)O
2002,CHEMBL1909072,P28223,PIPAMAZINE,OSJJYEUEJRVVOD-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,1.94,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7396018,DTCC01157069,1927019,46191,8.712198270069774,C1CN(CCC1C(=O)N)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl,NC(=O)C1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1
2004,CHEMBL1909073,P28223,PIPERILATE ETHOBROMIDE,VPUGSHLBERYQGC-UHFFFAOYSA-M,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7404674,DTCC01157070,348403,46191,,CC[N+]1(CCCCC1)CCOC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O.[Br-],CC[N+]1(CCOC(=O)C(O)(c2ccccc2)c2ccccc2)CCCCC1
2010,CHEMBL1909076,P28223,,RSTSYGXUDMJEFP-SECBINFHSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7475435,DTCC01157073,1894973,46191,,C1=CC=C(C=C1)CNC(=S)SC[C@H](C(=O)O)N,N[C@H](CSC(=S)NCc1ccccc1)C(=O)O
2012,CHEMBL1909078,P28223,SODIUM ARSENITE,PTLRDCMBXHILCL-UHFFFAOYSA-M,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7458292,DTCC01157074,1351117,46191,,[O-][As]=O.[Na+],O=[As][O-]
2016,CHEMBL1909080,P28223,STRONTIUM CHLORIDE HEXAHYDRATE,AMGRXJSJSONEEG-UHFFFAOYSA-L,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7486667,DTCC01157076,1124455,46191,,O.O.O.O.O.O.[Cl-].[Cl-].[Sr+2],O
2020,CHEMBL191,P28223,LOSARTAN,PSIFNNKUMBGKDQ-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7410424,DTCC00475883,1705876,46191,,CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl,CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1
2025,CHEMBL192,P28223,SILDENAFIL,BNRNXUUZRGQAQC-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7480021,DTCC00477686,639584,46191,,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12
2031,CHEMBL19215,P28223,METERGOLINE,WZHJKEUHNJHDLS-QTGUNEKASA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,0.395,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7417350,DTCC00150357,315666,46191,9.40340290437354,CN1C[C@@H](C[C@H]2[C@H]1CC3=CN(C4=CC=CC2=C34)C)CNC(=O)OCC5=CC=CC=C5,CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@@H]2c3cccc4c3c(cn4C)C[C@H]21
2033,CHEMBL19224,P28223,PAPAVERINE,XQYZDYMELSJDRZ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7371885,DTCC00150178,1351115,46191,,COC1=C(C=C(C=C1)CC2=NC=CC3=CC(=C(C=C32)OC)OC)OC,COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC
2036,CHEMBL19236,P28223,MOXONIDINE,WPNJAUFVNXKLIM-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7432819,DTCC00150160,1894970,46191,,CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC,COc1nc(C)nc(Cl)c1NC1=NCCN1
2041,CHEMBL19299,P28223,LOXOPROFEN,YMBXTVYHTMGZDW-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7419083,DTCC00151156,1960076,46191,,CC(C1=CC=C(C=C1)CC2CCCC2=O)C(=O)O,CC(C(=O)O)c1ccc(CC2CCCC2=O)cc1
2043,CHEMBL193,P28223,NIFEDIPINE,HYIMSNHJOBLJNT-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7401297,DTCC00485676,51493,46191,,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-]
2045,CHEMBL1933396,P28223,,ABIQOIQMOXNLQX-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,22153942.0,IC50,=,5900.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]Ketanserin from human recombinant 5HT2A receptor expressed in CHOK1 cells after 60 mins,,5-HT2c receptor selectivity and structure-activity relationship of N-methyl-N-(1-methylpiperidin-4-yl)benzenesulfonamide analogs.,Bioorg. Med. Chem. Lett.,2012.0,22.0,1.0,"Jang JW, Baek JS, Choi GD, Park WK, Cho YS, Baek DJ, Pae AN",,795018.0,DTCT0023186,7579155,DTCC01167826,1705986,46941,5.229147988357856,CN1CCC(CC1)N(C)S(=O)(=O)C2=CC=C(C=C2)F,CN1CCC(N(C)S(=O)(=O)c2ccc(F)cc2)CC1
2046,CHEMBL1933397,P28223,,AQTJQKXESLVQJG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,22153942.0,IC50,=,160.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]Ketanserin from human recombinant 5HT2A receptor expressed in CHOK1 cells after 60 mins,,5-HT2c receptor selectivity and structure-activity relationship of N-methyl-N-(1-methylpiperidin-4-yl)benzenesulfonamide analogs.,Bioorg. Med. Chem. Lett.,2012.0,22.0,1.0,"Jang JW, Baek JS, Choi GD, Park WK, Cho YS, Baek DJ, Pae AN",,795018.0,DTCT0023186,7579157,DTCC01167827,1480492,46941,6.795880017344075,CN1CCC(CC1)N(C)S(=O)(=O)C2=CC=C(C=C2)I,CN1CCC(N(C)S(=O)(=O)c2ccc(I)cc2)CC1
2047,CHEMBL1933398,P28223,,JMIOQNWZLYKZAA-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,22153942.0,IC50,=,1019.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]Ketanserin from human recombinant 5HT2A receptor expressed in CHOK1 cells after 60 mins,,5-HT2c receptor selectivity and structure-activity relationship of N-methyl-N-(1-methylpiperidin-4-yl)benzenesulfonamide analogs.,Bioorg. Med. Chem. Lett.,2012.0,22.0,1.0,"Jang JW, Baek JS, Choi GD, Park WK, Cho YS, Baek DJ, Pae AN",,795018.0,DTCT0023186,7579158,DTCC01167828,1862843,46941,5.991825815993574,CN1CCC(CC1)N(C)S(=O)(=O)C2=CC=CC=C2,CN1CCC(N(C)S(=O)(=O)c2ccccc2)CC1
2048,CHEMBL1933399,P28223,,KTFVJJTZAHUNDI-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,22153942.0,IC50,=,2130.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]Ketanserin from human recombinant 5HT2A receptor expressed in CHOK1 cells after 60 mins,,5-HT2c receptor selectivity and structure-activity relationship of N-methyl-N-(1-methylpiperidin-4-yl)benzenesulfonamide analogs.,Bioorg. Med. Chem. Lett.,2012.0,22.0,1.0,"Jang JW, Baek JS, Choi GD, Park WK, Cho YS, Baek DJ, Pae AN",,795018.0,DTCT0023186,7579159,DTCC01167829,833303,46941,5.671620396561262,CC1=CC=C(C=C1)S(=O)(=O)N(C)C2CCN(CC2)C,Cc1ccc(S(=O)(=O)N(C)C2CCN(C)CC2)cc1
2049,CHEMBL1933400,P28223,,IQOBETABGVPKIC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,22153942.0,IC50,=,161.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]Ketanserin from human recombinant 5HT2A receptor expressed in CHOK1 cells after 60 mins,,5-HT2c receptor selectivity and structure-activity relationship of N-methyl-N-(1-methylpiperidin-4-yl)benzenesulfonamide analogs.,Bioorg. Med. Chem. Lett.,2012.0,22.0,1.0,"Jang JW, Baek JS, Choi GD, Park WK, Cho YS, Baek DJ, Pae AN",,795018.0,DTCT0023186,7579160,DTCC01167830,51855,46941,6.79317412396815,CC(C)C1=CC=C(C=C1)S(=O)(=O)N(C)C2CCN(CC2)C,CC(C)c1ccc(S(=O)(=O)N(C)C2CCN(C)CC2)cc1
2050,CHEMBL1933401,P28223,,DAJNTHNLKGMDAK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,22153942.0,IC50,=,452.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]Ketanserin from human recombinant 5HT2A receptor expressed in CHOK1 cells after 60 mins,,5-HT2c receptor selectivity and structure-activity relationship of N-methyl-N-(1-methylpiperidin-4-yl)benzenesulfonamide analogs.,Bioorg. Med. Chem. Lett.,2012.0,22.0,1.0,"Jang JW, Baek JS, Choi GD, Park WK, Cho YS, Baek DJ, Pae AN",,795018.0,DTCT0023186,7579162,DTCC01167831,1512956,46941,6.3448615651886175,CCC1=CC=C(C=C1)S(=O)(=O)N(C)C2CCN(CC2)C,CCc1ccc(S(=O)(=O)N(C)C2CCN(C)CC2)cc1
2051,CHEMBL1933402,P28223,,HAUIGQOXVOXKHA-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,22153942.0,IC50,=,329.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]Ketanserin from human recombinant 5HT2A receptor expressed in CHOK1 cells after 60 mins,,5-HT2c receptor selectivity and structure-activity relationship of N-methyl-N-(1-methylpiperidin-4-yl)benzenesulfonamide analogs.,Bioorg. Med. Chem. Lett.,2012.0,22.0,1.0,"Jang JW, Baek JS, Choi GD, Park WK, Cho YS, Baek DJ, Pae AN",,795018.0,DTCT0023186,7579163,DTCC01167832,1960200,46941,6.482804102050026,CCCC1=CC=C(C=C1)S(=O)(=O)N(C)C2CCN(CC2)C,CCCc1ccc(S(=O)(=O)N(C)C2CCN(C)CC2)cc1
2052,CHEMBL1933403,P28223,,XDRCNFGQZMLUDX-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,22153942.0,IC50,=,281.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]Ketanserin from human recombinant 5HT2A receptor expressed in CHOK1 cells after 60 mins,,5-HT2c receptor selectivity and structure-activity relationship of N-methyl-N-(1-methylpiperidin-4-yl)benzenesulfonamide analogs.,Bioorg. Med. Chem. Lett.,2012.0,22.0,1.0,"Jang JW, Baek JS, Choi GD, Park WK, Cho YS, Baek DJ, Pae AN",,795018.0,DTCT0023186,7579164,DTCC01167833,250088,46941,6.55129368009492,CN1CCC(CC1)N(C)S(=O)(=O)C2=CC=C(C=C2)C3=CC=CC=C3,CN1CCC(N(C)S(=O)(=O)c2ccc(-c3ccccc3)cc2)CC1
2053,CHEMBL1933404,P28223,,QBWYEQWVMQICMX-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,22153942.0,IC50,=,77.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]Ketanserin from human recombinant 5HT2A receptor expressed in CHOK1 cells after 60 mins,,5-HT2c receptor selectivity and structure-activity relationship of N-methyl-N-(1-methylpiperidin-4-yl)benzenesulfonamide analogs.,Bioorg. Med. Chem. Lett.,2012.0,22.0,1.0,"Jang JW, Baek JS, Choi GD, Park WK, Cho YS, Baek DJ, Pae AN",,795018.0,DTCT0023186,7579166,DTCC01167834,1830817,46941,7.113509274827518,CCCCOC1=CC=C(C=C1)S(=O)(=O)N(C)C2CCN(CC2)C,CCCCOc1ccc(S(=O)(=O)N(C)C2CCN(C)CC2)cc1
2054,CHEMBL1933405,P28223,,LSDPEHNPWLMKGM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,22153942.0,IC50,=,2448.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]Ketanserin from human recombinant 5HT2A receptor expressed in CHOK1 cells after 60 mins,,5-HT2c receptor selectivity and structure-activity relationship of N-methyl-N-(1-methylpiperidin-4-yl)benzenesulfonamide analogs.,Bioorg. Med. Chem. Lett.,2012.0,22.0,1.0,"Jang JW, Baek JS, Choi GD, Park WK, Cho YS, Baek DJ, Pae AN",,795018.0,DTCT0023186,7579167,DTCC01167835,1383888,46941,5.611188586526477,CN1CCC(CC1)N(C)S(=O)(=O)C2=CC=C(C=C2)OC(F)(F)F,CN1CCC(N(C)S(=O)(=O)c2ccc(OC(F)(F)F)cc2)CC1
2055,CHEMBL1933406,P28223,,CCLYUEZDEYJDIO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,22153942.0,IC50,>,10000.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]Ketanserin from human recombinant 5HT2A receptor expressed in CHOK1 cells after 60 mins,,5-HT2c receptor selectivity and structure-activity relationship of N-methyl-N-(1-methylpiperidin-4-yl)benzenesulfonamide analogs.,Bioorg. Med. Chem. Lett.,2012.0,22.0,1.0,"Jang JW, Baek JS, Choi GD, Park WK, Cho YS, Baek DJ, Pae AN",,795018.0,DTCT0023186,7579168,DTCC01167836,1992949,46941,5.0,CN1CCC(CC1)N(C)S(=O)(=O)C2=CC=C(C=C2)C#N,CN1CCC(N(C)S(=O)(=O)c2ccc(C#N)cc2)CC1
2056,CHEMBL1933407,P28223,,IMMALSULMDTGJB-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,22153942.0,IC50,>,10000.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]Ketanserin from human recombinant 5HT2A receptor expressed in CHOK1 cells after 60 mins,,5-HT2c receptor selectivity and structure-activity relationship of N-methyl-N-(1-methylpiperidin-4-yl)benzenesulfonamide analogs.,Bioorg. Med. Chem. Lett.,2012.0,22.0,1.0,"Jang JW, Baek JS, Choi GD, Park WK, Cho YS, Baek DJ, Pae AN",,795018.0,DTCT0023186,7579169,DTCC01167837,51857,46941,5.0,CN1CCC(CC1)N(C)S(=O)(=O)C2=CC=C(C=C2)[N+](=O)[O-],CN1CCC(N(C)S(=O)(=O)c2ccc([N+](=O)[O-])cc2)CC1
2057,CHEMBL1933408,P28223,,GYQGHALALWJQKU-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,22153942.0,IC50,=,1683.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]Ketanserin from human recombinant 5HT2A receptor expressed in CHOK1 cells after 60 mins,,5-HT2c receptor selectivity and structure-activity relationship of N-methyl-N-(1-methylpiperidin-4-yl)benzenesulfonamide analogs.,Bioorg. Med. Chem. Lett.,2012.0,22.0,1.0,"Jang JW, Baek JS, Choi GD, Park WK, Cho YS, Baek DJ, Pae AN",,795018.0,DTCT0023186,7579170,DTCC01167838,833304,46941,5.773915884024176,CN1CCC(CC1)N(C)S(=O)(=O)C2=CC=C(C=C2)C(F)(F)F,CN1CCC(N(C)S(=O)(=O)c2ccc(C(F)(F)F)cc2)CC1
2058,CHEMBL1933409,P28223,,WSLJSAYZBXRCDJ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,22153942.0,IC50,=,1859.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]Ketanserin from human recombinant 5HT2A receptor expressed in CHOK1 cells after 60 mins,,5-HT2c receptor selectivity and structure-activity relationship of N-methyl-N-(1-methylpiperidin-4-yl)benzenesulfonamide analogs.,Bioorg. Med. Chem. Lett.,2012.0,22.0,1.0,"Jang JW, Baek JS, Choi GD, Park WK, Cho YS, Baek DJ, Pae AN",,795018.0,DTCT0023186,7579171,DTCC01167839,414109,46941,5.730720610228102,CN1CCC(CC1)N(C)S(=O)(=O)C2=CC=CC(=C2)F,CN1CCC(N(C)S(=O)(=O)c2cccc(F)c2)CC1
2059,CHEMBL1933410,P28223,,NLJMLUWAFFQJET-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,22153942.0,IC50,=,986.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]Ketanserin from human recombinant 5HT2A receptor expressed in CHOK1 cells after 60 mins,,5-HT2c receptor selectivity and structure-activity relationship of N-methyl-N-(1-methylpiperidin-4-yl)benzenesulfonamide analogs.,Bioorg. Med. Chem. Lett.,2012.0,22.0,1.0,"Jang JW, Baek JS, Choi GD, Park WK, Cho YS, Baek DJ, Pae AN",,795018.0,DTCT0023186,7579172,DTCC01167840,1577139,46941,6.006123085058789,CN1CCC(CC1)N(C)S(=O)(=O)C2=CC(=CC=C2)Cl,CN1CCC(N(C)S(=O)(=O)c2cccc(Cl)c2)CC1
2060,CHEMBL1933411,P28223,,XXXLFDTXRPCTJU-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,22153942.0,IC50,=,3450.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]Ketanserin from human recombinant 5HT2A receptor expressed in CHOK1 cells after 60 mins,,5-HT2c receptor selectivity and structure-activity relationship of N-methyl-N-(1-methylpiperidin-4-yl)benzenesulfonamide analogs.,Bioorg. Med. Chem. Lett.,2012.0,22.0,1.0,"Jang JW, Baek JS, Choi GD, Park WK, Cho YS, Baek DJ, Pae AN",,795018.0,DTCT0023186,7579173,DTCC01167841,444766,46941,5.462180904926726,CC1=CC(=CC=C1)S(=O)(=O)N(C)C2CCN(CC2)C,Cc1cccc(S(=O)(=O)N(C)C2CCN(C)CC2)c1
2061,CHEMBL1933412,P28223,,UKUHEWWBIAMUKL-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,22153942.0,IC50,>,10000.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]Ketanserin from human recombinant 5HT2A receptor expressed in CHOK1 cells after 60 mins,,5-HT2c receptor selectivity and structure-activity relationship of N-methyl-N-(1-methylpiperidin-4-yl)benzenesulfonamide analogs.,Bioorg. Med. Chem. Lett.,2012.0,22.0,1.0,"Jang JW, Baek JS, Choi GD, Park WK, Cho YS, Baek DJ, Pae AN",,795018.0,DTCT0023186,7579174,DTCC01167842,1448015,46941,5.0,CN1CCC(CC1)N(C)S(=O)(=O)C2=CC=CC=C2F,CN1CCC(N(C)S(=O)(=O)c2ccccc2F)CC1
2062,CHEMBL1933413,P28223,,FUTBMBRHTKOSLD-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,22153942.0,IC50,=,3180.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]Ketanserin from human recombinant 5HT2A receptor expressed in CHOK1 cells after 60 mins,,5-HT2c receptor selectivity and structure-activity relationship of N-methyl-N-(1-methylpiperidin-4-yl)benzenesulfonamide analogs.,Bioorg. Med. Chem. Lett.,2012.0,22.0,1.0,"Jang JW, Baek JS, Choi GD, Park WK, Cho YS, Baek DJ, Pae AN",,795018.0,DTCT0023186,7579175,DTCC01167843,250089,46941,5.497572880015567,CN1CCC(CC1)N(C)S(=O)(=O)C2=CC=CC=C2Cl,CN1CCC(N(C)S(=O)(=O)c2ccccc2Cl)CC1
2063,CHEMBL1933414,P28223,,FILDMRSIVMNLJX-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,22153942.0,IC50,=,1550.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]Ketanserin from human recombinant 5HT2A receptor expressed in CHOK1 cells after 60 mins,,5-HT2c receptor selectivity and structure-activity relationship of N-methyl-N-(1-methylpiperidin-4-yl)benzenesulfonamide analogs.,Bioorg. Med. Chem. Lett.,2012.0,22.0,1.0,"Jang JW, Baek JS, Choi GD, Park WK, Cho YS, Baek DJ, Pae AN",,795018.0,DTCT0023186,7579176,DTCC01167844,671914,46941,5.809668301829708,CC1=CC=CC=C1S(=O)(=O)N(C)C2CCN(CC2)C,Cc1ccccc1S(=O)(=O)N(C)C1CCN(C)CC1
2064,CHEMBL1933572,P28223,,XEYHORKOPPWQLD-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,22153942.0,IC50,=,5980.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]Ketanserin from human recombinant 5HT2A receptor expressed in CHOK1 cells after 60 mins,,5-HT2c receptor selectivity and structure-activity relationship of N-methyl-N-(1-methylpiperidin-4-yl)benzenesulfonamide analogs.,Bioorg. Med. Chem. Lett.,2012.0,22.0,1.0,"Jang JW, Baek JS, Choi GD, Park WK, Cho YS, Baek DJ, Pae AN",,795018.0,DTCT0023186,7579177,DTCC01168004,348546,46941,5.223298816011589,CC1=C(C=C(C=C1)S(=O)(=O)N(C)C2CCN(CC2)C)C,Cc1ccc(S(=O)(=O)N(C)C2CCN(C)CC2)cc1C
2065,CHEMBL1933573,P28223,,LIWASMXRSKETJJ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,22153942.0,IC50,=,502.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]Ketanserin from human recombinant 5HT2A receptor expressed in CHOK1 cells after 60 mins,,5-HT2c receptor selectivity and structure-activity relationship of N-methyl-N-(1-methylpiperidin-4-yl)benzenesulfonamide analogs.,Bioorg. Med. Chem. Lett.,2012.0,22.0,1.0,"Jang JW, Baek JS, Choi GD, Park WK, Cho YS, Baek DJ, Pae AN",,795018.0,DTCT0023186,7579178,DTCC01168005,1416179,46941,6.29929628285498,CN1CCC(CC1)N(C)S(=O)(=O)C2=CC=CC3=CC=CC=C32,CN1CCC(N(C)S(=O)(=O)c2cccc3ccccc23)CC1
2066,CHEMBL1933574,P28223,,CZNVPQZOZIPSFW-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,22153942.0,IC50,>,10000.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]Ketanserin from human recombinant 5HT2A receptor expressed in CHOK1 cells after 60 mins,,5-HT2c receptor selectivity and structure-activity relationship of N-methyl-N-(1-methylpiperidin-4-yl)benzenesulfonamide analogs.,Bioorg. Med. Chem. Lett.,2012.0,22.0,1.0,"Jang JW, Baek JS, Choi GD, Park WK, Cho YS, Baek DJ, Pae AN",,795018.0,DTCT0023186,7579179,DTCC01168006,1895109,46941,5.0,CN1CCC(CC1)N(C)S(=O)(=O)C2=CC=CC3=C2SC=C3,CN1CCC(N(C)S(=O)(=O)c2cccc3ccsc23)CC1
2068,CHEMBL193482,P28223,ESTRIOL,PROQIPRRNZUXQM-ZXXIGWHRSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7315623,DTCC00405591,348401,46191,,C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@H]([C@@H]2O)O)CCC4=C3C=CC(=C4)O,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1C[C@@H](O)[C@@H]2O
2099,CHEMBL194305,P28223,,ZQZWLJUKYOXRPN-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16055331.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,Inhibitory activity against 5-hydroxytryptamine 2A receptor in human,,"2-Alkyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles as novel 5-HT6 receptor agonists.",Bioorg. Med. Chem. Lett.,2005.0,15.0,19.0,"Mattsson C, Sonesson C, Sandahl A, Greiner HE, Gassen M, Plaschke J, Leibrock J, Böttcher H",,321342.0,DTCT0023186,1847925,DTCC00405026,337540,19721,6.0,CC1=C(C2=C(N1)C=CC(=C2)OC)C3=CCNCC3,COc1ccc2[nH]c(C)c(C3=CCNCC3)c2c1
2125,CHEMBL194837,P28223,,GKDBTHSYQZTDAJ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16134937.0,IC50,=,0.61,NM,,,,,,,,,,,,,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor,,"6-Acylamino-2-aminoquinolines as potent melanin-concentrating hormone 1 receptor antagonists. Identification, structure-activity relationship, and investigation of binding mode.",J. Med. Chem.,2005.0,48.0,18.0,"Ulven T, Frimurer TM, Receveur JM, Little PB, Rist O, Nørregaard PK, Högberg T",,321345.0,DTCT0023186,1850297,DTCC00405750,1586997,19863,9.214670164989233,CC1=CC(=NC2=C1C=C(C=C2)NC(=O)COC3=C(C=C(C=C3)Cl)Cl)OCCN(C)C,Cc1cc(OCCN(C)C)nc2ccc(NC(=O)COc3ccc(Cl)cc3Cl)cc12
2132,CHEMBL195437,P28223,4-OCTYLPHENOL,NTDQQZYCCIDJRK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7292072,DTCC00405592,1285870,46191,,CCCCCCCCC1=CC=C(C=C1)O,CCCCCCCCc1ccc(O)cc1
2160,CHEMBL196,P28223,ASCORBATE,CIWBSHSKHKDKBQ-JLAZNSOCSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7274937,DTCC00506386,282996,46191,,C([C@@H]([C@@H]1C(=C(C(=O)O1)O)O)O)O,O=C1O[C@H]([C@@H](O)CO)C(O)=C1O
2207,CHEMBL198949,P28223,,DUFKTZBQJIHIAQ-VGZDNEPHSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16198561.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,Inhibition of human 5HT2A receptor,,Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis.,Bioorg. Med. Chem. Lett.,2005.0,15.0,23.0,"Revesz L, Bollbuck B, Buhl T, Eder J, Esser R, Feifel R, Heng R, Hiestand P, Jachez-Demange B, Loetscher P, Sparrer H, Schlapbach A, Waelchli R",,325904.0,DTCT0023186,1867477,DTCC00408984,1501911,11231,6.0,C[C@@H]1CN(CCN1C(=O)/C=C/C2=C(C=C(C=C2)Cl)NC(=O)C)CC3=CC=C(C=C3)F,CC(=O)Nc1cc(Cl)ccc1/C=C/C(=O)N1CCN(Cc2ccc(F)cc2)C[C@H]1C
2218,CHEMBL2,P28223,PRAZOSIN,IENZQIKPVFGBNW-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7387683,DTCC00132268,1155685,46191,,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC,COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC
2220,CHEMBL20,P28223,ACETAZOLAMIDE,BZKPWHYZMXOIDC-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7281190,DTCC00133144,51441,46191,,CC(=O)NC1=NN=C(S1)S(=O)(=O)N,CC(=O)Nc1nnc(S(N)(=O)=O)s1
2353,CHEMBL203266,P28223,TRIMETAZIDINE,UHWVSEOVJBQKBE-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7444502,DTCC00417182,381018,46191,,COC1=C(C(=C(C=C1)CN2CCNCC2)OC)OC,COc1ccc(CN2CCNCC2)c(OC)c1OC
2391,CHEMBL205596,P28223,CHOLIC ACID,BHQCQFFYRZLCQQ-OELDTZBJSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7360367,DTCC00419527,1027049,46191,,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O)[C@@]21C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O
2447,CHEMBL2079587,P28223,STANOZOLOL,LKAJKIOFIWVMDJ-IYRCEVNGSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7469385,DTCC01253362,930087,46191,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(CC5=C(C4)NN=C5)C,C[C@]12Cc3cn[nH]c3C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O
2451,CHEMBL20883,P28223,TEGAFUR,WFWLQNSHRPWKFK-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7476485,DTCC00152531,1027060,46191,,C1CC(OC1)N2C=C(C(=O)NC2=O)F,O=c1[nH]c(=O)n(C2CCCO2)cc1F
2477,CHEMBL21,P28223,SULFANILAMIDE,FDDDEECHVMSUSB-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7469653,DTCC00133176,88635,46191,,C1=CC(=CC=C1N)S(=O)(=O)N,Nc1ccc(S(N)(=O)=O)cc1
2486,CHEMBL2103747,P28223,ACONITINE,XFSBVAOIAHNAPC-FKHWODAVSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7287079,DTCC00130938,671783,46191,,CCN1C[C@@]2([C@@H](C[C@H]([C@@]34[C@@H]2[C@H]([C@@H]([C@@H]31)[C@@]5([C@@H]6[C@H]4C[C@@]([C@@H]6OC(=O)C7=CC=CC=C7)([C@H]([C@@H]5O)OC)O)OC(=O)C)OC)OC)O)COC,CCN1C[C@@]2(COC)[C@H]3[C@@H](OC)[C@H]4[C@H]1[C@]3([C@H](OC)C[C@H]2O)[C@@H]1C[C@]2(O)[C@@H](OC)[C@H](O)[C@@]4(OC(C)=O)[C@H]1[C@H]2OC(=O)c1ccccc1
2488,CHEMBL2103774,P28223,TIBOLONE,WZDGZWOAQTVYBX-XOINTXKNSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7470357,DTCC01257131,1416037,46191,,C[C@@H]1CC2=C(CCC(=O)C2)[C@@H]3[C@@H]1[C@@H]4CC[C@]([C@]4(CC3)C)(C#C)O,C#C[C@]1(O)CC[C@H]2[C@H]3[C@H](CC[C@@]21C)C1=C(CC(=O)CC1)C[C@H]3C
2495,CHEMBL2105617,P28223,AJMALINE,CJDRUOGAGYHKKD-FUIWMBJSSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7295018,DTCC01258909,2089743,46191,,CCC1C2CC3C4C5(CC(C2[C@H]5O)N3C1O)C6=CC=CC=C6N4C,CCC1C2CC3C4N(C)c5ccccc5C45CC(C2[C@H]5O)N3C1O
2500,CHEMBL2105807,P28223,MADURAMICIN,WQGJEAMPBSZCIF-HKSLRPGUSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7431911,DTCC01259078,898292,46191,,C[C@H]1C[C@H]([C@@](O[C@@H]1[C@H]2C[C@@H]([C@@H](O2)[C@@]3(CC[C@@H](O3)[C@@]4(CC[C@@]5(O4)C[C@@H]([C@H]([C@H](O5)[C@@H](C)[C@H]6[C@@H]([C@H]([C@@H]([C@](O6)(CC(=O)O)O)C)OC)OC)C)O)C)C)O[C@@H]7C[C@@H]([C@H]([C@@H](O7)C)OC)OC)(C)O)C.N,CO[C@H]1C[C@@H](O[C@H]2C[C@H]([C@H]3O[C@](C)(O)[C@H](C)C[C@@H]3C)O[C@H]2[C@]2(C)CC[C@H]([C@]3(C)CC[C@]4(C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H]5O[C@](O)(CC(=O)O)[C@@H](C)[C@H](OC)[C@H]5OC)O4)O3)O2)O[C@@H](C)[C@@H]1OC
2502,CHEMBL2106399,P28223,KITASAMYCIN,IEMDOFXTVAPVLX-YWQHLDGFSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7414160,DTCC01259639,800579,46191,,C[C@@H]1C/C=C/C=C/[C@@H]([C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)O)OC)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)OC(=O)CC(C)C)(C)O)N(C)C)O)CC=O)C)O,CO[C@@H]1[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)[C@@H](O)/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]1O
2504,CHEMBL2107687,P28223,VALETHAMATE BROMIDE,CEJGGHKJHDHLAZ-UHFFFAOYSA-M,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7442490,DTCC01260864,1512819,46191,,CCC(C)C(C1=CC=CC=C1)C(=O)OCC[N+](C)(CC)CC.[Br-],CCC(C)C(C(=O)OCC[N+](C)(CC)CC)c1ccccc1
2506,CHEMBL2107797,P28223,NORGESTREL,WWYNJERNGUHSAO-CULCCENASA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7397185,DTCC01260973,1894972,46191,,CC[C@]12CC[C@H]3[C@H]([C@@H]1CCC2(C#C)O)CCC4=CC(=O)CC[C@H]34,C#CC1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21CC
2510,CHEMBL2110300,P28223,,JLDUTSKKXXJGGG-AGPCZUQZSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11262079.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,Binding affinity against rabbit aorta 5-HT2A receptor,,"Discovery of 4-[3-(trans-3-dimethylaminocyclobutyl)-1H-indol-5-ylmethyl]-(4S)-oxazolidin-2-one (4991W93), a 5HT(1B/1D) receptor partial agonist and a potent inhibitor of electrically induced plasma extravasation.",J. Med. Chem.,2001.0,44.0,5.0,"Jandu KS, Barrett V, Brockwell M, Cambridge D, Farrant DR, Foster C, Giles H, Glen RC, Hill AP, Hobbs H, Honey A, Martin GR, Salmon J, Smith D, Woollard P, Selwood DL",,2549.0,DTCT0023186,807729,DTCC01263199,1948383,16608,5.0,CN(C)C1CC(C1)C2=CNC3=C2C=C(C=C3)CC4COC(=O)N4,CN(C)C1CC(c2c[nH]c3ccc(CC4COC(=O)N4)cc23)C1
2513,CHEMBL2111101,P28223,PIMAVANSERIN,RKEWSXXUOLRFBX-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16469866.0,IC50,=,1.9,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0023186,14717928,DTCC01263749,2101282,68469,8.721246399047171,CC(C)COC1=CC=C(C=C1)CNC(=O)N(CC2=CC=C(C=C2)F)C3CCN(CC3)C,CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1
2529,CHEMBL211501,P28223,ANTIMYCIN A,UIFFUZWRFRDZJC-SBOOETFBSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7260679,DTCC00428375,930076,46191,,CCCCCC[C@@H]1[C@H]([C@@H](OC(=O)[C@H]([C@H](OC1=O)C)NC(=O)C2=C(C(=CC=C2)NC=O)O)C)OC(=O)CC(C)C,CCCCCC[C@H]1C(=O)O[C@H](C)[C@H](NC(=O)c2cccc(NC=O)c2O)C(=O)O[C@@H](C)[C@@H]1OC(=O)CC(C)C
2551,CHEMBL21343,P28223,,SUXLVXOMPKZBOV-CXAGYDPISA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,19783143.0,IC50,=,6.0,NM,,,,,,,,,,,,,,Inhibition of 5HT2A receptor,,"Special ergolines are highly selective, potent antagonists of the chemokine receptor CXCR3: discovery, characterization and preliminary SAR of a promising lead.",Bioorg. Med. Chem. Lett.,2009.0,19.0,21.0,"Thoma G, Baenteli R, Lewis I, Wagner T, Oberer L, Blum W, Glickman F, Streiff MB, Zerwes HG",,592327.0,DTCT0023186,3048580,DTCC00154974,1050729,35662,8.221848749616356,CCN(CC)C(=O)[C@H]1CN[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1,CCN(CC)C(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2NC1
2568,CHEMBL2158704,P28223,,MYJQZBNYMUUXQI-HXUWFJFHSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,22386241.0,IC50,=,5800.0,NM,,,,,,,,,,,,,,Antagonist activity at 5HT2A receptor,,Synthesis and pharmacological evaluation of carbamic acid 1-phenyl-3-(4-phenyl-piperazine-1-yl)-propyl ester derivatives as new analgesic agents.,Bioorg. Med. Chem. Lett.,2012.0,22.0,7.0,"Chae E, Yi H, Choi Y, Cho H, Lee K, Moon H",,856035.0,DTCT0023186,11373071,DTCC01287405,1812372,51025,5.236572006437063,COC1=CC=C(C=C1)N2CCN(CC2)CC[C@H](C3=CC=CC=C3)OC(=O)N,COc1ccc(N2CCN(CC[C@@H](OC(N)=O)c3ccccc3)CC2)cc1
2589,CHEMBL21731,P28223,MAPROTILINE,QSLMDECMDJKHMQ-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,64.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7410509,DTCC00155108,1059332,46191,7.1938200260161125,CNCCCC12CCC(C3=CC=CC=C31)C4=CC=CC=C24,CNCCCC12CCC(c3ccccc31)c1ccccc12
2630,CHEMBL218206,P28223,,BPLLYDDBOWVYJU-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16971119.0,IC50,=,71.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human 5HT2A receptor expressed in CHOK1 cells,,"Identification and optimisation of 5-amino-7-aryldihydro-1,4-diazepines as 5-HT2A ligands.",Bioorg. Med. Chem. Lett.,2006.0,16.0,23.0,"Swain CJ, Teran A, Maroto M, Cabello A",,424570.0,DTCT0023186,2013602,DTCC00440757,391505,21789,7.1487416512809245,CC1=CC(=C(C=C1)C2=CC(=NCCN2)NC(C)(C)C)C,Cc1ccc(C2=CC(NC(C)(C)C)=NCCN2)c(C)c1
2631,CHEMBL218336,P28223,,JLYDTHJIPVXXIE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16971119.0,IC50,>,1000.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human 5HT2A receptor expressed in CHOK1 cells,,"Identification and optimisation of 5-amino-7-aryldihydro-1,4-diazepines as 5-HT2A ligands.",Bioorg. Med. Chem. Lett.,2006.0,16.0,23.0,"Swain CJ, Teran A, Maroto M, Cabello A",,424570.0,DTCT0023186,2013620,DTCC00440771,843754,21789,6.0,CCN(CC)C1=NCCNC(=C1)C2=CC=C(C=C2)C,CCN(CC)C1=NCCNC(c2ccc(C)cc2)=C1
2632,CHEMBL218343,P28223,,WZVQCGWNABPJAB-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16971119.0,IC50,=,514.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human 5HT2A receptor expressed in CHOK1 cells,,"Identification and optimisation of 5-amino-7-aryldihydro-1,4-diazepines as 5-HT2A ligands.",Bioorg. Med. Chem. Lett.,2006.0,16.0,23.0,"Swain CJ, Teran A, Maroto M, Cabello A",,424570.0,DTCT0023186,2013604,DTCC00440742,260310,21789,6.289036881004725,CC(C)(C)NC1=NCCNC(=C1)C2=CC(=CC=C2)C(F)(F)F,CC(C)(C)NC1=NCCNC(c2cccc(C(F)(F)F)c2)=C1
2635,CHEMBL218479,P28223,,VUZLWOZHNQGLQA-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16971119.0,IC50,=,14.5,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human 5HT2A receptor expressed in CHOK1 cells,,"Identification and optimisation of 5-amino-7-aryldihydro-1,4-diazepines as 5-HT2A ligands.",Bioorg. Med. Chem. Lett.,2006.0,16.0,23.0,"Swain CJ, Teran A, Maroto M, Cabello A",,424570.0,DTCT0023186,2013618,DTCC00440758,810873,21789,7.838631997765025,CCC(C)(CC)NC1=NCCNC(=C1)C2=CC=CC=C2F,CCC(C)(CC)NC1=NCCNC(c2ccccc2F)=C1
2636,CHEMBL218533,P28223,,WWCXDIRSDFKQDA-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16971119.0,IC50,>,1000.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human 5HT2A receptor expressed in CHOK1 cells,,"Identification and optimisation of 5-amino-7-aryldihydro-1,4-diazepines as 5-HT2A ligands.",Bioorg. Med. Chem. Lett.,2006.0,16.0,23.0,"Swain CJ, Teran A, Maroto M, Cabello A",,424570.0,DTCT0023186,2013615,DTCC00110903,2035988,21789,6.0,CCN(CC)C1=NCCNC(=C1)C2=CC=CC=C2F,CCN(CC)C1=NCCNC(c2ccccc2F)=C1
2637,CHEMBL218587,P28223,,IAAGTZGGIXMUPK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16971119.0,IC50,=,3.7,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human 5HT2A receptor expressed in CHOK1 cells,,"Identification and optimisation of 5-amino-7-aryldihydro-1,4-diazepines as 5-HT2A ligands.",Bioorg. Med. Chem. Lett.,2006.0,16.0,23.0,"Swain CJ, Teran A, Maroto M, Cabello A",,424570.0,DTCT0023186,2013624,DTCC00110908,1744220,21789,8.431798275933005,CCC(CC)(CC)NC1=NCCNC(=C1)C2=C(C=C(C=C2)F)F,CCC(CC)(CC)NC1=NCCNC(c2ccc(F)cc2F)=C1
2638,CHEMBL218589,P28223,,JDVROHYUNYELGG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16971119.0,IC50,=,2.4,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human 5HT2A receptor expressed in CHOK1 cells,,"Identification and optimisation of 5-amino-7-aryldihydro-1,4-diazepines as 5-HT2A ligands.",Bioorg. Med. Chem. Lett.,2006.0,16.0,23.0,"Swain CJ, Teran A, Maroto M, Cabello A",,424570.0,DTCT0023186,2013622,DTCC00440778,617272,21789,8.619788758288394,CC1=CC=C(C=C1)C2=CC(=NCCN2)NC(C)(C)CC3=CC=CC=C3,Cc1ccc(C2=CC(NC(C)(C)Cc3ccccc3)=NCCN2)cc1
2639,CHEMBL218592,P28223,,LJGKTXZEJHDRQR-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16971119.0,IC50,=,21.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human 5HT2A receptor expressed in CHOK1 cells,,"Identification and optimisation of 5-amino-7-aryldihydro-1,4-diazepines as 5-HT2A ligands.",Bioorg. Med. Chem. Lett.,2006.0,16.0,23.0,"Swain CJ, Teran A, Maroto M, Cabello A",,424570.0,DTCT0023186,2013627,DTCC00440798,972519,21789,7.6777807052660805,CC(C)(C)NC1=NCCNC(=C1)C2=CC=C(C=C2)F,CC(C)(C)NC1=NCCNC(c2ccc(F)cc2)=C1
2641,CHEMBL219146,P28223,VINDESINE,HHJUWIANJFBDHT-KOTLKJBCSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7444195,DTCC00110817,833166,46191,,CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)N)O)O)CC)OC)C(=O)OC)O,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(N)=O)[C@H](O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
2643,CHEMBL219215,P28223,,DBBBDBCAUOTQCC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16971119.0,IC50,=,1.6,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human 5HT2A receptor expressed in CHOK1 cells,,"Identification and optimisation of 5-amino-7-aryldihydro-1,4-diazepines as 5-HT2A ligands.",Bioorg. Med. Chem. Lett.,2006.0,16.0,23.0,"Swain CJ, Teran A, Maroto M, Cabello A",,424570.0,DTCT0023186,2013613,DTCC00440748,1872985,21789,8.795880017344075,CC1(CCCCC1)NC2=NCCNC(=C2)C3=CC=C(C=C3)F,CC1(NC2=NCCNC(c3ccc(F)cc3)=C2)CCCCC1
2644,CHEMBL219265,P28223,,YLZMZAMSWUDWOE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16971119.0,IC50,=,1.5,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human 5HT2A receptor expressed in CHOK1 cells,,"Identification and optimisation of 5-amino-7-aryldihydro-1,4-diazepines as 5-HT2A ligands.",Bioorg. Med. Chem. Lett.,2006.0,16.0,23.0,"Swain CJ, Teran A, Maroto M, Cabello A",,424570.0,DTCT0023186,2013626,DTCC00440749,1069888,21789,8.823908740944319,CCC(C)(CC)NC1=NCCNC(=C1)C2=CC=C(C=C2)F,CCC(C)(CC)NC1=NCCNC(c2ccc(F)cc2)=C1
2645,CHEMBL219267,P28223,,MSMNVOOHUXHQTH-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16971119.0,IC50,=,14.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human 5HT2A receptor expressed in CHOK1 cells,,"Identification and optimisation of 5-amino-7-aryldihydro-1,4-diazepines as 5-HT2A ligands.",Bioorg. Med. Chem. Lett.,2006.0,16.0,23.0,"Swain CJ, Teran A, Maroto M, Cabello A",,424570.0,DTCT0023186,2013603,DTCC00440756,1744219,21789,7.853871964321762,CC1=CC(=C(C=C1)C2=CC(=NCCN2)NC(C)(C)C)F,Cc1ccc(C2=CC(NC(C)(C)C)=NCCN2)c(F)c1
2653,CHEMBL219916,P28223,DOMPERIDONE,FGXWKSZFVQUSTL-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,37.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7370746,DTCC00437363,898287,46191,7.431798275933005,C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O,O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1
2741,CHEMBL221249,P28223,,PTHBERMKWLNLOB-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16971119.0,IC50,>,1000.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human 5HT2A receptor expressed in CHOK1 cells,,"Identification and optimisation of 5-amino-7-aryldihydro-1,4-diazepines as 5-HT2A ligands.",Bioorg. Med. Chem. Lett.,2006.0,16.0,23.0,"Swain CJ, Teran A, Maroto M, Cabello A",,424570.0,DTCT0023186,2013621,DTCC00440754,1005083,21789,6.0,CC1=CC=C(C=C1)C2=CC(=NCCN2)N3CCOCC3,Cc1ccc(C2=CC(N3CCOCC3)=NCCN2)cc1
2742,CHEMBL221250,P28223,,HUXJJXGLYXULJW-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16971119.0,IC50,=,0.8,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human 5HT2A receptor expressed in CHOK1 cells,,"Identification and optimisation of 5-amino-7-aryldihydro-1,4-diazepines as 5-HT2A ligands.",Bioorg. Med. Chem. Lett.,2006.0,16.0,23.0,"Swain CJ, Teran A, Maroto M, Cabello A",,424570.0,DTCT0023186,2013612,DTCC00440763,1619969,21789,9.096910013008056,CCC1(CCCC1)NC2=NCCNC(=C2)C3=CC=C(C=C3)F,CCC1(NC2=NCCNC(c3ccc(F)cc3)=C2)CCCC1
2743,CHEMBL221297,P28223,,ITNZIQZSAYHIMY-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16971119.0,IC50,=,11.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human 5HT2A receptor expressed in CHOK1 cells,,"Identification and optimisation of 5-amino-7-aryldihydro-1,4-diazepines as 5-HT2A ligands.",Bioorg. Med. Chem. Lett.,2006.0,16.0,23.0,"Swain CJ, Teran A, Maroto M, Cabello A",,424570.0,DTCT0023186,2013607,DTCC00440717,1490772,21789,7.958607314841775,CC(C)(C)NC1=NCCNC(=C1)C2=C(C=C(C=C2)F)F,CC(C)(C)NC1=NCCNC(c2ccc(F)cc2F)=C1
2744,CHEMBL221305,P28223,,MOOPWFMRJQZSIJ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16971119.0,IC50,=,14.9,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human 5HT2A receptor expressed in CHOK1 cells,,"Identification and optimisation of 5-amino-7-aryldihydro-1,4-diazepines as 5-HT2A ligands.",Bioorg. Med. Chem. Lett.,2006.0,16.0,23.0,"Swain CJ, Teran A, Maroto M, Cabello A",,424570.0,DTCT0023186,2013623,DTCC00440752,617273,21789,7.826813731587726,CCC(C)(CC)NC1=NCCNC(=C1)C2=CC=C(C=C2)C,CCC(C)(CC)NC1=NCCNC(c2ccc(C)cc2)=C1
2745,CHEMBL221387,P28223,,GWYCOTJQPGWSMJ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16971119.0,IC50,=,35.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human 5HT2A receptor expressed in CHOK1 cells,,"Identification and optimisation of 5-amino-7-aryldihydro-1,4-diazepines as 5-HT2A ligands.",Bioorg. Med. Chem. Lett.,2006.0,16.0,23.0,"Swain CJ, Teran A, Maroto M, Cabello A",,424570.0,DTCT0023186,2013628,DTCC00440761,1715812,21789,7.455931955649724,CC(C)(C)NC1=NCCNC(=C1)C2=CC=CC=C2,CC(C)(C)NC1=NCCNC(c2ccccc2)=C1
2748,CHEMBL221753,P28223,BENZETHONIUM CHLORIDE,UREZNYTWGJKWBI-UHFFFAOYSA-M,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,129.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7261257,DTCC00440345,120969,46191,6.889410289700751,CC(C)(C)CC(C)(C)C1=CC=C(C=C1)OCCOCC[N+](C)(C)CC2=CC=CC=C2.[Cl-],CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1
2752,CHEMBL221886,P28223,SISOMICIN,URWAJWIAIPFPJE-YFMIWBNJSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7488509,DTCC00443300,703986,46191,,C[C@@]1(CO[C@@H]([C@@H]([C@H]1NC)O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]3[C@@H](CC=C(O3)CN)N)N)N)O,CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O
2754,CHEMBL2220427,P28223,ERYTHROMYCIN ESTOLATE,TYQXKHPOXXXCTP-CSLYCKPJSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7307029,DTCC01305390,639579,46191,,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)OC(=O)CC)(C)O)C)C)O)(C)O,CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C
2756,CHEMBL2220442,P28223,FLUVASTATIN,FJLGEFLZQAZZCD-VAWYXSNFSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7312141,DTCC01305406,1059330,46191,,CC(C)N1C2=CC=CC=C2C(=C1/C=C/C(CC(CC(=O)O)O)O)C3=CC=C(C=C3)F,CC(C)n1c(/C=C/C(O)CC(O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21
2758,CHEMBL222320,P28223,,NGDRNYJZVVTUJC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16971119.0,IC50,=,18.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human 5HT2A receptor expressed in CHOK1 cells,,"Identification and optimisation of 5-amino-7-aryldihydro-1,4-diazepines as 5-HT2A ligands.",Bioorg. Med. Chem. Lett.,2006.0,16.0,23.0,"Swain CJ, Teran A, Maroto M, Cabello A",,424570.0,DTCT0023186,2013608,DTCC00440785,455169,21789,7.7447274948966935,CC(C)(C)NC1=NCCNC(=C1)C2=CC=CC=C2F,CC(C)(C)NC1=NCCNC(c2ccccc2F)=C1
2771,CHEMBL222863,P28223,OUABAIN,LPMXVESGRSUGHW-HBYQJFLCSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7380105,DTCC00444362,1059335,46191,,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2C[C@H]([C@@]3([C@@H]4[C@@H](CC[C@@]3(C2)O)[C@]5(CC[C@@H]([C@]5(C[C@H]4O)C)C6=CC(=O)OC6)O)CO)O)O)O)O,C[C@@H]1O[C@@H](O[C@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@@H](C6=CC(=O)OC6)CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)[C@H](O)[C@H](O)[C@H]1O
2831,CHEMBL2252949,P28223,(-)-CAMPHOR,DSSYKIVIOFKYAU-OIBJUYFYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7422747,DTCC01315138,510302,46191,,C[C@]12CC[C@H](C1(C)C)CC2=O,CC1(C)[C@H]2CC[C@]1(C)C(=O)C2
2833,CHEMBL22587,P28223,ITRACONAZOLE,VHVPQPYKVGDNFY-ZPGVKDDISA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7414076,DTCC01738573,51481,46191,,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O
2836,CHEMBL227934,P28223,STRYCHNINE,QMGVPVSNSZLJIA-FVWCLLPLSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7456411,DTCC00448002,1092350,46191,,C1CN2CC3=CCO[C@H]4CC(=O)N5[C@H]6[C@H]4[C@H]3C[C@H]2[C@@]61C7=CC=CC=C75,O=C1C[C@@H]2OCC=C3CN4CC[C@]56c7ccccc7N1[C@H]5[C@H]2[C@H]3C[C@H]46
2847,CHEMBL23,P28223,DILTIAZEM,HSUGRBWQSSZJOP-RTWAWAEBSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7363998,DTCC00133282,866019,46191,,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1
2903,CHEMBL2322611,P28223,,DGPDTKNMPXWENB-ITNPDYSASA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23425156.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,Inhibition of 5-HT2A (unknown origin),,"The Discovery of Novel Potent trans-3,4-Disubstituted Pyrrolidine Inhibitors of the Human Aspartic Protease Renin from in Silico Three-Dimensional (3D) Pharmacophore Searches.",J. Med. Chem.,2013.0,56.0,6.0,"Lorthiois E, Breitenstein W, Cumin F, Ehrhardt C, Francotte E, Jacoby E, Ostermann N, Sellner H, Kosaka T, Webb RL, Rigel DF, Hassiepen U, Richert P, Wagner T, Maibaum J",,941694.0,DTCT0023186,11779036,DTCC01340969,706251,53627,6.0,CC(C)N(C[C@@H]1CNC[C@H]1CC2=CC=CC=C2)C(=O)C3=CC(=C(C=C3)OC)OCCCOC.Cl,COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2Cc2ccccc2)C(C)C)ccc1OC
2904,CHEMBL2323579,P28223,"1,6-DIMETHYLCABERGOLINE",OQPYDZQJBICVMH-SYYKKAFVSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,11500.0,NM,,cell_based,,,,,,,,,,,,Antagonist activity at human 5-HT2A receptor assessed as decrease in agonist-induced intracellular calcium mobilization preincubated for 10 mins prior to agonist addition measured by FLIPR analysis,,,ACS Med. Chem. Lett.,2013.0,4.0,2.0,,,938241.0,DTCT0023186,11791406,DTCC00045797,848240,53428,4.939302159646388,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CN(C4=CC=CC2=C34)C)N(C1)C,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@@H]2c3cccc4c3c(cn4C)C[C@H]2N(C)C1
3160,CHEMBL234926,P28223,ALLYL ALCOHOL,XXROGKLTLUQVRX-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7287201,DTCC00463304,1992799,46191,,C=CCO,C=CCO
3170,CHEMBL2367892,P28223,TEICOPLANIN,DDTDNCYHLGRFBM-YZEKDTGTSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7480843,DTCC01364937,1734064,46191,,CC(=O)N[C@H]1[C@H]([C@@H]([C@@H](O[C@H]1O[C@H]2[C@H]3C(=O)N[C@@H](C4=C(C(=CC(=C4)O)O[C@@H]5[C@H]([C@@H]([C@@H]([C@H](O5)CO)O)O)O)C6=C(C=CC(=C6)[C@H](C(=O)N3)NC(=O)[C@H]7C8=CC(=C(C(=C8)OC9=C(C=C2C=C9)Cl)O[C@H]1[C@H]([C@H]([C@@H]([C@@H](O1)CO)O)O)NC(=O)C)OC1=C(C=C(C[C@@H]2C(=O)N[C@@H](C3=CC(=CC(=C3)OC3=C(C=CC(=C3)[C@H](C(=O)N2)N)O)O)C(=O)N7)C=C1)Cl)O)C(=O)O)CO)O)O,CC(=O)N[C@@H]1[C@H](Oc2c3cc4cc2Oc2ccc(cc2Cl)[C@@H](O[C@@H]2O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]2NC(C)=O)[C@@H]2NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H]4NC(=O)[C@@H](Cc5ccc(c(Cl)c5)O3)NC(=O)[C@H](N)c3ccc(O)c(c3)Oc3cc(O)cc4c3)c3ccc(O)c(c3)-c3c(O[C@H]4O[C@H](CO)[C@@H](O)[C@@H](O)[C@@H]4O)cc(O)cc3[C@@H](C(=O)O)NC2=O)O[C@@H](CO)[C@@H](O)[C@@H]1O
3176,CHEMBL2376482,P28223,,CYOVOZKUTSWUJD-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23542166.0,IC50,=,400.0,NM,,,,,,,,,,,,,,Displacement of [3H]-ketanserin from human 5HT2A receptor,,"Structure-activity relationship of 5-chloro-2-methyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole analogues as 5-HT6 receptor agonists.",Eur. J. Med. Chem.,2013.0,63.0,,"Mattsson C, Svensson P, Boettcher H, Sonesson C",,957901.0,DTCT0023186,12414893,DTCC01372484,1962810,54449,6.3979400086720375,CC1=C(C2=C(N1)C=CC(=C2)Br)C3=CCNCC3,Cc1[nH]c2ccc(Br)cc2c1C1=CCNCC1
3177,CHEMBL2376483,P28223,,UQLMPELWUKMDTO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23542166.0,IC50,=,950.0,NM,,,,,,,,,,,,,,Displacement of [3H]-ketanserin from human 5HT2A receptor,,"Structure-activity relationship of 5-chloro-2-methyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole analogues as 5-HT6 receptor agonists.",Eur. J. Med. Chem.,2013.0,63.0,,"Mattsson C, Svensson P, Boettcher H, Sonesson C",,957901.0,DTCT0023186,12414892,DTCC01372485,1676772,54449,6.022276394711152,CC1=C(C2=C(N1)C=CC(=C2)F)C3=CCNCC3,Cc1[nH]c2ccc(F)cc2c1C1=CCNCC1
3178,CHEMBL2376484,P28223,,TVGSRQITRNMKJJ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23542166.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,Displacement of [3H]-ketanserin from human 5HT2A receptor,,"Structure-activity relationship of 5-chloro-2-methyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole analogues as 5-HT6 receptor agonists.",Eur. J. Med. Chem.,2013.0,63.0,,"Mattsson C, Svensson P, Boettcher H, Sonesson C",,957901.0,DTCT0023186,12414889,DTCC01372486,1929687,54449,6.0,CC1=C(C2=C(N1)C=CC(=C2)OS(=O)(=O)C(F)(F)F)C3=CCNCC3,Cc1[nH]c2ccc(OS(=O)(=O)C(F)(F)F)cc2c1C1=CCNCC1
3179,CHEMBL2376487,P28223,,BHGFZMQEWPXOSG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23542166.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,Displacement of [3H]-ketanserin from human 5HT2A receptor,,"Structure-activity relationship of 5-chloro-2-methyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole analogues as 5-HT6 receptor agonists.",Eur. J. Med. Chem.,2013.0,63.0,,"Mattsson C, Svensson P, Boettcher H, Sonesson C",,957901.0,DTCT0023186,12414891,DTCC01372489,123648,54449,6.0,CC1=C(C2=C(N1)C=CC(=C2)[N+](=O)[O-])C3=CCNCC3,Cc1[nH]c2ccc([N+](=O)[O-])cc2c1C1=CCNCC1
3180,CHEMBL2376490,P28223,,UOCWMSJTFCACEQ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23542166.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,Displacement of [3H]-ketanserin from human 5HT2A receptor,,"Structure-activity relationship of 5-chloro-2-methyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole analogues as 5-HT6 receptor agonists.",Eur. J. Med. Chem.,2013.0,63.0,,"Mattsson C, Svensson P, Boettcher H, Sonesson C",,957901.0,DTCT0023186,12414888,DTCC01372492,447291,54449,6.0,CC1=C(C2=C(N1)C=CC(=C2)C3=CSC=C3)C4=CCNCC4,Cc1[nH]c2ccc(-c3ccsc3)cc2c1C1=CCNCC1
3181,CHEMBL2376491,P28223,,CWYJMCYDDSRPBB-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23542166.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,Displacement of [3H]-ketanserin from human 5HT2A receptor,,"Structure-activity relationship of 5-chloro-2-methyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole analogues as 5-HT6 receptor agonists.",Eur. J. Med. Chem.,2013.0,63.0,,"Mattsson C, Svensson P, Boettcher H, Sonesson C",,957901.0,DTCT0023186,12414887,DTCC01372493,642375,54449,6.0,CC1=C(C2=C(N1)C=CC(=C2)C3=CC=CC=C3)C4=CCNCC4,Cc1[nH]c2ccc(-c3ccccc3)cc2c1C1=CCNCC1
3188,CHEMBL2387229,P28223,,QBXXUIOGPPBTJN-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23675993.0,IC50,=,39.2,NM,,cell_based,,,,,,,,,,,CHO-K1,Antagonist activity at 5HT2A receptor (unknown origin) expressed in CHOK1 cells coexpressing Galpha15 assessed as inhibition of agonist-induced response incubated for 60 mins in incubator followed by 15 mins at room temperature by FLIPR assay,,Synthesis and biological investigation of coumarin piperazine (piperidine) derivatives as potential multireceptor atypical antipsychotics.,J. Med. Chem.,2013.0,56.0,11.0,"Chen Y, Wang S, Xu X, Liu X, Yu M, Zhao S, Liu S, Qiu Y, Zhang T, Liu BF, Zhang G",,963044.0,DTCT0023186,12446666,DTCC01378143,1418800,54737,7.406713932979542,CC1=CC(=O)OC2=C1C=CC(=C2Cl)OCCCCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Cc1cc(=O)oc2c(Cl)c(OCCCCN3CCC(c4noc5cc(F)ccc45)CC3)ccc12
3203,CHEMBL2393230,P28223,,ZBNKRTMIDLSEFL-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,>,10000.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463325,DTCC01380933,513112,54812,5.0,CN1CCN(CC1)C2=NC=C3CCNCCC3=N2.Cl,CN1CCN(c2ncc3c(n2)CCNCC3)CC1
3205,CHEMBL2393231,P28223,,HEYZZANODHAAQU-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,>,10000.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463324,DTCC01380934,1612422,54812,5.0,CNC1=NC(=NC2=C1CCNCC2)N3CCN(CC3)C.Cl,CNc1nc(N2CCN(C)CC2)nc2c1CCNCC2
3206,CHEMBL2393232,P28223,,MJRYUPHPFNSQHX-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,>,10000.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463323,DTCC01380935,706664,54812,5.0,CCNC1=NC(=NC2=C1CCNCC2)N3CCN(CC3)C.Cl,CCNc1nc(N2CCN(C)CC2)nc2c1CCNCC2
3207,CHEMBL2393233,P28223,,IVBODCFNBFKNQQ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,>,10000.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463322,DTCC01380936,1995595,54812,5.0,CN1CCN(CC1)C2=NC3=C(CCNCC3)C(=N2)N(C)C.Cl,CN1CCN(c2nc3c(c(N(C)C)n2)CCNCC3)CC1
3209,CHEMBL2393234,P28223,,ZMZTXVXTPMZDNF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,>,10000.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463321,DTCC01380937,932950,54812,5.0,CCN(CC)C1=NC(=NC2=C1CCNCC2)N3CCN(CC3)C.Cl,CCN(CC)c1nc(N2CCN(C)CC2)nc2c1CCNCC2
3210,CHEMBL2393235,P28223,,SVVZYBWVGARFJK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,>,10000.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463320,DTCC01380938,1095163,54812,5.0,CN1CCN(CC1)C2=NC3=C(CCNCC3)C(=N2)N4CCOCC4.Cl,CN1CCN(c2nc3c(c(N4CCOCC4)n2)CCNCC3)CC1
3212,CHEMBL2393236,P28223,,XZMJUEBEHUZKPW-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,>,10000.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463319,DTCC01380939,1547614,54812,5.0,CN1CCN(CC1)C2=NC3=C(CCNCC3)C(=N2)N4CCSCC4.Cl,CN1CCN(c2nc3c(c(N4CCSCC4)n2)CCNCC3)CC1
3213,CHEMBL2393237,P28223,,XHLBNIKNOBEQPX-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,>,10000.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463318,DTCC01380940,609732,54812,5.0,CN1CCN(CC1)C2=NC3=C(CCNCC3)C(=N2)OC.Cl,COc1nc(N2CCN(C)CC2)nc2c1CCNCC2
3214,CHEMBL2393238,P28223,,JUFLGKJAKRLTCN-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,=,2625.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463379,DTCC01380941,1708542,54812,5.580870692258024,CN1CCN(CC1)C2=NC3=C(CCNCC3)C(=N2)OCC4=CC=CO4.Cl,CN1CCN(c2nc3c(c(OCc4ccco4)n2)CCNCC3)CC1
3215,CHEMBL2393239,P28223,,LOTVCVLYAPIQKE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,>,10000.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463317,DTCC01380942,642456,54812,5.0,CN1CCN(CC1)C2=NC3=C(CCNCC3)C(=N2)NC4=CC(=CC=C4)OC.Cl,COc1cccc(Nc2nc(N3CCN(C)CC3)nc3c2CCNCC3)c1
3217,CHEMBL2393240,P28223,,TZNYVZOPRMBWFF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,=,215.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463432,DTCC01380943,2060415,54812,6.667561540084395,CN1CCN(CC1)C2=NC3=C(CCNCC3)C(=N2)NC4=CC=C(C=C4)F.Cl,CN1CCN(c2nc3c(c(Nc4ccc(F)cc4)n2)CCNCC3)CC1
3218,CHEMBL2393241,P28223,,HMIHHQSBWPMEEL-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,=,684.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463418,DTCC01380944,868826,54812,6.164943898279883,CN1CCC2=C(CC1)N=C(N=C2NC3=CC=C(C=C3)F)N4CCN(CC4)C.Cl,CN1CCc2nc(N3CCN(C)CC3)nc(Nc3ccc(F)cc3)c2CC1
3220,CHEMBL2393242,P28223,,UQDVXBNWEDIKNY-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,=,1271.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463395,DTCC01380945,1801147,54812,5.8958544494459915,C1CNCCC2=C1C(=NC(=N2)CC3=CC=CC=C3)N4CCSCC4.Cl,c1ccc(Cc2nc3c(c(N4CCSCC4)n2)CCNCC3)cc1
3222,CHEMBL2393243,P28223,,IOZJZCVAWDDUQC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,=,2.69,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463311,DTCC01380946,1579836,54812,8.570247719997592,C1CNCCC2=C1C(=NC(=N2)CC3=CC=CC=C3)NC4=CC=CC=C4.Cl,c1ccc(Cc2nc3c(c(Nc4ccccc4)n2)CCNCC3)cc1
3224,CHEMBL2393244,P28223,,RSGCACAPJKNVTM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,=,4.92,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12464307,DTCC01380947,2060416,54812,8.30803489723264,C1CNCCC2=C1C(=NC(=N2)CC3=CC=CC=C3)NC4=CC(=CC=C4)F.Cl,Fc1cccc(Nc2nc(Cc3ccccc3)nc3c2CCNCC3)c1
3226,CHEMBL2393245,P28223,,QWIMGYUZKNAMQK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,=,3.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463310,DTCC01380948,1515579,54812,8.522878745280337,C1CNCCC2=C1C(=NC(=N2)CC3=CC=CC=C3)NC4=CC(=CC=C4)Cl.Cl,Clc1cccc(Nc2nc(Cc3ccccc3)nc3c2CCNCC3)c1
3228,CHEMBL2393246,P28223,,NFVRIUBTRSCFPB-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,=,84.4,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12464209,DTCC01380949,1995596,54812,7.073657553374345,COC1=CC=CC(=C1)NC2=NC(=NC3=C2CCNCC3)CC4=CC=CC=C4.Cl,COc1cccc(Nc2nc(Cc3ccccc3)nc3c2CCNCC3)c1
3229,CHEMBL2393247,P28223,,PDHYLJKLFLSTKE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,=,1.95,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12464318,DTCC01380950,836021,54812,8.709965388637482,C1CNCCC2=C1C(=NC(=N2)CC3=CC=CC=C3)NC4=CC=C(C=C4)F.Cl,Fc1ccc(Nc2nc(Cc3ccccc3)nc3c2CCNCC3)cc1
3230,CHEMBL2393248,P28223,,ZEQDXIOMGIAMFZ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,=,57.4,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12464242,DTCC01380951,965129,54812,7.241088107602026,COC1=CC=C(C=C1)NC2=NC(=NC3=C2CCNCC3)CC4=CC=CC=C4.Cl,COc1ccc(Nc2nc(Cc3ccccc3)nc3c2CCNCC3)cc1
3231,CHEMBL2393249,P28223,,QKAZNZCXHAGHTH-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,>,10000.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463340,DTCC01380952,901064,54812,5.0,CCNC1=NC2=C(C=NN2)C(=N1)NC3=CC=CC=C3,CCNc1nc(Nc2ccccc2)c2cn[nH]c2n1
3233,CHEMBL2393250,P28223,,OZYFGQSCKWOCMB-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,>,10000.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463338,DTCC01380953,803335,54812,5.0,CCCNC1=NC2=C(C=NN2)C(=N1)NC3=CC=CC=C3,CCCNc1nc(Nc2ccccc2)c2cn[nH]c2n1
3235,CHEMBL2393251,P28223,,MBJTXSZAOYIPJR-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,=,25.1,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12464272,DTCC01380954,771151,54812,7.600326278518962,CN1CCN(CC1)C2=NC3=C(C=NN3)C(=N2)NC4=CC=CC=C4,CN1CCN(c2nc(Nc3ccccc3)c3cn[nH]c3n2)CC1
3237,CHEMBL2393252,P28223,,KWDWXDXFNWMAEU-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,=,2753.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463378,DTCC01380955,1353888,54812,5.56019378860667,CCN(CC)C1=NC2=C(C=NN2)C(=N1)NC3=CC(=C(C=C3)C)C,CCN(CC)c1nc(Nc2ccc(C)c(C)c2)c2cn[nH]c2n1
3239,CHEMBL2393253,P28223,,BDBKOKIDJKLGPT-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,=,1894.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463386,DTCC01380956,1644674,54812,5.722620025332746,CCN(CC)C1=NC2=C(C=NN2)C(=N1)NC3=CC=C(C=C3)Cl,CCN(CC)c1nc(Nc2ccc(Cl)cc2)c2cn[nH]c2n1
3241,CHEMBL2393254,P28223,,HPQYRPAIXIPHQW-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,=,28.8,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12464266,DTCC01380957,965130,54812,7.540607512240769,CN1CCN(CC1)C2=NC3=C(C=NN3)C(=N2)NC4=CC=C(C=C4)Cl,CN1CCN(c2nc(Nc3ccc(Cl)cc3)c3cn[nH]c3n2)CC1
3243,CHEMBL2393255,P28223,,NXOQFSFZBCHUMS-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,=,4578.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463368,DTCC01380958,56704,54812,5.339324211661475,CCN(CC)C1=NC2=C(C=NN2)C(=N1)NC3=CC=CC=C3C,CCN(CC)c1nc(Nc2ccccc2C)c2cn[nH]c2n1
3245,CHEMBL2393256,P28223,,VTUUGWIPAVTEPC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,>,10000.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463337,DTCC01380959,123735,54812,5.0,CNC1=NC2=C(C=NN2)C(=N1)NC3=CC=C(C=C3)F,CNc1nc(Nc2ccc(F)cc2)c2cn[nH]c2n1
3247,CHEMBL2393257,P28223,,VXKJLYBMXFERHB-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,>,10000.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463336,DTCC01380960,1288560,54812,5.0,CCNC1=NC2=C(C=NN2)C(=N1)NC3=CC=C(C=C3)F,CCNc1nc(Nc2ccc(F)cc2)c2cn[nH]c2n1
3249,CHEMBL2393258,P28223,,WTQDDFAVNQAQFD-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,>,10000.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463335,DTCC01380961,577406,54812,5.0,C1=CC(=CC=C1NC2=NC(=NC3=C2C=NN3)NCCCO)F,OCCCNc1nc(Nc2ccc(F)cc2)c2cn[nH]c2n1
3251,CHEMBL2393259,P28223,,RVAPVOXFCTVDQA-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,>,10000.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463334,DTCC01380962,513113,54812,5.0,COCCNC1=NC2=C(C=NN2)C(=N1)NC3=CC=C(C=C3)F,COCCNc1nc(Nc2ccc(F)cc2)c2cn[nH]c2n1
3253,CHEMBL2393260,P28223,,UTLATNBNWPWWKI-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,=,5283.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463366,DTCC01380963,1865387,54812,5.277119389313061,COCCCNC1=NC2=C(C=NN2)C(=N1)NC3=CC=C(C=C3)F,COCCCNc1nc(Nc2ccc(F)cc2)c2cn[nH]c2n1
3255,CHEMBL2393261,P28223,,DNTLBOBIFCOTQA-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,=,6577.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463361,DTCC01380964,577407,54812,5.181972158140744,C=CCNC1=NC2=C(C=NN2)C(=N1)NC3=CC=C(C=C3)F,C=CCNc1nc(Nc2ccc(F)cc2)c2cn[nH]c2n1
3257,CHEMBL2393262,P28223,,JROSEQJBDJESRI-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,=,3666.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463374,DTCC01380965,1353889,54812,5.435807539373802,C1CCC(CC1)NC2=NC3=C(C=NN3)C(=N2)NC4=CC=C(C=C4)F,Fc1ccc(Nc2nc(NC3CCCCC3)nc3[nH]ncc23)cc1
3259,CHEMBL2393263,P28223,,YHPHPDDUBYQLEF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,=,4499.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463370,DTCC01380966,252760,54812,5.346884006834433,C1CCC(C1)NC2=NC3=C(C=NN3)C(=N2)NC4=CC=C(C=C4)F,Fc1ccc(Nc2nc(NC3CCCC3)nc3[nH]ncc23)cc1
3261,CHEMBL2393264,P28223,,OIDIVUKFWKFUKE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,=,1268.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463396,DTCC01380967,2060417,54812,5.896880746454286,C1=CC=C(C=C1)CNC2=NC3=C(C=NN3)C(=N2)NC4=CC=C(C=C4)F,Fc1ccc(Nc2nc(NCc3ccccc3)nc3[nH]ncc23)cc1
3263,CHEMBL2393265,P28223,,ZYVINOJEFXYQTC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,=,947.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463407,DTCC01380968,318430,54812,6.023650020996727,CC1=CC=C(C=C1)CNC2=NC3=C(C=NN3)C(=N2)NC4=CC=C(C=C4)F,Cc1ccc(CNc2nc(Nc3ccc(F)cc3)c3cn[nH]c3n2)cc1
3265,CHEMBL2393266,P28223,,WSOOKKKWRKBGTR-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,=,9741.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463357,DTCC01380969,513114,54812,5.011396456654336,C1COCCN1CCNC2=NC3=C(C=NN3)C(=N2)NC4=CC=C(C=C4)F,Fc1ccc(Nc2nc(NCCN3CCOCC3)nc3[nH]ncc23)cc1
3267,CHEMBL2393267,P28223,,MANCBIKCESTSDK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,=,4880.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463367,DTCC01380970,1929775,54812,5.311580177997289,CN(C)C1=NC2=C(C=NN2)C(=N1)NC3=CC=C(C=C3)F,CN(C)c1nc(Nc2ccc(F)cc2)c2cn[nH]c2n1
3269,CHEMBL2393268,P28223,,MQKOODQBUDKMEZ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,=,4535.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463369,DTCC01380971,1321145,54812,5.343422708603886,CCN(CC)C1=NC2=C(C=NN2)C(=N1)NC3=CC=C(C=C3)F,CCN(CC)c1nc(Nc2ccc(F)cc2)c2cn[nH]c2n1
3271,CHEMBL2393269,P28223,,ALXXXCXQNDTUNV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,=,2618.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463380,DTCC01380972,609733,54812,5.582030357785263,C1COCCN1C2=NC3=C(C=NN3)C(=N2)NC4=CC=C(C=C4)F,Fc1ccc(Nc2nc(N3CCOCC3)nc3[nH]ncc23)cc1
3273,CHEMBL2393270,P28223,,OZXSHKZLOMHBMC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,=,2198.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463383,DTCC01380973,513115,54812,5.657972311912529,C1CCN(CC1)C2=NC3=C(C=NN3)C(=N2)NC4=CC=C(C=C4)F,Fc1ccc(Nc2nc(N3CCCCC3)nc3[nH]ncc23)cc1
3275,CHEMBL2393271,P28223,,IOVQFLUXSBRREX-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,=,5866.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463362,DTCC01380974,1353890,54812,5.231657941355467,CC1CC(CN(C1)C2=NC3=C(C=NN3)C(=N2)NC4=CC=C(C=C4)F)C,CC1CC(C)CN(c2nc(Nc3ccc(F)cc3)c3cn[nH]c3n2)C1
3277,CHEMBL2393272,P28223,,UWBORGXYFBQQJS-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,=,3673.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463373,DTCC01380975,642457,54812,5.434979071654706,CC1CCN(CC1)C2=NC3=C(C=NN3)C(=N2)NC4=CC=C(C=C4)F,CC1CCN(c2nc(Nc3ccc(F)cc3)c3cn[nH]c3n2)CC1
3279,CHEMBL2393273,P28223,,KYVNAKFDWJNJRZ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,=,24.2,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12464275,DTCC01380976,1865388,54812,7.616184634019569,CN1CCN(CC1)C2=NC3=C(C=NN3)C(=N2)NC4=CC=C(C=C4)F,CN1CCN(c2nc(Nc3ccc(F)cc3)c3cn[nH]c3n2)CC1
3281,CHEMBL2393274,P28223,,DIMLKEYFPZRTJO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,=,163.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463434,DTCC01380977,1579837,54812,6.787812395596042,C1CN(CCN1CCO)C2=NC3=C(C=NN3)C(=N2)NC4=CC=C(C=C4)F,OCCN1CCN(c2nc(Nc3ccc(F)cc3)c3cn[nH]c3n2)CC1
3283,CHEMBL2393275,P28223,,OOFJTZQVWIXPHP-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,=,52.2,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12464245,DTCC01380978,1483119,54812,7.282329496997738,C1CN(CCN1CC2=CC=CC=C2)C3=NC4=C(C=NN4)C(=N3)NC5=CC=C(C=C5)F,Fc1ccc(Nc2nc(N3CCN(Cc4ccccc4)CC3)nc3[nH]ncc23)cc1
3285,CHEMBL2393276,P28223,,KDNSQBSCUAOXCF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,=,27.2,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12464269,DTCC01380979,480860,54812,7.565431095965801,C1CN(CCN1C2=CC=CC=C2)C3=NC4=C(C=NN4)C(=N3)NC5=CC=C(C=C5)F,Fc1ccc(Nc2nc(N3CCN(c4ccccc4)CC3)nc3[nH]ncc23)cc1
3287,CHEMBL2393277,P28223,,SXCANJNHFZQFPA-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,=,17.9,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12464284,DTCC01380980,91393,54812,7.747146969020107,C1CN(CCN1C2=CC=C(C=C2)F)C3=NC4=C(C=NN4)C(=N3)NC5=CC=C(C=C5)F,Fc1ccc(Nc2nc(N3CCN(c4ccc(F)cc4)CC3)nc3[nH]ncc23)cc1
3289,CHEMBL2393278,P28223,,UJJNMVKYNKUIRX-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,=,1378.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463393,DTCC01380981,351243,54812,5.860750782428393,COC1=CC=CC=C1N2CCN(CC2)C3=NC4=C(C=NN4)C(=N3)NC5=CC=C(C=C5)F,COc1ccccc1N1CCN(c2nc(Nc3ccc(F)cc3)c3cn[nH]c3n2)CC1
3291,CHEMBL2393279,P28223,,HGLBJEIAVUCWNG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,=,2084.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463384,DTCC01380982,1644675,54812,5.681102285372513,CCN(CC)C1=NC2=C(C=NN2)C(=N1)NC3=CC(=CC=C3)OC,CCN(CC)c1nc(Nc2cccc(OC)c2)c2cn[nH]c2n1
3293,CHEMBL2393402,P28223,,LOPJVAGARVXXHR-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,=,9.1,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12464295,DTCC01381106,91395,54812,8.040958607678906,CN1CCN(CC1)C2=NC3=C(C=NN3)C(=N2)NC4=CC(=CC=C4)OC,COc1cccc(Nc2nc(N3CCN(C)CC3)nc3[nH]ncc23)c1
3295,CHEMBL2393403,P28223,,IXGSJWCUFRFSHO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,=,350.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463426,DTCC01381107,1833391,54812,6.455931955649724,COC1=CC=CC(=C1)NC2=NC(=NC3=C2C=NN3)N4CCN(CC4)C5=CC=C(C=C5)F,COc1cccc(Nc2nc(N3CCN(c4ccc(F)cc4)CC3)nc3[nH]ncc23)c1
3297,CHEMBL2393404,P28223,,KJMXIYYOCRCVFT-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23537943.0,IC50,=,696.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]-ketanserin from human recombinant 5HT-2A receptor expressed in CHOK1 cell membranes after 60 mins,,Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity.,Eur. J. Med. Chem.,2013.0,63.0,,"Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Lee J, Choi K, Kim CH, Lee J, Pae AN",,963834.0,DTCT0023186,12463416,DTCC01381108,836026,54812,6.157390760389438,COC1=CC=C(C=C1)NC2=NC(=NC3=C2C=NN3)N4CCN(CC4)C5=CC=C(C=C5)F,COc1ccc(Nc2nc(N3CCN(c4ccc(F)cc4)CC3)nc3[nH]ncc23)cc1
3402,CHEMBL24,P28223,ATENOLOL,METKIMKYRPQLGS-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7263801,DTCC00133283,574620,46191,,CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O,CC(C)NCC(O)COc1ccc(CC(N)=O)cc1
3430,CHEMBL241694,P28223,ETHISTERONE,CHNXZKVNWQUJIB-CEGNMAFCSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7307140,DTCC00474598,1674144,46191,,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C#C)O)C,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
3434,CHEMBL242273,P28223,SAFROLE,ZMQAAUBTXCXRIC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7484069,DTCC00455925,315669,46191,,C=CCC1=CC2=C(C=C1)OCO2,C=CCc1ccc2c(c1)OCO2
3471,CHEMBL24441,P28223,BETAHISTINE,UUQMNUMQCIQDMZ-UHFFFAOYSA-N,1,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7274217,DTCC00159008,606968,46191,,CNCCC1=CC=CC=N1,CNCCc1ccccn1
3479,CHEMBL2447952,P28223,,NCYZHKYGOQPNHK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,327.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074888,DTCC01403827,1843906,45813,6.485452247339714,CCCC1=NC(=C(N1C2=CC=C(C=C2)F)C)C(=O)NCC(CN3CCN(CC3)C4=CC=CC(=C4C)C)O.Cl.Cl,CCCc1nc(C(=O)NCC(O)CN2CCN(c3cccc(C)c3C)CC2)c(C)n1-c1ccc(F)cc1
3480,CHEMBL2447969,P28223,,HPXNPYWRXHOUDB-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,175.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435454,DTCC01403841,1018935,40090,6.756961951313706,CC1=C(C=C(N1C)C2=CC=CC=C2)C(=O)NCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl.Cl,Cc1c(C(=O)NCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc(-c2ccccc2)n1C
3484,CHEMBL245416,P28223,L-MIMOSINE,WZNJWVWKTVETCG-YFKPBYRVSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7427033,DTCC00474857,2025639,46191,,C1=CN(C=C(C1=O)O)C[C@@H](C(=O)O)N,N[C@@H](Cn1ccc(=O)c(O)c1)C(=O)O
3492,CHEMBL248702,P28223,DEXFENFLURAMINE,DBGIVFWFUFKIQN-VIFPVBQESA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7344334,DTCC00487049,1351109,46191,,CCN[C@@H](C)CC1=CC(=CC=C1)C(F)(F)F,CCN[C@@H](C)Cc1cccc(C(F)(F)F)c1
3494,CHEMBL24944,P28223,TRIBROMSALAN,KVSKGMLNBAPGKH-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7448099,DTCC00154630,1830693,46191,,C1=CC(=CC=C1NC(=O)C2=C(C(=CC(=C2)Br)Br)O)Br,O=C(Nc1ccc(Br)cc1)c1cc(Br)cc(Br)c1O
3497,CHEMBL249854,P28223,,ZFRLEPMXXGKKBN-WPFOTENUSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,17418570.0,IC50,=,5300.0,NM,,,,,,,,,,,,,,Inhibition of 5HT2A receptor,,CC chemokine receptor-3 (CCR3) antagonists: improving the selectivity of DPC168 by reducing central ring lipophilicity.,Bioorg. Med. Chem. Lett.,2007.0,17.0,11.0,"Pruitt JR, Batt DG, Wacker DA, Bostrom LL, Booker SK, McLaughlin E, Houghton GC, Varnes JG, Christ DD, Covington M, Das AM, Davies P, Graden D, Kariv I, Orlovsky Y, Stowell NC, Vaddi KG, Wadman EA, Welch PK, Yeleswaram S, Solomon KA, Newton RC, Decicco CP, Carter PH, Ko SS",,458978.0,DTCT0023186,2259549,DTCC00487163,827723,24816,5.275724130399211,CC1=C(SC(=N1)NC(=O)N[C@@H]2CN(CC[C@H]2CN3CCC[C@H](C3)CC4=CC=C(C=C4)F)C(=O)C)C(=O)C,CC(=O)c1sc(NC(=O)N[C@@H]2CN(C(C)=O)CC[C@H]2CN2CCC[C@@H](Cc3ccc(F)cc3)C2)nc1C
3498,CHEMBL25,P28223,ASPIRIN,BSYNRYMUTXBXSQ-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7277871,DTCC00133284,51447,46191,,CC(=O)OC1=CC=CC=C1C(=O)O,CC(=O)Oc1ccccc1C(=O)O
3501,CHEMBL250689,P28223,,ASRDPULQBHFPGU-WFIHMLKPSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,17418570.0,IC50,=,920.0,NM,,,,,,,,,,,,,,Inhibition of 5HT2A receptor,,CC chemokine receptor-3 (CCR3) antagonists: improving the selectivity of DPC168 by reducing central ring lipophilicity.,Bioorg. Med. Chem. Lett.,2007.0,17.0,11.0,"Pruitt JR, Batt DG, Wacker DA, Bostrom LL, Booker SK, McLaughlin E, Houghton GC, Varnes JG, Christ DD, Covington M, Das AM, Davies P, Graden D, Kariv I, Orlovsky Y, Stowell NC, Vaddi KG, Wadman EA, Welch PK, Yeleswaram S, Solomon KA, Newton RC, Decicco CP, Carter PH, Ko SS",,458978.0,DTCT0023186,2259526,DTCC00487112,1857360,24816,6.036212172654444,CC(=O)C1=CC(=CC=C1)NC(=O)N[C@@H]2CCCC[C@H]2CN3CCC[C@H](C3)CC4=CC=C(C=C4)F,CC(=O)c1cccc(NC(=O)N[C@@H]2CCCC[C@H]2CN2CCC[C@@H](Cc3ccc(F)cc3)C2)c1
3502,CHEMBL250699,P28223,A-803467,VHKBTPQDHDSBSP-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,17483457.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat.",Proc. Natl. Acad. Sci. U.S.A.,2007.0,104.0,20.0,"Jarvis MF, Honore P, Shieh CC, Chapman M, Joshi S, Zhang XF, Kort M, Carroll W, Marron B, Atkinson R, Thomas J, Liu D, Krambis M, Liu Y, McGaraughty S, Chu K, Roeloffs R, Zhong C, Mikusa JP, Hernandez G, Gauvin D, Wade C, Zhu C, Pai M, Scanio M, Shi L, Drizin I, Gregg R, Matulenko M, Hakeem A, Gross M, Johnson M, Marsh K, Wagoner PK, Sullivan JP, Faltynek CR, Krafte DS",,466567.0,DTCT0023186,2351660,DTCC00003813,310509,25480,5.522878745280337,COC1=CC(=CC(=C1)NC(=O)C2=CC=C(O2)C3=CC=C(C=C3)Cl)OC,COc1cc(NC(=O)c2ccc(-c3ccc(Cl)cc3)o2)cc(OC)c1
3503,CHEMBL250699,P28223,A-803467,VHKBTPQDHDSBSP-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18176998.0,IC50,>,2000.0,NM,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor,,"Discovery and biological evaluation of 5-aryl-2-furfuramides, potent and selective blockers of the Nav1.8 sodium channel with efficacy in models of neuropathic and inflammatory pain.",J. Med. Chem.,2008.0,51.0,3.0,"Kort ME, Drizin I, Gregg RJ, Scanio MJ, Shi L, Gross MF, Atkinson RN, Johnson MS, Pacofsky GJ, Thomas JB, Carroll WA, Krambis MJ, Liu D, Shieh CC, Zhang X, Hernandez G, Mikusa JP, Zhong C, Joshi S, Honore P, Roeloffs R, Marsh KC, Murray BP, Liu J, Werness S, Faltynek CR, Krafte DS, Jarvis MF, Chapman ML, Marron BE",,460799.0,DTCT0023186,2270930,DTCC00003813,310418,25011,5.698970004336019,COC1=CC(=CC(=C1)NC(=O)C2=CC=C(O2)C3=CC=C(C=C3)Cl)OC,COc1cc(NC(=O)c2ccc(-c3ccc(Cl)cc3)o2)cc(OC)c1
3514,CHEMBL252556,P28223,IDEBENONE,JGPMMRGNQUBGND-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7332186,DTCC00485000,185554,46191,,CC1=C(C(=O)C(=C(C1=O)OC)OC)CCCCCCCCCCO,COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O
3516,CHEMBL252557,P28223,GLYCOLIC ACID,AEMRFAOFKBGASW-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7312531,DTCC00485664,962448,46191,,C(C(=O)O)O,O=C(O)CO
3535,CHEMBL253376,P28223,BROMHEXINE,OJGDCBLYJGHCIH-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7266041,DTCC00112211,444635,46191,,CN(CC1=C(C(=CC(=C1)Br)Br)N)C2CCCCC2,CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1
3556,CHEMBL254219,P28223,DIGITOXIN,WDJUZGPOPHTGOT-XUDUSOBPSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7346804,DTCC00112296,994591,46191,,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5CC[C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)C)C)C)O)O,C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6CC[C@]7(C)[C@@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O
3568,CHEMBL25719,P28223,GERANIOL,GLZPCOQZEFWAFX-JXMROGBWSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7316664,DTCC00159285,898289,46191,,CC(=CCC/C(=C/CO)/C)C,CC(C)=CCC/C(C)=C/CO
3570,CHEMBL257423,P28223,,WYCWVUGQDBCHEF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,1980.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789502,DTCC00501994,856132,31612,5.703334809738469,CN(C)CC1=CC=CC=C1OC2=CC=C(C=C2)Cl,CN(C)Cc1ccccc1Oc1ccc(Cl)cc1
3573,CHEMBL257704,P28223,EPLIVANSERIN,VAIOZOCLKVMIMN-PRJWTAEASA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16469866.0,IC50,=,1.0,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0023186,14709944,DTCC00498890,2098113,68469,9.0,CN(C)CCO/N=C(/C=C/C1=CC=C(C=C1)O)\C2=CC=CC=C2F,CN(C)CCO/N=C(/C=C/c1ccc(O)cc1)c1ccccc1F
3581,CHEMBL259199,P28223,,OBUBLVFQIMPZAM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18083580.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,Binding affinity at 5HT2A receptor,,Novel quinazolinone derivatives as 5-HT7 receptor ligands.,Bioorg. Med. Chem.,2008.0,16.0,5.0,"Na YH, Hong SH, Lee JH, Park WK, Baek DJ, Koh HY, Cho YS, Choo H, Pae AN",,474642.0,DTCT0023186,2341942,DTCC00496831,1652854,26061,5.6777807052660805,CCOC1=CC=CC=C1N2CCN(CC2)CCCC(=O)NCC3=NC4=C(C=CC(=C4)F)C(=O)N3C5=CC=C(C=C5)OC,CCOc1ccccc1N1CCN(CCCC(=O)NCc2nc3cc(F)ccc3c(=O)n2-c2ccc(OC)cc2)CC1
3582,CHEMBL259415,P28223,,LSBYSFJBFKEHKG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18083580.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,Binding affinity at 5HT2A receptor,,Novel quinazolinone derivatives as 5-HT7 receptor ligands.,Bioorg. Med. Chem.,2008.0,16.0,5.0,"Na YH, Hong SH, Lee JH, Park WK, Baek DJ, Koh HY, Cho YS, Choo H, Pae AN",,474642.0,DTCT0023186,2341894,DTCC00497070,1166644,26061,5.958607314841775,CC1=C(C(=CC=C1)N2CCN(CC2)CCCC(=O)NCC3=NC4=CC=CC=C4C(=O)N3C5=CC=CC=C5)C,Cc1cccc(N2CCN(CCCC(=O)NCc3nc4ccccc4c(=O)n3-c3ccccc3)CC2)c1C
3585,CHEMBL259776,P28223,,GMMMLQZLHXIAPP-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18083580.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,Binding affinity at 5HT2A receptor,,Novel quinazolinone derivatives as 5-HT7 receptor ligands.,Bioorg. Med. Chem.,2008.0,16.0,5.0,"Na YH, Hong SH, Lee JH, Park WK, Baek DJ, Koh HY, Cho YS, Choo H, Pae AN",,474642.0,DTCT0023186,2341926,DTCC00496745,617890,26061,5.0,COC1=CC=CC=C1N2CCN(CC2)CCCC(=O)NCC3=NC4=C(C=C(C=C4)F)C(=O)N3C5=CC=CC=C5,COc1ccccc1N1CCN(CCCC(=O)NCc2nc3ccc(F)cc3c(=O)n2-c2ccccc2)CC1
3589,CHEMBL26,P28223,SULPIRIDE,BGRJTUBHPOOWDU-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7478484,DTCC00133325,413978,46191,,CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC,CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC
3592,CHEMBL260907,P28223,,KOJCGDRJEPIJRS-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18083580.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,Binding affinity at 5HT2A receptor,,Novel quinazolinone derivatives as 5-HT7 receptor ligands.,Bioorg. Med. Chem.,2008.0,16.0,5.0,"Na YH, Hong SH, Lee JH, Park WK, Baek DJ, Koh HY, Cho YS, Choo H, Pae AN",,474642.0,DTCT0023186,2341934,DTCC00497197,1264221,26061,5.0,CCOC1=CC=CC=C1N2CCN(CC2)CCCC(=O)NCC3=NC4=C(C=C(C=C4)F)C(=O)N3C5=CC=CC=C5,CCOc1ccccc1N1CCN(CCCC(=O)NCc2nc3ccc(F)cc3c(=O)n2-c2ccccc2)CC1
3595,CHEMBL261019,P28223,,YBKCQCAJYCNQFK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18083580.0,IC50,=,620.0,NM,,,,,,,,,,,,,,Binding affinity at 5HT2A receptor,,Novel quinazolinone derivatives as 5-HT7 receptor ligands.,Bioorg. Med. Chem.,2008.0,16.0,5.0,"Na YH, Hong SH, Lee JH, Park WK, Baek DJ, Koh HY, Cho YS, Choo H, Pae AN",,474642.0,DTCT0023186,2341910,DTCC00496963,1937941,26061,6.2076083105017466,C1CN(CCN1CCCC(=O)NCC2=NC3=C(C=CC(=C3)F)C(=O)N2C4=CC=CC=C4)C5=CC=CC(=C5)C(F)(F)F,O=C(CCCN1CCN(c2cccc(C(F)(F)F)c2)CC1)NCc1nc2cc(F)ccc2c(=O)n1-c1ccccc1
3598,CHEMBL261102,P28223,,JLBUARJMJJDHRK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18083580.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,Binding affinity at 5HT2A receptor,,Novel quinazolinone derivatives as 5-HT7 receptor ligands.,Bioorg. Med. Chem.,2008.0,16.0,5.0,"Na YH, Hong SH, Lee JH, Park WK, Baek DJ, Koh HY, Cho YS, Choo H, Pae AN",,474642.0,DTCT0023186,2341902,DTCC00497198,1103253,26061,5.769551078621726,CC1=C(C(=CC=C1)N2CCN(CC2)CCCC(=O)NCC3=NC4=C(C=CC(=C4)F)C(=O)N3C5=CC=CC=C5)C,Cc1cccc(N2CCN(CCCC(=O)NCc3nc4cc(F)ccc4c(=O)n3-c3ccccc3)CC2)c1C
3599,CHEMBL261434,P28223,,XITNJWUZFRCEAM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18083580.0,IC50,=,420.0,NM,,,,,,,,,,,,,,Binding affinity at 5HT2A receptor,,Novel quinazolinone derivatives as 5-HT7 receptor ligands.,Bioorg. Med. Chem.,2008.0,16.0,5.0,"Na YH, Hong SH, Lee JH, Park WK, Baek DJ, Koh HY, Cho YS, Choo H, Pae AN",,474642.0,DTCT0023186,2341918,DTCC00496798,1937942,26061,6.376750709602099,CC1=C(C(=CC=C1)N2CCN(CC2)CCCC(=O)NCC3=NC4=C(C=C(C=C4)F)C(=O)N3C5=CC=CC=C5)C,Cc1cccc(N2CCN(CCCC(=O)NCc3nc4ccc(F)cc4c(=O)n3-c3ccccc3)CC2)c1C
3608,CHEMBL26260,P28223,BETA-NAPHTHOFLAVONE,OUGIDAPQYNCXRA-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7271264,DTCC00163498,1641845,46191,,C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=CC4=CC=CC=C43,O=c1cc(-c2ccccc2)oc2ccc3ccccc3c12
3610,CHEMBL262777,P28223,VANCOMYCIN,MYPYJXKWCTUITO-LYRMYLQWSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7448469,DTCC00189637,51514,46191,,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
3627,CHEMBL264374,P28223,BEZAFIBRATE,IIBYAHWJQTYFKB-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7263045,DTCC00179544,249938,46191,,CC(C)(C(=O)O)OC1=CC=C(C=C1)CCNC(=O)C2=CC=C(C=C2)Cl,CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(=O)O
3638,CHEMBL267044,P28223,LEVOSULPIRIDE,BGRJTUBHPOOWDU-NSHDSACASA-N,2,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7433831,DTCC00136073,1734057,46191,,CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC,CCN1CCC[C@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC
3641,CHEMBL267345,P28223,AMPHOTERICIN B,APKFDSVGJQXUKY-INPOYWNPSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7290109,DTCC00139627,51445,46191,,C[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@H]([C@@H](CC[C@H](C[C@H](CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)O)N)O,C[C@@H]1OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@]2(O)C[C@H](O)[C@@H](C(=O)O)[C@H](C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@H]1C)O2
3644,CHEMBL267615,P28223,,ZEYRDXUWJDGTLD-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16055331.0,IC50,=,620.0,NM,,,,,,,,,,,,,,Inhibitory activity against 5-hydroxytryptamine 2A receptor in human,,"2-Alkyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles as novel 5-HT6 receptor agonists.",Bioorg. Med. Chem. Lett.,2005.0,15.0,19.0,"Mattsson C, Sonesson C, Sandahl A, Greiner HE, Gassen M, Plaschke J, Leibrock J, Böttcher H",,321342.0,DTCT0023186,1847907,DTCC00133863,919058,19721,6.2076083105017466,CCC1=C(C2=C(N1)C=CC(=C2)OC)CCN(C)C,CCc1[nH]c2ccc(OC)cc2c1CCN(C)C
3645,CHEMBL267648,P28223,PEFLOXACIN,FHFYDNQZQSQIAI-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7389133,DTCC00141792,735393,46191,,CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCN(CC3)C)F)C(=O)O,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C)CC3)cc21
3647,CHEMBL267744,P28223,TICRYNAFEN,AGHANLSBXUWXTB-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7479087,DTCC00134562,1544902,46191,,C1=CSC(=C1)C(=O)C2=C(C(=C(C=C2)OCC(=O)O)Cl)Cl,O=C(O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl
3659,CHEMBL267777,P28223,RITANSERIN,JUQLTPCYUFPYKE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16469866.0,IC50,=,0.069,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0023186,14708152,DTCC00141159,2097637,68469,10.161150909262744,CC1=C(C(=O)N2C=CSC2=N1)CCN3CCC(=C(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F)CC3,Cc1nc2sccn2c(=O)c1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1
3662,CHEMBL267894,P28223,AMOBARBITAL,VIROVYVQCGLCII-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7281710,DTCC00134214,1092340,46191,,CCC1(C(=O)NC(=O)NC1=O)CCC(C)C,CCC1(CCC(C)C)C(=O)NC(=O)NC1=O
3689,CHEMBL268291,P28223,DIMETHYLFORMAMIDE,ZMXDDKWLCZADIW-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7420121,DTCC00136577,1765977,46191,,CN(C)C=O,CN(C)C=O
3705,CHEMBL269732,P28223,TACROLIMUS,QJJXYPPXXYFBGM-LFZNUXCKSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7461099,DTCC00132983,1765982,46191,,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC
3710,CHEMBL27,P28223,PROPRANOLOL,AQHHHDLHHXJYJD-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26565745.0,IC50,>,5011.87,NM,,,,,,,,,,,,,,Antagonist activity at human 5-HT2A receptor expressed in CHO-K1 cells assessed as seretonin-induced calcium level by FDSS assay,,Benzazaborinines as Novel Bioisosteric Replacements of Naphthalene: Propranolol as an Example.,J. Med. Chem.,2015.0,58.0,23.0,"Rombouts FJ, Tovar F, Austin N, Tresadern G, Trabanco AA.",,1539014.0,DTCT0023186,2792,DTCC00133355,534,65419,5.300000202445418,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,CC(C)NCC(O)COc1cccc2ccccc12
3711,CHEMBL27,P28223,PROPRANOLOL,AQHHHDLHHXJYJD-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,1466.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7403034,DTCC00133355,51503,46191,5.8338660296948905,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,CC(C)NCC(O)COc1cccc2ccccc12
3714,CHEMBL270299,P28223,BAY-11-7085,VHKZGNPOHPFPER-ONNFQVAWSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7269636,DTCC00504714,1220273,46191,,CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)/C=C/C#N,CC(C)(C)c1ccc(S(=O)(=O)/C=C/C#N)cc1
3736,CHEMBL273348,P28223,TOSUFLOXACIN,WUWFMDMBOJLQIV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7464070,DTCC00145035,2025645,46191,,C1CN(CC1N)C2=C(C=C3C(=O)C(=CN(C3=N2)C4=C(C=C(C=C4)F)F)C(=O)O)F,NC1CCN(c2nc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2F)C1
3762,CHEMBL275481,P28223,,WXEAKHMDZXZNIZ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,24547.09,NM,,,,,,,,,,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,,Bioorg. Med. Chem. Lett.,1996.0,6.0,10.0,,,2462.0,DTCT0023186,1249890,DTCC00139360,1308282,1628,4.609999985082743,CCCN1CCN(CC12CC3=C(C=CC=C3OC)OC2)CC4=CC=CC=C4,CCCN1CCN(Cc2ccccc2)CC12COc1cccc(OC)c1C2
3767,CHEMBL275742,P28223,DEXPROPRANOLOL,AQHHHDLHHXJYJD-CQSZACIVSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7468420,DTCC00140656,1674148,46191,,CC(C)NC[C@H](COC1=CC=CC2=CC=CC=C21)O,CC(C)NC[C@@H](O)COc1cccc2ccccc12
3769,CHEMBL27577,P28223,SALICYLAMIDE,SKZKKFZAGNVIMN-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7458074,DTCC00161342,185557,46191,,C1=CC=C(C(=C1)C(=O)N)O,NC(=O)c1ccccc1O
3781,CHEMBL276832,P28223,HYDRALAZINE,RPTUSVTUFVMDQK-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7327787,DTCC00139551,1416032,46191,,C1=CC=C2C(=C1)C=NN=C2NN,NNc1nncc2ccccc12
3783,CHEMBL277100,P28223,TEMAFLOXACIN,QKDHBVNJCZBTMR-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7485095,DTCC00145004,1124457,46191,,CC1CN(CCN1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4=C(C=C(C=C4)F)F)F,CC1CN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2F)CCN1
3786,CHEMBL277120,P28223,,VNICFCQJUVFULD-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16220969.0,IC50,=,62.0,NM,,,,,,,,,,,,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,Designed multiple ligands. An emerging drug discovery paradigm.,J. Med. Chem.,2005.0,48.0,21.0,"Morphy R, Rankovic Z",,321230.0,DTCT0023186,1862047,DTCC00149924,2035685,19940,7.2076083105017466,C1CN(CCN1)C2=CC=CC3=CC=CC=C32,c1ccc2c(N3CCNCC3)cccc2c1
3788,CHEMBL277474,P28223,ANTIPYRINE,VEQOALNAAJBPNY-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7263605,DTCC00154395,509231,46191,,CC1=CC(=O)N(N1C)C2=CC=CC=C2,Cc1cc(=O)n(-c2ccccc2)n1C
3790,CHEMBL27769,P28223,STANOLONE,NVKAWKQGWWIWPM-ABEVXSGRSA-N,2,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7465031,DTCC00161007,1318447,46191,,C[C@]12CCC(=O)C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4O)C,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O
3793,CHEMBL278172,P28223,BENZOCAINE,BLFLLBZGZJTVJG-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7269739,DTCC00146075,88623,46191,,CCOC(=O)C1=CC=C(C=C1)N,CCOC(=O)c1ccc(N)cc1
3801,CHEMBL28079,P28223,ZAPRINAST,REZGGXNDEMKIQB-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7445093,DTCC00165545,1862720,46191,,CCCOC1=CC=CC=C1C2=NC3=NNN=C3C(=O)N2,CCCOc1ccccc1-c1nc2n[nH]nc2c(=O)[nH]1
3803,CHEMBL280998,P28223,CATECHOL,YCIMNLLNPGFGHC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7342968,DTCC00161195,541717,46191,,C1=CC=C(C(=C1)O)O,Oc1ccccc1O
3812,CHEMBL282468,P28223,CHOLINE CHLORIDE,SGMZJAMFUVOLNK-UHFFFAOYSA-M,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7369101,DTCC00159655,120971,46191,,C[N+](C)(C)CCO.[Cl-],C[N+](C)(C)CCO
3814,CHEMBL282575,P28223,ESTRADIOL BENZOATE,UYIFTLBWAOGQBI-BZDYCCQFSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7268611,DTCC00165062,1674141,46191,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)OC(=O)C5=CC=CC=C5,C[C@]12CC[C@@H]3c4ccc(OC(=O)c5ccccc5)cc4CC[C@H]3[C@@H]1CC[C@@H]2O
3820,CHEMBL283196,P28223,ALPHA-NAPHTHOFLAVONE,VFMMPHCGEFXGIP-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7297960,DTCC00163499,671784,46191,,C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C4=CC=CC=C4C=C3,O=c1cc(-c2ccccc2)oc2c1ccc1ccccc12
3835,CHEMBL286398,P28223,PROPYLENE GLYCOL,DNIAPMSPPWPWGF-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7372947,DTCC00167384,1798417,46191,,CC(CO)O,CC(O)CO
3851,CHEMBL289469,P28223,GRANISETRON,MFWNKCLOYSRHCJ-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7333903,DTCC00177095,249942,46191,,CN1C2CCCC1CC(C2)NC(=O)C3=NN(C4=CC=CC=C43)C,CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2
3854,CHEMBL29,P28223,BENZYLPENICILLIN,JGSARLDLIJGVTE-MBNYWOFBSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7376268,DTCC00133537,51497,46191,,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C,CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(=O)O
3856,CHEMBL290106,P28223,BITHIONOL,JFIOVJDNOJYLKP-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7274331,DTCC00104360,153440,46191,,C1=C(C=C(C(=C1SC2=C(C(=CC(=C2)Cl)Cl)O)O)Cl)Cl,Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O
3864,CHEMBL290916,P28223,EDARAVONE,QELUYTUMUWHWMC-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7315424,DTCC00181825,443476,46191,,CC1=NN(C(=O)C1)C2=CC=CC=C2,CC1=NN(c2ccccc2)C(=O)C1
3866,CHEMBL291338,P28223,"3,3',4',5-TETRACHLOROSALICYLANILIDE",SJQBHPJLLIJASD-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7294564,DTCC00204573,1447875,46191,,C1=CC(=C(C=C1NC(=O)C2=C(C(=CC(=C2)Cl)Cl)O)Cl)Cl,O=C(Nc1ccc(Cl)c(Cl)c1)c1cc(Cl)cc(Cl)c1O
3874,CHEMBL292779,P28223,L-775606,ZUTQCPBDRJBADG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,9357515.0,IC50,=,370.0,NM,,,,,,,,,,,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,"Selective, orally active 5-HT1D receptor agonists as potential antimigraine agents.",J. Med. Chem.,1997.0,40.0,22.0,"MacLeod AM, Street LJ, Reeve AJ, Jelley RA, Sternfeld F, Beer MS, Stanton JA, Watt AP, Rathbone D, Matassa VG",,2467.0,DTCT0023186,729029,DTCC01740766,1240895,14385,6.431798275933005,C1CN(CCN1CCCC2=CNC3=C2C=C(C=C3)N4C=NN=C4)CCC5=CC(=CC=C5)F,Fc1cccc(CCN2CCN(CCCc3c[nH]c4ccc(-n5cnnc5)cc34)CC2)c1
3878,CHEMBL29292,P28223,UBENIMEX,VGGGPCQERPFHOB-RDBSUJKOSA-N,2,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7449389,DTCC00165773,120979,46191,,CC(C)C[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](CC1=CC=CC=C1)N)O,CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(=O)O
3882,CHEMBL293492,P28223,CINNAMALDEHYDE,KJPRLNWUNMBNBZ-QPJJXVBHSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7364796,DTCC00198978,1124447,46191,,C1=CC=C(C=C1)/C=C/C=O,O=C/C=C/c1ccccc1
3894,CHEMBL294199,P28223,CAPSAICIN,YKPUWZUDDOIDPM-SOFGYWHQSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7277593,DTCC00207211,736256,46191,,CC(C)/C=C/CCCCC(=O)NCC1=CC(=C(C=C1)O)OC,COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O
3908,CHEMBL295416,P28223,PIRINIXIC ACID,SZRPDCCEHVWOJX-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7378857,DTCC00183846,671791,46191,,CC1=C(C(=CC=C1)NC2=CC(=NC(=N2)SCC(=O)O)Cl)C,Cc1cccc(Nc2cc(Cl)nc(SCC(=O)O)n2)c1C
3913,CHEMBL295698,P28223,KETOCONAZOLE,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7431226,DTCC00191118,51483,46191,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
3921,CHEMBL296419,P28223,ASTEMIZOLE,GXDALQBWZGODGZ-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,20.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7279464,DTCC00186013,413968,46191,7.698970004336019,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1
3930,CHEMBL297446,P28223,,LLXUCLCWOOURAA-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,15026042.0,IC50,=,787.0,NM,,,,,,,,,,,,,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,Discovery of N-propylurea 3-benzylpiperidines as selective CC chemokine receptor-3 (CCR3) antagonists.,Bioorg. Med. Chem. Lett.,2004.0,14.0,7.0,"Varnes JG, Gardner DS, Santella JB, Duncia JV, Estrella M, Watson PS, Clark CM, Ko SS, Welch P, Covington M, Stowell N, Wadman E, Davies P, Solomon K, Newton RC, Trainor GL, Decicco CP, Wacker DA",,2445.0,DTCT0023186,1657311,DTCC00185287,1402740,6756,6.104025267640935,COC1=CC=CC(=C1)NC(=O)NCCCN2CCCC(C2)CCC3=CC=CC=C3,COc1cccc(NC(=O)NCCCN2CCCC(CCc3ccccc3)C2)c1
3953,CHEMBL3,P28223,NICOTINE,SNICXCGAKADSCV-JTQLQIEISA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7398986,DTCC00132283,51492,46191,,CN1CCC[C@H]1C2=CN=CC=C2,CN1CCC[C@H]1c1cccnc1
3955,CHEMBL30,P28223,CIMETIDINE,AQIXAKUUQRKLND-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7360484,DTCC00133542,282997,46191,,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CN=C(NC#N)NCCSCc1nc[nH]c1C
3957,CHEMBL30008,P28223,FLUNARIZINE,SMANXXCATUTDDT-QPJJXVBHSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,407.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7326751,DTCC00164139,542576,46191,6.39040559077478,C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,Fc1ccc(C(c2ccc(F)cc2)N2CCN(C/C=C/c3ccccc3)CC2)cc1
3970,CHEMBL302795,P28223,TENOXICAM,LZNWYQJJBLGYLT-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7459112,DTCC00224436,1641854,46191,,CN1C(=C(C2=C(S1(=O)=O)C=CS2)O)C(=O)NC3=CC=CC=N3,CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O
3972,CHEMBL30327,P28223,"2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN",HGUFODBRKLSHSI-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7283694,DTCC00168237,833154,46191,,C1=C2C(=CC(=C1Cl)Cl)OC3=CC(=C(C=C3O2)Cl)Cl,Clc1cc2c(cc1Cl)Oc1cc(Cl)c(Cl)cc1O2
3975,CHEMBL3039597,P28223,GENTAMICIN,NPEFREDMMVQEPL-RWPARATISA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7308105,DTCC01405528,51474,46191,,CC([C@@H]1CC[C@H]([C@H](O1)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@](CO3)(C)O)NC)O)N)N)N)N.CC([C@@H]1CC[C@H]([C@H](O1)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@](CO3)(C)O)NC)O)N)N)N)NC.C[C@@]1(CO[C@@H]([C@@H]([C@H]1NC)O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]3[C@@H](CC[C@H](O3)CN)N)N)N)O,CNC(C)[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1
3982,CHEMBL305660,P28223,EBASTINE,MJJALKDDGIKVBE-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,90.4,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7308898,DTCC00223547,1704690,46191,7.043831569524636,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4,CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1
3999,CHEMBL307145,P28223,PYROGALLOL,WQGWDDDVZFFDIG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7398803,DTCC00231461,1220280,46191,,C1=CC(=C(C(=C1)O)O)O,Oc1cccc(O)c1O
4018,CHEMBL3084803,P28223,ASTROMICIN,BIDUPMYXGFNAEJ-APGVDKLISA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7260878,DTCC01407776,768473,46191,,C[C@@H]([C@@H]1CC[C@H]([C@H](O1)O[C@@H]2[C@H]([C@@H]([C@@H]([C@H]([C@H]2O)N(C)C(=O)CN)OC)O)N)N)N,CO[C@H]1[C@@H](O)[C@H](N)[C@@H](O[C@H]2O[C@H]([C@H](C)N)CC[C@H]2N)[C@H](O)[C@@H]1N(C)C(=O)CN
4054,CHEMBL309904,P28223,,HXBMOXWVYIRYHK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755364.0,IC50,>,1000.0,NM,,cell_based,,,,,,,,,,,L929,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2508.0,DTCT0023186,808768,DTCC00240851,1947079,5128,6.0,CC(C)N(CC1CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1)C(C)C,CC(C)N(CC1CC2c3ccccc3Cc3ccccc3N2O1)C(C)C
4055,CHEMBL309981,P28223,,PZVJEHWECRAJMM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755364.0,IC50,>,1000.0,NM,,cell_based,,,,,,,,,,,L929,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2508.0,DTCT0023186,814742,DTCC00240875,497813,5128,6.0,C1CN(CCN1CC2CC3C4=CC=CC=C4CC5=CC=CC=C5N3O2)C6=CC=CC=C6,c1ccc(N2CCN(CC3CC4c5ccccc5Cc5ccccc5N4O3)CC2)cc1
4056,CHEMBL31,P28223,GATIFLOXACIN,XUBOMFCQGDBHNK-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7320805,DTCC00133611,185553,46191,,CC1CN(CCN1)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F,COc1c(N2CCNC(C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12
4058,CHEMBL310018,P28223,,CQJJYGDKIDMYJM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755364.0,IC50,=,3.89,NM,,cell_based,,,,,,,,,,,L929,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2508.0,DTCT0023186,814732,DTCC00240762,885461,5128,8.410050398674292,CN(C)CCCC1CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1,CN(C)CCCC1CC2c3ccccc3Cc3ccccc3N2O1
4061,CHEMBL310183,P28223,R-95292,VMLLHZVDHFWOOM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755364.0,IC50,=,1.91,NM,,cell_based,,,,,,,,,,,L929,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2508.0,DTCT0023186,796291,DTCC01741354,1850122,5128,8.718966632752272,CN(C)CC1CC2C3=CC=CC=C3OC4=C(N2O1)C=C(C=C4)Cl,CN(C)CC1CC2c3ccccc3Oc3ccc(Cl)cc3N2O1
4090,CHEMBL310555,P28223,OXYQUINOLINE,MCJGNVYPOGVAJF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7384664,DTCC00239255,1092347,46191,,C1=CC2=C(C(=C1)O)N=CC=C2,Oc1cccc2cccnc12
4099,CHEMBL310940,P28223,,BELFTABQPVPWDW-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755364.0,IC50,=,281.84,NM,,cell_based,,,,,,,,,,,L929,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2508.0,DTCT0023186,775205,DTCC00240925,2077149,5128,6.549997369826814,CN1CCN(CC1)CC2CC3C4=CC=CC=C4CC5=CC=CC=C5N3O2,CN1CCN(CC2CC3c4ccccc4Cc4ccccc4N3O2)CC1
4104,CHEMBL311231,P28223,,ONUZLDLDGNZGFE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755364.0,IC50,>,1000.0,NM,,cell_based,,,,,,,,,,,L929,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2508.0,DTCT0023186,793562,DTCC00240154,1914465,5128,6.0,C1CN(CCN1)CC2CC3C4=CC=CC=C4CC5=CC=CC=C5N3O2,c1ccc2c(c1)Cc1ccccc1N1OC(CN3CCNCC3)CC21
4105,CHEMBL311350,P28223,PIROMIDIC ACID,RCIMBBZXSXFZBV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7383191,DTCC00230394,1862718,46191,,CCN1C=C(C(=O)C2=CN=C(N=C21)N3CCCC3)C(=O)O,CCn1cc(C(=O)O)c(=O)c2cnc(N3CCCC3)nc21
4109,CHEMBL311469,P28223,2-ACETYLAMINOFLUORENE,CZIHNRWJTSTCEX-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7300068,DTCC00242606,2025633,46191,,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,CC(=O)Nc1ccc2c(c1)Cc1ccccc1-2
4114,CHEMBL31184,P28223,BENZO[DEF]CHRYSENE,FMMWHPNWAFZXNH-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7264171,DTCC00168186,866017,46191,,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,c1ccc2c(c1)cc1ccc3cccc4ccc2c1c34
4141,CHEMBL313189,P28223,,SWGWJQBPCJEQJC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755364.0,IC50,=,91.2,NM,,cell_based,,,,,,,,,,,L929,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2508.0,DTCT0023186,803200,DTCC00240837,2077150,5128,7.0400051616715835,CN(C)CCC1CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1,CN(C)CCC1CC2c3ccccc3Cc3ccccc3N2O1
4142,CHEMBL313493,P28223,METHANESULFONIC ACID METHYL ESTER,MBABOKRGFJTBAE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7417471,DTCC00245877,671790,46191,,COS(=O)(=O)C,COS(C)(=O)=O
4148,CHEMBL313604,P28223,,IRIGJBAWLKWASO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755365.0,IC50,=,32.36,NM,,cell_based,,,,,,,,,,,L929,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2509.0,DTCT0023186,1568107,DTCC00243821,128991,5129,7.489991487059766,CN(C)CC1CC2C3=CC=CC=C3CC4=C(N2O1)C(=CC=C4)Cl,CN(C)CC1CC2c3ccccc3Cc3cccc(Cl)c3N2O1
4150,CHEMBL313703,P28223,,XKZZKFWMYWZWDI-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755364.0,IC50,>,1000.0,NM,,cell_based,,,,,,,,,,,L929,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2508.0,DTCT0023186,772560,DTCC00240912,562137,5128,6.0,C1C(ON2C1C3=CC=CC=C3CC4=CC=CC=C42)CN5CC6=CC=CC=C6C5,c1ccc2c(c1)CN(CC1CC3c4ccccc4Cc4ccccc4N3O1)C2
4151,CHEMBL313714,P28223,,HNKDAQNYMJNLCC-SANMLTNESA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,10585208.0,IC50,=,1100.0,NM,,cell_based,,,,,,,,,,,CHO,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,3-[3-(Piperidin-1-yl)propyl]indoles as highly selective h5-HT(1D) receptor agonists.,J. Med. Chem.,1999.0,42.0,24.0,"Russell MG, Matassa VG, Pengilley RR, van Niel MB, Sohal B, Watt AP, Hitzel L, Beer MS, Stanton JA, Broughton HB, Castro JL",,2271.0,DTCT0023186,1612559,DTCC00252216,918231,15507,5.958607314841775,C1CN(CCC1N[C@@H](CO)C2=CC=C(C=C2)F)CCCC3=CNC4=C3C=C(C=C4)N5C=NN=C5,OC[C@H](NC1CCN(CCCc2c[nH]c3ccc(-n4cnnc4)cc23)CC1)c1ccc(F)cc1
4158,CHEMBL314107,P28223,,GEDGEGJCGBTAON-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755365.0,IC50,=,10.72,NM,,cell_based,,,,,,,,,,,L929,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2509.0,DTCT0023186,1570716,DTCC00243059,1870729,5129,7.969805214643249,CN(C)CC1CC2C3=C(CC4=C(N2O1)C=C(C=C4)F)C=CC(=C3)F,CN(C)CC1CC2c3cc(F)ccc3Cc3ccc(F)cc3N2O1
4160,CHEMBL314795,P28223,,ZTXJDBYCWAXXCA-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755365.0,IC50,=,47.86,NM,,cell_based,,,,,,,,,,,L929,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2509.0,DTCT0023186,1574601,DTCC00243831,1488569,5129,7.320027305722581,CC1=C2C3CC(ON3C4=CC=CC=C4CC2=CC=C1)CN(C)C,Cc1cccc2c1C1CC(CN(C)C)ON1c1ccccc1C2
4162,CHEMBL314885,P28223,,PWJDUASUWRTROR-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755365.0,IC50,=,53.7,NM,,cell_based,,,,,,,,,,,L929,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2509.0,DTCT0023186,1594230,DTCC00244386,258114,5129,7.270025714300444,CN(C)CC1CC2C3=C(CC4=CC=CC=C4N2O1)C=CC(=C3)F,CN(C)CC1CC2c3cc(F)ccc3Cc3ccccc3N2O1
4164,CHEMBL315044,P28223,,RTEBNFQOFLORPE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755365.0,IC50,=,302.0,NM,,cell_based,,,,,,,,,,,L929,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2509.0,DTCT0023186,1586526,DTCC00244365,1617808,5129,6.519993057042849,CN(C)CC1CC2C3=C(CC4=CC=CC=C4N2O1)C=CC(=C3)OC,COc1ccc2c(c1)C1CC(CN(C)C)ON1c1ccccc1C2
4167,CHEMBL315308,P28223,,RUWZQSJWDUNAEU-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755365.0,IC50,=,22.39,NM,,cell_based,,,,,,,,,,,L929,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2507.0,DTCT0023186,1581351,DTCC00243541,2000901,5129,7.64994590642097,CN(C)CC1CC2C3=CC=CC=C3CC4=C(N2O1)C=C(C=C4)C5=CC=CC=C5,CN(C)CC1CC2c3ccccc3Cc3ccc(-c4ccccc4)cc3N2O1
4168,CHEMBL315424,P28223,,YDCWINJIBUMKOY-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755365.0,IC50,>,1000.0,NM,,cell_based,,,,,,,,,,,L929,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2509.0,DTCT0023186,1567016,DTCC00243841,582696,5129,6.0,CN(C)CC1CC2C3=C(CC4=CC=CC=C4N2O1)C(=CC=C3)Cl,CN(C)CC1CC2c3cccc(Cl)c3Cc3ccccc3N2O1
4173,CHEMBL315772,P28223,,JTLCTTWVUAIQHD-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755365.0,IC50,=,3.47,NM,,cell_based,,,,,,,,,,,L929,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2509.0,DTCT0023186,1570702,DTCC00243316,1488568,5129,8.459670525209127,CN(C)CC1CC2C3=CC=CC=C3CC4=C(N2O1)C=C(C=C4)Cl,CN(C)CC1CC2c3ccccc3Cc3ccc(Cl)cc3N2O1
4174,CHEMBL315772,P28223,,JTLCTTWVUAIQHD-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,12443779.0,IC50,=,3.47,NM,,,,,,,,,,,,,,Binding affinity against 5-hydroxytryptamine 2A receptor,,2-(Dimethylaminomethyl)-tetrahydroisoxazolopyridobenzazepine derivatives. Synthesis of a new 5-HT(2C) antagonist with potential anxiolytic properties.,Bioorg. Med. Chem. Lett.,2002.0,12.0,24.0,"Andrés JI, Alonso JM, Fernández J, Iturrino L, Martínez P, Meert TF, Sipido VK",,2512.0,DTCT0023186,961168,DTCC00243316,1489186,5276,8.459670525209127,CN(C)CC1CC2C3=CC=CC=C3CC4=C(N2O1)C=C(C=C4)Cl,CN(C)CC1CC2c3ccccc3Cc3ccc(Cl)cc3N2O1
4176,CHEMBL315834,P28223,,QBPDZEVGAGDUQY-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755365.0,IC50,=,23.99,NM,,cell_based,,,,,,,,,,,L929,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2509.0,DTCT0023186,1567021,DTCC00243261,389200,5129,7.619969752032169,CN(C)CC1CC2C3=CC=CC=C3CC4=C(N2O1)C=CC=C4F,CN(C)CC1CC2c3ccccc3Cc3c(F)cccc3N2O1
4182,CHEMBL316438,P28223,,SHNQYDFOONPSKV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755364.0,IC50,=,25.12,NM,,cell_based,,,,,,,,,,,L929,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2508.0,DTCT0023186,805935,DTCC00241156,1175396,5128,7.599980364934842,C1CCN(C1)CC2CC3C4=CC=CC=C4CC5=CC=CC=C5N3O2,c1ccc2c(c1)Cc1ccccc1N1OC(CN3CCCC3)CC21
4185,CHEMBL316561,P28223,PROGLUMIDE,DGMKFQYCZXERLX-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7379222,DTCC00259031,1383781,46191,,CCCN(CCC)C(=O)C(CCC(=O)O)NC(=O)C1=CC=CC=C1,CCCN(CCC)C(=O)C(CCC(=O)O)NC(=O)c1ccccc1
4197,CHEMBL319244,P28223,CAFFEIC ACID PHENETHYL ESTER,SWUARLUWKZWEBQ-VQHVLOKHSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7263330,DTCC00274084,88625,46191,,C1=CC=C(C=C1)CCOC(=O)/C=C/C2=CC(=C(C=C2)O)O,O=C(/C=C/c1ccc(O)c(O)c1)OCCc1ccccc1
4207,CHEMBL3215298,P28223,ABAMECTIN,IBSREHMXUMOFBB-JFUDTMANSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7286961,DTCC01462720,2025634,46191,,CC[C@H](C)[C@@H]1[C@H](C=C[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)C.C[C@H]1/C=C/C=C/2\CO[C@H]3[C@@]2([C@@H](C=C([C@H]3O)C)C(=O)O[C@H]4C[C@@H](C/C=C(/[C@H]1O[C@H]5C[C@@H]([C@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O)OC)OC)\C)O[C@]7(C4)C=C[C@@H]([C@H](O7)C(C)C)C)O,CC[C@H](C)[C@H]1O[C@]2(C=C[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2
4209,CHEMBL3215618,P28223,,GSKYZLBVDVDULB-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,31.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074764,DTCC01463036,1331877,45813,7.508638306165727,CCCC1=NC(=C(N1C2=CC=C(C=C2)F)C)C(=O)NCCCN3CCN(CC3)C4=CC=CC(=C4C)C.Cl.Cl,CCCc1nc(C(=O)NCCCN2CCN(c3cccc(C)c3C)CC2)c(C)n1-c1ccc(F)cc1
4210,CHEMBL3215619,P28223,,VQYKDNMXSRRZHV-VJURXQOVSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,95.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074947,DTCC01463037,684965,45813,7.022276394711152,CC1=C(C=CC=C1Cl)N2CCN(CC2)C[C@@H](CNC(=O)C3=C(N(C(=N3)C4=CC=CC=C4)C5=CC=C(C=C5)F)C)O.Cl.Cl.Cl,Cc1c(Cl)cccc1N1CCN(C[C@H](O)CNC(=O)c2nc(-c3ccccc3)n(-c3ccc(F)cc3)c2C)CC1
4211,CHEMBL3215620,P28223,,BVDBGMCXMCRRIP-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,20.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6092217,DTCC01463038,1072887,45813,7.698970004336019,CC1=C(N=C(N1C2=CC=C(C=C2)OC)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl.Cl.Cl.Cl.Cl,COc1ccc(-n2c(C)nc(C(=O)NCCCN3CCN(c4cccc(Cl)c4Cl)CC3)c2C)cc1
4212,CHEMBL3215621,P28223,,GLTOYHJCCONIPL-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,5.17,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6092220,DTCC01463039,1623073,45813,8.286509456906057,CCCC1=NC(=C(N1C2=CC=C(C=C2)OC)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl.Cl.Cl.Cl.Cl,CCCc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccc(OC)cc1
4213,CHEMBL3215622,P28223,,VLBTWFRVOWYSPD-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,13.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6092224,DTCC01463040,394685,45813,7.886056647693163,CC1=C(N=C(N1C2=CC=C(C=C2)OC)C3=CC=CC=C3)C(=O)NCCCN4CCN(CC4)C5=C(C(=CC=C5)Cl)Cl.Cl.Cl.Cl.Cl,COc1ccc(-n2c(-c3ccccc3)nc(C(=O)NCCCN3CCN(c4cccc(Cl)c4Cl)CC3)c2C)cc1
4214,CHEMBL3215623,P28223,,DCKDJZMKJFQLQR-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,16.8,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6092227,DTCC01463041,166703,45813,7.774690718274137,CC1=C(N=C(N1C2=CC=CC=C2F)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl.Cl.Cl.Cl.Cl,Cc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccccc1F
4215,CHEMBL3215624,P28223,,PIGJUEVNUFCZRG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,21.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6092230,DTCC01463042,1233850,45813,7.6777807052660805,CCCC1=NC(=C(N1C2=CC=CC=C2F)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl.Cl.Cl.Cl.Cl,CCCc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccccc1F
4216,CHEMBL3215626,P28223,,FHZYXSVRJRPRLY-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,318.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074900,DTCC01463044,684964,45813,6.497572880015567,CC1=C(C(=CC=C1)N2CCN(CC2)CC(CNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4Cl)C)O)C.Cl.Cl.Cl,Cc1cccc(N2CCN(CC(O)CNC(=O)c3nc(C)n(-c4ccccc4Cl)c3C)CC2)c1C
4217,CHEMBL3215627,P28223,,PODZZNQVHOQILO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,204.5,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074867,DTCC01463045,1718683,45813,6.689306687656639,CC1=C(C(=CC=C1)N2CCN(CC2)CC(CNC(=O)C3=C(N(C(=N3)C)C4=CC(=C(C=C4)OC)OC)C)O)C.Cl.Cl,COc1ccc(-n2c(C)nc(C(=O)NCC(O)CN3CCN(c4cccc(C)c4C)CC3)c2C)cc1OC
4218,CHEMBL3215628,P28223,,XDYZTKVZFPFHPY-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,62.7,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074731,DTCC01463046,749639,45813,7.202732459169283,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4=CC=C(C=C4)OC)C)C.Cl.Cl,COc1ccc(-n2c(C)nc(C(=O)NCCCN3CCN(c4cccc(C)c4C)CC3)c2C)cc1
4219,CHEMBL3215629,P28223,,RZEPNQXMLMYOMR-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,19.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074746,DTCC01463047,1493749,45813,7.721246399047171,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=CN(C(=N3)C4=CC=CC=C4)C5=CC=C(C=C5)OC)C.Cl.Cl,COc1ccc(-n2cc(C(=O)NCCCN3CCN(c4cccc(C)c4C)CC3)nc2-c2ccccc2)cc1
4220,CHEMBL3215630,P28223,,YHGNNFYOPDSKLN-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,8.63,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074674,DTCC01463048,102037,45813,8.063989204284791,CC1=C(N=C(N1C2=CC3=C(C=C2)OCCO3)C)C(=O)NCCCN4CCN(CC4)C5=C(C(=CC=C5)Cl)Cl.Cl.Cl.Cl.Cl,Cc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccc2c(c1)OCCO2
4221,CHEMBL3215631,P28223,,AJQXITCKVIMUJA-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,133.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074692,DTCC01463049,1558091,45813,6.876148359032914,CCCC1=NC(=CN1C2=CC=CC=C2)C(=O)NCCCN3CCN(CC3)C4=CC=CC(=C4C)C.Cl.Cl,CCCc1nc(C(=O)NCCCN2CCN(c3cccc(C)c3C)CC2)cn1-c1ccccc1
4222,CHEMBL3215638,P28223,,BJGUUWDWWRFFOD-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,19.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074812,DTCC01463056,1940489,45813,7.721246399047171,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C4=CC=CC=C4)C5=CC6=C(C=C5)OCCO6)C)C.Cl.Cl,Cc1cccc(N2CCN(CCCNC(=O)c3nc(-c4ccccc4)n(-c4ccc5c(c4)OCCO5)c3C)CC2)c1C
4224,CHEMBL3215846,P28223,,BKWLOABPBICULI-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,94.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074894,DTCC01463264,1331881,45813,7.026872146400302,CC1=C(N=C(N1C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NCC(CN4CCN(CC4)C5=C(C(=CC=C5)Cl)Cl)O.Cl.Cl.Cl.Cl,Cc1c(C(=O)NCC(O)CN2CCN(c3cccc(Cl)c3Cl)CC2)nc(-c2ccccc2)n1-c1ccc(F)cc1
4225,CHEMBL3215847,P28223,,VJBXPFKNFQRVPS-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,231.5,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074925,DTCC01463265,911968,45813,6.635449004646028,CC1=C(C(=CC=C1)N2CCN(CC2)CC(CNC(=O)C3=C(N(C(=N3)C)C4=CC5=C(C=C4)OCCO5)C)O)C.Cl.Cl,Cc1cccc(N2CCN(CC(O)CNC(=O)c3nc(C)n(-c4ccc5c(c4)OCCO5)c3C)CC2)c1C
4226,CHEMBL3215848,P28223,,SMDCFOFHHKIHOL-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,19.5,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6092234,DTCC01463266,17252,45813,7.709965388637482,CC1=C(N=C(N1C2=CC=CC=C2F)C3=CC=CC=C3)C(=O)NCCCN4CCN(CC4)C5=C(C(=CC=C5)Cl)Cl.Cl.Cl.Cl.Cl,Cc1c(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)nc(-c2ccccc2)n1-c1ccccc1F
4227,CHEMBL3215849,P28223,,FTGOEZGULLSYCF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,70.9,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6092240,DTCC01463267,975550,45813,7.149353764816933,CCCC1=NC(=CN1C2=CC=C(C=C2)Cl)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl.Cl.Cl.Cl.Cl.Cl,CCCc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)cn1-c1ccc(Cl)cc1
4228,CHEMBL3215850,P28223,,WVTAOBVWAHTAMN-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,12.3,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074713,DTCC01463268,491511,45813,7.910094888560602,CC1=C(C=CC=C1Cl)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C4=CC=CC=C4)C5=CC=CC=C5)CN6C=NC=N6.Cl.Cl.Cl,Cc1c(Cl)cccc1N1CCN(CCCNC(=O)c2nc(-c3ccccc3)n(-c3ccccc3)c2Cn2cncn2)CC1
4229,CHEMBL3215851,P28223,,NCJAGHZGWIFIGV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,294.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074931,DTCC01463269,1396997,45813,6.531652669587842,CCCC1=NC(=C(N1C2=CC3=C(C=C2)OCCO3)C)C(=O)NCC(CN4CCN(CC4)C5=CC=CC(=C5C)C)O.Cl.Cl,CCCc1nc(C(=O)NCC(O)CN2CCN(c3cccc(C)c3C)CC2)c(C)n1-c1ccc2c(c1)OCCO2
4230,CHEMBL3215852,P28223,,XFQCUMCROPJRDA-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,52.1,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074839,DTCC01463270,879332,45813,7.283162276700476,CC1=C(N=C(N1C2=CC=CC=C2OC)C)C(=O)NCC(CN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl)O.Cl.Cl.Cl.Cl,COc1ccccc1-n1c(C)nc(C(=O)NCC(O)CN2CCN(c3cccc(Cl)c3Cl)CC2)c1C
4231,CHEMBL3215853,P28223,,SWKGPRHMAJRBND-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,45.5,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074695,DTCC01463271,1429192,45813,7.341988603342887,CC1=C(C=CC=C1Cl)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)CC(C)C)C.Cl.Cl.Cl,Cc1c(Cl)cccc1N1CCN(CCCNC(=O)c2nc(C)n(CC(C)C)c2C)CC1
4232,CHEMBL3215862,P28223,,WTHLTXBIFADIQK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,67.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074788,DTCC01463280,1908309,45813,7.173925197299173,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4=CC=C(C=C4)Cl)C)C.Cl.Cl.Cl,Cc1cccc(N2CCN(CCCNC(=O)c3nc(C)n(-c4ccc(Cl)cc4)c3C)CC2)c1C
4233,CHEMBL3215863,P28223,,XEUSTIMXMIWHQL-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,20.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074791,DTCC01463281,1590445,45813,7.698970004336019,CCCC1=NC(=CN1C2=CC=C(C=C2)Cl)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)C.Cl.Cl.Cl.Cl,CCCc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3C)CC2)cn1-c1ccc(Cl)cc1
4234,CHEMBL3215864,P28223,,RBEWBQVBFXYCLE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,40.6,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074803,DTCC01463282,1461274,45813,7.391473966422806,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4=CC5=C(C=C4)OCCO5)C)C.Cl.Cl,Cc1cccc(N2CCN(CCCNC(=O)c3nc(C)n(-c4ccc5c(c4)OCCO5)c3C)CC2)c1C
4236,CHEMBL3216073,P28223,,CXILCPZOTOWUEG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,196.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074885,DTCC01463490,2070821,45813,6.707743928643524,CCCC1=NC(=C(N1C2=CC=C(C=C2)F)C)C(=O)NCC(CN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl)O.Cl.Cl.Cl.Cl,CCCc1nc(C(=O)NCC(O)CN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccc(F)cc1
4237,CHEMBL3216074,P28223,,SPADXPJNKDBNNJ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,71.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074891,DTCC01463491,2006332,45813,7.1487416512809245,CC1=C(C(=CC=C1)N2CCN(CC2)CC(CNC(=O)C3=C(N(C(=N3)C4=CC=CC=C4)C5=CC=C(C=C5)F)C)O)C.Cl.Cl,Cc1cccc(N2CCN(CC(O)CNC(=O)c3nc(-c4ccccc4)n(-c4ccc(F)cc4)c3C)CC2)c1C
4238,CHEMBL3216075,P28223,,HGXGPKMUSUJSBG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,107.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074913,DTCC01463492,458293,45813,6.97061622231479,CCCC1=NC(=CN1C2=CC=C(C=C2)Cl)C(=O)NCC(CN3CCN(CC3)C4=C(C(=CC=C4)Cl)C)O.Cl.Cl.Cl.Cl,CCCc1nc(C(=O)NCC(O)CN2CCN(c3cccc(Cl)c3C)CC2)cn1-c1ccc(Cl)cc1
4239,CHEMBL3216076,P28223,,ZEERPTKETJJYHM-PPLJNSMQSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,72.5,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074934,DTCC01463493,1266735,45813,7.139661993429006,CC1=C(C(=CC=C1)N2CCN(CC2)C[C@@H](CNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4)C)O)C.Cl.Cl,Cc1cccc(N2CCN(C[C@H](O)CNC(=O)c3nc(C)n(-c4ccccc4)c3C)CC2)c1C
4240,CHEMBL3216077,P28223,,ODLFNFICONRURU-GJICFQLNSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,270.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074941,DTCC01463494,1811585,45813,6.568636235841013,CC1=C(C(=CC=C1)N2CCN(CC2)C[C@@H](CNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4F)C)O)C.Cl.Cl,Cc1cccc(N2CCN(C[C@H](O)CNC(=O)c3nc(C)n(-c4ccccc4F)c3C)CC2)c1C
4241,CHEMBL3216078,P28223,,LPAHEXXZYWDDRX-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,141.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074767,DTCC01463495,523757,45813,6.85078088734462,CCCC1=NC(=CN1C2=CC=C(C=C2)F)C(=O)NCCCN3CCN(CC3)C4=CC=CC(=C4C)C.Cl.Cl,CCCc1nc(C(=O)NCCCN2CCN(c3cccc(C)c3C)CC2)cn1-c1ccc(F)cc1
4242,CHEMBL3216079,P28223,,ODLFNFICONRURU-IKXQUJFKSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,244.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074944,DTCC01463496,1590448,45813,6.61261017366127,CC1=C(C(=CC=C1)N2CCN(CC2)C[C@H](CNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4F)C)O)C.Cl.Cl,Cc1cccc(N2CCN(C[C@@H](O)CNC(=O)c3nc(C)n(-c4ccccc4F)c3C)CC2)c1C
4243,CHEMBL3216081,P28223,,HEJMMJXWOXRXAW-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,144.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074719,DTCC01463498,1875989,45813,6.841637507904751,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4OC)C)C.Cl.Cl,COc1ccccc1-n1c(C)nc(C(=O)NCCCN2CCN(c3cccc(C)c3C)CC2)c1C
4244,CHEMBL3216082,P28223,,WVAPBKRVGSEBBR-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,104.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074870,DTCC01463499,2070820,45813,6.982966660701219,CC1=C(N=C(N1C2=CC=CC=C2F)C)C(=O)NCC(CN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl)O.Cl.Cl.Cl.Cl,Cc1nc(C(=O)NCC(O)CN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccccc1F
4245,CHEMBL3216083,P28223,,VCZFGLQXQHGRMA-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,106.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074677,DTCC01463500,1811582,45813,6.97469413473523,CCCC1=NC(=C(N1C2=CC3=C(C=C2)OCCO3)C)C(=O)NCCCN4CCN(CC4)C5=C(C(=CC=C5)Cl)Cl.Cl.Cl.Cl.Cl,CCCc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccc2c(c1)OCCO2
4246,CHEMBL3216084,P28223,,KEZOYKSAZRTJCI-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,185.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074864,DTCC01463501,1461277,45813,6.732828271596986,CC1=C(C(=CC=C1)N2CCN(CC2)CC(CNC(=O)C3=C(N(C(=N3)C4=CC=CC=C4)C5=CC=C(C=C5)OC)C)O)C.Cl.Cl,COc1ccc(-n2c(-c3ccccc3)nc(C(=O)NCC(O)CN3CCN(c4cccc(C)c4C)CC3)c2C)cc1
4247,CHEMBL3216085,P28223,,OMWBMAVZKFUNAR-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,75.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074686,DTCC01463502,2039034,45813,7.1249387366083,CCCC1=NC(=C(N1C2=CC=CC=C2)C)C(=O)NCCCN3CCN(CC3)C4=CC=CC(=C4C)C.Cl.Cl,CCCc1nc(C(=O)NCCCN2CCN(c3cccc(C)c3C)CC2)c(C)n1-c1ccccc1
4248,CHEMBL3216093,P28223,,DRBJQVSARVVSFS-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,29.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074776,DTCC01463510,458289,45813,7.5376020021010435,CC1=C(C=CC=C1Cl)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4Cl)C.Cl.Cl.Cl.Cl,Cc1c(Cl)cccc1N1CCN(CCCNC(=O)c2nc(C)n(-c3ccccc3Cl)c2C)CC1
4249,CHEMBL3216094,P28223,,RVFJTARJNASOQS-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,32.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074797,DTCC01463511,296702,45813,7.494850021680094,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4=CC(=CC(=C4)OC)OC)C)C.Cl.Cl,COc1cc(OC)cc(-n2c(C)nc(C(=O)NCCCN3CCN(c4cccc(C)c4C)CC3)c2C)c1
4250,CHEMBL3216095,P28223,,ZXDXKRRJXWMGKE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,24.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074821,DTCC01463512,458290,45813,7.619788758288394,CC1=C(N=C(N1C2=CC=CC=C2)C3=CC=CC=C3)C(=O)NCC(CN4CCN(CC4)C5=C(C(=CC=C5)Cl)Cl)O.Cl.Cl.Cl.Cl,Cc1c(C(=O)NCC(O)CN2CCN(c3cccc(Cl)c3Cl)CC2)nc(-c2ccccc2)n1-c1ccccc1
4251,CHEMBL3216097,P28223,,HCAYKYREUQDJKX-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,27.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6092187,DTCC01463514,2070812,45813,7.568636235841013,CCC1=NC(=C(N1C2=CC=CC=C2)C)C(=O)NCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl.Cl.Cl.Cl.Cl,CCc1nc(C(=O)NCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccccc1
4252,CHEMBL3216098,P28223,,VXPNNEACONQTET-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,18.6,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6092193,DTCC01463515,1364543,45813,7.730487055782084,CC1=C(N=C(N1C2=CC=CC=C2)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl.Cl.Cl.Cl.Cl,Cc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccccc1
4254,CHEMBL3216259,P28223,,VJCXQFZISDAORM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,43.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435509,DTCC01463675,1666035,40090,7.366531544420414,CC1=C(C=C(N1C)C2=CC=CC=N2)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl.Cl.Cl.Cl.Cl,Cc1c(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc(-c2ccccn2)n1C
4255,CHEMBL3216282,P28223,,SVHKSIZLWYJLIC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,275.1,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074906,DTCC01463698,1590447,45813,6.560509409610316,CC1=C(C(=CC=C1)N2CCN(CC2)CC(CNC(=O)C3=C(N(C(=N3)C)C4=CC(=CC=C4)Cl)C)O)C.Cl.Cl.Cl,Cc1cccc(N2CCN(CC(O)CNC(=O)c3nc(C)n(-c4cccc(Cl)c4)c3C)CC2)c1C
4256,CHEMBL3216284,P28223,,LYRJLGBBEXHUOS-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,139.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6092214,DTCC01463700,555908,45813,6.856985199745905,CCCC1=NC(=C(N1C2=CC=CC=C2OC)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl.Cl.Cl.Cl.Cl,CCCc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccccc1OC
4257,CHEMBL3216285,P28223,,WBMLOPUGTHXLTH-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,78.3,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074882,DTCC01463701,296704,45813,7.106238237942057,CC1=C(C(=CC=C1)N2CCN(CC2)CC(CNC(=O)C3=C(N(C(=N3)C)C4=CC=C(C=C4)F)C)O)C.Cl.Cl,Cc1cccc(N2CCN(CC(O)CNC(=O)c3nc(C)n(-c4ccc(F)cc4)c3C)CC2)c1C
4258,CHEMBL3216286,P28223,,LQEYFGIPMXEKNF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,171.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074722,DTCC01463702,684961,45813,6.767003889607846,CCCC1=NC(=C(N1C2=CC=CC=C2OC)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)C.Cl.Cl.Cl,CCCc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3C)CC2)c(C)n1-c1ccccc1OC
4259,CHEMBL3216287,P28223,,UOPQXQMOOIJXPT-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,23.1,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074728,DTCC01463703,1105653,45813,7.636388020107856,CC1=C(C=CC=C1Cl)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4=CC=C(C=C4)OC)C.Cl.Cl.Cl,COc1ccc(-n2c(C)nc(C(=O)NCCCN3CCN(c4cccc(Cl)c4C)CC3)c2C)cc1
4260,CHEMBL3216288,P28223,,OIEOPYYQLYJREJ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,197.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074873,DTCC01463704,1396996,45813,6.705533773838407,CC1=C(C=CC=C1Cl)N2CCN(CC2)CC(CNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4F)C)O.Cl.Cl.Cl,Cc1c(Cl)cccc1N1CCN(CC(O)CNC(=O)c2nc(C)n(-c3ccccc3F)c2C)CC1
4261,CHEMBL3216289,P28223,,ODLFNFICONRURU-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,579.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074876,DTCC01463705,17271,45813,6.2373214362725635,CC1=C(C(=CC=C1)N2CCN(CC2)CC(CNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4F)C)O)C.Cl.Cl,Cc1cccc(N2CCN(CC(O)CNC(=O)c3nc(C)n(-c4ccccc4F)c3C)CC2)c1C
4262,CHEMBL3216290,P28223,,YHODSIBRMIUXTB-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,254.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074879,DTCC01463706,1940495,45813,6.5951662833800615,CC1=C(C=CC=C1Cl)N2CCN(CC2)CC(CNC(=O)C3=C(N(C(=N3)C)C4=CC=C(C=C4)F)C)O.Cl.Cl.Cl,Cc1c(Cl)cccc1N1CCN(CC(O)CNC(=O)c2nc(C)n(-c3ccc(F)cc3)c2C)CC1
4263,CHEMBL3216291,P28223,,ZXKNWRZGVWCZHI-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,24.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074743,DTCC01463707,1105654,45813,7.619788758288394,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C4=CC=CC=C4)C5=CC=C(C=C5)OC)C)C.Cl.Cl,COc1ccc(-n2c(-c3ccccc3)nc(C(=O)NCCCN3CCN(c4cccc(C)c4C)CC3)c2C)cc1
4264,CHEMBL3216293,P28223,,RBWRWRUMXOYJKE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,63.1,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074852,DTCC01463709,813980,45813,7.199970640755866,CCCC1=NC(=C(N1C2=CC=C(C=C2)OC)C)C(=O)NCC(CN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl)O.Cl.Cl.Cl.Cl,CCCc1nc(C(=O)NCC(O)CN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccc(OC)cc1
4265,CHEMBL3216298,P28223,,JNJFGMMXZQTTEV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,80.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074779,DTCC01463714,231129,45813,7.096910013008056,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4Cl)C)C.Cl.Cl.Cl,Cc1cccc(N2CCN(CCCNC(=O)c3nc(C)n(-c4ccccc4Cl)c3C)CC2)c1C
4266,CHEMBL3216299,P28223,,ZEERPTKETJJYHM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,247.6,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074815,DTCC01463715,1040452,45813,6.60624935965192,CC1=C(C(=CC=C1)N2CCN(CC2)CC(CNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4)C)O)C.Cl.Cl,Cc1cccc(N2CCN(CC(O)CNC(=O)c3nc(C)n(-c4ccccc4)c3C)CC2)c1C
4267,CHEMBL3216300,P28223,,NUTMGKBJAOIBHX-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,39.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6092190,DTCC01463716,2039032,45813,7.4089353929735005,CCCC1=NC(=C(N1C2=CC=CC=C2)C)C(=O)NCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl.Cl.Cl.Cl.Cl,CCCc1nc(C(=O)NCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccccc1
4268,CHEMBL3216302,P28223,,OVIIPPCBZKDAAQ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,21.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6092199,DTCC01463718,1558086,45813,7.6777807052660805,CCCC1=NC(=C(N1C2=CC=CC=C2)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl.Cl.Cl.Cl.Cl,CCCc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccccc1
4269,CHEMBL3216303,P28223,,ZHOMTXVBUKNSDX-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,55.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6092208,DTCC01463719,1747213,45813,7.259637310505756,CC1=C(N=C(N1C2CCCC2)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl.Cl.Cl.Cl.Cl,Cc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1C1CCCC1
4270,CHEMBL3216497,P28223,,YLAGOQSVTAZIFM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,176.6,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074910,DTCC01463912,1718684,45813,6.753009300758451,CCCC1=NC(=CN1C2=CC=C(C=C2)Cl)C(=O)NCC(CN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl)O.Cl.Cl.Cl.Cl.Cl,CCCc1nc(C(=O)NCC(O)CN2CCN(c3cccc(Cl)c3Cl)CC2)cn1-c1ccc(Cl)cc1
4271,CHEMBL3216498,P28223,,SRAFZLULPKVDLY-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,54.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074761,DTCC01463913,911962,45813,7.267606240177032,CCCC1=NC(=C(N1C2=CC=C(C=C2)F)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)C.Cl.Cl.Cl,CCCc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3C)CC2)c(C)n1-c1ccc(F)cc1
4272,CHEMBL3216499,P28223,,DIGYIZAMQAEQIR-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,30.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6092237,DTCC01463914,1843900,45813,7.522878745280337,CC1=C(N=C(N1C2=CC=CC=C2Cl)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl.Cl.Cl.Cl.Cl.Cl,Cc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccccc1Cl
4273,CHEMBL3216501,P28223,,IZALGFLYXJGOOO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,13.2,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074710,DTCC01463916,1908308,45813,7.87942606879415,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=CN(C(=N3)C4=CC=CC=C4)C5=CC=CC=C5)C.Cl.Cl,Cc1cccc(N2CCN(CCCNC(=O)c3cn(-c4ccccc4)c(-c4ccccc4)n3)CC2)c1C
4274,CHEMBL3216502,P28223,,VQYKDNMXSRRZHV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,26.7,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074897,DTCC01463917,231136,45813,7.573488738635425,CC1=C(C=CC=C1Cl)N2CCN(CC2)CC(CNC(=O)C3=C(N(C(=N3)C4=CC=CC=C4)C5=CC=C(C=C5)F)C)O.Cl.Cl.Cl,Cc1c(Cl)cccc1N1CCN(CC(O)CNC(=O)c2nc(-c3ccccc3)n(-c3ccc(F)cc3)c2C)CC1
4275,CHEMBL3216503,P28223,,FIZGSYPLNGLOLR-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,40.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074749,DTCC01463918,781589,45813,7.3979400086720375,CC1=C(C=CC=C1Cl)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4F)C.Cl.Cl.Cl,Cc1c(Cl)cccc1N1CCN(CCCNC(=O)c2nc(C)n(-c3ccccc3F)c2C)CC1
4276,CHEMBL3216504,P28223,,SWOBQRROCOYPOH-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,237.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074928,DTCC01463919,717310,45813,6.6252516539898965,CCCC1=NC(=C(N1C2=CC3=C(C=C2)OCCO3)C)C(=O)NCC(CN4CCN(CC4)C5=C(C(=CC=C5)Cl)C)O.Cl.Cl.Cl,CCCc1nc(C(=O)NCC(O)CN2CCN(c3cccc(Cl)c3C)CC2)c(C)n1-c1ccc2c(c1)OCCO2
4277,CHEMBL3216505,P28223,,VOTXTHVYINRCPN-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,97.6,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074836,DTCC01463920,1137945,45813,7.010550182333308,CC1=C(C=CC=C1Cl)N2CCN(CC2)CC(CNC(=O)C3=C(N(C(=N3)C)C4CCCC4)C)O.Cl.Cl.Cl,Cc1c(Cl)cccc1N1CCN(CC(O)CNC(=O)c2nc(C)n(C3CCCC3)c2C)CC1
4278,CHEMBL3216506,P28223,,ZTWIBBACQZFZIB-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,174.9,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074849,DTCC01463921,134424,45813,6.757210190521324,CC1=C(C(=CC=C1)N2CCN(CC2)CC(CNC(=O)C3=C(N(C(=N3)C)C4=CC=C(C=C4)OC)C)O)C.Cl.Cl,COc1ccc(-n2c(C)nc(C(=O)NCC(O)CN3CCN(c4cccc(C)c4C)CC3)c2C)cc1
4279,CHEMBL3216507,P28223,,YEMWOFQTNGNAFV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,170.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074861,DTCC01463922,1655252,45813,6.769551078621726,CC1=C(C=CC=C1Cl)N2CCN(CC2)CC(CNC(=O)C3=C(N(C(=N3)C4=CC=CC=C4)C5=CC=C(C=C5)OC)C)O.Cl.Cl.Cl,COc1ccc(-n2c(-c3ccccc3)nc(C(=O)NCC(O)CN3CCN(c4cccc(Cl)c4C)CC3)c2C)cc1
4280,CHEMBL3216508,P28223,,OQDYFLMNZYARMO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,154.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074683,DTCC01463923,166710,45813,6.812479279163537,CCCC1=NC(=C(N1C2=CC=CC=C2)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)C.Cl.Cl.Cl,CCCc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3C)CC2)c(C)n1-c1ccccc1
4281,CHEMBL3216517,P28223,,JHZFIHCYFUBLGI-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,32.4,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074794,DTCC01463932,2006328,45813,7.489454989793388,CCCC1=NC(=CN1C2=CC=C(C=C2)Cl)C(=O)NCCCN3CCN(CC3)C4=CC=CC(=C4C)C.Cl.Cl.Cl,CCCc1nc(C(=O)NCCCN2CCN(c3cccc(C)c3C)CC2)cn1-c1ccc(Cl)cc1
4282,CHEMBL3216518,P28223,,KYGICLMSOSRLTJ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,241.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074809,DTCC01463933,1779254,45813,6.617982957425132,CCCC1=NC(=C(N1C2=CC3=C(C=C2)OCCO3)C)C(=O)NCCCN4CCN(CC4)C5=CC=CC(=C5C)C.Cl.Cl,CCCc1nc(C(=O)NCCCN2CCN(c3cccc(C)c3C)CC2)c(C)n1-c1ccc2c(c1)OCCO2
4283,CHEMBL3216521,P28223,,QEUMYSDUIYHEAC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,58.6,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074827,DTCC01463936,263496,45813,7.23210238398191,CC1=C(C(=CC=C1)N2CCN(CC2)CC(CNC(=O)C3=C(N(C(=N3)C4=CC=CC=C4)C5=CC=CC=C5)C)O)C.Cl.Cl,Cc1cccc(N2CCN(CC(O)CNC(=O)c3nc(-c4ccccc4)n(-c4ccccc4)c3C)CC2)c1C
4284,CHEMBL3216651,P28223,,KWSJSWCQZPEIPC-LQVXLWKRSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,9182127.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,Displacement of radioligand from 5HT2 receptor by liquid scintillation spectrometry,,"Perhydrogenation of tabersonine, ans Aspidiosperma indole alkaloid.",J. Nat. Prod.,1997.0,60.0,4.0,"Lewin G, Schaeffer C, Dacquet C",,549545.0,DTCT0023186,2539165,DTCC01464065,1788318,27062,5.0,CC[C@@]12CCCN3[C@@H]1[C@@]4(CC3)[C@H]5CCCC[C@H]5N[C@H]4[C@H](C2)C(=O)OC.Cl.Cl,CC[C@]12CCCN3CC[C@]4([C@@H](N[C@@H]5CCCC[C@@H]54)[C@@H](C(=O)OC)C1)[C@@H]32
4285,CHEMBL3216702,P28223,,LPQDPPUUJMDKDK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,58.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435512,DTCC01464116,663612,40090,7.236572006437063,CCCN1C(=C(C=C1C2=CC=CC=N2)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl)C.Cl.Cl.Cl.Cl,CCCn1c(-c2ccccn2)cc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1C
4286,CHEMBL3216707,P28223,,DYASBLFKQRHGMH-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,4559.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435406,DTCC01464121,1212110,40090,5.341130407798038,CC1=C(C=C(N1C)C2=CC=CC=C2)C(=O)NCCCN3CCN(CC3)C4=CC=NC=C4.Cl.Cl,Cc1c(C(=O)NCCCN2CCN(c3ccncc3)CC2)cc(-c2ccccc2)n1C
4287,CHEMBL3216737,P28223,,UFRTWRKBDQMEBQ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,27.8,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074773,DTCC01464151,911963,45813,7.555955204081924,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C4=CC=CC=C4)C5=CC=C(C=C5)F)C)C.Cl.Cl,Cc1cccc(N2CCN(CCCNC(=O)c3nc(-c4ccccc4)n(-c4ccc(F)cc4)c3C)CC2)c1C
4288,CHEMBL3216738,P28223,,NWHNWKCRNKQQEQ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,58.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074671,DTCC01464152,1908303,45813,7.236572006437063,CC1=C(N=C(N1C2=CC=CC=C2C(F)(F)F)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl.Cl.Cl.Cl.Cl,Cc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccccc1C(F)(F)F
4289,CHEMBL3216740,P28223,,YWBSZSNPFVWWRT-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,15.2,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074734,DTCC01464154,458288,45813,7.818156412055227,CCCC1=NC(=C(N1C2=CC=C(C=C2)OC)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)C.Cl.Cl.Cl,CCCc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3C)CC2)c(C)n1-c1ccc(OC)cc1
4290,CHEMBL3216741,P28223,,OHVIMHICPLSQCY-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,64.8,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074752,DTCC01464155,555912,45813,7.188424994129407,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4F)C)C.Cl.Cl,Cc1cccc(N2CCN(CCCNC(=O)c3nc(C)n(-c4ccccc4F)c3C)CC2)c1C
4291,CHEMBL3216742,P28223,,RSRGRXSHFMZQPO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,38.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074755,DTCC01464156,491512,45813,7.42021640338319,CC1=C(C=CC=C1Cl)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4=CC=C(C=C4)F)C.Cl.Cl.Cl,Cc1c(Cl)cccc1N1CCN(CCCNC(=O)c2nc(C)n(-c3ccc(F)cc3)c2C)CC1
4292,CHEMBL3216744,P28223,,DMAYWVDWAYQQNP-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,1011.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074833,DTCC01464158,1364555,45813,5.995248844408999,CC1=C(C(=CC=C1)N2CCN(CC2)CC(CNC(=O)C3=C(N(C(=N3)C)CC(C)C)C)O)C.Cl.Cl,Cc1cccc(N2CCN(CC(O)CNC(=O)c3nc(C)n(CC(C)C)c3C)CC2)c1C
4293,CHEMBL3216745,P28223,,RCOCMICOYJEDIW-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,105.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074689,DTCC01464159,1747218,45813,6.978810700930062,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C(C)C)C4=CC=CC=C4)C)C.Cl.Cl,Cc1cccc(N2CCN(CCCNC(=O)c3nc(C(C)C)n(-c4ccccc4)c3C)CC2)c1C
4294,CHEMBL3216746,P28223,,WBZPIHFUNDZQSB-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,216.8,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074698,DTCC01464160,1875988,45813,6.663940722133651,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)CC(C)C)C)C.Cl.Cl,Cc1cccc(N2CCN(CCCNC(=O)c3nc(C)n(CC(C)C)c3C)CC2)c1C
4295,CHEMBL3216754,P28223,,DODAKNRHJOZSNV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,90.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074782,DTCC01464168,1655247,45813,7.045757490560675,CCCC1=NC(=C(N1C2=CC=CC=C2Cl)C)C(=O)NCCCN3CCN(CC3)C4=CC=CC(=C4C)C.Cl.Cl.Cl,CCCc1nc(C(=O)NCCCN2CCN(c3cccc(C)c3C)CC2)c(C)n1-c1ccccc1Cl
4296,CHEMBL3216755,P28223,,BZRTXOROILQDJS-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,28.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074800,DTCC01464169,1493750,45813,7.552841968657781,CC1=C(C=CC=C1Cl)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4=CC5=C(C=C4)OCCO5)C.Cl.Cl.Cl,Cc1c(Cl)cccc1N1CCN(CCCNC(=O)c2nc(C)n(-c3ccc4c(c3)OCCO4)c2C)CC1
4297,CHEMBL3216756,P28223,,PJIFNDKPRTUYSL-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,201.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074818,DTCC01464170,2070815,45813,6.696803942579511,CCCC1=NC(=C(N1C2=CC=CC=C2)C)C(=O)NCC(CN3CCN(CC3)C4=C(C(=CC=C4)Cl)C)O.Cl.Cl.Cl,CCCc1nc(C(=O)NCC(O)CN2CCN(c3cccc(Cl)c3C)CC2)c(C)n1-c1ccccc1
4298,CHEMBL3216757,P28223,,NHYJAEYQQPWYLG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,57.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074824,DTCC01464171,1718681,45813,7.2441251443275085,CC1=C(C=CC=C1Cl)N2CCN(CC2)CC(CNC(=O)C3=C(N(C(=N3)C4=CC=CC=C4)C5=CC=CC=C5)C)O.Cl.Cl.Cl,Cc1c(Cl)cccc1N1CCN(CC(O)CNC(=O)c2nc(-c3ccccc3)n(-c3ccccc3)c2C)CC1
4299,CHEMBL3216758,P28223,,GNLAUOZRIHVBBM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,31.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6092184,DTCC01464172,1008002,45813,7.508638306165727,CC1=C(N=C(N1C2=CC=CC=C2)C)C(=O)NCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl.Cl.Cl.Cl.Cl,Cc1nc(C(=O)NCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccccc1
4300,CHEMBL3216956,P28223,,XNWJMMGPMVYPNQ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,147.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074916,DTCC01464370,1493753,45813,6.8326826652518236,CCCC1=NC(=C(N1C2=CC=C(C=C2)Cl)C)C(=O)NCC(CN3CCN(CC3)C4=CC=CC(=C4C)C)O.Cl.Cl.Cl,CCCc1nc(C(=O)NCC(O)CN2CCN(c3cccc(C)c3C)CC2)c(C)n1-c1ccc(Cl)cc1
4301,CHEMBL3216957,P28223,,SMGIYSPPPRPALV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,127.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074922,DTCC01464371,555916,45813,6.896196279044043,CC1=C(C=CC=C1Cl)N2CCN(CC2)CC(CNC(=O)C3=C(N(C(=N3)C)C4=CC5=C(C=C4)OCCO5)C)O.Cl.Cl.Cl,Cc1c(Cl)cccc1N1CCN(CC(O)CNC(=O)c2nc(C)n(-c3ccc4c(c3)OCCO4)c2C)CC1
4302,CHEMBL3216958,P28223,,ZEERPTKETJJYHM-ASMAMLKCSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,646.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074938,DTCC01464372,1747225,45813,6.189767482004916,CC1=C(C(=CC=C1)N2CCN(CC2)C[C@H](CNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4)C)O)C.Cl.Cl,Cc1cccc(N2CCN(C[C@@H](O)CNC(=O)c3nc(C)n(-c4ccccc4)c3C)CC2)c1C
4303,CHEMBL3216959,P28223,,BOMBSIJXZSOHOC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,12.2,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074770,DTCC01464373,1747219,45813,7.913640169325252,CC1=C(C=CC=C1Cl)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C4=CC=CC=C4)C5=CC=C(C=C5)F)C.Cl.Cl.Cl,Cc1c(Cl)cccc1N1CCN(CCCNC(=O)c2nc(-c3ccccc3)n(-c3ccc(F)cc3)c2C)CC1
4304,CHEMBL3216960,P28223,,VQYKDNMXSRRZHV-DOTPTTDOSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,20.1,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074950,DTCC01464374,588038,45813,7.696803942579511,CC1=C(C=CC=C1Cl)N2CCN(CC2)C[C@H](CNC(=O)C3=C(N(C(=N3)C4=CC=CC=C4)C5=CC=C(C=C5)F)C)O.Cl.Cl.Cl,Cc1c(Cl)cccc1N1CCN(C[C@@H](O)CNC(=O)c2nc(-c3ccccc3)n(-c3ccc(F)cc3)c2C)CC1
4305,CHEMBL3216961,P28223,,SMSHVHSHMWGMMU-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,80.6,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074701,DTCC01464375,1493748,45813,7.09366495819491,CC1=C(C=CC=C1Cl)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4CCCC4)C.Cl.Cl.Cl,Cc1c(Cl)cccc1N1CCN(CCCNC(=O)c2nc(C)n(C3CCCC3)c2C)CC1
4306,CHEMBL3216962,P28223,,BUCOXHAADOMEPP-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,12.8,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074716,DTCC01464376,975553,45813,7.892790030352131,CC1=C(C=CC=C1Cl)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4OC)C.Cl.Cl.Cl,COc1ccccc1-n1c(C)nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3C)CC2)c1C
4307,CHEMBL3216963,P28223,,BOIGIQAENFPLJQ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,70.8,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074737,DTCC01464377,1718680,45813,7.149966742310231,CCCC1=NC(=C(N1C2=CC=C(C=C2)OC)C)C(=O)NCCCN3CCN(CC3)C4=CC=CC(=C4C)C.Cl.Cl,CCCc1nc(C(=O)NCCCN2CCN(c3cccc(C)c3C)CC2)c(C)n1-c1ccc(OC)cc1
4308,CHEMBL3216964,P28223,,CBFQTQWBFHZIAJ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,21.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074740,DTCC01464378,1590444,45813,7.6777807052660805,CC1=C(C=CC=C1Cl)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C4=CC=CC=C4)C5=CC=C(C=C5)OC)C.Cl.Cl.Cl,COc1ccc(-n2c(-c3ccccc3)nc(C(=O)NCCCN3CCN(c4cccc(Cl)c4C)CC3)c2C)cc1
4309,CHEMBL3216965,P28223,,NNZLXFACAXESEI-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,56.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074846,DTCC01464379,1137947,45813,7.251811972993799,CC1=C(C=CC=C1Cl)N2CCN(CC2)CC(CNC(=O)C3=C(N(C(=N3)C)C4=CC=C(C=C4)OC)C)O.Cl.Cl.Cl,COc1ccc(-n2c(C)nc(C(=O)NCC(O)CN3CCN(c4cccc(Cl)c4C)CC3)c2C)cc1
4310,CHEMBL3216966,P28223,,ROUOSCZSMFKJAM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,582.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074855,DTCC01464380,1137948,45813,6.235077015350112,CCCC1=NC(=C(N1C2=CC=C(C=C2)OC)C)C(=O)NCC(CN3CCN(CC3)C4=C(C(=CC=C4)Cl)C)O.Cl.Cl.Cl,CCCc1nc(C(=O)NCC(O)CN2CCN(c3cccc(Cl)c3C)CC2)c(C)n1-c1ccc(OC)cc1
4311,CHEMBL3216967,P28223,,WNWCRDAUDPBIJU-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,126.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074858,DTCC01464381,1233858,45813,6.8996294548824375,CCCC1=NC(=C(N1C2=CC=C(C=C2)OC)C)C(=O)NCC(CN3CCN(CC3)C4=CC=CC(=C4C)C)O.Cl.Cl,CCCc1nc(C(=O)NCC(O)CN2CCN(c3cccc(C)c3C)CC2)c(C)n1-c1ccc(OC)cc1
4312,CHEMBL3216974,P28223,,TXPWXTFSLYAPNT-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,96.8,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074785,DTCC01464388,975554,45813,7.014124642691606,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4=CC(=CC=C4)Cl)C)C.Cl.Cl.Cl,Cc1cccc(N2CCN(CCCNC(=O)c3nc(C)n(-c4cccc(Cl)c4)c3C)CC2)c1C
4313,CHEMBL3216975,P28223,,RJQHKLIXZKCDHE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,47.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074806,DTCC01464389,1843904,45813,7.327902142064283,CCCC1=NC(=C(N1C2=CC3=C(C=C2)OCCO3)C)C(=O)NCCCN4CCN(CC4)C5=C(C(=CC=C5)Cl)C.Cl.Cl.Cl,CCCc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3C)CC2)c(C)n1-c1ccc2c(c1)OCCO2
4314,CHEMBL3216979,P28223,,FLLFVAKBHLEHPL-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,26.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6092205,DTCC01464393,1655241,45813,7.585026652029182,CCCN1C(=C(N=C1C)C(=O)NCCCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl)C.Cl.Cl.Cl.Cl,CCCn1c(C)nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1C
4315,CHEMBL3217141,P28223,,VVNJPSKWLPMSHV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20637635.0,IC50,=,21.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A expressed in CHOK1 cells,,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem.,2010.0,18.0,16.0,"Kang SY, Park EJ, Park WK, Kim HJ, Choi G, Jung ME, Seo HJ, Kim MJ, Pae AN, Kim J, Lee J",,647226.0,DTCT0023186,3435506,DTCC01464554,566750,40090,7.6777807052660805,CC1=C(C=C(N1)C2=CC=CC=N2)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl.Cl.Cl.Cl.Cl,Cc1[nH]c(-c2ccccn2)cc1C(=O)NCCCN1CCN(c2cccc(Cl)c2Cl)CC1
4316,CHEMBL3217167,P28223,,KLHMHYDSNNINBR-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,9.86,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074919,DTCC01464580,846864,45813,8.006123085058789,CC1=C(N=C(N1C2=CC3=C(C=C2)OCCO3)C)C(=O)NCC(CN4CCN(CC4)C5=C(C(=CC=C5)Cl)Cl)O.Cl.Cl.Cl.Cl,Cc1nc(C(=O)NCC(O)CN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccc2c(c1)OCCO2
4317,CHEMBL3217169,P28223,,GQROKINCBADIKJ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,29.4,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074704,DTCC01464582,458287,45813,7.531652669587842,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C4=CC=CC=C4)C5=CC=CC=C5)C)C.Cl.Cl,Cc1cccc(N2CCN(CCCNC(=O)c3nc(-c4ccccc4)n(-c4ccccc4)c3C)CC2)c1C
4318,CHEMBL3217170,P28223,,JYUAHTUNBVFGGJ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,13.9,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074707,DTCC01464583,1429193,45813,7.856985199745905,CC1=C(C=CC=C1Cl)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C4=CC=CC=C4)C5=CC=CC=C5)C.Cl.Cl.Cl,Cc1c(Cl)cccc1N1CCN(CCCNC(=O)c2nc(-c3ccccc3)n(-c3ccccc3)c2C)CC1
4319,CHEMBL3217171,P28223,,HLJSHTGLXJFIPU-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,253.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074725,DTCC01464584,717308,45813,6.5968794788241825,CCCC1=NC(=C(N1C2=CC=CC=C2OC)C)C(=O)NCCCN3CCN(CC3)C4=CC=CC(=C4C)C.Cl.Cl,CCCc1nc(C(=O)NCCCN2CCN(c3cccc(C)c3C)CC2)c(C)n1-c1ccccc1OC
4320,CHEMBL3217172,P28223,,HHKSZLSPNQMMEM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,182.1,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074903,DTCC01464585,491516,45813,6.73969005420508,CC1=C(C=CC=C1Cl)N2CCN(CC2)CC(CNC(=O)C3=C(N(C(=N3)C)C4=CC(=CC=C4)Cl)C)O.Cl.Cl.Cl.Cl,Cc1c(Cl)cccc1N1CCN(CC(O)CNC(=O)c2nc(C)n(-c3cccc(Cl)c3)c2C)CC1
4321,CHEMBL3217173,P28223,,OEVPCXMTWJIQHA-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,117.9,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074758,DTCC01464586,749640,45813,6.928486194904911,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4=CC=C(C=C4)F)C)C.Cl.Cl,Cc1cccc(N2CCN(CCCNC(=O)c3nc(C)n(-c4ccc(F)cc4)c3C)CC2)c1C
4322,CHEMBL3217175,P28223,,IXWZIHDBVQYVSS-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,370.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074843,DTCC01464588,69766,45813,6.431798275933005,CC1=C(C=CC=C1Cl)N2CCN(CC2)CC(CNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4OC)C)O.Cl.Cl.Cl,COc1ccccc1-n1c(C)nc(C(=O)NCC(O)CN2CCN(c3cccc(Cl)c3C)CC2)c1C
4323,CHEMBL3217176,P28223,,SVYQLZGVECCISN-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,91.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074680,DTCC01464589,1875987,45813,7.040958607678906,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4)C)C.Cl.Cl,Cc1cccc(N2CCN(CCCNC(=O)c3nc(C)n(-c4ccccc4)c3C)CC2)c1C
4324,CHEMBL3217181,P28223,,RVDGYYJVZIZWPA-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,839.9,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6074830,DTCC01464594,231130,45813,6.0757724187398825,CCCN1C(=C(N=C1C)C(=O)NCC(CN2CCN(CC2)C3=CC=CC(=C3C)C)O)C.Cl.Cl,CCCn1c(C)nc(C(=O)NCC(O)CN2CCN(c3cccc(C)c3C)CC2)c1C
4325,CHEMBL3217182,P28223,,QKKGTZYAXGQHHZ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,48.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6092196,DTCC01464595,1590439,45813,7.318758762624412,CCC1=NC(=C(N1C2=CC=CC=C2)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl.Cl.Cl.Cl.Cl,CCc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccccc1
4326,CHEMBL3217183,P28223,,CGWQHMXRAWXWKF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,14.2,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6092202,DTCC01464596,329315,45813,7.847711655616943,CC1=C(N=C(N1C2=CC=CC=C2)C3=CC=CC=C3)C(=O)NCCCN4CCN(CC4)C5=C(C(=CC=C5)Cl)Cl.Cl.Cl.Cl.Cl,Cc1c(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)nc(-c2ccccc2)n1-c1ccccc1
4327,CHEMBL3217184,P28223,,FYYYKBVBZNOVGT-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,21823597.0,IC50,=,10.3,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant serotonin 5-HT2A receptor expressed in CHO-K1 cells,,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54.0,18.0,"Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J",,766793.0,DTCT0023186,6092211,DTCC01464597,1072886,45813,7.987162775294828,CC1=C(N=C(N1C2=CC=CC=C2OC)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl.Cl.Cl.Cl.Cl,COc1ccccc1-n1c(C)nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1C
4350,CHEMBL3233142,P28223,,LHAPOGAFBLSJJQ-GUTACTQSSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,24559051.0,IC50,=,7.0,NM,,cell_based,,,,,,,,,,,,Antagonist activity at human recombinant 5HT2A receptor expressed in HEK293a cells assessed as inhibition of serotonin-induced increase in calcium fluorescence,,Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.,J. Med. Chem.,2014.0,57.0,6.0,"Li P, Zhang Q, Robichaud AJ, Lee T, Tomesch J, Yao W, Beard JD, Snyder GL, Zhu H, Peng Y, Hendrick JP, Vanover KE, Davis RE, Mates S, Wennogle LP",,1339962.0,DTCT0023186,13624914,DTCC01472158,1268946,57999,8.154901959985743,CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCN2[C@H]3CCN(C[C@H]3C4=C2C1=CC=C4)CCCC(=O)C5=CC=C(C=C5)F,CN1CCN2c3c(cccc31)[C@@H]1CN(CCCC(=O)c3ccc(F)cc3)CC[C@@H]12
4415,CHEMBL325258,P28223,,UQMFUNLNAONENR-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11585444.0,IC50,=,854.0,NM,,,,,,,,,,,,,,Inhibition of human 5-hydroxytryptamine 2A receptor,,From hit to lead. Analyzing structure-profile relationships.,J. Med. Chem.,2001.0,44.0,21.0,"Poulain R, Horvath D, Bonnet B, Eckhoff C, Chapelain B, Bodinier MC, Déprez B",,2270.0,DTCT0023186,1394306,DTCC00289108,712515,16444,6.068542129310995,C1CN(CCN1CCCC2=CC=CC=C2)C(=O)OCCC3=CC=C(C=C3)C#N,N#Cc1ccc(CCOC(=O)N2CCN(CCCc3ccccc3)CC2)cc1
4416,CHEMBL325372,P28223,METHYLPARABEN,LXCFILQKKLGQFO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7434575,DTCC00280408,315667,46191,,COC(=O)C1=CC=C(C=C1)O,COC(=O)c1ccc(O)cc1
4418,CHEMBL325516,P28223,,NEUFWHZAVWYYSZ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11585444.0,IC50,=,1060.0,NM,,,,,,,,,,,,,,Inhibition of human 5-hydroxytryptamine 2A receptor,,From hit to lead. Analyzing structure-profile relationships.,J. Med. Chem.,2001.0,44.0,21.0,"Poulain R, Horvath D, Bonnet B, Eckhoff C, Chapelain B, Bodinier MC, Déprez B",,2270.0,DTCT0023186,1393124,DTCC00289332,2066106,16444,5.97469413473523,C1CN(CCN1CCCC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C(=O)OCCC4=CC=C(C=C4)F,O=C(OCCc1ccc(F)cc1)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
4432,CHEMBL326263,P28223,,JJKPSOUEWPDPFS-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11585444.0,IC50,=,715.0,NM,,,,,,,,,,,,,,Inhibition of human 5-hydroxytryptamine 2A receptor,,From hit to lead. Analyzing structure-profile relationships.,J. Med. Chem.,2001.0,44.0,21.0,"Poulain R, Horvath D, Bonnet B, Eckhoff C, Chapelain B, Bodinier MC, Déprez B",,2270.0,DTCT0023186,1369079,DTCC00288867,1618322,16444,6.145693958198919,C1CN(CCN1CCCC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C(=O)OCCC4=CC=C(C=C4)C#N,N#Cc1ccc(CCOC(=O)N2CCN(CCCC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1
4434,CHEMBL3264204,P28223,,WUYOECAJFJFUFC-CMDGGOBGSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,24937185.0,IC50,=,75000.0,NM,,,,,,,,,,,,,,Inhibition of 5HT2A receptor (unknown origin),,Development of second generation EP2 antagonists with high selectivity.,Eur. J. Med. Chem.,2014.0,82.0,,"Ganesh T, Jiang J, Dingledine R",,1364236.0,DTCT0023186,13769800,DTCC01489665,136776,59558,4.1249387366083,COC1=CC(=CC(=C1OC)OC)/C=C/C(=O)NCCN2C3=CC=CC=C3C=C2C(F)(F)F,COc1cc(/C=C/C(=O)NCCn2c(C(F)(F)F)cc3ccccc32)cc(OC)c1OC
4439,CHEMBL32749,P28223,FERULIC ACID,KSEBMYQBYZTDHS-HWKANZROSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7313865,DTCC00171237,1544898,46191,,COC1=C(C=CC(=C1)/C=C/C(=O)O)O,COc1cc(/C=C/C(=O)O)ccc1O
4452,CHEMBL3286556,P28223,,IHHALLDEDARSAL-LBPRGKRZSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,24878222.0,IC50,=,360.0,NM,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor (unknown origin),,"Multiparameter optimization in CNS drug discovery: design of pyrimido[4,5-d]azepines as potent 5-hydroxytryptamine 2C (5-HT2C) receptor agonists with exquisite functional selectivity over 5-HT2A and 5-HT2B receptors.",J. Med. Chem.,2014.0,57.0,12.0,"Storer RI, Brennan PE, Brown AD, Bungay PJ, Conlon KM, Corbett MS, DePianta RP, Fish PV, Heifetz A, Ho DK, Jessiman AS, McMurray G, de Oliveira CA, Roberts LR, Root JA, Shanmugasundaram V, Shapiro MJ, Skerten M, Westbrook D, Wheeler S, Whitlock GA, Wright J",,1361191.0,DTCT0023186,13764221,DTCC01497517,945852,59482,6.443697499232713,C[C@H]1CNCCC2=C1N=C(N=C2NC)CC3=CC=CC=C3,CNc1nc(Cc2ccccc2)nc2c1CCNC[C@@H]2C
4454,CHEMBL3286557,P28223,,XYHWHDGNYCZFTQ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,24878222.0,IC50,=,119.0,NM,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor (unknown origin),,"Multiparameter optimization in CNS drug discovery: design of pyrimido[4,5-d]azepines as potent 5-hydroxytryptamine 2C (5-HT2C) receptor agonists with exquisite functional selectivity over 5-HT2A and 5-HT2B receptors.",J. Med. Chem.,2014.0,57.0,12.0,"Storer RI, Brennan PE, Brown AD, Bungay PJ, Conlon KM, Corbett MS, DePianta RP, Fish PV, Heifetz A, Ho DK, Jessiman AS, McMurray G, de Oliveira CA, Roberts LR, Root JA, Shanmugasundaram V, Shapiro MJ, Skerten M, Westbrook D, Wheeler S, Whitlock GA, Wright J",,1361191.0,DTCT0023186,13764252,DTCC01497518,1431513,59482,6.924453038607469,CNC1=NC(=NC2=C1CCNCC2)C(C3=CC=CC=C3)(F)F,CNc1nc(C(F)(F)c2ccccc2)nc2c1CCNCC2
4613,CHEMBL33,P28223,LEVOFLOXACIN,GSDSWSVVBLHKDQ-JTQLQIEISA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7429569,DTCC00133684,51486,46191,,C[C@H]1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
4624,CHEMBL331077,P28223,,QQWLSTBNUSPPGV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,12443779.0,IC50,=,389.05,NM,,,,,,,,,,,,,,Binding affinity against 5-hydroxytryptamine 2A receptor,,2-(Dimethylaminomethyl)-tetrahydroisoxazolopyridobenzazepine derivatives. Synthesis of a new 5-HT(2C) antagonist with potential anxiolytic properties.,Bioorg. Med. Chem. Lett.,2002.0,12.0,24.0,"Andrés JI, Alonso JM, Fernández J, Iturrino L, Martínez P, Meert TF, Sipido VK",,2512.0,DTCT0023186,937672,DTCC00295278,1521430,5276,6.409994580348671,CN(C)CC1CC2C3=CC=CC=C3CC4=C(N2O1)C=NC=C4,CN(C)CC1CC2c3ccccc3Cc3ccncc3N2O1
4626,CHEMBL3311308,P28223,,FQUAFMNPXPXOJE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,24881566.0,IC50,>,39810.72,NM,,cell_based,,,,,,,,,,,,Antagonist activity at human 5-HT2A receptor expressed in HEK cells by luminescence/summary (Abse5) assay,,Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120).,Bioorg. Med. Chem. Lett.,2014.0,24.0,14.0,"Sparks SM, Chen G, Collins JL, Danger D, Dock ST, Jayawickreme C, Jenkinson S, Laudeman C, Leesnitzer MA, Liang X, Maloney P, McCoy DC, Moncol D, Rash V, Rimele T, Vulimiri P, Way JM, Ross S",,1457119.0,DTCT0023186,13918528,DTCC01511540,558563,60691,4.399999967876858,CC1=CC(=C(C(=C1)C)NS(=O)(=O)C2=CC=C(C=C2)OC)C,COc1ccc(S(=O)(=O)Nc2c(C)cc(C)cc2C)cc1
4627,CHEMBL331188,P28223,,VPZDYZMLWKUTOB-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,12443779.0,IC50,<,1000.0,NM,,,,,,,,,,,,,,Binding affinity against 5-HT2A receptor,,2-(Dimethylaminomethyl)-tetrahydroisoxazolopyridobenzazepine derivatives. Synthesis of a new 5-HT(2C) antagonist with potential anxiolytic properties.,Bioorg. Med. Chem. Lett.,2002.0,12.0,24.0,"Andrés JI, Alonso JM, Fernández J, Iturrino L, Martínez P, Meert TF, Sipido VK",,2511.0,DTCT0023186,976195,DTCC00294849,1359853,5276,6.0,CN(C)CC1CC2C3=C(CC4=CC=CC=C4N2O1)N=CC=C3,CN(C)CC1CC2c3cccnc3Cc3ccccc3N2O1
4678,CHEMBL3338677,P28223,,DYIMTVFKTDCCMM-XNNVEVGKSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,25241924.0,IC50,>,30000.0,NM,,cell_based,,,,,,,,,,,,Antagonist activity at 5HT2A receptor (unknown origin) expressed in CHOK1 cells after 15 mins by calcium flux/FLIPR assay in presence of 5HT,,The design and implementation of a generic lipopeptide scanning platform to enable the identification of 'locally acting' agonists for the apelin receptor.,Bioorg. Med. Chem. Lett.,2014.0,24.0,20.0,"McKeown SC, Zecri FJ, Fortier E, Taggart A, Sviridenko L, Adams CM, McAllister KH, Pin SS",,1436830.0,DTCT0023186,13993351,DTCC01524132,708082,59956,4.522878745280337,CCCCCCCCCCCCCCCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N,CCCCCCCCCCCCCCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C
4681,CHEMBL334255,P28223,CETYLPYRIDINIUM BROMIDE,DVBJBNKEBPCGSY-UHFFFAOYSA-M,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,3173.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7338764,DTCC00294369,510299,46191,5.498529927899588,CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1.[Br-],CCCCCCCCCCCCCCCC[n+]1ccccc1
4702,CHEMBL3350037,P28223,,DEQANNDTNATYII-JDBXKHNRSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7388722,DTCC01529235,510306,46191,,C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)[C@@H](CC5=CC=CC=C5)N)C(=O)N[C@@H](CO)[C@@H](C)O)O,C[C@@H](O)[C@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@H](N)Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1
4745,CHEMBL338790,P28223,,SSMIFVHARFVINF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7282325,DTCC00302791,1512803,46191,,C1=CC2=C(C=CC3=C2C(=C1)C(=O)NC3=O)N,Nc1ccc2c3c(cccc13)C(=O)NC2=O
4750,CHEMBL3398389,P28223,,KOFGVSAYINHBLL-UFTLRZAHSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,25684421.0,IC50,=,329.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]Ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 15 mins,,Synthesis and biological evaluation of 4-nitroindole derivatives as 5-HT2A receptor antagonists.,Bioorg. Med. Chem.,2015.0,23.0,6.0,"Hayat F, Viswanath AN, Pae AN, Rhim H, Park WK, Choo HY",,1462593.0,DTCT0023186,14036424,DTCC01543337,2041823,61474,6.482804102050026,CN(C)/C=N/N=C/C1=CN(C2=C1C(=CC=C2)[N+](=O)[O-])S(=O)(=O)C3=CC=CC=C3,CN(C)/C=N/N=C/c1cn(S(=O)(=O)c2ccccc2)c2cccc([N+](=O)[O-])c12
4752,CHEMBL3398390,P28223,,UPLUTOURLJDMHI-YARIIHNNSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,25684421.0,IC50,=,702.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]Ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 15 mins,,Synthesis and biological evaluation of 4-nitroindole derivatives as 5-HT2A receptor antagonists.,Bioorg. Med. Chem.,2015.0,23.0,6.0,"Hayat F, Viswanath AN, Pae AN, Rhim H, Park WK, Choo HY",,1462593.0,DTCT0023186,14032705,DTCC01543338,1399878,61474,6.153662887870195,CN(C)/C=N/N=C/C1=CN(C2=C1C(=CC=C2)[N+](=O)[O-])S(=O)(=O)C3=CC=C(C=C3)F,CN(C)/C=N/N=C/c1cn(S(=O)(=O)c2ccc(F)cc2)c2cccc([N+](=O)[O-])c12
4754,CHEMBL3398391,P28223,,COIOPUPPZJCDDB-YARIIHNNSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,25684421.0,IC50,=,247.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]Ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 15 mins,,Synthesis and biological evaluation of 4-nitroindole derivatives as 5-HT2A receptor antagonists.,Bioorg. Med. Chem.,2015.0,23.0,6.0,"Hayat F, Viswanath AN, Pae AN, Rhim H, Park WK, Choo HY",,1462593.0,DTCT0023186,14032704,DTCC01543339,1846630,61474,6.607303046740334,CN(C)/C=N/N=C/C1=CN(C2=C1C(=CC=C2)[N+](=O)[O-])S(=O)(=O)C3=CC=C(C=C3)I,CN(C)/C=N/N=C/c1cn(S(=O)(=O)c2ccc(I)cc2)c2cccc([N+](=O)[O-])c12
4756,CHEMBL3398392,P28223,,WDBVJENEMCPSQN-VZLKJUJQSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,25684421.0,IC50,=,253.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]Ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 15 mins,,Synthesis and biological evaluation of 4-nitroindole derivatives as 5-HT2A receptor antagonists.,Bioorg. Med. Chem.,2015.0,23.0,6.0,"Hayat F, Viswanath AN, Pae AN, Rhim H, Park WK, Choo HY",,1462593.0,DTCT0023186,14032703,DTCC01543340,1043391,61474,6.5968794788241825,CC1=CC=C(C=C1)S(=O)(=O)N2C=C(C3=C2C=CC=C3[N+](=O)[O-])/C=N/N=C/N(C)C,Cc1ccc(S(=O)(=O)n2cc(/C=N/N=C/N(C)C)c3c([N+](=O)[O-])cccc32)cc1
4759,CHEMBL3398394,P28223,,TXSMFFIDZSZTGL-VZLKJUJQSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,25684421.0,IC50,=,205.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]Ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 15 mins,,Synthesis and biological evaluation of 4-nitroindole derivatives as 5-HT2A receptor antagonists.,Bioorg. Med. Chem.,2015.0,23.0,6.0,"Hayat F, Viswanath AN, Pae AN, Rhim H, Park WK, Choo HY",,1462593.0,DTCT0023186,14032702,DTCC01543342,2041824,61474,6.688246138944246,CN(C)/C=N/N=C/C1=CN(C2=C1C(=CC=C2)[N+](=O)[O-])S(=O)(=O)C3=CC=C(C=C3)OC,COc1ccc(S(=O)(=O)n2cc(/C=N/N=C/N(C)C)c3c([N+](=O)[O-])cccc32)cc1
4761,CHEMBL3398395,P28223,,PZTYDECAEFZEHV-ZGRPYONQSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,25684421.0,IC50,=,479.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]Ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 15 mins,,Synthesis and biological evaluation of 4-nitroindole derivatives as 5-HT2A receptor antagonists.,Bioorg. Med. Chem.,2015.0,23.0,6.0,"Hayat F, Viswanath AN, Pae AN, Rhim H, Park WK, Choo HY",,1462593.0,DTCT0023186,14032701,DTCC01543343,461346,61474,6.319664486585436,CN(C)/C=N/N=C/C1=CN(C2=C1C(=CC=C2)[N+](=O)[O-])S(=O)(=O)C3=C(C=CC(=C3)OC)OC,COc1ccc(OC)c(S(=O)(=O)n2cc(/C=N/N=C/N(C)C)c3c([N+](=O)[O-])cccc32)c1
4763,CHEMBL3398396,P28223,,RRTOSIFESTZQCW-KZVLYIKRSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,25684421.0,IC50,=,1593.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]Ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 15 mins,,Synthesis and biological evaluation of 4-nitroindole derivatives as 5-HT2A receptor antagonists.,Bioorg. Med. Chem.,2015.0,23.0,6.0,"Hayat F, Viswanath AN, Pae AN, Rhim H, Park WK, Choo HY",,1462593.0,DTCT0023186,14032700,DTCC01543344,1529045,61474,5.797784224198868,CN(C)/C=N/N=C/C1=CN(C2=C1C(=CC=C2)[N+](=O)[O-])S(=O)(=O)C3=C(C=CC(=C3)Cl)OC,COc1ccc(Cl)cc1S(=O)(=O)n1cc(/C=N/N=C/N(C)C)c2c([N+](=O)[O-])cccc21
4765,CHEMBL3398397,P28223,,MAHOFXYCPVJZAM-CLKIXKSOSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,25684421.0,IC50,=,555.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]Ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 15 mins,,Synthesis and biological evaluation of 4-nitroindole derivatives as 5-HT2A receptor antagonists.,Bioorg. Med. Chem.,2015.0,23.0,6.0,"Hayat F, Viswanath AN, Pae AN, Rhim H, Park WK, Choo HY",,1462593.0,DTCT0023186,14032699,DTCC01543345,1204200,61474,6.255707016877324,CN(C)/C=N/N=C/C1=CN(C2=C1C(=CC=C2)[N+](=O)[O-])S(=O)(=O)C3=CC=CC4=CC=CC=C43,CN(C)/C=N/N=C/c1cn(S(=O)(=O)c2cccc3ccccc23)c2cccc([N+](=O)[O-])c12
4767,CHEMBL3398398,P28223,,QHTBVDSIELWDNS-CLKIXKSOSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,25684421.0,IC50,=,433.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]Ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cells after 15 mins,,Synthesis and biological evaluation of 4-nitroindole derivatives as 5-HT2A receptor antagonists.,Bioorg. Med. Chem.,2015.0,23.0,6.0,"Hayat F, Viswanath AN, Pae AN, Rhim H, Park WK, Choo HY",,1462593.0,DTCT0023186,14036435,DTCC01543346,978588,61474,6.363512103646634,CN(C)/C=N/N=C/C1=CN(C2=C1C(=CC=C2)[N+](=O)[O-])S(=O)(=O)C3=CC4=CC=CC=C4C=C3,CN(C)/C=N/N=C/c1cn(S(=O)(=O)c2ccc3ccccc3c2)c2cccc([N+](=O)[O-])c12
4825,CHEMBL3408841,P28223,,HOFWSEVNXPHVMC-SFQUDFHCSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,25599836.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,Inhibition of serotonin 5-HT2A receptor (unknown origin),,"Multi-parameter optimization of aza-follow-ups to BI 207524, a thumb pocket 1 HCV NS5B polymerase inhibitor. Part 2: Impact of lipophilicity on promiscuity and in vivo toxicity.",Bioorg. Med. Chem. Lett.,2015.0,25.0,5.0,"Beaulieu PL, Bolger G, Deon D, Duplessis M, Fazal G, Gagnon A, Garneau M, LaPlante S, Stammers T, Kukolj G, Duan J",,1469022.0,DTCT0023186,14073669,DTCC01548819,1529105,61816,5.221848749616356,CCOC1=C(C=CC(=N1)NC(=O)C(C)(C)NC(=O)C2=CC3=C(C=C2)C(=C(N3C)C4=NC=C(C=C4)F)C5CCCC5)/C=C/C(=O)O,CCOc1nc(NC(=O)C(C)(C)NC(=O)c2ccc3c(C4CCCC4)c(-c4ccc(F)cn4)n(C)c3c2)ccc1/C=C/C(=O)O
4826,CHEMBL3408847,P28223,,HMGWRGKXWIZPEI-OUKQBFOZSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,25599836.0,IC50,=,5200.0,NM,,,,,,,,,,,,,,Inhibition of serotonin 5-HT2A receptor (unknown origin),,"Multi-parameter optimization of aza-follow-ups to BI 207524, a thumb pocket 1 HCV NS5B polymerase inhibitor. Part 2: Impact of lipophilicity on promiscuity and in vivo toxicity.",Bioorg. Med. Chem. Lett.,2015.0,25.0,5.0,"Beaulieu PL, Bolger G, Deon D, Duplessis M, Fazal G, Gagnon A, Garneau M, LaPlante S, Stammers T, Kukolj G, Duan J",,1469022.0,DTCT0023186,14073670,DTCC01548825,1334955,61816,5.2839966563652006,CCOC1=NC(=CN=C1/C=C/C(=O)O)NC(=O)C(C)(C)NC(=O)C2=CC3=C(C=C2)C(=C(N3C)C4=NC=C(C=N4)Cl)C5CCCC5,CCOc1nc(NC(=O)C(C)(C)NC(=O)c2ccc3c(C4CCCC4)c(-c4ncc(Cl)cn4)n(C)c3c2)cnc1/C=C/C(=O)O
4832,CHEMBL340978,P28223,BENOXAPROFEN,MITFXPHMIHQXPI-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7278363,DTCC00314414,510297,46191,,CC(C1=CC2=C(C=C1)OC(=N2)C3=CC=C(C=C3)Cl)C(=O)O,CC(C(=O)O)c1ccc2oc(-c3ccc(Cl)cc3)nc2c1
4834,CHEMBL34139,P28223,GENACONAZOLE,HFGZFHCWKKQGIS-NOZJJQNGSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7333674,DTCC00173585,1416030,46191,,C[C@H]([C@](CN1C=NC=N1)(C2=C(C=C(C=C2)F)F)O)S(=O)(=O)C,C[C@H]([C@](O)(Cn1cncn1)c1ccc(F)cc1F)S(C)(=O)=O
4926,CHEMBL34259,P28223,METHOTREXATE,FBOZXECLQNJBKD-ZDUSSCGKSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7438689,DTCC00173293,1351113,46191,,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1
4931,CHEMBL34431,P28223,CILOSTAMIDE,UIAYVIIHMORPSJ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7351828,DTCC00173669,1894963,46191,,CN(C1CCCCC1)C(=O)CCCOC2=CC3=C(C=C2)NC(=O)C=C3,CN(C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1)C1CCCCC1
4952,CHEMBL35,P28223,FUROSEMIDE,ZZUFCTLCJUWOSV-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7324941,DTCC00133917,51472,46191,,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl
4971,CHEMBL35226,P28223,,UTMXFLLOSBJGIE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,12502367.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,"New benzo[h][1,6]naphthyridine and azepino[3,2-c]quinoline derivatives as selective antagonists of 5-HT4 receptors: binding profile and pharmacological characterization.",J. Med. Chem.,2003.0,46.0,1.0,"Hinschberger A, Butt S, Lelong V, Boulouard M, Dumuis A, Dauphin F, Bureau R, Pfeiffer B, Renard P, Rault S",,2466.0,DTCT0023186,1514484,DTCC00172576,948970,17260,5.301029995663981,CCCN1CCC(CC1)COC2=NC3=CC=CC=C3C4=C2CCCN4,CCCN1CCC(COc2nc3ccccc3c3c2CCCN3)CC1
4980,CHEMBL3545252,P28223,DOCETAXEL HYDRATE,XCDIRYDKECHIPE-QHEQPUDQSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7366342,DTCC01631667,51465,46191,,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O.O.O.O,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C
5001,CHEMBL357995,P28223,BOPINDOLOL,UUOJIACWOAYWEZ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,1581.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7280258,DTCC00343658,510298,46191,5.801068130067791,CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C3=CC=CC=C3,Cc1cc2c(OCC(CNC(C)(C)C)OC(=O)c3ccccc3)cccc2[nH]1
5088,CHEMBL3600801,P28223,,HAKKERAGHOXDDR-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26112443.0,IC50,=,107.0,NM,,,,,,,,,,,,,,Inhibition of 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part I: Optimization of HTS hits towards an in vivo efficacious tool compound BI 414.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Müller SG, Heckel A, Kley JT, Lehmann T, Lustenberger P, Oost T, Roth GJ, Rudolf K, Arndt K, Lenter M, Lotz RR, Maier GM, Markert M, Schindler M, Stenkamp D",,1509303.0,DTCT0023186,14492026,DTCC01655441,1205725,63240,6.97061622231479,C1CCN(C1)CC2=CC=C(C=C2)CCNC(=O)C3=CC=C(C=C3)C4=CC=C(C=C4)Cl,O=C(NCCc1ccc(CN2CCCC2)cc1)c1ccc(-c2ccc(Cl)cc2)cc1
5089,CHEMBL3600814,P28223,,ZGQSHOMCFXQQCY-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26112443.0,IC50,=,2330.0,NM,,,,,,,,,,,,,,Inhibition of 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part I: Optimization of HTS hits towards an in vivo efficacious tool compound BI 414.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Müller SG, Heckel A, Kley JT, Lehmann T, Lustenberger P, Oost T, Roth GJ, Rudolf K, Arndt K, Lenter M, Lotz RR, Maier GM, Markert M, Schindler M, Stenkamp D",,1509303.0,DTCT0023186,14492027,DTCC01655455,689437,63240,5.632644078973981,CC(=O)N1CCN(CC1)CC2=CC=C(C=C2)CCNC(=O)C3=CC=C(C=C3)C4=CC=C(C=C4)Cl,CC(=O)N1CCN(Cc2ccc(CCNC(=O)c3ccc(-c4ccc(Cl)cc4)cc3)cc2)CC1
5090,CHEMBL3600815,P28223,,MNKSLZNPCRRMKJ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26112443.0,IC50,=,360.0,NM,,,,,,,,,,,,,,Inhibition of 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part I: Optimization of HTS hits towards an in vivo efficacious tool compound BI 414.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Müller SG, Heckel A, Kley JT, Lehmann T, Lustenberger P, Oost T, Roth GJ, Rudolf K, Arndt K, Lenter M, Lotz RR, Maier GM, Markert M, Schindler M, Stenkamp D",,1509303.0,DTCT0023186,14492028,DTCC01655456,1751423,63240,6.443697499232713,CC(=O)NC1CCN(CC1)CC2=CC=C(C=C2)CCNC(=O)C3=CC=C(C=C3)C4=CC=C(C=C4)F,CC(=O)NC1CCN(Cc2ccc(CCNC(=O)c3ccc(-c4ccc(F)cc4)cc3)cc2)CC1
5091,CHEMBL3600816,P28223,,MGORRVRDTUOGIX-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26112443.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,Inhibition of 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part I: Optimization of HTS hits towards an in vivo efficacious tool compound BI 414.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Müller SG, Heckel A, Kley JT, Lehmann T, Lustenberger P, Oost T, Roth GJ, Rudolf K, Arndt K, Lenter M, Lotz RR, Maier GM, Markert M, Schindler M, Stenkamp D",,1509303.0,DTCT0023186,14492029,DTCC01655457,1783589,63240,5.0,CC(=O)NC1CCN(CC1)CC2=CC=C(C=C2)CCN(C)C(=O)C3=CC=C(C=C3)C4=CC=C(C=C4)F,CC(=O)NC1CCN(Cc2ccc(CCN(C)C(=O)c3ccc(-c4ccc(F)cc4)cc3)cc2)CC1
5092,CHEMBL3600817,P28223,,ARFXECJNWZZFLK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26112443.0,IC50,=,528.0,NM,,,,,,,,,,,,,,Inhibition of 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part I: Optimization of HTS hits towards an in vivo efficacious tool compound BI 414.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Müller SG, Heckel A, Kley JT, Lehmann T, Lustenberger P, Oost T, Roth GJ, Rudolf K, Arndt K, Lenter M, Lotz RR, Maier GM, Markert M, Schindler M, Stenkamp D",,1509303.0,DTCT0023186,14492030,DTCC01655458,1465664,63240,6.277366077466188,CC(=O)CNC1CCN(CC1)CC2=CC=C(C=C2)CCNC(=O)C3=CC=C(C=C3)C4=CC=C(C=C4)F,CC(=O)CNC1CCN(Cc2ccc(CCNC(=O)c3ccc(-c4ccc(F)cc4)cc3)cc2)CC1
5093,CHEMBL3600818,P28223,,GBMCACAKPAOTOV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26112443.0,IC50,=,8150.0,NM,,,,,,,,,,,,,,Inhibition of 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part I: Optimization of HTS hits towards an in vivo efficacious tool compound BI 414.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Müller SG, Heckel A, Kley JT, Lehmann T, Lustenberger P, Oost T, Roth GJ, Rudolf K, Arndt K, Lenter M, Lotz RR, Maier GM, Markert M, Schindler M, Stenkamp D",,1509303.0,DTCT0023186,14492031,DTCC01655459,366371,63240,5.088842391260023,CCNC(=O)N(C)CC1=CC=C(C=C1)CCNC(=O)C2=C(C=C(C=C2)C3=CC=C(C=C3)Cl)F,CCNC(=O)N(C)Cc1ccc(CCNC(=O)c2ccc(-c3ccc(Cl)cc3)cc2F)cc1
5094,CHEMBL3600828,P28223,,XKNDXALUSFQZAX-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26112443.0,IC50,=,500.0,NM,,,,,,,,,,,,,,Inhibition of 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part I: Optimization of HTS hits towards an in vivo efficacious tool compound BI 414.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Müller SG, Heckel A, Kley JT, Lehmann T, Lustenberger P, Oost T, Roth GJ, Rudolf K, Arndt K, Lenter M, Lotz RR, Maier GM, Markert M, Schindler M, Stenkamp D",,1509303.0,DTCT0023186,14492072,DTCC01655469,1880522,63240,6.301029995663981,C1CCN(C1)CCOC2=CC=C(C=C2)C#CC3=NC=C(C=C3)C4=CC=C(C=C4)Cl,Clc1ccc(-c2ccc(C#Cc3ccc(OCCN4CCCC4)cc3)nc2)cc1
5095,CHEMBL3600830,P28223,,UWQLUXHEVKAZSK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26112443.0,IC50,=,1354.0,NM,,,,,,,,,,,,,,Inhibition of 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part I: Optimization of HTS hits towards an in vivo efficacious tool compound BI 414.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Müller SG, Heckel A, Kley JT, Lehmann T, Lustenberger P, Oost T, Roth GJ, Rudolf K, Arndt K, Lenter M, Lotz RR, Maier GM, Markert M, Schindler M, Stenkamp D",,1509303.0,DTCT0023186,14492073,DTCC01655471,528046,63240,5.8683813356508745,CC1CCN(CC1)CCOC2=CC=C(C=C2)C#CC3=NC=C(C=C3)C4=CC=C(C=C4)Cl,CC1CCN(CCOc2ccc(C#Cc3ccc(-c4ccc(Cl)cc4)cn3)cc2)CC1
5096,CHEMBL3600831,P28223,,YMOPRQZMFXJLSA-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26112443.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,Inhibition of 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part I: Optimization of HTS hits towards an in vivo efficacious tool compound BI 414.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Müller SG, Heckel A, Kley JT, Lehmann T, Lustenberger P, Oost T, Roth GJ, Rudolf K, Arndt K, Lenter M, Lotz RR, Maier GM, Markert M, Schindler M, Stenkamp D",,1509303.0,DTCT0023186,14492074,DTCC01655472,657260,63240,5.0,C1CN(CCC1C(=O)N)CCOC2=CC=C(C=C2)C#CC3=NC=C(C=C3)C4=CC=C(C=C4)Cl,NC(=O)C1CCN(CCOc2ccc(C#Cc3ccc(-c4ccc(Cl)cc4)cn3)cc2)CC1
5097,CHEMBL3600970,P28223,,KFIBFLUHCJZUTE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26077492.0,IC50,=,680.0,NM,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Roth GJ, Heckel A, Kley JT, Lehmann T, Müller SG, Oost T, Rudolf K, Arndt K, Budzinski R, Lenter M, Lotz RR, Schindler M, Thomas L, Stenkamp D",,1508611.0,DTCT0023186,14496748,DTCC01655612,612649,63209,6.167491087293763,C1CCN(CC1)CC2=CC=C(C=C2)NCCCC3=CC=C(C=C3)C4=CC=C(C=C4)Cl,Clc1ccc(-c2ccc(CCCNc3ccc(CN4CCCCC4)cc3)cc2)cc1
5098,CHEMBL3600971,P28223,,JNOSYXLLGUQJNO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26077492.0,IC50,,,,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor (unknown origin),Not Determined,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Roth GJ, Heckel A, Kley JT, Lehmann T, Müller SG, Oost T, Rudolf K, Arndt K, Budzinski R, Lenter M, Lotz RR, Schindler M, Thomas L, Stenkamp D",,1508611.0,DTCT0023186,14496747,DTCC01655613,1193906,63209,,C1CCN(CC1)CC2=CC=C(C=C2)NC(=O)C#CC3=CC=C(C=C3)C4=CC=C(C=C4)Cl,O=C(C#Cc1ccc(-c2ccc(Cl)cc2)cc1)Nc1ccc(CN2CCCCC2)cc1
5099,CHEMBL3600972,P28223,,HSFWTAVXXXJJRW-CAOOACKPSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26077492.0,IC50,=,1932.0,NM,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Roth GJ, Heckel A, Kley JT, Lehmann T, Müller SG, Oost T, Rudolf K, Arndt K, Budzinski R, Lenter M, Lotz RR, Schindler M, Thomas L, Stenkamp D",,1508611.0,DTCT0023186,14496746,DTCC01655614,2031487,63209,5.713992877920526,C1CCN(CC1)CC2=CC=C(C=C2)NC(=O)/C=C/C3=CC=C(C=C3)C4=CC=C(C=C4)Cl,O=C(/C=C/c1ccc(-c2ccc(Cl)cc2)cc1)Nc1ccc(CN2CCCCC2)cc1
5100,CHEMBL3600973,P28223,,NIRCOASKORGSKJ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26077492.0,IC50,=,646.0,NM,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Roth GJ, Heckel A, Kley JT, Lehmann T, Müller SG, Oost T, Rudolf K, Arndt K, Budzinski R, Lenter M, Lotz RR, Schindler M, Thomas L, Stenkamp D",,1508611.0,DTCT0023186,14496745,DTCC01655615,1804066,63209,6.189767482004916,CN(CCCC1=CC=C(C=C1)C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)CN4CCCCC4,CN(CCCc1ccc(-c2ccc(Cl)cc2)cc1)c1ccc(CN2CCCCC2)cc1
5101,CHEMBL3600974,P28223,,VDTTVUDVHKAPMC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26077492.0,IC50,=,138.0,NM,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Roth GJ, Heckel A, Kley JT, Lehmann T, Müller SG, Oost T, Rudolf K, Arndt K, Budzinski R, Lenter M, Lotz RR, Schindler M, Thomas L, Stenkamp D",,1508611.0,DTCT0023186,14496744,DTCC01655616,1582664,63209,6.860120913598763,C1CCN(CC1)CC2=CC=C(C=C2)NC(=O)CCC3=CC=C(C=C3)C4=CC=C(C=C4)Cl,O=C(CCc1ccc(-c2ccc(Cl)cc2)cc1)Nc1ccc(CN2CCCCC2)cc1
5102,CHEMBL3600975,P28223,,MHPRRIFCBPETQG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26077492.0,IC50,=,91.0,NM,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Roth GJ, Heckel A, Kley JT, Lehmann T, Müller SG, Oost T, Rudolf K, Arndt K, Budzinski R, Lenter M, Lotz RR, Schindler M, Thomas L, Stenkamp D",,1508611.0,DTCT0023186,14496743,DTCC01655617,354107,63209,7.040958607678906,C1CCN(CC1)CC2=CC=C(C=C2)NC(=O)COC3=CC=C(C=C3)C4=CC=C(C=C4)Cl,O=C(COc1ccc(-c2ccc(Cl)cc2)cc1)Nc1ccc(CN2CCCCC2)cc1
5103,CHEMBL3600976,P28223,,BEWRGASHJMEIJG-GIJQJNRQSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26077492.0,IC50,=,362.0,NM,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Roth GJ, Heckel A, Kley JT, Lehmann T, Müller SG, Oost T, Rudolf K, Arndt K, Budzinski R, Lenter M, Lotz RR, Schindler M, Thomas L, Stenkamp D",,1508611.0,DTCT0023186,14496742,DTCC01655618,386710,63209,6.441291429466834,CN(C1=CC=C(C=C1)CN2CCCCC2)C(=O)/C=C/C3=CC=C(C=C3)C4=CC=C(C=C4)Cl,CN(C(=O)/C=C/c1ccc(-c2ccc(Cl)cc2)cc1)c1ccc(CN2CCCCC2)cc1
5104,CHEMBL3600977,P28223,,PNEQLTWPDVHRRF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26077492.0,IC50,=,29.0,NM,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Roth GJ, Heckel A, Kley JT, Lehmann T, Müller SG, Oost T, Rudolf K, Arndt K, Budzinski R, Lenter M, Lotz RR, Schindler M, Thomas L, Stenkamp D",,1508611.0,DTCT0023186,14496741,DTCC01655619,1453495,63209,7.5376020021010435,C1CCN(CC1)CC2=CC=C(C=C2)NC(=O)NCC3=CC=C(C=C3)C4=CC=C(C=C4)Cl,O=C(NCc1ccc(-c2ccc(Cl)cc2)cc1)Nc1ccc(CN2CCCCC2)cc1
5105,CHEMBL3600978,P28223,,ODSPZLQLPQOLJR-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26077492.0,IC50,=,138.0,NM,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Roth GJ, Heckel A, Kley JT, Lehmann T, Müller SG, Oost T, Rudolf K, Arndt K, Budzinski R, Lenter M, Lotz RR, Schindler M, Thomas L, Stenkamp D",,1508611.0,DTCT0023186,14496790,DTCC01655620,903978,63209,6.860120913598763,C1CCN(CC1)CC2=CC=C(C=C2)NCCCC3=NN=C(C=C3)C4=CC=C(C=C4)Cl,Clc1ccc(-c2ccc(CCCNc3ccc(CN4CCCCC4)cc3)nn2)cc1
5106,CHEMBL3600979,P28223,,CFIVGUWEJMEWCY-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26077492.0,IC50,=,34.0,NM,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Roth GJ, Heckel A, Kley JT, Lehmann T, Müller SG, Oost T, Rudolf K, Arndt K, Budzinski R, Lenter M, Lotz RR, Schindler M, Thomas L, Stenkamp D",,1508611.0,DTCT0023186,14496791,DTCC01655621,773945,63209,7.468521082957745,C1CCN(CC1)CC2=CC=C(C=C2)NCCCC3=NN=C(C=C3)C4=CC=C(C=C4)F,Fc1ccc(-c2ccc(CCCNc3ccc(CN4CCCCC4)cc3)nn2)cc1
5107,CHEMBL3600980,P28223,,UKHHETYTQCSWPT-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26077492.0,IC50,=,1810.0,NM,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Roth GJ, Heckel A, Kley JT, Lehmann T, Müller SG, Oost T, Rudolf K, Arndt K, Budzinski R, Lenter M, Lotz RR, Schindler M, Thomas L, Stenkamp D",,1508611.0,DTCT0023186,14496792,DTCC01655622,223382,63209,5.7423214251308154,COC1=CC=C(C=C1)C2=NN=C(C=C2)CCCNC3=CC=C(C=C3)CN4CCCCC4,COc1ccc(-c2ccc(CCCNc3ccc(CN4CCCCC4)cc3)nn2)cc1
5108,CHEMBL3600981,P28223,,ULODTCAXRIIVLU-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26077492.0,IC50,=,1460.0,NM,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Roth GJ, Heckel A, Kley JT, Lehmann T, Müller SG, Oost T, Rudolf K, Arndt K, Budzinski R, Lenter M, Lotz RR, Schindler M, Thomas L, Stenkamp D",,1508611.0,DTCT0023186,14496793,DTCC01655623,2095895,63209,5.835647144215563,C1CCN(CC1)CC2=CC=C(C=C2)NCCCC3=NN=C(C=C3)C4=CC=C(C=C4)C#N,N#Cc1ccc(-c2ccc(CCCNc3ccc(CN4CCCCC4)cc3)nn2)cc1
5109,CHEMBL3600982,P28223,,POMBVMXDKDZTLK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26077492.0,IC50,,,,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor (unknown origin),Not Determined,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Roth GJ, Heckel A, Kley JT, Lehmann T, Müller SG, Oost T, Rudolf K, Arndt K, Budzinski R, Lenter M, Lotz RR, Schindler M, Thomas L, Stenkamp D",,1508611.0,DTCT0023186,14496794,DTCC01655624,1193907,63209,,C1CCN(CC1)CC2=CC=C(C=C2)NCCCC3=NN=C(C=C3)C4=CC=NC=C4,c1cc(-c2ccc(CCCNc3ccc(CN4CCCCC4)cc3)nn2)ccn1
5110,CHEMBL3601021,P28223,,MABBTFRQYAXJAE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26112443.0,IC50,=,3290.0,NM,,,,,,,,,,,,,,Inhibition of 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part I: Optimization of HTS hits towards an in vivo efficacious tool compound BI 414.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Müller SG, Heckel A, Kley JT, Lehmann T, Lustenberger P, Oost T, Roth GJ, Rudolf K, Arndt K, Lenter M, Lotz RR, Maier GM, Markert M, Schindler M, Stenkamp D",,1509303.0,DTCT0023186,14492075,DTCC01655664,1238407,63240,5.482804102050026,CC1CCN(CC1)CCOC2=CC=C(C=C2)C#CC3=C(C=C(C=N3)C4=CC=C(C=C4)Cl)F,CC1CCN(CCOc2ccc(C#Cc3ncc(-c4ccc(Cl)cc4)cc3F)cc2)CC1
5111,CHEMBL3601022,P28223,,GGTZHCUZWHTXIC-RUZDIDTESA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26112443.0,IC50,=,1640.0,NM,,,,,,,,,,,,,,Inhibition of 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part I: Optimization of HTS hits towards an in vivo efficacious tool compound BI 414.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Müller SG, Heckel A, Kley JT, Lehmann T, Lustenberger P, Oost T, Roth GJ, Rudolf K, Arndt K, Lenter M, Lotz RR, Maier GM, Markert M, Schindler M, Stenkamp D",,1509303.0,DTCT0023186,14492076,DTCC01655665,1271172,63240,5.785156151952302,C1C[C@@H](N(C1)CCOC2=CC=C(C=C2)C#CC3=NC=C(C=C3)C4=CC=C(C=C4)Cl)CO,OC[C@H]1CCCN1CCOc1ccc(C#Cc2ccc(-c3ccc(Cl)cc3)cn2)cc1
5112,CHEMBL3601023,P28223,,ZOKQZJZIENINDP-SANMLTNESA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26112443.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,Inhibition of 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part I: Optimization of HTS hits towards an in vivo efficacious tool compound BI 414.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Müller SG, Heckel A, Kley JT, Lehmann T, Lustenberger P, Oost T, Roth GJ, Rudolf K, Arndt K, Lenter M, Lotz RR, Maier GM, Markert M, Schindler M, Stenkamp D",,1509303.0,DTCT0023186,14492077,DTCC01655666,431573,63240,5.0,CC1=C(C=CC(=C1)C#CC2=NC=C(C=C2)C3=CC=C(C=C3)Cl)OCCN4CCC[C@H]4CO,Cc1cc(C#Cc2ccc(-c3ccc(Cl)cc3)cn2)ccc1OCCN1CCC[C@H]1CO
5113,CHEMBL3601029,P28223,,WNWAYKVHLHKOTN-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26077492.0,IC50,,,,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor (unknown origin),Not Determined,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Roth GJ, Heckel A, Kley JT, Lehmann T, Müller SG, Oost T, Rudolf K, Arndt K, Budzinski R, Lenter M, Lotz RR, Schindler M, Thomas L, Stenkamp D",,1508611.0,DTCT0023186,14496795,DTCC01655672,871736,63209,,COC1=NN=C(C=C1)CCCNC2=CC=C(C=C2)CN3CCCCC3,COc1ccc(CCCNc2ccc(CN3CCCCC3)cc2)nn1
5114,CHEMBL3601030,P28223,,HHCFMFBXBGMIMS-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26077492.0,IC50,=,4540.0,NM,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Roth GJ, Heckel A, Kley JT, Lehmann T, Müller SG, Oost T, Rudolf K, Arndt K, Budzinski R, Lenter M, Lotz RR, Schindler M, Thomas L, Stenkamp D",,1508611.0,DTCT0023186,14496796,DTCC01655673,1130076,63209,5.342944147142896,COC1=CC=C(C=C1)C2=NN=C(C=C2)CCCNC3=CC=C(C=C3)CN4CCCC4,COc1ccc(-c2ccc(CCCNc3ccc(CN4CCCC4)cc3)nn2)cc1
5115,CHEMBL3601031,P28223,,MOBSKCBBMWWXRY-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26077492.0,IC50,=,4580.0,NM,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Roth GJ, Heckel A, Kley JT, Lehmann T, Müller SG, Oost T, Rudolf K, Arndt K, Budzinski R, Lenter M, Lotz RR, Schindler M, Thomas L, Stenkamp D",,1508611.0,DTCT0023186,14496797,DTCC01655674,2063225,63209,5.33913452199613,CN(C)CC1=CC=C(C=C1)NCCCC2=NN=C(C=C2)C3=CC=C(C=C3)OC,COc1ccc(-c2ccc(CCCNc3ccc(CN(C)C)cc3)nn2)cc1
5116,CHEMBL3601032,P28223,,BATJAOQOPVVCFL-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26077492.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Roth GJ, Heckel A, Kley JT, Lehmann T, Müller SG, Oost T, Rudolf K, Arndt K, Budzinski R, Lenter M, Lotz RR, Schindler M, Thomas L, Stenkamp D",,1508611.0,DTCT0023186,14496798,DTCC01655675,126590,63209,5.0,COC1=CC=C(C=C1)C2=NN=C(C=C2)CCCNC3=CC=C(C=C3)CN4CCOCC4,COc1ccc(-c2ccc(CCCNc3ccc(CN4CCOCC4)cc3)nn2)cc1
5117,CHEMBL3601033,P28223,,DZSBFILJNZKJGY-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26077492.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Roth GJ, Heckel A, Kley JT, Lehmann T, Müller SG, Oost T, Rudolf K, Arndt K, Budzinski R, Lenter M, Lotz RR, Schindler M, Thomas L, Stenkamp D",,1508611.0,DTCT0023186,14496799,DTCC01655676,839065,63209,5.0,COC1=CC=C(C=C1)C2=NN=C(C=C2)CCCNC3=CC=C(C=C3)CN4CCCC(C4)O,COc1ccc(-c2ccc(CCCNc3ccc(CN4CCCC(O)C4)cc3)nn2)cc1
5118,CHEMBL3601034,P28223,,OPZGAKRVINWIHN-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26077492.0,IC50,=,8820.0,NM,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Roth GJ, Heckel A, Kley JT, Lehmann T, Müller SG, Oost T, Rudolf K, Arndt K, Budzinski R, Lenter M, Lotz RR, Schindler M, Thomas L, Stenkamp D",,1508611.0,DTCT0023186,14496800,DTCC01655677,1615389,63209,5.054531414868181,COC1=CC=C(C=C1)C2=NN=C(C=C2)CCCNC3=CC=C(C=C3)CN4CCC(CC4)O,COc1ccc(-c2ccc(CCCNc3ccc(CN4CCC(O)CC4)cc3)nn2)cc1
5119,CHEMBL3601035,P28223,,SAYDHMAEZCXKDT-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26077492.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Roth GJ, Heckel A, Kley JT, Lehmann T, Müller SG, Oost T, Rudolf K, Arndt K, Budzinski R, Lenter M, Lotz RR, Schindler M, Thomas L, Stenkamp D",,1508611.0,DTCT0023186,14496801,DTCC01655678,1965882,63209,5.0,CC(=O)NC1CCN(CC1)CC2=CC=C(C=C2)NCCCC3=NN=C(C=C3)C4=CC=C(C=C4)OC,COc1ccc(-c2ccc(CCCNc3ccc(CN4CCC(NC(C)=O)CC4)cc3)nn2)cc1
5120,CHEMBL3601036,P28223,,MJYOVAQKEPMTHM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26077492.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Roth GJ, Heckel A, Kley JT, Lehmann T, Müller SG, Oost T, Rudolf K, Arndt K, Budzinski R, Lenter M, Lotz RR, Schindler M, Thomas L, Stenkamp D",,1508611.0,DTCT0023186,14496802,DTCC01655679,1356824,63209,5.0,C1CN(CCC1O)CC2=CC=C(C=C2)NCCCC3=NN=C(C=C3)OCC4=CC=CC=C4,OC1CCN(Cc2ccc(NCCCc3ccc(OCc4ccccc4)nn3)cc2)CC1
5121,CHEMBL3601037,P28223,,FXIMXZUTJXQUOO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26077492.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Roth GJ, Heckel A, Kley JT, Lehmann T, Müller SG, Oost T, Rudolf K, Arndt K, Budzinski R, Lenter M, Lotz RR, Schindler M, Thomas L, Stenkamp D",,1508611.0,DTCT0023186,14496803,DTCC01655680,1000500,63209,5.0,C1CN(CCC1O)CC2=CC=C(C=C2)NCCCC3=NN=C(C=C3)OC4=CC=CC=C4,OC1CCN(Cc2ccc(NCCCc3ccc(Oc4ccccc4)nn3)cc2)CC1
5122,CHEMBL3601038,P28223,,FMANFSUOSWWJNA-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26077492.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Roth GJ, Heckel A, Kley JT, Lehmann T, Müller SG, Oost T, Rudolf K, Arndt K, Budzinski R, Lenter M, Lotz RR, Schindler M, Thomas L, Stenkamp D",,1508611.0,DTCT0023186,14496804,DTCC01655681,1000501,63209,5.0,CC(=O)NC1CCN(CC1)CC2=CC=C(C=C2)NCCCC3=NN=C(C=C3)OC4=CC=CC=C4,CC(=O)NC1CCN(Cc2ccc(NCCCc3ccc(Oc4ccccc4)nn3)cc2)CC1
5123,CHEMBL3601039,P28223,,KURYMMXNUSXWIX-HSZRJFAPSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26077492.0,IC50,=,595.0,NM,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Roth GJ, Heckel A, Kley JT, Lehmann T, Müller SG, Oost T, Rudolf K, Arndt K, Budzinski R, Lenter M, Lotz RR, Schindler M, Thomas L, Stenkamp D",,1508611.0,DTCT0023186,14496871,DTCC01655682,2095898,63209,6.22548303427145,C1C[C@H](CN(C1)CC2=CC=C(C=C2)OCCCC3=NN=C(C=C3)C4=CC=C(C=C4)Cl)O,O[C@@H]1CCCN(Cc2ccc(OCCCc3ccc(-c4ccc(Cl)cc4)nn3)cc2)C1
5124,CHEMBL3601040,P28223,,MQOANKATOVPZEV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26077492.0,IC50,=,790.0,NM,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Roth GJ, Heckel A, Kley JT, Lehmann T, Müller SG, Oost T, Rudolf K, Arndt K, Budzinski R, Lenter M, Lotz RR, Schindler M, Thomas L, Stenkamp D",,1508611.0,DTCT0023186,14496872,DTCC01655683,1647533,63209,6.102372908709558,C1CN(CCC1CO)CC2=CC=C(C=C2)OCCCC3=NN=C(C=C3)C4=CC=C(C=C4)Cl,OCC1CCN(Cc2ccc(OCCCc3ccc(-c4ccc(Cl)cc4)nn3)cc2)CC1
5125,CHEMBL3601041,P28223,,ZAJWCDMUELNBFR-JOCHJYFZSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26077492.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Roth GJ, Heckel A, Kley JT, Lehmann T, Müller SG, Oost T, Rudolf K, Arndt K, Budzinski R, Lenter M, Lotz RR, Schindler M, Thomas L, Stenkamp D",,1508611.0,DTCT0023186,14496873,DTCC01655684,1647534,63209,5.0,C1C[C@H](CN(C1)CC2=CC=C(C=C2)OCCCC3=NN=C(C=C3)OC4=CC=CC=C4)O,O[C@@H]1CCCN(Cc2ccc(OCCCc3ccc(Oc4ccccc4)nn3)cc2)C1
5126,CHEMBL3601042,P28223,,QOJATLFQZGUAPH-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26077492.0,IC50,=,1410.0,NM,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Roth GJ, Heckel A, Kley JT, Lehmann T, Müller SG, Oost T, Rudolf K, Arndt K, Budzinski R, Lenter M, Lotz RR, Schindler M, Thomas L, Stenkamp D",,1508611.0,DTCT0023186,14496874,DTCC01655685,1804068,63209,5.85078088734462,C1CN(CCC1O)CC2=CC=C(C=C2)OCCCC3=NN=C(C=C3)C4=CC=C(C=C4)Cl,OC1CCN(Cc2ccc(OCCCc3ccc(-c4ccc(Cl)cc4)nn3)cc2)CC1
5127,CHEMBL3601043,P28223,,DARAALXZQWSOKR-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26077492.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Roth GJ, Heckel A, Kley JT, Lehmann T, Müller SG, Oost T, Rudolf K, Arndt K, Budzinski R, Lenter M, Lotz RR, Schindler M, Thomas L, Stenkamp D",,1508611.0,DTCT0023186,14496875,DTCC01655686,1161355,63209,5.0,C1CN(CCC1CO)CC2=CC=C(C=C2)OCCCC3=NN=C(C=C3)OC4=CC=CC=C4,OCC1CCN(Cc2ccc(OCCCc3ccc(Oc4ccccc4)nn3)cc2)CC1
5128,CHEMBL3601044,P28223,,XFYUYPSWQGVSKG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26077492.0,IC50,=,242.0,NM,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Roth GJ, Heckel A, Kley JT, Lehmann T, Müller SG, Oost T, Rudolf K, Arndt K, Budzinski R, Lenter M, Lotz RR, Schindler M, Thomas L, Stenkamp D",,1508611.0,DTCT0023186,14496876,DTCC01655687,1486153,63209,6.616184634019569,C1CN(CCC1O)CC2=CC=C(C=C2)OCCCC3=NN=C(C=C3)C4=CC=C(C=C4)F,OC1CCN(Cc2ccc(OCCCc3ccc(-c4ccc(F)cc4)nn3)cc2)CC1
5129,CHEMBL3601045,P28223,,MZYXOMZPGDOVJK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26077492.0,IC50,=,713.0,NM,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Roth GJ, Heckel A, Kley JT, Lehmann T, Müller SG, Oost T, Rudolf K, Arndt K, Budzinski R, Lenter M, Lotz RR, Schindler M, Thomas L, Stenkamp D",,1508611.0,DTCT0023186,14496877,DTCC01655688,839066,63209,6.146910470148135,CC(=O)NC1CCN(CC1)CC2=CC=C(C=C2)OCCCC3=NN=C(C=C3)C4=CC=C(C=C4)F,CC(=O)NC1CCN(Cc2ccc(OCCCc3ccc(-c4ccc(F)cc4)nn3)cc2)CC1
5130,CHEMBL3601046,P28223,,LGZBYUKKHXYCMF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26077492.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Roth GJ, Heckel A, Kley JT, Lehmann T, Müller SG, Oost T, Rudolf K, Arndt K, Budzinski R, Lenter M, Lotz RR, Schindler M, Thomas L, Stenkamp D",,1508611.0,DTCT0023186,14496878,DTCC01655689,126591,63209,5.0,CC(=O)NC1CCN(CC1)CC2=CC=C(C=C2)OCCCC3=NN=C(C=C3)CC4=CC=CC=C4,CC(=O)NC1CCN(Cc2ccc(OCCCc3ccc(Cc4ccccc4)nn3)cc2)CC1
5131,CHEMBL3601047,P28223,,HNLWHEXUEWHTOF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26077492.0,IC50,=,9650.0,NM,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor (unknown origin),,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition.",Bioorg. Med. Chem. Lett.,2015.0,25.0,16.0,"Roth GJ, Heckel A, Kley JT, Lehmann T, Müller SG, Oost T, Rudolf K, Arndt K, Budzinski R, Lenter M, Lotz RR, Schindler M, Thomas L, Stenkamp D",,1508611.0,DTCT0023186,14496879,DTCC01655690,1771469,63209,5.015472686656207,CC(=O)NC1CCN(CC1)CC2=CC=C(C=C2)OCCCC3=NN=C(C=C3)OC4=CC=CC=C4,CC(=O)NC1CCN(Cc2ccc(OCCCc3ccc(Oc4ccccc4)nn3)cc2)CC1
5165,CHEMBL3609158,P28223,,NQWNBJBXJZFGNU-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26227779.0,IC50,=,21260.0,NM,,cell_based,,,,,,,,,,,,Antagonist activity against 5-HT2A receptor (unknown origin) expressed in HEK293 cell membranes assessed as reduction in [35S]-GTPgammaS binding incubated for 30 mins by liquid scintillation counting method,,Discovery of novel potent and selective ligands for 5-HT2A receptor with quinazoline scaffold.,Bioorg. Med. Chem. Lett.,2015.0,25.0,18.0,"Deng X, Guo L, Xu L, Zhen X, Yu K, Zhao W, Fu W",,1512600.0,DTCT0023186,14523163,DTCC01659775,126621,63448,4.6724367398127225,C1CN(CCN1CCO)C2=NC3=CC=CC=C3C(=N2)NC4=CC=C(C=C4)F,OCCN1CCN(c2nc(Nc3ccc(F)cc3)c3ccccc3n2)CC1
5169,CHEMBL3609159,P28223,,GJEDYNSZFXRQPO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26227779.0,IC50,=,7430.0,NM,,cell_based,,,,,,,,,,,,Antagonist activity against 5-HT2A receptor (unknown origin) expressed in HEK293 cell membranes assessed as reduction in [35S]-GTPgammaS binding incubated for 30 mins by liquid scintillation counting method,,Discovery of novel potent and selective ligands for 5-HT2A receptor with quinazoline scaffold.,Bioorg. Med. Chem. Lett.,2015.0,25.0,18.0,"Deng X, Guo L, Xu L, Zhen X, Yu K, Zhao W, Fu W",,1512600.0,DTCT0023186,14523164,DTCC01659776,1932653,63448,5.129011186239425,C1CN(CCN1CCO)C2=NC3=CC=CC=C3C(=N2)NC4=CC=C(C=C4)Cl,OCCN1CCN(c2nc(Nc3ccc(Cl)cc3)c3ccccc3n2)CC1
5173,CHEMBL3609160,P28223,,FVURRBVVEFEGAB-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26227779.0,IC50,=,27720.0,NM,,cell_based,,,,,,,,,,,,Antagonist activity against 5-HT2A receptor (unknown origin) expressed in HEK293 cell membranes assessed as reduction in [35S]-GTPgammaS binding incubated for 30 mins by liquid scintillation counting method,,Discovery of novel potent and selective ligands for 5-HT2A receptor with quinazoline scaffold.,Bioorg. Med. Chem. Lett.,2015.0,25.0,18.0,"Deng X, Guo L, Xu L, Zhen X, Yu K, Zhao W, Fu W",,1512600.0,DTCT0023186,14523165,DTCC01659777,450318,63448,4.557206774060231,C1CN(CCN1CCO)C2=NC3=CC=CC=C3C(=N2)NC4=CC=C(C=C4)Br,OCCN1CCN(c2nc(Nc3ccc(Br)cc3)c3ccccc3n2)CC1
5185,CHEMBL3609165,P28223,,ZXDTVKUJALXHQJ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26227779.0,IC50,=,1370.0,NM,,cell_based,,,,,,,,,,,,Antagonist activity against 5-HT2A receptor (unknown origin) expressed in HEK293 cell membranes assessed as reduction in [35S]-GTPgammaS binding incubated for 30 mins by liquid scintillation counting method,,Discovery of novel potent and selective ligands for 5-HT2A receptor with quinazoline scaffold.,Bioorg. Med. Chem. Lett.,2015.0,25.0,18.0,"Deng X, Guo L, Xu L, Zhen X, Yu K, Zhao W, Fu W",,1512600.0,DTCT0023186,14523166,DTCC01659782,321447,63448,5.863279432843593,C1CN(CCN1CCO)C2=NC3=CC=CC=C3C(=N2)NC4=CC=CC=C4F,OCCN1CCN(c2nc(Nc3ccccc3F)c3ccccc3n2)CC1
5191,CHEMBL3609167,P28223,,VREKGJXMPYIDLJ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26227779.0,IC50,=,9120.0,NM,,cell_based,,,,,,,,,,,,Antagonist activity against 5-HT2A receptor (unknown origin) expressed in HEK293 cell membranes assessed as reduction in [35S]-GTPgammaS binding incubated for 30 mins by liquid scintillation counting method,,Discovery of novel potent and selective ligands for 5-HT2A receptor with quinazoline scaffold.,Bioorg. Med. Chem. Lett.,2015.0,25.0,18.0,"Deng X, Guo L, Xu L, Zhen X, Yu K, Zhao W, Fu W",,1512600.0,DTCT0023186,14523167,DTCC01659784,450319,63448,5.0400051616715835,C1CN(CCN1CCO)C2=NC3=CC=CC=C3C(=N2)NC4=CC(=CC=C4)O,OCCN1CCN(c2nc(Nc3cccc(O)c3)c3ccccc3n2)CC1
5197,CHEMBL3609169,P28223,,CXEHMADGEZJANZ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26227779.0,IC50,,,,,cell_based,,,,,,,,,,,,Antagonist activity against 5-HT2A receptor (unknown origin) expressed in HEK293 cell membranes assessed as reduction in [35S]-GTPgammaS binding incubated for 30 mins by liquid scintillation counting method,Not Determined,Discovery of novel potent and selective ligands for 5-HT2A receptor with quinazoline scaffold.,Bioorg. Med. Chem. Lett.,2015.0,25.0,18.0,"Deng X, Guo L, Xu L, Zhen X, Yu K, Zhao W, Fu W",,1512600.0,DTCT0023186,14523168,DTCC01659786,1324025,63448,,COC1=CC=CC=C1NC2=NC(=NC3=CC=CC=C32)N4CCNCC4,COc1ccccc1Nc1nc(N2CCNCC2)nc2ccccc12
5201,CHEMBL3609170,P28223,,RUFUASLXIKBFNG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26227779.0,IC50,,,,,cell_based,,,,,,,,,,,,Antagonist activity against 5-HT2A receptor (unknown origin) expressed in HEK293 cell membranes assessed as reduction in [35S]-GTPgammaS binding incubated for 30 mins by liquid scintillation counting method,Not Determined,Discovery of novel potent and selective ligands for 5-HT2A receptor with quinazoline scaffold.,Bioorg. Med. Chem. Lett.,2015.0,25.0,18.0,"Deng X, Guo L, Xu L, Zhen X, Yu K, Zhao W, Fu W",,1512600.0,DTCT0023186,14523169,DTCC01659787,1932654,63448,,C1CN(CCN1)C2=NC3=CC=CC=C3C(=N2)NC4=CC=CC=C4F,Fc1ccccc1Nc1nc(N2CCNCC2)nc2ccccc12
5205,CHEMBL3609171,P28223,,BULIRMIXOHACFW-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26227779.0,IC50,=,1660.0,NM,,cell_based,,,,,,,,,,,,Antagonist activity against 5-HT2A receptor (unknown origin) expressed in HEK293 cell membranes assessed as reduction in [35S]-GTPgammaS binding incubated for 30 mins by liquid scintillation counting method,,Discovery of novel potent and selective ligands for 5-HT2A receptor with quinazoline scaffold.,Bioorg. Med. Chem. Lett.,2015.0,25.0,18.0,"Deng X, Guo L, Xu L, Zhen X, Yu K, Zhao W, Fu W",,1512600.0,DTCT0023186,14523170,DTCC01659788,223428,63448,5.779891911959945,C1CN(CCN1)C2=NC3=CC=CC=C3C(=N2)NC4=CC=C(C=C4)Cl,Clc1ccc(Nc2nc(N3CCNCC3)nc3ccccc23)cc1
5266,CHEMBL364005,P28223,,BPPGPYJBCVXILI-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16055331.0,IC50,=,240.0,NM,,,,,,,,,,,,,,Inhibitory activity against 5-hydroxytryptamine 2A receptor in human,,"2-Alkyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles as novel 5-HT6 receptor agonists.",Bioorg. Med. Chem. Lett.,2005.0,15.0,19.0,"Mattsson C, Sonesson C, Sandahl A, Greiner HE, Gassen M, Plaschke J, Leibrock J, Böttcher H",,321342.0,DTCT0023186,1847953,DTCC00405036,1113810,19721,6.619788758288394,CC1=C(C2=C(N1)C=CC(=C2)Cl)C3=CCNCC3,Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1
5409,CHEMBL364713,P28223,NOSCAPINE,AKNNEGZIBPJZJG-MSOLQXFVSA-N,1,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7405838,DTCC00398932,898293,46191,,CN1CCC2=CC3=C(C(=C2[C@@H]1[C@@H]4C5=C(C(=C(C=C5)OC)OC)C(=O)O4)OC)OCO3,COc1ccc2c(c1OC)C(=O)O[C@@H]2[C@H]1c2c(cc3c(c2OC)OCO3)CCN1C
5413,CHEMBL3652592,P28223,,FFRHZNYHCQFSHO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,0.025,NM,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assays. Radioligand binding assays for human 5-HT2A receptor was conducted using the 5-HT2 agonist [125]DOI as radioligand. To define nonspecific binding, 10 µM DOI was used for all assays. For competitive binding studies, 0.5 nM [125]DOI was used and compounds were assayed over a range of 0.01 nM to 10 µM. Assays were conducted in a total volume of 200 µl in 96-well Perkin Elmer GF/C filter plates in assay buffer (50 mM Tris-HCl, pH 7.4, 0.5 mM EDTA, 5 mM MgCl2, and 10 µM pargyline). Assay incubations were performed for 60 min at room temperature and were terminated by rapid filtration under vacuum pressure of the reaction mixture over Whatman GF/C glass fiber filters presoaked in 0.5% PEI using a Brandell cell harvestor.",,Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto,,2014.0,,,,,1528080.0,DTCT0023186,14655209,DTCC01684993,1130074,64476,10.602059991327963,CN1C(=CC=N1)C2=C(C=CC(=C2)NC(=O)C(=O)C3=CC=C(C=C3)F)OCCN,Cn1nccc1-c1cc(NC(=O)C(=O)c2ccc(F)cc2)ccc1OCCN
5414,CHEMBL3652593,P28223,,ZJRLWVGNHAAAMD-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,91.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assays. Radioligand binding assays for human 5-HT2A receptor was conducted using the 5-HT2 agonist [125]DOI as radioligand. To define nonspecific binding, 10 µM DOI was used for all assays. For competitive binding studies, 0.5 nM [125]DOI was used and compounds were assayed over a range of 0.01 nM to 10 µM. Assays were conducted in a total volume of 200 µl in 96-well Perkin Elmer GF/C filter plates in assay buffer (50 mM Tris-HCl, pH 7.4, 0.5 mM EDTA, 5 mM MgCl2, and 10 µM pargyline). Assay incubations were performed for 60 min at room temperature and were terminated by rapid filtration under vacuum pressure of the reaction mixture over Whatman GF/C glass fiber filters presoaked in 0.5% PEI using a Brandell cell harvestor.",,Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto,,2014.0,,,,,1528080.0,DTCT0023186,14655213,DTCC01684994,1582674,64476,7.040958607678906,CN1C(=CC=N1)C2=C(C=CC(=C2)NC(=O)C3=CC=NO3)OCCN,Cn1nccc1-c1cc(NC(=O)c2ccno2)ccc1OCCN
5415,CHEMBL3652594,P28223,,RJTDCESQPZRXMX-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,1.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assays. Radioligand binding assays for human 5-HT2A receptor was conducted using the 5-HT2 agonist [125]DOI as radioligand. To define nonspecific binding, 10 µM DOI was used for all assays. For competitive binding studies, 0.5 nM [125]DOI was used and compounds were assayed over a range of 0.01 nM to 10 µM. Assays were conducted in a total volume of 200 µl in 96-well Perkin Elmer GF/C filter plates in assay buffer (50 mM Tris-HCl, pH 7.4, 0.5 mM EDTA, 5 mM MgCl2, and 10 µM pargyline). Assay incubations were performed for 60 min at room temperature and were terminated by rapid filtration under vacuum pressure of the reaction mixture over Whatman GF/C glass fiber filters presoaked in 0.5% PEI using a Brandell cell harvestor.",,Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto,,2014.0,,,,,1528080.0,DTCT0023186,14655211,DTCC01684995,450282,64476,9.0,CN1C(=C(C=N1)Cl)C2=C(C=CC(=C2)NC(=O)C3=CC(=C(C=C3)F)C(F)(F)F)OCCN,Cn1ncc(Cl)c1-c1cc(NC(=O)c2ccc(F)c(C(F)(F)F)c2)ccc1OCCN
5416,CHEMBL3652595,P28223,,IYXOGPUSAMQKGR-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,0.26,NM,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assays. Radioligand binding assays for human 5-HT2A receptor was conducted using the 5-HT2 agonist [125]DOI as radioligand. To define nonspecific binding, 10 µM DOI was used for all assays. For competitive binding studies, 0.5 nM [125]DOI was used and compounds were assayed over a range of 0.01 nM to 10 µM. Assays were conducted in a total volume of 200 µl in 96-well Perkin Elmer GF/C filter plates in assay buffer (50 mM Tris-HCl, pH 7.4, 0.5 mM EDTA, 5 mM MgCl2, and 10 µM pargyline). Assay incubations were performed for 60 min at room temperature and were terminated by rapid filtration under vacuum pressure of the reaction mixture over Whatman GF/C glass fiber filters presoaked in 0.5% PEI using a Brandell cell harvestor.",,Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto,,2014.0,,,,,1528080.0,DTCT0023186,14655210,DTCC01684996,1259035,64476,9.585026652029182,CN1C(=C(C=N1)Cl)C2=C(C=CC(=C2)NC(=O)C3CCC(CC3)C(F)(F)F)OCCN,Cn1ncc(Cl)c1-c1cc(NC(=O)C2CCC(C(F)(F)F)CC2)ccc1OCCN
5417,CHEMBL3652596,P28223,,ACVPBIAKHSWASO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,1.2,NM,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assays. Radioligand binding assays for human 5-HT2A receptor was conducted using the 5-HT2 agonist [125]DOI as radioligand. To define nonspecific binding, 10 µM DOI was used for all assays. For competitive binding studies, 0.5 nM [125]DOI was used and compounds were assayed over a range of 0.01 nM to 10 µM. Assays were conducted in a total volume of 200 µl in 96-well Perkin Elmer GF/C filter plates in assay buffer (50 mM Tris-HCl, pH 7.4, 0.5 mM EDTA, 5 mM MgCl2, and 10 µM pargyline). Assay incubations were performed for 60 min at room temperature and were terminated by rapid filtration under vacuum pressure of the reaction mixture over Whatman GF/C glass fiber filters presoaked in 0.5% PEI using a Brandell cell harvestor.",,Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto,,2014.0,,,,,1528080.0,DTCT0023186,14655212,DTCC01684997,321407,64476,8.920818753952375,CN1C(=C(C=N1)Cl)C2=C(C=CC(=C2)NC(=O)C(=O)C3=CC(=CS3)Br)OCCN,Cn1ncc(Cl)c1-c1cc(NC(=O)C(=O)c2cc(Br)cs2)ccc1OCCN
5732,CHEMBL3665544,P28223,,VWJAKEHIBAUNPC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,0.08199999999999999,NM,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Radioligand binding assays for human 5-HT2A receptor was conducted using the 5-HT2 agonist [125I]DOI as radioligand. To define nonspecific binding, 10 µM DOI was used for all assays. For competitive binding studies, 0.5 nM [125I]DOI was used and compounds were assayed over a range of 0.01 nM to 10 µM. Assays were conducted in a total volume of 200 µl in 96-well Perkin Elmer GF/C filter plates in assay buffer (50 mM Tris-HCl, pH 7.4, 0.5 mM EDTA, 5 mM MgCl2, and 10 µM pargyline). Assay incubations were performed for 60 mM at room temperature and were terminated by rapid filtration under vacuum pressure of the reaction mixture over Whatman GF/C glass fiber filters presoaked in 0.5% PEI using a Brandell cell harvester.",,"Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto",,2014.0,,,,,1527628.0,DTCT0023186,14632491,DTCC01698075,1161720,64489,10.086186147616283,CN1C(=C(C=N1)Cl)C2=C(C=CC(=C2)NC(=O)C3=CC(=CC=C3)C(F)(F)F)OCCNCCOC,COCCNCCOc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1-c1c(Cl)cnn1C
5733,CHEMBL3665545,P28223,,CJNRCOWLIRPSLZ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,4.4,NM,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Radioligand binding assays for human 5-HT2A receptor was conducted using the 5-HT2 agonist [125I]DOI as radioligand. To define nonspecific binding, 10 µM DOI was used for all assays. For competitive binding studies, 0.5 nM [125I]DOI was used and compounds were assayed over a range of 0.01 nM to 10 µM. Assays were conducted in a total volume of 200 µl in 96-well Perkin Elmer GF/C filter plates in assay buffer (50 mM Tris-HCl, pH 7.4, 0.5 mM EDTA, 5 mM MgCl2, and 10 µM pargyline). Assay incubations were performed for 60 mM at room temperature and were terminated by rapid filtration under vacuum pressure of the reaction mixture over Whatman GF/C glass fiber filters presoaked in 0.5% PEI using a Brandell cell harvester.",,"Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto",,2014.0,,,,,1527628.0,DTCT0023186,14632493,DTCC01698076,774312,64489,8.356547323513812,CN1C(=CC=N1)C2=C(C=CC(=C2)NC(=O)C3=CC(=CC=C3)C(F)(F)F)OCCOC,COCCOc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1-c1ccnn1C
5734,CHEMBL3665546,P28223,,BFXMIEZUXQDHNZ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,52.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Radioligand binding assays for human 5-HT2A receptor was conducted using the 5-HT2 agonist [125I]DOI as radioligand. To define nonspecific binding, 10 µM DOI was used for all assays. For competitive binding studies, 0.5 nM [125I]DOI was used and compounds were assayed over a range of 0.01 nM to 10 µM. Assays were conducted in a total volume of 200 µl in 96-well Perkin Elmer GF/C filter plates in assay buffer (50 mM Tris-HCl, pH 7.4, 0.5 mM EDTA, 5 mM MgCl2, and 10 µM pargyline). Assay incubations were performed for 60 mM at room temperature and were terminated by rapid filtration under vacuum pressure of the reaction mixture over Whatman GF/C glass fiber filters presoaked in 0.5% PEI using a Brandell cell harvester.",,"Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto",,2014.0,,,,,1527628.0,DTCT0023186,14632494,DTCC01698077,516466,64489,7.2839966563652006,CN1C(=C(C=N1)Cl)C2=C(C=CC(=C2)NC(=O)C3=CC(=CC=C3)C(F)(F)F)OCC(=O)NCCOC,COCCNC(=O)COc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1-c1c(Cl)cnn1C
5735,CHEMBL3665547,P28223,,YNPPKWRFHGJIMF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,0.51,NM,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Radioligand binding assays for human 5-HT2A receptor was conducted using the 5-HT2 agonist [125I]DOI as radioligand. To define nonspecific binding, 10 µM DOI was used for all assays. For competitive binding studies, 0.5 nM [125I]DOI was used and compounds were assayed over a range of 0.01 nM to 10 µM. Assays were conducted in a total volume of 200 µl in 96-well Perkin Elmer GF/C filter plates in assay buffer (50 mM Tris-HCl, pH 7.4, 0.5 mM EDTA, 5 mM MgCl2, and 10 µM pargyline). Assay incubations were performed for 60 mM at room temperature and were terminated by rapid filtration under vacuum pressure of the reaction mixture over Whatman GF/C glass fiber filters presoaked in 0.5% PEI using a Brandell cell harvester.",,"Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto",,2014.0,,,,,1527628.0,DTCT0023186,14632492,DTCC01698078,1901058,64489,9.292429823902063,CN1C(=C(C=N1)Cl)C2=C(C=CC(=C2)NC(=O)C3=CC(=CC=C3)OC)OCCO,COc1cccc(C(=O)Nc2ccc(OCCO)c(-c3c(Cl)cnn3C)c2)c1
5738,CHEMBL36715,P28223,PIRACETAM,GMZVRMREEHBGGF-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7374564,DTCC00176308,1383779,46191,,C1CC(=O)N(C1)CC(=O)N,NC(=O)CN1CCCC1=O
5832,CHEMBL3681350,P28223,,DCUZDOXGNVJQQL-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,34.6,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605698,DTCC01714041,1680227,64683,7.460923901207224,C1CN(CCN1)C2=CC=CC3=C2N=CC=C3,c1cnc2c(N3CCNCC3)cccc2c1
5833,CHEMBL3681350,P28223,,DCUZDOXGNVJQQL-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,70.9,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605640,DTCC01714041,1680227,64683,7.149353764816933,C1CN(CCN1)C2=CC=CC3=C2N=CC=C3,c1cnc2c(N3CCNCC3)cccc2c1
5834,CHEMBL3681350,P28223,,DCUZDOXGNVJQQL-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,70.9,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264239,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,168456,DTCC01714041,1680227,64683,7.149353764816933,C1CN(CCN1)C2=CC=CC3=C2N=CC=C3,c1cnc2c(N3CCNCC3)cccc2c1
5835,CHEMBL3681351,P28223,,XEOCHFFUOJNUJC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,69.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605642,DTCC01714042,1130588,64683,7.161150909262744,CCCC1=NC(=CN1C2=CC=C(C=C2)Cl)C(=O)NCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,CCCc1nc(C(=O)NCCN2CCN(c3cccc(Cl)c3Cl)CC2)cn1-c1ccc(Cl)cc1
5836,CHEMBL3681351,P28223,,XEOCHFFUOJNUJC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,69.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264241,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,176393,DTCC01714042,1130588,64683,7.161150909262744,CCCC1=NC(=CN1C2=CC=C(C=C2)Cl)C(=O)NCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,CCCc1nc(C(=O)NCCN2CCN(c3cccc(Cl)c3Cl)CC2)cn1-c1ccc(Cl)cc1
5837,CHEMBL3681351,P28223,,XEOCHFFUOJNUJC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,136.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605700,DTCC01714042,1130588,64683,6.866461091629782,CCCC1=NC(=CN1C2=CC=C(C=C2)Cl)C(=O)NCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,CCCc1nc(C(=O)NCCN2CCN(c3cccc(Cl)c3Cl)CC2)cn1-c1ccc(Cl)cc1
5838,CHEMBL3681352,P28223,,OLAMLYBYQCPMGU-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,30.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605647,DTCC01714043,1194426,64683,7.522878745280337,CC1=C(N=C(N1C2=CC=C(C=C2)Cl)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Cc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccc(Cl)cc1
5839,CHEMBL3681352,P28223,,OLAMLYBYQCPMGU-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,30.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264246,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,172688,DTCC01714043,1194426,64683,7.522878745280337,CC1=C(N=C(N1C2=CC=C(C=C2)Cl)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Cc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccc(Cl)cc1
5840,CHEMBL3681352,P28223,,OLAMLYBYQCPMGU-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,127.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605705,DTCC01714043,1194426,64683,6.896196279044043,CC1=C(N=C(N1C2=CC=C(C=C2)Cl)C)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Cc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccc(Cl)cc1
5841,CHEMBL3681353,P28223,,SPHYMLXPNYQMAB-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,319.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605708,DTCC01714044,1740146,64683,6.496209316942819,CCC1=C(N=C(N1C2=CC=C(C=C2)Br)C3=C(C=C(C=C3)Cl)Cl)C(=O)NCCCN4CCN(CC4)C5=C(C(=CC=C5)Cl)Cl,CCc1c(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)nc(-c2ccc(Cl)cc2Cl)n1-c1ccc(Br)cc1
5842,CHEMBL3681353,P28223,,SPHYMLXPNYQMAB-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,2320.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605650,DTCC01714044,1740146,64683,5.634512015109101,CCC1=C(N=C(N1C2=CC=C(C=C2)Br)C3=C(C=C(C=C3)Cl)Cl)C(=O)NCCCN4CCN(CC4)C5=C(C(=CC=C5)Cl)Cl,CCc1c(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)nc(-c2ccc(Cl)cc2Cl)n1-c1ccc(Br)cc1
5843,CHEMBL3681353,P28223,,SPHYMLXPNYQMAB-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,2320.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264249,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,179000,DTCC01714044,1740146,64683,5.634512015109101,CCC1=C(N=C(N1C2=CC=C(C=C2)Br)C3=C(C=C(C=C3)Cl)Cl)C(=O)NCCCN4CCN(CC4)C5=C(C(=CC=C5)Cl)Cl,CCc1c(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)nc(-c2ccc(Cl)cc2Cl)n1-c1ccc(Br)cc1
5844,CHEMBL3681354,P28223,,PXWTVOJRXKUHBC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,127.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605651,DTCC01714045,1486634,64683,6.896196279044043,CCC1=C(N=C(N1C2=CC=C(C=C2)Br)C3=C(C=C(C=C3)Cl)Cl)C(=O)NCCCN4CCN(CC4)C5=CC=CC(=C5C)C,CCc1c(C(=O)NCCCN2CCN(c3cccc(C)c3C)CC2)nc(-c2ccc(Cl)cc2Cl)n1-c1ccc(Br)cc1
5845,CHEMBL3681354,P28223,,PXWTVOJRXKUHBC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,127.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264250,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,183606,DTCC01714045,1486634,64683,6.896196279044043,CCC1=C(N=C(N1C2=CC=C(C=C2)Br)C3=C(C=C(C=C3)Cl)Cl)C(=O)NCCCN4CCN(CC4)C5=CC=CC(=C5C)C,CCc1c(C(=O)NCCCN2CCN(c3cccc(C)c3C)CC2)nc(-c2ccc(Cl)cc2Cl)n1-c1ccc(Br)cc1
5846,CHEMBL3681354,P28223,,PXWTVOJRXKUHBC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,146.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605709,DTCC01714045,1486634,64683,6.835647144215563,CCC1=C(N=C(N1C2=CC=C(C=C2)Br)C3=C(C=C(C=C3)Cl)Cl)C(=O)NCCCN4CCN(CC4)C5=CC=CC(=C5C)C,CCc1c(C(=O)NCCCN2CCN(c3cccc(C)c3C)CC2)nc(-c2ccc(Cl)cc2Cl)n1-c1ccc(Br)cc1
5847,CHEMBL3681355,P28223,,ULVJNAKJPCJFNL-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,480.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605656,DTCC01714046,1615912,64683,6.318758762624412,CCCN1C(=C(N=C1C)C(=O)NCC(CN2CCN(CC2)C3=C(C(=CC=C3)Cl)C)O)C,CCCn1c(C)nc(C(=O)NCC(O)CN2CCN(c3cccc(Cl)c3C)CC2)c1C
5848,CHEMBL3681355,P28223,,ULVJNAKJPCJFNL-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,480.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264255,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,162268,DTCC01714046,1615912,64683,6.318758762624412,CCCN1C(=C(N=C1C)C(=O)NCC(CN2CCN(CC2)C3=C(C(=CC=C3)Cl)C)O)C,CCCn1c(C)nc(C(=O)NCC(O)CN2CCN(c3cccc(Cl)c3C)CC2)c1C
5849,CHEMBL3681355,P28223,,ULVJNAKJPCJFNL-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,815.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605714,DTCC01714046,1615912,64683,6.088842391260023,CCCN1C(=C(N=C1C)C(=O)NCC(CN2CCN(CC2)C3=C(C(=CC=C3)Cl)C)O)C,CCCn1c(C)nc(C(=O)NCC(O)CN2CCN(c3cccc(Cl)c3C)CC2)c1C
5850,CHEMBL3681356,P28223,,YEQXNYBUJMFQJY-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,207.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605716,DTCC01714047,936318,64683,6.684029654543083,CC1=C(C(=CC=C1)N2CCN(CC2)CC(CNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4OC)C)O)C,COc1ccccc1-n1c(C)nc(C(=O)NCC(O)CN2CCN(c3cccc(C)c3C)CC2)c1C
5851,CHEMBL3681356,P28223,,YEQXNYBUJMFQJY-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,389.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605658,DTCC01714047,936318,64683,6.410050398674292,CC1=C(C(=CC=C1)N2CCN(CC2)CC(CNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4OC)C)O)C,COc1ccccc1-n1c(C)nc(C(=O)NCC(O)CN2CCN(c3cccc(C)c3C)CC2)c1C
5852,CHEMBL3681356,P28223,,YEQXNYBUJMFQJY-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,389.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264257,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,167277,DTCC01714047,936318,64683,6.410050398674292,CC1=C(C(=CC=C1)N2CCN(CC2)CC(CNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4OC)C)O)C,COc1ccccc1-n1c(C)nc(C(=O)NCC(O)CN2CCN(c3cccc(C)c3C)CC2)c1C
5853,CHEMBL3681357,P28223,,SPAJSYZGCASIAM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,12.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605660,DTCC01714048,450799,64683,7.920818753952375,CC1=C(C(=CC=C1)N2CCN(CC2)CCCCNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4Cl)C)C,Cc1cccc(N2CCN(CCCCNC(=O)c3nc(C)n(-c4ccccc4Cl)c3C)CC2)c1C
5854,CHEMBL3681357,P28223,,SPAJSYZGCASIAM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,12.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264259,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,167876,DTCC01714048,450799,64683,7.920818753952375,CC1=C(C(=CC=C1)N2CCN(CC2)CCCCNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4Cl)C)C,Cc1cccc(N2CCN(CCCCNC(=O)c3nc(C)n(-c4ccccc4Cl)c3C)CC2)c1C
5855,CHEMBL3681357,P28223,,SPAJSYZGCASIAM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,39.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605718,DTCC01714048,450799,64683,7.4089353929735005,CC1=C(C(=CC=C1)N2CCN(CC2)CCCCNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=C4Cl)C)C,Cc1cccc(N2CCN(CCCCNC(=O)c3nc(C)n(-c4ccccc4Cl)c3C)CC2)c1C
5856,CHEMBL3681358,P28223,,INVALLJJWAMREW-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,438.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605721,DTCC01714049,968422,64683,6.3585258894959,CC1=C(C(=CC=C1)N2CCN(CC2)CC(CNC(=O)C3=C(N(C(=N3)C(C)C)C4=CC=CC=C4)C)O)C,Cc1cccc(N2CCN(CC(O)CNC(=O)c3nc(C(C)C)n(-c4ccccc4)c3C)CC2)c1C
5857,CHEMBL3681358,P28223,,INVALLJJWAMREW-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,731.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605663,DTCC01714049,968422,64683,6.13608262304214,CC1=C(C(=CC=C1)N2CCN(CC2)CC(CNC(=O)C3=C(N(C(=N3)C(C)C)C4=CC=CC=C4)C)O)C,Cc1cccc(N2CCN(CC(O)CNC(=O)c3nc(C(C)C)n(-c4ccccc4)c3C)CC2)c1C
5858,CHEMBL3681358,P28223,,INVALLJJWAMREW-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,731.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264262,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,170508,DTCC01714049,968422,64683,6.13608262304214,CC1=C(C(=CC=C1)N2CCN(CC2)CC(CNC(=O)C3=C(N(C(=N3)C(C)C)C4=CC=CC=C4)C)O)C,Cc1cccc(N2CCN(CC(O)CNC(=O)c3nc(C(C)C)n(-c4ccccc4)c3C)CC2)c1C
5859,CHEMBL3681359,P28223,,SUSGUHROFJZWAC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,469.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605664,DTCC01714050,1680228,64683,6.328827157284917,CCC1=NC(=C(N1C2=CC=CC=C2)C)C(=O)NCC(CN3CCN(CC3)C4=CC=CC(=C4C)C)O,CCc1nc(C(=O)NCC(O)CN2CCN(c3cccc(C)c3C)CC2)c(C)n1-c1ccccc1
5860,CHEMBL3681359,P28223,,SUSGUHROFJZWAC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,469.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264263,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,163002,DTCC01714050,1680228,64683,6.328827157284917,CCC1=NC(=C(N1C2=CC=CC=C2)C)C(=O)NCC(CN3CCN(CC3)C4=CC=CC(=C4C)C)O,CCc1nc(C(=O)NCC(O)CN2CCN(c3cccc(C)c3C)CC2)c(C)n1-c1ccccc1
5861,CHEMBL3681359,P28223,,SUSGUHROFJZWAC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,542.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605722,DTCC01714050,1680228,64683,6.266000713461613,CCC1=NC(=C(N1C2=CC=CC=C2)C)C(=O)NCC(CN3CCN(CC3)C4=CC=CC(=C4C)C)O,CCc1nc(C(=O)NCC(O)CN2CCN(c3cccc(C)c3C)CC2)c(C)n1-c1ccccc1
5862,CHEMBL3681360,P28223,,XQNUHOBXWNJGHV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,147.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605665,DTCC01714051,936319,64683,6.8326826652518236,CCCC1=NC(=CN1C2=CC=C(C=C2)Cl)C(=O)NCC(CN3CCN(CC3)C4=CC=CC(=C4C)C)O,CCCc1nc(C(=O)NCC(O)CN2CCN(c3cccc(C)c3C)CC2)cn1-c1ccc(Cl)cc1
5863,CHEMBL3681360,P28223,,XQNUHOBXWNJGHV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,147.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264264,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,169990,DTCC01714051,936319,64683,6.8326826652518236,CCCC1=NC(=CN1C2=CC=C(C=C2)Cl)C(=O)NCC(CN3CCN(CC3)C4=CC=CC(=C4C)C)O,CCCc1nc(C(=O)NCC(O)CN2CCN(c3cccc(C)c3C)CC2)cn1-c1ccc(Cl)cc1
5864,CHEMBL3681360,P28223,,XQNUHOBXWNJGHV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,661.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605723,DTCC01714051,936319,64683,6.179798540514359,CCCC1=NC(=CN1C2=CC=C(C=C2)Cl)C(=O)NCC(CN3CCN(CC3)C4=CC=CC(=C4C)C)O,CCCc1nc(C(=O)NCC(O)CN2CCN(c3cccc(C)c3C)CC2)cn1-c1ccc(Cl)cc1
5865,CHEMBL3681361,P28223,,JIACONMAGCAQCX-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,63.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605724,DTCC01714052,2031982,64683,7.200659450546418,CC1=C(C(=CC=C1)N2CCN(CC2)CCNC(=O)C3=C(N(C(=N3)C)C4=CC(=CC(=C4)OC)OC)C)C,COc1cc(OC)cc(-n2c(C)nc(C(=O)NCCN3CCN(c4cccc(C)c4C)CC3)c2C)c1
5866,CHEMBL3681361,P28223,,JIACONMAGCAQCX-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,97.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605666,DTCC01714052,2031982,64683,7.013228265733755,CC1=C(C(=CC=C1)N2CCN(CC2)CCNC(=O)C3=C(N(C(=N3)C)C4=CC(=CC(=C4)OC)OC)C)C,COc1cc(OC)cc(-n2c(C)nc(C(=O)NCCN3CCN(c4cccc(C)c4C)CC3)c2C)c1
5867,CHEMBL3681361,P28223,,JIACONMAGCAQCX-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,97.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264265,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,175195,DTCC01714052,2031982,64683,7.013228265733755,CC1=C(C(=CC=C1)N2CCN(CC2)CCNC(=O)C3=C(N(C(=N3)C)C4=CC(=CC(=C4)OC)OC)C)C,COc1cc(OC)cc(-n2c(C)nc(C(=O)NCCN3CCN(c4cccc(C)c4C)CC3)c2C)c1
5868,CHEMBL3681362,P28223,,OYSYRCCOWAOQDG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,16.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605667,DTCC01714053,645877,64683,7.795880017344075,CC1=C(C(=CC=C1)N2CCN(CC2)CCNC(=O)C3=C(N(C(=N3)C(C)C)C4=CC=CC=C4)C)C,Cc1cccc(N2CCN(CCNC(=O)c3nc(C(C)C)n(-c4ccccc4)c3C)CC2)c1C
5869,CHEMBL3681362,P28223,,OYSYRCCOWAOQDG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,16.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264266,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,163003,DTCC01714053,645877,64683,7.795880017344075,CC1=C(C(=CC=C1)N2CCN(CC2)CCNC(=O)C3=C(N(C(=N3)C(C)C)C4=CC=CC=C4)C)C,Cc1cccc(N2CCN(CCNC(=O)c3nc(C(C)C)n(-c4ccccc4)c3C)CC2)c1C
5870,CHEMBL3681362,P28223,,OYSYRCCOWAOQDG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,59.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605725,DTCC01714053,645877,64683,7.229147988357856,CC1=C(C(=CC=C1)N2CCN(CC2)CCNC(=O)C3=C(N(C(=N3)C(C)C)C4=CC=CC=C4)C)C,Cc1cccc(N2CCN(CCNC(=O)c3nc(C(C)C)n(-c4ccccc4)c3C)CC2)c1C
5871,CHEMBL3681363,P28223,,GOTNCIJNEMSYQD-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,23.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605668,DTCC01714054,1065574,64683,7.638272163982407,CC1=C(C(=CC=C1)N2CCN(CC2)CCNC(=O)C3=C(N(C(=N3)C)C4=CC=C(C=C4)F)C)C,Cc1cccc(N2CCN(CCNC(=O)c3nc(C)n(-c4ccc(F)cc4)c3C)CC2)c1C
5872,CHEMBL3681363,P28223,,GOTNCIJNEMSYQD-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,23.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264267,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,162597,DTCC01714054,1065574,64683,7.638272163982407,CC1=C(C(=CC=C1)N2CCN(CC2)CCNC(=O)C3=C(N(C(=N3)C)C4=CC=C(C=C4)F)C)C,Cc1cccc(N2CCN(CCNC(=O)c3nc(C)n(-c4ccc(F)cc4)c3C)CC2)c1C
5873,CHEMBL3681363,P28223,,GOTNCIJNEMSYQD-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,46.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605726,DTCC01714054,1065574,64683,7.337242168318426,CC1=C(C(=CC=C1)N2CCN(CC2)CCNC(=O)C3=C(N(C(=N3)C)C4=CC=C(C=C4)F)C)C,Cc1cccc(N2CCN(CCNC(=O)c3nc(C)n(-c4ccc(F)cc4)c3C)CC2)c1C
5874,CHEMBL3681364,P28223,,ASCMXYZEXRDQLG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,27.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605727,DTCC01714055,127091,64683,7.568636235841013,CC1=C(C(=CC=C1)N2CCN(CC2)CCNC(=O)C3=C(N(C(=N3)C)C4=CC5=C(C=C4)OCO5)C)C,Cc1cccc(N2CCN(CCNC(=O)c3nc(C)n(-c4ccc5c(c4)OCO5)c3C)CC2)c1C
5875,CHEMBL3681364,P28223,,ASCMXYZEXRDQLG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,29.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605669,DTCC01714055,127091,64683,7.5376020021010435,CC1=C(C(=CC=C1)N2CCN(CC2)CCNC(=O)C3=C(N(C(=N3)C)C4=CC5=C(C=C4)OCO5)C)C,Cc1cccc(N2CCN(CCNC(=O)c3nc(C)n(-c4ccc5c(c4)OCO5)c3C)CC2)c1C
5876,CHEMBL3681364,P28223,,ASCMXYZEXRDQLG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,29.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264268,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,161290,DTCC01714055,127091,64683,7.5376020021010435,CC1=C(C(=CC=C1)N2CCN(CC2)CCNC(=O)C3=C(N(C(=N3)C)C4=CC5=C(C=C4)OCO5)C)C,Cc1cccc(N2CCN(CCNC(=O)c3nc(C)n(-c4ccc5c(c4)OCO5)c3C)CC2)c1C
5877,CHEMBL3681365,P28223,,ASQAAUGFBFTGLB-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,504.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605671,DTCC01714056,248,64683,6.297569463554475,CCCC1=NC(=CN1C2=CC=CC=C2)C(=O)NCC(CN3CCN(CC3)C4=CC=CC(=C4C)C)O,CCCc1nc(C(=O)NCC(O)CN2CCN(c3cccc(C)c3C)CC2)cn1-c1ccccc1
5878,CHEMBL3681365,P28223,,ASQAAUGFBFTGLB-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,504.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264270,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,158860,DTCC01714056,248,64683,6.297569463554475,CCCC1=NC(=CN1C2=CC=CC=C2)C(=O)NCC(CN3CCN(CC3)C4=CC=CC(=C4C)C)O,CCCc1nc(C(=O)NCC(O)CN2CCN(c3cccc(C)c3C)CC2)cn1-c1ccccc1
5879,CHEMBL3681365,P28223,,ASQAAUGFBFTGLB-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,635.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605729,DTCC01714056,248,64683,6.197226274708024,CCCC1=NC(=CN1C2=CC=CC=C2)C(=O)NCC(CN3CCN(CC3)C4=CC=CC(=C4C)C)O,CCCc1nc(C(=O)NCC(O)CN2CCN(c3cccc(C)c3C)CC2)cn1-c1ccccc1
5880,CHEMBL3681366,P28223,,MKONVJWMCLCPCH-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,297.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605673,DTCC01714057,289381,64683,6.527243550682788,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=N4)C)C,Cc1cccc(N2CCN(CCCNC(=O)c3nc(C)n(-c4ccccn4)c3C)CC2)c1C
5881,CHEMBL3681366,P28223,,MKONVJWMCLCPCH-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,297.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264272,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,159515,DTCC01714057,289381,64683,6.527243550682788,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=N4)C)C,Cc1cccc(N2CCN(CCCNC(=O)c3nc(C)n(-c4ccccn4)c3C)CC2)c1C
5882,CHEMBL3681366,P28223,,MKONVJWMCLCPCH-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,388.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605731,DTCC01714057,289381,64683,6.411168274405793,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4=CC=CC=N4)C)C,Cc1cccc(N2CCN(CCCNC(=O)c3nc(C)n(-c4ccccn4)c3C)CC2)c1C
5883,CHEMBL3681367,P28223,,CUBBXRQMBRNCPR-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,137.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605674,DTCC01714058,159711,64683,6.863279432843593,COC1=CC=C(C=C1)N2C=C(N=C2C3=CC=CC=C3)C(=O)NCC(CN4CCN(CC4)C5=C(C(=CC=C5)Cl)Cl)O,COc1ccc(-n2cc(C(=O)NCC(O)CN3CCN(c4cccc(Cl)c4Cl)CC3)nc2-c2ccccc2)cc1
5884,CHEMBL3681367,P28223,,CUBBXRQMBRNCPR-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,137.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264273,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,177068,DTCC01714058,159711,64683,6.863279432843593,COC1=CC=C(C=C1)N2C=C(N=C2C3=CC=CC=C3)C(=O)NCC(CN4CCN(CC4)C5=C(C(=CC=C5)Cl)Cl)O,COc1ccc(-n2cc(C(=O)NCC(O)CN3CCN(c4cccc(Cl)c4Cl)CC3)nc2-c2ccccc2)cc1
5885,CHEMBL3681367,P28223,,CUBBXRQMBRNCPR-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,463.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605732,DTCC01714058,159711,64683,6.334419008982047,COC1=CC=C(C=C1)N2C=C(N=C2C3=CC=CC=C3)C(=O)NCC(CN4CCN(CC4)C5=C(C(=CC=C5)Cl)Cl)O,COc1ccc(-n2cc(C(=O)NCC(O)CN3CCN(c4cccc(Cl)c4Cl)CC3)nc2-c2ccccc2)cc1
5886,CHEMBL3681368,P28223,,JFXAHYFMZDUZMA-FQEVSTJZSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,264.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605682,DTCC01714059,1615913,64683,6.578396073130169,CCCC1=NC(=CN1C2=CC=C(C=C2)Cl)C(=O)NC[C@@H](CN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl)O,CCCc1nc(C(=O)NC[C@H](O)CN2CCN(c3cccc(Cl)c3Cl)CC2)cn1-c1ccc(Cl)cc1
5887,CHEMBL3681368,P28223,,JFXAHYFMZDUZMA-FQEVSTJZSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,264.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264281,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,182893,DTCC01714059,1615913,64683,6.578396073130169,CCCC1=NC(=CN1C2=CC=C(C=C2)Cl)C(=O)NC[C@@H](CN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl)O,CCCc1nc(C(=O)NC[C@H](O)CN2CCN(c3cccc(Cl)c3Cl)CC2)cn1-c1ccc(Cl)cc1
5888,CHEMBL3681368,P28223,,JFXAHYFMZDUZMA-FQEVSTJZSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,737.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605740,DTCC01714059,1615913,64683,6.132532512140949,CCCC1=NC(=CN1C2=CC=C(C=C2)Cl)C(=O)NC[C@@H](CN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl)O,CCCc1nc(C(=O)NC[C@H](O)CN2CCN(c3cccc(Cl)c3Cl)CC2)cn1-c1ccc(Cl)cc1
5889,CHEMBL3681369,P28223,,FZBPFTYHSMCPFA-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,33.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605688,DTCC01714060,2031983,64683,7.481486060122113,CC1=CC=C(C=C1)N2C(=C(N=C2C)C(=O)NCCCN3CCN(CC3)C4=CC=CC(=C4C)C)C,Cc1ccc(-n2c(C)nc(C(=O)NCCCN3CCN(c4cccc(C)c4C)CC3)c2C)cc1
5890,CHEMBL3681369,P28223,,FZBPFTYHSMCPFA-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,33.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264287,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,183647,DTCC01714060,2031983,64683,7.481486060122113,CC1=CC=C(C=C1)N2C(=C(N=C2C)C(=O)NCCCN3CCN(CC3)C4=CC=CC(=C4C)C)C,Cc1ccc(-n2c(C)nc(C(=O)NCCCN3CCN(c4cccc(C)c4C)CC3)c2C)cc1
5891,CHEMBL3681369,P28223,,FZBPFTYHSMCPFA-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,78.1,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605746,DTCC01714060,2031983,64683,7.1073489661227,CC1=CC=C(C=C1)N2C(=C(N=C2C)C(=O)NCCCN3CCN(CC3)C4=CC=CC(=C4C)C)C,Cc1ccc(-n2c(C)nc(C(=O)NCCCN3CCN(c4cccc(C)c4C)CC3)c2C)cc1
5892,CHEMBL3681370,P28223,,DODNFAIZJDWBTC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,68.2,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605689,DTCC01714061,159712,64683,7.166215625343521,CC1=CC=C(C=C1)N2C(=C(N=C2C)C(=O)NCC(CN3CCN(CC3)C4=CC=CC(=C4C)C)O)C,Cc1ccc(-n2c(C)nc(C(=O)NCC(O)CN3CCN(c4cccc(C)c4C)CC3)c2C)cc1
5893,CHEMBL3681370,P28223,,DODNFAIZJDWBTC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,68.2,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",264288,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,169676,DTCC01714061,159712,64683,7.166215625343521,CC1=CC=C(C=C1)N2C(=C(N=C2C)C(=O)NCC(CN3CCN(CC3)C4=CC=CC(=C4C)C)O)C,Cc1ccc(-n2c(C)nc(C(=O)NCC(O)CN3CCN(c4cccc(C)c4C)CC3)c2C)cc1
5894,CHEMBL3681370,P28223,,DODNFAIZJDWBTC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,705.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14605747,DTCC01714061,159712,64683,6.151810883008602,CC1=CC=C(C=C1)N2C(=C(N=C2C)C(=O)NCC(CN3CCN(CC3)C4=CC=CC(=C4C)C)O)C,Cc1ccc(-n2c(C)nc(C(=O)NCC(O)CN3CCN(c4cccc(C)c4C)CC3)c2C)cc1
5895,CHEMBL3681371,P28223,,RRISOQPBQQGKQY-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,321.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14635521,DTCC01714062,2063735,64683,6.493494967595128,CCC1=C(N=C(N1C2=CC=C(C=C2)Br)C3=C(C=C(C=C3)Cl)Cl)C(=O)NCCCN4CCN(CC4)C5=CC(=CC=C5)Cl,CCc1c(C(=O)NCCCN2CCN(c3cccc(Cl)c3)CC2)nc(-c2ccc(Cl)cc2Cl)n1-c1ccc(Br)cc1
5896,CHEMBL3681371,P28223,,RRISOQPBQQGKQY-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,1262.0,NM,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,14635520,DTCC01714062,2063735,64683,5.898940645091884,CCC1=C(N=C(N1C2=CC=C(C=C2)Br)C3=C(C=C(C=C3)Cl)Cl)C(=O)NCCCN4CCN(CC4)C5=CC(=CC=C5)Cl,CCc1c(C(=O)NCCCN2CCN(c3cccc(Cl)c3)CC2)nc(-c2ccc(Cl)cc2Cl)n1-c1ccc(Br)cc1
5897,CHEMBL3681371,P28223,,RRISOQPBQQGKQY-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,1262.0,NM,,cell_based,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27Â° C. using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac). For serotonin 5-HT2C binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT2C receptor.",22214,Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same,,2014.0,,,,,1528794.0,DTCT0023186,169719,DTCC01714062,2063735,64683,5.898940645091884,CCC1=C(N=C(N1C2=CC=C(C=C2)Br)C3=C(C=C(C=C3)Cl)Cl)C(=O)NCCCN4CCN(CC4)C5=CC(=CC=C5)Cl,CCc1c(C(=O)NCCCN2CCN(c3cccc(Cl)c3)CC2)nc(-c2ccc(Cl)cc2Cl)n1-c1ccc(Br)cc1
6070,CHEMBL36994,P28223,ANIRACETAM,ZXNRTKGTQJPIJK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7274808,DTCC00176277,1447877,46191,,COC1=CC=C(C=C1)C(=O)N2CCCC2=O,COc1ccc(C(=O)N2CCCC2=O)cc1
6087,CHEMBL37161,P28223,FENBENDAZOLE,HDDSHPAODJUKPD-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7332962,DTCC00174892,2089748,46191,,COC(=O)NC1=NC2=C(N1)C=C(C=C2)SC3=CC=CC=C3,COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1
6100,CHEMBL372795,P28223,STREPTOMYCIN,UCSJYZPVAKXKNQ-HZYVHMACSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7478125,DTCC00411395,51509,46191,,C[C@H]1[C@@]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H]([C@@H]([C@H]2O)O)N=C(N)N)O)N=C(N)N)O[C@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)O)NC)(C=O)O,CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@@H]3[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]3O)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O
6107,CHEMBL373389,P28223,,VQCNZOZVOVKWNU-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16971119.0,IC50,=,534.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human 5HT2A receptor expressed in CHOK1 cells,,"Identification and optimisation of 5-amino-7-aryldihydro-1,4-diazepines as 5-HT2A ligands.",Bioorg. Med. Chem. Lett.,2006.0,16.0,23.0,"Swain CJ, Teran A, Maroto M, Cabello A",,424570.0,DTCT0023186,2013609,DTCC00110907,1808535,21789,6.272458742971444,CC(C)(C)NC1=NCCNC(=C1)C2=CC=C(C=C2)OC,COc1ccc(C2=CC(NC(C)(C)C)=NCCN2)cc1
6126,CHEMBL3735756,P28223,,,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,5011.87,NM,,,,,,,,,,,,,,Antagonist activity at human recombinant 5-HT2A receptor expressed in Flp-In HEK cells in the presence of agonist preincubated for 10 mins by FLIPR based calcium mobilization assay,,Identification of tris-(phenylalkyl)amines as new selective h5-HT2Breceptor antagonists,MedChemComm,2015.0,6.0,4.0,"Ponnala S, Kapadia N, Harding WW",,1538872.0,DTCT0023186,1787,DTCC00063276,2011614,65324,5.300000202445418,COC1=C(C=C(C=C1)CCN(CCCC2=CC=CC=C2)CCC3=CC4=C(C=C3)OCO4)OC,COc1ccc(CCN(CCCc2ccccc2)CCc2ccc3c(c2)OCO3)cc1OC
6136,CHEMBL3736156,P28223,,,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26565745.0,IC50,>,5011.87,NM,,,,,,,,,,,,,,Antagonist activity at human 5-HT2A receptor expressed in CHO-K1 cells assessed as seretonin-induced calcium level by FDSS assay,,Benzazaborinines as Novel Bioisosteric Replacements of Naphthalene: Propranolol as an Example.,J. Med. Chem.,2015.0,58.0,23.0,"Rombouts FJ, Tovar F, Austin N, Tresadern G, Trabanco AA.",,1539014.0,DTCT0023186,2794,DTCC00063664,1162142,65419,5.300000202445418,B1(C=CC2=C(N1)C=CC=C2OCC(CN(C)C)O)C,CB1C=Cc2c(cccc2OCC(O)CN(C)C)N1
6142,CHEMBL3736433,P28223,,,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26565745.0,IC50,>,5011.87,NM,,,,,,,,,,,,,,Antagonist activity at human 5-HT2A receptor expressed in CHO-K1 cells assessed as seretonin-induced calcium level by FDSS assay,,Benzazaborinines as Novel Bioisosteric Replacements of Naphthalene: Propranolol as an Example.,J. Med. Chem.,2015.0,58.0,23.0,"Rombouts FJ, Tovar F, Austin N, Tresadern G, Trabanco AA.",,1539014.0,DTCT0023186,2793,DTCC00063663,1648350,65419,5.300000202445418,B1(C=CC2=C(N1)C(=CC=C2)OCC(CN(C)C)O)C,CB1C=Cc2cccc(OCC(O)CN(C)C)c2N1
6152,CHEMBL373966,P28223,,SQBGPLLCLFWTHC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16971119.0,IC50,=,1.1,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human 5HT2A receptor expressed in CHOK1 cells,,"Identification and optimisation of 5-amino-7-aryldihydro-1,4-diazepines as 5-HT2A ligands.",Bioorg. Med. Chem. Lett.,2006.0,16.0,23.0,"Swain CJ, Teran A, Maroto M, Cabello A",,424570.0,DTCT0023186,2013625,DTCC00440764,584988,21789,8.958607314841775,CCC1(CCCC1)NC2=NCCNC(=C2)C3=C(C=C(C=C3)F)F,CCC1(NC2=NCCNC(c3ccc(F)cc3F)=C2)CCCC1
6166,CHEMBL374478,P28223,RIFAMPICIN,JQXXHWHPUNPDRT-WLSIYKJHSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7481593,DTCC00437710,51504,46191,,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C
6168,CHEMBL374497,P28223,,QOPHIHKLLMGENT-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16971119.0,IC50,>,1000.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human 5HT2A receptor expressed in CHOK1 cells,,"Identification and optimisation of 5-amino-7-aryldihydro-1,4-diazepines as 5-HT2A ligands.",Bioorg. Med. Chem. Lett.,2006.0,16.0,23.0,"Swain CJ, Teran A, Maroto M, Cabello A",,424570.0,DTCT0023186,2013619,DTCC00440773,1263595,21789,6.0,CC1=CC=C(C=C1)C2=CC(=NCCN2)N3CCNCC3,Cc1ccc(C2=CC(N3CCNCC3)=NCCN2)cc1
6198,CHEMBL374874,P28223,,PCRFUGMTSSHGAT-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16971119.0,IC50,=,2800.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human 5HT2A receptor expressed in CHOK1 cells,,"Identification and optimisation of 5-amino-7-aryldihydro-1,4-diazepines as 5-HT2A ligands.",Bioorg. Med. Chem. Lett.,2006.0,16.0,23.0,"Swain CJ, Teran A, Maroto M, Cabello A",,424570.0,DTCT0023186,2013605,DTCC00440732,876222,21789,5.552841968657781,CC(C)(C)NC1=NCCNC(=C1)C2=CC=C(C=C2)C#N,CC(C)(C)NC1=NCCNC(c2ccc(C#N)cc2)=C1
6213,CHEMBL375369,P28223,,IFEOHSTXNWWLJY-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16971119.0,IC50,=,11.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human 5HT2A receptor expressed in CHOK1 cells,,"Identification and optimisation of 5-amino-7-aryldihydro-1,4-diazepines as 5-HT2A ligands.",Bioorg. Med. Chem. Lett.,2006.0,16.0,23.0,"Swain CJ, Teran A, Maroto M, Cabello A",,424570.0,DTCT0023186,2013601,DTCC00440762,1872984,21789,7.958607314841775,CC1=CC=C(C=C1)C2=CC(=NCCN2)NC(C)(C)C,Cc1ccc(C2=CC(NC(C)(C)C)=NCCN2)cc1
6230,CHEMBL376180,P28223,AMINOPTERIN,TVZGACDUOSZQKY-LBPRGKRZSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7287416,DTCC00445374,120968,46191,,C1=CC(=CC=C1C(=O)N[C@@H](CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=NC(=N3)N)N,Nc1nc(N)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2n1
6246,CHEMBL376753,P28223,,PDPLVZXRJYIVQH-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16971119.0,IC50,=,76.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human 5HT2A receptor expressed in CHOK1 cells,,"Identification and optimisation of 5-amino-7-aryldihydro-1,4-diazepines as 5-HT2A ligands.",Bioorg. Med. Chem. Lett.,2006.0,16.0,23.0,"Swain CJ, Teran A, Maroto M, Cabello A",,424570.0,DTCT0023186,2013606,DTCC00440724,1937304,21789,7.119186407719209,CC(C)(C)NC1=NCCNC(=C1)C2=CC=CC=C2Cl,CC(C)(C)NC1=NCCNC(c2ccccc2Cl)=C1
6355,CHEMBL3775576,P28223,,,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26852363.0,IC50,=,240.0,NM,,,,,,,,,,,,,,Inhibition of 5HT2A (unknown origin),,Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore.,Bioorg. Med. Chem. Lett.,2016.0,26.0,5.0,"Schiemann K, Mallinger A, Wienke D, Esdar C, Poeschke O, Busch M, Rohdich F, Eccles SA, Schneider R, Raynaud FI, Czodrowski P, Musil D, Schwarz D, Urbahns K, Blagg J.",,1559659.0,DTCT0023186,124380,DTCC00081348,981081,66363,6.619788758288394,CNC(=O)C1=CC2=C(NN=C2C=C1)CC3=CC4=C(C=C3)N(N=C4)C,CNC(=O)c1ccc2n[nH]c(Cc3ccc4c(cnn4C)c3)c2c1
6358,CHEMBL37858,P28223,SARAFLOXACIN,XBHBWNFJWIASRO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7479936,DTCC00180187,51508,46191,,C1CN(CCN1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4=CC=C(C=C4)F)F,O=C(O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O
6370,CHEMBL38,P28223,TRETINOIN,SHGAZHPCJJPHSC-YCNIQYBTSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7453436,DTCC00134063,51513,46191,,CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
6376,CHEMBL3804943,P28223,,,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,27173799.0,IC50,=,840.0,NM,,,,,,,,,,,,,,Antagonistic activity at human 5-HT2A receptor assessed as calcium flux after 10 mins by FLIPR assay,,"Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.",Bioorg. Med. Chem. Lett.,2016.0,26.0,13.0,"Yang F, Jiang X, Li J, Wang Y, Liu Y, Bi M, Wu C, Zhao Q, Chen W, Yin J, Zhang J, Xie Y, Hu T, Xu M, Guo S, Wang Z, He Y, Shen J.",,1576959.0,DTCT0023186,259721,DTCC00092630,852271,67092,6.075720713938118,CNC(=O)C1=CC(=C(C=C1)OC)OCCCCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl,CNC(=O)c1ccc(OC)c(OCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1
6377,CHEMBL3804954,P28223,,,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,27173799.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,Antagonistic activity at human 5-HT2A receptor assessed as calcium flux after 10 mins by FLIPR assay,,"Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.",Bioorg. Med. Chem. Lett.,2016.0,26.0,13.0,"Yang F, Jiang X, Li J, Wang Y, Liu Y, Bi M, Wu C, Zhao Q, Chen W, Yin J, Zhang J, Xie Y, Hu T, Xu M, Guo S, Wang Z, He Y, Shen J.",,1576959.0,DTCT0023186,259353,DTCC00092742,367330,67092,5.657577319177793,CNC(=O)C1=CC=CC=C1OCCCCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl,CNC(=O)c1ccccc1OCCCCN1CCN(c2cccc(Cl)c2Cl)CC1
6378,CHEMBL3804965,P28223,,,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,27173799.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,Antagonistic activity at human 5-HT2A receptor assessed as calcium flux after 10 mins by FLIPR assay,,"Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.",Bioorg. Med. Chem. Lett.,2016.0,26.0,13.0,"Yang F, Jiang X, Li J, Wang Y, Liu Y, Bi M, Wu C, Zhao Q, Chen W, Yin J, Zhang J, Xie Y, Hu T, Xu M, Guo S, Wang Z, He Y, Shen J.",,1576959.0,DTCT0023186,259400,DTCC00092751,1045887,67092,5.721246399047171,CNC(=O)C1=C(C=CC(=C1)OCCCCN2CCN(CC2)C3=C4C(=CC=C3)OC(O4)(F)F)F,CNC(=O)c1cc(OCCCCN2CCN(c3cccc4c3OC(F)(F)O4)CC2)ccc1F
6379,CHEMBL3805046,P28223,,,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,27173799.0,IC50,=,30.3,NM,,,,,,,,,,,,,,Antagonistic activity at human 5-HT2A receptor assessed as calcium flux after 10 mins by FLIPR assay,,"Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.",Bioorg. Med. Chem. Lett.,2016.0,26.0,13.0,"Yang F, Jiang X, Li J, Wang Y, Liu Y, Bi M, Wu C, Zhao Q, Chen W, Yin J, Zhang J, Xie Y, Hu T, Xu M, Guo S, Wang Z, He Y, Shen J.",,1576959.0,DTCT0023186,259742,DTCC00092741,107324,67092,7.518557371497695,CNC(=O)C1=C(C(=CC=C1)OCCCCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl)F,CNC(=O)c1cccc(OCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1F
6380,CHEMBL3805077,P28223,,,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,27173799.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,Antagonistic activity at human 5-HT2A receptor assessed as calcium flux after 10 mins by FLIPR assay,,"Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.",Bioorg. Med. Chem. Lett.,2016.0,26.0,13.0,"Yang F, Jiang X, Li J, Wang Y, Liu Y, Bi M, Wu C, Zhao Q, Chen W, Yin J, Zhang J, Xie Y, Hu T, Xu M, Guo S, Wang Z, He Y, Shen J.",,1576959.0,DTCT0023186,259403,DTCC00092623,432467,67092,5.958607314841775,CNC(=O)C1=CC(=CC=C1)OCCCCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl,CNC(=O)c1cccc(OCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1
6381,CHEMBL3805099,P28223,,,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,27173799.0,IC50,=,35.0,NM,,,,,,,,,,,,,,Antagonistic activity at human 5-HT2A receptor assessed as calcium flux after 10 mins by FLIPR assay,,"Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.",Bioorg. Med. Chem. Lett.,2016.0,26.0,13.0,"Yang F, Jiang X, Li J, Wang Y, Liu Y, Bi M, Wu C, Zhao Q, Chen W, Yin J, Zhang J, Xie Y, Hu T, Xu M, Guo S, Wang Z, He Y, Shen J.",,1576959.0,DTCT0023186,259384,DTCC00092747,269051,67092,7.455931955649724,CNC(=O)C1=C(C=CC(=C1)OCCCCN2CCN(CC2)C3=NSC4=CC=CC=C43)F,CNC(=O)c1cc(OCCCCN2CCN(c3nsc4ccccc34)CC2)ccc1F
6383,CHEMBL3805120,P28223,,,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,27173799.0,IC50,=,460.0,NM,,,,,,,,,,,,,,Antagonistic activity at human 5-HT2A receptor assessed as calcium flux after 10 mins by FLIPR assay,,"Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.",Bioorg. Med. Chem. Lett.,2016.0,26.0,13.0,"Yang F, Jiang X, Li J, Wang Y, Liu Y, Bi M, Wu C, Zhao Q, Chen W, Yin J, Zhang J, Xie Y, Hu T, Xu M, Guo S, Wang Z, He Y, Shen J.",,1576959.0,DTCT0023186,259712,DTCC00092627,625879,67092,6.337242168318426,CC1=C(C=C(C=C1)OCCCCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl)C(=O)NC,CNC(=O)c1cc(OCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)ccc1C
6384,CHEMBL3805165,P28223,,,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,27173799.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,Antagonistic activity at human 5-HT2A receptor assessed as calcium flux after 10 mins by FLIPR assay,,"Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.",Bioorg. Med. Chem. Lett.,2016.0,26.0,13.0,"Yang F, Jiang X, Li J, Wang Y, Liu Y, Bi M, Wu C, Zhao Q, Chen W, Yin J, Zhang J, Xie Y, Hu T, Xu M, Guo S, Wang Z, He Y, Shen J.",,1576959.0,DTCT0023186,259397,DTCC00092750,400136,67092,5.0,CNC(=O)C1=CC(=CC=C1)OCCCCN2CCN(CC2)C3=C4C(=CC=C3)OC(O4)(F)F,CNC(=O)c1cccc(OCCCCN2CCN(c3cccc4c3OC(F)(F)O4)CC2)c1
6385,CHEMBL3805262,P28223,,,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,27173799.0,IC50,=,1320.0,NM,,,,,,,,,,,,,,Antagonistic activity at human 5-HT2A receptor assessed as calcium flux after 10 mins by FLIPR assay,,"Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.",Bioorg. Med. Chem. Lett.,2016.0,26.0,13.0,"Yang F, Jiang X, Li J, Wang Y, Liu Y, Bi M, Wu C, Zhao Q, Chen W, Yin J, Zhang J, Xie Y, Hu T, Xu M, Guo S, Wang Z, He Y, Shen J.",,1576959.0,DTCT0023186,259736,DTCC00092635,107323,67092,5.87942606879415,CNC(=O)C1=CC(=CC(=C1)F)OCCCCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl,CNC(=O)c1cc(F)cc(OCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1
6386,CHEMBL3805327,P28223,,,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,27173799.0,IC50,=,1380.0,NM,,,,,,,,,,,,,,Antagonistic activity at human 5-HT2A receptor assessed as calcium flux after 10 mins by FLIPR assay,,"Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.",Bioorg. Med. Chem. Lett.,2016.0,26.0,13.0,"Yang F, Jiang X, Li J, Wang Y, Liu Y, Bi M, Wu C, Zhao Q, Chen W, Yin J, Zhang J, Xie Y, Hu T, Xu M, Guo S, Wang Z, He Y, Shen J.",,1576959.0,DTCT0023186,259733,DTCC00092634,496887,67092,5.860120913598763,CNC(=O)C1=CC(=C(C=C1)Cl)OCCCCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl,CNC(=O)c1ccc(Cl)c(OCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1
6387,CHEMBL3805376,P28223,,,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,27173799.0,IC50,=,820.0,NM,,,,,,,,,,,,,,Antagonistic activity at human 5-HT2A receptor assessed as calcium flux after 10 mins by FLIPR assay,,"Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.",Bioorg. Med. Chem. Lett.,2016.0,26.0,13.0,"Yang F, Jiang X, Li J, Wang Y, Liu Y, Bi M, Wu C, Zhao Q, Chen W, Yin J, Zhang J, Xie Y, Hu T, Xu M, Guo S, Wang Z, He Y, Shen J.",,1576959.0,DTCT0023186,259350,DTCC00092743,1045886,67092,6.086186147616283,CNC(=O)C1=CC=C(C=C1)OCCCCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl,CNC(=O)c1ccc(OCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc1
6388,CHEMBL3805434,P28223,,,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,27173799.0,IC50,=,494.0,NM,,,,,,,,,,,,,,Antagonistic activity at human 5-HT2A receptor assessed as calcium flux after 10 mins by FLIPR assay,,"Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.",Bioorg. Med. Chem. Lett.,2016.0,26.0,13.0,"Yang F, Jiang X, Li J, Wang Y, Liu Y, Bi M, Wu C, Zhao Q, Chen W, Yin J, Zhang J, Xie Y, Hu T, Xu M, Guo S, Wang Z, He Y, Shen J.",,1576959.0,DTCT0023186,259730,DTCC00092633,948779,67092,6.306273051076353,CC(=O)C1=CC(=CC(=C1)OCCCCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl)C(=O)NC,CNC(=O)c1cc(OCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc(C(C)=O)c1
6389,CHEMBL3805515,P28223,,,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,27173799.0,IC50,=,720.0,NM,,,,,,,,,,,,,,Antagonistic activity at human 5-HT2A receptor assessed as calcium flux after 10 mins by FLIPR assay,,"Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.",Bioorg. Med. Chem. Lett.,2016.0,26.0,13.0,"Yang F, Jiang X, Li J, Wang Y, Liu Y, Bi M, Wu C, Zhao Q, Chen W, Yin J, Zhang J, Xie Y, Hu T, Xu M, Guo S, Wang Z, He Y, Shen J.",,1576959.0,DTCT0023186,259739,DTCC00092636,1531487,67092,6.142667503568732,CNC(=O)C1=C(C(=CC=C1)OCCCCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl)OC,CNC(=O)c1cccc(OCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1OC
6390,CHEMBL3805518,P28223,,,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,27173799.0,IC50,=,15.0,NM,,,,,,,,,,,,,,Antagonistic activity at human 5-HT2A receptor assessed as calcium flux after 10 mins by FLIPR assay,,"Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.",Bioorg. Med. Chem. Lett.,2016.0,26.0,13.0,"Yang F, Jiang X, Li J, Wang Y, Liu Y, Bi M, Wu C, Zhao Q, Chen W, Yin J, Zhang J, Xie Y, Hu T, Xu M, Guo S, Wang Z, He Y, Shen J.",,1576959.0,DTCT0023186,259331,DTCC00092745,28028,67092,7.823908740944319,CNC(=O)C1=C(C=CC(=C1)OCCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)F,CNC(=O)c1cc(OCCCCN2CCC(c3noc4cc(F)ccc34)CC2)ccc1F
6391,CHEMBL3805559,P28223,,,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,27173799.0,IC50,=,46.0,NM,,,,,,,,,,,,,,Antagonistic activity at human 5-HT2A receptor assessed as calcium flux after 10 mins by FLIPR assay,,"Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.",Bioorg. Med. Chem. Lett.,2016.0,26.0,13.0,"Yang F, Jiang X, Li J, Wang Y, Liu Y, Bi M, Wu C, Zhao Q, Chen W, Yin J, Zhang J, Xie Y, Hu T, Xu M, Guo S, Wang Z, He Y, Shen J.",,1576959.0,DTCT0023186,259347,DTCC00092744,948782,67092,7.337242168318426,CNC(=O)C1=CC(=CC=C1)OCCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F,CNC(=O)c1cccc(OCCCCN2CCC(c3noc4cc(F)ccc34)CC2)c1
6392,CHEMBL3805600,P28223,,,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,27173799.0,IC50,=,1050.0,NM,,,,,,,,,,,,,,Antagonistic activity at human 5-HT2A receptor assessed as calcium flux after 10 mins by FLIPR assay,,"Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.",Bioorg. Med. Chem. Lett.,2016.0,26.0,13.0,"Yang F, Jiang X, Li J, Wang Y, Liu Y, Bi M, Wu C, Zhao Q, Chen W, Yin J, Zhang J, Xie Y, Hu T, Xu M, Guo S, Wang Z, He Y, Shen J.",,1576959.0,DTCT0023186,259356,DTCC00092622,236399,67092,5.978810700930062,CC(=O)NC1=CC(=CC=C1)OCCCCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl,CC(=O)Nc1cccc(OCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1
6393,CHEMBL3805649,P28223,,,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,27173799.0,IC50,=,80.0,NM,,,,,,,,,,,,,,Antagonistic activity at human 5-HT2A receptor assessed as calcium flux after 10 mins by FLIPR assay,,"Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.",Bioorg. Med. Chem. Lett.,2016.0,26.0,13.0,"Yang F, Jiang X, Li J, Wang Y, Liu Y, Bi M, Wu C, Zhao Q, Chen W, Yin J, Zhang J, Xie Y, Hu T, Xu M, Guo S, Wang Z, He Y, Shen J.",,1576959.0,DTCT0023186,259392,DTCC00092749,203913,67092,7.096910013008056,CNC(=O)C1=C(C=CC(=C1)OCCCCN2CCN(CC2)C3=C4C=CSC4=CC=C3)F,CNC(=O)c1cc(OCCCCN2CCN(c3cccc4sccc34)CC2)ccc1F
6394,CHEMBL3805704,P28223,,,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,27173799.0,IC50,=,216.0,NM,,,,,,,,,,,,,,Antagonistic activity at human 5-HT2A receptor assessed as calcium flux after 10 mins by FLIPR assay,,"Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.",Bioorg. Med. Chem. Lett.,2016.0,26.0,13.0,"Yang F, Jiang X, Li J, Wang Y, Liu Y, Bi M, Wu C, Zhao Q, Chen W, Yin J, Zhang J, Xie Y, Hu T, Xu M, Guo S, Wang Z, He Y, Shen J.",,1576959.0,DTCT0023186,259389,DTCC00092748,1817064,67092,6.665546248849069,CNC(=O)C1=CC(=CC=C1)OCCCCN2CCN(CC2)C3=C4C=CSC4=CC=C3,CNC(=O)c1cccc(OCCCCN2CCN(c3cccc4sccc34)CC2)c1
6395,CHEMBL3805772,P28223,,,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,27173799.0,IC50,=,670.0,NM,,,,,,,,,,,,,,Antagonistic activity at human 5-HT2A receptor assessed as calcium flux after 10 mins by FLIPR assay,,"Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.",Bioorg. Med. Chem. Lett.,2016.0,26.0,13.0,"Yang F, Jiang X, Li J, Wang Y, Liu Y, Bi M, Wu C, Zhao Q, Chen W, Yin J, Zhang J, Xie Y, Hu T, Xu M, Guo S, Wang Z, He Y, Shen J.",,1576959.0,DTCT0023186,259409,DTCC00092625,787003,67092,6.173925197299173,CCNC(=O)C1=CC(=CC=C1)OCCCCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl,CCNC(=O)c1cccc(OCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1
6396,CHEMBL3805826,P28223,,,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,27173799.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,Antagonistic activity at human 5-HT2A receptor assessed as calcium flux after 10 mins by FLIPR assay,,"Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.",Bioorg. Med. Chem. Lett.,2016.0,26.0,13.0,"Yang F, Jiang X, Li J, Wang Y, Liu Y, Bi M, Wu C, Zhao Q, Chen W, Yin J, Zhang J, Xie Y, Hu T, Xu M, Guo S, Wang Z, He Y, Shen J.",,1576959.0,DTCT0023186,259709,DTCC00092626,367327,67092,5.958607314841775,CCCCCNC(=O)C1=CC(=CC=C1)OCCCCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl,CCCCCNC(=O)c1cccc(OCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1
6397,CHEMBL3805860,P28223,,,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,27173799.0,IC50,=,180.0,NM,,,,,,,,,,,,,,Antagonistic activity at human 5-HT2A receptor assessed as calcium flux after 10 mins by FLIPR assay,,"Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.",Bioorg. Med. Chem. Lett.,2016.0,26.0,13.0,"Yang F, Jiang X, Li J, Wang Y, Liu Y, Bi M, Wu C, Zhao Q, Chen W, Yin J, Zhang J, Xie Y, Hu T, Xu M, Guo S, Wang Z, He Y, Shen J.",,1576959.0,DTCT0023186,259381,DTCC00092746,1563371,67092,6.7447274948966935,CNC(=O)C1=CC(=CC=C1)OCCCCN2CCN(CC2)C3=NSC4=CC=CC=C43,CNC(=O)c1cccc(OCCCCN2CCN(c3nsc4ccccc34)CC2)c1
6398,CHEMBL3805884,P28223,,,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,27173799.0,IC50,=,360.0,NM,,,,,,,,,,,,,,Antagonistic activity at human 5-HT2A receptor assessed as calcium flux after 10 mins by FLIPR assay,,"Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.",Bioorg. Med. Chem. Lett.,2016.0,26.0,13.0,"Yang F, Jiang X, Li J, Wang Y, Liu Y, Bi M, Wu C, Zhao Q, Chen W, Yin J, Zhang J, Xie Y, Hu T, Xu M, Guo S, Wang Z, He Y, Shen J.",,1576959.0,DTCT0023186,259715,DTCC00092628,236400,67092,6.443697499232713,CNC(=O)C1=C(C=CC(=C1)OCCCCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl)F,CNC(=O)c1cc(OCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)ccc1F
6399,CHEMBL3806047,P28223,,,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,27173799.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,Antagonistic activity at human 5-HT2A receptor assessed as calcium flux after 10 mins by FLIPR assay,,"Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.",Bioorg. Med. Chem. Lett.,2016.0,26.0,13.0,"Yang F, Jiang X, Li J, Wang Y, Liu Y, Bi M, Wu C, Zhao Q, Chen W, Yin J, Zhang J, Xie Y, Hu T, Xu M, Guo S, Wang Z, He Y, Shen J.",,1576959.0,DTCT0023186,259727,DTCC00092632,916103,67092,5.853871964321762,CC1=CC(=CC(=C1)OCCCCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl)C(=O)NC,CNC(=O)c1cc(C)cc(OCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1
6400,CHEMBL3806091,P28223,,,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,27173799.0,IC50,=,860.0,NM,,,,,,,,,,,,,,Antagonistic activity at human 5-HT2A receptor assessed as calcium flux after 10 mins by FLIPR assay,,"Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.",Bioorg. Med. Chem. Lett.,2016.0,26.0,13.0,"Yang F, Jiang X, Li J, Wang Y, Liu Y, Bi M, Wu C, Zhao Q, Chen W, Yin J, Zhang J, Xie Y, Hu T, Xu M, Guo S, Wang Z, He Y, Shen J.",,1576959.0,DTCT0023186,259718,DTCC00092629,690405,67092,6.0655015487564325,CC1=C(C=CC=C1OCCCCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl)C(=O)NC,CNC(=O)c1cccc(OCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1C
6401,CHEMBL3806169,P28223,,,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,27173799.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,Antagonistic activity at human 5-HT2A receptor assessed as calcium flux after 10 mins by FLIPR assay,,"Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.",Bioorg. Med. Chem. Lett.,2016.0,26.0,13.0,"Yang F, Jiang X, Li J, Wang Y, Liu Y, Bi M, Wu C, Zhao Q, Chen W, Yin J, Zhang J, Xie Y, Hu T, Xu M, Guo S, Wang Z, He Y, Shen J.",,1576959.0,DTCT0023186,259406,DTCC00092624,658221,67092,5.958607314841775,C1CN(CCN1CCCCOC2=CC=CC(=C2)C(=O)N)C3=C(C(=CC=C3)Cl)Cl,NC(=O)c1cccc(OCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1
6402,CHEMBL3806224,P28223,,,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,27173799.0,IC50,=,340.0,NM,,,,,,,,,,,,,,Antagonistic activity at human 5-HT2A receptor assessed as calcium flux after 10 mins by FLIPR assay,,"Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.",Bioorg. Med. Chem. Lett.,2016.0,26.0,13.0,"Yang F, Jiang X, Li J, Wang Y, Liu Y, Bi M, Wu C, Zhao Q, Chen W, Yin J, Zhang J, Xie Y, Hu T, Xu M, Guo S, Wang Z, He Y, Shen J.",,1576959.0,DTCT0023186,259724,DTCC00092631,107322,67092,6.468521082957745,CNC(=O)C1=C(C=CC(=C1)OCCCCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl)Cl,CNC(=O)c1cc(OCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)ccc1Cl
6467,CHEMBL3823832,P28223,,,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,356.0,NM,,,,,,,,,,,,,,Antagonist activity at 5HT2A (unknown origin),,In vivo phenotypic drug discovery: applying a behavioral assay to the discovery and optimization of novel antipsychotic agents,MedChemComm,2016.0,7.0,6.0,"Shao L, Campbell UC, Fang QK, Powell NA, Campbell JE, Jones PG, Hanania T, Alexandrov V, Morganstern I, Sabath E, Zhong HM, Large TH, Spear KL",,1586716.0,DTCT0023186,303640,DTCC00099681,1722211,67430,6.448550002027125,CC1=C(C2=CC=CC=C2S1)[C@@H]3C=CNC=N3,Cc1sc2ccccc2c1[C@@H]1C=CNC=N1
6482,CHEMBL383530,P28223,,GDWBWUCRKAYOMD-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16632354.0,IC50,=,319.0,NM,,cell_based,,,,,,,,,,,CHO,Antagonist activity against human 5HT2A transfected in CHO cells by aurora beta lactamase reporter gene assay,,"A new class of selective, non-basic 5-HT2A receptor antagonists.",Bioorg. Med. Chem. Lett.,2006.0,16.0,12.0,"Ladduwahetty T, Boase AL, Mitchinson A, Quin C, Patel S, Chapman K, MacLeod AM",,361718.0,DTCT0023186,1937560,DTCC00423513,78041,20884,6.496209316942819,C1CN(CCC1CCC2=C(C=C(C=C2)F)F)S(=O)(=O)C3=CC=CC(=C3)F,O=S(=O)(c1cccc(F)c1)N1CCC(CCc2ccc(F)cc2F)CC1
6488,CHEMBL384467,P28223,DEXAMETHASONE,UREBDLICKHMUKA-CXSFZGCWSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7370195,DTCC00437785,639578,46191,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
6501,CHEMBL386612,P28223,,HFLSARBZSBXRJZ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16971119.0,IC50,=,3.8,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human 5HT2A receptor expressed in CHOK1 cells,,"Identification and optimisation of 5-amino-7-aryldihydro-1,4-diazepines as 5-HT2A ligands.",Bioorg. Med. Chem. Lett.,2006.0,16.0,23.0,"Swain CJ, Teran A, Maroto M, Cabello A",,424570.0,DTCT0023186,2013617,DTCC00110901,972521,21789,8.42021640338319,CC(C)(CC1=CC=CC=C1)NC2=NCCNC(=C2)C3=CC=CC=C3F,CC(C)(Cc1ccccc1)NC1=NCCNC(c2ccccc2F)=C1
6502,CHEMBL386613,P28223,,HEIQANPLPPUURQ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16971119.0,IC50,=,3.6,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human 5HT2A receptor expressed in CHOK1 cells,,"Identification and optimisation of 5-amino-7-aryldihydro-1,4-diazepines as 5-HT2A ligands.",Bioorg. Med. Chem. Lett.,2006.0,16.0,23.0,"Swain CJ, Teran A, Maroto M, Cabello A",,424570.0,DTCT0023186,2013616,DTCC00110902,617271,21789,8.443697499232712,CCC1(CCCC1)NC2=NCCNC(=C2)C3=CC=CC=C3F,CCC1(NC2=NCCNC(c3ccccc3F)=C2)CCCC1
6503,CHEMBL386630,P28223,TESTOSTERONE,MUMGGOZAMZWBJJ-DYKIIFRCSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7483179,DTCC00437190,477923,46191,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)CC[C@]34C,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O
6510,CHEMBL38737,P28223,THIOACETAMIDE,YUKQRDCYNOVPGJ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7483302,DTCC00179105,88637,46191,,CC(=S)N,CC(N)=S
6516,CHEMBL388590,P28223,BENZBROMARONE,WHQCHUCQKNIQEC-UHFFFAOYSA-N,1,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7258347,DTCC00445492,153438,46191,,CCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)Br)O)Br,CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1
6523,CHEMBL389621,P28223,HYDROCORTISONE,JYGXADMDTFJGBT-VWUMJDOOSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7306497,DTCC00445397,800578,46191,,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C)O,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO
6608,CHEMBL395110,P28223,MEPAZINE,CBHCDHNUZWWAPP-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,385.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7430110,DTCC00464417,477046,46191,6.414539270491499,CN1CCCC(C1)CN2C3=CC=CC=C3SC4=CC=CC=C42,CN1CCCC(CN2c3ccccc3Sc3ccccc32)C1
6651,CHEMBL398440,P28223,CHLOROXYLENOL,OSDLLIBGSJNGJE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7364582,DTCC00485552,1059329,46191,,CC1=CC(=CC(=C1Cl)C)O,Cc1cc(O)cc(C)c1Cl
6661,CHEMBL4,P28223,OFLOXACIN,GSDSWSVVBLHKDQ-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7392986,DTCC00132314,1641850,46191,,CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O,CC1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
6663,CHEMBL40,P28223,PHENOBARBITAL,DDBREPKUVSBGFI-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7385019,DTCC00134072,51499,46191,,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CCC1(c2ccccc2)C(=O)NC(=O)NC1=O
6676,CHEMBL402794,P28223,BIS(2-ETHYLHEXYL)PHTHALATE,BJQHLKABXJIVAM-BGYRXZFFSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7265957,DTCC00499603,153439,46191,,CCCC[C@@H](CC)COC(=O)C1=CC=CC=C1C(=O)OC[C@@H](CC)CCCC,CCCC[C@H](CC)COC(=O)c1ccccc1C(=O)OC[C@H](CC)CCCC
6679,CHEMBL403,P28223,SULBACTAM,FKENQMMABCRJMK-RITPCOANSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7460743,DTCC00132361,671795,46191,,CC1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)O)C,CC1(C)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O
6688,CHEMBL404,P28223,TAZOBACTAM,LPQZKKCYTLCDGQ-WEDXCCLWSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7472122,DTCC00132373,88636,46191,,C[C@@]1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)O)CN3C=CN=N3,C[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O
6696,CHEMBL404520,P28223,CHLORTETRACYCLINE,CYDMQBQPVICBEU-XRNKAMNCSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7343145,DTCC00502280,1027048,46191,,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C(C=CC(=C41)Cl)O)O)O)O)C(=O)N)N(C)C)O,CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)ccc(Cl)c4[C@@](C)(O)[C@H]3C[C@@H]12
6700,CHEMBL404811,P28223,DIGITONIN,UVYVLBIGDKGWPX-YCCXZQINSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7342519,DTCC00199357,249941,46191,,C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)[C@H]([C@@H]4[C@@]3(CC[C@H]5[C@H]4CC[C@@H]6[C@@]5(C[C@H]([C@@H](C6)O[C@H]7[C@@H]([C@H]([C@H]([C@H](O7)CO)O[C@H]8[C@@H]([C@H](C([C@H](O8)CO)O)O[C@H]9[C@@H]([C@H]([C@@H](CO9)O)O)O)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)O)O)O)C)C)O)C)OC1,C[C@H]1[C@H]2[C@@H](O[C@]13CC[C@@H](C)CO3)[C@@H](O)[C@H]1[C@@H]3CC[C@H]4C[C@@H](O[C@@H]5O[C@H](CO)[C@H](O[C@@H]6O[C@H](CO)C(O)[C@H](O[C@@H]7OC[C@@H](O)[C@H](O)[C@H]7O)[C@H]6O[C@@H]6O[C@H](CO)[C@H](O)[C@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)C[C@]4(C)[C@H]3CC[C@@]12C
6710,CHEMBL40583,P28223,3-METHYLCHOLANTHRENE,PPQNQXQZIWHJRB-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7291839,DTCC00181233,1894962,46191,,CC1=C2CCC3=C2C(=CC4=C3C=CC5=CC=CC=C54)C=C1,Cc1ccc2cc3c(ccc4ccccc43)c3c2c1CC3
6714,CHEMBL406,P28223,INDAPAMIDE,NDDAHWYSQHTHNT-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7422429,DTCC00132717,1609547,46191,,CC1CC2=CC=CC=C2N1NC(=O)C3=CC(=C(C=C3)Cl)S(=O)(=O)N,CC1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(S(N)(=O)=O)c1
6716,CHEMBL406221,P28223,,DBJFBHNMHQIBDU-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18083580.0,IC50,=,7900.0,NM,,,,,,,,,,,,,,Binding affinity at 5HT2A receptor,,Novel quinazolinone derivatives as 5-HT7 receptor ligands.,Bioorg. Med. Chem.,2008.0,16.0,5.0,"Na YH, Hong SH, Lee JH, Park WK, Baek DJ, Koh HY, Cho YS, Choo H, Pae AN",,474642.0,DTCT0023186,2341950,DTCC00496796,455766,26061,5.102372908709558,CCOC1=CC=CC=C1N2CCN(CC2)CCCC(=O)NCC3=NC4=C(C=C(C=C4)F)C(=O)N3C5=CC=C(C=C5)OC,CCOc1ccccc1N1CCN(CCCC(=O)NCc2nc3ccc(F)cc3c(=O)n2-c2ccc(OC)cc2)CC1
6724,CHEMBL407,P28223,FLUMAZENIL,OFBIFZUFASYYRE-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7322492,DTCC00132733,1609545,46191,,CCOC(=O)C1=C2CN(C(=O)C3=C(N2C=N1)C=CC(=C3)F)C,CCOC(=O)c1ncn2c1CN(C)C(=O)c1cc(F)ccc1-2
6726,CHEMBL407030,P28223,GAMMA-CYCLODEXTRIN,MIFVTYPADKEWAV-HGRQBIKSSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7312285,DTCC00003162,88629,46191,,C([C@@H]1[C@@H]2[C@@H]([C@H]([C@H](O1)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](OC([C@@H]([C@H]5O)O)OC6[C@H](OC([C@@H]([C@H]6O)O)C7[C@H](OC([C@@H]([C@H]7O)O)O[C@@H]8[C@H](O[C@@H]([C@@H]([C@H]8O)O)O[C@@H]9[C@H](O[C@H](O2)[C@@H]([C@H]9O)O)CO)CO)CO)CO)CO)CO)CO)O)O)O,OC[C@H]1OC2O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@@H]6[C@@H](CO)O[C@H](O[C@@H]7[C@@H](CO)O[C@H](O[C@@H]8[C@@H](CO)OC(OC9[C@@H](CO)OC(C1[C@H](O)[C@H]2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O
6728,CHEMBL407135,P28223,COLISTINE,YKQOSKADJPQZHB-YNWHQGOSSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7352483,DTCC00494880,1705874,46191,,CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCN)CC(C)C)CC(C)C)CCN)CCN)[C@H](C)O,CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@H](C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O
6743,CHEMBL408,P28223,TROGLITAZONE,GXPHKUHSUJUWKP-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7450087,DTCC00132763,800583,46191,,CC1=C(C2=C(CCC(O2)(C)COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4)C(=C1O)C)C,Cc1c(C)c2c(c(C)c1O)CCC(C)(COc1ccc(CC3SC(=O)NC3=O)cc1)O2
6764,CHEMBL41,P28223,FLUOXETINE,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,194.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7324863,DTCC00134078,1609546,46191,6.7121982700697735,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
6767,CHEMBL411,P28223,DIETHYLSTILBESTROL,RGLYKWWBQGJZGM-ISLYRVAYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,4790.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7363913,DTCC00132930,2057648,46191,5.319664486585436,CC/C(=C(/CC)\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)O,CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1
6772,CHEMBL412873,P28223,SPARTEINE,SLRCCWJSBJZJBV-TUVASFSCSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7480166,DTCC00141609,1674150,46191,,C1CCN2C[C@H]3C[C@@H]([C@H]2C1)CN4[C@H]3CCCC4,C1CCN2C[C@H]3C[C@H](CN4CCCC[C@H]34)[C@@H]2C1
6775,CHEMBL413,P28223,SIROLIMUS,QFJCIRLUMZQUOT-HPLJOQBZSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7459749,DTCC00132982,477921,46191,,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C
6780,CHEMBL413965,P28223,FELBINAC,QRZAKQDHEVVFRX-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7324361,DTCC00106501,1285874,46191,,C1=CC=C(C=C1)C2=CC=C(C=C2)CC(=O)O,O=C(O)Cc1ccc(-c2ccccc2)cc1
6784,CHEMBL414668,P28223,,IAUMSVMHUGIVJE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23542166.0,IC50,=,50.0,NM,,,,,,,,,,,,,,Displacement of [3H]-ketanserin from human 5HT2A receptor,,"Structure-activity relationship of 5-chloro-2-methyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole analogues as 5-HT6 receptor agonists.",Eur. J. Med. Chem.,2013.0,63.0,,"Mattsson C, Svensson P, Boettcher H, Sonesson C",,957901.0,DTCT0023186,12414844,DTCC00405071,1515493,54449,7.301029995663981,C1CNCC=C1C2=C(NC3=CC=CC=C32)C4=CC=CC=C4,C1=C(c2c(-c3ccccc3)[nH]c3ccccc23)CCNC1
6790,CHEMBL415,P28223,CLOMIPRAMINE,GDLIGKIOYRNHDA-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,67.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7369590,DTCC00133038,217576,46191,7.173925197299173,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21
6797,CHEMBL415324,P28223,TRANILAST,NZHGWWWHIYHZNX-CSKARUKUSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7447993,DTCC00281196,1674153,46191,,COC1=C(C=C(C=C1)/C=C/C(=O)NC2=CC=CC=C2C(=O)O)OC,COc1ccc(/C=C/C(=O)Nc2ccccc2C(=O)O)cc1OC
6799,CHEMBL41543,P28223,,PHNLCHMJDSSPDQ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7294471,DTCC00180007,866015,46191,,C1CC2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N,NC(=O)N1c2ccccc2CCc2ccccc21
6802,CHEMBL415690,P28223,BETADEX,WHGYBXFWUBPSRW-FOUAGVGXSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7264253,DTCC00463534,249937,46191,,C([C@@H]1[C@@H]2[C@@H]([C@H]([C@H](O1)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5O)O)O[C@@H]6[C@H](O[C@@H]([C@@H]([C@H]6O)O)O[C@@H]7[C@H](O[C@@H]([C@@H]([C@H]7O)O)O[C@@H]8[C@H](O[C@H](O2)[C@@H]([C@H]8O)O)CO)CO)CO)CO)CO)CO)O)O)O,OC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@@H]6[C@@H](CO)O[C@H](O[C@@H]7[C@@H](CO)O[C@H](O[C@@H]8[C@@H](CO)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O
6805,CHEMBL416,P28223,METHOXSALEN,QXKHYNVANLEOEG-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7408808,DTCC00133091,1765976,46191,,COC1=C2C(=CC3=C1OC=C3)C=CC(=O)O2,COc1c2occc2cc2ccc(=O)oc12
6807,CHEMBL416336,P28223,,IVNWUIYPKNHGSZ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,213796.21,NM,,,,,,,,,,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,,Bioorg. Med. Chem. Lett.,1996.0,6.0,10.0,,,2462.0,DTCT0023186,1276481,DTCC00139387,305540,1628,3.669999997867538,CCCN(CCC)CC1(CC2=C(C=CC=C2OC)OC1)N(CCC)CCC,CCCN(CCC)CC1(N(CCC)CCC)COc2cccc(OC)c2C1
6808,CHEMBL416523,P28223,,SPJPXOJVCGSOOK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,48.98,NM,,,,,,,,,,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,,Bioorg. Med. Chem. Lett.,1996.0,6.0,10.0,,,2462.0,DTCT0023186,1272172,DTCC00139386,1695965,1628,7.309981219211305,COC1=CC=CC2=C1CC(CO2)CNCCCCN3C(=O)CC4(CCCC4)CC3=O,COc1cccc2c1CC(CNCCCCN1C(=O)CC3(CCCC3)CC1=O)CO2
6814,CHEMBL417,P28223,EPIRUBICIN,AOJJSUZBOXZQNB-VTZDEGQISA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7315545,DTCC00133135,671788,46191,,C[C@H]1[C@@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1
6817,CHEMBL417608,P28223,,PXTNZNWAFOHMBS-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,7762.47,NM,,,,,,,,,,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,,Bioorg. Med. Chem. Lett.,1996.0,6.0,10.0,,,2462.0,DTCT0023186,1256932,DTCC00139248,2079631,1628,5.110000065251387,CCCN(CCCCN1C(=O)CC2(CCCC2)CC1=O)CC3CC4=C(C=CC=C4OC)OC3,CCCN(CCCCN1C(=O)CC2(CCCC2)CC1=O)CC1COc2cccc(OC)c2C1
6826,CHEMBL418971,P28223,BISPHENOL A,IISBACLAFKSPIT-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7271393,DTCC00260853,88624,46191,,CC(C)(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O,CC(C)(c1ccc(O)cc1)c1ccc(O)cc1
6837,CHEMBL42,P28223,CLOZAPINE,QZUDBNBUXVUHMW-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,8831770.0,IC50,=,12.0,NM,,cell_based,,,,,,,,,,,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,"Structure-activity relationships of a series of novel (piperazinylbutyl)thiazolidinone antipsychotic agents related to 3-[4-[4-(6-fluorobenzo[b]thien-3-yl)-1-piperazinyl]butyl]-2,5,5- trimethyl-4-thiazolidinone maleate.",J. Med. Chem.,1996.0,39.0,20.0,"Hrib NJ, Jurcak JG, Bregna DE, Burgher KL, Hartman HB, Kafka S, Kerman LL, Kongsamut S, Roehr JE, Szewczak MR, Woods-Kettelberger AT, Corbett R",,2272.0,DTCT0023186,1628992,DTCC00134115,5361,13832,7.920818753952375,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
6860,CHEMBL42,P28223,CLOZAPINE,QZUDBNBUXVUHMW-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16469866.0,IC50,=,13.0,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0023186,14720332,DTCC00134115,2102034,68469,7.886056647693163,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
6880,CHEMBL42,P28223,CLOZAPINE,QZUDBNBUXVUHMW-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,4.2,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7365343,DTCC00134115,51460,46191,8.3767507096021,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
6893,CHEMBL420,P28223,GUANABENZ,WDZVGELJXXEGPV-YIXHJXPBSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,392.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7316930,DTCC00133212,1416031,46191,6.406713932979542,C1=CC(=C(C(=C1)Cl)/C=N/N=C(N)N)Cl,NC(N)=N/N=C/c1c(Cl)cccc1Cl
6902,CHEMBL420965,P28223,L-760790,JCFDYNJSFCXYRT-FQEVSTJZSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,10052975.0,IC50,=,4400.0,NM,,,,,,,,,,,,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,Synthesis and serotonergic activity of 3-[2-(pyrrolidin-1-yl)ethyl]indoles: potent agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B receptor.,J. Med. Chem.,1999.0,42.0,4.0,"Sternfeld F, Guiblin AR, Jelley RA, Matassa VG, Reeve AJ, Hunt PA, Beer MS, Heald A, Stanton JA, Sohal B, Watt AP, Street LJ",,1048.0,DTCT0023186,1393224,DTCC01741409,1694803,15594,5.356547323513812,C1CN(C[C@@H]1CNCC2=CC=CC=C2)CCC3=CNC4=C3C=C(C=C4)N5C=NN=C5,c1ccc(CNC[C@@H]2CCN(CCc3c[nH]c4ccc(-n5cnnc5)cc34)C2)cc1
6903,CHEMBL421,P28223,SULFASALAZINE,NCEXYHBECQHGNR-QZQOTICOSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7478390,DTCC00133232,2025643,46191,,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,O=C(O)c1cc(N=Nc2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O
6913,CHEMBL422,P28223,TRIFLUOPERAZINE,ZEWQUBUPAILYHI-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7441318,DTCC00133320,962453,46191,,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F,CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1
6924,CHEMBL422931,P28223,,GZAMCYJCPQMIHJ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23477943.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,Inhibition of 5HT2A receptor (unknown origin),,Discovery of disubstituted piperidines and homopiperidines as potent dual NK1 receptor antagonists-serotonin reuptake transporter inhibitors for the treatment of depression.,Bioorg. Med. Chem.,2013.0,21.0,8.0,"Wu YJ, He H, Bertekap R, Westphal R, Lelas S, Newton A, Wallace T, Taber M, Davis C, Macor JE, Bronson J",,951577.0,DTCT0023186,11855619,DTCC00156158,751057,54264,6.0,C1CNCCC1(COCC2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)C3=CC=CC=C3,FC(F)(F)c1cc(COCC2(c3ccccc3)CCNCC2)cc(C(F)(F)F)c1
6925,CHEMBL423192,P28223,ANISOMYCIN,YKJYKKNCCRKFSL-RDBSUJKOSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7280735,DTCC00329526,866016,46191,,CC(=O)O[C@@H]1[C@H](CN[C@@H]1CC2=CC=C(C=C2)OC)O,COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1
6930,CHEMBL424,P28223,SALICYLIC ACID,YGSDEFSMJLZEOE-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7462447,DTCC00133347,51507,46191,,C1=CC=C(C(=C1)C(=O)O)O,O=C(O)c1ccccc1O
6934,CHEMBL42442,P28223,OXFENDAZOLE,BEZZFPOZAYTVHN-UHFFFAOYSA-N,2,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7397385,DTCC00184703,282999,46191,,COC(=O)NC1=NC2=C(N1)C=C(C=C2)S(=O)C3=CC=CC=C3,COC(=O)Nc1nc2ccc([S+]([O-])c3ccccc3)cc2[nH]1
6946,CHEMBL426123,P28223,(-)-THALIDOMIDE,UEJJHQNACJXSKW-VIFPVBQESA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7301218,DTCC00001569,1609540,46191,,C1CC(=O)NC(=O)[C@H]1N2C(=O)C3=CC=CC=C3C2=O,O=C1CC[C@H](N2C(=O)c3ccccc3C2=O)C(=O)N1
6951,CHEMBL426712,P28223,,WFQHOINSWLZFOC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16971119.0,IC50,=,112.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human 5HT2A receptor expressed in CHOK1 cells,,"Identification and optimisation of 5-amino-7-aryldihydro-1,4-diazepines as 5-HT2A ligands.",Bioorg. Med. Chem. Lett.,2006.0,16.0,23.0,"Swain CJ, Teran A, Maroto M, Cabello A",,424570.0,DTCT0023186,2013610,DTCC00110900,195681,21789,6.950781977329818,CC1=CC=CC=C1C2=CC(=NCCN2)NC(C)(C)C,Cc1ccccc1C1=CC(NC(C)(C)C)=NCCN1
6954,CHEMBL42710,P28223,EUGENOL,RRAFCDWBNXTKKO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7311591,DTCC00183810,1253322,46191,,COC1=C(C=CC(=C1)CC=C)O,C=CCc1ccc(O)c(OC)c1
6956,CHEMBL427216,P28223,GLICLAZIDE,BOVGTQGAOIONJV-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7320901,DTCC00422269,800576,46191,,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CC3CCCC3C2,Cc1ccc(S(=O)(=O)NC(=O)NN2CC3CCCC3C2)cc1
6959,CHEMBL427518,P28223,,FJGYVPIKFQWJJI-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18456500.0,IC50,=,5168.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in CHOK1 cell membrane,,Preparation of piperazine derivatives as 5-HT7 receptor antagonists.,Bioorg. Med. Chem.,2008.0,16.0,10.0,"Yoon J, Yoo EA, Kim JY, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,556690.0,DTCT0023186,2557312,DTCC00393160,1341666,28856,5.286677495012972,COC1=CC=C(C=C1)S(=O)(=O)NCCCN2CCN(CC2)C3=CC=CC=C3OC,COc1ccc(S(=O)(=O)NCCCN2CCN(c3ccccc3OC)CC2)cc1
6960,CHEMBL427526,P28223,(R)-IBUPROPHEN,HEFNNWSXXWATRW-SNVBAGLBSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7472791,DTCC00396930,671793,46191,,C[C@H](C1=CC=C(C=C1)CC(C)C)C(=O)O,CC(C)Cc1ccc([C@@H](C)C(=O)O)cc1
6964,CHEMBL428,P28223,TROVAFLOXACIN,WVPSKSLAZQPAKQ-CDMJZVDBSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7443040,DTCC00133538,1577011,46191,,C1[C@@H]2[C@@H](C2N)CN1C3=C(C=C4C(=O)C(=CN(C4=N3)C5=C(C=C(C=C5)F)F)C(=O)O)F,NC1[C@@H]2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)C[C@H]12
6968,CHEMBL428647,P28223,PACLITAXEL,RCINICONZNJXQF-MZXODVADSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7393288,DTCC00138918,51496,46191,,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C
6971,CHEMBL428880,P28223,CROMOLYN,IMZMKUWMOSJXDT-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7339763,DTCC00138605,671787,46191,,C1=CC2=C(C(=C1)OCC(COC3=CC=CC4=C3C(=O)C=C(O4)C(=O)O)O)C(=O)C=C(O2)C(=O)O,O=C(O)c1cc(=O)c2c(OCC(O)COc3cccc4oc(C(=O)O)cc(=O)c34)cccc2o1
6973,CHEMBL429,P28223,LABETALOL,SGUAFYQXFOLMHL-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7429314,DTCC00133676,120973,46191,,CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1
6975,CHEMBL429023,P28223,ROTENONE,JUVIOZPCNVVQFO-HBGVWJBISA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7488181,DTCC00134556,1027058,46191,,CC(=C)[C@H]1CC2=C(O1)C=CC3=C2O[C@@H]4COC5=CC(=C(C=C5[C@@H]4C3=O)OC)OC,C=C(C)[C@H]1Cc2c(ccc3c2O[C@@H]2COc4cc(OC)c(OC)cc4[C@@H]2C3=O)O1
6983,CHEMBL43064,P28223,CINNARIZINE,DERZBLKQOCDDDZ-JLHYYAGUSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,360.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7367112,DTCC01738588,930078,46191,6.443697499232713,C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=CC=C3)C4=CC=CC=C4,C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1
6995,CHEMBL433257,P28223,HARRINGTONINE,HAVJATCHLFRDHY-KSZYUSJVSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7310705,DTCC00188822,1447883,46191,,CC(C)(CC[C@@](CC(=O)OC)(C(=O)O[C@H]1[C@H]2C3=CC4=C(C=C3CCN5[C@@]2(CCC5)C=C1OC)OCO4)O)O,COC(=O)C[C@](O)(CCC(C)(C)O)C(=O)O[C@@H]1C(OC)=C[C@]23CCCN2CCc2cc4c(cc2[C@H]13)OCO4
6999,CHEMBL434,P28223,ISOPROTERENOL,JWZZKOKVBUJMES-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7439630,DTCC00133870,315665,46191,,CC(C)NCC(C1=CC(=C(C=C1)O)O)O,CC(C)NCC(O)c1ccc(O)c(O)c1
7001,CHEMBL434063,P28223,GW1929,QTQMRBZOBKYXCG-MHZLTWQESA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7329744,DTCC01743578,994594,46191,,CN(CCOC1=CC=C(C=C1)C[C@@H](C(=O)O)NC2=CC=CC=C2C(=O)C3=CC=CC=C3)C4=CC=CC=N4,CN(CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c2ccccc2)C(=O)O)cc1)c1ccccn1
7005,CHEMBL435,P28223,HYDROCHLOROTHIAZIDE,JZUFKLXOESDKRF-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7336359,DTCC00133916,1285877,46191,,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O
7011,CHEMBL436513,P28223,,JWZBRHICAGOWSR-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16971119.0,IC50,=,1.4,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human 5HT2A receptor expressed in CHOK1 cells,,"Identification and optimisation of 5-amino-7-aryldihydro-1,4-diazepines as 5-HT2A ligands.",Bioorg. Med. Chem. Lett.,2006.0,16.0,23.0,"Swain CJ, Teran A, Maroto M, Cabello A",,424570.0,DTCT0023186,2013611,DTCC00440765,1808536,21789,8.853871964321762,CC(C)(C1CCC1)NC2=NCCNC(=C2)C3=C(C=C(C=C3)F)F,CC(C)(NC1=NCCNC(c2ccc(F)cc2F)=C1)C1CCC1
7017,CHEMBL437,P28223,SULFATHIAZOLE,JNMRHUJNCSQMMB-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7482698,DTCC00133961,1027059,46191,,C1=CC(=CC=C1N)S(=O)(=O)NC2=NC=CS2,Nc1ccc(S(=O)(=O)Nc2nccs2)cc1
7019,CHEMBL437002,P28223,,LEVTWCPGXIVKEH-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7294381,DTCC00473690,1734052,46191,,C1CN(CCC1CC2=CC=CC=C2)C(=O)C3=CC=CC=C3F,O=C(c1ccccc1F)N1CCC(Cc2ccccc2)CC1
7023,CHEMBL437147,P28223,,FIQYTMTZEUGCAK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16971119.0,IC50,=,1515.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human 5HT2A receptor expressed in CHOK1 cells,,"Identification and optimisation of 5-amino-7-aryldihydro-1,4-diazepines as 5-HT2A ligands.",Bioorg. Med. Chem. Lett.,2006.0,16.0,23.0,"Swain CJ, Teran A, Maroto M, Cabello A",,424570.0,DTCT0023186,2013614,DTCC00440747,488524,21789,5.8195873671616765,CC(C)(C)CNC1=NCCNC(=C1)C2=CC=CC=C2F,CC(C)(C)CNC1=NCCNC(c2ccccc2F)=C1
7026,CHEMBL438,P28223,SULFAMERAZINE,QPPBRPIAZZHUNT-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7486782,DTCC00133994,1798418,46191,,CC1=NC(=NC=C1)NS(=O)(=O)C2=CC=C(C=C2)N,Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1
7032,CHEMBL438755,P28223,,VRMULSJRQNKWMK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,10000.0,NM,,,,,,,,,,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,,Bioorg. Med. Chem. Lett.,1996.0,6.0,10.0,,,2462.0,DTCT0023186,1281043,DTCC00139236,305541,1628,5.0,CCCN1CCN(C2(C1)CC3=C(C=CC=C3OC)OC2)CCC,CCCN1CCN(CCC)C2(COc3cccc(OC)c3C2)C1
7033,CHEMBL43882,P28223,TRICHLOROETHANE,UBOXGVDOUJQMTN-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7453567,DTCC00104711,1830694,46191,,C(C(Cl)Cl)Cl,ClCC(Cl)Cl
7037,CHEMBL439,P28223,SULFADIAZINE,SEEPANYCNGTZFQ-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7473865,DTCC00133995,1734063,46191,,C1=CN=C(N=C1)NS(=O)(=O)C2=CC=C(C=C2)N,Nc1ccc(S(=O)(=O)Nc2ncccn2)cc1
7046,CHEMBL44,P28223,GENISTEIN,TZBJGXHYKVUXJN-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,10469.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7303831,DTCC00134437,2089749,46191,4.980094800195386,C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12
7059,CHEMBL441687,P28223,GLYCYRRHIZIN,LPLVUJXQOOQHMX-QWBHMCJMSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7316807,DTCC00424760,1992805,46191,,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O[C@@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)C(=O)O)O)O)O)C)(C)C(=O)O,CC1(C)[C@@H](O[C@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@@](C)(C(=O)O)CC[C@]3(C)CC[C@]21C
7064,CHEMBL442,P28223,ERGOTAMINE,XCGSFFUVFURLIX-VFGNJEKYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,6.49,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7332580,DTCC00134058,1027052,46191,8.18775530319963,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21
7070,CHEMBL442923,P28223,,HJIWIMXZBPSSTO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,575.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789539,DTCC00514383,371226,31612,6.2403321553103694,CNCC1=C(C=CC(=C1)F)OC2=CC(=C(C=C2)F)Cl,CNCc1cc(F)ccc1Oc1ccc(F)c(Cl)c1
7071,CHEMBL443,P28223,SULFAMETHOXAZOLE,JLKIGFTWXXRPMT-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7465301,DTCC00134101,315670,46191,,CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N,Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1
7079,CHEMBL443922,P28223,,RUEHEMMKOYGDGT-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,144.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789501,DTCC00514072,2047953,31612,6.841637507904751,CN(C)CC1=CC=CC=C1OC2=CC(=C(C=C2)Cl)Cl,CN(C)Cc1ccccc1Oc1ccc(Cl)c(Cl)c1
7081,CHEMBL444203,P28223,,WJHPAIHCWWZGFM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,206.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789524,DTCC00514253,240216,31612,6.686132779630847,CC(C1=C(C=CC(=C1)F)OC2=CC=C(C=C2)Cl)NC,CNC(C)c1cc(F)ccc1Oc1ccc(Cl)cc1
7083,CHEMBL444633,P28223,RIFABUTIN,ATEBXHFBFRCZMA-VXTBVIBXSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7477270,DTCC00465352,1092349,46191,,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)O[C@@](C4=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C5=NC6(CCN(CC6)CC(C)C)N=C25)O)/C,CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(c4c3C2=O)=NC2(CCN(CC(C)C)CC2)N=5)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C
7087,CHEMBL445,P28223,NORTRIPTYLINE,PHVGLTMQBUFIQQ-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,51.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7401500,DTCC00134116,1092345,46191,7.292429823902063,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCC=C1c2ccccc2CCc2ccccc21
7096,CHEMBL445206,P28223,ISOEUGENOL,BJIOGJUNALELMI-ARJAWSKDSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7431122,DTCC00115215,1830686,46191,,C/C=C\C1=CC(=C(C=C1)O)OC,C/C=C\c1ccc(O)c(OC)c1
7104,CHEMBL445754,P28223,,VHFYWGRJQKGNOJ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,58.1,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789563,DTCC00513566,1049673,31612,7.235823867609669,CNCC1=C(C=C(C=C1)Cl)OC2=CC(=C(C=C2)Cl)F,CNCc1ccc(Cl)cc1Oc1ccc(Cl)c(F)c1
7106,CHEMBL446,P28223,SULFAMETHAZINE,ASWVTGNCAZCNNR-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7456530,DTCC00134119,574627,46191,,CC1=CC(=NC(=N1)NS(=O)(=O)C2=CC=C(C=C2)N)C,Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1
7108,CHEMBL44618,P28223,CHLOROFORM,HEDRZPFGACZZDS-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7360280,DTCC00187868,1383774,46191,,C(Cl)(Cl)Cl,ClC(Cl)Cl
7110,CHEMBL44657,P28223,ETOPOSIDE,VJJPUSNTGOMMGY-MRVIYFEKSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7337102,DTCC00188464,51468,46191,,C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O,COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O
7113,CHEMBL447,P28223,SECOBARBITAL,KQPKPCNLIDLUMF-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7458192,DTCC00134177,1862719,46191,,CCCC(C)C1(C(=O)NC(=O)NC1=O)CC=C,C=CCC1(C(C)CCC)C(=O)NC(=O)NC1=O
7115,CHEMBL447733,P28223,,AWYCWRNBPPRCNF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789511,DTCC00514129,564977,31612,6.0,CN(C)CC1=CC=CC=C1OC2=CC(=C(C=C2)F)F,CN(C)Cc1ccccc1Oc1ccc(F)c(F)c1
7116,CHEMBL447864,P28223,,VLILXOARRQRILJ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,1.18,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789548,DTCC00514445,1853077,31612,8.928117992693874,CC1=CC=C(C=C1)OC2=C(C=CC(=C2)Cl)CNC,CNCc1ccc(Cl)cc1Oc1ccc(C)cc1
7117,CHEMBL44814,P28223,CARBON TETRACHLORIDE,VZGDMQKNWNREIO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7353447,DTCC00187852,1512806,46191,,C(Cl)(Cl)(Cl)Cl,ClC(Cl)(Cl)Cl
7120,CHEMBL448461,P28223,,QLVUBIIDSKNVLZ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,2010.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789538,DTCC00514382,1982843,31612,5.696803942579511,CNCC1=C(C=CC(=C1)F)OC2=CC(=C(C=C2)Cl)F,CNCc1cc(F)ccc1Oc1ccc(Cl)c(F)c1
7121,CHEMBL44884,P28223,ETHAMBUTOL,AEUTYOVWOVBAKS-UWVGGRQHSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7328429,DTCC00187691,381010,46191,,CC[C@@H](CO)NCCN[C@@H](CC)CO,CC[C@@H](CO)NCCN[C@@H](CC)CO
7126,CHEMBL449048,P28223,,LUADZZDXMMUMIJ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,48.6,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789559,DTCC00513562,143577,31612,7.313363730737707,CNCC1=C(C=C(C=C1)Cl)OC2=CC(=CC=C2)Cl,CNCc1ccc(Cl)cc1Oc1cccc(Cl)c1
7130,CHEMBL449542,P28223,,FAHALPZKMLQCNC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,47.1,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789550,DTCC00514447,1853078,31612,7.326979092871104,CCC1=C(C=CC(=C1)OC2=C(C=CC(=C2)Cl)CNC)Cl,CCc1cc(Oc2cc(Cl)ccc2CNC)ccc1Cl
7136,CHEMBL45,P28223,MELATONIN,DRLFMBDRBRZALE-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7419289,DTCC00134723,50368,46191,,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,COc1ccc2[nH]cc(CCNC(C)=O)c2c1
7142,CHEMBL450714,P28223,,OTZOXYLBDMECOK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,458.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789507,DTCC00514077,1017264,31612,6.339134521996131,CN(C)CC1=CC=CC=C1OC2=CC=C(C=C2)SC,CSc1ccc(Oc2ccccc2CN(C)C)cc1
7143,CHEMBL451,P28223,CHLORDIAZEPOXIDE,ANTSCNMPPGJYLG-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7351626,DTCC00134272,574622,46191,,CN=C1CN(C(=C2C=C(C=CC2=N1)Cl)C3=CC=CC=C3)O,CN=C1CN(O)C(c2ccccc2)=c2cc(Cl)ccc2=N1
7145,CHEMBL451076,P28223,,ZPJJDPPFWWSPPB-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,3180.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789530,DTCC00514315,175665,31612,5.497572880015567,CNCC1=C(C=CC(=C1)C#N)OC2=CC(=C(C=C2)Cl)Cl,CNCc1cc(C#N)ccc1Oc1ccc(Cl)c(Cl)c1
7146,CHEMBL451137,P28223,,WJQHBBMQIFJYHD-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,66.8,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789526,DTCC00514255,404164,31612,7.175223537524454,CNCC1=C(C=C(C=C1)Br)OC2=CC(=C(C=C2)Cl)Cl,CNCc1ccc(Br)cc1Oc1ccc(Cl)c(Cl)c1
7147,CHEMBL451178,P28223,,WNUWIJYSIXZFML-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,2240.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789506,DTCC00514076,404161,31612,5.649751981665837,CN(C)CC1=C(C=CC(=C1)CC(=O)N)OC2=CC(=C(C=C2)Cl)Cl,CN(C)Cc1cc(CC(N)=O)ccc1Oc1ccc(Cl)c(Cl)c1
7151,CHEMBL451330,P28223,,AUAYVYITDWOTFU-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,9.11,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789557,DTCC00514512,143587,31612,8.040481623027002,CC1=C(C=C(C=C1)OC2=C(C=CC(=C2)Cl)CNC)Cl,CNCc1ccc(Cl)cc1Oc1ccc(C)c(Cl)c1
7157,CHEMBL452,P28223,CLONAZEPAM,DGBIGWXXNGSACT-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7337304,DTCC00134302,574623,46191,,C1C(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3Cl,O=C1CN=C(c2ccccc2Cl)c2cc([N+](=O)[O-])ccc2N1
7160,CHEMBL452091,P28223,,OYPUPHAIQNBOIY-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,9.04,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789558,DTCC00513561,2047945,31612,8.043831569524636,CC1=C(C=CC(=C1)OC2=C(C=CC(=C2)Cl)CNC)Cl,CNCc1ccc(Cl)cc1Oc1ccc(Cl)c(C)c1
7162,CHEMBL45245,P28223,PHENANTHRIDIN-6(5H)-ONE,RZFVLEJOHSLEFR-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7284022,DTCC01739960,2057642,46191,,C1=CC=C2C(=C1)C3=CC=CC=C3NC2=O,O=c1[nH]c2ccccc2c2ccccc12
7168,CHEMBL452861,P28223,(-)-PROPANOLOL ,AQHHHDLHHXJYJD-AWEZNQCLSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,1883.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7471069,DTCC00515151,1253328,46191,5.7251496799833355,CC(C)NC[C@@H](COC1=CC=CC2=CC=CC=C21)O,CC(C)NC[C@H](O)COc1cccc2ccccc12
7170,CHEMBL453,P28223,SULFISOXAZOLE,NHUHCSRWZMLRLA-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7456671,DTCC00134318,477922,46191,,CC1=C(ON=C1C)NS(=O)(=O)C2=CC=C(C=C2)N,Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C
7172,CHEMBL453023,P28223,,IAORVHGBICJISE-STYPWORHSA-M,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,9182127.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,Displacement of radioligand from 5HT2 receptor by liquid scintillation spectrometry,,"Perhydrogenation of tabersonine, ans Aspidiosperma indole alkaloid.",J. Nat. Prod.,1997.0,60.0,4.0,"Lewin G, Schaeffer C, Dacquet C",,549545.0,DTCT0023186,2539164,DTCC00113358,597145,27062,5.0,CC[C@@]12CCCN3[C@@H]1[C@@]4(CC3)[C@H]5CCCC[C@H]5N[C@H]4[C@H](C2)C(=O)[O-].[Na+],CC[C@]12CCCN3CC[C@]4([C@@H](N[C@@H]5CCCC[C@@H]54)[C@@H](C(=O)[O-])C1)[C@@H]32
7176,CHEMBL453630,P28223,,FZIODVGUIQNDEG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,291.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789540,DTCC00514384,1885203,31612,6.536107011014093,CC(C1=C(C=CC(=C1)C(F)(F)F)OC2=CC(=C(C=C2)Cl)Cl)NC,CNC(C)c1cc(C(F)(F)F)ccc1Oc1ccc(Cl)c(Cl)c1
7177,CHEMBL453631,P28223,,ALIKLTHFBZBJOJ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,172.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789541,DTCC00514385,1982844,31612,6.764471553092451,CC1=CC(=C(C=C1)OC2=CC(=C(C=C2)Cl)Cl)C(C)NC,CNC(C)c1cc(C)ccc1Oc1ccc(Cl)c(Cl)c1
7178,CHEMBL453879,P28223,,CPLHAFLWFOQFKD-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,60.9,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789561,DTCC00513564,790777,31612,7.215382707367125,CNCC1=C(C=C(C=C1)Cl)OC2=CC(=C(C=C2)F)Cl,CNCc1ccc(Cl)cc1Oc1ccc(F)c(Cl)c1
7179,CHEMBL453880,P28223,,GHUHMNXJEGXLAR-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,48.9,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789562,DTCC00513565,1820934,31612,7.31069114087638,CNCC1=C(C=C(C=C1)Cl)OC2=CC(=C(C=C2)F)C(F)(F)F,CNCc1ccc(Cl)cc1Oc1ccc(F)c(C(F)(F)F)c1
7180,CHEMBL454288,P28223,,ZQZLOZOZZUMOJF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,74.2,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789509,DTCC00514127,790787,31612,7.129596094720973,CC1=CC=C(C=C1)OC2=CC=CC=C2CN(C)C,Cc1ccc(Oc2ccccc2CN(C)C)cc1
7182,CHEMBL454656,P28223,,IPPWLIAXZPMPOE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,378.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789542,DTCC00514441,1756214,31612,6.422508200162775,CNCC1=C(C=CC(=C1)F)OC2=CC=C(C=C2)C3=CC=CC=C3,CNCc1cc(F)ccc1Oc1ccc(-c2ccccc2)cc1
7183,CHEMBL454657,P28223,,IBQGQTKTKQIZKP-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,74.6,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789544,DTCC00514443,2047956,31612,7.127261172527331,CNCC1=CC(=C(C=C1OC2=CC(=C(C=C2)Cl)Cl)OC)F,CNCc1cc(F)c(OC)cc1Oc1ccc(Cl)c(Cl)c1
7184,CHEMBL455184,P28223,,KUWISOBIRVPNDN-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,32.9,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789560,DTCC00513563,564971,31612,7.482804102050026,CC1=C(C=CC(=C1)OC2=C(C=CC(=C2)Cl)CNC)F,CNCc1ccc(Cl)cc1Oc1ccc(F)c(C)c1
7186,CHEMBL455423,P28223,,BWBOBCUPLKYBOV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,36.8,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789529,DTCC00514314,1950108,31612,7.434152181326482,CN(C)CC1=C(C=C(C=C1)OC)OC2=CC(=C(C=C2)Cl)Cl,COc1ccc(CN(C)C)c(Oc2ccc(Cl)c(Cl)c2)c1
7187,CHEMBL455424,P28223,,DDAOSNKKPKGLIN-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,5570.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789531,DTCC00514316,1599744,31612,5.254144804826271,CNCC1=C(C=CC(=C1)S(=O)(=O)NC)OC2=CC(=C(C=C2)Cl)Cl,CNCc1cc(S(=O)(=O)NC)ccc1Oc1ccc(Cl)c(Cl)c1
7188,CHEMBL455425,P28223,,NPJYROQKHDJYRQ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,79.4,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789532,DTCC00514317,175666,31612,7.100179497572904,CC1=CC(=C(C=C1C)OC2=CC(=C(C=C2)Cl)Cl)CNC,CNCc1cc(C)c(C)cc1Oc1ccc(Cl)c(Cl)c1
7189,CHEMBL455426,P28223,,SVWCQZXWJWYSJD-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,1550.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789534,DTCC00514319,78895,31612,5.809668301829708,CNCC1=C(C=CC(=C1)C(=O)N)OC2=CC(=C(C=C2)Cl)Cl,CNCc1cc(C(N)=O)ccc1Oc1ccc(Cl)c(Cl)c1
7190,CHEMBL455511,P28223,,ARYNSJMHZVVGNH-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,376.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789525,DTCC00514254,2047954,31612,6.424812155072339,CC1=CC(=C(C=C1)OC2=CC(=C(C=C2)Cl)Cl)CN(C)C,Cc1ccc(Oc2ccc(Cl)c(Cl)c2)c(CN(C)C)c1
7191,CHEMBL455675,P28223,,COWKMDDTQXILJL-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,230.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789536,DTCC00514380,694190,31612,6.638272163982407,CNCC1=CC(=C(C=C1OC2=CC(=C(C=C2)Cl)Cl)Cl)F,CNCc1cc(F)c(Cl)cc1Oc1ccc(Cl)c(Cl)c1
7192,CHEMBL456,P28223,ETHACRYNIC ACID,AVOLMBLBETYQHX-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7324109,DTCC00134433,1155679,46191,,CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)O)Cl)Cl,C=C(CC)C(=O)c1ccc(OCC(=O)O)c(Cl)c1Cl
7194,CHEMBL456807,P28223,PHENYLHYDRAZINE,HKOOXMFOFWEVGF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7372200,DTCC00514646,413975,46191,,C1=CC=C(C=C1)NN,NNc1ccccc1
7196,CHEMBL457,P28223,GEMFIBROZIL,HEMJJKBWTPKOJG-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7329408,DTCC00134705,1285875,46191,,CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O,Cc1ccc(C)c(OCCCC(C)(C)C(=O)O)c1
7200,CHEMBL457299,P28223,ETHYLENE GLYCOL,LYCAIKOWRPUZTN-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7315737,DTCC00525050,1383777,46191,,C(CO)O,OCCO
7204,CHEMBL458019,P28223,PARAQUAT DICHLORIDE,FIKAKWIAUPDISJ-UHFFFAOYSA-L,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7376142,DTCC00549932,283000,46191,,C[N+]1=CC=C(C=C1)C2=CC=[N+](C=C2)C.[Cl-].[Cl-],C[n+]1ccc(-c2cc[n+](C)cc2)cc1
7207,CHEMBL459,P28223,METHYLDOPA,CJCSPKMFHVPWAR-JTQLQIEISA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7426032,DTCC00135281,185555,46191,,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N,C[C@](N)(Cc1ccc(O)c(O)c1)C(=O)O
7212,CHEMBL46,P28223,ONDANSETRON,FELGMEQIXOGIFQ-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7405950,DTCC00134875,315668,46191,,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O
7217,CHEMBL460291,P28223,LACIDIPINE,GKQPCPXONLDCMU-CCEZHUSRSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7433569,DTCC00514659,736260,46191,,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2/C=C/C(=O)OC(C)(C)C)C(=O)OCC)C)C,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1c1ccccc1/C=C/C(=O)OC(C)(C)C
7220,CHEMBL460499,P28223,CARMOFUR,AOCCBINRVIKJHY-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7366433,DTCC00515303,51452,46191,,CCCCCCNC(=O)N1C=C(C(=O)NC1=O)F,CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O
7223,CHEMBL461631,P28223,,QDOMMYSGYWUWRB-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,3.54,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789552,DTCC00514507,404168,31612,8.450996737974211,CC1=CC=C(C=C1)OC2=C(C=CC(=C2)Cl)C(C)NC,CNC(C)c1ccc(Cl)cc1Oc1ccc(C)cc1
7224,CHEMBL461727,P28223,AMYGDALIN,XUCIJNAGGSZNQT-JHSLDZJXSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7281809,DTCC00113956,1674140,46191,,C1=CC=C(C=C1)[C@H](C#N)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)O)O,N#C[C@H](O[C@@H]1O[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)c1ccccc1
7227,CHEMBL462225,P28223,,URIPXECKECEIEF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,51.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789554,DTCC00514509,856138,31612,7.292429823902063,CC1=C(C=C(C=C1)OC2=C(C=C(C=C2)Cl)CNC)C,CNCc1cc(Cl)ccc1Oc1ccc(C)c(C)c1
7228,CHEMBL462226,P28223,,VUKSTBYHKMJOPK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,90.2,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789556,DTCC00514511,726487,31612,7.044793462458058,CNCC1=C(C=CC(=C1)Cl)OC2=CC=C(C=C2)Cl,CNCc1cc(Cl)ccc1Oc1ccc(Cl)cc1
7229,CHEMBL462387,P28223,,LIXNFPLJNWIWDI-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,6.59,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789551,DTCC00514506,35572,31612,8.18111458540599,CNCC1=C(C=C(C=C1)Cl)OC2=CC=C(C=C2)Cl,CNCc1ccc(Cl)cc1Oc1ccc(Cl)cc1
7230,CHEMBL462547,P28223,URETHANE,JOYRKODLDBILNP-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7452049,DTCC00513785,1155688,46191,,CCOC(=O)N,CCOC(N)=O
7259,CHEMBL467,P28223,HYDROXYUREA,VSNHCAURESNICA-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7319350,DTCC00136099,1155681,46191,,C(=O)(N)NO,NC(=O)NO
7271,CHEMBL468,P28223,THALIDOMIDE,UEJJHQNACJXSKW-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7461517,DTCC00136280,348406,46191,,C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O,O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1
7276,CHEMBL469,P28223,KETOROLAC,OZWKMVRBQXNZKK-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7439728,DTCC00136324,120972,46191,,C1CN2C(=CC=C2C(=O)C3=CC=CC=C3)C1C(=O)O,O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
7279,CHEMBL469149,P28223,,YTPZPOLQLHGGBC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,19328689.0,IC50,=,4600.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Antagonist activity at human 5HT2A receptor expressed in EC80 serotonin-stimulated CHOK1 cells by calcium mobilization assay,,(+/-)-Nantenine analogs as antagonists at human 5-HT(2A) receptors: C1 and flexible congeners.,Bioorg. Med. Chem. Lett.,2009.0,19.0,9.0,"Chaudhary S, Pecic S, Legendre O, Navarro HA, Harding WW",,500213.0,DTCT0023186,2723313,DTCC00537196,1788668,34192,5.337242168318426,CN1CCC2=CC(=C(C3=C2C1CC4=CC5=C(C=C43)OCO5)OCC6=CC=CC=C6)OC,COc1cc2c3c(c1OCc1ccccc1)-c1cc4c(cc1CC3N(C)CC2)OCO4
7282,CHEMBL469668,P28223,WAY-256805,DJVJRXDBDBMWFD-JPKZNVRTSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18557608.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,Inhibition of 5HT2A receptor by competition radioligand binding assay,,Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.,J. Med. Chem.,2008.0,51.0,13.0,"Mahaney PE, Gavrin LK, Trybulski EJ, Stack GP, Vu TA, Cohn ST, Ye F, Belardi JK, Santilli AA, Sabatucci JP, Leiter J, Johnston GH, Bray JA, Burroughs KD, Cosmi SA, Leventhal L, Koury EJ, Zhang Y, Mugford CA, Ho DM, Rosenzweig-Lipson SJ, Platt B, Smith VA, Deecher DC",,487438.0,DTCT0023186,2657294,DTCC00005224,1458894,30478,5.0,CN1CCN(CC1)C[C@H](C2=CC(=CC=C2)OC(F)(F)F)C3(CCCCC3)O.Cl.Cl,CN1CCN(C[C@H](c2cccc(OC(F)(F)F)c2)C2(O)CCCCC2)CC1
7288,CHEMBL469912,P28223,PUROMYCIN,RXWNCPJZOCPEPQ-NVWDDTSBSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7385916,DTCC00511258,477920,46191,,CN(C)C1=NC=NC2=C1N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)NC(=O)[C@H](CC4=CC=C(C=C4)OC)N)O,COc1ccc(C[C@H](N)C(=O)N[C@@H]2[C@@H](CO)O[C@@H](n3cnc4c(N(C)C)ncnc43)[C@@H]2O)cc1
7290,CHEMBL47,P28223,VITAMIN E,GVJHHUAWPYXKBD-IEOSBIPESA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7300715,DTCC00135004,348395,46191,,CC1=C(C2=C(CC[C@@](O2)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C(=C1O)C)C,Cc1c(C)c2c(c(C)c1O)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2
7292,CHEMBL470432,P28223,,FZGWDCDUMFWUEO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,19261477.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin form human recombinant 5HT2A receptor,,Novel antagonists of serotonin-4 receptors: synthesis and biological evaluation of pyrrolothienopyrazines.,Bioorg. Med. Chem.,2009.0,17.0,6.0,"Lemaître S, Lepailleur A, Bureau R, Butt-Gueulle S, Lelong-Boulouard V, Duchatelle P, Boulouard M, Dumuis A, Daveu C, Lezoualc'h F, Pfeiffer B, Dauphin F, Rault S",,564580.0,DTCT0023186,2613737,DTCC00570224,1082935,33265,5.0,CCCN1CCC(CC1)COC2=NC3=C(C(=CS3)C)N4C2=CC=C4,CCCN1CCC(COc2nc3scc(C)c3n3cccc23)CC1
7293,CHEMBL471,P28223,SOTALOL,ZBMZVLHSJCTVON-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7471434,DTCC00136675,88634,46191,,CC(C)NCC(C1=CC=C(C=C1)NS(=O)(=O)C)O,CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1
7297,CHEMBL471663,P28223,,CZPMNOSNQHHGTD-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,19261477.0,IC50,=,165.96,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin form human recombinant 5HT2A receptor,,Novel antagonists of serotonin-4 receptors: synthesis and biological evaluation of pyrrolothienopyrazines.,Bioorg. Med. Chem.,2009.0,17.0,6.0,"Lemaître S, Lepailleur A, Bureau R, Butt-Gueulle S, Lelong-Boulouard V, Duchatelle P, Boulouard M, Dumuis A, Daveu C, Lezoualc'h F, Pfeiffer B, Dauphin F, Rault S",,564580.0,DTCT0023186,2613031,DTCC00569998,371836,33265,6.779996573843064,CCCCN1CCC(CC1)COC2=NC3=C(N4C2=CC=C4)SC=C3,CCCCN1CCC(COc2nc3ccsc3n3cccc23)CC1
7302,CHEMBL472,P28223,GLYBURIDE,ZNNLBTZKUZBEKO-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7303938,DTCC00136719,51475,46191,,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1
7305,CHEMBL472388,P28223,,VHTSIIQUFKEBDS-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,34.7,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789546,DTCC00514010,1147234,31612,7.459670525209126,CC1=CC=C(C=C1)OC2=C(C=C(C=C2)C(F)(F)F)CNC,CNCc1cc(C(F)(F)F)ccc1Oc1ccc(C)cc1
7306,CHEMBL472389,P28223,,JDHPXUQPTBDLHJ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,670.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789500,DTCC00514011,467956,31612,6.173925197299173,CNCC1=C(C=CC(=C1)F)OC2=CC=CC=C2,CNCc1cc(F)ccc1Oc1ccccc1
7307,CHEMBL47244,P28223,PICROTOXININ,PIMZUZSSNYHVCU-YKWPQBAZSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7343924,DTCC00186559,217577,46191,,CC(=C)[C@@H]1[C@@H]2[C@@H]3[C@@]4([C@]([C@H]1C(=O)O2)(C[C@@H]5[C@]4(O5)C(=O)O3)O)C,C=C(C)[C@H]1[C@@H]2C(=O)O[C@H]1[C@H]1OC(=O)[C@@]34O[C@@H]3C[C@]2(O)[C@@]14C
7386,CHEMBL475121,P28223,,RJGZDIPTAGBJQV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,3.42,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789547,DTCC00514009,1885199,31612,8.465973893943865,CC1=C(C=C(C=C1)OC2=C(C=CC(=C2)Cl)CNC)C,CNCc1ccc(Cl)cc1Oc1ccc(C)c(C)c1
7394,CHEMBL475534,P28223,NITRENDIPINE,PVHUJELLJLJGLN-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7401409,DTCC00514677,88633,46191,,CCOC(=O)C1=C(NC(=C(C1C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC)C)C,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc([N+](=O)[O-])c1
7404,CHEMBL476,P28223,DACARBAZINE,FDKXTQMXEQVLRF-ZHACJKMWSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7361339,DTCC00136858,800573,46191,,CN(C)/N=N/C1=C(NC=N1)C(=O)N,CN(C)/N=N/c1nc[nH]c1C(N)=O
7463,CHEMBL479,P28223,THIORIDAZINE,KLBQZWRITKRQQV-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,4.37,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7461620,DTCC00137035,185558,46191,8.359518563029578,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2
7470,CHEMBL479952,P28223,,BVEOZKOLIKNPKQ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18602261.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from human cloned 5HT2A receptor,,Synthesis and structure-activity relationship of 1H-indole-3-carboxylic acid pyridine-3-ylamides: a novel series of 5-HT2C receptor antagonists.,Bioorg. Med. Chem. Lett.,2008.0,18.0,14.0,"Park CM, Kim SY, Park WK, Park NS, Seong CM",,488684.0,DTCT0023186,2776330,DTCC00525838,175804,30600,6.0,C1=CC=C2C(=C1)C(=CN2)C(=O)NC3=CN=C(C=C3)OC4=CN=CC=C4,O=C(Nc1ccc(Oc2cccnc2)nc1)c1c[nH]c2ccccc12
7471,CHEMBL480,P28223,LANSOPRAZOLE,MJIHNNLFOKEZEW-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7416588,DTCC00137040,1027055,46191,,CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F,Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1
7473,CHEMBL480127,P28223,,ICOOFOPJNLACRM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18602261.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from human cloned 5HT2A receptor,,Synthesis and structure-activity relationship of 1H-indole-3-carboxylic acid pyridine-3-ylamides: a novel series of 5-HT2C receptor antagonists.,Bioorg. Med. Chem. Lett.,2008.0,18.0,14.0,"Park CM, Kim SY, Park WK, Park NS, Seong CM",,488684.0,DTCT0023186,2776333,DTCC00525783,790930,30600,6.0,CC1=CC2=C(C=C1)NC=C2C(=O)NC3=CN=C(C=C3)OC4=C(N=CC=C4)C,Cc1ccc2[nH]cc(C(=O)Nc3ccc(Oc4cccnc4C)nc3)c2c1
7474,CHEMBL480699,P28223,,BOLGHGNEFZUVST-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18602261.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from human cloned 5HT2A receptor,,Synthesis and structure-activity relationship of 1H-indole-3-carboxylic acid pyridine-3-ylamides: a novel series of 5-HT2C receptor antagonists.,Bioorg. Med. Chem. Lett.,2008.0,18.0,14.0,"Park CM, Kim SY, Park WK, Park NS, Seong CM",,488684.0,DTCT0023186,2776332,DTCC00525784,2048086,30600,5.0,CC1=C(C=CC=N1)OC2=NC=C(C=C2)NC(=O)C3=CNC4=C3C=C(C=C4)OC,COc1ccc2[nH]cc(C(=O)Nc3ccc(Oc4cccnc4C)nc3)c2c1
7475,CHEMBL481,P28223,IRINOTECAN,UWKQSNNFCGGAFS-XIFFEERXSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7422552,DTCC00137047,381014,46191,,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC
7493,CHEMBL48449,P28223,CANTHARIDIN,DHZBEENLJMYSHQ-XCVPVQRUSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7274655,DTCC00189104,1544894,46191,,C[C@@]12[C@H]3CC[C@@H]([C@@]1(C(=O)OC2=O)C)O3,C[C@]12C(=O)OC(=O)[C@@]1(C)[C@@H]1CC[C@H]2O1
7502,CHEMBL485259,P28223,EUCALYPTOL,WEEGYLXZBRQIMU-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7307271,DTCC00539560,542575,46191,,CC1(C2CCC(O1)(CC2)C)C,CC12CCC(CC1)C(C)(C)O2
7504,CHEMBL485549,P28223,NIFURSOL,XXUXXCZCUGIGPP-WLRTZDKTSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7375497,DTCC00563507,2057651,46191,,C1=C(OC(=C1)[N+](=O)[O-])/C=N/NC(=O)C2=C(C(=CC(=C2)[N+](=O)[O-])[N+](=O)[O-])O,O=C(N/N=C/c1ccc([N+](=O)[O-])o1)c1cc([N+](=O)[O-])cc([N+](=O)[O-])c1O
7506,CHEMBL487053,P28223,,QFDTVBGMNGXZGK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,87.8,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789508,DTCC00514126,1756211,31612,7.056505484093898,CC(C1=CC=CC=C1OC2=CC(=C(C=C2)Cl)Cl)N(C)C,CC(c1ccccc1Oc1ccc(Cl)c(Cl)c1)N(C)C
7509,CHEMBL487188,P28223,,XNKUKCFVELTTTO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,249.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789528,DTCC00514257,467960,31612,6.603800652904264,CNCC1=CC(=C(C=C1OC2=CC(=C(C=C2)Cl)Cl)OC)OC,CNCc1cc(OC)c(OC)cc1Oc1ccc(Cl)c(Cl)c1
7510,CHEMBL487221,P28223,,LWHZIZQQEKJCCP-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,379.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789520,DTCC00514189,1820943,31612,6.421360790031928,CC(C1=CC=CC=C1OC2=CC(=C(C=C2)Cl)Cl)NC,CNC(C)c1ccccc1Oc1ccc(Cl)c(Cl)c1
7511,CHEMBL487222,P28223,,MNHWUSSFFCLNEP-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,179.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789521,DTCC00514190,1502904,31612,6.747146969020107,CC(C1=CC=CC=C1OC2=CC=C(C=C2)Cl)NC,CNC(C)c1ccccc1Oc1ccc(Cl)cc1
7512,CHEMBL487223,P28223,,JRUPTUARQBYPIN-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,651.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789519,DTCC00514188,175663,31612,6.186419011431808,CNCC1=C(C=C(C=C1)F)OC2=CC(=C(C=C2)Cl)Cl,CNCc1ccc(F)cc1Oc1ccc(Cl)c(Cl)c1
7517,CHEMBL487894,P28223,DIPYRONE SODIUM,DJGAAPFSPWAYTJ-UHFFFAOYSA-M,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7353415,DTCC00513255,1416028,46191,,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N(C)CS(=O)(=O)[O-].[Na+],Cc1c(N(C)CS(=O)(=O)[O-])c(=O)n(-c2ccccc2)n1C
7519,CHEMBL488,P28223,AMINOGLUTETHIMIDE,ROBVIMPUHSLWNV-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7281524,DTCC00137354,477910,46191,,CCC1(CCC(=O)NC1=O)C2=CC=C(C=C2)N,CCC1(c2ccc(N)cc2)CCC(=O)NC1=O
7521,CHEMBL488021,P28223,,QXCZXBWYQMHJNE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,52.4,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789512,DTCC00514130,952600,31612,7.280668713016273,CC1=C(C=C(C=C1)OC2=C(C=C(C=C2)F)CNC)C,CNCc1cc(F)ccc1Oc1ccc(C)c(C)c1
7522,CHEMBL488025,P28223,EXISULIND,MVGSNCBCUWPVDA-MFOYZWKCSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7469777,DTCC00113831,1674151,46191,,CC\1=C(C2=C(/C1=C\C3=CC=C(C=C3)S(=O)(=O)C)C=CC(=C2)F)CC(=O)O,CC1=C(CC(=O)O)c2cc(F)ccc2/C1=C\c1ccc(S(C)(=O)=O)cc1
7524,CHEMBL488060,P28223,,FQEBOQLYHASAOY-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,206.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789503,DTCC00514073,1275937,31612,6.686132779630847,CNCC1=C(C=CC(=C1)F)OC2=CC(=C(C=C2)Cl)Cl,CNCc1cc(F)ccc1Oc1ccc(Cl)c(Cl)c1
7525,CHEMBL488069,P28223,,AAQZZAVVFRIEOD-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,41.5,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789510,DTCC00514128,694186,31612,7.3819519032879075,CN(C)CC1=C(C=C(C=C1)C(F)(F)F)OC2=CC(=C(C=C2)Cl)Cl,CN(C)Cc1ccc(C(F)(F)F)cc1Oc1ccc(Cl)c(Cl)c1
7526,CHEMBL488241,P28223,,ADJFMCUPDBBCOE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,66.4,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789513,DTCC00514131,1114809,31612,7.1778319206319825,CC1=C(C=C(C=C1)OC2=CC=CC=C2CNC)C,CNCc1ccccc1Oc1ccc(C)c(C)c1
7527,CHEMBL488242,P28223,,RIJHAFWKICFLDW-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,1050.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789514,DTCC00514132,371223,31612,5.978810700930062,CNCC1=CC=CC=C1OC2=CC=C(C=C2)Cl,CNCc1ccccc1Oc1ccc(Cl)cc1
7528,CHEMBL488260,P28223,,ONXYECUKUIZIBT-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,362.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789516,DTCC00514185,404163,31612,6.441291429466834,CNCC1=C(C=C(C=C1)C(F)(F)F)OC2=CC(=C(C=C2)Cl)Cl,CNCc1ccc(C(F)(F)F)cc1Oc1ccc(Cl)c(Cl)c1
7529,CHEMBL488261,P28223,,KGEKHVCIFGADFG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,89.5,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789517,DTCC00514186,2080068,31612,7.048176964684088,CNCC1=C(C=C(C=C1)Cl)OC2=CC(=C(C=C2)Cl)Cl,CNCc1ccc(Cl)cc1Oc1ccc(Cl)c(Cl)c1
7530,CHEMBL488434,P28223,,PMXOUAJLQYBUOO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,495.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789523,DTCC00514252,1535269,31612,6.305394801066432,CNCC1=C(C=CC(=C1)F)OC2=CC=C(C=C2)Cl,CNCc1cc(F)ccc1Oc1ccc(Cl)cc1
7531,CHEMBL488435,P28223,,XKFGLVWDKDNTGI-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,787.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789527,DTCC00514256,1178168,31612,6.104025267640935,CNCC1=C(C=CC(=C1)Br)OC2=CC(=C(C=C2)Cl)Cl,CNCc1cc(Br)ccc1Oc1ccc(Cl)c(Cl)c1
7532,CHEMBL488437,P28223,,HYLYTRKKGFVHIE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,301.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789518,DTCC00514187,1853072,31612,6.521433504406157,CC(C1=C(C=CC(=C1)F)OC2=CC(=C(C=C2)Cl)Cl)NC,CNC(C)c1cc(F)ccc1Oc1ccc(Cl)c(Cl)c1
7533,CHEMBL488911,P28223,,NMVPOKRBXPYPSQ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,724.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789504,DTCC00514074,467957,31612,6.140261433802853,CN(C)CC1=C(C=CC(=C1)N)OC2=CC(=C(C=C2)Cl)Cl,CN(C)Cc1cc(N)ccc1Oc1ccc(Cl)c(Cl)c1
7534,CHEMBL488912,P28223,,CPHHHCKJXRNBLC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,721.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789505,DTCC00514075,1178167,31612,6.142064735280571,CNCC1=CC=CC=C1OC2=CC(=C(C=C2)Cl)Cl,CNCc1ccccc1Oc1ccc(Cl)c(Cl)c1
7541,CHEMBL49,P28223,BUSPIRONE,QWCRAEMEVRGPNT-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,2286.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7266146,DTCC00135177,120970,46191,5.640923773940737,C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1
7547,CHEMBL490,P28223,PAROXETINE,AHOUBRCZNHFOSL-YOEHRIQHSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7380444,DTCC00137638,1188071,46191,,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1
7555,CHEMBL49080,P28223,CLENBUTEROL,STJMRWALKKWQGH-UHFFFAOYSA-N,1,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7345728,DTCC00193265,1155678,46191,,CC(C)(C)NCC(C1=CC(=C(C(=C1)Cl)N)Cl)O,CC(C)(C)NCC(O)c1cc(Cl)c(N)c(Cl)c1
7583,CHEMBL493,P28223,BROMOCRIPTINE,OZVBMTJYIDMWIL-AYFBDAFISA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,36.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7274433,DTCC00137993,1544893,46191,7.443697499232713,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
7595,CHEMBL493625,P28223,,CKRQXBZZTZEABO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18456500.0,IC50,=,352.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in CHOK1 cell membrane,,Preparation of piperazine derivatives as 5-HT7 receptor antagonists.,Bioorg. Med. Chem.,2008.0,16.0,10.0,"Yoon J, Yoo EA, Kim JY, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,556690.0,DTCT0023186,2557298,DTCC00541424,888631,28856,6.453457336521869,COC1=CC=C(C=C1)S(=O)(=O)NCCCN2CCN(CC2)C3=CC=CC(=C3)C(F)(F)F,COc1ccc(S(=O)(=O)NCCCN2CCN(c3cccc(C(F)(F)F)c3)CC2)cc1
7598,CHEMBL493816,P28223,,ZHZAXFCAXCANQE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18456500.0,IC50,=,74.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in CHOK1 cell membrane,,Preparation of piperazine derivatives as 5-HT7 receptor antagonists.,Bioorg. Med. Chem.,2008.0,16.0,10.0,"Yoon J, Yoo EA, Kim JY, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,556690.0,DTCT0023186,2557311,DTCC00541491,726812,28856,7.130768280269024,COC1=CC=C(C=C1)S(=O)(=O)NCCCN2CCN(CC2)C3=CC=C(C=C3)F,COc1ccc(S(=O)(=O)NCCCN2CCN(c3ccc(F)cc3)CC2)cc1
7611,CHEMBL495212,P28223,,SBUQDLLDTGCUFS-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18456500.0,IC50,=,19.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in CHOK1 cell membrane,,Preparation of piperazine derivatives as 5-HT7 receptor antagonists.,Bioorg. Med. Chem.,2008.0,16.0,10.0,"Yoon J, Yoo EA, Kim JY, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,556690.0,DTCT0023186,2557308,DTCC00540786,985258,28856,7.721246399047171,C1CN(CCN1CCCNS(=O)(=O)C2=CC3=CC=CC=C3C=C2)C4=CC(=C(C=C4)Cl)Cl,O=S(=O)(NCCCN1CCN(c2ccc(Cl)c(Cl)c2)CC1)c1ccc2ccccc2c1
7612,CHEMBL495250,P28223,,ARWQQHFFCBOLCO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18456500.0,IC50,=,1824.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in CHOK1 cell membrane,,Preparation of piperazine derivatives as 5-HT7 receptor antagonists.,Bioorg. Med. Chem.,2008.0,16.0,10.0,"Yoon J, Yoo EA, Kim JY, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,556690.0,DTCT0023186,2557307,DTCC00540944,1567549,28856,5.738975166007602,CC(CCN1CCN(CC1)C2=CC=CC(=C2)C(F)(F)F)NS(=O)(=O)C3=CC=C(C=C3)OC,COc1ccc(S(=O)(=O)NC(C)CCN2CCN(c3cccc(C(F)(F)F)c3)CC2)cc1
7613,CHEMBL495678,P28223,,PVIMMAOWNLCQJD-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18456500.0,IC50,=,95.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in CHOK1 cell membrane,,Preparation of piperazine derivatives as 5-HT7 receptor antagonists.,Bioorg. Med. Chem.,2008.0,16.0,10.0,"Yoon J, Yoo EA, Kim JY, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,556690.0,DTCT0023186,2557310,DTCC00541603,1664638,28856,7.022276394711152,C1CN(CCN1CCCNS(=O)(=O)C2=CC3=CC=CC=C3C=C2)C4=CC=CC(=C4)C(F)(F)F,O=S(=O)(NCCCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1ccc2ccccc2c1
7614,CHEMBL495778,P28223,PENICILLIC ACID,YCOFRPYSZKIPBQ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7372009,DTCC00115404,866022,46191,,CC(=C)C1(C(=CC(=O)O1)OC)O,C=C(C)C1(O)OC(=O)C=C1OC
7616,CHEMBL496,P28223,HEXACHLOROPHENE,ACGUYXCXAPNIKK-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7314984,DTCC00138998,1765973,46191,,C1=C(C(=C(C(=C1Cl)Cl)CC2=C(C(=CC(=C2Cl)Cl)Cl)O)O)Cl,Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl
7626,CHEMBL497749,P28223,,YRVKJIDCHIEELY-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18456500.0,IC50,=,85.0,NM,,cell_based,,,,,,,,,,,,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in CHOK1 cell membrane,,Preparation of piperazine derivatives as 5-HT7 receptor antagonists.,Bioorg. Med. Chem.,2008.0,16.0,10.0,"Yoon J, Yoo EA, Kim JY, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,556690.0,DTCT0023186,2557309,DTCC00541605,791107,28856,7.070581074285707,COC1=CC=CC=C1N2CCN(CC2)CCCNS(=O)(=O)C3=CC4=CC=CC=C4C=C3,COc1ccccc1N1CCN(CCCNS(=O)(=O)c2ccc3ccccc3c2)CC1
7630,CHEMBL498,P28223,CHLORPROPAMIDE,RKWGIWYCVPQPMF-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7338843,DTCC00139298,1253319,46191,,CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl,CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1
7635,CHEMBL498847,P28223,SECNIDAZOLE,KPQZUUQMTUIKBP-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7488412,DTCC00550707,1765980,46191,,CC1=NC=C(N1CC(C)O)[N+](=O)[O-],Cc1ncc([N+](=O)[O-])n1CC(C)O
7639,CHEMBL499,P28223,TIMOLOL,BLJRIMJGRPQVNF-JTQLQIEISA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7483375,DTCC00139310,1894976,46191,,CC(C)(C)NC[C@@H](COC1=NSN=C1N2CCOCC2)O,CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1
7641,CHEMBL499815,P28223,ATRACTYLOSIDE,IUCNQFHEWLYECJ-CXCSZTQTSA-L,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7269369,DTCC00539373,1765970,46191,,CC(C)CC(=O)O[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O[C@@H]2C[C@H]([C@H]3CC[C@@]45C[C@@H](CCC4[C@@]3(C2)C)C(=C)[C@H]5O)C(=O)O)CO)OS(=O)(=O)[O-])OS(=O)(=O)[O-].[K+].[K+],C=C1[C@@H]2CCC3[C@]4(C)C[C@H](O[C@@H]5O[C@H](CO)[C@@H](OS(=O)(=O)[O-])[C@H](OS(=O)(=O)[O-])[C@H]5OC(=O)CC(C)C)C[C@@H](C(=O)O)[C@H]4CC[C@]3(C2)[C@@H]1O
7645,CHEMBL500,P28223,PINDOLOL,JZQKKSLKJUAGIC-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7389479,DTCC00139321,736265,46191,,CC(C)NCC(COC1=CC=CC2=C1C=CN2)O,CC(C)NCC(O)COc1cccc2[nH]ccc12
7649,CHEMBL500329,P28223,,DKXDRPCDKRMICS-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,105.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789537,DTCC00514381,1470625,31612,6.978810700930062,CNCC1=C(C=C(C=C1)OC)OC2=CC(=C(C=C2)Cl)Cl,CNCc1ccc(OC)cc1Oc1ccc(Cl)c(Cl)c1
7653,CHEMBL501235,P28223,SINAPIC ACID METHYL ETHER,YTFVRYKNXDADBI-SNAWJCMRSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,19555163.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0023186,14720949,DTCC00525198,2102148,68228,5.0,COC1=CC(=CC(=C1OC)OC)/C=C/C(=O)O,COc1cc(/C=C/C(=O)O)cc(OC)c1OC
7661,CHEMBL502620,P28223,ACLARUBICIN,USZYSDMBJDPRIF-SVEJIMAYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7284137,DTCC00522599,1383771,46191,,CC[C@]1(C[C@@H](C2=C(C3=C(C=C2[C@H]1C(=O)OC)C(=O)C4=C(C3=O)C(=CC=C4)O)O)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@@H]([C@@H](O6)C)O[C@H]7CCC(=O)[C@@H](O7)C)O)N(C)C)O,CC[C@@]1(O)C[C@H](O[C@H]2C[C@H](N(C)C)[C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4CCC(=O)[C@H](C)O4)[C@H](C)O3)[C@H](C)O2)c2c(cc3c(c2O)C(=O)c2c(O)cccc2C3=O)[C@H]1C(=O)OC
7663,CHEMBL502896,P28223,CETRAXATE HYDROCHLORIDE,USROQQUKEBHOFF-SKKCDYJJSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7368889,DTCC00521861,477913,46191,,C1CC(CCC1CN)C(=O)OC2=CC=C(C=C2)CCC(=O)O.Cl,NCC1CCC(C(=O)Oc2ccc(CCC(=O)O)cc2)CC1
7667,CHEMBL503,P28223,LOVASTATIN,PCZOHLXUXFIOCF-BXMDZJJMSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7414745,DTCC00140133,1480347,46191,,CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21
7670,CHEMBL504,P28223,DIMETHYL SULFOXIDE,IAZDPXIOMUYVGZ-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7338264,DTCC00140586,1798409,46191,,CS(=O)C,C[S+](C)[O-]
7675,CHEMBL504760,P28223,CAMPHOR,DSSYKIVIOFKYAU-XCBNKYQSSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7352718,DTCC00113446,217578,46191,,C[C@@]12CC[C@@H](C1(C)C)CC2=O,CC1(C)[C@@H]2CC[C@@]1(C)C(=O)C2
7677,CHEMBL505091,P28223,,MRDDAOFLRIQUHE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,429.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789555,DTCC00514510,1438190,31612,6.367542707815276,CNCC1=C(C=CC(=C1)Cl)OC2=CC(=C(C=C2)Cl)Cl,CNCc1cc(Cl)ccc1Oc1ccc(Cl)c(Cl)c1
7679,CHEMBL50588,P28223,EMETINE,AUVVAXYIELKVAI-CKBKHPSWSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7319652,DTCC00195239,216401,46191,,CC[C@H]1CN2CCC3=CC(=C(C=C3[C@@H]2C[C@@H]1C[C@@H]4C5=CC(=C(C=C5CCN4)OC)OC)OC)OC,CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21
7681,CHEMBL506,P28223,PRIMAQUINE,INDBQLZJXZLFIT-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7374825,DTCC00140892,1155686,46191,,CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2,COc1cc(NC(C)CCCN)c2ncccc2c1
7683,CHEMBL506247,P28223,TANNIC ACID,LRBQNJMCXXYXIU-PPKXGCFTSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7467757,DTCC00524002,444643,46191,,C1=C(C=C(C(=C1O)O)O)C(=O)OC2=CC(=CC(=C2O)O)C(=O)OC[C@@H]3[C@H]([C@@H]([C@H]([C@@H](O3)OC(=O)C4=CC(=C(C(=C4)OC(=O)C5=CC(=C(C(=C5)O)O)O)O)O)OC(=O)C6=CC(=C(C(=C6)OC(=O)C7=CC(=C(C(=C7)O)O)O)O)O)OC(=O)C8=CC(=C(C(=C8)OC(=O)C9=CC(=C(C(=C9)O)O)O)O)O)OC(=O)C1=CC(=C(C(=C1)OC(=O)C1=CC(=C(C(=C1)O)O)O)O)O,O=C(OC[C@H]1O[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H]1OC(=O)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1
7689,CHEMBL506736,P28223,,VLFJECXUHXIQBJ-HNNXBMFYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,19346128.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor,,Synthesis and SAR of tolylamine 5-HT6 antagonists.,Bioorg. Med. Chem. Lett.,2009.0,19.0,9.0,"Singer JM, Wilson MW, Johnson PD, Graham SR, Cooke LW, Roof RL, Boxer PA, Gold LH, Meltzer LT, Janssen A, Roush N, Campbell JE, Su TZ, Hurst SI, Stoner CL, Schwarz JB",,501448.0,DTCT0023186,2730579,DTCC00569475,1983466,34022,6.0,CC1=C(C=CC=C1O[C@@H](C)C2=CC(=CC=C2)F)C3CCNCC3,Cc1c(O[C@@H](C)c2cccc(F)c2)cccc1C1CCNCC1
7692,CHEMBL507075,P28223,,OJLXPNXGJXIUAY-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,324.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789545,DTCC00514444,1470626,31612,6.489454989793388,CNCC1=C(C=C(C=C1)C(F)(F)F)OC2=CC=C(C=C2)Cl,CNCc1ccc(C(F)(F)F)cc1Oc1ccc(Cl)cc1
7693,CHEMBL507721,P28223,,YPHRWQVQSQXYJT-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,274.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789549,DTCC00514446,1725992,31612,6.562249437179612,CCC1=C(C=CC(=C1)OC2=C(C=C(C=C2)F)CNC)Cl,CCc1cc(Oc2ccc(F)cc2CNC)ccc1Cl
7695,CHEMBL507884,P28223,,VXVOMNFSZSXTSE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789535,DTCC00514379,1082283,31612,5.7447274948966935,CNCC1=C(C=CC(=C1)C(F)(F)F)OC2=CC(=C(C=C2)Cl)Cl,CNCc1cc(C(F)(F)F)ccc1Oc1ccc(Cl)c(Cl)c1
7697,CHEMBL508102,P28223,CARBIMAZOLE,CFOYWRHIYXMDOT-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7260535,DTCC00566137,1351108,46191,,CCOC(=O)N1C=CN(C1=S)C,CCOC(=O)n1ccn(C)c1=S
7699,CHEMBL508112,P28223,BENZOTHIAZYL DISULFIDE,AFZSMODLJJCVPP-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7275491,DTCC00534219,606967,46191,,C1=CC=C2C(=C1)N=C(S2)SSC3=NC4=CC=CC=C4S3,c1ccc2sc(SSc3nc4ccccc4s3)nc2c1
7701,CHEMBL508192,P28223,,OOXDLOHZHJLEFV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,55.1,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789515,DTCC00514184,920194,31612,7.258848401148215,CC1=CC=C(C=C1)OC2=CC=CC=C2C(C)NC,CNC(C)c1ccccc1Oc1ccc(C)cc1
7707,CHEMBL509,P28223,MECLOFENAMIC ACID,SBDNJUWAMKYJOX-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7432014,DTCC00140998,510304,46191,,CC1=C(C(=C(C=C1)Cl)NC2=CC=CC=C2C(=O)O)Cl,Cc1ccc(Cl)c(Nc2ccccc2C(=O)O)c1Cl
7711,CHEMBL509387,P28223,(-)-TABERSONINE HCL,BFVXDLZRORZNHX-OCIDDWSYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,9182127.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,Displacement of radioligand from 5HT2 receptor by liquid scintillation spectrometry,,"Perhydrogenation of tabersonine, ans Aspidiosperma indole alkaloid.",J. Nat. Prod.,1997.0,60.0,4.0,"Lewin G, Schaeffer C, Dacquet C",,549545.0,DTCT0023186,2539163,DTCC00004852,1406207,27062,5.0,CC[C@@]12CCCN3[C@@H]1[C@@]4(CC3)C5=CC=CC=C5NC4=C(C2)C(=O)OC.Cl,CC[C@]12CCCN3CC[C@]4(C(=C(C(=O)OC)C1)Nc1ccccc14)[C@@H]32
7731,CHEMBL51,P28223,KETANSERIN,FPCCSQOGAWCVBH-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18588282.0,IC50,=,13.0,NM,,,,,,,,,,,,,,Inhibition of human 5HT2A receptor,,"Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.",J. Med. Chem.,2008.0,51.0,14.0,"Grice CA, Tays KL, Savall BM, Wei J, Butler CR, Axe FU, Bembenek SD, Fourie AM, Dunford PJ, Lundeen K, Coles F, Xue X, Riley JP, Williams KN, Karlsson L, Edwards JP",,488292.0,DTCT0023186,2775811,DTCC00135242,36059,30579,7.886056647693163,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O,O=C(c1ccc(F)cc1)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1
7733,CHEMBL51,P28223,KETANSERIN,FPCCSQOGAWCVBH-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18983139.0,IC50,=,2.5,NM,,,,,,,,,,,,,,Displacement of radiolabeled ketanserin from human 5HT2A receptor,,"cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.",J. Med. Chem.,2008.0,51.0,22.0,"Liu H, Altenbach RJ, Carr TL, Chandran P, Hsieh GC, Lewis LG, Manelli AM, Milicic I, Marsh KC, Miller TR, Strakhova MI, Vortherms TA, Wakefield BD, Wetter JM, Witte DG, Honore P, Esbenshade TA, Brioni JD, Cowart MD",,494482.0,DTCT0023186,2604407,DTCC00135242,15062,32034,8.602059991327963,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O,O=C(c1ccc(F)cc1)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1
7735,CHEMBL51,P28223,KETANSERIN,FPCCSQOGAWCVBH-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,19328689.0,IC50,=,32.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Antagonist activity at human 5HT2A receptor expressed in EC80 serotonin-stimulated CHOK1 cells by calcium mobilization assay,,(+/-)-Nantenine analogs as antagonists at human 5-HT(2A) receptors: C1 and flexible congeners.,Bioorg. Med. Chem. Lett.,2009.0,19.0,9.0,"Chaudhary S, Pecic S, Legendre O, Navarro HA, Harding WW",,500213.0,DTCT0023186,2723310,DTCC00135242,36291,34192,7.494850021680094,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O,O=C(c1ccc(F)cc1)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1
7737,CHEMBL51,P28223,KETANSERIN,FPCCSQOGAWCVBH-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20875743.0,IC50,=,2.6,NM,,,,,,,,,,,,,,Inhibition of human 5-HT2A receptor,,"Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: design, synthesis, and structure-activity relationships.",Bioorg. Med. Chem.,2010.0,18.0,21.0,"Hayashi S, Nakata E, Morita A, Mizuno K, Yamamura K, Kato A, Ohashi K",,714800.0,DTCT0023186,5075510,DTCC00135242,15578,43117,8.585026652029182,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O,O=C(c1ccc(F)cc1)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1
7740,CHEMBL51,P28223,KETANSERIN,FPCCSQOGAWCVBH-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23466604.0,IC50,=,0.9,NM,,,,,,,,,,,,,,Binding affinity to human 5-HT2A receptor by radioligand displacement assay,,Synthesis and structure-activity relationship studies in serotonin 5-HT1A receptor agonists based on fused pyrrolidone scaffolds.,Eur. J. Med. Chem.,2013.0,63.0,,"Cappelli A, Manini M, Valenti S, Castriconi F, Giuliani G, Anzini M, Brogi S, Butini S, Gemma S, Campiani G, Giorgi G, Mennuni L, Lanza M, Giordani A, Caselli G, Letari O, Makovec F",,966020.0,DTCT0023186,12471211,DTCC00135242,56691,54801,9.045757490560675,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O,O=C(c1ccc(F)cc1)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1
7743,CHEMBL51,P28223,KETANSERIN,FPCCSQOGAWCVBH-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23582449.0,IC50,=,0.77,NM,,,,,,,,,,,,,,Binding affinity to human 5-HT2A receptor by radioligand displacement assay,,Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.,Bioorg. Med. Chem.,2013.0,21.0,10.0,"Veinberg G, Vorona M, Zvejniece L, Vilskersts R, Vavers E, Liepinsh E, Kazoka H, Belyakov S, Mishnev A, Kuznecovs J, Vikainis S, Orlova N, Lebedev A, Ponomaryov Y, Dambrova M",,964171.0,DTCT0023186,12465313,DTCC00135242,56641,54817,9.113509274827518,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O,O=C(c1ccc(F)cc1)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1
7744,CHEMBL51,P28223,KETANSERIN,FPCCSQOGAWCVBH-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23675993.0,IC50,=,80.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Antagonist activity at 5HT2A receptor (unknown origin) expressed in CHOK1 cells coexpressing Galpha15 assessed as inhibition of agonist-induced response incubated for 60 mins in incubator followed by 15 mins at room temperature by FLIPR assay,,Synthesis and biological investigation of coumarin piperazine (piperidine) derivatives as potential multireceptor atypical antipsychotics.,J. Med. Chem.,2013.0,56.0,11.0,"Chen Y, Wang S, Xu X, Liu X, Yu M, Zhao S, Liu S, Qiu Y, Zhang T, Liu BF, Zhang G",,963044.0,DTCT0023186,12446665,DTCC00135242,56618,54737,7.096910013008056,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O,O=C(c1ccc(F)cc1)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1
7746,CHEMBL51,P28223,KETANSERIN,FPCCSQOGAWCVBH-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,24805037.0,IC50,=,14.0,NM,,,,,,,,,,,,,,Antagonist activity at human recombinant 5-HT2A receptor assessed as inhibition of serotonin-induced inositol phosphate accumulation,,Novel Arylsulfonamide Derivatives with 5-HT6/5-HT7 Receptor Antagonism Targeting Behavioral and Psychological Symptoms of Dementia.,J. Med. Chem.,2014.0,57.0,11.0,"Kolaczkowski M, Marcinkowska M, Bucki A, Pawlowski M, Mitka K, Jaskowska J, Kowalski P, Kazek G, Siwek A, Wasik A, Wesolowska A, Mierzejewski P, Bienkowski P",,1361029.0,DTCT0023186,13779862,DTCC00135242,59253,59370,7.853871964321762,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O,O=C(c1ccc(F)cc1)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1
7749,CHEMBL51,P28223,KETANSERIN,FPCCSQOGAWCVBH-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,25557493.0,IC50,=,11.0,NM,,cell_based,,,,,,,,,,,,Antagonist activity against human recombinant 5-HT2A receptor expressed in CHOK1 cells assessed as reduction in alpha-methylserotonin-induced increase in intracellular Ca2+ levels by aequorin based radiometric and luminescence plate counting method,,Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.,Eur. J. Med. Chem.,2015.0,92.0,,"Kolaczkowski M, Marcinkowska M, Bucki A, Sniecikowska J, Pawlowski M, Kazek G, Siwek A, Jastrzebska-Wiesek M, Partyka A, Wasik A, Wesolowska A, Mierzejewski P, Bienkowski P",,1468778.0,DTCT0023186,14065109,DTCC00135242,60236,61768,7.958607314841775,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O,O=C(c1ccc(F)cc1)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1
7751,CHEMBL51,P28223,KETANSERIN,FPCCSQOGAWCVBH-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26475518.0,IC50,=,32.0,NM,,,,,,,,,,,,,,Antagonist activity at human 5-HT2A receptor assessed as inhibition of 5-HT-mediated internal calcium mobilization by FLIPR assay,,Synthesis and evaluation of aporphine analogs containing C1 allyl isosteres at the h5-HT2A receptor.,Bioorg. Med. Chem. Lett.,2015.0,25.0,22.0,"Ponnala S, Kapadia N, Madapa S, Alberts IL, Harding WW",,1527238.0,DTCT0023186,14599716,DTCC00135242,26778,64247,7.494850021680094,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O,O=C(c1ccc(F)cc1)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1
7752,CHEMBL51,P28223,KETANSERIN,FPCCSQOGAWCVBH-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26988801.0,IC50,=,0.35,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in HEK293 cells,,"Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.",Bioorg. Med. Chem.,2016.0,24.0,8.0,"Waszkielewicz AM, Gunia-Krzyzak A, Powroznik B, Soczynska K, Pekala E, Walczak M, Bednarski M, Zesawska E, Nitek W, Marona H.",,1559792.0,DTCT0023186,117202,DTCC00135242,890,66408,9.455931955649724,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O,O=C(c1ccc(F)cc1)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1
7754,CHEMBL510139,P28223,CITRININ,CQIUKKVOEOPUDV-IYSWYEEDSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7362821,DTCC00525343,249940,46191,,C[C@@H]1[C@H](OC=C2C1=C(C(=C(C2=O)C(=O)O)O)C)C,CC1=C2C(=CO[C@H](C)[C@H]2C)C(=O)C(C(=O)O)=C1O
7760,CHEMBL510435,P28223,,QFWNAKAETMKRTM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,315.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789533,DTCC00514318,1853075,31612,6.501689446210399,CNCC1=C(C=C(C=C1)C#N)OC2=CC(=C(C=C2)Cl)Cl,CNCc1ccc(C#N)cc1Oc1ccc(Cl)c(Cl)c1
7761,CHEMBL511,P28223,PYRILAMINE,YECBIJXISLIIDS-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,997.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7394519,DTCC00141084,1830688,46191,6.001304841688344,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1
7763,CHEMBL511312,P28223,,RZFPSYUVZCCIFI-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,19261477.0,IC50,=,8128.31,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin form human recombinant 5HT2A receptor,,Novel antagonists of serotonin-4 receptors: synthesis and biological evaluation of pyrrolothienopyrazines.,Bioorg. Med. Chem.,2009.0,17.0,6.0,"Lemaître S, Lepailleur A, Bureau R, Butt-Gueulle S, Lelong-Boulouard V, Duchatelle P, Boulouard M, Dumuis A, Daveu C, Lezoualc'h F, Pfeiffer B, Dauphin F, Rault S",,564580.0,DTCT0023186,2613021,DTCC00569996,371835,33265,5.089999741487069,CCN1CCC(CC1)COC2=NC3=C(N4C2=CC=C4)SC=C3,CCN1CCC(COc2nc3ccsc3n3cccc23)CC1
7771,CHEMBL513,P28223,CARMUSTINE,DLGOEMSEDOSKAD-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7370850,DTCC00141242,1383773,46191,,C(CCl)NC(=O)N(CCCl)N=O,O=NN(CCCl)C(=O)NCCCl
7773,CHEMBL513629,P28223,,WWJSYNMBTQKWCP-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,6.82,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789553,DTCC00514508,305960,31612,8.16621562534352,CC1=C(C=C(C=C1)OC2=C(C=CC(=C2)Cl)C(C)NC)C,CNC(C)c1ccc(Cl)cc1Oc1ccc(C)c(C)c1
7777,CHEMBL514,P28223,LOMUSTINE,GQYIWUVLTXOXAJ-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7429674,DTCC00141290,1765975,46191,,C1CCC(CC1)NC(=O)N(CCCl)N=O,O=NN(CCCl)C(=O)NC1CCCCC1
7785,CHEMBL515,P28223,CHLORAMBUCIL,JCKYGMPEJWAADB-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7343065,DTCC00141382,477914,46191,,C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl,O=C(O)CCCc1ccc(N(CCCl)CCCl)cc1
7787,CHEMBL515170,P28223,,MSJCAWWJIHDUAU-OSTNNTLRSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,17428923.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,Inhibition of 5HT2A receptor,,Discovery of a small molecule antagonist of the parathyroid hormone receptor by using an N-terminal parathyroid hormone peptide probe.,Proc. Natl. Acad. Sci. U.S.A.,2007.0,104.0,16.0,"Carter PH, Liu RQ, Foster WR, Tamasi JA, Tebben AJ, Favata M, Staal A, Cvijic ME, French MH, Dell V, Apanovitch D, Lei M, Zhao Q, Cunningham M, Decicco CP, Trzaskos JM, Feyen JH",,505745.0,DTCT0023186,2401781,DTCC00557371,1210869,29253,4.823908740944319,CC[C@H]1C(=O)NC2=C(C(=C(C=C2)F)F)[C@@](O1)(/C=C/C3CC3)C(F)(F)F,CC[C@@H]1O[C@](/C=C/C2CC2)(C(F)(F)F)c2c(ccc(F)c2F)NC1=O
7797,CHEMBL515914,P28223,AZARIBINE,QQOBRRFOVWGIMD-OJAKKHQRSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7258064,DTCC00514747,477912,46191,,CC(=O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C(=O)NC(=O)C=N2)OC(=O)C)OC(=O)C,CC(=O)OC[C@H]1O[C@@H](n2ncc(=O)[nH]c2=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O
7806,CHEMBL516,P28223,CYPROHEPTADINE,JJCFRYNCJDLXIK-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,0.973,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7369971,DTCC00141384,833160,46191,9.011887159731648,CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1,CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1
7808,CHEMBL516452,P28223,,SMRGPXRMTZVWME-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18602261.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from human cloned 5HT2A receptor,,Synthesis and structure-activity relationship of 1H-indole-3-carboxylic acid pyridine-3-ylamides: a novel series of 5-HT2C receptor antagonists.,Bioorg. Med. Chem. Lett.,2008.0,18.0,14.0,"Park CM, Kim SY, Park WK, Park NS, Seong CM",,488684.0,DTCT0023186,2776299,DTCC00525837,1373999,30600,6.0,C1=CC=C2C(=C1)C(=CN2)C(=O)NC3=CN=C(C=C3)OC4=C(N=CC=C4)Cl,O=C(Nc1ccc(Oc2cccnc2Cl)nc1)c1c[nH]c2ccccc12
7814,CHEMBL517712,P28223,ATROPINE,RKUNBYITZUJHSG-SPUOUPEWSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7272160,DTCC00507754,1577004,46191,,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3,CN1[C@H]2CC[C@@H]1CC(OC(=O)C(CO)c1ccccc1)C2
7816,CHEMBL519103,P28223,,IVCPUOLRERPDSF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18602261.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from human cloned 5HT2A receptor,,Synthesis and structure-activity relationship of 1H-indole-3-carboxylic acid pyridine-3-ylamides: a novel series of 5-HT2C receptor antagonists.,Bioorg. Med. Chem. Lett.,2008.0,18.0,14.0,"Park CM, Kim SY, Park WK, Park NS, Seong CM",,488684.0,DTCT0023186,2776331,DTCC00114680,2015906,30600,5.0,CC1=CC2=C(C=C1)C(=CN2)C(=O)NC3=CN=C(C=C3)OC4=C(N=CC=C4)C,Cc1ccc2c(C(=O)Nc3ccc(Oc4cccnc4C)nc3)c[nH]c2c1
7824,CHEMBL521,P28223,IBUPROFEN,HEFNNWSXXWATRW-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7323601,DTCC00141944,833161,46191,,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,CC(C)Cc1ccc(C(C)C(=O)O)cc1
7828,CHEMBL521589,P28223,BAMBUTEROL,ANZXOIAKUNOVQU-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7266985,DTCC00514881,1318439,46191,,CC(C)(C)NCC(C1=CC(=CC(=C1)OC(=O)N(C)C)OC(=O)N(C)C)O,CN(C)C(=O)Oc1cc(OC(=O)N(C)C)cc(C(O)CNC(C)(C)C)c1
7839,CHEMBL52440,P28223,DEXTROMETHORPHAN,MKXZASYAUGDDCJ-NJAFHUGGSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7357245,DTCC00195499,315664,46191,,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3
7842,CHEMBL526,P28223,PROPOFOL,OLBCVFGFOZPWHH-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7398689,DTCC00142061,51502,46191,,CC(C)C1=C(C(=CC=C1)C(C)C)O,CC(C)c1cccc(C(C)C)c1O
7845,CHEMBL527,P28223,PIROXICAM,QYSPLQLAKJAUJT-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7387549,DTCC00142164,866023,46191,,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O
7847,CHEMBL527094,P28223,,UDPHDSFZPAJMRT-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,88.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789543,DTCC00514442,1632011,31612,7.055517327849832,CC(C1=C(C=C(C=C1)OC)OC2=CC(=C(C=C2)Cl)Cl)NC,CNC(C)c1ccc(OC)cc1Oc1ccc(Cl)c(Cl)c1
7849,CHEMBL529,P28223,AZITHROMYCIN,MQTOSJVFKKJCRP-BICOPXKESA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7272301,DTCC00142593,1512804,46191,,CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
7852,CHEMBL529660,P28223,,SHXLCIMINLRWNL-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,18948001.0,IC50,=,1450.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5HT2A receptor,,"Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.",Bioorg. Med. Chem. Lett.,2008.0,18.0,23.0,"Mente S, Gallaschun R, Schmidt A, Lebel L, Vanase-Frawley M, Fliri A",,558174.0,DTCT0023186,2789522,DTCC00514251,1788388,31612,5.838631997765025,CNCC1=C(C=CC(=C1)OC)OC2=CC(=C(C=C2)Cl)Cl,CNCc1cc(OC)ccc1Oc1ccc(Cl)c(Cl)c1
7858,CHEMBL531,P28223,PERGOLIDE,YEHCICAEULNIGD-MZMPZRCHSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,14.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7389239,DTCC00142656,1318444,46191,7.853871964321762,CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC,CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21
7862,CHEMBL532,P28223,ERYTHROMYCIN,ULGZDMOVFRHVEP-RWJQBGPGSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7336857,DTCC00142668,51467,46191,,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
7866,CHEMBL534,P28223,KETOTIFEN,ZCVMWBYGMWKGHF-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,31.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7409838,DTCC00142999,217580,46191,7.508638306165727,CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1,CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1
7869,CHEMBL53463,P28223,DOXORUBICIN,AOJJSUZBOXZQNB-TZSSRYMLSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7325936,DTCC00196573,51466,46191,,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1
7885,CHEMBL54,P28223,HALOPERIDOL,LNEPOXFFQSENCJ-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,8831770.0,IC50,=,288.0,NM,,cell_based,,,,,,,,,,,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,"Structure-activity relationships of a series of novel (piperazinylbutyl)thiazolidinone antipsychotic agents related to 3-[4-[4-(6-fluorobenzo[b]thien-3-yl)-1-piperazinyl]butyl]-2,5,5- trimethyl-4-thiazolidinone maleate.",J. Med. Chem.,1996.0,39.0,20.0,"Hrib NJ, Jurcak JG, Bregna DE, Burgher KL, Hartman HB, Kafka S, Kerman LL, Kongsamut S, Roehr JE, Szewczak MR, Woods-Kettelberger AT, Corbett R",,2272.0,DTCT0023186,1637853,DTCC00135385,5362,13832,6.540607512240769,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
7914,CHEMBL54,P28223,HALOPERIDOL,LNEPOXFFQSENCJ-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,75.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7336269,DTCC00135385,51476,46191,7.1249387366083,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
7924,CHEMBL540445,P28223,PARTHENOLIDE,KTEXNACQROZXEV-SLXBATTESA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7384782,DTCC00556195,574624,46191,,CC1=CCC[C@@]2([C@@H](O2)[C@@H]3[C@@H](CC1)C(=C)C(=O)O3)C,C=C1C(=O)O[C@H]2[C@H]1CCC(C)=CCC[C@@]1(C)O[C@@H]21
7928,CHEMBL541,P28223,BENZOIC ACID,WPYMKLBDIGXBTP-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7272543,DTCC00143343,833157,46191,,C1=CC=C(C=C1)C(=O)O,O=C(O)c1ccccc1
7930,CHEMBL54126,P28223,NEOSTIGMINE BROMIDE,LULNWZDBKTWDGK-UHFFFAOYSA-M,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7375371,DTCC00197200,1027056,46191,,CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C.[Br-],CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1
7935,CHEMBL54440,P28223,MEVASTATIN,AJLFOPYRIVGYMJ-INTXDZFKSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7438926,DTCC00201440,51490,46191,,CC[C@H](C)C(=O)O[C@H]1CCC=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O,CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21
7939,CHEMBL545,P28223,ALCOHOL,LFQSCWFLJHTTHZ-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7332713,DTCC00143522,1416029,46191,,CCO,CCO
7946,CHEMBL547,P28223,ISOTRETINOIN,SHGAZHPCJJPHSC-XFYACQKRSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7409753,DTCC00143769,930080,46191,,CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C\C(=O)O)/C)/C,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1
7954,CHEMBL54786,P28223,,GEJKYGSJUJTWOZ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16220969.0,IC50,=,20.0,NM,,,,,,,,,,,,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,Designed multiple ligands. An emerging drug discovery paradigm.,J. Med. Chem.,2005.0,48.0,21.0,"Morphy R, Rankovic Z",,321230.0,DTCT0023186,1862071,DTCC00200924,1554841,19940,7.698970004336019,C1CN(CCN1CCC2=CC3=C(C=C2)NC(=O)C3)C4=CC=CC5=CC=CC=C54,O=C1Cc2cc(CCN3CCN(c4cccc5ccccc45)CC3)ccc2N1
7958,CHEMBL549,P28223,CITALOPRAM,WSEQXVZVJXJVFP-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7354193,DTCC00144121,444637,46191,,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21
7961,CHEMBL55,P28223,PENTAMIDINE,XDRYMKDFEDOLFX-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,1639.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7380574,DTCC00135468,51498,46191,5.785421046429501,C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N,N=C(N)c1ccc(OCCCCCOc2ccc(C(=N)N)cc2)cc1
7967,CHEMBL553025,P28223,VINORELBINE BASE,GBABOYUKABKIAF-IELIFDKJSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7445908,DTCC00587683,1027061,46191,,CCC1=C[C@H]2C[C@@](C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
7977,CHEMBL557555,P28223,CIPROFIBRATE,KPSRODZRAIWAKH-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7371510,DTCC00590844,1447879,46191,,CC(C)(C(=O)O)OC1=CC=C(C=C1)C2CC2(Cl)Cl,CC(C)(Oc1ccc(C2CC2(Cl)Cl)cc1)C(=O)O
7981,CHEMBL558,P28223,MEXILETINE,VLPIATFUUWWMKC-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7409051,DTCC00145505,1351114,46191,,CC1=C(C(=CC=C1)C)OCC(C)N,Cc1cccc(C)c1OCC(C)N
7983,CHEMBL558551,P28223,(R)-THALIDOMIDE,UEJJHQNACJXSKW-SECBINFHSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7302818,DTCC00022784,1220271,46191,,C1CC(=O)NC(=O)[C@@H]1N2C(=O)C3=CC=CC=C3C2=O,O=C1CC[C@@H](N2C(=O)c3ccccc3C2=O)C(=O)N1
7986,CHEMBL559147,P28223,Y-27632,IYOZTVGMEWJPKR-IJLUTSLNSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7451492,DTCC00589732,1798420,46191,,C[C@H](C1CCC(CC1)C(=O)NC2=CC=NC=C2)N,C[C@@H](N)C1CCC(C(=O)Nc2ccncc2)CC1
8003,CHEMBL561,P28223,LOMEFLOXACIN,ZEKZLJVOYLTDKK-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7425376,DTCC00145731,1480346,46191,,CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)N3CCNC(C3)C)F)C(=O)O,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c21
8005,CHEMBL562,P28223,GRISEOFULVIN,DDUHZTYCFQRHIY-RBHXEPJQSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7308355,DTCC00145751,800577,46191,,C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(O2)C(=C(C=C3OC)OC)Cl)OC,COC1=CC(=O)C[C@@H](C)[C@]12Oc1c(Cl)c(OC)cc(OC)c1C2=O
8010,CHEMBL563,P28223,FLURBIPROFEN,SYTBZMRGLBWNTM-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7303556,DTCC00145756,1447882,46191,,CC(C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O,CC(C(=O)O)c1ccc(-c2ccccc2)c(F)c1
8013,CHEMBL56337,P28223,EPALRESTAT,CHNUOJQWGUIOLD-NFZZJPOKSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7336793,DTCC00204779,2025636,46191,,C/C(=C\C1=CC=CC=C1)/C=C\2/C(=O)N(C(=S)S2)CC(=O)O,CC(/C=C1\SC(=S)N(CC(=O)O)C1=O)=C\c1ccccc1
8015,CHEMBL56367,P28223,NIMESULIDE,HYWYRSMBCFDLJT-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7379810,DTCC00201992,736262,46191,,CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2=CC=CC=C2,CS(=O)(=O)Nc1ccc([N+](=O)[O-])cc1Oc1ccccc1
8018,CHEMBL564,P28223,PROMAZINE,ZGUGWUXLJSTTMA-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,23.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7383528,DTCC00145816,413977,46191,7.638272163982407,CN(C)CCCN1C2=CC=CC=C2SC3=CC=CC=C31,CN(C)CCCN1c2ccccc2Sc2ccccc21
8022,CHEMBL564201,P28223,6-AZAURIDINE,WYXSYVWAUAUWLD-SHUUEZRQSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7269497,DTCC00485142,768474,46191,,C1=NN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O,O=c1cnn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1
8025,CHEMBL565,P28223,CLOFIBRATE,KNHUKKLJHYUCFP-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7358623,DTCC00145838,1641847,46191,,CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl,CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1
8033,CHEMBL565552,P28223,,NSQFNGCVKOBFOP-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,19523834.0,IC50,=,938.0,NM,,cell_based,,,,,,,,,,,CHO,Displacement of [125I]DOI from human cloned 5HT2A receptor expressed in CHO cells,,"Novel 1-aminoethyl-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines are potent 5-HT(6) agonists.",Bioorg. Med. Chem.,2009.0,17.0,14.0,"Bernotas RC, Lenicek S, Antane S, Cole DC, Harrison BL, Robichaud AJ, Zhang GM, Smith D, Platt B, Lin Q, Li P, Coupet J, Rosenzweig-Lipson S, Beyer CE, Schechter LE",,598766.0,DTCT0023186,3090781,DTCC00601725,1568271,36019,6.027797161620936,CN(C)CCN1C=C(C2=C1N=CC=C2)S(=O)(=O)C3=CC=CC4=CC=CC=C43,CN(C)CCn1cc(S(=O)(=O)c2cccc3ccccc23)c2cccnc21
8035,CHEMBL56564,P28223,TROPISETRON,ZNRGQMMCGHDTEI-ITGUQSILSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7441431,DTCC00204705,736266,46191,,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C3=CNC4=CC=CC=C43,CN1[C@H]2CC[C@@H]1CC(OC(=O)c1c[nH]c3ccccc13)C2
8037,CHEMBL565745,P28223,,XGXHANFTDNWBFA-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,19523834.0,IC50,=,11.0,NM,,cell_based,,,,,,,,,,,CHO,Displacement of [125I]DOI from human cloned 5HT2A receptor expressed in CHO cells,,"Novel 1-aminoethyl-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines are potent 5-HT(6) agonists.",Bioorg. Med. Chem.,2009.0,17.0,14.0,"Bernotas RC, Lenicek S, Antane S, Cole DC, Harrison BL, Robichaud AJ, Zhang GM, Smith D, Platt B, Lin Q, Li P, Coupet J, Rosenzweig-Lipson S, Beyer CE, Schechter LE",,598766.0,DTCT0023186,3090780,DTCC00601773,598294,36019,7.958607314841775,C1=CC(=CC(=C1)Cl)S(=O)(=O)C2=CN(C3=C2C=CC=N3)CCN,NCCn1cc(S(=O)(=O)c2cccc(Cl)c2)c2cccnc21
8043,CHEMBL566534,P28223,ARTEMETHER,SXYIRMFQILZOAM-HVNFFKDJSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7269173,DTCC00600123,736254,46191,,C[C@@H]1CC[C@H]2[C@H]([C@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)OC)C,CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@]42OO3
8048,CHEMBL567,P28223,PERPHENAZINE,RGCVKNLCSQQDEP-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7397807,DTCC00145901,1798415,46191,,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1
8056,CHEMBL567597,P28223,ARTEMISININ,BLUAFEHZUWYNDE-DKGJTOOQSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7271964,DTCC00601707,1960072,46191,,C[C@@H]1CC[C@H]2[C@H](C(=O)O[C@H]3[C@@]24[C@H]1CC[C@@](O3)(OO4)C)C,C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@]4(C)CC[C@@H]1[C@]32OO4
8073,CHEMBL569,P28223,PROCAINE,MFDFERRIHVXMIY-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7396412,DTCC00145963,930084,46191,,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,CCN(CC)CCOC(=O)c1ccc(N)cc1
8081,CHEMBL569475,P28223,,GFRJMFXDXSQXNX-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,19665894.0,IC50,=,1.9,NM,,cell_based,,,,,,,,,,,,Agonist activity at 5HT2A receptor expressed in HEK cells assessed as inhibition of serotonin-induced inositol phosphate accumulation,,"Solubilized phenyl-pyrazole ureas as potent, selective 5-HT(2A) inverse-agonists and their application as antiplatelet agents.",Bioorg. Med. Chem. Lett.,2009.0,19.0,18.0,"Dosa PI, Strah-Pleynet S, Jayakumar H, Casper M, Decaire M, Xiong Y, Lehmann J, Choi K, Elwell K, Wong A, Webb RR, Adams JW, Ramirez J, Richman JG, Thomsen W, Semple G, Teegarden BR",,600348.0,DTCT0023186,3098568,DTCC00606345,1757289,36168,8.721246399047171,CN1C(=C(C=N1)Br)C2=C(C=CC(=C2)NC(=O)NC3=CC=C(C=C3)Cl)OCCN4CCCC4,Cn1ncc(Br)c1-c1cc(NC(=O)Nc2ccc(Cl)cc2)ccc1OCCN1CCCC1
8092,CHEMBL57,P28223,NEVIRAPINE,NQDJXKOVJZTUJA-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7386077,DTCC00135799,51491,46191,,CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1
8103,CHEMBL571,P28223,KETOPROFEN,DKYWVDODHFEZIM-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7435477,DTCC00145969,2025638,46191,,CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1
8108,CHEMBL571858,P28223,WAY-208466,SFSFIDVAEMDPIP-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,19523834.0,IC50,=,351.0,NM,,cell_based,,,,,,,,,,,CHO,Displacement of [125I]DOI from human cloned 5HT2A receptor expressed in CHO cells,,"Novel 1-aminoethyl-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines are potent 5-HT(6) agonists.",Bioorg. Med. Chem.,2009.0,17.0,14.0,"Bernotas RC, Lenicek S, Antane S, Cole DC, Harrison BL, Robichaud AJ, Zhang GM, Smith D, Platt B, Lin Q, Li P, Coupet J, Rosenzweig-Lipson S, Beyer CE, Schechter LE",,598766.0,DTCT0023186,3090778,DTCC00023274,857259,36019,6.454692883534176,CN(C)CCN1C=C(C2=C1N=CC=C2)S(=O)(=O)C3=CC=CC(=C3)F,CN(C)CCn1cc(S(=O)(=O)c2cccc(F)c2)c2cccnc21
8112,CHEMBL572,P28223,NITROFURANTOIN,NXFQHRVNIOXGAQ-YCRREMRBSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7405759,DTCC00145970,1927018,46191,,C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],O=C1CN(/N=C/c2ccc([N+](=O)[O-])o2)C(=O)N1
8122,CHEMBL573,P28223,NIACIN,PVNIIMVLHYAWGP-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7390400,DTCC00146015,381015,46191,,C1=CC(=CN=C1)C(=O)O,O=C(O)c1cccnc1
8131,CHEMBL576315,P28223,,CJMJDAAXKOQSCO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,19523834.0,IC50,>,5000.0,NM,,cell_based,,,,,,,,,,,CHO,Displacement of [125I]DOI from human cloned 5HT2A receptor expressed in CHO cells,,"Novel 1-aminoethyl-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines are potent 5-HT(6) agonists.",Bioorg. Med. Chem.,2009.0,17.0,14.0,"Bernotas RC, Lenicek S, Antane S, Cole DC, Harrison BL, Robichaud AJ, Zhang GM, Smith D, Platt B, Lin Q, Li P, Coupet J, Rosenzweig-Lipson S, Beyer CE, Schechter LE",,598766.0,DTCT0023186,3090777,DTCC00601791,630839,36019,5.301029995663981,C1=CC=C(C=C1)S(=O)(=O)C2=CN(C3=C2C=CC=N3)CCN,NCCn1cc(S(=O)(=O)c2ccccc2)c2cccnc21
8138,CHEMBL578,P28223,ENALAPRIL,GBXSMTUPTTWBMN-XIRDDKMYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7323905,DTCC00146157,49658,46191,,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)O,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O
8148,CHEMBL58,P28223,MITOXANTRONE,KKZJGLLVHKMTCM-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7407054,DTCC00103487,1092344,46191,,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO,O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21
8150,CHEMBL580,P28223,LORAZEPAM,DIWRORZWFLOCLC-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7406120,DTCC00146251,1285879,46191,,C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,O=C1Nc2ccc(Cl)cc2C(c2ccccc2Cl)=NC1O
8161,CHEMBL583,P28223,GREPAFLOXACIN,AIJTTZAVMXIJGM-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7304072,DTCC00146380,542577,46191,,CC1CN(CCN1)C2=C(C(=C3C(=C2)N(C=C(C3=O)C(=O)O)C4CC4)C)F,Cc1c(F)c(N2CCNC(C)C2)cc2c1c(=O)c(C(=O)O)cn2C1CC1
8166,CHEMBL584,P28223,NELFINAVIR,QAGYKUNXZHXKMR-HKWSIXNMSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7403216,DTCC01738575,1798414,46191,,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
8168,CHEMBL584046,P28223,,QFJMKWALUAWNKC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,19523834.0,IC50,=,131.0,NM,,cell_based,,,,,,,,,,,CHO,Displacement of [125I]DOI from human cloned 5HT2A receptor expressed in CHO cells,,"Novel 1-aminoethyl-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines are potent 5-HT(6) agonists.",Bioorg. Med. Chem.,2009.0,17.0,14.0,"Bernotas RC, Lenicek S, Antane S, Cole DC, Harrison BL, Robichaud AJ, Zhang GM, Smith D, Platt B, Lin Q, Li P, Coupet J, Rosenzweig-Lipson S, Beyer CE, Schechter LE",,598766.0,DTCT0023186,3090779,DTCC00601763,144663,36019,6.882728704344236,CN(C)CCN1C=C(C2=C1N=CC=C2)S(=O)(=O)C3=CC(=CC=C3)Cl,CN(C)CCn1cc(S(=O)(=O)c2cccc(Cl)c2)c2cccnc21
8170,CHEMBL584554,P28223,,QIPWTYSOANVUKJ-WZONZLPQSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,19783143.0,IC50,=,750.0,NM,,,,,,,,,,,,,,Inhibition of 5HT2A receptor,,"Special ergolines are highly selective, potent antagonists of the chemokine receptor CXCR3: discovery, characterization and preliminary SAR of a promising lead.",Bioorg. Med. Chem. Lett.,2009.0,19.0,21.0,"Thoma G, Baenteli R, Lewis I, Wagner T, Oberer L, Blum W, Glickman F, Streiff MB, Zerwes HG",,592327.0,DTCT0023186,3048578,DTCC00597400,38146,35662,6.1249387366083,CCN(CC)C(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C(=O)NC5=CC=CC=C5,CCN(CC)C(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C(=O)Nc2ccccc2)C1
8172,CHEMBL585,P28223,TRIAMTERENE,FNYLWPVRPXGIIP-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7446224,DTCC00146599,1674154,46191,,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1
8187,CHEMBL588119,P28223,SULOCTIDIL,BFCDFTHTSVTWOG-YLJYHZDGSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7474117,DTCC00123899,2057654,46191,,CCCCCCCCN[C@H](C)[C@H](C1=CC=C(C=C1)SC(C)C)O,CCCCCCCCN[C@H](C)[C@@H](O)c1ccc(SC(C)C)cc1
8238,CHEMBL591223,P28223,,OLSNXEOXWIBURX-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20143782.0,IC50,=,0.794,NM,,cell_based,,,,,,,,,,,HEK293,Activity at human 5HT2A receptor expressed in HEK293 cells assessed as [3H]inositol phosphate production by scintillation counting,,"Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia.",J. Med. Chem.,2010.0,53.0,5.0,"Teegarden BR, Li H, Jayakumar H, Strah-Pleynet S, Dosa PI, Selaya SD, Kato N, Elwell KH, Davidson J, Cheng K, Saldana H, Frazer JM, Whelan K, Foster J, Espitia S, Webb RR, Beeley NR, Thomsen W, Morairty SR, Kilduff TS, Al-Shamma HA",,612567.0,DTCT0023186,3210395,DTCC00621312,469355,37122,9.100179497572904,CN1C(=C(C=N1)Br)C2=C(C=CC(=C2)NC(=O)NC3=CC=C(C=C3)Cl)OC,COc1ccc(NC(=O)Nc2ccc(Cl)cc2)cc1-c1c(Br)cnn1C
8242,CHEMBL593527,P28223,,XJPCNUDKTWEBSY-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,19836247.0,IC50,=,1105.0,NM,,cell_based,,,,,,,,,,,CHO,Antagonist activity at human 5HT2A receptor expressed in CHO cells assessed as inhibition of (R)-(-)-DOI hydrochloride-induced intracellular calcium mobilization by FLIPR assay,,"Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(phenylsulfonyl)-1H-indoles.",Bioorg. Med. Chem.,2009.0,17.0,22.0,"Heffernan GD, Coghlan RD, Manas ES, McDevitt RE, Li Y, Mahaney PE, Robichaud AJ, Huselton C, Alfinito P, Bray JA, Cosmi SA, Johnston GH, Kenney T, Koury E, Winneker RC, Deecher DC, Trybulski EJ",,603455.0,DTCT0023186,3155483,DTCC00611226,1375146,36729,5.95663772197887,CNCCC1=C2C(=CC=C1)NC=C2S(=O)(=O)C3=CC=CC=C3,CNCCc1cccc2[nH]cc(S(=O)(=O)c3ccccc3)c12
8248,CHEMBL593614,P28223,,MCPOSCCUUUPTRR-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,19836247.0,IC50,=,69.0,NM,,cell_based,,,,,,,,,,,CHO,Antagonist activity at human 5HT2A receptor expressed in CHO cells assessed as inhibition of (R)-(-)-DOI hydrochloride-induced intracellular calcium mobilization by FLIPR assay,,"Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(phenylsulfonyl)-1H-indoles.",Bioorg. Med. Chem.,2009.0,17.0,22.0,"Heffernan GD, Coghlan RD, Manas ES, McDevitt RE, Li Y, Mahaney PE, Robichaud AJ, Huselton C, Alfinito P, Bray JA, Cosmi SA, Johnston GH, Kenney T, Koury E, Winneker RC, Deecher DC, Trybulski EJ",,603455.0,DTCT0023186,3155520,DTCC00611292,631014,36729,7.161150909262744,C1CCCN(CC1)CCC2=C3C(=CC=C2)NC=C3S(=O)(=O)C4=CC=CC=C4,O=S(=O)(c1ccccc1)c1c[nH]c2cccc(CCN3CCCCCC3)c12
8251,CHEMBL593821,P28223,,FWMIXTKPPHIFDD-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,19836247.0,IC50,=,477.0,NM,,cell_based,,,,,,,,,,,CHO,Antagonist activity at human 5HT2A receptor expressed in CHO cells assessed as inhibition of (R)-(-)-DOI hydrochloride-induced intracellular calcium mobilization by FLIPR assay,,"Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(phenylsulfonyl)-1H-indoles.",Bioorg. Med. Chem.,2009.0,17.0,22.0,"Heffernan GD, Coghlan RD, Manas ES, McDevitt RE, Li Y, Mahaney PE, Robichaud AJ, Huselton C, Alfinito P, Bray JA, Cosmi SA, Johnston GH, Kenney T, Koury E, Winneker RC, Deecher DC, Trybulski EJ",,603455.0,DTCT0023186,3155532,DTCC00611317,857464,36729,6.321481620959886,CCN(C)CCCC1=C2C(=CC=C1)NC=C2S(=O)(=O)C3=CC=CC=C3,CCN(C)CCCc1cccc2[nH]cc(S(=O)(=O)c3ccccc3)c12
8257,CHEMBL594519,P28223,,YHPHFVMVXIQRCD-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,19836247.0,IC50,=,5979.0,NM,,cell_based,,,,,,,,,,,CHO,Antagonist activity at human 5HT2A receptor expressed in CHO cells assessed as inhibition of (R)-(-)-DOI hydrochloride-induced intracellular calcium mobilization by FLIPR assay,,"Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(phenylsulfonyl)-1H-indoles.",Bioorg. Med. Chem.,2009.0,17.0,22.0,"Heffernan GD, Coghlan RD, Manas ES, McDevitt RE, Li Y, Mahaney PE, Robichaud AJ, Huselton C, Alfinito P, Bray JA, Cosmi SA, Johnston GH, Kenney T, Koury E, Winneker RC, Deecher DC, Trybulski EJ",,603455.0,DTCT0023186,3155536,DTCC00611330,1757413,36729,5.22337144657985,CC(C)NCCCC1=C2C(=CC=C1)NC=C2S(=O)(=O)C3=CC=CC=C3,CC(C)NCCCc1cccc2[nH]cc(S(=O)(=O)c3ccccc3)c12
8261,CHEMBL594717,P28223,,ZAZVLBZIEZHJFV-BEFAXECRSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,19914063.0,IC50,=,46.0,NM,,,,,,,,,,,,,,Agonist activity against human 5HT2A receptor by FLIPR assay relative to 5HT,,Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity.,Bioorg. Med. Chem. Lett.,2010.0,20.0,1.0,"Liu KK, Cornelius P, Patterson TA, Zeng Y, Santucci S, Tomlinson E, Gibbons C, Maurer TS, Marala R, Brown J, Kong JX, Lee E, Werner W, Wenzel Z, Vage C",,606261.0,DTCT0023186,3169725,DTCC00614925,100843,36793,7.337242168318426,C[C@@H]1CNCCN1C2=NC3=C(CC[C@@H]3OCC4=C(C=CC(=C4)F)C)C=C2,Cc1ccc(F)cc1CO[C@H]1CCc2ccc(N3CCNC[C@H]3C)nc21
8263,CHEMBL595,P28223,PIOGLITAZONE,HYAFETHFCAUJAY-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7393752,DTCC00148462,1318445,46191,,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1
8265,CHEMBL595133,P28223,,AVHPWUACYYPSMI-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,19836247.0,IC50,=,1025.0,NM,,cell_based,,,,,,,,,,,CHO,Antagonist activity at human 5HT2A receptor expressed in CHO cells assessed as inhibition of (R)-(-)-DOI hydrochloride-induced intracellular calcium mobilization by FLIPR assay,,"Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(phenylsulfonyl)-1H-indoles.",Bioorg. Med. Chem.,2009.0,17.0,22.0,"Heffernan GD, Coghlan RD, Manas ES, McDevitt RE, Li Y, Mahaney PE, Robichaud AJ, Huselton C, Alfinito P, Bray JA, Cosmi SA, Johnston GH, Kenney T, Koury E, Winneker RC, Deecher DC, Trybulski EJ",,603455.0,DTCT0023186,3155487,DTCC00611236,1050934,36729,5.989276134608227,CCNCCC1=C2C(=CC=C1)NC=C2S(=O)(=O)C3=CC=CC=C3,CCNCCc1cccc2[nH]cc(S(=O)(=O)c3ccccc3)c12
8272,CHEMBL595252,P28223,,WLLDZAMGIXUOIX-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,19836247.0,IC50,=,180.0,NM,,cell_based,,,,,,,,,,,CHO,Antagonist activity at human 5HT2A receptor expressed in CHO cells assessed as inhibition of (R)-(-)-DOI hydrochloride-induced intracellular calcium mobilization by FLIPR assay,,"Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(phenylsulfonyl)-1H-indoles.",Bioorg. Med. Chem.,2009.0,17.0,22.0,"Heffernan GD, Coghlan RD, Manas ES, McDevitt RE, Li Y, Mahaney PE, Robichaud AJ, Huselton C, Alfinito P, Bray JA, Cosmi SA, Johnston GH, Kenney T, Koury E, Winneker RC, Deecher DC, Trybulski EJ",,603455.0,DTCT0023186,3155515,DTCC00611284,1789677,36729,6.7447274948966935,C1CCN(CC1)CCC2=C3C(=CC=C2)NC=C3S(=O)(=O)C4=CC=CC=C4,O=S(=O)(c1ccccc1)c1c[nH]c2cccc(CCN3CCCCC3)c12
8274,CHEMBL595449,P28223,,ILPANLYEJQKXKY-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,19646882.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,Inhibition of 5HT2A receptor,,Novel delta opioid receptor agonists exhibit differential stimulation of signaling pathways.,Bioorg. Med. Chem.,2009.0,17.0,17.0,"Peng Y, Zhang Q, Arora S, Keenan SM, Kortagere S, Wannemacher KM, Howells RD, Welsh WJ",,601693.0,DTCT0023186,3163159,DTCC00612138,1136637,36541,5.0,CC(C)(C)C1=CC=C(C=C1)C2=NC(=NN2C3=CC(=CC=C3)O)CN(C)C,CN(C)Cc1nc(-c2ccc(C(C)(C)C)cc2)n(-c2cccc(O)c2)n1
8275,CHEMBL595457,P28223,,BNWDHFFDZARHMY-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,19836247.0,IC50,=,650.0,NM,,cell_based,,,,,,,,,,,CHO,Antagonist activity at human 5HT2A receptor expressed in CHO cells assessed as inhibition of (R)-(-)-DOI hydrochloride-induced intracellular calcium mobilization by FLIPR assay,,"Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(phenylsulfonyl)-1H-indoles.",Bioorg. Med. Chem.,2009.0,17.0,22.0,"Heffernan GD, Coghlan RD, Manas ES, McDevitt RE, Li Y, Mahaney PE, Robichaud AJ, Huselton C, Alfinito P, Bray JA, Cosmi SA, Johnston GH, Kenney T, Koury E, Winneker RC, Deecher DC, Trybulski EJ",,603455.0,DTCT0023186,3155495,DTCC00611247,921542,36729,6.187086643357144,CC(C)NCCC1=C2C(=CC=C1)NC=C2S(=O)(=O)C3=CC=CC=C3,CC(C)NCCc1cccc2[nH]cc(S(=O)(=O)c3ccccc3)c12
8282,CHEMBL596148,P28223,,AHCAMFIUFHMBFK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,19836247.0,IC50,=,459.0,NM,,cell_based,,,,,,,,,,,CHO,Antagonist activity at human 5HT2A receptor expressed in CHO cells assessed as inhibition of (R)-(-)-DOI hydrochloride-induced intracellular calcium mobilization by FLIPR assay,,"Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(phenylsulfonyl)-1H-indoles.",Bioorg. Med. Chem.,2009.0,17.0,22.0,"Heffernan GD, Coghlan RD, Manas ES, McDevitt RE, Li Y, Mahaney PE, Robichaud AJ, Huselton C, Alfinito P, Bray JA, Cosmi SA, Johnston GH, Kenney T, Koury E, Winneker RC, Deecher DC, Trybulski EJ",,603455.0,DTCT0023186,3155503,DTCC00611264,534014,36729,6.338187314462739,CN(C)CCC1=C2C(=CC=C1)NC=C2S(=O)(=O)C3=CC=CC=C3,CN(C)CCc1cccc2[nH]cc(S(=O)(=O)c3ccccc3)c12
8284,CHEMBL596735,P28223,,JCEKFLMKRPIGFR-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20143782.0,IC50,=,15.85,NM,,cell_based,,,,,,,,,,,HEK293,Activity at human 5HT2A receptor expressed in HEK293 cells assessed as [3H]inositol phosphate production by scintillation counting,,"Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia.",J. Med. Chem.,2010.0,53.0,5.0,"Teegarden BR, Li H, Jayakumar H, Strah-Pleynet S, Dosa PI, Selaya SD, Kato N, Elwell KH, Davidson J, Cheng K, Saldana H, Frazer JM, Whelan K, Foster J, Espitia S, Webb RR, Beeley NR, Thomsen W, Morairty SR, Kilduff TS, Al-Shamma HA",,612567.0,DTCT0023186,3210459,DTCC00621570,663253,37122,7.79997073344623,CN1C(=C(C=N1)Br)C2=C(C=CC(=C2)NC(=O)NC3=CC=C(C=C3)Cl)OC(F)(F)F,Cn1ncc(Br)c1-c1cc(NC(=O)Nc2ccc(Cl)cc2)ccc1OC(F)(F)F
8286,CHEMBL596753,P28223,,GQIUEHHCLZDZIU-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20143782.0,IC50,=,3.98,NM,,cell_based,,,,,,,,,,,HEK293,Activity at human 5HT2A receptor expressed in HEK293 cells assessed as [3H]inositol phosphate production by scintillation counting,,"Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia.",J. Med. Chem.,2010.0,53.0,5.0,"Teegarden BR, Li H, Jayakumar H, Strah-Pleynet S, Dosa PI, Selaya SD, Kato N, Elwell KH, Davidson J, Cheng K, Saldana H, Frazer JM, Whelan K, Foster J, Espitia S, Webb RR, Beeley NR, Thomsen W, Morairty SR, Kilduff TS, Al-Shamma HA",,612567.0,DTCT0023186,3210519,DTCC00621809,144972,37122,8.400116927926312,CN1C(=C(C=N1)Cl)C2=C(C=CC(=C2)NC(=O)NC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)OC,COc1ccc(NC(=O)Nc2cc(C(F)(F)F)cc(C(F)(F)F)c2)cc1-c1c(Cl)cnn1C
8288,CHEMBL596975,P28223,,PLZPXAPBUQCPAL-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20143782.0,IC50,=,50.12,NM,,cell_based,,,,,,,,,,,HEK293,Activity at human 5HT2A receptor expressed in HEK293 cells assessed as [3H]inositol phosphate production by scintillation counting,,"Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia.",J. Med. Chem.,2010.0,53.0,5.0,"Teegarden BR, Li H, Jayakumar H, Strah-Pleynet S, Dosa PI, Selaya SD, Kato N, Elwell KH, Davidson J, Cheng K, Saldana H, Frazer JM, Whelan K, Foster J, Espitia S, Webb RR, Beeley NR, Thomsen W, Morairty SR, Kilduff TS, Al-Shamma HA",,612567.0,DTCT0023186,3210435,DTCC00621472,405551,37122,7.299988937677887,CN1C(=C(C=N1)Br)C2=C(C=CC(=C2)NC(=O)NC3=CC=C(C=C3)N(C)C)OC,COc1ccc(NC(=O)Nc2ccc(N(C)C)cc2)cc1-c1c(Br)cnn1C
8290,CHEMBL596976,P28223,,YZVIJLBIWGHYKU-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20143782.0,IC50,=,2.51,NM,,cell_based,,,,,,,,,,,HEK293,Activity at human 5HT2A receptor expressed in HEK293 cells assessed as [3H]inositol phosphate production by scintillation counting,,"Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia.",J. Med. Chem.,2010.0,53.0,5.0,"Teegarden BR, Li H, Jayakumar H, Strah-Pleynet S, Dosa PI, Selaya SD, Kato N, Elwell KH, Davidson J, Cheng K, Saldana H, Frazer JM, Whelan K, Foster J, Espitia S, Webb RR, Beeley NR, Thomsen W, Morairty SR, Kilduff TS, Al-Shamma HA",,612567.0,DTCT0023186,3210439,DTCC00621473,534126,37122,8.600326278518962,CC(C)C1=CC=C(C=C1)NC(=O)NC2=CC(=C(C=C2)OC)C3=C(C=NN3C)Br,COc1ccc(NC(=O)Nc2ccc(C(C)C)cc2)cc1-c1c(Br)cnn1C
8293,CHEMBL597,P28223,PHENTOLAMINE,MRBDMNSDAVCSSF-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,359.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7397925,DTCC00148793,1641852,46191,6.444905551421681,CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O,Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1
8295,CHEMBL597151,P28223,,LHGXUNFGKTTZQP-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20143782.0,IC50,=,12.59,NM,,cell_based,,,,,,,,,,,HEK293,Activity at human 5HT2A receptor expressed in HEK293 cells assessed as [3H]inositol phosphate production by scintillation counting,,"Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia.",J. Med. Chem.,2010.0,53.0,5.0,"Teegarden BR, Li H, Jayakumar H, Strah-Pleynet S, Dosa PI, Selaya SD, Kato N, Elwell KH, Davidson J, Cheng K, Saldana H, Frazer JM, Whelan K, Foster J, Espitia S, Webb RR, Beeley NR, Thomsen W, Morairty SR, Kilduff TS, Al-Shamma HA",,612567.0,DTCT0023186,3210475,DTCC00621640,1310118,37122,7.899974269892137,CN1C(=C(C=N1)Br)C2=C(C=CC(=C2)NC(=O)NC3=CC=C(C=C3)Cl)OCC4=CC=C(C=C4)Cl,Cn1ncc(Br)c1-c1cc(NC(=O)Nc2ccc(Cl)cc2)ccc1OCc1ccc(Cl)cc1
8297,CHEMBL597152,P28223,,DWWNKZZQDZOLGU-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20143782.0,IC50,=,50.12,NM,,cell_based,,,,,,,,,,,HEK293,Activity at human 5HT2A receptor expressed in HEK293 cells assessed as [3H]inositol phosphate production by scintillation counting,,"Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia.",J. Med. Chem.,2010.0,53.0,5.0,"Teegarden BR, Li H, Jayakumar H, Strah-Pleynet S, Dosa PI, Selaya SD, Kato N, Elwell KH, Davidson J, Cheng K, Saldana H, Frazer JM, Whelan K, Foster J, Espitia S, Webb RR, Beeley NR, Thomsen W, Morairty SR, Kilduff TS, Al-Shamma HA",,612567.0,DTCT0023186,3210479,DTCC00621641,760071,37122,7.299988937677887,CN1C(=C(C=N1)Br)C2=C(C=CC(=C2)NC(=O)NC3=CC=C(C=C3)Cl)OCCC4=CC=CC=C4,Cn1ncc(Br)c1-c1cc(NC(=O)Nc2ccc(Cl)cc2)ccc1OCCc1ccccc1
8301,CHEMBL597983,P28223,,IQZBUIXIRRPSOX-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20143782.0,IC50,=,2.51,NM,,cell_based,,,,,,,,,,,HEK293,Activity at human 5HT2A receptor expressed in HEK293 cells assessed as [3H]inositol phosphate production by scintillation counting,,"Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia.",J. Med. Chem.,2010.0,53.0,5.0,"Teegarden BR, Li H, Jayakumar H, Strah-Pleynet S, Dosa PI, Selaya SD, Kato N, Elwell KH, Davidson J, Cheng K, Saldana H, Frazer JM, Whelan K, Foster J, Espitia S, Webb RR, Beeley NR, Thomsen W, Morairty SR, Kilduff TS, Al-Shamma HA",,612567.0,DTCT0023186,3210511,DTCC00622379,921662,37122,8.600326278518962,CN1C(=C(C=N1)F)C2=C(C=CC(=C2)NC(=O)NC3=CC(=C(C=C3)F)F)OC,COc1ccc(NC(=O)Nc2ccc(F)c(F)c2)cc1-c1c(F)cnn1C
8303,CHEMBL598171,P28223,,YMVIRCYNRMVMJQ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20143782.0,IC50,=,1.26,NM,,cell_based,,,,,,,,,,,HEK293,Activity at human 5HT2A receptor expressed in HEK293 cells assessed as [3H]inositol phosphate production by scintillation counting,,"Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia.",J. Med. Chem.,2010.0,53.0,5.0,"Teegarden BR, Li H, Jayakumar H, Strah-Pleynet S, Dosa PI, Selaya SD, Kato N, Elwell KH, Davidson J, Cheng K, Saldana H, Frazer JM, Whelan K, Foster J, Espitia S, Webb RR, Beeley NR, Thomsen W, Morairty SR, Kilduff TS, Al-Shamma HA",,612567.0,DTCT0023186,3210495,DTCC00621753,1018582,37122,8.899629454882437,CN1C(=C(C=N1)Br)C2=C(C=CC(=C2)NC(=O)NC3=CC(=CC(=C3)F)F)OC,COc1ccc(NC(=O)Nc2cc(F)cc(F)c2)cc1-c1c(Br)cnn1C
8305,CHEMBL598172,P28223,NELOTANSERIN,COSPVUFTLGQDQL-UHFFFAOYSA-N,2,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20143782.0,IC50,=,0.631,NM,,cell_based,,,,,,,,,,,HEK293,Activity at human 5HT2A receptor expressed in HEK293 cells assessed as [3H]inositol phosphate production by scintillation counting,,"Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia.",J. Med. Chem.,2010.0,53.0,5.0,"Teegarden BR, Li H, Jayakumar H, Strah-Pleynet S, Dosa PI, Selaya SD, Kato N, Elwell KH, Davidson J, Cheng K, Saldana H, Frazer JM, Whelan K, Foster J, Espitia S, Webb RR, Beeley NR, Thomsen W, Morairty SR, Kilduff TS, Al-Shamma HA",,612567.0,DTCT0023186,3210499,DTCC00621754,1536625,37122,9.199970640755865,CN1C(=C(C=N1)Br)C2=C(C=CC(=C2)NC(=O)NC3=C(C=C(C=C3)F)F)OC,COc1ccc(NC(=O)Nc2ccc(F)cc2F)cc1-c1c(Br)cnn1C
8308,CHEMBL598173,P28223,,UKZQBKVXASGHBG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20143782.0,IC50,=,1.0,NM,,cell_based,,,,,,,,,,,HEK293,Activity at human 5HT2A receptor expressed in HEK293 cells assessed as [3H]inositol phosphate production by scintillation counting,,"Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia.",J. Med. Chem.,2010.0,53.0,5.0,"Teegarden BR, Li H, Jayakumar H, Strah-Pleynet S, Dosa PI, Selaya SD, Kato N, Elwell KH, Davidson J, Cheng K, Saldana H, Frazer JM, Whelan K, Foster J, Espitia S, Webb RR, Beeley NR, Thomsen W, Morairty SR, Kilduff TS, Al-Shamma HA",,612567.0,DTCT0023186,3210503,DTCC00621755,1375253,37122,9.0,CN1C(=C(C=N1)Cl)C2=C(C=CC(=C2)NC(=O)NC3=C(C=C(C=C3)F)F)OC,COc1ccc(NC(=O)Nc2ccc(F)cc2F)cc1-c1c(Cl)cnn1C
8310,CHEMBL598378,P28223,,KNHPQCFZWPOLFQ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20143782.0,IC50,=,7.94,NM,,cell_based,,,,,,,,,,,HEK293,Activity at human 5HT2A receptor expressed in HEK293 cells assessed as [3H]inositol phosphate production by scintillation counting,,"Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia.",J. Med. Chem.,2010.0,53.0,5.0,"Teegarden BR, Li H, Jayakumar H, Strah-Pleynet S, Dosa PI, Selaya SD, Kato N, Elwell KH, Davidson J, Cheng K, Saldana H, Frazer JM, Whelan K, Foster J, Espitia S, Webb RR, Beeley NR, Thomsen W, Morairty SR, Kilduff TS, Al-Shamma HA",,612567.0,DTCT0023186,3210471,DTCC00621639,372580,37122,8.100179497572904,CN1C(=C(C=N1)Br)C2=C(C=CC(=C2)NC(=O)NC3=CC=C(C=C3)Cl)OCC4=CC=CC=C4,Cn1ncc(Br)c1-c1cc(NC(=O)Nc2ccc(Cl)cc2)ccc1OCc1ccccc1
8314,CHEMBL599,P28223,MELOXICAM,ZRVUJXDFFKFLMG-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7423553,DTCC00149080,638767,46191,,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1
8316,CHEMBL599193,P28223,,NCGLCBITYFKBDE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20143782.0,IC50,=,1.58,NM,,cell_based,,,,,,,,,,,HEK293,Activity at human 5HT2A receptor expressed in HEK293 cells assessed as [3H]inositol phosphate production by scintillation counting,,"Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia.",J. Med. Chem.,2010.0,53.0,5.0,"Teegarden BR, Li H, Jayakumar H, Strah-Pleynet S, Dosa PI, Selaya SD, Kato N, Elwell KH, Davidson J, Cheng K, Saldana H, Frazer JM, Whelan K, Foster J, Espitia S, Webb RR, Beeley NR, Thomsen W, Morairty SR, Kilduff TS, Al-Shamma HA",,612567.0,DTCT0023186,3210463,DTCC00621571,566362,37122,8.801342913045577,CCOC1=C(C=C(C=C1)NC(=O)NC2=CC=C(C=C2)Cl)C3=C(C=NN3C)Br,CCOc1ccc(NC(=O)Nc2ccc(Cl)cc2)cc1-c1c(Br)cnn1C
8318,CHEMBL599194,P28223,,IRENRIFYNDPXQK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20143782.0,IC50,=,1.58,NM,,cell_based,,,,,,,,,,,HEK293,Activity at human 5HT2A receptor expressed in HEK293 cells assessed as [3H]inositol phosphate production by scintillation counting,,"Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia.",J. Med. Chem.,2010.0,53.0,5.0,"Teegarden BR, Li H, Jayakumar H, Strah-Pleynet S, Dosa PI, Selaya SD, Kato N, Elwell KH, Davidson J, Cheng K, Saldana H, Frazer JM, Whelan K, Foster J, Espitia S, Webb RR, Beeley NR, Thomsen W, Morairty SR, Kilduff TS, Al-Shamma HA",,612567.0,DTCT0023186,3210467,DTCC00621572,921654,37122,8.801342913045577,CC(C)OC1=C(C=C(C=C1)NC(=O)NC2=CC=C(C=C2)Cl)C3=C(C=NN3C)Br,CC(C)Oc1ccc(NC(=O)Nc2ccc(Cl)cc2)cc1-c1c(Br)cnn1C
8320,CHEMBL599225,P28223,,JOYVKNXZLYVXDI-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20143782.0,IC50,=,0.501,NM,,cell_based,,,,,,,,,,,HEK293,Activity at human 5HT2A receptor expressed in HEK293 cells assessed as [3H]inositol phosphate production by scintillation counting,,"Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia.",J. Med. Chem.,2010.0,53.0,5.0,"Teegarden BR, Li H, Jayakumar H, Strah-Pleynet S, Dosa PI, Selaya SD, Kato N, Elwell KH, Davidson J, Cheng K, Saldana H, Frazer JM, Whelan K, Foster J, Espitia S, Webb RR, Beeley NR, Thomsen W, Morairty SR, Kilduff TS, Al-Shamma HA",,612567.0,DTCT0023186,3210415,DTCC00621396,1310109,37122,9.300162274132754,CN1C(=C(C=N1)Br)C2=C(C=CC(=C2)NC(=O)NC3=CC=C(C=C3)Br)OC,COc1ccc(NC(=O)Nc2ccc(Br)cc2)cc1-c1c(Br)cnn1C
8322,CHEMBL599226,P28223,,FCFLWJSPGSCBSZ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20143782.0,IC50,=,0.39799999999999996,NM,,cell_based,,,,,,,,,,,HEK293,Activity at human 5HT2A receptor expressed in HEK293 cells assessed as [3H]inositol phosphate production by scintillation counting,,"Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia.",J. Med. Chem.,2010.0,53.0,5.0,"Teegarden BR, Li H, Jayakumar H, Strah-Pleynet S, Dosa PI, Selaya SD, Kato N, Elwell KH, Davidson J, Cheng K, Saldana H, Frazer JM, Whelan K, Foster J, Espitia S, Webb RR, Beeley NR, Thomsen W, Morairty SR, Kilduff TS, Al-Shamma HA",,612567.0,DTCT0023186,3210419,DTCC00621397,38757,37122,9.400116927926312,CN1C(=C(C=N1)Br)C2=C(C=CC(=C2)NC(=O)NC3=CC=CC(=C3)C(F)(F)F)OC,COc1ccc(NC(=O)Nc2cccc(C(F)(F)F)c2)cc1-c1c(Br)cnn1C
8324,CHEMBL599429,P28223,,RZKKRHPYWSDEPC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20143782.0,IC50,=,3.98,NM,,cell_based,,,,,,,,,,,HEK293,Activity at human 5HT2A receptor expressed in HEK293 cells assessed as [3H]inositol phosphate production by scintillation counting,,"Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia.",J. Med. Chem.,2010.0,53.0,5.0,"Teegarden BR, Li H, Jayakumar H, Strah-Pleynet S, Dosa PI, Selaya SD, Kato N, Elwell KH, Davidson J, Cheng K, Saldana H, Frazer JM, Whelan K, Foster J, Espitia S, Webb RR, Beeley NR, Thomsen W, Morairty SR, Kilduff TS, Al-Shamma HA",,612567.0,DTCT0023186,3210427,DTCC00621399,760066,37122,8.400116927926312,CC(=O)C1=CC(=CC=C1)NC(=O)NC2=CC(=C(C=C2)OC)C3=C(C=NN3C)Br,COc1ccc(NC(=O)Nc2cccc(C(C)=O)c2)cc1-c1c(Br)cnn1C
8328,CHEMBL599828,P28223,,LGBYNYFPEYOEJE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20143782.0,IC50,=,2.0,NM,,cell_based,,,,,,,,,,,HEK293,Activity at human 5HT2A receptor expressed in HEK293 cells assessed as [3H]inositol phosphate production by scintillation counting,,"Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia.",J. Med. Chem.,2010.0,53.0,5.0,"Teegarden BR, Li H, Jayakumar H, Strah-Pleynet S, Dosa PI, Selaya SD, Kato N, Elwell KH, Davidson J, Cheng K, Saldana H, Frazer JM, Whelan K, Foster J, Espitia S, Webb RR, Beeley NR, Thomsen W, Morairty SR, Kilduff TS, Al-Shamma HA",,612567.0,DTCT0023186,3210515,DTCC00621808,2049320,37122,8.698970004336019,CN1C(=C(C=N1)Br)C2=C(C=CC(=C2)NC(=O)NC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)OC,COc1ccc(NC(=O)Nc2cc(C(F)(F)F)cc(C(F)(F)F)c2)cc1-c1c(Br)cnn1C
8330,CHEMBL6,P28223,INDOMETHACIN,CGIGDMFJXJATDK-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7430995,DTCC00132340,51479,46191,,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1
8332,CHEMBL600012,P28223,,LOLCALFUQXGZTP-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20096593.0,IC50,=,0.7,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in avCHO-K1 cells,,Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsulfonamides as selective 5-HT(2A) receptor antagonists.,Bioorg. Med. Chem.,2010.0,18.0,4.0,"Yoo E, Yoon J, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,608657.0,DTCT0023186,3180572,DTCC00620600,780437,37024,9.154901959985743,C1CCC(CC1)CN(CCCN2CCN(CC2)C3=CC=CC=C3)S(=O)(=O)C4=CC5=CC=CC=C5C=C4,O=S(=O)(c1ccc2ccccc2c1)N(CCCN1CCN(c2ccccc2)CC1)CC1CCCCC1
8334,CHEMBL600210,P28223,,DVKVDTQSWBEYCJ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20096593.0,IC50,=,11.6,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in avCHO-K1 cells,,Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsulfonamides as selective 5-HT(2A) receptor antagonists.,Bioorg. Med. Chem.,2010.0,18.0,4.0,"Yoo E, Yoon J, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,608657.0,DTCT0023186,3180573,DTCC00620601,133241,37024,7.935542010773082,COC1=CC=CC=C1N2CCN(CC2)CCCN(CC3CCCCC3)S(=O)(=O)C4=CC5=CC=CC=C5C=C4,COc1ccccc1N1CCN(CCCN(CC2CCCCC2)S(=O)(=O)c2ccc3ccccc3c2)CC1
8335,CHEMBL600325,P28223,PROSCILLARIDIN,MYEJFUXQJGHEQK-ALRJYLEOSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7381566,DTCC00486948,1705878,46191,,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2CC[C@@]3([C@H]4CC[C@@]5([C@H](CC[C@@]5([C@@H]4CCC3=C2)O)C6=COC(=O)C=C6)C)C)O)O)O,C[C@@H]1O[C@@H](O[C@@H]2C=C3CC[C@@H]4[C@H](CC[C@]5(C)[C@@H](c6ccc(=O)oc6)CC[C@]45O)[C@@]3(C)CC2)[C@H](O)[C@H](O)[C@H]1O
8337,CHEMBL600606,P28223,,VVTDHDJLGYYTGA-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20096593.0,IC50,=,51.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in avCHO-K1 cells,,Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsulfonamides as selective 5-HT(2A) receptor antagonists.,Bioorg. Med. Chem.,2010.0,18.0,4.0,"Yoo E, Yoon J, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,608657.0,DTCT0023186,3180593,DTCC00620995,1460106,37024,7.292429823902063,C1CC1CN(CCCN2CCN(CC2)C3=CC=C(C=C3)F)S(=O)(=O)C4=CC5=CC=CC=C5C=C4,O=S(=O)(c1ccc2ccccc2c1)N(CCCN1CCN(c2ccc(F)cc2)CC1)CC1CC1
8338,CHEMBL600607,P28223,,XWVOPOKWTRXOEH-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20096593.0,IC50,=,292.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in avCHO-K1 cells,,Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsulfonamides as selective 5-HT(2A) receptor antagonists.,Bioorg. Med. Chem.,2010.0,18.0,4.0,"Yoo E, Yoon J, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,608657.0,DTCT0023186,3180594,DTCC00620996,1717586,37024,6.534617148551582,C1CC1CN(CCCN2CCN(CC2)C3=CC=CC=C3)S(=O)(=O)C4=CC=CC5=C4N=CC=C5,O=S(=O)(c1cccc2cccnc12)N(CCCN1CCN(c2ccccc2)CC1)CC1CC1
8339,CHEMBL600822,P28223,,JKNQEPCKBWGZDH-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20096593.0,IC50,=,16.3,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in avCHO-K1 cells,,Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsulfonamides as selective 5-HT(2A) receptor antagonists.,Bioorg. Med. Chem.,2010.0,18.0,4.0,"Yoo E, Yoon J, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,608657.0,DTCT0023186,3180569,DTCC00620537,1778019,37024,7.787812395596042,COC1=CC=C(C=C1)S(=O)(=O)N(CCCN2CCN(CC2)C3=CC=CC=C3OC)CC4CCCCC4,COc1ccc(S(=O)(=O)N(CCCN2CCN(c3ccccc3OC)CC2)CC2CCCCC2)cc1
8340,CHEMBL601022,P28223,,XRFNGTPQLMHMKC-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20096593.0,IC50,=,19.5,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in avCHO-K1 cells,,Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsulfonamides as selective 5-HT(2A) receptor antagonists.,Bioorg. Med. Chem.,2010.0,18.0,4.0,"Yoo E, Yoon J, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,608657.0,DTCT0023186,3180570,DTCC00620598,1746079,37024,7.709965388637482,COC1=CC=C(C=C1)S(=O)(=O)N(CCCN2CCN(CC2)C3=CC=CC(=C3)C(F)(F)F)CC4CCCCC4,COc1ccc(S(=O)(=O)N(CCCN2CCN(c3cccc(C(F)(F)F)c3)CC2)CC2CCCCC2)cc1
8341,CHEMBL601037,P28223,,TYVAAESJXOVBND-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20096593.0,IC50,=,180.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in avCHO-K1 cells,,Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsulfonamides as selective 5-HT(2A) receptor antagonists.,Bioorg. Med. Chem.,2010.0,18.0,4.0,"Yoo E, Yoon J, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,608657.0,DTCT0023186,3180585,DTCC00620863,1298034,37024,6.7447274948966935,C1CC1CN(CCCN2CCN(CC2)C3=CC=CC=C3)S(=O)(=O)C4=CC=C(C=C4)[N+](=O)[O-],O=[N+]([O-])c1ccc(S(=O)(=O)N(CCCN2CCN(c3ccccc3)CC2)CC2CC2)cc1
8342,CHEMBL601097,P28223,,CKTGWMCLLCJMCX-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20143782.0,IC50,=,1.58,NM,,cell_based,,,,,,,,,,,HEK293,Activity at human 5HT2A receptor expressed in HEK293 cells assessed as [3H]inositol phosphate production by scintillation counting,,"Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia.",J. Med. Chem.,2010.0,53.0,5.0,"Teegarden BR, Li H, Jayakumar H, Strah-Pleynet S, Dosa PI, Selaya SD, Kato N, Elwell KH, Davidson J, Cheng K, Saldana H, Frazer JM, Whelan K, Foster J, Espitia S, Webb RR, Beeley NR, Thomsen W, Morairty SR, Kilduff TS, Al-Shamma HA",,612567.0,DTCT0023186,3210411,DTCC00621395,1504284,37122,8.801342913045577,CN1C(=C(C=N1)Br)C2=C(C=CC(=C2)NC(=O)NC3=CC=CC=C3F)OC,COc1ccc(NC(=O)Nc2ccccc2F)cc1-c1c(Br)cnn1C
8344,CHEMBL601220,P28223,,KTNLSECYGZNUNR-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20096593.0,IC50,=,221.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in avCHO-K1 cells,,Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsulfonamides as selective 5-HT(2A) receptor antagonists.,Bioorg. Med. Chem.,2010.0,18.0,4.0,"Yoo E, Yoon J, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,608657.0,DTCT0023186,3180592,DTCC00620934,457133,37024,6.655607726314889,C1CC1CN(CCCN2CCN(CC2)C3=CC=CC(=C3)C(F)(F)F)S(=O)(=O)C4=CC5=CC=CC=C5C=C4,O=S(=O)(c1ccc2ccccc2c1)N(CCCN1CCN(c2cccc(C(F)(F)F)c2)CC1)CC1CC1
8345,CHEMBL601249,P28223,,KCQYIQQSKRODHM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20096593.0,IC50,=,136.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in avCHO-K1 cells,,Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsulfonamides as selective 5-HT(2A) receptor antagonists.,Bioorg. Med. Chem.,2010.0,18.0,4.0,"Yoo E, Yoon J, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,608657.0,DTCT0023186,3180586,DTCC00620864,1460104,37024,6.866461091629782,COC1=CC=C(C=C1)S(=O)(=O)N(CCCN2CCN(CC2)C3=CC=CC=C3)CC4CC4,COc1ccc(S(=O)(=O)N(CCCN2CCN(c3ccccc3)CC2)CC2CC2)cc1
8346,CHEMBL601250,P28223,,MSKOJOSBKMRZIN-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20096593.0,IC50,=,2210.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in avCHO-K1 cells,,Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsulfonamides as selective 5-HT(2A) receptor antagonists.,Bioorg. Med. Chem.,2010.0,18.0,4.0,"Yoo E, Yoon J, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,608657.0,DTCT0023186,3180587,DTCC00620865,1589273,37024,5.655607726314889,COC1=CC=C(C=C1)S(=O)(=O)N(CCCN2CCN(CC2)C3=CC=CC=C3OC)CC4CC4,COc1ccc(S(=O)(=O)N(CCCN2CCN(c3ccccc3OC)CC2)CC2CC2)cc1
8347,CHEMBL601457,P28223,,AHYJMKNQHZIKJN-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20096593.0,IC50,=,171.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in avCHO-K1 cells,,Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsulfonamides as selective 5-HT(2A) receptor antagonists.,Bioorg. Med. Chem.,2010.0,18.0,4.0,"Yoo E, Yoon J, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,608657.0,DTCT0023186,3180582,DTCC00620796,2005133,37024,6.767003889607846,C1CC1CN(CCCN2CCN(CC2)C3=CC=CC=C3)S(=O)(=O)C4=CC=CC5=CC=CC=C54,O=S(=O)(c1cccc2ccccc12)N(CCCN1CCN(c2ccccc2)CC1)CC1CC1
8348,CHEMBL601458,P28223,,KCKBXDZTJJWHFS-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20096593.0,IC50,=,70.8,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in avCHO-K1 cells,,Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsulfonamides as selective 5-HT(2A) receptor antagonists.,Bioorg. Med. Chem.,2010.0,18.0,4.0,"Yoo E, Yoon J, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,608657.0,DTCT0023186,3180583,DTCC00620797,1298031,37024,7.149966742310231,C1CC1CN(CCCN2CCN(CC2)C3=CC=CC=C3)S(=O)(=O)C4=CC=C(C=C4)C(F)(F)F,O=S(=O)(c1ccc(C(F)(F)F)cc1)N(CCCN1CCN(c2ccccc2)CC1)CC1CC1
8349,CHEMBL601659,P28223,,OEOUVICYBFVIJH-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20096593.0,IC50,=,13.2,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in avCHO-K1 cells,,Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsulfonamides as selective 5-HT(2A) receptor antagonists.,Bioorg. Med. Chem.,2010.0,18.0,4.0,"Yoo E, Yoon J, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,608657.0,DTCT0023186,3180566,DTCC00620534,1621871,37024,7.87942606879415,C1CCC(CC1)CN(CCCN2CCN(CC2)C3=CC=CC=C3)S(=O)(=O)C4=CC=C(C=C4)F,O=S(=O)(c1ccc(F)cc1)N(CCCN1CCN(c2ccccc2)CC1)CC1CCCCC1
8350,CHEMBL601673,P28223,,IKAPDKMVJPPGFU-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20096593.0,IC50,=,142.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in avCHO-K1 cells,,Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsulfonamides as selective 5-HT(2A) receptor antagonists.,Bioorg. Med. Chem.,2010.0,18.0,4.0,"Yoo E, Yoon J, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,608657.0,DTCT0023186,3180584,DTCC00620798,1298032,37024,6.847711655616943,C1CC1CN(CCCN2CCN(CC2)C3=CC=CC=C3)S(=O)(=O)C4=CC=C(C=C4)F,O=S(=O)(c1ccc(F)cc1)N(CCCN1CCN(c2ccccc2)CC1)CC1CC1
8351,CHEMBL601855,P28223,,WUCMKNBEIOKYLN-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20096593.0,IC50,=,726.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in avCHO-K1 cells,,Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsulfonamides as selective 5-HT(2A) receptor antagonists.,Bioorg. Med. Chem.,2010.0,18.0,4.0,"Yoo E, Yoon J, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,608657.0,DTCT0023186,3180588,DTCC00620866,68637,37024,6.139063379299906,COC1=CC=C(C=C1)S(=O)(=O)N(CCCN2CCN(CC2)C3=CC=CC(=C3)C(F)(F)F)CC4CC4,COc1ccc(S(=O)(=O)N(CCCN2CCN(c3cccc(C(F)(F)F)c3)CC2)CC2CC2)cc1
8352,CHEMBL601859,P28223,,XNQGQGPTDOGIFO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20096593.0,IC50,=,72.5,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in avCHO-K1 cells,,Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsulfonamides as selective 5-HT(2A) receptor antagonists.,Bioorg. Med. Chem.,2010.0,18.0,4.0,"Yoo E, Yoon J, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,608657.0,DTCT0023186,3180589,DTCC00620931,262277,37024,7.139661993429006,COC1=CC=C(C=C1)S(=O)(=O)N(CCCN2CCN(CC2)C3=CC=C(C=C3)F)CC4CC4,COc1ccc(S(=O)(=O)N(CCCN2CCN(c3ccc(F)cc3)CC2)CC2CC2)cc1
8353,CHEMBL601872,P28223,,PAJUHBYYUOFCMD-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20096593.0,IC50,=,9.4,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in avCHO-K1 cells,,Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsulfonamides as selective 5-HT(2A) receptor antagonists.,Bioorg. Med. Chem.,2010.0,18.0,4.0,"Yoo E, Yoon J, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,608657.0,DTCT0023186,3180568,DTCC00620536,1939295,37024,8.0268721464003,COC1=CC=C(C=C1)S(=O)(=O)N(CCCN2CCN(CC2)C3=CC=CC=C3)CC4CCCCC4,COc1ccc(S(=O)(=O)N(CCCN2CCN(c3ccccc3)CC2)CC2CCCCC2)cc1
8354,CHEMBL601885,P28223,,AGDOTHDBWYNHAX-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20096593.0,IC50,=,59.9,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in avCHO-K1 cells,,Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsulfonamides as selective 5-HT(2A) receptor antagonists.,Bioorg. Med. Chem.,2010.0,18.0,4.0,"Yoo E, Yoon J, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,608657.0,DTCT0023186,3180578,DTCC00620734,1167992,37024,7.2225731776106885,COC1=CC=CC=C1N2CCN(CC2)CCCN(CC3CCCCC3)S(=O)(=O)C4=CC=CC5=C4N=CC=C5,COc1ccccc1N1CCN(CCCN(CC2CCCCC2)S(=O)(=O)c2cccc3cccnc23)CC1
8355,CHEMBL601886,P28223,,JDDSTHHDIDUGFN-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20096593.0,IC50,=,29.1,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in avCHO-K1 cells,,Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsulfonamides as selective 5-HT(2A) receptor antagonists.,Bioorg. Med. Chem.,2010.0,18.0,4.0,"Yoo E, Yoon J, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,608657.0,DTCT0023186,3180579,DTCC00620735,1556975,37024,7.536107011014093,C1CCC(CC1)CN(CCCN2CCN(CC2)C3=CC=CC(=C3)C(F)(F)F)S(=O)(=O)C4=CC=CC5=C4N=CC=C5,O=S(=O)(c1cccc2cccnc12)N(CCCN1CCN(c2cccc(C(F)(F)F)c2)CC1)CC1CCCCC1
8356,CHEMBL601887,P28223,,ZKUHCHZEFSTLSS-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20096593.0,IC50,=,5.1,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in avCHO-K1 cells,,Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsulfonamides as selective 5-HT(2A) receptor antagonists.,Bioorg. Med. Chem.,2010.0,18.0,4.0,"Yoo E, Yoon J, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,608657.0,DTCT0023186,3180580,DTCC00620736,812808,37024,8.292429823902063,C1CCC(CC1)CN(CCCN2CCN(CC2)C3=CC=C(C=C3)F)S(=O)(=O)C4=CC=CC5=C4N=CC=C5,O=S(=O)(c1cccc2cccnc12)N(CCCN1CCN(c2ccc(F)cc2)CC1)CC1CCCCC1
8357,CHEMBL602060,P28223,,MLMHNPCGKOQQQO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20096593.0,IC50,=,35.9,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in avCHO-K1 cells,,Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsulfonamides as selective 5-HT(2A) receptor antagonists.,Bioorg. Med. Chem.,2010.0,18.0,4.0,"Yoo E, Yoon J, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,608657.0,DTCT0023186,3180590,DTCC00620932,2005136,37024,7.444905551421681,C1CC1CN(CCCN2CCN(CC2)C3=CC=CC=C3)S(=O)(=O)C4=CC5=CC=CC=C5C=C4,O=S(=O)(c1ccc2ccccc2c1)N(CCCN1CCN(c2ccccc2)CC1)CC1CC1
8358,CHEMBL602064,P28223,,HBIPIGQKQYCXGR-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20143782.0,IC50,=,0.794,NM,,cell_based,,,,,,,,,,,HEK293,Activity at human 5HT2A receptor expressed in HEK293 cells assessed as [3H]inositol phosphate production by scintillation counting,,"Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia.",J. Med. Chem.,2010.0,53.0,5.0,"Teegarden BR, Li H, Jayakumar H, Strah-Pleynet S, Dosa PI, Selaya SD, Kato N, Elwell KH, Davidson J, Cheng K, Saldana H, Frazer JM, Whelan K, Foster J, Espitia S, Webb RR, Beeley NR, Thomsen W, Morairty SR, Kilduff TS, Al-Shamma HA",,612567.0,DTCT0023186,3210407,DTCC00621315,2017181,37122,9.100179497572904,CN1C(=C(C=N1)Br)C2=C(C=CC(=C2)NC(=O)NC3=CC(=CC=C3)F)OC,COc1ccc(NC(=O)Nc2cccc(F)c2)cc1-c1c(Br)cnn1C
8360,CHEMBL602087,P28223,,QZDVKRCKJBDEKO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20096593.0,IC50,=,13.1,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in avCHO-K1 cells,,Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsulfonamides as selective 5-HT(2A) receptor antagonists.,Bioorg. Med. Chem.,2010.0,18.0,4.0,"Yoo E, Yoon J, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,608657.0,DTCT0023186,3180575,DTCC00620665,1907192,37024,7.882728704344236,C1CCC(CC1)CN(CCCN2CCN(CC2)C3=CC=CC(=C3)C(F)(F)F)S(=O)(=O)C4=CC5=CC=CC=C5C=C4,O=S(=O)(c1ccc2ccccc2c1)N(CCCN1CCN(c2cccc(C(F)(F)F)c2)CC1)CC1CCCCC1
8361,CHEMBL602274,P28223,,VTKYRAJUGURCGT-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20096593.0,IC50,=,7.1,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in avCHO-K1 cells,,Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsulfonamides as selective 5-HT(2A) receptor antagonists.,Bioorg. Med. Chem.,2010.0,18.0,4.0,"Yoo E, Yoon J, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,608657.0,DTCT0023186,3180565,DTCC00620475,197568,37024,8.148741651280925,C1CCC(CC1)CN(CCCN2CCN(CC2)C3=CC=CC=C3)S(=O)(=O)C4=CC=C(C=C4)C(F)(F)F,O=S(=O)(c1ccc(C(F)(F)F)cc1)N(CCCN1CCN(c2ccccc2)CC1)CC1CCCCC1
8362,CHEMBL602279,P28223,,QSBMDWLJXJISML-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20096593.0,IC50,=,6.2,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in avCHO-K1 cells,,Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsulfonamides as selective 5-HT(2A) receptor antagonists.,Bioorg. Med. Chem.,2010.0,18.0,4.0,"Yoo E, Yoon J, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,608657.0,DTCT0023186,3180601,DTCC00621184,554726,37024,8.207608310501746,CC(CCN1CCN(CC1)C2=CC=C(C=C2)F)NS(=O)(=O)C3=CC4=CC=CC=C4C=C3,CC(CCN1CCN(c2ccc(F)cc2)CC1)NS(=O)(=O)c1ccc2ccccc2c1
8363,CHEMBL602284,P28223,,LSGJWSJZDUYGNN-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20096593.0,IC50,=,0.5,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in avCHO-K1 cells,,Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsulfonamides as selective 5-HT(2A) receptor antagonists.,Bioorg. Med. Chem.,2010.0,18.0,4.0,"Yoo E, Yoon J, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,608657.0,DTCT0023186,3180576,DTCC00620666,1039316,37024,9.301029995663981,C1CCC(CC1)CN(CCCN2CCN(CC2)C3=CC=C(C=C3)F)S(=O)(=O)C4=CC5=CC=CC=C5C=C4,O=S(=O)(c1ccc2ccccc2c1)N(CCCN1CCN(c2ccc(F)cc2)CC1)CC1CCCCC1
8364,CHEMBL602285,P28223,,POKYWZWHSFVCNV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20096593.0,IC50,=,34.6,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in avCHO-K1 cells,,Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsulfonamides as selective 5-HT(2A) receptor antagonists.,Bioorg. Med. Chem.,2010.0,18.0,4.0,"Yoo E, Yoon J, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,608657.0,DTCT0023186,3180577,DTCC00620667,1298030,37024,7.460923901207224,C1CCC(CC1)CN(CCCN2CCN(CC2)C3=CC=CC=C3)S(=O)(=O)C4=CC=CC5=C4N=CC=C5,O=S(=O)(c1cccc2cccnc12)N(CCCN1CCN(c2ccccc2)CC1)CC1CCCCC1
8365,CHEMBL602677,P28223,,BUZRERKWTGJPRW-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20096593.0,IC50,=,561.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in avCHO-K1 cells,,Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsulfonamides as selective 5-HT(2A) receptor antagonists.,Bioorg. Med. Chem.,2010.0,18.0,4.0,"Yoo E, Yoon J, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,608657.0,DTCT0023186,3180595,DTCC00620997,1167996,37024,6.251037138743839,COC1=CC=CC=C1N2CCN(CC2)CCCN(CC3CC3)S(=O)(=O)C4=CC=CC5=C4N=CC=C5,COc1ccccc1N1CCN(CCCN(CC2CC2)S(=O)(=O)c2cccc3cccnc23)CC1
8369,CHEMBL602873,P28223,,AODZXHQGKFCEBO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20143782.0,IC50,=,0.794,NM,,cell_based,,,,,,,,,,,HEK293,Activity at human 5HT2A receptor expressed in HEK293 cells assessed as [3H]inositol phosphate production by scintillation counting,,"Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia.",J. Med. Chem.,2010.0,53.0,5.0,"Teegarden BR, Li H, Jayakumar H, Strah-Pleynet S, Dosa PI, Selaya SD, Kato N, Elwell KH, Davidson J, Cheng K, Saldana H, Frazer JM, Whelan K, Foster J, Espitia S, Webb RR, Beeley NR, Thomsen W, Morairty SR, Kilduff TS, Al-Shamma HA",,612567.0,DTCT0023186,3210527,DTCC00621311,1051047,37122,9.100179497572904,CN1C(=C(C=N1)Br)C2=C(C=CC(=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)OC,COc1ccc(NC(=O)Nc2ccc(Cl)c(C(F)(F)F)c2)cc1-c1c(Br)cnn1C
8371,CHEMBL602874,P28223,,BQDQNHMUANFRRQ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20143782.0,IC50,=,0.39799999999999996,NM,,cell_based,,,,,,,,,,,HEK293,Activity at human 5HT2A receptor expressed in HEK293 cells assessed as [3H]inositol phosphate production by scintillation counting,,"Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia.",J. Med. Chem.,2010.0,53.0,5.0,"Teegarden BR, Li H, Jayakumar H, Strah-Pleynet S, Dosa PI, Selaya SD, Kato N, Elwell KH, Davidson J, Cheng K, Saldana H, Frazer JM, Whelan K, Foster J, Espitia S, Webb RR, Beeley NR, Thomsen W, Morairty SR, Kilduff TS, Al-Shamma HA",,612567.0,DTCT0023186,3210399,DTCC00621313,663249,37122,9.400116927926312,CN1C(=C(C=N1)Br)C2=C(C=CC(=C2)NC(=O)NC3=CC(=CC=C3)Cl)OC,COc1ccc(NC(=O)Nc2cccc(Cl)c2)cc1-c1c(Br)cnn1C
8373,CHEMBL602878,P28223,,MOHNVYNDWAHEEY-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20096593.0,IC50,=,75.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in avCHO-K1 cells,,Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsulfonamides as selective 5-HT(2A) receptor antagonists.,Bioorg. Med. Chem.,2010.0,18.0,4.0,"Yoo E, Yoon J, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,608657.0,DTCT0023186,3180596,DTCC00620998,780442,37024,7.1249387366083,C1CC1CN(CCCN2CCN(CC2)C3=CC=CC(=C3)C(F)(F)F)S(=O)(=O)C4=CC=CC5=C4N=CC=C5,O=S(=O)(c1cccc2cccnc12)N(CCCN1CCN(c2cccc(C(F)(F)F)c2)CC1)CC1CC1
8374,CHEMBL602882,P28223,,CVHVMGILPDMNDK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20096593.0,IC50,=,2.6,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in avCHO-K1 cells,,Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsulfonamides as selective 5-HT(2A) receptor antagonists.,Bioorg. Med. Chem.,2010.0,18.0,4.0,"Yoo E, Yoon J, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,608657.0,DTCT0023186,3180564,DTCC00620474,748434,37024,8.585026652029182,C1CCC(CC1)CN(CCCN2CCN(CC2)C3=CC=CC=C3)S(=O)(=O)C4=CC=CC5=CC=CC=C54,O=S(=O)(c1cccc2ccccc12)N(CCCN1CCN(c2ccccc2)CC1)CC1CCCCC1
8375,CHEMBL602889,P28223,,VFUQKLHANIZIQH-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20096593.0,IC50,=,8.3,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in avCHO-K1 cells,,Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsulfonamides as selective 5-HT(2A) receptor antagonists.,Bioorg. Med. Chem.,2010.0,18.0,4.0,"Yoo E, Yoon J, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,608657.0,DTCT0023186,3180597,DTCC00621135,554724,37024,8.080921907623926,C1CC1CN(CCCN2CCN(CC2)C3=CC=C(C=C3)F)S(=O)(=O)C4=CC=CC5=C4N=CC=C5,O=S(=O)(c1cccc2cccnc12)N(CCCN1CCN(c2ccc(F)cc2)CC1)CC1CC1
8376,CHEMBL603,P28223,ZAFIRLUKAST,YEEZWCHGZNKEEK-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7441911,DTCC00150003,1830696,46191,,CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)NC(=O)OC5CCCC5)C)OC,COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12
8378,CHEMBL603061,P28223,,YYMVSSUNYFFUMF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20143782.0,IC50,=,0.501,NM,,cell_based,,,,,,,,,,,HEK293,Activity at human 5HT2A receptor expressed in HEK293 cells assessed as [3H]inositol phosphate production by scintillation counting,,"Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia.",J. Med. Chem.,2010.0,53.0,5.0,"Teegarden BR, Li H, Jayakumar H, Strah-Pleynet S, Dosa PI, Selaya SD, Kato N, Elwell KH, Davidson J, Cheng K, Saldana H, Frazer JM, Whelan K, Foster J, Espitia S, Webb RR, Beeley NR, Thomsen W, Morairty SR, Kilduff TS, Al-Shamma HA",,612567.0,DTCT0023186,3210507,DTCC00621807,2081469,37122,9.300162274132754,CN1C(=C(C=N1)Cl)C2=C(C=CC(=C2)NC(=O)NC3=CC(=C(C=C3)F)F)OC,COc1ccc(NC(=O)Nc2ccc(F)c(F)c2)cc1-c1c(Cl)cnn1C
8380,CHEMBL603078,P28223,,MUUOYNXCYHNXFB-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20143782.0,IC50,=,0.251,NM,,cell_based,,,,,,,,,,,HEK293,Activity at human 5HT2A receptor expressed in HEK293 cells assessed as [3H]inositol phosphate production by scintillation counting,,"Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia.",J. Med. Chem.,2010.0,53.0,5.0,"Teegarden BR, Li H, Jayakumar H, Strah-Pleynet S, Dosa PI, Selaya SD, Kato N, Elwell KH, Davidson J, Cheng K, Saldana H, Frazer JM, Whelan K, Foster J, Espitia S, Webb RR, Beeley NR, Thomsen W, Morairty SR, Kilduff TS, Al-Shamma HA",,612567.0,DTCT0023186,3210403,DTCC00621314,501989,37122,9.600326278518962,CN1C(=C(C=N1)Br)C2=C(C=CC(=C2)NC(=O)NC3=CC=C(C=C3)F)OC,COc1ccc(NC(=O)Nc2ccc(F)cc2)cc1-c1c(Br)cnn1C
8382,CHEMBL603092,P28223,,MFBRVGWZBCQSSV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20096593.0,IC50,=,12.7,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in avCHO-K1 cells,,Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsulfonamides as selective 5-HT(2A) receptor antagonists.,Bioorg. Med. Chem.,2010.0,18.0,4.0,"Yoo E, Yoon J, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,608657.0,DTCT0023186,3180598,DTCC00621136,780443,37024,7.896196279044043,CC(CCN1CCN(CC1)C2=CC=CC=C2)NS(=O)(=O)C3=CC4=CC=CC=C4C=C3,CC(CCN1CCN(c2ccccc2)CC1)NS(=O)(=O)c1ccc2ccccc2c1
8383,CHEMBL603093,P28223,,DPYUFQCUTCRCNH-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20096593.0,IC50,=,180.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in avCHO-K1 cells,,Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsulfonamides as selective 5-HT(2A) receptor antagonists.,Bioorg. Med. Chem.,2010.0,18.0,4.0,"Yoo E, Yoon J, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,608657.0,DTCT0023186,3180600,DTCC00124374,426123,37024,6.7447274948966935,CC(CCN1CCN(CC1)C2=CC=CC(=C2)C(F)(F)F)NS(=O)(=O)C3=CC4=CC=CC=C4C=C3,CC(CCN1CCN(c2cccc(C(F)(F)F)c2)CC1)NS(=O)(=O)c1ccc2ccccc2c1
8384,CHEMBL603272,P28223,,RKSWEYYIIAAEAF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20096593.0,IC50,=,85.8,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in avCHO-K1 cells,,Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsulfonamides as selective 5-HT(2A) receptor antagonists.,Bioorg. Med. Chem.,2010.0,18.0,4.0,"Yoo E, Yoon J, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,608657.0,DTCT0023186,3180591,DTCC00620933,197572,37024,7.066512712151295,COC1=CC=CC=C1N2CCN(CC2)CCCN(CC3CC3)S(=O)(=O)C4=CC5=CC=CC=C5C=C4,COc1ccccc1N1CCN(CCCN(CC2CC2)S(=O)(=O)c2ccc3ccccc3c2)CC1
8385,CHEMBL603417,P28223,,BOQKMDDOTKOYRK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,19836247.0,IC50,=,92.0,NM,,cell_based,,,,,,,,,,,CHO,Antagonist activity at human 5HT2A receptor expressed in CHO cells assessed as inhibition of (R)-(-)-DOI hydrochloride-induced intracellular calcium mobilization by FLIPR assay,,"Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(phenylsulfonyl)-1H-indoles.",Bioorg. Med. Chem.,2009.0,17.0,22.0,"Heffernan GD, Coghlan RD, Manas ES, McDevitt RE, Li Y, Mahaney PE, Robichaud AJ, Huselton C, Alfinito P, Bray JA, Cosmi SA, Johnston GH, Kenney T, Koury E, Winneker RC, Deecher DC, Trybulski EJ",,603455.0,DTCT0023186,3155524,DTCC00611293,598454,36729,7.036212172654444,CC1CCCCN1CCC2=C3C(=CC=C2)NC=C3S(=O)(=O)C4=CC=CC=C4,CC1CCCCN1CCc1cccc2[nH]cc(S(=O)(=O)c3ccccc3)c12
8387,CHEMBL603430,P28223,,XTGQHXCVZRGUAO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,19836247.0,IC50,=,832.0,NM,,cell_based,,,,,,,,,,,CHO,Antagonist activity at human 5HT2A receptor expressed in CHO cells assessed as inhibition of (R)-(-)-DOI hydrochloride-induced intracellular calcium mobilization by FLIPR assay,,"Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(phenylsulfonyl)-1H-indoles.",Bioorg. Med. Chem.,2009.0,17.0,22.0,"Heffernan GD, Coghlan RD, Manas ES, McDevitt RE, Li Y, Mahaney PE, Robichaud AJ, Huselton C, Alfinito P, Bray JA, Cosmi SA, Johnston GH, Kenney T, Koury E, Winneker RC, Deecher DC, Trybulski EJ",,603455.0,DTCT0023186,3155507,DTCC00611265,1148522,36729,6.079876673709276,CCN(C)CCC1=C2C(=CC=C1)NC=C2S(=O)(=O)C3=CC=CC=C3,CCN(C)CCc1cccc2[nH]cc(S(=O)(=O)c3ccccc3)c12
8389,CHEMBL603499,P28223,,FLTTZQVAMFZDGS-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20096593.0,IC50,=,664.0,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in avCHO-K1 cells,,Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsulfonamides as selective 5-HT(2A) receptor antagonists.,Bioorg. Med. Chem.,2010.0,18.0,4.0,"Yoo E, Yoon J, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,608657.0,DTCT0023186,3180599,DTCC00621137,1874901,37024,6.1778319206319825,CC(CCN1CCN(CC1)C2=CC=CC=C2OC)NS(=O)(=O)C3=CC4=CC=CC=C4C=C3,COc1ccccc1N1CCN(CCC(C)NS(=O)(=O)c2ccc3ccccc3c2)CC1
8392,CHEMBL603609,P28223,,XOBFSDQTMCDCAD-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20143782.0,IC50,=,0.39799999999999996,NM,,cell_based,,,,,,,,,,,HEK293,Activity at human 5HT2A receptor expressed in HEK293 cells assessed as [3H]inositol phosphate production by scintillation counting,,"Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia.",J. Med. Chem.,2010.0,53.0,5.0,"Teegarden BR, Li H, Jayakumar H, Strah-Pleynet S, Dosa PI, Selaya SD, Kato N, Elwell KH, Davidson J, Cheng K, Saldana H, Frazer JM, Whelan K, Foster J, Espitia S, Webb RR, Beeley NR, Thomsen W, Morairty SR, Kilduff TS, Al-Shamma HA",,612567.0,DTCT0023186,3210431,DTCC00621471,112479,37122,9.400116927926312,CN1C(=C(C=N1)Br)C2=C(C=CC(=C2)NC(=O)NC3=CC=C(C=C3)OC)OC,COc1ccc(NC(=O)Nc2ccc(OC)c(-c3c(Br)cnn3C)c2)cc1
8394,CHEMBL604082,P28223,,FYBKVSDLSUOGGI-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20143782.0,IC50,=,2.51,NM,,cell_based,,,,,,,,,,,HEK293,Activity at human 5HT2A receptor expressed in HEK293 cells assessed as [3H]inositol phosphate production by scintillation counting,,"Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia.",J. Med. Chem.,2010.0,53.0,5.0,"Teegarden BR, Li H, Jayakumar H, Strah-Pleynet S, Dosa PI, Selaya SD, Kato N, Elwell KH, Davidson J, Cheng K, Saldana H, Frazer JM, Whelan K, Foster J, Espitia S, Webb RR, Beeley NR, Thomsen W, Morairty SR, Kilduff TS, Al-Shamma HA",,612567.0,DTCT0023186,3210523,DTCC00621810,1951479,37122,8.600326278518962,CN1C(=C(C=N1)Br)C2=C(C=CC(=C2)NC(=O)NC3=C(C=C(C=C3)Cl)C(F)(F)F)OC,COc1ccc(NC(=O)Nc2ccc(Cl)cc2C(F)(F)F)cc1-c1c(Br)cnn1C
8396,CHEMBL604586,P28223,,UDZTXQOLLVEQRE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20143782.0,IC50,=,1.26,NM,,cell_based,,,,,,,,,,,HEK293,Activity at human 5HT2A receptor expressed in HEK293 cells assessed as [3H]inositol phosphate production by scintillation counting,,"Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia.",J. Med. Chem.,2010.0,53.0,5.0,"Teegarden BR, Li H, Jayakumar H, Strah-Pleynet S, Dosa PI, Selaya SD, Kato N, Elwell KH, Davidson J, Cheng K, Saldana H, Frazer JM, Whelan K, Foster J, Espitia S, Webb RR, Beeley NR, Thomsen W, Morairty SR, Kilduff TS, Al-Shamma HA",,612567.0,DTCT0023186,3210447,DTCC00621475,1277313,37122,8.899629454882437,CC(C)N1C(=C(C=N1)Br)C2=C(C=CC(=C2)NC(=O)NC3=CC=C(C=C3)Cl)OC,COc1ccc(NC(=O)Nc2ccc(Cl)cc2)cc1-c1c(Br)cnn1C(C)C
8398,CHEMBL604685,P28223,,IZXAGSUHTCPYKG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,19836247.0,IC50,=,7972.0,NM,,cell_based,,,,,,,,,,,CHO,Antagonist activity at human 5HT2A receptor expressed in CHO cells assessed as inhibition of (R)-(-)-DOI hydrochloride-induced intracellular calcium mobilization by FLIPR assay,,"Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(phenylsulfonyl)-1H-indoles.",Bioorg. Med. Chem.,2009.0,17.0,22.0,"Heffernan GD, Coghlan RD, Manas ES, McDevitt RE, Li Y, Mahaney PE, Robichaud AJ, Huselton C, Alfinito P, Bray JA, Cosmi SA, Johnston GH, Kenney T, Koury E, Winneker RC, Deecher DC, Trybulski EJ",,603455.0,DTCT0023186,3155540,DTCC00611331,1439398,36729,5.09843270997155,C1CCN(CC1)CCCC2=C3C(=CC=C2)NC=C3S(=O)(=O)C4=CC=CC=C4,O=S(=O)(c1ccccc1)c1c[nH]c2cccc(CCCN3CCCCC3)c12
8400,CHEMBL604952,P28223,,RVRLBOIJZVWHOH-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20096593.0,IC50,=,7.7,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in avCHO-K1 cells,,Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsulfonamides as selective 5-HT(2A) receptor antagonists.,Bioorg. Med. Chem.,2010.0,18.0,4.0,"Yoo E, Yoon J, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,608657.0,DTCT0023186,3180581,DTCC00620795,295518,37024,8.113509274827518,C1CCC(CC1)CN(CCCN2CCN(CC2)C3=CC(=C(C=C3)Cl)Cl)S(=O)(=O)C4=CC=CC5=C4N=CC=C5,O=S(=O)(c1cccc2cccnc12)N(CCCN1CCN(c2ccc(Cl)c(Cl)c2)CC1)CC1CCCCC1
8401,CHEMBL605001,P28223,,VCHNOCSZCQRIQZ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20143782.0,IC50,=,1.0,NM,,cell_based,,,,,,,,,,,HEK293,Activity at human 5HT2A receptor expressed in HEK293 cells assessed as [3H]inositol phosphate production by scintillation counting,,"Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia.",J. Med. Chem.,2010.0,53.0,5.0,"Teegarden BR, Li H, Jayakumar H, Strah-Pleynet S, Dosa PI, Selaya SD, Kato N, Elwell KH, Davidson J, Cheng K, Saldana H, Frazer JM, Whelan K, Foster J, Espitia S, Webb RR, Beeley NR, Thomsen W, Morairty SR, Kilduff TS, Al-Shamma HA",,612567.0,DTCT0023186,3210487,DTCC00621751,566365,37122,9.0,CN1C(=CC=N1)C2=C(C=CC(=C2)NC(=O)NC3=CC=C(C=C3)Cl)OC,COc1ccc(NC(=O)Nc2ccc(Cl)cc2)cc1-c1ccnn1C
8404,CHEMBL605089,P28223,,JBNMIXNIEIEPSS-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,19836247.0,IC50,=,57.0,NM,,cell_based,,,,,,,,,,,CHO,Antagonist activity at human 5HT2A receptor expressed in CHO cells assessed as inhibition of (R)-(-)-DOI hydrochloride-induced intracellular calcium mobilization by FLIPR assay,,"Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(phenylsulfonyl)-1H-indoles.",Bioorg. Med. Chem.,2009.0,17.0,22.0,"Heffernan GD, Coghlan RD, Manas ES, McDevitt RE, Li Y, Mahaney PE, Robichaud AJ, Huselton C, Alfinito P, Bray JA, Cosmi SA, Johnston GH, Kenney T, Koury E, Winneker RC, Deecher DC, Trybulski EJ",,603455.0,DTCT0023186,3155528,DTCC00611316,2017074,36729,7.2441251443275085,CC1CCCN(C1)CCC2=C3C(=CC=C2)NC=C3S(=O)(=O)C4=CC=CC=C4,CC1CCCN(CCc2cccc3[nH]cc(S(=O)(=O)c4ccccc4)c23)C1
8406,CHEMBL605309,P28223,,HTHJJCBRKUSTFT-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,19836247.0,IC50,=,31.0,NM,,cell_based,,,,,,,,,,,CHO,Antagonist activity at human 5HT2A receptor expressed in CHO cells assessed as inhibition of (R)-(-)-DOI hydrochloride-induced intracellular calcium mobilization by FLIPR assay,,"Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(phenylsulfonyl)-1H-indoles.",Bioorg. Med. Chem.,2009.0,17.0,22.0,"Heffernan GD, Coghlan RD, Manas ES, McDevitt RE, Li Y, Mahaney PE, Robichaud AJ, Huselton C, Alfinito P, Bray JA, Cosmi SA, Johnston GH, Kenney T, Koury E, Winneker RC, Deecher DC, Trybulski EJ",,603455.0,DTCT0023186,3155499,DTCC00611248,953819,36729,7.508638306165727,C1CCC(C1)NCCC2=C3C(=CC=C2)NC=C3S(=O)(=O)C4=CC=CC=C4,O=S(=O)(c1ccccc1)c1c[nH]c2cccc(CCNC3CCCC3)c12
8412,CHEMBL605582,P28223,,LMOKVEBHFYFLTH-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20096593.0,IC50,=,4.2,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in avCHO-K1 cells,,Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsulfonamides as selective 5-HT(2A) receptor antagonists.,Bioorg. Med. Chem.,2010.0,18.0,4.0,"Yoo E, Yoon J, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,608657.0,DTCT0023186,3180567,DTCC00620535,1200310,37024,8.3767507096021,C1CCC(CC1)CN(CCCN2CCN(CC2)C3=CC=CC=C3)S(=O)(=O)C4=CC=C(C=C4)[N+](=O)[O-],O=[N+]([O-])c1ccc(S(=O)(=O)N(CCCN2CCN(c3ccccc3)CC2)CC2CCCCC2)cc1
8413,CHEMBL605636,P28223,,YVULDVDQRKNGCM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20143782.0,IC50,=,1.58,NM,,cell_based,,,,,,,,,,,HEK293,Activity at human 5HT2A receptor expressed in HEK293 cells assessed as [3H]inositol phosphate production by scintillation counting,,"Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia.",J. Med. Chem.,2010.0,53.0,5.0,"Teegarden BR, Li H, Jayakumar H, Strah-Pleynet S, Dosa PI, Selaya SD, Kato N, Elwell KH, Davidson J, Cheng K, Saldana H, Frazer JM, Whelan K, Foster J, Espitia S, Webb RR, Beeley NR, Thomsen W, Morairty SR, Kilduff TS, Al-Shamma HA",,612567.0,DTCT0023186,3210455,DTCC00621569,792112,37122,8.801342913045577,CN1C(=C(C=N1)Br)C2=C(C=CC(=C2)NC(=O)NC3=CC=C(C=C3)Cl)O,Cn1ncc(Br)c1-c1cc(NC(=O)Nc2ccc(Cl)cc2)ccc1O
8416,CHEMBL605787,P28223,,LJEKTDPOLMVDTE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20096593.0,IC50,=,3.4,NM,,cell_based,,,,,,,,,,,CHO-K1,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in avCHO-K1 cells,,Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsulfonamides as selective 5-HT(2A) receptor antagonists.,Bioorg. Med. Chem.,2010.0,18.0,4.0,"Yoo E, Yoon J, Pae AN, Rhim H, Park WK, Kong JY, Park Choo HY",,608657.0,DTCT0023186,3180571,DTCC00620599,1167991,37024,8.468521082957745,COC1=CC=C(C=C1)S(=O)(=O)N(CCCN2CCN(CC2)C3=CC=C(C=C3)F)CC4CCCCC4,COc1ccc(S(=O)(=O)N(CCCN2CCN(c3ccc(F)cc3)CC2)CC2CCCCC2)cc1
8419,CHEMBL606144,P28223,,GRBCPJNRLNFZRM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,19836247.0,IC50,=,258.0,NM,,cell_based,,,,,,,,,,,CHO,Antagonist activity at human 5HT2A receptor expressed in CHO cells assessed as inhibition of (R)-(-)-DOI hydrochloride-induced intracellular calcium mobilization by FLIPR assay,,"Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(phenylsulfonyl)-1H-indoles.",Bioorg. Med. Chem.,2009.0,17.0,22.0,"Heffernan GD, Coghlan RD, Manas ES, McDevitt RE, Li Y, Mahaney PE, Robichaud AJ, Huselton C, Alfinito P, Bray JA, Cosmi SA, Johnston GH, Kenney T, Koury E, Winneker RC, Deecher DC, Trybulski EJ",,603455.0,DTCT0023186,3155511,DTCC00611283,1083563,36729,6.58838029403677,C1CCN(C1)CCC2=C3C(=CC=C2)NC=C3S(=O)(=O)C4=CC=CC=C4,O=S(=O)(c1ccccc1)c1c[nH]c2cccc(CCN3CCCC3)c12
8421,CHEMBL606150,P28223,,CQNQTEGBNDNNMO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,19836247.0,IC50,=,1078.0,NM,,cell_based,,,,,,,,,,,CHO,Antagonist activity at human 5HT2A receptor expressed in CHO cells assessed as inhibition of (R)-(-)-DOI hydrochloride-induced intracellular calcium mobilization by FLIPR assay,,"Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(phenylsulfonyl)-1H-indoles.",Bioorg. Med. Chem.,2009.0,17.0,22.0,"Heffernan GD, Coghlan RD, Manas ES, McDevitt RE, Li Y, Mahaney PE, Robichaud AJ, Huselton C, Alfinito P, Bray JA, Cosmi SA, Johnston GH, Kenney T, Koury E, Winneker RC, Deecher DC, Trybulski EJ",,603455.0,DTCT0023186,3155491,DTCC00611237,1179437,36729,5.96738123914928,CCCNCCC1=C2C(=CC=C1)NC=C2S(=O)(=O)C3=CC=CC=C3,CCCNCCc1cccc2[nH]cc(S(=O)(=O)c3ccccc3)c12
8423,CHEMBL606178,P28223,,CLAZIASNFJPUOW-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20143782.0,IC50,=,1.26,NM,,cell_based,,,,,,,,,,,HEK293,Activity at human 5HT2A receptor expressed in HEK293 cells assessed as [3H]inositol phosphate production by scintillation counting,,"Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia.",J. Med. Chem.,2010.0,53.0,5.0,"Teegarden BR, Li H, Jayakumar H, Strah-Pleynet S, Dosa PI, Selaya SD, Kato N, Elwell KH, Davidson J, Cheng K, Saldana H, Frazer JM, Whelan K, Foster J, Espitia S, Webb RR, Beeley NR, Thomsen W, Morairty SR, Kilduff TS, Al-Shamma HA",,612567.0,DTCT0023186,3210491,DTCC00621752,339971,37122,8.899629454882437,CN1C(=C(C=N1)Br)C2=C(C=CC(=C2)NC(=O)NC3=C(C=C(C=C3)Cl)Cl)OC,COc1ccc(NC(=O)Nc2ccc(Cl)cc2Cl)cc1-c1c(Br)cnn1C
8425,CHEMBL606191,P28223,,PFXSDMITUDDRFI-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20143782.0,IC50,=,1.58,NM,,cell_based,,,,,,,,,,,HEK293,Activity at human 5HT2A receptor expressed in HEK293 cells assessed as [3H]inositol phosphate production by scintillation counting,,"Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia.",J. Med. Chem.,2010.0,53.0,5.0,"Teegarden BR, Li H, Jayakumar H, Strah-Pleynet S, Dosa PI, Selaya SD, Kato N, Elwell KH, Davidson J, Cheng K, Saldana H, Frazer JM, Whelan K, Foster J, Espitia S, Webb RR, Beeley NR, Thomsen W, Morairty SR, Kilduff TS, Al-Shamma HA",,612567.0,DTCT0023186,3210423,DTCC00621398,339967,37122,8.801342913045577,CN1C(=C(C=N1)Br)C2=C(C=CC(=C2)NC(=O)NC3=CC=C(C=C3)C(F)(F)F)OC,COc1ccc(NC(=O)Nc2ccc(C(F)(F)F)cc2)cc1-c1c(Br)cnn1C
8429,CHEMBL606622,P28223,,AUGKRYGTYDFPKP-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20143782.0,IC50,=,1.0,NM,,cell_based,,,,,,,,,,,HEK293,Activity at human 5HT2A receptor expressed in HEK293 cells assessed as [3H]inositol phosphate production by scintillation counting,,"Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia.",J. Med. Chem.,2010.0,53.0,5.0,"Teegarden BR, Li H, Jayakumar H, Strah-Pleynet S, Dosa PI, Selaya SD, Kato N, Elwell KH, Davidson J, Cheng K, Saldana H, Frazer JM, Whelan K, Foster J, Espitia S, Webb RR, Beeley NR, Thomsen W, Morairty SR, Kilduff TS, Al-Shamma HA",,612567.0,DTCT0023186,3210451,DTCC00621568,695557,37122,9.0,CC(C)N1C(=C(C=N1)Br)C2=C(C=CC(=C2)NC(=O)NC3=CC=C(C=C3)F)OC,COc1ccc(NC(=O)Nc2ccc(F)cc2)cc1-c1c(Br)cnn1C(C)C
8433,CHEMBL608,P28223,PROBUCOL,FYPMFJGVHOHGLL-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7387821,DTCC00150969,962450,46191,,CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)SC(C)(C)SC2=CC(=C(C(=C2)C(C)(C)C)O)C(C)(C)C,CC(C)(Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1
8438,CHEMBL608425,P28223,,SXWCGHMZZQORDP-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20143782.0,IC50,=,6.31,NM,,cell_based,,,,,,,,,,,HEK293,Activity at human 5HT2A receptor expressed in HEK293 cells assessed as [3H]inositol phosphate production by scintillation counting,,"Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia.",J. Med. Chem.,2010.0,53.0,5.0,"Teegarden BR, Li H, Jayakumar H, Strah-Pleynet S, Dosa PI, Selaya SD, Kato N, Elwell KH, Davidson J, Cheng K, Saldana H, Frazer JM, Whelan K, Foster J, Espitia S, Webb RR, Beeley NR, Thomsen W, Morairty SR, Kilduff TS, Al-Shamma HA",,612567.0,DTCT0023186,3210443,DTCC00621474,469357,37122,8.199970640755867,CN1C(=C(C=N1)Br)C2=C(C=CC(=C2)NC(=O)NC3=CC=CC(=C3)C#N)OC,COc1ccc(NC(=O)Nc2cccc(C#N)c2)cc1-c1c(Br)cnn1C
8444,CHEMBL60889,P28223,MOSAPRIDE,YPELFRMCRYSPKZ-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7428546,DTCC00208987,217581,46191,,CCOC1=CC(=C(C=C1C(=O)NCC2CN(CCO2)CC3=CC=C(C=C3)F)Cl)N,CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1
8451,CHEMBL61,P28223,PODOFILOX,YJGVMLPVUAXIQN-XVVDYKMHSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7391849,DTCC00136120,51501,46191,,COC1=CC(=CC(=C1OC)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](C4=CC5=C(C=C24)OCO5)O,COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OC
8456,CHEMBL610208,P28223,,GGJYDEZYCACGIQ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,20143782.0,IC50,=,0.501,NM,,cell_based,,,,,,,,,,,HEK293,Activity at human 5HT2A receptor expressed in HEK293 cells assessed as [3H]inositol phosphate production by scintillation counting,,"Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia.",J. Med. Chem.,2010.0,53.0,5.0,"Teegarden BR, Li H, Jayakumar H, Strah-Pleynet S, Dosa PI, Selaya SD, Kato N, Elwell KH, Davidson J, Cheng K, Saldana H, Frazer JM, Whelan K, Foster J, Espitia S, Webb RR, Beeley NR, Thomsen W, Morairty SR, Kilduff TS, Al-Shamma HA",,612567.0,DTCT0023186,3210483,DTCC00621642,953929,37122,9.300162274132754,CN1C(=C(C=N1)Cl)C2=C(C=CC(=C2)NC(=O)NC3=CC=C(C=C3)Cl)OC,COc1ccc(NC(=O)Nc2ccc(Cl)cc2)cc1-c1c(Cl)cnn1C
8459,CHEMBL611,P28223,TERAZOSIN,VCKUSRYTPJJLNI-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7463531,DTCC00103842,2025644,46191,,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC,COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC
8463,CHEMBL614,P28223,PYRAZINAMIDE,IPEHBUMCGVEMRF-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7390240,DTCC00151678,898296,46191,,C1=CN=C(C=N1)C(=O)N,NC(=O)c1cnccn1
8475,CHEMBL621,P28223,TRAZODONE,PHLBKPHSAVXXEF-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,20.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7451693,DTCC00154041,51512,46191,7.698970004336019,C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12
8477,CHEMBL62193,P28223,SULFADIMETHOXINE,ZZORFUFYDOWNEF-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7478243,DTCC00208934,703987,46191,,COC1=NC(=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N)OC,COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1
8479,CHEMBL622,P28223,ETODOLAC,NNYBQONXHNTVIJ-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7332825,DTCC00154070,153443,46191,,CCC1=C2C(=CC=C1)C3=C(N2)C(OCC3)(CC)CC(=O)O,CCc1cccc2c3c([nH]c12)C(CC)(CC(=O)O)OCC3
8484,CHEMBL625,P28223,THIABENDAZOLE,WJCNZQLZVWNLKY-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7470279,DTCC00154204,217588,46191,,C1=CC=C2C(=C1)NC(=N2)C3=CSC=N3,c1ccc2[nH]c(-c3cscn3)nc2c1
8486,CHEMBL6273,P28223,FLEROXACIN,XBJBPGROQZJDOJ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7330956,DTCC00132376,1220277,46191,,CN1CCN(CC1)C2=C(C=C3C(=C2F)N(C=C(C3=O)C(=O)O)CCF)F,CN1CCN(c2c(F)cc3c(=O)c(C(=O)O)cn(CCF)c3c2F)CC1
8488,CHEMBL628,P28223,PENTOXIFYLLINE,BYPFEZZEUUWMEJ-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7384908,DTCC00154570,1641851,46191,,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O
8493,CHEMBL629,P28223,AMITRIPTYLINE,KRMDCWKBEZIMAB-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,15.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7298295,DTCC00154602,477911,46191,7.823908740944319,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCC=C1c2ccccc2CCc2ccccc21
8497,CHEMBL631,P28223,PROPAFENONE,JWHAUXFOSRPERK-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,654.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7390124,DTCC00154637,1927020,46191,6.184422251675732,CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O,CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1
8499,CHEMBL632,P28223,BETAMETHASONE,UREBDLICKHMUKA-DVTGEIKXSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7277174,DTCC00154673,1188064,46191,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
8501,CHEMBL633,P28223,AMIODARONE,IYIKLHRQXLHMJQ-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,3590.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7294004,DTCC00154700,768472,46191,5.444905551421681,CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I,CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1
8503,CHEMBL63323,P28223,NIFLUMIC ACID,JZFPYUNJRRFVQU-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7405641,DTCC00211494,639583,46191,,C1=CC(=CC(=C1)NC2=C(C=CC=N2)C(=O)O)C(F)(F)F,O=C(O)c1cccnc1Nc1cccc(C(F)(F)F)c1
8505,CHEMBL635,P28223,PREDNISONE,XOFYZVNMUHMLCC-ZPOLXVRWSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7396271,DTCC00154731,381016,46191,,C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO
8507,CHEMBL63560,P28223,(R)-BICALUTAMIDE,LKJPYSCBVHEWIU-KRWDZBQOSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7283519,DTCC00216573,833153,46191,,C[C@](CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O,C[C@](O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1
8513,CHEMBL637,P28223,VENLAFAXINE,PNVNVHUZROJLTJ-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7452182,DTCC00154763,1512820,46191,,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1
8521,CHEMBL64,P28223,ISONIAZID,QRXWMOHMRWLFEY-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7435382,DTCC00136222,51480,46191,,C1=CN=CC=C1C(=O)NN,NNC(=O)c1ccncc1
8523,CHEMBL640,P28223,PROCAINAMIDE,REQCZEXYDRLIBE-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7392114,DTCC00154806,1577009,46191,,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,CCN(CC)CCNC(=O)c1ccc(N)cc1
8525,CHEMBL642,P28223,ACEBUTOLOL,GOEMGAFJFRBGGG-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7292186,DTCC00154812,1798405,46191,,CCCC(=O)NC1=CC(=C(C=C1)OCC(CNC(C)C)O)C(=O)C,CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(C(C)=O)c1
8527,CHEMBL643,P28223,PROMETHAZINE,PWWVAXIEGOYWEE-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23919353.0,IC50,=,23.0,NM,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor (unknown origin) by radioligand binding assay,,Polypharmacology - foe or friend?,J. Med. Chem.,2013.0,56.0,22.0,,,1275659.0,DTCT0023186,12936376,DTCC00154825,1191210,56376,7.638272163982407,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,CC(CN1c2ccccc2Sc2ccccc21)N(C)C
8528,CHEMBL643,P28223,PROMETHAZINE,PWWVAXIEGOYWEE-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,67.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7387855,DTCC00154825,1188074,46191,7.173925197299173,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,CC(CN1c2ccccc2Sc2ccccc21)N(C)C
8530,CHEMBL6437,P28223,MIANSERIN,UEQUQVLFIPOEMF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755364.0,IC50,=,10.47,NM,,cell_based,,,,,,,,,,,L929,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2508.0,DTCT0023186,813110,DTCC00132673,1370908,5128,7.980053318321158,CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42,CN1CCN2c3ccccc3Cc3ccccc3C2C1
8531,CHEMBL6437,P28223,MIANSERIN,UEQUQVLFIPOEMF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755365.0,IC50,=,20.89,NM,,,,,,,,,,,,,,Binding affinity for human cloned Alpha-2A adrenergic receptor,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,33212.0,DTCT0023186,1590340,DTCC00132673,1359243,5129,7.680061560019691,CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42,CN1CCN2c3ccccc3Cc3ccccc3C2C1
8537,CHEMBL6437,P28223,MIANSERIN,UEQUQVLFIPOEMF-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,1.76,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7413333,DTCC00132673,1383778,46191,8.75448733218585,CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42,CN1CCN2c3ccccc3Cc3ccccc3C2C1
8539,CHEMBL6466,P28223,COUMARIN,ZYGHJZDHTFUPRJ-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7369872,DTCC00133265,833159,46191,,C1=CC=C2C(=C1)C=CC(=O)O2,O=c1ccc2ccccc2o1
8541,CHEMBL648,P28223,CYCLIZINE,UVKZSORBKUEBAZ-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,225.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7352618,DTCC00154967,381007,46191,6.647817481888637,CN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3,CN1CCN(C(c2ccccc2)c2ccccc2)CC1
8543,CHEMBL64894,P28223,GENTIAN VIOLET,ZXJXZNDDNMQXFV-UHFFFAOYSA-M,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,2627.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7312388,DTCC00212699,703981,46191,5.5805399272139296,CN(C)C1=CC=C(C=C1)C(=C2C=CC(=[N+](C)C)C=C2)C3=CC=C(C=C3)N(C)C.[Cl-],CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1
8545,CHEMBL649,P28223,NADOLOL,VWPOSFSPZNDTMJ-UCWKZMIHSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7432956,DTCC00154988,2057650,46191,,CC(C)(C)NCC(COC1=CC=CC2=C1C[C@@H]([C@@H](C2)O)O)O,CC(C)(C)NCC(O)COc1cccc2c1C[C@H](O)[C@H](O)C2
8547,CHEMBL65,P28223,CAMPTOTHECIN,VSJKWCGYPAHWDS-FQEVSTJZSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7269025,DTCC00136347,51451,46191,,CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)O,CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3ccccc3nc2-1
8549,CHEMBL650,P28223,METHYLPREDNISOLONE,VHRSUDSXCMQTMA-PJHHCJLFSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7438809,DTCC00154993,1447885,46191,,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O,C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12
8555,CHEMBL653,P28223,NIZATIDINE,SGXXNSQHWDMGGP-IZZDOVSWSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7375616,DTCC00155018,866021,46191,,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CSC(=N1)CN(C)C,CN/C(=C\[N+](=O)[O-])NCCSCc1csc(CN(C)C)n1
8568,CHEMBL657,P28223,DIPHENHYDRAMINE,ZZVUWRFHKOJYTH-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,1295.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7340578,DTCC00155038,1285873,46191,5.887730231582729,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,CN(C)CCOC(c1ccccc1)c1ccccc1
8570,CHEMBL659,P28223,GALANTAMINE,ASUTZQLVASHGKV-JDFRZJQESA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7303696,DTCC00155049,994592,46191,,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O,COc1ccc2c3c1O[C@H]1C[C@@H](O)C=C[C@@]31CCN(C)C2
8572,CHEMBL660,P28223,AMANTADINE,DKNWSYNQZKUICI-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7287289,DTCC00155056,1285872,46191,,C1C2CC3CC1CC(C2)(C3)N,NC12CC3CC(CC(C3)C1)C2
8584,CHEMBL661,P28223,ALPRAZOLAM,VREFGVBLTWBCJP-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7281399,DTCC00155057,994588,46191,,CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4,Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2
8609,CHEMBL66227,P28223,CP-293019,QXWNESOGWFJDFR-PBHICJAKSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,9871530.0,IC50,=,150.0,NM,,cell_based,,,,,,,,,,,CHO,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,,"Synthesis, SAR and pharmacology of CP-293,019: a potent, selective dopamine D4 receptor antagonist.",Bioorg. Med. Chem. Lett.,1998.0,8.0,7.0,"Sanner MA, Chappie TA, Dunaiskis AR, Fliri AF, Desai KA, Zorn SH, Jackson ER, Johnson CG, Morrone JM, Seymour PA, Majchrzak MJ, Faraci WS, Collins JL, Duignan DB, Prete Di CC, Lee JS, Trozzi A",,2468.0,DTCT0023186,1498772,DTCC01740801,842808,3042,6.823908740944319,C1C[C@H]2CN(CCN2C[C@@H]1COC3=CC=C(C=C3)F)C4=NC=C(C=N4)F,Fc1ccc(OC[C@@H]2CC[C@H]3CN(c4ncc(F)cn4)CCN3C2)cc1
8622,CHEMBL666,P28223,FOSCARNET,ZJAOAACCNHFJAH-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7316424,DTCC00155151,1765971,46191,,C(=O)(O)P(=O)(O)O,O=C(O)P(=O)(O)O
8624,CHEMBL672,P28223,FENOFIBRATE,YMTINGFKWWXKFG-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,2118.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7305252,DTCC01738591,1220276,46191,5.674074044228534,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,CC(C)OC(=O)C(C)(C)Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1
8627,CHEMBL679,P28223,EPINEPHRINE,UCTWMZQNUQWSLP-VIFPVBQESA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7311271,DTCC00156188,1512808,46191,,CNC[C@@H](C1=CC(=C(C=C1)O)O)O,CNC[C@H](O)c1ccc(O)c(O)c1
8631,CHEMBL683,P28223,CLOFIBRIC ACID,TXCGAZHTZHNUAI-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7362923,DTCC00156551,1894964,46191,,CC(C)(C(=O)O)OC1=CC=C(C=C1)Cl,CC(C)(Oc1ccc(Cl)cc1)C(=O)O
8633,CHEMBL685,P28223,MEBENDAZOLE,OPXLLQIJSORQAM-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7427723,DTCC00156769,800580,46191,,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CC=C3,COC(=O)Nc1nc2ccc(C(=O)c3ccccc3)cc2[nH]1
8635,CHEMBL686,P28223,MEFENAMIC ACID,HYYBABOKPJLUIN-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7410631,DTCC00157071,1416034,46191,,CC1=C(C(=CC=C1)NC2=CC=CC=C2C(=O)O)C,Cc1cccc(Nc2ccccc2C(=O)O)c1C
8638,CHEMBL689,P28223,MANNITOL,FBPFZTCFMRRESA-KVTDHHQDSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7406229,DTCC00157212,1960078,46191,,C([C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)O,OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
8640,CHEMBL691,P28223,ETHINYL ESTRADIOL,BFPYWIDHMRZLRN-SLHNCBLASA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7336975,DTCC00158050,2089747,46191,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C
8644,CHEMBL695,P28223,TRIMETHADIONE,IRYJRGCIQBGHIV-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7446349,DTCC00158510,1830695,46191,,CC1(C(=O)N(C(=O)O1)C)C,CN1C(=O)OC(C)(C)C1=O
8646,CHEMBL696,P28223,ETHOSUXIMIDE,HAPOVYFOVVWLRS-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7311460,DTCC00158516,88627,46191,,CCC1(CC(=O)NC1=O)C,CCC1(C)CC(=O)NC1=O
8648,CHEMBL6966,P28223,VERAPAMIL,SGTNSNPWRIOYBX-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,442.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7453248,DTCC00133226,51515,46191,6.354577730650908,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC
8652,CHEMBL698,P28223,TETRACAINE,GKCBAIGFKIBETG-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,3415.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7487406,DTCC00158693,866024,46191,5.466609291982449,CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C,CCCCNc1ccc(C(=O)OCCN(C)C)cc1
8654,CHEMBL7002,P28223,CIGLITAZONE,YZFWTZACSRHJQD-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7347560,DTCC00133474,413970,46191,,CC1(CCCCC1)COC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,CC1(COc2ccc(CC3SC(=O)NC3=O)cc2)CCCCC1
8656,CHEMBL701,P28223,BACLOFEN,KPYSYYIEGFHWSV-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7261141,DTCC00159319,1318438,46191,,C1=CC(=CC=C1C(CC(=O)O)CN)Cl,NCC(CC(=O)O)c1ccc(Cl)cc1
8658,CHEMBL702,P28223,PIPERACILLIN,IVBHGBMCVLDMKU-GXNBUGAJSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7400323,DTCC00159449,962449,46191,,CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2=CC=CC=C2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O,CCN1CCN(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3[C@@H](C(=O)O)C(C)(C)S[C@H]23)c2ccccc2)C(=O)C1=O
8660,CHEMBL70586,P28223,SPIRADOLINE,NYKCGQQJNVPOLU-ONTIZHBOSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7488647,DTCC00226650,1318446,46191,,CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N3CCCC3)C(=O)CC4=CC(=C(C=C4)Cl)Cl,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1
8662,CHEMBL707,P28223,DOXAZOSIN,RUZYUOTYCVRMRZ-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7347035,DTCC00159683,1992804,46191,,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC,COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC
8674,CHEMBL708,P28223,ZIPRASIDONE,MVWVFYHBGMAFLY-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,16220969.0,IC50,=,0.42,NM,,,,,,,,,,,,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,Designed multiple ligands. An emerging drug discovery paradigm.,J. Med. Chem.,2005.0,48.0,21.0,"Morphy R, Rankovic Z",,321230.0,DTCT0023186,1862093,DTCC00159929,713875,19940,9.3767507096021,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1
8687,CHEMBL70927,P28223,DEFERIPRONE,TZXKOCQBRNJULO-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7352822,DTCC00224426,348396,46191,,CC1=C(C(=O)C=CN1C)O,Cc1c(O)c(=O)ccn1C
8698,CHEMBL71,P28223,CHLORPROMAZINE,ZPEIMTDSQAKGNT-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23919353.0,IC50,=,3.4,NM,,,,,,,,,,,,,,Binding affinity to 5HT2A receptor (unknown origin) by radioligand binding assay,,Polypharmacology - foe or friend?,J. Med. Chem.,2013.0,56.0,22.0,,,1275659.0,DTCT0023186,12936382,DTCC00137262,57544,56376,8.468521082957745,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21
8701,CHEMBL71,P28223,CHLORPROMAZINE,ZPEIMTDSQAKGNT-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,3.85,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7368956,DTCC00137262,51456,46191,8.414539270491499,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21
8703,CHEMBL710,P28223,FINASTERIDE,DBEPLOCGEIEOCV-WSBQPABSSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7322351,DTCC00159940,348402,46191,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NC(C)(C)C)CC[C@@H]4[C@@]3(C=CC(=O)N4)C,CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C
8705,CHEMBL711,P28223,PHENINDIONE,NFBAXHOPROOJAW-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7380676,DTCC00159969,185556,46191,,C1=CC=C(C=C1)C2C(=O)C3=CC=CC=C3C2=O,O=C1c2ccccc2C(=O)C1c1ccccc1
8707,CHEMBL712,P28223,ANISINDIONE,XRCFXMGQEVUZFC-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7277743,DTCC00160027,574619,46191,,COC1=CC=C(C=C1)C2C(=O)C3=CC=CC=C3C2=O,COc1ccc(C2C(=O)c3ccccc3C2=O)cc1
8709,CHEMBL714,P28223,ALBUTEROL,NDAUXUAQIAJITI-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7488297,DTCC00160256,962451,46191,,CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O,CC(C)(C)NCC(O)c1ccc(O)c(CO)c1
8715,CHEMBL715,P28223,OLANZAPINE,KVWDHTXUZHCGIO-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,8831770.0,IC50,=,9.0,NM,,cell_based,,,,,,,,,,,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,"Structure-activity relationships of a series of novel (piperazinylbutyl)thiazolidinone antipsychotic agents related to 3-[4-[4-(6-fluorobenzo[b]thien-3-yl)-1-piperazinyl]butyl]-2,5,5- trimethyl-4-thiazolidinone maleate.",J. Med. Chem.,1996.0,39.0,20.0,"Hrib NJ, Jurcak JG, Bregna DE, Burgher KL, Hartman HB, Kafka S, Kerman LL, Kongsamut S, Roehr JE, Szewczak MR, Woods-Kettelberger AT, Corbett R",,2272.0,DTCT0023186,1612323,DTCC00160346,1489363,13832,8.045757490560675,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1
8732,CHEMBL715,P28223,OLANZAPINE,KVWDHTXUZHCGIO-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,23466228.0,IC50,=,7.0,NM,,,,,,,,,,,,,,Displacement of [3H]ketanserin from 5-HT2A receptor in human frontal cortex after 30 mins by scintillation counting,,"[11C]olanzapine, radiosynthesis and lipophilicity of a new potential PET 5-HT2 and D2 receptor radioligand.",Bioorg. Med. Chem. Lett.,2013.0,23.0,7.0,"Gao M, Shi Z, Wang M, Zheng QH",,950920.0,DTCT0023186,11851985,DTCC00160346,1495230,54249,8.154901959985743,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1
8737,CHEMBL715,P28223,OLANZAPINE,KVWDHTXUZHCGIO-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,26227779.0,IC50,=,100.0,NM,,cell_based,,,,,,,,,,,,Antagonist activity against 5-HT2A receptor (unknown origin) expressed in HEK293 cell membranes assessed as reduction in [35S]-GTPgammaS binding incubated for 30 mins by liquid scintillation counting method,,Discovery of novel potent and selective ligands for 5-HT2A receptor with quinazoline scaffold.,Bioorg. Med. Chem. Lett.,2015.0,25.0,18.0,"Deng X, Guo L, Xu L, Zhen X, Yu K, Zhao W, Fu W",,1512600.0,DTCT0023186,14523171,DTCC00160346,1486191,63448,7.0,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1
8738,CHEMBL715,P28223,OLANZAPINE,KVWDHTXUZHCGIO-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,5.02,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7397267,DTCC00160346,1512814,46191,8.29929628285498,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1
8766,CHEMBL716,P28223,QUETIAPINE,URKOMYMAXPYINW-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,117.8,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7403146,DTCC00160380,1734062,46191,6.928854709548917,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42,OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1
8777,CHEMBL717,P28223,MEDROXYPROGESTERONE ACETATE,PSGAAPLEWMOORI-PEINSRQWSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7406333,DTCC00160710,1188070,46191,,C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
8778,CHEMBL717,P28223,MEDROXYPROGESTERONE ACETATE,PSGAAPLEWMOORI-PEINSRQWSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7436247,DTCC00160710,1188069,46191,,C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
8791,CHEMBL72,P28223,DESIPRAMINE,HCYAFALTSJYZDH-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7357161,DTCC00137288,1124448,46191,,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCN1c2ccccc2CCc2ccccc21
8793,CHEMBL720,P28223,BENZYL ALCOHOL,WVDDGKGOMKODPV-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7258407,DTCC00161432,1641844,46191,,C1=CC=C(C=C1)CO,OCc1ccccc1
8795,CHEMBL723,P28223,CARVEDILOL,OGHNVEJMJSYVRP-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,410.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7338651,DTCC00162415,993764,46191,6.3872161432802645,COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O,COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12
8809,CHEMBL726,P28223,FLUPHENAZINE,PLDUPXSUYLZYBN-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,5.1,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7329128,DTCC00162562,1734056,46191,8.292429823902063,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1
8812,CHEMBL727,P28223,THIOGUANINE,WYWHKKSPHMUBEB-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7457284,DTCC00162578,120978,46191,,C1=NC2=C(N1)C(=S)N=C(N2)N,Nc1nc(=S)c2[nH]cnc2[nH]1
8814,CHEMBL728,P28223,PROCHLORPERAZINE,WIKYUJGCLQQFNW-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,7.06,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7405061,DTCC00162902,1512815,46191,8.151195298948196,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl,CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1
8823,CHEMBL741,P28223,LAMOTRIGINE,PYZRQGJRPPTADH-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7412220,DTCC00164108,1512811,46191,,C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,Nc1nnc(-c2cccc(Cl)c2Cl)c(N)n1
8825,CHEMBL742,P28223,KETAMINE,YQEZLKZALYSWHR-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7426949,DTCC00164207,1862716,46191,,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,CNC1(c2ccccc2Cl)CCCCC1=O
8838,CHEMBL744,P28223,RILUZOLE,FTALBRSUTCGOEG-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7455558,DTCC00164269,348405,46191,,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N,Nc1nc2ccc(OC(F)(F)F)cc2s1
8843,CHEMBL748,P28223,PRALIDOXIME CHLORIDE,HIGSLXSBYYMVKI-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7404816,DTCC00164888,1798416,46191,,C[N+]1=CC=CC=C1/C=N/O.[Cl-],C[n+]1ccccc1/C=N/O
8848,CHEMBL75435,P28223,DEXKETOPROFEN,DKYWVDODHFEZIM-NSHDSACASA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7352902,DTCC00229147,1447880,46191,,C[C@@H](C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1
8851,CHEMBL7568,P28223,QUINACRINE,GPKJTRJOBQGKQK-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,2663.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7373026,DTCC00134204,2089751,46191,5.574628833561059,CCN(CC)CCCC(C)NC1=C2C=C(C=CC2=NC3=C1C=CC(=C3)Cl)OC,CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12
8853,CHEMBL757,P28223,NANDROLONE,NPAGDVCDWIYMMC-IZPLOLCNSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7390284,DTCC00166843,930082,46191,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)CC[C@H]34,C[C@]12CC[C@@H]3[C@H]4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@H]2O
8859,CHEMBL75880,P28223,PERHEXILINE,CYXKNKQEMFBLER-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7393501,DTCC00230384,1124453,46191,,C1CCC(CC1)C(CC2CCCCN2)C3CCCCC3,C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1
8869,CHEMBL762,P28223,OXYMETAZOLINE,WYWIFABBXFUGLM-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,1285.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7376009,DTCC00167236,2025641,46191,5.891096872332687,CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1
8890,CHEMBL765,P28223,GUANETHIDINE,ACGDKVXYNVEAGU-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7321162,DTCC00167701,2089750,46191,,C1CCCN(CCC1)CCN=C(N)N,NC(N)=NCCN1CCCCCCC1
8906,CHEMBL768,P28223,ESMOLOL,AQNDDEOPVVGCPG-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7311351,DTCC00167907,1253321,46191,,CC(C)NCC(COC1=CC=C(C=C1)CCC(=O)OC)O,COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1
8908,CHEMBL76904,P28223,TYRPHOSTIN 23,VTJXFTPMFYAJJU-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7446467,DTCC00233094,1765983,46191,,C1=CC(=C(C=C1C=C(C#N)C#N)O)O,N#CC(C#N)=Cc1ccc(O)c(O)c1
8914,CHEMBL772,P28223,RESERPINE,QEVHRUUCFGRFIF-MDEJGZGSSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7464152,DTCC00168399,1992810,46191,,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5cc(OC)ccc5c4CCN3C[C@H]2C[C@@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC
8918,CHEMBL773,P28223,GLYCINE,DHMQDGOQFOQNFH-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7308221,DTCC00168448,1544900,46191,,C(C(=O)O)N,NCC(=O)O
8922,CHEMBL77675,P28223,"N,N'-DIPHENYL-GUANIDINE",OWRCNXZUPFZXOS-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7291741,DTCC01741294,1155675,46191,,C1=CC=C(C=C1)NC(=NC2=CC=CC=C2)N,NC(=Nc1ccccc1)Nc1ccccc1
8935,CHEMBL783,P28223,NATEGLINIDE,OELFLUMRDSZNSF-BRWVUGGUSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7398861,DTCC00170640,1512813,46191,,CC(C)C1CCC(CC1)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)O,CC(C)C1CCC(C(=O)N[C@H](Cc2ccccc2)C(=O)O)CC1
8937,CHEMBL787,P28223,MONTELUKAST,UCHDWCPVSPXUMX-TZIWLTJVSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7424261,DTCC00171266,1798413,46191,,CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1
8939,CHEMBL788,P28223,IDOXURIDINE,XQFRJNBWHJMXHO-RRKCRQDMSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7336487,DTCC00171444,510301,46191,,C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)I)CO)O,O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1I
8941,CHEMBL79,P28223,LIDOCAINE,NNJVILVZKWQKPM-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7438072,DTCC00137707,1609550,46191,,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,CCN(CC)CC(=O)Nc1c(C)cccc1C
8944,CHEMBL79249,P28223,,XCCCRVPCDJNFIY-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755364.0,IC50,=,141.25,NM,,cell_based,,,,,,,,,,,L929,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2508.0,DTCT0023186,790650,DTCC00241216,626814,5128,6.850011543508524,C1COCCN1CC2CC3C4=CC=CC=C4CC5=CC=CC=C5N3O2,c1ccc2c(c1)Cc1ccccc1N1OC(CN3CCOCC3)CC21
8946,CHEMBL79496,P28223,,CIIWLVZNBDXUIV-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755364.0,IC50,>,1000.0,NM,,cell_based,,,,,,,,,,,L929,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2508.0,DTCT0023186,776539,DTCC00241215,1079305,5128,6.0,CN(C)C(=O)C1CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1,CN(C)C(=O)C1CC2c3ccccc3Cc3ccccc3N2O1
8947,CHEMBL79568,P28223,,RUNAWWHMBJYHQQ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755364.0,IC50,>,1000.0,NM,,cell_based,,,,,,,,,,,L929,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2508.0,DTCT0023186,816051,DTCC00240865,1370907,5128,6.0,CN(C)CCCCC1CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1,CN(C)CCCCC1CC2c3ccccc3Cc3ccccc3N2O1
8949,CHEMBL79834,P28223,SPIRAMIDE,FJUKDAZEABGEIH-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11078195.0,IC50,=,0.316,NM,,,,,,,,,,,,,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,Multistep solution-phase parallel synthesis of spiperone analogues.,Bioorg. Med. Chem. Lett.,2000.0,10.0,21.0,"Hansen HC, Olsson R, Croston G, Andersson CM",,2461.0,DTCT0023186,1338903,DTCC00238779,1661327,3980,9.500312917381596,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCOC4=CC=C(C=C4)F,O=C1NCN(c2ccccc2)C12CCN(CCCOc1ccc(F)cc1)CC2
8951,CHEMBL79838,P28223,,OZETYYSIKGRYTO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755364.0,IC50,>,1000.0,NM,,cell_based,,,,,,,,,,,L929,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2508.0,DTCT0023186,793567,DTCC00240874,1467622,5128,6.0,C1CN(CCN1CC2CC3C4=CC=CC=C4CC5=CC=CC=C5N3O2)C6=CC(=CC=C6)Cl,Clc1cccc(N2CCN(CC3CC4c5ccccc5Cc5ccccc5N4O3)CC2)c1
8952,CHEMBL799,P28223,CILOSTAZOL,RRGUKTPIGVIEKM-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7356166,DTCC00173670,2057647,46191,,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1
8954,CHEMBL8,P28223,CIPROFLOXACIN,MYSWGUAQZAJSOK-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7341378,DTCC00103423,51457,46191,,C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O,O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O
8956,CHEMBL80,P28223,NALOXONE,UZHSEJADLWPNLE-GRGSLBFTSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7418094,DTCC00137855,1155683,46191,,C=CCN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
8958,CHEMBL80093,P28223,AC-165043,KKDALAZYEILFRD-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11078195.0,IC50,=,79.43,NM,,,,,,,,,,,,,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,Multistep solution-phase parallel synthesis of spiperone analogues.,Bioorg. Med. Chem. Lett.,2000.0,10.0,21.0,"Hansen HC, Olsson R, Croston G, Andersson CM",,2461.0,DTCT0023186,1349246,DTCC01741315,1014372,3980,7.100015437450609,CC(C)NC(=O)N(C1CCCCCCC1)C2CCN(CC2)CCCOC3=CC=C(C=C3)F,CC(C)NC(=O)N(C1CCCCCCC1)C1CCN(CCCOc2ccc(F)cc2)CC1
8959,CHEMBL802,P28223,MINOXIDIL,ZFMITUMMTDLWHR-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7428454,DTCC00174151,1641849,46191,,C1CCN(CC1)C2=NC(=N)N(C(=C2)N)O,N=c1nc(N2CCCCC2)cc(N)n1O
8964,CHEMBL803,P28223,CYTARABINE,UHDGCWIWMRVCDJ-CCXZUQQUSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7348416,DTCC00174264,51462,46191,,C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
8973,CHEMBL806,P28223,FLUTAMIDE,MKXKFYHWDHIYRV-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7307830,DTCC00175006,1253324,46191,,CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F,CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1
8980,CHEMBL808,P28223,ECONAZOLE,LEZWWPYKPKIXLL-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,4034.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7313168,DTCC00175675,1764791,46191,5.394264106123253,C1=CC(=CC=C1COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1
8985,CHEMBL809,P28223,SERTRALINE,VGKDLMBJGBXTGI-SJCJKPOMSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,2740.9,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7471300,DTCC00176302,1414866,46191,5.562106809130486,CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
8988,CHEMBL81,P28223,RALOXIFENE,GZUITABIAKMVPG-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,1450.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7481465,DTCC01738582,1960080,46191,5.838631997765025,C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12
8991,CHEMBL81377,P28223,AC-165024,LQAZWKSHGLDNPG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11078195.0,IC50,=,12.59,NM,,,,,,,,,,,,,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,Multistep solution-phase parallel synthesis of spiperone analogues.,Bioorg. Med. Chem. Lett.,2000.0,10.0,21.0,"Hansen HC, Olsson R, Croston G, Andersson CM",,2461.0,DTCT0023186,1357657,DTCC01741311,1499951,3980,7.899974269892137,CCC(=O)N(C1CCCCCCC1)C2CCN(CC2)CCCOC3=CC=C(C=C3)F,CCC(=O)N(C1CCCCCCC1)C1CCN(CCCOc2ccc(F)cc2)CC1
8994,CHEMBL81435,P28223,,ZXIPGUHBRFTYRJ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755364.0,IC50,>,1000.0,NM,,cell_based,,,,,,,,,,,L929,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2508.0,DTCT0023186,800473,DTCC00240689,172915,5128,6.0,C1C(ON2C1C3=CC=CC=C3CC4=CC=CC=C42)CN5C(=O)C6=CC=CC=C6C5=O,O=C1c2ccccc2C(=O)N1CC1CC2c3ccccc3Cc3ccccc3N2O1
8995,CHEMBL81485,P28223,,LCKBEOTXTNWYRG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755364.0,IC50,=,13.18,NM,,cell_based,,,,,,,,,,,L929,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2508.0,DTCT0023186,796297,DTCC00240690,1435300,5128,7.880084589742009,CNCC1CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1,CNCC1CC2c3ccccc3Cc3ccccc3N2O1
9005,CHEMBL817,P28223,TOLAZAMIDE,OUDSBRTVNLOZBN-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7470479,DTCC00178466,1285883,46191,,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CCCCCC2,Cc1ccc(S(=O)(=O)NC(=O)NN2CCCCCC2)cc1
9009,CHEMBL81977,P28223,3-AMINOBENZAMIDE,GSCPDZHWVNUUFI-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7289298,DTCC00237769,1798404,46191,,C1=CC(=CC(=C1)N)C(=O)N,NC(=O)c1cccc(N)c1
9011,CHEMBL820,P28223,BUSULFAN,COVZYZSDYWQREU-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7268923,DTCC00178870,898285,46191,,CS(=O)(=O)OCCCCOS(=O)(=O)C,CS(=O)(=O)OCCCCOS(C)(=O)=O
9013,CHEMBL822,P28223,TERBINAFINE,DOMXUEMWDBAQBQ-WEVVVXLNSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7467888,DTCC00179021,833164,46191,,CC(C)(C)C#C/C=C/CN(C)CC1=CC=CC2=CC=CC=C21,CN(C/C=C/C#CC(C)(C)C)Cc1cccc2ccccc12
9016,CHEMBL826,P28223,ENOXACIN,IDYZIJYBMGIQMJ-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7328225,DTCC00179302,1219085,46191,,CCN1C=C(C(=O)C2=CC(=C(N=C21)N3CCNCC3)F)C(=O)O,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)nc21
9018,CHEMBL82635,P28223,,KTWZXHKXAGXWOB-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755365.0,IC50,=,91.2,NM,,cell_based,,,,,,,,,,,L929,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2509.0,DTCT0023186,1580110,DTCC00243088,518536,5129,7.0400051616715835,CC1=C2CC3=CC=CC=C3C4CC(ON4C2=CC=C1)CN(C)C,Cc1cccc2c1Cc1ccccc1C1CC(CN(C)C)ON21
9019,CHEMBL82714,P28223,,CQGTWGRGLDAJSE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755364.0,IC50,=,57.54,NM,,cell_based,,,,,,,,,,,L929,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2508.0,DTCT0023186,805930,DTCC00240520,140707,5128,7.2400301424456925,CC1(CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1)CN(C)C,CN(C)CC1(C)CC2c3ccccc3Cc3ccccc3N2O1
9020,CHEMBL82714,P28223,,CQGTWGRGLDAJSE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755364.0,IC50,>,1000.0,NM,,cell_based,,,,,,,,,,,L929,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2508.0,DTCT0023186,783736,DTCC00240520,140706,5128,6.0,CC1(CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1)CN(C)C,CN(C)CC1(C)CC2c3ccccc3Cc3ccccc3N2O1
9022,CHEMBL828,P28223,PHENOTHIAZINE,WJFKNYWRSNBZNX-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7393631,DTCC00179549,1734060,46191,,C1=CC=C2C(=C1)NC3=CC=CC=C3S2,c1ccc2c(c1)Nc1ccccc1S2
9024,CHEMBL82966,P28223,,LHTXSHOSMCEFFX-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755365.0,IC50,=,31.62,NM,,cell_based,,,,,,,,,,,L929,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2509.0,DTCT0023186,1589125,DTCC00244370,1424135,5129,7.50003813440381,CN(C)CC1CC2C3=C(CC4=CC=CC=C4N2O1)C(=CC=C3)F,CN(C)CC1CC2c3cccc(F)c3Cc3ccccc3N2O1
9025,CHEMBL83,P28223,TAMOXIFEN,NKANXQFJJICGDU-QPLCGJKRSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,4801.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7463413,DTCC00137911,51510,46191,5.318668294030834,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1
9028,CHEMBL83073,P28223,,MMEQHMVQEKIHIG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755365.0,IC50,=,1000.0,NM,,cell_based,,,,,,,,,,,L929,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2509.0,DTCT0023186,1577289,DTCC00244337,970367,5129,6.0,CN(C)CC1CC2C3=C(CC4=CC=CC=C4N2O1)C(=CC=C3)C(F)(F)F,CN(C)CC1CC2c3cccc(C(F)(F)F)c3Cc3ccccc3N2O1
9039,CHEMBL832,P28223,SULFINPYRAZONE,MBGGBVCUIVRRBF-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7486922,DTCC00181706,1124456,46191,,C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)CCS(=O)C4=CC=CC=C4,O=C1C(CC[S+]([O-])c2ccccc2)C(=O)N(c2ccccc2)N1c1ccccc1
9041,CHEMBL83220,P28223,,DQAMCNMFLLPWQR-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755364.0,IC50,>,1000.0,NM,,cell_based,,,,,,,,,,,L929,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2508.0,DTCT0023186,772555,DTCC00240153,853206,5128,6.0,CN(CC1CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1)C(=O)C(F)(F)F,CN(CC1CC2c3ccccc3Cc3ccccc3N2O1)C(=O)C(F)(F)F
9043,CHEMBL833,P28223,TICLOPIDINE,PHWBOXQYWZNQIN-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7474725,DTCC00181784,1285882,46191,,C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl,Clc1ccccc1CN1CCc2sccc2C1
9048,CHEMBL83658,P28223,,BTSCZNWXJQSJIE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755364.0,IC50,=,22.91,NM,,cell_based,,,,,,,,,,,L929,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2508.0,DTCT0023186,798969,DTCC00240667,1014400,5128,7.6399749108106025,CN(C)CC1CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1,CN(C)CC1CC2c3ccccc3Cc3ccccc3N2O1
9049,CHEMBL83658,P28223,,BTSCZNWXJQSJIE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755364.0,IC50,>,1000.0,NM,,cell_based,,,,,,,,,,,L929,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2508.0,DTCT0023186,803217,DTCC00240667,1014399,5128,6.0,CN(C)CC1CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1,CN(C)CC1CC2c3ccccc3Cc3ccccc3N2O1
9050,CHEMBL83658,P28223,,BTSCZNWXJQSJIE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755365.0,IC50,=,22.91,NM,,cell_based,,,,,,,,,,,L929,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2509.0,DTCT0023186,1580095,DTCC00240667,1002897,5129,7.6399749108106025,CN(C)CC1CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1,CN(C)CC1CC2c3ccccc3Cc3ccccc3N2O1
9051,CHEMBL83658,P28223,,BTSCZNWXJQSJIE-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,12443779.0,IC50,=,22.91,NM,,,,,,,,,,,,,,Binding affinity against 5-hydroxytryptamine 2A receptor,,2-(Dimethylaminomethyl)-tetrahydroisoxazolopyridobenzazepine derivatives. Synthesis of a new 5-HT(2C) antagonist with potential anxiolytic properties.,Bioorg. Med. Chem. Lett.,2002.0,12.0,24.0,"Andrés JI, Alonso JM, Fernández J, Iturrino L, Martínez P, Meert TF, Sipido VK",,2512.0,DTCT0023186,945332,DTCC00240667,1003486,5276,7.6399749108106025,CN(C)CC1CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1,CN(C)CC1CC2c3ccccc3Cc3ccccc3N2O1
9052,CHEMBL83668,P28223,TOLNAFTATE,FUSNMLFNXJSCDI-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7479214,DTCC00242570,1124458,46191,,CC1=CC(=CC=C1)N(C)C(=S)OC2=CC3=CC=CC=C3C=C2,Cc1cccc(N(C)C(=S)Oc2ccc3ccccc3c2)c1
9054,CHEMBL83731,P28223,,YRZFLXOYFQEHFH-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755364.0,IC50,=,15.85,NM,,cell_based,,,,,,,,,,,L929,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2508.0,DTCT0023186,794825,DTCC00240719,562136,5128,7.79997073344623,C1C(ON2C1C3=CC=CC=C3CC4=CC=CC=C42)CN,NCC1CC2c3ccccc3Cc3ccccc3N2O1
9055,CHEMBL83777,P28223,,RJYJDEQXOIQEGZ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755365.0,IC50,>,1000.0,NM,,cell_based,,,,,,,,,,,L929,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2509.0,DTCT0023186,1596912,DTCC00243038,1617809,5129,6.0,CN(C)CC1CC2C3=C(CC4=CC=CC=C4N2O1)C=CC=C3F,CN(C)CC1CC2c3c(F)cccc3Cc3ccccc3N2O1
9056,CHEMBL838,P28223,BENAZEPRIL,XPCFTKFZXHTYIP-PMACEKPBSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7275403,DTCC00182957,574621,46191,,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCC3=CC=CC=C3N(C2=O)CC(=O)O,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O
9064,CHEMBL84,P28223,TOPOTECAN,UCFGDBYHRUNTLO-QHCPKHFHSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7487727,DTCC00138393,315672,46191,,CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O,CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1
9066,CHEMBL84081,P28223,,PSVLBKXIZLIMQR-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755365.0,IC50,=,6.92,NM,,cell_based,,,,,,,,,,,L929,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2509.0,DTCT0023186,1581326,DTCC00243315,1552904,5129,8.159893905543242,CN(C)CC1CC2C3=CC=CC=C3CC4=C(N2O1)C=CC(=C4)F,CN(C)CC1CC2c3ccccc3Cc3cc(F)ccc3N2O1
9067,CHEMBL841,P28223,LOPERAMIDE,RDOIQAHITMMDAJ-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7433929,DTCC00183381,1092343,46191,,CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4,CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1
9069,CHEMBL84158,P28223,TIAPRIDE,JTVPZMFULRWINT-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7466007,DTCC00241707,1734065,46191,,CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC,CCN(CC)CCNC(=O)c1cc(S(C)(=O)=O)ccc1OC
9072,CHEMBL84293,P28223,,UOSUONQDJGNZCQ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755364.0,IC50,=,42.66,NM,,cell_based,,,,,,,,,,,L929,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2508.0,DTCT0023186,814737,DTCC00240869,204874,5128,7.36997914888659,CCN(CC)CC1CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1,CCN(CC)CC1CC2c3ccccc3Cc3ccccc3N2O1
9073,CHEMBL844,P28223,BRIMONIDINE,XYLJNLCSTIOKRM-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7260202,DTCC00183812,2057645,46191,,C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br,Brc1c(NC2=NCCN2)ccc2nccnc12
9075,CHEMBL84810,P28223,,ZNWOCPPAOLYORT-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755365.0,IC50,=,67.61,NM,,cell_based,,,,,,,,,,,L929,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2509.0,DTCT0023186,1590334,DTCC00244388,712013,5129,7.169989064063882,CN(C)CC1CC2C3=C(CC4=CC=CC=C4N2O1)C=CC=C3C(F)(F)F,CN(C)CC1CC2c3c(cccc3C(F)(F)F)Cc3ccccc3N2O1
9077,CHEMBL84931,P28223,,MSQRTETUBFIHMP-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755365.0,IC50,=,1.15,NM,,cell_based,,,,,,,,,,,L929,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2509.0,DTCT0023186,1568112,DTCC00243060,1100439,5129,8.939302159646388,CN(C)CC1CC2C3=CC=CC=C3CC4=C(N2O1)C=C(C=C4)F,CN(C)CC1CC2c3ccccc3Cc3ccc(F)cc3N2O1
9111,CHEMBL85,P28223,RISPERIDONE,RAPZEAPATHNIPO-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,0.34600000000000003,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7466599,DTCC00138594,1383782,46191,9.460923901207224,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2
9122,CHEMBL850,P28223,SPARFLOXACIN,DZZWHBIBMUVIIW-DTORHVGOSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7475807,DTCC00185794,1124454,46191,,C[C@@H]1CN(C[C@@H](N1)C)C2=C(C(=C3C(=C2F)N(C=C(C3=O)C(=O)O)C4CC4)N)F,C[C@H]1CN(c2c(F)c(N)c3c(=O)c(C(=O)O)cn(C4CC4)c3c2F)C[C@@H](C)N1
9130,CHEMBL85155,P28223,,LDUDMYAXGOQOGO-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755365.0,IC50,=,10.47,NM,,cell_based,,,,,,,,,,,L929,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2509.0,DTCT0023186,1589120,DTCC00243809,874055,5129,7.980053318321158,CC1=CC2=C(C=C1)C3CC(ON3C4=CC=CC=C4C2)CN(C)C,Cc1ccc2c(c1)Cc1ccccc1N1OC(CN(C)C)CC21
9137,CHEMBL852,P28223,MELPHALAN,SGDBTWWWUNNDEQ-LBPRGKRZSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7427849,DTCC00185853,249079,46191,,C1=CC(=CC=C1C[C@@H](C(=O)O)N)N(CCCl)CCCl,N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O
9142,CHEMBL856,P28223,PRIMIDONE,DQMZLTXERSFNPB-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7379124,DTCC00186106,1674147,46191,,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,CCC1(c2ccccc2)C(=O)NCNC1=O
9145,CHEMBL85728,P28223,"4,4'-METHYLENEDIANILINE",YBRVSVVVWCFQMG-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7294785,DTCC00242937,1318436,46191,,C1=CC(=CC=C1CC2=CC=C(C=C2)N)N,Nc1ccc(Cc2ccc(N)cc2)cc1
9147,CHEMBL85735,P28223,,IEMJYQZKJFERDW-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755365.0,IC50,=,3.09,NM,,cell_based,,,,,,,,,,,L929,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2509.0,DTCT0023186,1581331,DTCC00243832,1935110,5129,8.510041520575164,CC1=CC2=C(CC3=CC=CC=C3C4N2OC(C4)CN(C)C)C=C1,Cc1ccc2c(c1)N1OC(CN(C)C)CC1c1ccccc1C2
9150,CHEMBL86,P28223,METOCLOPRAMIDE,TTWJBBZEZQICBI-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,3675.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7413212,DTCC00138614,51488,46191,5.434742656579786,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC
9155,CHEMBL86091,P28223,,WPLHYZJLPBROHU-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,11755365.0,IC50,>,1000.0,NM,,cell_based,,,,,,,,,,,L929,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,2002.0,12.0,2.0,"Andrés JI, Alcázar J, Alonso JM, Díaz A, Fernández J, Gil P, Iturrino L, Matesanz E, Meert TF, Megens A, Sipido VK",,2509.0,DTCT0023186,1587725,DTCC00244340,550565,5129,6.0,CN(C)CC1CC2C3=C(CC4=CC=CC=C4N2O1)C=CC(=C3)C(F)(F)F,CN(C)CC1CC2c3cc(C(F)(F)F)ccc3Cc3ccccc3N2O1
9158,CHEMBL862,P28223,GUANFACINE,INJOMKTZOLKMBF-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,3014.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7325439,DTCC00186365,1351111,46191,5.520856752021387,C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl,NC(N)=NC(=O)Cc1c(Cl)cccc1Cl
9161,CHEMBL86304,P28223,MOCLOBEMIDE,YHXISWVBGDMDLQ-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7411369,DTCC00246764,833162,46191,,C1COCCN1CCNC(=O)C2=CC=C(C=C2)Cl,O=C(NCCN1CCOCC1)c1ccc(Cl)cc1
9165,CHEMBL865,P28223,VALDECOXIB,LNPDTQAFDNKSHK-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7441549,DTCC00187234,866025,46191,,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,Cc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1
9167,CHEMBL866,P28223,MYCOPHENOLIC ACID,HPNSFSBZBAHARI-RUDMXATFSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7407157,DTCC00188298,120975,46191,,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)O)O,COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)O)C(=O)OC2
9170,CHEMBL86754,P28223,IODOQUINOL,UXZFQZANDVDGMM-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7439495,DTCC00246886,1220278,46191,,C1=CC2=C(C(=C(C=C2I)I)O)N=C1,Oc1c(I)cc(I)c2cccnc12
9173,CHEMBL870,P28223,ALENDRONIC ACID,OGSPWJRAVKPPFI-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7300626,DTCC00190086,800568,46191,,C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN,NCCCC(O)(P(=O)(O)O)P(=O)(O)O
9175,CHEMBL871,P28223,ETIDRONIC ACID,DBVJJBKOTRCVKF-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7328539,DTCC00190087,542574,46191,,CC(O)(P(=O)(O)O)P(=O)(O)O,CC(O)(P(=O)(O)O)P(=O)(O)O
9178,CHEMBL87285,P28223,ANDROSTERONE,QGXBDMJGAMFCBF-HLUDHZFRSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7271835,DTCC00245174,930075,46191,,C[C@]12CC[C@H](C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C)O,C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@@]43C)[C@@H]1CCC2=O
9184,CHEMBL877,P28223,TRANEXAMIC ACID,GYDJEQRTZSCIOI-LJGSYFOKSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7446114,DTCC00192310,1544904,46191,,C1CC(CCC1CN)C(=O)O,NCC1CCC(C(=O)O)CC1
9187,CHEMBL878,P28223,METOLAZONE,AQCHWTWZEMGIFD-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7417568,DTCC00192311,1253327,46191,,CC1NC2=CC(=C(C=C2C(=O)N1C3=CC=CC=C3C)S(=O)(=O)N)Cl,Cc1ccccc1N1C(=O)c2cc(S(N)(=O)=O)c(Cl)cc2NC1C
9190,CHEMBL88,P28223,CYCLOPHOSPHAMIDE,CMSMOCZEIVJLDB-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7361237,DTCC00139205,994590,46191,,C1CNP(=O)(OC1)N(CCCl)CCCl,O=P1(N(CCCl)CCCl)NCCCO1
9192,CHEMBL880,P28223,FAMCICLOVIR,GGXKWVWZWMLJEH-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7315870,DTCC00192933,444642,46191,,CC(=O)OCC(CCN1C=NC2=CN=C(N=C21)N)COC(=O)C,CC(=O)OCC(CCn1cnc2cnc(N)nc21)COC(C)=O
9204,CHEMBL888,P28223,GEMCITABINE,SDUQYLNIPVEERB-QPPQHZFASA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7325085,DTCC00194280,51473,46191,,C1=CN(C(=O)N=C1N)[C@H]2C([C@@H]([C@H](O2)CO)O)(F)F,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
9209,CHEMBL891,P28223,CLOXACILLIN,LQOLIRLGBULYKD-JKIFEVAISA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7363043,DTCC00194952,2089744,46191,,CC1=C(C(=NO1)C2=CC=CC=C2Cl)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O,Cc1onc(-c2ccccc2Cl)c1C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12
9214,CHEMBL894,P28223,BUPROPION,SNPPWIUOZRMYNY-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7263236,DTCC00195238,800571,46191,,CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
9218,CHEMBL895,P28223,NALBUPHINE,NETZHAKZCGBWSS-CEDHKZHLSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7407288,DTCC00195307,413972,46191,,C1CC(C1)CN2CC[C@]34[C@@H]5[C@H](CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O)O,Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314
9220,CHEMBL897,P28223,PROBENECID,DBABZHXKTCFAPX-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7383457,DTCC00195516,1188073,46191,,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,CCCN(CCC)S(=O)(=O)c1ccc(C(=O)O)cc1
9225,CHEMBL898,P28223,DIFLUNISAL,HUPFGZXOMWLGNK-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7338197,DTCC00195664,477917,46191,,C1=CC(=C(C=C1C2=C(C=C(C=C2)F)F)C(=O)O)O,O=C(O)c1cc(-c2ccc(F)cc2F)ccc1O
9227,CHEMBL89934,P28223,,IWOQWCKSTOAOMQ-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,8831770.0,IC50,=,17.0,NM,,cell_based,,,,,,,,,,,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,"Structure-activity relationships of a series of novel (piperazinylbutyl)thiazolidinone antipsychotic agents related to 3-[4-[4-(6-fluorobenzo[b]thien-3-yl)-1-piperazinyl]butyl]-2,5,5- trimethyl-4-thiazolidinone maleate.",J. Med. Chem.,1996.0,39.0,20.0,"Hrib NJ, Jurcak JG, Bregna DE, Burgher KL, Hartman HB, Kafka S, Kerman LL, Kongsamut S, Roehr JE, Szewczak MR, Woods-Kettelberger AT, Corbett R",,2272.0,DTCT0023186,1621549,DTCC00254662,292179,13832,7.769551078621726,CC1N(C(=O)C(S1)(C)C)CCCCN2CCN(CC2)C3=CSC4=C3C=CC(=C4)F,CC1SC(C)(C)C(=O)N1CCCCN1CCN(c2csc3cc(F)ccc23)CC1
9230,CHEMBL9,P28223,NORFLOXACIN,OGJPXUAPXNRGGI-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7392891,DTCC00132409,51494,46191,,CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCNCC3)F)C(=O)O,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)cc21
9232,CHEMBL900,P28223,ORPHENADRINE,QVYRGXJJSLMXQH-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,436.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7375791,DTCC00195771,217582,46191,6.360513510731414,CC1=CC=CC=C1C(C2=CC=CC=C2)OCCN(C)C,Cc1ccccc1C(OCCN(C)C)c1ccccc1
9236,CHEMBL902,P28223,FAMOTIDINE,XUFQPHANEAPEMJ-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7320106,DTCC00196201,1155680,46191,,C1=C(N=C(S1)N=C(N)N)CSCC/C(=N/S(=O)(=O)N)/N,NC(N)=Nc1nc(CSCC/C(N)=N/S(N)(=O)=O)cs1
9244,CHEMBL905,P28223,RIZATRIPTAN,ULFRLSNUDGIQQP-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,7752204.0,IC50,=,7943.28,NM,,,,,,,,,,,,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,"Synthesis and serotonergic activity of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine and analogues: potent agonists for 5-HT1D receptors.",J. Med. Chem.,1995.0,38.0,10.0,"Street LJ, Baker R, Davey WB, Guiblin AR, Jelley RA, Reeve AJ, Routledge H, Sternfeld F, Watt AP, Beer MS",,2506.0,DTCT0023186,529645,DTCC00196801,236861,13017,5.100000128334196,CN(C)CCC1=CNC2=C1C=C(C=C2)CN3C=NC=N3,CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12
9246,CHEMBL90555,P28223,VINCRISTINE,OGWKCGZFUXNPDA-XQKSVPLYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7442609,DTCC00249955,51516,46191,,CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
9253,CHEMBL91,P28223,MICONAZOLE,BYBLEWFAAKGYCD-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,3907.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7415610,DTCC00139665,1317286,46191,5.408156588775215,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1
9263,CHEMBL914,P28223,FEXOFENADINE,RWTNPBWLLIMQHL-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7318115,DTCC00198847,413971,46191,,CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O,CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
9273,CHEMBL917,P28223,FLOXURIDINE,ODKNJVUHOIMIIZ-RRKCRQDMSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7297637,DTCC00199915,1609542,46191,,C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)F)CO)O,O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1F
9275,CHEMBL918,P28223,PHENACEMIDE,XPFRXWCVYUEORT-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7402146,DTCC00199924,1577008,46191,,C1=CC=C(C=C1)CC(=O)NC(=O)N,NC(=O)NC(=O)Cc1ccccc1
9279,CHEMBL923,P28223,RISEDRONIC ACID,IIDJRNMFWXDHID-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7464297,DTCC00200598,1927022,46191,,C1=CC(=CN=C1)CC(O)(P(=O)(O)O)P(=O)(O)O,O=P(O)(O)C(O)(Cc1cccnc1)P(=O)(O)O
9283,CHEMBL92401,P28223,IPRONIAZID,NYMGNSNKLVNMIA-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7413943,DTCC00256735,1992806,46191,,CC(C)NNC(=O)C1=CC=NC=C1,CC(C)NNC(=O)c1ccncc1
9289,CHEMBL926,P28223,DOBUTAMINE,JRWZLRBJNMZMFE-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7362017,DTCC00105095,1383776,46191,,CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O,CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1
9296,CHEMBL93,P28223,ZILEUTON,MWLSOWXNZPKENC-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7448823,DTCC00139913,51518,46191,,CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O,CC(c1cc2ccccc2s1)N(O)C(N)=O
9299,CHEMBL932,P28223,DIPYRIDAMOLE,IZEKFCXSFNUWAM-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7349112,DTCC00202383,444640,46191,,C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO,OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1
9305,CHEMBL934,P28223,METYRAPONE,FJLBFSROUSIWMA-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7430432,DTCC00202598,1992807,46191,,CC(C)(C1=CN=CC=C1)C(=O)C2=CN=CC=C2,CC(C)(C(=O)c1cccnc1)c1cccnc1
9308,CHEMBL936,P28223,DIPHENIDOL,OGAKLTJNUQRZJU-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,2586.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7344849,DTCC00202761,1416027,46191,5.587371479455625,C1CCN(CC1)CCCC(C2=CC=CC=C2)(C3=CC=CC=C3)O,OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1
9310,CHEMBL93645,P28223,ACECLOFENAC,MNIPYSSQXLZQLJ-UHFFFAOYSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7294899,DTCC00256586,1285871,46191,,C1=CC=C(C(=C1)CC(=O)OCC(=O)O)NC2=C(C=CC=C2Cl)Cl,O=C(O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl
9315,CHEMBL94,P28223,PHYSOSTIGMINE,PIJVFDBKTWXHHD-HIFRSBDPSA-N,3,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7380788,DTCC00139956,1862717,46191,,C[C@@]12CCN([C@@H]1N(C3=C2C=C(C=C3)OC(=O)NC)C)C,CNC(=O)Oc1ccc2c(c1)[C@]1(C)CCN(C)[C@@H]1N2C
9317,CHEMBL940,P28223,GABAPENTIN,UGJMXCAKCUNAIE-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7329264,DTCC00204291,2025637,46191,,C1CCC(CC1)(CC(=O)O)CN,NCC1(CC(=O)O)CCCCC1
9319,CHEMBL941,P28223,IMATINIB,KTUFNOKKBVMGRW-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,1891.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7313105,DTCC01738580,51477,46191,5.723308471154961,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
9321,CHEMBL9419,P28223,METACETAMOL,QLNWXBAGRTUKKI-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7286636,DTCC00136686,477909,46191,,CC(=O)NC1=CC(=CC=C1)O,CC(=O)Nc1cccc(O)c1
9323,CHEMBL942,P28223,BISACODYL,KHOITXIGCFIULA-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7268740,DTCC00204742,736255,46191,,CC(=O)OC1=CC=C(C=C1)C(C2=CC=C(C=C2)OC(=O)C)C3=CC=CC=N3,CC(=O)Oc1ccc(C(c2ccc(OC(C)=O)cc2)c2ccccn2)cc1
9328,CHEMBL945,P28223,AMILORIDE,XSDQTOBWRPYKKA-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7298081,DTCC00205274,2057644,46191,,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N,NC(N)=NC(=O)c1nc(Cl)c(N)nc1N
9331,CHEMBL95,P28223,TACRINE,YLJREFDVOIBQDA-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7456761,DTCC00140002,283001,46191,,C1CCC2=NC3=CC=CC=C3C(=C2C1)N,Nc1c2c(nc3ccccc13)CCCC2
9335,CHEMBL9514,P28223,NOCODAZOLE,KYRVNWMVYQXFEU-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7379932,DTCC00136712,2025640,46191,,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CS3,COC(=O)Nc1nc2ccc(C(=O)c3cccs3)cc2[nH]1
9337,CHEMBL954,P28223,ENCLOMIPHENE,GKIRPKYJQBWNGO-OCEACIFDSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,3308.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7367277,DTCC00208231,1383775,46191,5.480434499119491,CCN(CC)CCOC1=CC=C(C=C1)/C(=C(\C2=CC=CC=C2)/Cl)/C3=CC=CC=C3,CCN(CC)CCOc1ccc(/C(=C(/Cl)c2ccccc2)c2ccccc2)cc1
9340,CHEMBL95764,P28223,GLYPHOSATE,XDDAORKBJWWYJS-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7321044,DTCC00263189,1894968,46191,,C(C(=O)O)NCP(=O)(O)O,O=C(O)CNCP(=O)(O)O
9343,CHEMBL959,P28223,RIMANTADINE,UBCHPRBFMUDMNC-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7459885,DTCC00208870,574626,46191,,CC(C12CC3CC(C1)CC(C3)C2)N,CC(N)C12CC3CC(CC(C3)C1)C2
9345,CHEMBL960,P28223,LEFLUNOMIDE,VHOGYURTWQBHIL-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7429436,DTCC00208904,249943,46191,,CC1=C(C=NO1)C(=O)NC2=CC=C(C=C2)C(F)(F)F,Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1
9350,CHEMBL964,P28223,DISULFIRAM,AUZONCFQVSMFAP-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7357732,DTCC00209451,1318441,46191,,CCN(CC)C(=S)SSC(=S)N(CC)CC,CCN(CC)C(=S)SSC(=S)N(CC)CC
9364,CHEMBL972,P28223,SELEGILINE,MEZLKOACVSPNER-GFCCVEGCSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7462560,DTCC00210689,51433,46191,,C[C@H](CC1=CC=CC=C1)N(C)CC#C,C#CCN(C)[C@H](C)Cc1ccccc1
9368,CHEMBL975,P28223,MESNA,XOGTZOOQQBDUSI-UHFFFAOYSA-M,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7408724,DTCC00211154,1960079,46191,,C(CS(=O)(=O)[O-])S.[Na+],O=S(=O)([O-])CCS
9371,CHEMBL976,P28223,PRAZIQUANTEL,FSVJFNAIGNNGKK-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7383332,DTCC00213280,1383780,46191,,C1CCC(CC1)C(=O)N2CC3C4=CC=CC=C4CCN3C(=O)C2,O=C(C1CCCCC1)N1CC(=O)N2CCc3ccccc3C2C1
9375,CHEMBL980,P28223,GUAIFENESIN,HSRJKNPTNIJEKV-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7312665,DTCC00214269,994593,46191,,COC1=CC=CC=C1OCC(CO)O,COc1ccccc1OCC(O)CO
9377,CHEMBL983,P28223,SUCCINYLCHOLINE CHLORIDE,YOEWQQVKRJEPAE-UHFFFAOYSA-L,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7487012,DTCC00215702,1674152,46191,,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C.[Cl-].[Cl-],C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C
9379,CHEMBL98350,P28223,LY-294002,CZQHHVNHHHRRDU-UHFFFAOYSA-N,0,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,=,2796.0,NM,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7423335,DTCC00262208,1960077,46191,5.553462832926356,C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12
9381,CHEMBL989,P28223,FLUOCINOLONE ACETONIDE,FEBLZLNTKCEFIT-VSXGLTOVSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7305491,DTCC00218597,1351110,46191,,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)C[C@@H](C5=CC(=O)C=C[C@@]53C)F)F)O,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
9384,CHEMBL990,P28223,BUTENAFINE,ABJKWBDEJIDSJZ-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7274552,DTCC00218762,1862713,46191,,CC(C)(C)C1=CC=C(C=C1)CN(C)CC2=CC=CC3=CC=CC=C32,CN(Cc1ccc(C(C)(C)C)cc1)Cc1cccc2ccccc12
9386,CHEMBL991,P28223,STAVUDINE,XNKLLVCARDGLGL-JGVFFNPUSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7473746,DTCC00220129,1927023,46191,,CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@H](O2)CO,Cc1cn([C@H]2C=C[C@@H](CO)O2)c(=O)[nH]c1=O
9390,CHEMBL998,P28223,LORATADINE,JCCNYMKQOSZNPW-UHFFFAOYSA-N,4,SEROTONIN 2A (5-HT2A) RECEPTOR,HTR2A,GPCR,,,,IC50,,,,,,,,,,,,,,,,CHO-K1,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774690.0,DTCT0023186,7438157,DTCC00223343,1253325,46191,,CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1,CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1
